(lp0
(dp1
S'line'
p2
S'Loss of Tfap2b results in altered Bmp expression that may cause the heart-limb defects observed in Tfap2b mouse mutants and Char syndrome patients.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I34
sS'uniprot'
p8
VP18075
p9
sS'lengthInChars'
p10
I3
sS'name'
p11
VBmp
p12
sS'lengthInWords'
p13
I1
sa(dp14
g7
I8
sg8
S''
p15
sg10
I6
sg11
VTfap2b
p16
sg13
I1
sa(dp17
g7
I99
sg8
g15
sg10
I20
sg11
VTfap2b mouse mutants
p18
sg13
I3
sasS'diseases'
p19
(lp20
(dp21
g7
I74
sS'cui'
p22
VC0740404
p23
sg10
I12
sg11
Vlimb defects
p24
sg13
I2
sa(dp25
g7
I124
sg22
VC1868570
p26
sg10
I13
sg11
VChar syndrome
p27
sg13
I2
sasa(dp28
g2
S'The present data suggest that AP-2 may suppress trophoblast migration and invasion, thus leading to a shallow placentation in preeclampsia.\n'
p29
sg4
(lp30
(dp31
g7
I30
sg8
VP05549
p32
sg10
I4
sg11
VAP-2
p33
sg13
I1
sasg19
(lp34
(dp35
g7
I74
sg22
VC2699153
p36
sg10
I8
sg11
Vinvasion
p37
sg13
I1
sa(dp38
g7
I126
sg22
VC0032914
p39
sg10
I12
sg11
Vpreeclampsia
p40
sg13
I1
sasa(dp41
g2
S'PKD/AP2 system can be a potent pharmacological target for prevention of atherosclerosis.\n'
p42
sg4
(lp43
(dp44
g7
I0
sg8
VP98161
p45
sg10
I3
sg11
VPKD
p46
sg13
I1
sa(dp47
g7
I4
sg8
VP05549
p48
sg10
I3
sg11
VAP2
p49
sg13
I1
sasg19
(lp50
(dp51
g7
I0
sg22
VC1868682
p52
sg10
I3
sg11
VPKD
p53
sg13
I1
sa(dp54
g7
I72
sg22
VC0004153
p55
sg10
I15
sg11
Vatherosclerosis
p56
sg13
I1
sasa(dp57
g2
S'In general, IMO is fatal, as patients fail to grow and expire  due to complications of the disease such as severe chronic anemia, bleeding, and/or infections.\n'
p58
sg4
(lp59
sg19
(lp60
(dp61
g7
I130
sg22
VC0019080
p62
sg10
I8
sg11
Vbleeding
p63
sg13
I1
sa(dp64
g7
I114
sg22
VC0581384
p65
sg10
I14
sg11
Vchronic anemia
p66
sg13
I2
sa(dp67
g7
I147
sg22
VC0021311
p68
sg10
I10
sg11
Vinfections
p69
sg13
I1
sasa(dp70
g2
S'Therefore, IL-7 delivery could represent a new therapeutic perspective to circumvent the lymphopenia observed in infantile malignant osteopetrosis patients.\n'
p71
sg4
(lp72
(dp73
g7
I11
sg8
VP13232
p74
sg10
I4
sg11
VIL-7
p75
sg13
I1
sasg19
(lp76
(dp77
g7
I113
sg22
VC1318518
p78
sg10
I33
sg11
Vinfantile malignant osteopetrosis
p79
sg13
I3
sa(dp80
g7
I89
sg22
VC0024312
p81
sg10
I11
sg11
Vlymphopenia
p82
sg13
I1
sasa(dp83
g2
S'The CD2 associated protein (CD2AP) is characterized as a T-lymphocyte CD2 adapter protein and is found to be related to glomerulosclerosis, and CD2AP knockout mice develop a rapid onset nephrotic syndrome and die of renal failure.\n'
p84
sg4
(lp85
(dp86
g7
I70
sg8
VP06729
p87
sg10
I19
sg11
VCD2 adapter protein
p88
sg13
I3
sa(dp89
g7
I28
sg8
g15
sg10
I5
sg11
VCD2AP
p90
sg13
I1
sa(dp91
g7
I4
sg8
g15
sg10
I22
sg11
VCD2 associated protein
p92
sg13
I3
sa(dp93
g7
I28
sg8
g15
sg10
I5
sg11
VCD2AP
p94
sg13
I1
sasg19
(lp95
(dp96
g7
I120
sg22
VC0178664
p97
sg10
I18
sg11
Vglomerulosclerosis
p98
sg13
I1
sa(dp99
g7
I216
sg22
VC0035078
p100
sg10
I13
sg11
Vrenal failure
p101
sg13
I2
sa(dp102
g7
I186
sg22
VC0027726
p103
sg10
I18
sg11
Vnephrotic syndrome
p104
sg13
I2
sasa(dp105
g2
S'In vivo, to determine the effects of reduced Smad3 or CD2AP gene dosage on podocyte apoptosis and proteinuria characteristic of TGF-beta1 transgenic mice, we generated TGF-beta1 transgenic mice deficient for Smad3 or heterozygous for CD2AP.\n'
p106
sg4
(lp107
(dp108
g7
I54
sg8
g15
sg10
I5
sg11
VCD2AP
p109
sg13
I1
sa(dp110
g7
I128
sg8
VP01137
p111
sg10
I9
sg11
VTGF-beta1
p112
sg13
I1
sa(dp113
g7
I54
sg8
g15
sg10
I10
sg11
VCD2AP gene
p114
sg13
I2
sa(dp115
g7
I128
sg8
VP01137
p116
sg10
I9
sg11
VTGF-beta1
p117
sg13
I1
sasg19
(lp118
sa(dp119
g2
S'Smad3 deficiency ameliorated podocyte apoptosis, and CD2AP heterozygosity increased both podocyte apoptosis and proteinuria.\n'
p120
sg4
(lp121
(dp122
g7
I53
sg8
g15
sg10
I5
sg11
VCD2AP
p123
sg13
I1
sasg19
(lp124
sa(dp125
g2
S'However, the expression and biological function of NEAT1 in hepatoblastoma (HB) and the underlying mechanisms for the function of NEAT1 in HB remain largely uncharacterized.\n'
p126
sg4
(lp127
(dp128
g7
I60
sg8
VP09382
p129
sg10
I19
sg11
Vhepatoblastoma (HB)
p130
sg13
I2
sasg19
(lp131
(dp132
g7
I76
sg22
VC0206624
p133
sg10
I2
sg11
VHB
p134
sg13
I1
sa(dp135
g7
I60
sg22
VC0206624
p136
sg10
I14
sg11
Vhepatoblastoma
p137
sg13
I1
sa(dp138
g7
I76
sg22
VC0206624
p139
sg10
I2
sg11
VHB
p140
sg13
I1
sasa(dp141
g2
S'The aim of this study was to investigate the role of NEAT1 in hepatocellular carcinoma (HCC), and probe whether NEAT1 participate in the epithelial-mesenchymal transition (EMT) and metastasis regulated by HIF-2Alfa.\n'
p142
sg4
(lp143
sg19
(lp144
(dp145
g7
I160
sg22
VC0599156
p146
sg10
I10
sg11
Vtransition
p147
sg13
I1
sa(dp148
g7
I181
sg22
VC0027627
p149
sg10
I10
sg11
Vmetastasis
p150
sg13
I1
sa(dp151
g7
I62
sg22
VC2239176
p152
sg10
I24
sg11
Vhepatocellular carcinoma
p153
sg13
I2
sa(dp154
g7
I88
sg22
VC2239176
p155
sg10
I3
sg11
VHCC
p156
sg13
I1
sasa(dp157
g2
S'We investigated the role of Nuclear Paraspeckle Assembly Transcript 1 (NEAT1) lncRNA in promoting cholangiocarcinoma (CCA).\n'
p158
sg4
(lp159
(dp160
g7
I98
sg8
VP35556
p161
sg10
I24
sg11
Vcholangiocarcinoma (CCA)
p162
sg13
I2
sasg19
(lp163
(dp164
g7
I98
sg22
VC0206698
p165
sg10
I18
sg11
Vcholangiocarcinoma
p166
sg13
I1
sa(dp167
g7
I118
sg22
VC0220668
p168
sg10
I3
sg11
VCCA
p169
sg13
I1
sasa(dp170
g2
S'Long non-coding RNA nuclear-enriched abundant transcript 1 (NEAT1) was found to be participated in tumorigenesis in various cancers including hepatocellular carcinoma (HCC).\n'
p171
sg4
(lp172
sg19
(lp173
(dp174
g7
I99
sg22
VC0007621
p175
sg10
I13
sg11
Vtumorigenesis
p176
sg13
I1
sa(dp177
g7
I142
sg22
VC2239176
p178
sg10
I24
sg11
Vhepatocellular carcinoma
p179
sg13
I2
sa(dp180
g7
I168
sg22
VC2239176
p181
sg10
I3
sg11
VHCC
p182
sg13
I1
sa(dp183
g7
I124
sg22
VC0006826
p184
sg10
I7
sg11
Vcancers
p185
sg13
I1
sasa(dp186
g2
S'A BAP1 dependent alteration in expression of lncRNA NEAT-1 was identified by RT-PCR based lncRNA expression profiling, and an inverse relationship between this lncRNA and BAP1 was observed in analysis of the Tumor Cancer Genome Atlas cholangiocarcinoma dataset.\n'
p187
sg4
(lp188
(dp189
g7
I2
sg8
g15
sg10
I4
sg11
VBAP1
p190
sg13
I1
sa(dp191
g7
I2
sg8
g15
sg10
I4
sg11
VBAP1
p192
sg13
I1
sasg19
(lp193
(dp194
g7
I234
sg22
VC0206698
p195
sg10
I18
sg11
Vcholangiocarcinoma
p196
sg13
I1
sa(dp197
g7
I208
sg22
VC0027651
p198
sg10
I5
sg11
VTumor
p199
sg13
I1
sa(dp200
g7
I214
sg22
VC0006826
p201
sg10
I6
sg11
VCancer
p202
sg13
I1
sasa(dp203
g2
S'The pooled standard mean deviation (SMD) indicated that NEAT1 was down-regulated in esophageal carcinoma (ESCA, SMD = -0.35, 95% CI: -0.5~-0.20, P &lt; 0.0001) and hepatocellular carcinoma (HCC, SMD = -0.47, 95% CI: -0.60~-0.34, P &lt; 0.0001), while in pancreatic cancer (PC), NEAT1 was up-regulated (SMD = 0.45, 95% CI: 0.2~0.71, P = 0.001).\n'
p204
sg4
(lp205
sg19
(lp206
(dp207
g7
I106
sg22
VC0152018
p208
sg10
I4
sg11
VESCA
p209
sg13
I1
sa(dp210
g7
I36
sg22
VC0700635
p211
sg10
I3
sg11
VSMD
p212
sg13
I1
sa(dp213
g7
I254
sg22
VC0235974
p214
sg10
I17
sg11
Vpancreatic cancer
p215
sg13
I2
sa(dp216
g7
I84
sg22
VC0152018
p217
sg10
I20
sg11
Vesophageal carcinoma
p218
sg13
I2
sa(dp219
g7
I190
sg22
VC2239176
p220
sg10
I3
sg11
VHCC
p221
sg13
I1
sa(dp222
g7
I11
sg22
VC0700635
p223
sg10
I23
sg11
Vstandard mean deviation
p224
sg13
I3
sa(dp225
g7
I273
sg22
VC0235974
p226
sg10
I2
sg11
VPC
p227
sg13
I1
sa(dp228
g7
I36
sg22
VC0700635
p229
sg10
I3
sg11
VSMD
p230
sg13
I1
sa(dp231
g7
I164
sg22
VC2239176
p232
sg10
I24
sg11
Vhepatocellular carcinoma
p233
sg13
I2
sa(dp234
g7
I36
sg22
VC0700635
p235
sg10
I3
sg11
VSMD
p236
sg13
I1
sa(dp237
g7
I36
sg22
VC0700635
p238
sg10
I3
sg11
VSMD
p239
sg13
I1
sasa(dp240
g2
S'However, NEAT1 expression in gastric cancer (GC), colorectal cancer (CRC), biliary tract cancer (BTC) and gallbladder carcinoma (GBC) showed no significant difference between cancer and control groups.\n'
p241
sg4
(lp242
(dp243
g7
I97
sg8
VP35070
p244
sg10
I3
sg11
VBTC
p245
sg13
I1
sa(dp246
g7
I29
sg8
VP12830
p247
sg10
I66
sg11
Vgastric cancer (GC), colorectal cancer (CRC), biliary tract cancer
p248
sg13
I9
sasg19
(lp249
(dp250
g7
I75
sg22
VC0750952
p251
sg10
I20
sg11
Vbiliary tract cancer
p252
sg13
I3
sa(dp253
g7
I50
sg22
VC1527249
p254
sg10
I17
sg11
Vcolorectal cancer
p255
sg13
I2
sa(dp256
g7
I106
sg22
VC0235782
p257
sg10
I21
sg11
Vgallbladder carcinoma
p258
sg13
I2
sa(dp259
g7
I69
sg22
VC1527249
p260
sg10
I3
sg11
VCRC
p261
sg13
I1
sa(dp262
g7
I37
sg22
VC0006826
p263
sg10
I6
sg11
Vcancer
p264
sg13
I1
sa(dp265
g7
I129
sg22
VC0235782
p266
sg10
I3
sg11
VGBC
p267
sg13
I1
sa(dp268
g7
I45
sg22
VC0024623
p269
sg10
I2
sg11
VGC
p270
sg13
I1
sa(dp271
g7
I29
sg22
VC0024623
p272
sg10
I14
sg11
Vgastric cancer
p273
sg13
I2
sa(dp274
g7
I97
sg22
VC0750952
p275
sg10
I3
sg11
VBTC
p276
sg13
I1
sasa(dp277
g2
S'Aberrant overexpression of the long non-coding RNA NEAT1 (nuclear paraspeckle assembly transcript 1) has been documented in different types of solid tumours, such as lung cancer, oesophageal cancer, colorectal cancer and hepatocellular carcinoma, in which its high levels are associated with poor prognosis.\n'
p278
sg4
(lp279
sg19
(lp280
(dp281
g7
I221
sg22
VC1512411
p282
sg10
I24
sg11
Vhepatocellular carcinoma
p283
sg13
I2
sa(dp284
g7
I166
sg22
VC0684249
p285
sg10
I11
sg11
Vlung cancer
p286
sg13
I2
sa(dp287
g7
I171
sg22
VC0006826
p288
sg10
I6
sg11
Vcancer
p289
sg13
I1
sa(dp290
g7
I149
sg22
VC0027651
p291
sg10
I7
sg11
Vtumours
p292
sg13
I1
sa(dp293
g7
I191
sg22
VC1527249
p294
sg10
I18
sg11
Vcancer, colorectal
p295
sg13
I2
sasa(dp296
g2
S'The role of lncRNA NEAT1 (nuclear paraspeckle assembly transcript 1, Gene ID: 283131) in colorectal cancer (CRC) keeps unknown.\n'
p297
sg4
(lp298
sg19
(lp299
(dp300
g7
I108
sg22
VC1527249
p301
sg10
I3
sg11
VCRC
p302
sg13
I1
sa(dp303
g7
I89
sg22
VC1527249
p304
sg10
I17
sg11
Vcolorectal cancer
p305
sg13
I2
sasa(dp306
g2
S'RESULTS After successfully establishing a rapid atrial pacing of the left atrial appendage induced atrial fibrillation model, we found that expression of choline acetyl transferase, tyrosine hydroxylase, nerve growth factor, and neurturin was significantly higher in the rapid atrial pacing group than the control group (p&lt;0.05).\n'
p307
sg4
(lp308
(dp309
g7
I154
sg8
VP28329
p310
sg10
I26
sg11
Vcholine acetyl transferase
p311
sg13
I3
sa(dp312
g7
I182
sg8
VP07101
p313
sg10
I20
sg11
Vtyrosine hydroxylase
p314
sg13
I2
sa(dp315
g7
I204
sg8
g15
sg10
I34
sg11
Vnerve growth factor, and neurturin
p316
sg13
I5
sasg19
(lp317
(dp318
g7
I99
sg22
VC0004238
p319
sg10
I19
sg11
Vatrial fibrillation
p320
sg13
I2
sasa(dp321
g2
S'This study focused on cholinergic, choline acetyltransferase (ChAT)-immunopositive, and tyrosine hydroxylase (TH)-containing neurons in association with the vasculature to explore the neurovascular complex of the AD brain affected by stroke.\n'
p322
sg4
(lp323
(dp324
g7
I35
sg8
VP28329
p325
sg10
I25
sg11
Vcholine acetyltransferase
p326
sg13
I2
sa(dp327
g7
I88
sg8
VP07101
p328
sg10
I20
sg11
Vtyrosine hydroxylase
p329
sg13
I2
sa(dp330
g7
I110
sg8
VP07101
p331
sg10
I2
sg11
VTH
p332
sg13
I1
sa(dp333
g7
I62
sg8
VP28329
p334
sg10
I4
sg11
VChAT
p335
sg13
I1
sasg19
(lp336
(dp337
g7
I234
sg22
VC0038454
p338
sg10
I6
sg11
Vstroke
p339
sg13
I1
sasa(dp340
g2
S'Choline acetyltransferase-positive (ChAT+) neurons within the subventricular zone (SVZ) have been shown to promote neurogenesis after stroke in mice by secreting acetylcholine (ACh); however, the mechanisms remain unclear.\n'
p341
sg4
(lp342
(dp343
g7
I0
sg8
VP28329
p344
sg10
I25
sg11
VCholine acetyltransferase
p345
sg13
I2
sasg19
(lp346
(dp347
g7
I177
sg22
VC0234238
p348
sg10
I3
sg11
VACh
p349
sg13
I1
sa(dp350
g7
I162
sg22
VC0234238
p351
sg10
I13
sg11
Vacetylcholine
p352
sg13
I1
sa(dp353
g7
I134
sg22
VC0038454
p354
sg10
I6
sg11
Vstroke
p355
sg13
I1
sasa(dp356
g2
S'In this study, we assessed whether these ChAT+ neurons also participate in stroke-induced neurogenesis.\n'
p357
sg4
(lp358
sg19
(lp359
(dp360
g7
I75
sg22
VC0038454
p361
sg10
I6
sg11
Vstroke
p362
sg13
I1
sasa(dp363
g2
S'We used a permanent middle cerebral artery occlusion (MCAO) model produced by transcranial electrocoagulation in mice, atropine (muscarinic cholinergic receptor [mAchR] antagonist), and donepezil (acetylcholinesterase inhibitor) to investigate the role of ChAT+ neurons in stroke-induced neurogenesis.\n'
p364
sg4
(lp365
(dp366
g7
I197
sg8
VP12821
p367
sg10
I20
sg11
Vacetylcholinesterase
p368
sg13
I1
sa(dp369
g7
I162
sg8
VP08912
p370
sg10
I5
sg11
VmAchR
p371
sg13
I1
sasg19
(lp372
(dp373
g7
I54
sg22
VC0740391
p374
sg10
I4
sg11
VMCAO
p375
sg13
I1
sa(dp376
g7
I273
sg22
VC0038454
p377
sg10
I6
sg11
Vstroke
p378
sg13
I1
sa(dp379
g7
I20
sg22
VC0740391
p380
sg10
I32
sg11
Vmiddle cerebral artery occlusion
p381
sg13
I4
sasa(dp382
g2
S'We conclude that ChAT+ neurons in the SVZ may participate in stroke-induced neurogenesis, suggesting a new mechanism for neurogenesis after stroke.\n'
p383
sg4
(lp384
sg19
(lp385
(dp386
g7
I61
sg22
VC0038454
p387
sg10
I6
sg11
Vstroke
p388
sg13
I1
sa(dp389
g7
I61
sg22
VC0038454
p390
sg10
I6
sg11
Vstroke
p391
sg13
I1
sasa(dp392
g2
S'Mutations in the genes that encode mucosa-specific keratin-4 and keratin-13 are strongly linked to the manifestation of white sponge nevus.\n'
p393
sg4
(lp394
(dp395
g7
I65
sg8
VP13646
p396
sg10
I10
sg11
Vkeratin-13
p397
sg13
I1
sa(dp398
g7
I51
sg8
VP13646
p399
sg10
I9
sg11
Vkeratin-4
p400
sg13
I1
sasg19
(lp401
(dp402
g7
I120
sg22
VC1721005
p403
sg10
I18
sg11
Vwhite sponge nevus
p404
sg13
I3
sasa(dp405
g2
S'This study involved mutational analysis of the genes encoding keratin-4 and keratin-13 in two Swedish families with white sponge nevus.\n'
p406
sg4
(lp407
(dp408
g7
I62
sg8
VP13646
p409
sg10
I9
sg11
Vkeratin-4
p410
sg13
I1
sa(dp411
g7
I76
sg8
VP13646
p412
sg10
I10
sg11
Vkeratin-13
p413
sg13
I1
sasg19
(lp414
(dp415
g7
I116
sg22
VC1721005
p416
sg10
I18
sg11
Vwhite sponge nevus
p417
sg13
I3
sasa(dp418
g2
S'We describe a novel heterozygous missense mutation in the keratin-4 gene of a Swedish family with white sponge nevus.\n'
p419
sg4
(lp420
(dp421
g7
I58
sg8
VP13646
p422
sg10
I14
sg11
Vkeratin-4 gene
p423
sg13
I2
sasg19
(lp424
(dp425
g7
I98
sg22
VC1721005
p426
sg10
I18
sg11
Vwhite sponge nevus
p427
sg13
I3
sasa(dp428
g2
S'Our results support the notion that mutations in keratin-4 and keratin-13 are the underlying cause of white sponge nevus.\n'
p429
sg4
(lp430
(dp431
g7
I49
sg8
VP13646
p432
sg10
I9
sg11
Vkeratin-4
p433
sg13
I1
sa(dp434
g7
I63
sg8
VP13646
p435
sg10
I10
sg11
Vkeratin-13
p436
sg13
I1
sasg19
(lp437
(dp438
g7
I102
sg22
VC1721005
p439
sg10
I18
sg11
Vwhite sponge nevus
p440
sg13
I3
sasa(dp441
g2
S'The genes associated with WSN include mutant cytokeratin keratin 4 (KRT4) and keratin 13 (KRT13).\n'
p442
sg4
(lp443
(dp444
g7
I78
sg8
VP13646
p445
sg10
I10
sg11
Vkeratin 13
p446
sg13
I2
sa(dp447
g7
I90
sg8
VP02533
p448
sg10
I5
sg11
VKRT13
p449
sg13
I1
sa(dp450
g7
I68
sg8
VP19013
p451
sg10
I4
sg11
VKRT4
p452
sg13
I1
sa(dp453
g7
I38
sg8
g15
sg10
I28
sg11
Vmutant cytokeratin keratin 4
p454
sg13
I4
sa(dp455
g7
I26
sg8
VP13646
p456
sg10
I3
sg11
VWSN
p457
sg13
I1
sasg19
(lp458
(dp459
g7
I26
sg22
VC0796195
p460
sg10
I3
sg11
VWSN
p461
sg13
I1
sa(dp462
g7
I38
sg22
VC0596988
p463
sg10
I6
sg11
Vmutant
p464
sg13
I1
sasa(dp465
g2
S'Keratin 4 (KRT4) and Keratin 13 (KRT13) gene mutations were involved in the WSN.\n'
p466
sg4
(lp467
(dp468
g7
I33
sg8
VP02533
p469
sg10
I5
sg11
VKRT13
p470
sg13
I1
sa(dp471
g7
I21
sg8
VP13646
p472
sg10
I10
sg11
VKeratin 13
p473
sg13
I2
sa(dp474
g7
I11
sg8
VP19013
p475
sg10
I4
sg11
VKRT4
p476
sg13
I1
sa(dp477
g7
I0
sg8
VP13646
p478
sg10
I9
sg11
VKeratin 4
p479
sg13
I2
sasg19
(lp480
(dp481
g7
I76
sg22
VC0796195
p482
sg10
I3
sg11
VWSN
p483
sg13
I1
sasa(dp484
g2
S'This may lead to alterations in integrity and differentiation of the tissue (as suggested by the up-regulation of KRT4 in the cholesteatoma).\n'
p485
sg4
(lp486
(dp487
g7
I114
sg8
VP19013
p488
sg10
I4
sg11
VKRT4
p489
sg13
I1
sasg19
(lp490
(dp491
g7
I126
sg22
VC0008373
p492
sg10
I13
sg11
Vcholesteatoma
p493
sg13
I1
sasa(dp494
g2
S'Immunohistochemical study was carried out in 30 cholesteatoma tissues and 10 retroauricular skins to examine the expression of involucrin, filaggrin, cytokeratin 4, 10 and 16.\n'
p495
sg4
(lp496
(dp497
g7
I127
sg8
VP07476
p498
sg10
I10
sg11
Vinvolucrin
p499
sg13
I1
sa(dp500
g7
I150
sg8
VP13646
p501
sg10
I13
sg11
Vcytokeratin 4
p502
sg13
I2
sa(dp503
g7
I139
sg8
VP20930
p504
sg10
I9
sg11
Vfilaggrin
p505
sg13
I1
sasg19
(lp506
(dp507
g7
I48
sg22
VC0008373
p508
sg10
I13
sg11
Vcholesteatoma
p509
sg13
I1
sasa(dp510
g2
S'Cytokeratin 4 was expressed in basal layer of retroauricular skin, but occasionally expressed in suprabasal layer of cholesteatoma.\n'
p511
sg4
(lp512
(dp513
g7
I0
sg8
VP13646
p514
sg10
I13
sg11
VCytokeratin 4
p515
sg13
I2
sasg19
(lp516
(dp517
g7
I117
sg22
VC0008373
p518
sg10
I13
sg11
Vcholesteatoma
p519
sg13
I1
sasa(dp520
g2
S'Mutations of keratin 4 or 13 gene have been identified as causing WSN.\n'
p521
sg4
(lp522
(dp523
g7
I13
sg8
VP13646
p524
sg10
I20
sg11
Vkeratin 4 or 13 gene
p525
sg13
I5
sasg19
(lp526
(dp527
g7
I66
sg22
VC0796195
p528
sg10
I3
sg11
VWSN
p529
sg13
I1
sasa(dp530
g2
S'The aim of this study is to determine whether keratin 4 or 13 gene mutation was the molecular basis of WSN in a Japanese family.\n'
p531
sg4
(lp532
(dp533
g7
I46
sg8
VP13646
p534
sg10
I20
sg11
Vkeratin 4 or 13 gene
p535
sg13
I5
sasg19
(lp536
(dp537
g7
I103
sg22
VC0796195
p538
sg10
I3
sg11
VWSN
p539
sg13
I1
sasa(dp540
g2
S'The authors identified a mutation of the keratin 4 gene recurrent in a family affected by WSN.\n'
p541
sg4
(lp542
(dp543
g7
I41
sg8
VP13646
p544
sg10
I14
sg11
Vkeratin 4 gene
p545
sg13
I3
sasg19
(lp546
(dp547
g7
I90
sg22
VC0796195
p548
sg10
I3
sg11
VWSN
p549
sg13
I1
sasa(dp550
g2
S'Muscle-specific ablation of the Alfa-thalassemia mental retardation syndrome mutant protein, Atrx, in transgenic mice results in animals with a severely reduced muscle mass at three weeks of age; yet this muscle mass reduction resolves by adult age.\n'
p551
sg4
(lp552
sg19
(lp553
(dp554
g7
I49
sg22
VC0025362
p555
sg10
I18
sg11
Vmental retardation
p556
sg13
I2
sa(dp557
g7
I93
sg22
VC1845055
p558
sg10
I4
sg11
VAtrx
p559
sg13
I1
sa(dp560
g7
I37
sg22
VC0039730
p561
sg10
I11
sg11
Vthalassemia
p562
sg13
I1
sa(dp563
g7
I77
sg22
VC0596988
p564
sg10
I6
sg11
Vmutant
p565
sg13
I1
sa(dp566
g7
I68
sg22
VC0039082
p567
sg10
I8
sg11
Vsyndrome
p568
sg13
I1
sasa(dp569
g2
S'Their diagnoses were compared with a final classification supported by immunohistochemistry (retinoblastoma (RB), death domain- associated protein (DAXX), and Alfa thalassemia/mental retardation syndrome X-linked (ATRX) protein expression), targeted mutation analysis (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets), prior history of G1/G2 histology, and consensus.\n'
p570
sg4
(lp571
(dp572
g7
I93
sg8
g15
sg10
I53
sg11
Vretinoblastoma (RB), death domain- associated protein
p573
sg13
I6
sa(dp574
g7
I148
sg8
g15
sg10
I4
sg11
VDAXX
p575
sg13
I1
sasg19
(lp576
(dp577
g7
I338
sg22
VC0006826
p578
sg10
I6
sg11
VCancer
p579
sg13
I1
sa(dp580
g7
I214
sg22
VC1845055
p581
sg10
I4
sg11
VATRX
p582
sg13
I1
sa(dp583
g7
I93
sg22
VC0035335
p584
sg10
I14
sg11
Vretinoblastoma
p585
sg13
I1
sa(dp586
g7
I159
sg22
VC1845055
p587
sg10
I53
sg11
VAlfa thalassemia/mental retardation syndrome X-linked
p588
sg13
I5
sasa(dp589
g2
S'We also evaluated the protein loss of O-6-methylguanine-DNA methyltransferase (MGMT) and alpha-thalassemia/mental retardation, X-linked (ATRX) during disease recurrence.\n'
p590
sg4
(lp591
(dp592
g7
I38
sg8
VP16455
p593
sg10
I39
sg11
VO-6-methylguanine-DNA methyltransferase
p594
sg13
I2
sa(dp595
g7
I79
sg8
VP16455
p596
sg10
I4
sg11
VMGMT
p597
sg13
I1
sasg19
(lp598
(dp599
g7
I89
sg22
VC0002312
p600
sg10
I17
sg11
Valpha-thalassemia
p601
sg13
I1
sa(dp602
g7
I107
sg22
VC1136249
p603
sg10
I28
sg11
Vmental retardation, X-linked
p604
sg13
I3
sa(dp605
g7
I158
sg22
VC1458156
p606
sg10
I10
sg11
Vrecurrence
p607
sg13
I1
sa(dp608
g7
I137
sg22
VC1845055
p609
sg10
I4
sg11
VATRX
p610
sg13
I1
sasa(dp611
g2
S'These mutations co-occur with other recurrent molecular alterations, including 1p/19q codeletions and tumor suppressor protein 53 (TP53) and alpha thalassemia/mental retardation (ATRX) mutations, which together help to define a molecular signature that aids in the classification of gliomas and helps to better predict clinical behavior.\n'
p612
sg4
(lp613
sg19
(lp614
(dp615
g7
I283
sg22
VC0017638
p616
sg10
I7
sg11
Vgliomas
p617
sg13
I1
sa(dp618
g7
I102
sg22
VC0027651
p619
sg10
I5
sg11
Vtumor
p620
sg13
I1
sa(dp621
g7
I179
sg22
VC1845055
p622
sg10
I4
sg11
VATRX
p623
sg13
I1
sa(dp624
g7
I159
sg22
VC0025362
p625
sg10
I18
sg11
Vmental retardation
p626
sg13
I2
sa(dp627
g7
I141
sg22
VC0002312
p628
sg10
I17
sg11
Valpha thalassemia
p629
sg13
I2
sasa(dp630
g2
S'Diffuse gliomas of WHO grade II and III diagnosed in our institute in the year 2016 were analysed for histological and IHC features, using the markers isocitrate dehydrogenase 1 (IDH1R132H) and Alfa thalassemia/mental retardation syndrome X-linked gene (ATRX).\n'
p631
sg4
(lp632
(dp633
g7
I162
sg8
VP49366
p634
sg10
I15
sg11
Vdehydrogenase 1
p635
sg13
I2
sasg19
(lp636
(dp637
g7
I254
sg22
VC1845055
p638
sg10
I4
sg11
VATRX
p639
sg13
I1
sa(dp640
g7
I194
sg22
VC1845055
p641
sg10
I58
sg11
VAlfa thalassemia/mental retardation syndrome X-linked gene
p642
sg13
I6
sa(dp643
g7
I8
sg22
VC0017638
p644
sg10
I7
sg11
Vgliomas
p645
sg13
I1
sasa(dp646
g2
S'Immunohistochemical (IHC) staining for isocitrate dehydrogenase 1 (IDH1), p53, alpha thalassemia/mental retardation syndrome X-linked (ATRX), and H3K27M, and direct DNA sequencing of IDH1/2, telomerase reverse transcriptase (TERT) promoter, Histone H3.3 (H3F3A) and B-Raf (BRAF) genes was performed.\n'
p647
sg4
(lp648
(dp649
g7
I183
sg8
g15
sg10
I6
sg11
VIDH1/2
p650
sg13
I1
sa(dp651
g7
I39
sg8
VP48735
p652
sg10
I26
sg11
Visocitrate dehydrogenase 1
p653
sg13
I3
sa(dp654
g7
I191
sg8
g15
sg10
I32
sg11
Vtelomerase reverse transcriptase
p655
sg13
I3
sa(dp656
g7
I67
sg8
g15
sg10
I4
sg11
VIDH1
p657
sg13
I1
sa(dp658
g7
I266
sg8
VP62304
p659
sg10
I5
sg11
VB-Raf
p660
sg13
I1
sa(dp661
g7
I273
sg8
VP15056
p662
sg10
I4
sg11
VBRAF
p663
sg13
I1
sa(dp664
g7
I255
sg8
VP84243
p665
sg10
I5
sg11
VH3F3A
p666
sg13
I1
sa(dp667
g7
I241
sg8
VP84243
p668
sg10
I12
sg11
VHistone H3.3
p669
sg13
I2
sa(dp670
g7
I225
sg8
g15
sg10
I4
sg11
VTERT
p671
sg13
I1
sa(dp672
g7
I74
sg8
VP42771
p673
sg10
I3
sg11
Vp53
p674
sg13
I1
sasg19
(lp675
(dp676
g7
I135
sg22
VC1845055
p677
sg10
I4
sg11
VATRX
p678
sg13
I1
sa(dp679
g7
I79
sg22
VC1845055
p680
sg10
I54
sg11
Valpha thalassemia/mental retardation syndrome X-linked
p681
sg13
I5
sasa(dp682
g2
S'We propose that mutations in alpha thalassemia-mental retardation syndrome X-linked (ATRX)/death-domain associated protein (DAXX) prime ALT activation by disrupting telomeric heterochromatin.\n'
p683
sg4
(lp684
(dp685
g7
I124
sg8
g15
sg10
I4
sg11
VDAXX
p686
sg13
I1
sa(dp687
g7
I136
sg8
VP13716
p688
sg10
I3
sg11
VALT
p689
sg13
I1
sa(dp690
g7
I91
sg8
g15
sg10
I31
sg11
Vdeath-domain associated protein
p691
sg13
I3
sasg19
(lp692
(dp693
g7
I85
sg22
VC1845055
p694
sg10
I4
sg11
VATRX
p695
sg13
I1
sa(dp696
g7
I29
sg22
VC1845055
p697
sg10
I54
sg11
Valpha thalassemia-mental retardation syndrome X-linked
p698
sg13
I5
sasa(dp699
g2
S'In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT) protein expression were studied to investigate potential correlations between these molecular characteristics and clinical features or outcomes in neuroblastoma.\n'
p700
sg4
(lp701
(dp702
g7
I229
sg8
g15
sg10
I4
sg11
VTERT
p703
sg13
I1
sa(dp704
g7
I43
sg8
g15
sg10
I3
sg11
VALK
p705
sg13
I1
sa(dp706
g7
I76
sg8
g15
sg10
I11
sg11
VALK protein
p707
sg13
I2
sa(dp708
g7
I195
sg8
g15
sg10
I32
sg11
Vtelomerase reverse transcriptase
p709
sg13
I3
sa(dp710
g7
I15
sg8
g15
sg10
I26
sg11
Vanaplastic lymphoma kinase
p711
sg13
I3
sasg19
(lp712
(dp713
g7
I120
sg22
VC1845055
p714
sg10
I54
sg11
Valpha thalassemia/mental retardation syndrome X-linked
p715
sg13
I5
sa(dp716
g7
I15
sg22
VC1321546
p717
sg10
I19
sg11
Vanaplastic lymphoma
p718
sg13
I2
sa(dp719
g7
I61
sg22
VC1705759
p720
sg10
I13
sg11
Vamplification
p721
sg13
I1
sa(dp722
g7
I176
sg22
VC1845055
p723
sg10
I4
sg11
VATRX
p724
sg13
I1
sa(dp725
g7
I382
sg22
VC0027819
p726
sg10
I13
sg11
Vneuroblastoma
p727
sg13
I1
sasa(dp728
g2
S'Alpha-thalassemia/mental retardation syndrome X-linked (ATRX; OMIM #301040), which is caused by mutations in the ATRX gene, is characterized by alpha-thalassemia, distinct dysmorphic facies, psychomotor development delay and genital abnormalities.\n'
p729
sg4
(lp730
sg19
(lp731
(dp732
g7
I56
sg22
VC1845055
p733
sg10
I4
sg11
VATRX
p734
sg13
I1
sa(dp735
g7
I0
sg22
VC1845055
p736
sg10
I54
sg11
VAlpha-thalassemia/mental retardation syndrome X-linked
p737
sg13
I4
sa(dp738
g7
I56
sg22
VC1845055
p739
sg10
I4
sg11
VATRX
p740
sg13
I1
sa(dp741
g7
I203
sg22
VC0424605
p742
sg10
I17
sg11
Vdevelopment delay
p743
sg13
I2
sa(dp744
g7
I144
sg22
VC0002312
p745
sg10
I17
sg11
Valpha-thalassemia
p746
sg13
I1
sasa(dp747
g2
S'The former retained alpha-thalassaemia/mental retardation X-linked (ATRX) immuno-expression and had absent staining for p53, while the latter had ATRX loss and p53 over-expression.\n'
p748
sg4
(lp749
(dp750
g7
I120
sg8
VP42771
p751
sg10
I3
sg11
Vp53
p752
sg13
I1
sa(dp753
g7
I120
sg8
VP42771
p754
sg10
I3
sg11
Vp53
p755
sg13
I1
sasg19
(lp756
(dp757
g7
I68
sg22
VC1845055
p758
sg10
I4
sg11
VATRX
p759
sg13
I1
sa(dp760
g7
I20
sg22
VC1845055
p761
sg10
I46
sg11
Valpha-thalassaemia/mental retardation X-linked
p762
sg13
I3
sa(dp763
g7
I68
sg22
VC1845055
p764
sg10
I4
sg11
VATRX
p765
sg13
I1
sasa(dp766
g2
S'Although dysregulation of several HOX genes in ovarian cancer has been reported, little is known about HOXC6 expression in epithelial ovarian cancer.\n'
p767
sg4
(lp768
(dp769
g7
I34
sg8
VP52954
p770
sg10
I9
sg11
VHOX genes
p771
sg13
I2
sa(dp772
g7
I103
sg8
VP31260
p773
sg10
I5
sg11
VHOXC6
p774
sg13
I1
sasg19
(lp775
(dp776
g7
I123
sg22
VC0677886
p777
sg10
I25
sg11
Vepithelial ovarian cancer
p778
sg13
I3
sa(dp779
g7
I47
sg22
VC1140680
p780
sg10
I14
sg11
Vovarian cancer
p781
sg13
I2
sasa(dp782
g2
S'In this report, analysis of laser capture microdissected samples determined HOXC6 expression patterns in normal versus malignant serous ovarian carcinoma tissues.\n'
p783
sg4
(lp784
(dp785
g7
I76
sg8
VP31260
p786
sg10
I5
sg11
VHOXC6
p787
sg13
I1
sasg19
(lp788
(dp789
g7
I136
sg22
VC0029925
p790
sg10
I17
sg11
Vovarian carcinoma
p791
sg13
I2
sasa(dp792
g2
S'HOXC6 protein was quantified by ELISA in parallel serum samples and further validated in a larger cohort of serum samples collected from women with and without serous ovarian carcinoma.\n'
p793
sg4
(lp794
(dp795
g7
I0
sg8
VP31260
p796
sg10
I13
sg11
VHOXC6 protein
p797
sg13
I2
sasg19
(lp798
(dp799
g7
I167
sg22
VC0029925
p800
sg10
I17
sg11
Vovarian carcinoma
p801
sg13
I2
sasa(dp802
g2
S'These data demonstrate significant downregulation of HOXC6 in serous ovarian cancer.\n'
p803
sg4
(lp804
(dp805
g7
I53
sg8
VP31260
p806
sg10
I5
sg11
VHOXC6
p807
sg13
I1
sasg19
(lp808
(dp809
g7
I69
sg22
VC1140680
p810
sg10
I14
sg11
Vovarian cancer
p811
sg13
I2
sasa(dp812
g2
S'After quantitative PCR analysis on tissue specimens and urinary sediments, eight promising biomarkers for the urinary detection of prostate cancer were selected (ONECUT2, HOXC4, HOXC6, DLX1, TDRD1, NKAIN1, MS4A8B, PPFIA2).\n'
p813
sg4
(lp814
(dp815
g7
I214
sg8
g15
sg10
I6
sg11
VPPFIA2
p816
sg13
I1
sa(dp817
g7
I191
sg8
g15
sg10
I5
sg11
VTDRD1
p818
sg13
I1
sa(dp819
g7
I178
sg8
VP31260
p820
sg10
I5
sg11
VHOXC6
p821
sg13
I1
sa(dp822
g7
I198
sg8
g15
sg10
I6
sg11
VNKAIN1
p823
sg13
I1
sa(dp824
g7
I185
sg8
VP56177
p825
sg10
I4
sg11
VDLX1
p826
sg13
I1
sa(dp827
g7
I162
sg8
g15
sg10
I7
sg11
VONECUT2
p828
sg13
I1
sa(dp829
g7
I206
sg8
g15
sg10
I6
sg11
VMS4A8B
p830
sg13
I1
sa(dp831
g7
I171
sg8
VP09017
p832
sg10
I5
sg11
VHOXC4
p833
sg13
I1
sasg19
(lp834
(dp835
g7
I131
sg22
VC0600139
p836
sg10
I15
sg11
Vprostate cancer
p837
sg13
I2
sasa(dp838
g2
S'A urinary three-gene panel (HOXC6, TDRD1, and DLX1) had higher accuracy [area under the curve (AUC), 0.77; 95% confidence interval (CI), 0.71-0.83] to predict Gleason score &gt;=7 prostate cancer in biopsies compared with Progensa PCA3 (AUC, 0.68; 95% CI, 0.62-0.75) or sPSA (AUC, 0.72; 95% CI, 0.65-0.78).\n'
p839
sg4
(lp840
(dp841
g7
I46
sg8
VP56177
p842
sg10
I4
sg11
VDLX1
p843
sg13
I1
sa(dp844
g7
I28
sg8
VP31260
p845
sg10
I5
sg11
VHOXC6
p846
sg13
I1
sa(dp847
g7
I35
sg8
g15
sg10
I5
sg11
VTDRD1
p848
sg13
I1
sasg19
(lp849
(dp850
g7
I180
sg22
VC0600139
p851
sg10
I15
sg11
Vprostate cancer
p852
sg13
I2
sasa(dp853
g2
S'The urinary three-gene panel (HOXC6, TDRD1, and DLX1) represents a promising tool to identify patients with aggressive prostate cancer, also in those with low sPSA values.\n'
p854
sg4
(lp855
(dp856
g7
I37
sg8
g15
sg10
I5
sg11
VTDRD1
p857
sg13
I1
sa(dp858
g7
I48
sg8
VP56177
p859
sg10
I4
sg11
VDLX1
p860
sg13
I1
sa(dp861
g7
I30
sg8
VP31260
p862
sg10
I5
sg11
VHOXC6
p863
sg13
I1
sasg19
(lp864
(dp865
g7
I108
sg22
VC0001807
p866
sg10
I10
sg11
Vaggressive
p867
sg13
I1
sa(dp868
g7
I119
sg22
VC0600139
p869
sg10
I15
sg11
Vprostate cancer
p870
sg13
I2
sasa(dp871
g2
S'Overexpression of the classical homeobox transcription factor HOXC6 is frequent in prostate cancers and correlates with adverse clinical parameters.\n'
p872
sg4
(lp873
(dp874
g7
I32
sg8
VP35453
p875
sg10
I35
sg11
Vhomeobox transcription factor HOXC6
p876
sg13
I4
sasg19
(lp877
(dp878
g7
I83
sg22
VC0376358
p879
sg10
I16
sg11
Vprostate cancers
p880
sg13
I2
sasa(dp881
g2
S'Since surprisingly many HOXC6 target genes are downregulated in prostate cancer, it has been posited that oncogenic effects of HOXC6 in prostate cancer may be unmasked by concurrent epigenetic downregulation of target genes exerting tumor suppressive effects.\n'
p882
sg4
(lp883
(dp884
g7
I24
sg8
VP31260
p885
sg10
I18
sg11
VHOXC6 target genes
p886
sg13
I3
sa(dp887
g7
I24
sg8
VP31260
p888
sg10
I5
sg11
VHOXC6
p889
sg13
I1
sasg19
(lp890
(dp891
g7
I233
sg22
VC0027651
p892
sg10
I5
sg11
Vtumor
p893
sg13
I1
sa(dp894
g7
I64
sg22
VC0600139
p895
sg10
I15
sg11
Vprostate cancer
p896
sg13
I2
sa(dp897
g7
I64
sg22
VC0600139
p898
sg10
I15
sg11
Vprostate cancer
p899
sg13
I2
sasa(dp900
g2
S'Our data support the hypothesis that HOXC6 target genes exerting tumor-suppressive effects are epigenetically downregulated in prostate cancer, but DNA methylation appears to follow or bolster rather than to cause their transcriptional inactivation.\n'
p901
sg4
(lp902
(dp903
g7
I37
sg8
VP31260
p904
sg10
I5
sg11
VHOXC6
p905
sg13
I1
sasg19
(lp906
(dp907
g7
I65
sg22
VC0027651
p908
sg10
I5
sg11
Vtumor
p909
sg13
I1
sa(dp910
g7
I236
sg22
VC0544461
p911
sg10
I12
sg11
Vinactivation
p912
sg13
I1
sa(dp913
g7
I127
sg22
VC0600139
p914
sg10
I15
sg11
Vprostate cancer
p915
sg13
I2
sasa(dp916
g2
S"Alzheimer's disease-related genes, such as APOE, A2M, PON2 and MAP4, and cardiovascular disease-associated genes, including COMT, CBS and WNK1, all congregated in a single module.\n"
p917
sg4
(lp918
(dp919
g7
I124
sg8
VP21964
p920
sg10
I4
sg11
VCOMT
p921
sg13
I1
sa(dp922
g7
I63
sg8
VP27816
p923
sg10
I4
sg11
VMAP4
p924
sg13
I1
sa(dp925
g7
I130
sg8
VP07858
p926
sg10
I3
sg11
VCBS
p927
sg13
I1
sa(dp928
g7
I49
sg8
VP01023
p929
sg10
I3
sg11
VA2M
p930
sg13
I1
sa(dp931
g7
I54
sg8
g15
sg10
I4
sg11
VPON2
p932
sg13
I1
sa(dp933
g7
I43
sg8
VP02649
p934
sg10
I4
sg11
VAPOE
p935
sg13
I1
sa(dp936
g7
I138
sg8
g15
sg10
I4
sg11
VWNK1
p937
sg13
I1
sasg19
(lp938
(dp939
g7
I73
sg22
VC0007222
p940
sg10
I22
sg11
Vcardiovascular disease
p941
sg13
I2
sa(dp942
g7
I0
sg22
VC1521724
p943
sg10
I19
sg11
VAlzheimer's disease
p944
sg13
I2
sasa(dp945
g2
S'Histones H3 and H4 were hyperacetylated and H3 was di-methylated at K4 across the LCR, however, the H3 K4 MLL methyltransferase component Ash2L and histone acetyltransferases CBP and p300 occupied essentially only HS2 and the NF-E2 motif in HS2 was required for Ash2L recruitment.\n'
p946
sg4
(lp947
(dp948
g7
I138
sg8
g15
sg10
I5
sg11
VAsh2L
p949
sg13
I1
sa(dp950
g7
I0
sg8
VP62805
p951
sg10
I11
sg11
VHistones H3
p952
sg13
I2
sa(dp953
g7
I148
sg8
VP62805
p954
sg10
I26
sg11
Vhistone acetyltransferases
p955
sg13
I2
sa(dp956
g7
I100
sg8
g15
sg10
I27
sg11
VH3 K4 MLL methyltransferase
p957
sg13
I4
sa(dp958
g7
I183
sg8
g15
sg10
I4
sg11
Vp300
p959
sg13
I1
sa(dp960
g7
I175
sg8
g15
sg10
I3
sg11
VCBP
p961
sg13
I1
sa(dp962
g7
I226
sg8
g15
sg10
I11
sg11
VNF-E2 motif
p963
sg13
I2
sa(dp964
g7
I138
sg8
g15
sg10
I5
sg11
VAsh2L
p965
sg13
I1
sasg19
(lp966
(dp967
g7
I268
sg22
VC0271510
p968
sg10
I11
sg11
Vrecruitment
p969
sg13
I1
sasa(dp970
g2
S'SLC27A2, IL6 and TNFAlfa PBMC expression analysis resulted especially interesting to determine obesity-related n-3 LCPUFA insensitivity.\n'
p971
sg4
(lp972
(dp973
g7
I9
sg8
VP05231
p974
sg10
I3
sg11
VIL6
p975
sg13
I1
sa(dp976
g7
I0
sg8
g15
sg10
I7
sg11
VSLC27A2
p977
sg13
I1
sasg19
(lp978
(dp979
g7
I95
sg22
VC0028754
p980
sg10
I7
sg11
Vobesity
p981
sg13
I1
sasa(dp982
g2
S'Interestingly, SLC27A2 expression correlated negatively with diabetes- and obesity-related traits in a replication cohort of 142 individuals.\n'
p983
sg4
(lp984
(dp985
g7
I15
sg8
g15
sg10
I7
sg11
VSLC27A2
p986
sg13
I1
sasg19
(lp987
(dp988
g7
I61
sg22
VC0011849
p989
sg10
I8
sg11
Vdiabetes
p990
sg13
I1
sa(dp991
g7
I75
sg22
VC0028754
p992
sg10
I7
sg11
Vobesity
p993
sg13
I1
sasa(dp994
g2
S'We found that the ratio of CD8+CD28+/CD8+CD28- T lymphocytes decreased, as did the level of interleukin-7, but not IL-12p40, IL-13, or IL-15, in the blood; however, the ratio increased along with JAK3, STAT6, NFATc2, and GATA3 in the colon of the rats with colitis.\n'
p995
sg4
(lp996
(dp997
g7
I135
sg8
VP40933
p998
sg10
I5
sg11
VIL-15
p999
sg13
I1
sa(dp1000
g7
I92
sg8
VP13232
p1001
sg10
I13
sg11
Vinterleukin-7
p1002
sg13
I1
sa(dp1003
g7
I221
sg8
VP23771
p1004
sg10
I5
sg11
VGATA3
p1005
sg13
I1
sa(dp1006
g7
I209
sg8
g15
sg10
I6
sg11
VNFATc2
p1007
sg13
I1
sa(dp1008
g7
I125
sg8
VP35225
p1009
sg10
I5
sg11
VIL-13
p1010
sg13
I1
sa(dp1011
g7
I27
sg8
VP01732
p1012
sg10
I9
sg11
VCD8+CD28+
p1013
sg13
I1
sa(dp1014
g7
I202
sg8
VP42226
p1015
sg10
I5
sg11
VSTAT6
p1016
sg13
I1
sa(dp1017
g7
I196
sg8
VP52333
p1018
sg10
I4
sg11
VJAK3
p1019
sg13
I1
sa(dp1020
g7
I27
sg8
VP01732
p1021
sg10
I8
sg11
VCD8+CD28
p1022
sg13
I1
sasg19
(lp1023
(dp1024
g7
I257
sg22
VC0009319
p1025
sg10
I7
sg11
Vcolitis
p1026
sg13
I1
sasa(dp1027
g2
S'Here, we used an experimental model of colitis-associated colorectal carcinoma to investigate the contribution of NFATc2 to the promotion of colonic tumors.\n'
p1028
sg4
(lp1029
(dp1030
g7
I114
sg8
g15
sg10
I6
sg11
VNFATc2
p1031
sg13
I1
sasg19
(lp1032
(dp1033
g7
I39
sg22
VC0009319
p1034
sg10
I7
sg11
Vcolitis
p1035
sg13
I1
sa(dp1036
g7
I149
sg22
VC0027651
p1037
sg10
I6
sg11
Vtumors
p1038
sg13
I1
sa(dp1039
g7
I58
sg22
VC0009402
p1040
sg10
I20
sg11
Vcolorectal carcinoma
p1041
sg13
I2
sasa(dp1042
g2
S'Severe colitis in LRRK2-deficient mice was associated with enhanced nuclear localization of NFAT1.\n'
p1043
sg4
(lp1044
(dp1045
g7
I18
sg8
g15
sg10
I5
sg11
VLRRK2
p1046
sg13
I1
sa(dp1047
g7
I92
sg8
g15
sg10
I5
sg11
VNFAT1
p1048
sg13
I1
sasg19
(lp1049
(dp1050
g7
I7
sg22
VC0009319
p1051
sg10
I7
sg11
Vcolitis
p1052
sg13
I1
sasa(dp1053
g2
S'In this study, we have identified a crucial regulatory role of the transcription factor NFATc2 in T cell-dependent experimental colitis.\n'
p1054
sg4
(lp1055
(dp1056
g7
I88
sg8
g15
sg10
I6
sg11
VNFATc2
p1057
sg13
I1
sasg19
(lp1058
(dp1059
g7
I128
sg22
VC0009319
p1060
sg10
I7
sg11
Vcolitis
p1061
sg13
I1
sasa(dp1062
g2
S'Similar to ulcerative colitis in humans, the expression of NFATc2 was up-regulated in oxazolone-induced chronic intestinal inflammation.\n'
p1063
sg4
(lp1064
(dp1065
g7
I59
sg8
g15
sg10
I6
sg11
VNFATc2
p1066
sg13
I1
sasg19
(lp1067
(dp1068
g7
I123
sg22
VC0021368
p1069
sg10
I12
sg11
Vinflammation
p1070
sg13
I1
sa(dp1071
g7
I11
sg22
VC0009324
p1072
sg10
I18
sg11
Vulcerative colitis
p1073
sg13
I2
sasa(dp1074
g2
S'Furthermore, NFATc2 deficiency suppressed colitis induced by oxazolone administration.\n'
p1075
sg4
(lp1076
(dp1077
g7
I13
sg8
g15
sg10
I6
sg11
VNFATc2
p1078
sg13
I1
sasg19
(lp1079
(dp1080
g7
I42
sg22
VC0009319
p1081
sg10
I7
sg11
Vcolitis
p1082
sg13
I1
sasa(dp1083
g2
S'Administration of hyper-IL-6 blocked the protective effects of NFATc2 deficiency in experimental colitis, suggesting that IL-6 signal transduction plays a major pathogenic role in vivo.\n'
p1084
sg4
(lp1085
(dp1086
g7
I63
sg8
g15
sg10
I6
sg11
VNFATc2
p1087
sg13
I1
sa(dp1088
g7
I18
sg8
VP05231
p1089
sg10
I10
sg11
Vhyper-IL-6
p1090
sg13
I1
sa(dp1091
g7
I24
sg8
VP05231
p1092
sg10
I4
sg11
VIL-6
p1093
sg13
I1
sasg19
(lp1094
(dp1095
g7
I97
sg22
VC0009319
p1096
sg10
I7
sg11
Vcolitis
p1097
sg13
I1
sasa(dp1098
g2
S'Collectively, these results define a unique regulatory role for NFATc2 in colitis by controlling mucosal T cell activation in an IL-6-dependent manner.\n'
p1099
sg4
(lp1100
(dp1101
g7
I129
sg8
VP05231
p1102
sg10
I4
sg11
VIL-6
p1103
sg13
I1
sa(dp1104
g7
I64
sg8
g15
sg10
I6
sg11
VNFATc2
p1105
sg13
I1
sasg19
(lp1106
(dp1107
g7
I74
sg22
VC0009319
p1108
sg10
I7
sg11
Vcolitis
p1109
sg13
I1
sasa(dp1110
g2
S'NFATc2 in T cells thus emerges as a potentially new therapeutic target for inflammatory bowel diseases.\n'
p1111
sg4
(lp1112
(dp1113
g7
I0
sg8
g15
sg10
I6
sg11
VNFATc2
p1114
sg13
I1
sasg19
(lp1115
(dp1116
g7
I75
sg22
VC0021390
p1117
sg10
I27
sg11
Vinflammatory bowel diseases
p1118
sg13
I3
sasa(dp1119
g2
S'Relative risk(RR) from Poisson regression ranked dichotomized chylomicronemia risk factors for individuals, and population attributable fractions(PAF) for the community: type 2 diabetes, alcohol intake, obesity, fat intake, hypothyroidism, kidney function, education, sedentary lifestyle, menopause and hormone replacement (women).\n'
p1120
sg4
(lp1121
sg19
(lp1122
(dp1123
g7
I203
sg22
VC0028754
p1124
sg10
I7
sg11
Vobesity
p1125
sg13
I1
sa(dp1126
g7
I224
sg22
VC0020676
p1127
sg10
I14
sg11
Vhypothyroidism
p1128
sg13
I1
sa(dp1129
g7
I146
sg22
VC0235480
p1130
sg10
I3
sg11
VPAF
p1131
sg13
I1
sa(dp1132
g7
I170
sg22
VC0011860
p1133
sg10
I15
sg11
Vtype 2 diabetes
p1134
sg13
I3
sasa(dp1135
g2
S'For the community, top-ranked risk factors in women were menopause (PAF:63%), obesity (PAF:29%), and type 2 diabetes (PAF:15%).\n'
p1136
sg4
(lp1137
(dp1138
g7
I68
sg8
g15
sg10
I3
sg11
VPAF
p1139
sg13
I1
sasg19
(lp1140
(dp1141
g7
I78
sg22
VC0028754
p1142
sg10
I7
sg11
Vobesity
p1143
sg13
I1
sa(dp1144
g7
I68
sg22
VC0235480
p1145
sg10
I3
sg11
VPAF
p1146
sg13
I1
sa(dp1147
g7
I68
sg22
VC0235480
p1148
sg10
I3
sg11
VPAF
p1149
sg13
I1
sa(dp1150
g7
I68
sg22
VC0235480
p1151
sg10
I3
sg11
VPAF
p1152
sg13
I1
sa(dp1153
g7
I101
sg22
VC0011860
p1154
sg10
I15
sg11
Vtype 2 diabetes
p1155
sg13
I3
sasa(dp1156
g2
S'Corresponding top-ranked risk factors in men were obesity (PAF:29%), type 2 diabetes (PAF:6.4%), and sedentary lifestyle (PAF:6.0%).\n'
p1157
sg4
(lp1158
sg19
(lp1159
(dp1160
g7
I59
sg22
VC0235480
p1161
sg10
I3
sg11
VPAF
p1162
sg13
I1
sa(dp1163
g7
I59
sg22
VC0235480
p1164
sg10
I3
sg11
VPAF
p1165
sg13
I1
sa(dp1166
g7
I59
sg22
VC0235480
p1167
sg10
I3
sg11
VPAF
p1168
sg13
I1
sa(dp1169
g7
I69
sg22
VC0011860
p1170
sg10
I15
sg11
Vtype 2 diabetes
p1171
sg13
I3
sa(dp1172
g7
I50
sg22
VC0028754
p1173
sg10
I7
sg11
Vobesity
p1174
sg13
I1
sasa(dp1175
g2
S'In the PAF group, asymptomatic patients were older (asymptomatic vs symptomatic group, 74.1 vs 71.1 years of age; P &lt; .01), more often male (62.1% vs 55.6%; P &lt; .01), and had a higher CHA2DS2-VASc (congestive heart failure, hypertension, age &gt;= 75 years, diabetes mellitus, history of stroke, vascular disease, age 65-74 years, and female sex) score (mean, 3.37 +/- 1.73 vs 2.99 +/- 1.63; P &lt; .01), whereas the prevalence of major co-morbidities and CHA2DS2-VASc scores were comparable in the SAF group.\n'
p1176
sg4
(lp1177
(dp1178
g7
I7
sg8
g15
sg10
I3
sg11
VPAF
p1179
sg13
I1
sasg19
(lp1180
(dp1181
g7
I302
sg22
VC0042373
p1182
sg10
I16
sg11
Vvascular disease
p1183
sg13
I2
sa(dp1184
g7
I230
sg22
VC0020538
p1185
sg10
I12
sg11
Vhypertension
p1186
sg13
I1
sa(dp1187
g7
I264
sg22
VC0011849
p1188
sg10
I17
sg11
Vdiabetes mellitus
p1189
sg13
I2
sa(dp1190
g7
I294
sg22
VC0038454
p1191
sg10
I6
sg11
Vstroke
p1192
sg13
I1
sa(dp1193
g7
I204
sg22
VC0018802
p1194
sg10
I24
sg11
Vcongestive heart failure
p1195
sg13
I3
sa(dp1196
g7
I7
sg22
VC0235480
p1197
sg10
I3
sg11
VPAF
p1198
sg13
I1
sasa(dp1199
g2
S'PAFs of cerebrovascular diseases, hypertension, and diabetes were higher for males than for females; on the other hand, PAFs of orthopedic diseases were higher among females.\n'
p1200
sg4
(lp1201
sg19
(lp1202
(dp1203
g7
I52
sg22
VC0011849
p1204
sg10
I8
sg11
Vdiabetes
p1205
sg13
I1
sa(dp1206
g7
I8
sg22
VC0007820
p1207
sg10
I24
sg11
Vcerebrovascular diseases
p1208
sg13
I2
sa(dp1209
g7
I34
sg22
VC0020538
p1210
sg10
I12
sg11
Vhypertension
p1211
sg13
I1
sasa(dp1212
g2
S'Predicting CVD, in the presence of general adiposity and its mediators, significant positive associations were found for hypercholesterolemia (1.59, 1.36-1.85, PAF 16.69), low HDL-C (1.21, 1.03-1.41, PAF 12.32), diabetes (1.86, 1.57-2.27, PAF 13.87), hypertension (1.79, 1.46-2.19, PAF 21.62) and current smoking (1.61, 1.34-1.94, PAF 7.57).\n'
p1213
sg4
(lp1214
(dp1215
g7
I160
sg8
g15
sg10
I9
sg11
VPAF 16.69
p1216
sg13
I2
sa(dp1217
g7
I176
sg8
VP28845
p1218
sg10
I5
sg11
VHDL-C
p1219
sg13
I1
sa(dp1220
g7
I200
sg8
g15
sg10
I9
sg11
VPAF 12.32
p1221
sg13
I2
sasg19
(lp1222
(dp1223
g7
I160
sg22
VC0235480
p1224
sg10
I3
sg11
VPAF
p1225
sg13
I1
sa(dp1226
g7
I11
sg22
VC0007222
p1227
sg10
I3
sg11
VCVD
p1228
sg13
I1
sa(dp1229
g7
I160
sg22
VC0235480
p1230
sg10
I3
sg11
VPAF
p1231
sg13
I1
sa(dp1232
g7
I160
sg22
VC0235480
p1233
sg10
I3
sg11
VPAF
p1234
sg13
I1
sa(dp1235
g7
I212
sg22
VC0011849
p1236
sg10
I8
sg11
Vdiabetes
p1237
sg13
I1
sa(dp1238
g7
I160
sg22
VC0235480
p1239
sg10
I3
sg11
VPAF
p1240
sg13
I1
sa(dp1241
g7
I160
sg22
VC0235480
p1242
sg10
I3
sg11
VPAF
p1243
sg13
I1
sa(dp1244
g7
I121
sg22
VC0020443
p1245
sg10
I20
sg11
Vhypercholesterolemia
p1246
sg13
I1
sa(dp1247
g7
I43
sg22
VC0028754
p1248
sg10
I9
sg11
Vadiposity
p1249
sg13
I1
sa(dp1250
g7
I251
sg22
VC0020538
p1251
sg10
I12
sg11
Vhypertension
p1252
sg13
I1
sasa(dp1253
g2
S'Predictors including diabetes (2.56, 2.08-3.16, PAF 24.37), hypertension (1.43, 1.11-1.84, PAF 17.13), current smoking (1.75, 1.38-2.22, PAF 7.71), and low education level (1.59, 1.01-2.51, PAF 27.08) were associated with higher risk, however, hypertriglyceridemia (0.83, 0.68-1.01) and being overweight (0.71, 0.58-0.87) were associated with lower risk.\n'
p1254
sg4
(lp1255
(dp1256
g7
I137
sg8
g15
sg10
I8
sg11
VPAF 7.71
p1257
sg13
I2
sasg19
(lp1258
(dp1259
g7
I60
sg22
VC0020538
p1260
sg10
I12
sg11
Vhypertension
p1261
sg13
I1
sa(dp1262
g7
I48
sg22
VC0235480
p1263
sg10
I3
sg11
VPAF
p1264
sg13
I1
sa(dp1265
g7
I48
sg22
VC0235480
p1266
sg10
I3
sg11
VPAF
p1267
sg13
I1
sa(dp1268
g7
I48
sg22
VC0235480
p1269
sg10
I3
sg11
VPAF
p1270
sg13
I1
sa(dp1271
g7
I293
sg22
VC0497406
p1272
sg10
I10
sg11
Voverweight
p1273
sg13
I1
sa(dp1274
g7
I21
sg22
VC0011849
p1275
sg10
I8
sg11
Vdiabetes
p1276
sg13
I1
sa(dp1277
g7
I48
sg22
VC0235480
p1278
sg10
I3
sg11
VPAF
p1279
sg13
I1
sasa(dp1280
g2
S'Although micellar EKC gave baseline separation of a standard mixture of 10 EM, the LOQs using UV detection were not suitable for the assay of the low level estrogens in biological samples.\n'
p1281
sg4
(lp1282
sg19
(lp1283
(dp1284
g7
I18
sg22
VC0014493
p1285
sg10
I3
sg11
VEKC
p1286
sg13
I1
sa(dp1287
g7
I36
sg22
VC0036679
p1288
sg10
I10
sg11
Vseparation
p1289
sg13
I1
sasa(dp1290
g2
S'Recently, six patients with craniosynostosis and Noonan syndrome involving KRAS mutations were described in a review, and a patient with craniosynostosis and Noonan syndrome involving a SHOC2 mutation has also been reported.\n'
p1291
sg4
(lp1292
(dp1293
g7
I75
sg8
VP01116
p1294
sg10
I4
sg11
VKRAS
p1295
sg13
I1
sa(dp1296
g7
I186
sg8
g15
sg10
I14
sg11
VSHOC2 mutation
p1297
sg13
I2
sasg19
(lp1298
(dp1299
g7
I49
sg22
VC0028326
p1300
sg10
I15
sg11
VNoonan syndrome
p1301
sg13
I2
sa(dp1302
g7
I28
sg22
VC0010278
p1303
sg10
I16
sg11
Vcraniosynostosis
p1304
sg13
I1
sa(dp1305
g7
I28
sg22
VC0010278
p1306
sg10
I16
sg11
Vcraniosynostosis
p1307
sg13
I1
sa(dp1308
g7
I49
sg22
VC0028326
p1309
sg10
I15
sg11
VNoonan syndrome
p1310
sg13
I2
sasa(dp1311
g2
S'Noonan syndrome shares clinical features with other rare conditions, including LEOPARD syndrome, cardio-facio-cutaneous syndrome, Noonan-like syndrome with loose anagen hair, and Costello syndrome.\n'
p1312
sg4
(lp1313
sg19
(lp1314
(dp1315
g7
I7
sg22
VC0039082
p1316
sg10
I8
sg11
Vsyndrome
p1317
sg13
I1
sa(dp1318
g7
I120
sg22
VC0028326
p1319
sg10
I16
sg11
Vsyndrome, Noonan
p1320
sg13
I2
sa(dp1321
g7
I0
sg22
VC0028326
p1322
sg10
I15
sg11
VNoonan syndrome
p1323
sg13
I2
sa(dp1324
g7
I79
sg22
VC0175704
p1325
sg10
I16
sg11
VLEOPARD syndrome
p1326
sg13
I2
sa(dp1327
g7
I179
sg22
VC0587248
p1328
sg10
I17
sg11
VCostello syndrome
p1329
sg13
I2
sa(dp1330
g7
I97
sg22
VC1275081
p1331
sg10
I31
sg11
Vcardio-facio-cutaneous syndrome
p1332
sg13
I2
sasa(dp1333
g2
S'We previously reported that the p.Ser2Gly substitution in SHOC2 underlies Mazzanti syndrome, a RASopathy clinically overlapping Noonan syndrome, promoting N-myristoylation and constitutive targeting of the mutant to the plasma membrane.\n'
p1334
sg4
(lp1335
(dp1336
g7
I58
sg8
g15
sg10
I5
sg11
VSHOC2
p1337
sg13
I1
sasg19
(lp1338
(dp1339
g7
I128
sg22
VC0028326
p1340
sg10
I15
sg11
VNoonan syndrome
p1341
sg13
I2
sa(dp1342
g7
I83
sg22
VC0039082
p1343
sg10
I8
sg11
Vsyndrome
p1344
sg13
I1
sa(dp1345
g7
I206
sg22
VC0596988
p1346
sg10
I6
sg11
Vmutant
p1347
sg13
I1
sasa(dp1348
g2
S'Noonan syndrome with loose anagen hair (NS-LAH) is characterized by its distinctive hair anomalies, developmental differences, and structural brain abnormalities and is caused by a single recurrent missense SHOC2 mutation.\n'
p1349
sg4
(lp1350
(dp1351
g7
I207
sg8
g15
sg10
I5
sg11
VSHOC2
p1352
sg13
I1
sasg19
(lp1353
(dp1354
g7
I43
sg22
VC1842839
p1355
sg10
I3
sg11
VLAH
p1356
sg13
I1
sa(dp1357
g7
I0
sg22
VC0028326
p1358
sg10
I15
sg11
VNoonan syndrome
p1359
sg13
I2
sasa(dp1360
g2
S'Most cases of Noonan syndrome (NS) result from mutations in one of the RAS-MAPK signaling genes, including PTPN11, SOS1, KRAS, NRAS, RAF1, BRAF, SHOC2, MEK1 (MAP2K1), and CBL.\n'
p1361
sg4
(lp1362
(dp1363
g7
I75
sg8
VP53779
p1364
sg10
I4
sg11
VMAPK
p1365
sg13
I1
sa(dp1366
g7
I127
sg8
VP01111
p1367
sg10
I4
sg11
VNRAS
p1368
sg13
I1
sa(dp1369
g7
I139
sg8
VP15056
p1370
sg10
I4
sg11
VBRAF
p1371
sg13
I1
sa(dp1372
g7
I152
sg8
g15
sg10
I4
sg11
VMEK1
p1373
sg13
I1
sa(dp1374
g7
I133
sg8
VP04049
p1375
sg10
I4
sg11
VRAF1
p1376
sg13
I1
sa(dp1377
g7
I121
sg8
VP01116
p1378
sg10
I4
sg11
VKRAS
p1379
sg13
I1
sa(dp1380
g7
I107
sg8
g15
sg10
I6
sg11
VPTPN11
p1381
sg13
I1
sa(dp1382
g7
I71
sg8
VP01116
p1383
sg10
I3
sg11
VRAS
p1384
sg13
I1
sa(dp1385
g7
I145
sg8
g15
sg10
I5
sg11
VSHOC2
p1386
sg13
I1
sa(dp1387
g7
I171
sg8
VP22681
p1388
sg10
I3
sg11
VCBL
p1389
sg13
I1
sa(dp1390
g7
I115
sg8
g15
sg10
I4
sg11
VSOS1
p1391
sg13
I1
sa(dp1392
g7
I158
sg8
g15
sg10
I6
sg11
VMAP2K1
p1393
sg13
I1
sasg19
(lp1394
(dp1395
g7
I14
sg22
VC0028326
p1396
sg10
I15
sg11
VNoonan syndrome
p1397
sg13
I2
sa(dp1398
g7
I31
sg22
VC0028326
p1399
sg10
I2
sg11
VNS
p1400
sg13
I1
sasa(dp1401
g2
S'We report a case of progressive radiculopathy in a 52-year-old man with spontaneously occurring cervical epidural hematoma (SCEH).\n'
p1402
sg4
(lp1403
sg19
(lp1404
(dp1405
g7
I114
sg22
VC0018944
p1406
sg10
I8
sg11
Vhematoma
p1407
sg13
I1
sa(dp1408
g7
I32
sg22
VC0700594
p1409
sg10
I13
sg11
Vradiculopathy
p1410
sg13
I1
sasa(dp1411
g2
S'To the best of our knowledge, this is the second reported case in the worldwide literature of pure radiculopathy in a patient with chronic SCEH.\n'
p1412
sg4
(lp1413
sg19
(lp1414
(dp1415
g7
I99
sg22
VC0700594
p1416
sg10
I13
sg11
Vradiculopathy
p1417
sg13
I1
sasa(dp1418
g2
S'Here, we report that the tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton and cancer cell invasion, which is closely associated with cancer progression.\n'
p1419
sg4
(lp1420
(dp1421
g7
I25
sg8
g15
sg10
I34
sg11
Vtankyrase-binding protein TNKS1BP1
p1422
sg13
I3
sasg19
(lp1423
(dp1424
g7
I100
sg22
VC2699153
p1425
sg10
I13
sg11
Vcell invasion
p1426
sg13
I2
sa(dp1427
g7
I148
sg22
VC0178874
p1428
sg10
I18
sg11
Vcancer progression
p1429
sg13
I2
sa(dp1430
g7
I93
sg22
VC0006826
p1431
sg10
I6
sg11
Vcancer
p1432
sg13
I1
sasa(dp1433
g2
S'In clinical samples of pancreatic cancer, TNKS1BP1 expression was reduced in invasive regions.\n'
p1434
sg4
(lp1435
(dp1436
g7
I42
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1437
sg13
I1
sasg19
(lp1438
(dp1439
g7
I23
sg22
VC0235974
p1440
sg10
I17
sg11
Vpancreatic cancer
p1441
sg13
I2
sasa(dp1442
g2
S'We propose that the tankyrase-TNKS1BP1 axis constitutes a posttranslational modulator of cell invasion whose aberration promotes cancer malignancy.\n'
p1443
sg4
(lp1444
(dp1445
g7
I20
sg8
g15
sg10
I9
sg11
Vtankyrase
p1446
sg13
I1
sa(dp1447
g7
I30
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1448
sg13
I1
sasg19
(lp1449
(dp1450
g7
I89
sg22
VC2699153
p1451
sg10
I13
sg11
Vcell invasion
p1452
sg13
I2
sa(dp1453
g7
I129
sg22
VC0006826
p1454
sg10
I6
sg11
Vcancer
p1455
sg13
I1
sa(dp1456
g7
I136
sg22
VC0006826
p1457
sg10
I10
sg11
Vmalignancy
p1458
sg13
I1
sasa(dp1459
g2
S'But whether and how TNKS1BP1 associates with cancer is still not clear.\n'
p1460
sg4
(lp1461
(dp1462
g7
I20
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1463
sg13
I1
sasg19
(lp1464
(dp1465
g7
I45
sg22
VC0006826
p1466
sg10
I6
sg11
Vcancer
p1467
sg13
I1
sasa(dp1468
g2
S'Here, we found that TNKS1BP1 was upregulated in human lung adenocarcinoma (LAC) tissues, and was associated with poor overall survival (OS) in LAC patients.\n'
p1469
sg4
(lp1470
(dp1471
g7
I20
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1472
sg13
I1
sasg19
(lp1473
(dp1474
g7
I75
sg22
VC0152013
p1475
sg10
I3
sg11
VLAC
p1476
sg13
I1
sa(dp1477
g7
I54
sg22
VC0152013
p1478
sg10
I19
sg11
Vlung adenocarcinoma
p1479
sg13
I2
sa(dp1480
g7
I75
sg22
VC0152013
p1481
sg10
I3
sg11
VLAC
p1482
sg13
I1
sasa(dp1483
g2
S'Overall, our study indicates that, in LAC, aberrant expressions of TNKS1BP1 are common events, and overexpression of TNKS1BP1 might affect outcomes of cancer patients to chemotherapy and radiotherapy.\n'
p1484
sg4
(lp1485
(dp1486
g7
I67
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1487
sg13
I1
sa(dp1488
g7
I67
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1489
sg13
I1
sasg19
(lp1490
(dp1491
g7
I151
sg22
VC0006826
p1492
sg10
I6
sg11
Vcancer
p1493
sg13
I1
sasa(dp1494
g2
S'Here we firstly identified that TNKS1BP1 was up-regulated by ionizing radiation (IR) and the depletion of TNKS1BP1 significantly sensitized cancer cells to IR.\n'
p1495
sg4
(lp1496
(dp1497
g7
I32
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1498
sg13
I1
sa(dp1499
g7
I32
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1500
sg13
I1
sasg19
(lp1501
(dp1502
g7
I140
sg22
VC0006826
p1503
sg10
I6
sg11
Vcancer
p1504
sg13
I1
sasa(dp1505
g2
S'TNKS1BP1 is a newly described component of the DNA DSB repair machinery, which provides much more mechanistic evidence for the rationale of developing effective anticancer measures by targeting PARP-1 and DNA-PKcs.\n'
p1506
sg4
(lp1507
(dp1508
g7
I205
sg8
g15
sg10
I8
sg11
VDNA-PKcs
p1509
sg13
I1
sa(dp1510
g7
I0
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1511
sg13
I1
sa(dp1512
g7
I194
sg8
VP09874
p1513
sg10
I6
sg11
VPARP-1
p1514
sg13
I1
sasg19
(lp1515
sa(dp1516
g2
S'In addition, three novel miR-26b targets were identified (TNKS1BP1, CPSF7, COL12A1) and the expression of each in cancer stroma was shown to be significantly associated with breast cancer recurrence.\n'
p1517
sg4
(lp1518
(dp1519
g7
I58
sg8
g15
sg10
I8
sg11
VTNKS1BP1
p1520
sg13
I1
sa(dp1521
g7
I25
sg8
g15
sg10
I15
sg11
VmiR-26b targets
p1522
sg13
I2
sa(dp1523
g7
I68
sg8
g15
sg10
I5
sg11
VCPSF7
p1524
sg13
I1
sa(dp1525
g7
I75
sg8
g15
sg10
I7
sg11
VCOL12A1
p1526
sg13
I1
sasg19
(lp1527
(dp1528
g7
I181
sg22
VC0920420
p1529
sg10
I17
sg11
Vcancer recurrence
p1530
sg13
I2
sa(dp1531
g7
I114
sg22
VC0006826
p1532
sg10
I6
sg11
Vcancer
p1533
sg13
I1
sasa(dp1534
g2
S'An increasing number of epileptic syndromes belongs to this group of rare disorders: Autosomal dominant nocturnal frontal lobe epilepsy is caused by mutations in a neuronal nicotinic acetylcholine receptor (affected genes: CHRNA4, CHRNB2), benign familial neonatal convulsions by mutations in potassium channels constituting the M-current (KCNQ2, KCNQ3), generalized epilepsy with febrile seizures plus by mutations in subunits of the voltage-gated sodium channel or the GABA(A) receptor (SCN1B, SCN1A, GABRG2), and episodic ataxia type 1-which is associated with epilepsy in a few patients--by mutations within another voltage-gated potassium channel (KCNA1).\n'
p1535
sg4
(lp1536
(dp1537
g7
I347
sg8
g15
sg10
I5
sg11
VKCNQ3
p1538
sg13
I1
sa(dp1539
g7
I223
sg8
VP43681
p1540
sg10
I6
sg11
VCHRNA4
p1541
sg13
I1
sa(dp1542
g7
I653
sg8
g15
sg10
I5
sg11
VKCNA1
p1543
sg13
I1
sa(dp1544
g7
I489
sg8
g15
sg10
I5
sg11
VSCN1B
p1545
sg13
I1
sa(dp1546
g7
I496
sg8
VP35498
p1547
sg10
I5
sg11
VSCN1A
p1548
sg13
I1
sa(dp1549
g7
I340
sg8
g15
sg10
I5
sg11
VKCNQ2
p1550
sg13
I1
sa(dp1551
g7
I173
sg8
g15
sg10
I32
sg11
Vnicotinic acetylcholine receptor
p1552
sg13
I3
sa(dp1553
g7
I231
sg8
VP17787
p1554
sg10
I6
sg11
VCHRNB2
p1555
sg13
I1
sa(dp1556
g7
I471
sg8
VP18507
p1557
sg10
I16
sg11
VGABA(A) receptor
p1558
sg13
I2
sa(dp1559
g7
I503
sg8
VP18507
p1560
sg10
I6
sg11
VGABRG2
p1561
sg13
I1
sasg19
(lp1562
(dp1563
g7
I355
sg22
VC0014548
p1564
sg10
I20
sg11
Vgeneralized epilepsy
p1565
sg13
I2
sa(dp1566
g7
I34
sg22
VC0039082
p1567
sg10
I9
sg11
Vsyndromes
p1568
sg13
I1
sa(dp1569
g7
I114
sg22
VC0085541
p1570
sg10
I21
sg11
Vfrontal lobe epilepsy
p1571
sg13
I3
sa(dp1572
g7
I240
sg22
VC0220669
p1573
sg10
I36
sg11
Vbenign familial neonatal convulsions
p1574
sg13
I4
sa(dp1575
g7
I381
sg22
VC0009952
p1576
sg10
I16
sg11
Vfebrile seizures
p1577
sg13
I2
sa(dp1578
g7
I127
sg22
VC0014544
p1579
sg10
I8
sg11
Vepilepsy
p1580
sg13
I1
sa(dp1581
g7
I24
sg22
VC0014544
p1582
sg10
I9
sg11
Vepileptic
p1583
sg13
I1
sa(dp1584
g7
I516
sg22
VC1719788
p1585
sg10
I22
sg11
Vepisodic ataxia type 1
p1586
sg13
I4
sasa(dp1587
g2
S'In the present study, we characterized the hormonal regulation of proliferation of two immortalized cell lines, BLT-1, originating from a Leydig cell tumor, and NT-1, originating from a granulosa cell tumor.\n'
p1588
sg4
(lp1589
(dp1590
g7
I112
sg8
g15
sg10
I5
sg11
VBLT-1
p1591
sg13
I1
sasg19
(lp1592
(dp1593
g7
I66
sg22
VC0334094
p1594
sg10
I13
sg11
Vproliferation
p1595
sg13
I1
sa(dp1596
g7
I186
sg22
VC0018206
p1597
sg10
I20
sg11
Vgranulosa cell tumor
p1598
sg13
I3
sa(dp1599
g7
I138
sg22
VC0023601
p1600
sg10
I17
sg11
VLeydig cell tumor
p1601
sg13
I3
sasa(dp1602
g2
S"We suggest screening for MYO1E and other non-COL4 'podocyte gene' mutations in XLAS when clinical nephropathy is more severe than expected for an individual's age and sex.\n"
p1603
sg4
(lp1604
(dp1605
g7
I25
sg8
g15
sg10
I5
sg11
VMYO1E
p1606
sg13
I1
sasg19
(lp1607
(dp1608
g7
I79
sg22
VC0265216
p1609
sg10
I4
sg11
VXLAS
p1610
sg13
I1
sa(dp1611
g7
I98
sg22
VC0022658
p1612
sg10
I11
sg11
Vnephropathy
p1613
sg13
I1
sasa(dp1614
g2
S'Activation of the transient receptor potential melastatin 2 (TRPM2) channel occurs during the response to oxidative stress under physiological conditions as well as in pathological processes such as ischemia and diabetes.\n'
p1615
sg4
(lp1616
(dp1617
g7
I18
sg8
VP10909
p1618
sg10
I41
sg11
Vtransient receptor potential melastatin 2
p1619
sg13
I5
sa(dp1620
g7
I61
sg8
VP10909
p1621
sg10
I5
sg11
VTRPM2
p1622
sg13
I1
sasg19
(lp1623
(dp1624
g7
I212
sg22
VC0011849
p1625
sg10
I8
sg11
Vdiabetes
p1626
sg13
I1
sa(dp1627
g7
I168
sg22
VC0030660
p1628
sg10
I22
sg11
Vpathological processes
p1629
sg13
I2
sa(dp1630
g7
I106
sg22
VC0242606
p1631
sg10
I16
sg11
Voxidative stress
p1632
sg13
I2
sa(dp1633
g7
I199
sg22
VC0022116
p1634
sg10
I8
sg11
Vischemia
p1635
sg13
I1
sasa(dp1636
g2
S'Otherwise, a fasting plasma glucose level &gt; or = 126 mg/dL or a 2-hour plasma glucose level &gt; or = 200 mg/dL after an oral glucose challenge of 75 g on 2 occasions is sufficient evidence upon which to diagnose diabetes mellitus.\n'
p1637
sg4
(lp1638
sg19
(lp1639
(dp1640
g7
I216
sg22
VC0011849
p1641
sg10
I17
sg11
Vdiabetes mellitus
p1642
sg13
I2
sasa(dp1643
g2
S'MecTHaR TepanNR HecTepoNAHblMN npoTNBoBocnanNTenbHblMN npenapaTaMN N cNcTeMHoe ETNonorN4ecKoe ne4eHNe npN NHTpaoKynRpHoM BocnaneHNN Ha ooHe HZO no3BonNT yMeHbwNTb pNcK pa3BNTNR TRXenblx nocneAcTBNN peaKTNBamyNN BB3 N N3beXaTb pemyNANBoB 3aboneBaHNR BnocneAcTBNN.\n'
p1644
sg4
(lp1645
(dp1646
g7
I0
sg8
g15
sg10
I261
sg11
VMecTHaR TepanNR HecTepoNAHblMN npoTNBoBocnanNTenbHblMN npenapaTaMN N cNcTeMHoe ETNonorN4ecKoe ne4eHNe npN NHTpaoKynRpHoM BocnaneHNN Ha ooHe HZO no3BonNT yMeHbwNTb pNcK pa3BNTNR TRXenblx nocneAcTBNN peaKTNBamyNN BB3 N N3beXaTb pemyNANBoB 3aboneBaHNR BnocneAcTBNN
p1647
sg13
I28
sasg19
(lp1648
sa(dp1649
g2
S'MecTHaR TepanNR HecTepoNAHblMN npoTNBoBocnanNTenbHblMN npenapaTaMN N cNcTeMHoe ETNonorN4ecKoe ne4eHNe npN NHTpaoKynRpHoM BocnaneHNN Ha ooHe HZO no3BonNT yMeHbwNTb pNcK pa3BNTNR TRXenblx nocneAcTBNN peaKTNBamyNN BB3 N N3beXaTb pemyNANBoB 3aboneBaHNR BnocneAcTBNN.\n'
p1650
sg4
(lp1651
(dp1652
g7
I0
sg8
g15
sg10
I261
sg11
VMecTHaR TepanNR HecTepoNAHblMN npoTNBoBocnanNTenbHblMN npenapaTaMN N cNcTeMHoe ETNonorN4ecKoe ne4eHNe npN NHTpaoKynRpHoM BocnaneHNN Ha ooHe HZO no3BonNT yMeHbwNTb pNcK pa3BNTNR TRXenblx nocneAcTBNN peaKTNBamyNN BB3 N N3beXaTb pemyNANBoB 3aboneBaHNR BnocneAcTBNN
p1653
sg13
I28
sasg19
(lp1654
sa(dp1655
g2
S'y namyNeHToB, nony4aBwNx NHrNbNTopbl aHrNoTeH3NHnpeBpawahwero oepMeHTa, pNcK rocnNTanN3amyNN B Te4eHNe 6 Mec npN Ao3NpoBKe 25% N MeHee oT TepaneBTN4ecKoN cocTaBnRn 21,18% (oTHoweHNe waHcoB - OW 1,41 npN 95% AoBepNTenbHoM NHTepBane - ON oT 1,13 Ao 1,76), npN Ao3NpoBKe 50% oT TepaneBTN4ecKoN - 16% (OW 0,71 npN 95% ON oT 0,56 Ao 0,88), npN Ao3NpoBKe 100% TepaneBTN4ecKoN - 34% (OW 0,51 npN 95% ON oT 0,43 Ao 0,60).\n'
p1656
sg4
(lp1657
(dp1658
g7
I196
sg8
g15
sg10
I52
sg11
V41 npN 95% AoBepNTenbHoM NHTepBane - ON oT 1,13 Ao 1
p1659
sg13
I11
sa(dp1660
g7
I72
sg8
g15
sg10
I36
sg11
VpNcK rocnNTanN3amyNN B Te4eHNe 6 Mec
p1661
sg13
I6
sa(dp1662
g7
I109
sg8
g15
sg10
I13
sg11
VnpN Ao3NpoBKe
p1663
sg13
I2
sasg19
(lp1664
sa(dp1665
g2
S"Control cases of histologic mimics (biphasic synovial sarcoma, leiomyoma, leiomyosarcoma, desmoid-type fibromatosis, EWSR1-FLI1-positive Ewing sarcoma, Wilms' tumor, gastrointestinal stromal tumor, plexiform fibromyxoma, Sonic hedgehog-type medulloblastomas, and normal gastric mucosa and muscularis propria were also analyzed.\n"
p1666
sg4
(lp1667
(dp1668
g7
I123
sg8
g15
sg10
I4
sg11
VFLI1
p1669
sg13
I1
sa(dp1670
g7
I117
sg8
g15
sg10
I5
sg11
VEWSR1
p1671
sg13
I1
sasg19
(lp1672
(dp1673
g7
I241
sg22
VC0025149
p1674
sg10
I16
sg11
Vmedulloblastomas
p1675
sg13
I1
sa(dp1676
g7
I137
sg22
VC0553580
p1677
sg10
I13
sg11
VEwing sarcoma
p1678
sg13
I2
sa(dp1679
g7
I36
sg22
VC0334507
p1680
sg10
I25
sg11
Vbiphasic synovial sarcoma
p1681
sg13
I3
sa(dp1682
g7
I159
sg22
VC0027651
p1683
sg10
I5
sg11
Vtumor
p1684
sg13
I1
sa(dp1685
g7
I159
sg22
VC0238198
p1686
sg10
I31
sg11
Vtumor, gastrointestinal stromal
p1687
sg13
I3
sa(dp1688
g7
I90
sg22
VC0079218
p1689
sg10
I25
sg11
Vdesmoid-type fibromatosis
p1690
sg13
I2
sa(dp1691
g7
I208
sg22
VC0205766
p1692
sg10
I11
sg11
Vfibromyxoma
p1693
sg13
I1
sa(dp1694
g7
I63
sg22
VC0023267
p1695
sg10
I9
sg11
Vleiomyoma
p1696
sg13
I1
sa(dp1697
g7
I74
sg22
VC0023269
p1698
sg10
I14
sg11
Vleiomyosarcoma
p1699
sg13
I1
sasa(dp1700
g2
S'In light of the unusual findings in this case as well as the proximity of the EWSR1 locus and SMARCB1 locus on chromosome 22 and frequent CD99 staining in both tumors, we examined 16 ES cases and 17 ATRT, renal rhabdoid tumor (RRT), and extrarenal rhabdoid tumor (ERRT) cases for CD99 and INI1 staining and for EWSR1 rearrangement.\n'
p1701
sg4
(lp1702
(dp1703
g7
I138
sg8
VP14209
p1704
sg10
I4
sg11
VCD99
p1705
sg13
I1
sa(dp1706
g7
I78
sg8
g15
sg10
I5
sg11
VEWSR1
p1707
sg13
I1
sa(dp1708
g7
I94
sg8
g15
sg10
I13
sg11
VSMARCB1 locus
p1709
sg13
I2
sa(dp1710
g7
I138
sg8
VP14209
p1711
sg10
I4
sg11
VCD99
p1712
sg13
I1
sa(dp1713
g7
I289
sg8
g15
sg10
I4
sg11
VINI1
p1714
sg13
I1
sa(dp1715
g7
I78
sg8
g15
sg10
I11
sg11
VEWSR1 locus
p1716
sg13
I2
sasg19
(lp1717
(dp1718
g7
I227
sg22
VC0854917
p1719
sg10
I3
sg11
VRRT
p1720
sg13
I1
sa(dp1721
g7
I237
sg22
VC1304517
p1722
sg10
I25
sg11
Vextrarenal rhabdoid tumor
p1723
sg13
I3
sa(dp1724
g7
I264
sg22
VC1304517
p1725
sg10
I4
sg11
VERRT
p1726
sg13
I1
sa(dp1727
g7
I160
sg22
VC0027651
p1728
sg10
I6
sg11
Vtumors
p1729
sg13
I1
sa(dp1730
g7
I205
sg22
VC0854917
p1731
sg10
I20
sg11
Vrenal rhabdoid tumor
p1732
sg13
I3
sasa(dp1733
g2
S'In light of the unusual findings in this case as well as the proximity of the EWSR1 locus and SMARCB1 locus on chromosome 22 and frequent CD99 staining in both tumors, we examined 16 ES cases and 17 ATRT, renal rhabdoid tumor (RRT), and extrarenal rhabdoid tumor (ERRT) cases for CD99 and INI1 staining and for EWSR1 rearrangement.\n'
p1734
sg4
(lp1735
(dp1736
g7
I138
sg8
VP14209
p1737
sg10
I4
sg11
VCD99
p1738
sg13
I1
sa(dp1739
g7
I78
sg8
g15
sg10
I5
sg11
VEWSR1
p1740
sg13
I1
sa(dp1741
g7
I94
sg8
g15
sg10
I13
sg11
VSMARCB1 locus
p1742
sg13
I2
sa(dp1743
g7
I138
sg8
VP14209
p1744
sg10
I4
sg11
VCD99
p1745
sg13
I1
sa(dp1746
g7
I289
sg8
g15
sg10
I4
sg11
VINI1
p1747
sg13
I1
sa(dp1748
g7
I78
sg8
g15
sg10
I11
sg11
VEWSR1 locus
p1749
sg13
I2
sasg19
(lp1750
(dp1751
g7
I227
sg22
VC0854917
p1752
sg10
I3
sg11
VRRT
p1753
sg13
I1
sa(dp1754
g7
I237
sg22
VC1304517
p1755
sg10
I25
sg11
Vextrarenal rhabdoid tumor
p1756
sg13
I3
sa(dp1757
g7
I264
sg22
VC1304517
p1758
sg10
I4
sg11
VERRT
p1759
sg13
I1
sa(dp1760
g7
I160
sg22
VC0027651
p1761
sg10
I6
sg11
Vtumors
p1762
sg13
I1
sa(dp1763
g7
I205
sg22
VC0854917
p1764
sg10
I20
sg11
Vrenal rhabdoid tumor
p1765
sg13
I3
sasa(dp1766
g2
S'This report should increase awareness of pulmonary sarcoidosis development in patient treated with tumor necrosis factor-alpha blocking agent, etanercept.\n'
p1767
sg4
(lp1768
(dp1769
g7
I99
sg8
VP01375
p1770
sg10
I27
sg11
Vtumor necrosis factor-alpha
p1771
sg13
I3
sasg19
(lp1772
(dp1773
g7
I99
sg22
VC0333516
p1774
sg10
I14
sg11
Vtumor necrosis
p1775
sg13
I2
sa(dp1776
g7
I127
sg22
VC0233660
p1777
sg10
I8
sg11
Vblocking
p1778
sg13
I1
sa(dp1779
g7
I41
sg22
VC0036205
p1780
sg10
I21
sg11
Vpulmonary sarcoidosis
p1781
sg13
I2
sasa(dp1782
g2
S'We report on a 72 year-old woman with long-standing rheumatoid arthritis diagnosed as granulomatosis due to pulmonary sarcoidosis after 49 months of treatment with etanercept.\n'
p1783
sg4
(lp1784
sg19
(lp1785
(dp1786
g7
I52
sg22
VC0003873
p1787
sg10
I20
sg11
Vrheumatoid arthritis
p1788
sg13
I2
sa(dp1789
g7
I108
sg22
VC0036205
p1790
sg10
I21
sg11
Vpulmonary sarcoidosis
p1791
sg13
I2
sa(dp1792
g7
I86
sg22
VC0521173
p1793
sg10
I14
sg11
Vgranulomatosis
p1794
sg13
I1
sasa(dp1795
g2
S'We present a case of probable pulmonary sarcoidosis associated with the use of etanercept for psoriatic arthritis.\n'
p1796
sg4
(lp1797
sg19
(lp1798
(dp1799
g7
I94
sg22
VC0003872
p1800
sg10
I19
sg11
Vpsoriatic arthritis
p1801
sg13
I2
sa(dp1802
g7
I30
sg22
VC0036205
p1803
sg10
I21
sg11
Vpulmonary sarcoidosis
p1804
sg13
I2
sasa(dp1805
g2
S'Other cases of etanercept-induced granulomas and skin sarcoidosis were recently published in the medical literature, but we found only one case that involved lung sarcoidosis during etanercept therapy.\n'
p1806
sg4
(lp1807
sg19
(lp1808
(dp1809
g7
I34
sg22
VC0018188
p1810
sg10
I10
sg11
Vgranulomas
p1811
sg13
I1
sa(dp1812
g7
I49
sg22
VC0036203
p1813
sg10
I16
sg11
Vskin sarcoidosis
p1814
sg13
I2
sa(dp1815
g7
I158
sg22
VC0036205
p1816
sg10
I16
sg11
Vlung sarcoidosis
p1817
sg13
I2
sasa(dp1818
g2
S'The C-4 2-pyridyl compounds (enantiomers) constitute a novel type of 1,4-dihydropyridine calcium channel modulator that could provide a new drug design concept directed toward the treatment of congestive heart failure, and for use as probes to study the structure-function relationships of calcium channels.\n'
p1819
sg4
(lp1820
sg19
(lp1821
(dp1822
g7
I193
sg22
VC0018802
p1823
sg10
I24
sg11
Vcongestive heart failure
p1824
sg13
I3
sasa(dp1825
g2
S'However, whether miR-300 could regulate the DNA damage responses induced by extrinsic genotoxic stress in human lung cancer and the underlying mechanism remain unknown.\n'
p1826
sg4
(lp1827
(dp1828
g7
I17
sg8
g15
sg10
I7
sg11
VmiR-300
p1829
sg13
I1
sasg19
(lp1830
(dp1831
g7
I86
sg22
VC1257899
p1832
sg10
I16
sg11
Vgenotoxic stress
p1833
sg13
I2
sa(dp1834
g7
I112
sg22
VC0684249
p1835
sg10
I11
sg11
Vlung cancer
p1836
sg13
I2
sa(dp1837
g7
I44
sg22
VC0012860
p1838
sg10
I10
sg11
VDNA damage
p1839
sg13
I2
sasa(dp1840
g2
S'In this study, the expression of miR-300 was examined in lung cancer cells treated with IR, and the effects of miR-300 on DNA damage repair, cell cycle arrest, apoptosis and senescence induced by IR were investigated.\n'
p1841
sg4
(lp1842
(dp1843
g7
I33
sg8
g15
sg10
I7
sg11
VmiR-300
p1844
sg13
I1
sa(dp1845
g7
I33
sg8
g15
sg10
I7
sg11
VmiR-300
p1846
sg13
I1
sasg19
(lp1847
(dp1848
g7
I122
sg22
VC0012860
p1849
sg10
I10
sg11
VDNA damage
p1850
sg13
I2
sa(dp1851
g7
I57
sg22
VC0684249
p1852
sg10
I11
sg11
Vlung cancer
p1853
sg13
I2
sasa(dp1854
g2
S'Flow cytomertry analysis and colony formation assay showed that miR-300 desensitized lung cancer cells to IR by suppressing p53-dependent G2 cell cycle arrest, apoptosis and senescence.\n'
p1855
sg4
(lp1856
(dp1857
g7
I124
sg8
VP42771
p1858
sg10
I3
sg11
Vp53
p1859
sg13
I1
sa(dp1860
g7
I64
sg8
g15
sg10
I7
sg11
VmiR-300
p1861
sg13
I1
sasg19
(lp1862
(dp1863
g7
I85
sg22
VC0684249
p1864
sg10
I11
sg11
Vlung cancer
p1865
sg13
I2
sasa(dp1866
g2
S'These data demonstrate that miR-300 regulates the cellular sensitivity to IR through targeting p53 and apaf1 in lung cancer cells.\n'
p1867
sg4
(lp1868
(dp1869
g7
I95
sg8
VP42771
p1870
sg10
I3
sg11
Vp53
p1871
sg13
I1
sa(dp1872
g7
I28
sg8
g15
sg10
I7
sg11
VmiR-300
p1873
sg13
I1
sa(dp1874
g7
I74
sg8
VP06213
p1875
sg10
I2
sg11
VIR
p1876
sg13
I1
sasg19
(lp1877
(dp1878
g7
I112
sg22
VC0684249
p1879
sg10
I11
sg11
Vlung cancer
p1880
sg13
I2
sasa(dp1881
g2
S'The study aims to verify the hypothesis that up-regulation of microRNA-300 (miR-300) targeting CUL4B promotes apoptosis and suppresses proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of pancreatic cancer cells by regulating the Wnt/Beta-catenin signaling pathway.\n'
p1882
sg4
(lp1883
(dp1884
g7
I62
sg8
g15
sg10
I12
sg11
VmicroRNA-300
p1885
sg13
I1
sa(dp1886
g7
I76
sg8
g15
sg10
I7
sg11
VmiR-300
p1887
sg13
I1
sasg19
(lp1888
(dp1889
g7
I198
sg22
VC0599156
p1890
sg10
I10
sg11
Vtransition
p1891
sg13
I1
sa(dp1892
g7
I135
sg22
VC0334094
p1893
sg10
I13
sg11
Vproliferation
p1894
sg13
I1
sa(dp1895
g7
I161
sg22
VC2699153
p1896
sg10
I8
sg11
Vinvasion
p1897
sg13
I1
sa(dp1898
g7
I218
sg22
VC0235974
p1899
sg10
I17
sg11
Vpancreatic cancer
p1900
sg13
I2
sasa(dp1901
g2
S'Pancreatic cancer tissues showed increased CUL4B expression but decreased miR-300 expression.\n'
p1902
sg4
(lp1903
sg19
(lp1904
(dp1905
g7
I0
sg22
VC0235974
p1906
sg10
I17
sg11
VPancreatic cancer
p1907
sg13
I2
sasa(dp1908
g2
S'Our study concludes that lowly expressed miR-300 may contribute to highly expressed CUL4B activating the Wnt/Beta-catenin signaling pathway and further stimulating EMT, thus promoting proliferation and migration but suppressing apoptosis of pancreatic cancer cells.\n'
p1909
sg4
(lp1910
(dp1911
g7
I164
sg8
g15
sg10
I3
sg11
VEMT
p1912
sg13
I1
sa(dp1913
g7
I41
sg8
g15
sg10
I7
sg11
VmiR-300
p1914
sg13
I1
sasg19
(lp1915
(dp1916
g7
I241
sg22
VC0235974
p1917
sg10
I17
sg11
Vpancreatic cancer
p1918
sg13
I2
sa(dp1919
g7
I184
sg22
VC0334094
p1920
sg10
I13
sg11
Vproliferation
p1921
sg13
I1
sasa(dp1922
g2
S'miR-300 has been demonstrated to play an important role in the progression of several tumors, but its role in tumorigenesis of laryngeal squamous cell carcinoma (LSCC) is still unclear.\n'
p1923
sg4
(lp1924
(dp1925
g7
I0
sg8
g15
sg10
I7
sg11
VmiR-300
p1926
sg13
I1
sasg19
(lp1927
(dp1928
g7
I110
sg22
VC0007621
p1929
sg10
I13
sg11
Vtumorigenesis
p1930
sg13
I1
sa(dp1931
g7
I127
sg22
VC0280324
p1932
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p1933
sg13
I4
sa(dp1934
g7
I86
sg22
VC0027651
p1935
sg10
I6
sg11
Vtumors
p1936
sg13
I1
sasa(dp1937
g2
S'The purpose of this study was to explore miR-300 expression in LSCC patients and analyze its association with clinicopathological factors and prognosis.\n'
p1938
sg4
(lp1939
(dp1940
g7
I41
sg8
g15
sg10
I7
sg11
VmiR-300
p1941
sg13
I1
sasg19
(lp1942
sa(dp1943
g2
S'In the present study, we measured the expression level of miR-300 in LSCC tissues by RT-PCR.\n'
p1944
sg4
(lp1945
(dp1946
g7
I58
sg8
g15
sg10
I7
sg11
VmiR-300
p1947
sg13
I1
sasg19
(lp1948
sa(dp1949
g2
S'miR-300 expression was significantly increased in LSCC tissues compared with that in adjacent non-cancerous tissues (p &lt; 0.01).\n'
p1950
sg4
(lp1951
(dp1952
g7
I0
sg8
g15
sg10
I7
sg11
VmiR-300
p1953
sg13
I1
sasg19
(lp1954
sa(dp1955
g2
S'More importantly, Kaplan-Meier analysis showed that LSCC patients with low miR-300 expression tended to have shorter overall survival (p &lt; 0.001).\n'
p1956
sg4
(lp1957
(dp1958
g7
I75
sg8
g15
sg10
I7
sg11
VmiR-300
p1959
sg13
I1
sasg19
(lp1960
sa(dp1961
g2
S'Finally, multivariate analysis revealed that miR-300 expression was an independent prognostic factor for LSCC patients.\n'
p1962
sg4
(lp1963
(dp1964
g7
I45
sg8
g15
sg10
I7
sg11
VmiR-300
p1965
sg13
I1
sasg19
(lp1966
sa(dp1967
g2
S'Our results pointed to miR-300 as a powerful prognostic marker in LSCC and as a novel target for tumor-suppressive therapy.\n'
p1968
sg4
(lp1969
(dp1970
g7
I23
sg8
g15
sg10
I7
sg11
VmiR-300
p1971
sg13
I1
sasg19
(lp1972
(dp1973
g7
I97
sg22
VC0027651
p1974
sg10
I5
sg11
Vtumor
p1975
sg13
I1
sasa(dp1976
g2
S'Furthermore, we identified that miR-300, which has been reported as a suppressor in other types of cancer, is negatively regulated by TUG1.\n'
p1977
sg4
(lp1978
(dp1979
g7
I32
sg8
g15
sg10
I7
sg11
VmiR-300
p1980
sg13
I1
sasg19
(lp1981
(dp1982
g7
I99
sg22
VC0006826
p1983
sg10
I6
sg11
Vcancer
p1984
sg13
I1
sasa(dp1985
g2
S'In the present study, we found that miR-300 and p53 were significantly increased in colorectal cancer (CRC) tissues when compared with levels noted in adjacent colorectal tissues.\n'
p1986
sg4
(lp1987
(dp1988
g7
I48
sg8
VP42771
p1989
sg10
I3
sg11
Vp53
p1990
sg13
I1
sa(dp1991
g7
I36
sg8
g15
sg10
I7
sg11
VmiR-300
p1992
sg13
I1
sasg19
(lp1993
(dp1994
g7
I84
sg22
VC1527249
p1995
sg10
I17
sg11
Vcolorectal cancer
p1996
sg13
I2
sa(dp1997
g7
I103
sg22
VC1527249
p1998
sg10
I3
sg11
VCRC
p1999
sg13
I1
sasa(dp2000
g2
S'In this study, we showed that miR-300 expression was downregulated in LSCC tissues compared with adjacent no-tumor tissues.\n'
p2001
sg4
(lp2002
(dp2003
g7
I30
sg8
g15
sg10
I7
sg11
VmiR-300
p2004
sg13
I1
sasg19
(lp2005
(dp2006
g7
I109
sg22
VC0027651
p2007
sg10
I5
sg11
Vtumor
p2008
sg13
I1
sasa(dp2009
g2
S'Interesting, there were an inverse correlation between ROS1 and miR-300 expression in the LSCC tissues.\n'
p2010
sg4
(lp2011
(dp2012
g7
I55
sg8
VP08922
p2013
sg10
I4
sg11
VROS1
p2014
sg13
I1
sa(dp2015
g7
I64
sg8
g15
sg10
I7
sg11
VmiR-300
p2016
sg13
I1
sasg19
(lp2017
sa(dp2018
g2
S'Therefore, our data suggested that miR-300 acted as a tumor suppressive gene in LSCC.\n'
p2019
sg4
(lp2020
sg19
(lp2021
(dp2022
g7
I54
sg22
VC0027651
p2023
sg10
I5
sg11
Vtumor
p2024
sg13
I1
sasa(dp2025
g2
S'To investigate the interaction on smoking and the lung cancer related genes miR-196a2 rs11614913, miR-146a rs2910164, miR-300 rs12894467, miR-26a-1 rs7372209, miR-27a rs895819 in Fujian Han population.\n'
p2026
sg4
(lp2027
(dp2028
g7
I118
sg8
g15
sg10
I18
sg11
VmiR-300 rs12894467
p2029
sg13
I2
sa(dp2030
g7
I98
sg8
g15
sg10
I18
sg11
VmiR-146a rs2910164
p2031
sg13
I2
sa(dp2032
g7
I138
sg8
g15
sg10
I19
sg11
VmiR-26a-1 rs7372209
p2033
sg13
I2
sa(dp2034
g7
I50
sg8
g15
sg10
I46
sg11
Vlung cancer related genes miR-196a2 rs11614913
p2035
sg13
I6
sa(dp2036
g7
I159
sg8
g15
sg10
I16
sg11
VmiR-27a rs895819
p2037
sg13
I2
sasg19
(lp2038
(dp2039
g7
I50
sg22
VC0684249
p2040
sg10
I11
sg11
Vlung cancer
p2041
sg13
I2
sasa(dp2042
g2
S'The pathogenesis of celiac disease (CD) has been related to polymorphisms in the regulator of G-protein signaling 1 (RGS1) and interleukin-12 A (IL12A) genes, but the existing findings are inconsistent.\n'
p2043
sg4
(lp2044
(dp2045
g7
I81
sg8
g15
sg10
I34
sg11
Vregulator of G-protein signaling 1
p2046
sg13
I5
sa(dp2047
g7
I117
sg8
g15
sg10
I4
sg11
VRGS1
p2048
sg13
I1
sa(dp2049
g7
I145
sg8
VP29459
p2050
sg10
I5
sg11
VIL12A
p2051
sg13
I1
sa(dp2052
g7
I127
sg8
VP60568
p2053
sg10
I16
sg11
Vinterleukin-12 A
p2054
sg13
I2
sasg19
(lp2055
(dp2056
g7
I20
sg22
VC0007570
p2057
sg10
I14
sg11
Vceliac disease
p2058
sg13
I2
sa(dp2059
g7
I4
sg22
VC0699748
p2060
sg10
I12
sg11
Vpathogenesis
p2061
sg13
I1
sa(dp2062
g7
I36
sg22
VC0007570
p2063
sg10
I2
sg11
VCD
p2064
sg13
I1
sasa(dp2065
g2
S'The RGS1 gene is associated with celiac disease, multiple sclerosis, and type I diabetes, which are all T cell-mediated pathologies, yet there is no reported analysis of regulator of G protein signaling (RGS)1 biology in human T cells.\n'
p2066
sg4
(lp2067
(dp2068
g7
I183
sg8
g15
sg10
I26
sg11
VG protein signaling (RGS)1
p2069
sg13
I4
sa(dp2070
g7
I4
sg8
g15
sg10
I9
sg11
VRGS1 gene
p2071
sg13
I2
sasg19
(lp2072
(dp2073
g7
I33
sg22
VC0007570
p2074
sg10
I14
sg11
Vceliac disease
p2075
sg13
I2
sa(dp2076
g7
I73
sg22
VC0011854
p2077
sg10
I15
sg11
Vtype I diabetes
p2078
sg13
I3
sa(dp2079
g7
I170
sg22
VC0265341
p2080
sg10
I32
sg11
Vregulator of G protein signaling
p2081
sg13
I5
sa(dp2082
g7
I4
sg22
VC0265341
p2083
sg10
I3
sg11
VRGS
p2084
sg13
I1
sa(dp2085
g7
I49
sg22
VC0026769
p2086
sg10
I18
sg11
Vmultiple sclerosis
p2087
sg13
I2
sasa(dp2088
g2
S'The RGS1 risk allele is shared with celiac disease (CD), and the IL12A risk allele seems to be protective for celiac disease.\n'
p2089
sg4
(lp2090
(dp2091
g7
I65
sg8
VP29459
p2092
sg10
I5
sg11
VIL12A
p2093
sg13
I1
sa(dp2094
g7
I4
sg8
g15
sg10
I16
sg11
VRGS1 risk allele
p2095
sg13
I3
sasg19
(lp2096
(dp2097
g7
I36
sg22
VC0007570
p2098
sg10
I14
sg11
Vceliac disease
p2099
sg13
I2
sa(dp2100
g7
I52
sg22
VC0007570
p2101
sg10
I2
sg11
VCD
p2102
sg13
I1
sa(dp2103
g7
I36
sg22
VC0007570
p2104
sg10
I14
sg11
Vceliac disease
p2105
sg13
I2
sasa(dp2106
g2
S'Recent genome-wide association studies have identified 1q31 (RGS1), 2q11-12 (IL18RAP), 3p21 (CCR1/CCR3/CCR2), 3q25-26 (IL12A/SCHIP1), 3q28 (LPP), 4q27 (IL2/IL21), 6q25 (TAGAP) and 12q24 (SH2B3) as susceptibility regions for coeliac disease (CD).\n'
p2107
sg4
(lp2108
(dp2109
g7
I77
sg8
g15
sg10
I7
sg11
VIL18RAP
p2110
sg13
I1
sa(dp2111
g7
I152
sg8
VP60568
p2112
sg10
I3
sg11
VIL2
p2113
sg13
I1
sa(dp2114
g7
I103
sg8
VP41597
p2115
sg10
I4
sg11
VCCR2
p2116
sg13
I1
sa(dp2117
g7
I98
sg8
VP51677
p2118
sg10
I4
sg11
VCCR3
p2119
sg13
I1
sa(dp2120
g7
I187
sg8
g15
sg10
I5
sg11
VSH2B3
p2121
sg13
I1
sa(dp2122
g7
I156
sg8
g15
sg10
I4
sg11
VIL21
p2123
sg13
I1
sa(dp2124
g7
I119
sg8
VP29459
p2125
sg10
I5
sg11
VIL12A
p2126
sg13
I1
sa(dp2127
g7
I93
sg8
VP32246
p2128
sg10
I4
sg11
VCCR1
p2129
sg13
I1
sasg19
(lp2130
(dp2131
g7
I241
sg22
VC0007570
p2132
sg10
I2
sg11
VCD
p2133
sg13
I1
sa(dp2134
g7
I224
sg22
VC0007570
p2135
sg10
I15
sg11
Vcoeliac disease
p2136
sg13
I2
sasa(dp2137
g2
S'Three celiac disease loci--RGS1 on chromosome 1q31, IL18RAP on chromosome 2q12, and TAGAP on chromosome 6q25--were associated with type 1 diabetes (P&lt;1.00x10(-4)).\n'
p2138
sg4
(lp2139
(dp2140
g7
I52
sg8
g15
sg10
I7
sg11
VIL18RAP
p2141
sg13
I1
sa(dp2142
g7
I84
sg8
g15
sg10
I5
sg11
VTAGAP
p2143
sg13
I1
sa(dp2144
g7
I27
sg8
g15
sg10
I4
sg11
VRGS1
p2145
sg13
I1
sasg19
(lp2146
(dp2147
g7
I131
sg22
VC0011854
p2148
sg10
I15
sg11
Vtype 1 diabetes
p2149
sg13
I3
sa(dp2150
g7
I6
sg22
VC0007570
p2151
sg10
I14
sg11
Vceliac disease
p2152
sg13
I2
sasa(dp2153
g2
S'In this study, we investigated the role of PD-1 systemic engagement with PD-L1-Ig in lupus-like nephritis in SLE mice.\n'
p2154
sg4
(lp2155
(dp2156
g7
I43
sg8
VP18621
p2157
sg10
I4
sg11
VPD-1
p2158
sg13
I1
sasg19
(lp2159
(dp2160
g7
I109
sg22
VC0014060
p2161
sg10
I3
sg11
VSLE
p2162
sg13
I1
sa(dp2163
g7
I85
sg22
VC0024131
p2164
sg10
I5
sg11
Vlupus
p2165
sg13
I1
sa(dp2166
g7
I96
sg22
VC0027697
p2167
sg10
I9
sg11
Vnephritis
p2168
sg13
I1
sasa(dp2169
g2
S'The systemic administration of PD-L1-Ig activated PD-1-PD-L1 axis of CD4+ T lymphocytes, suppressed Th17 formation in many organs, including the spleen and the kidney, demolished abnormal production of cytokines (IFN-Gamma, IL-17, and IL-10) and anti-dsDNA autoantibodies in serum, inhibited immunoglobulin G deposition in the glomeruli with the decrease of proteinuria, and activated T cells in urine.\n'
p2170
sg4
(lp2171
(dp2172
g7
I292
sg8
g15
sg10
I16
sg11
Vimmunoglobulin G
p2173
sg13
I2
sa(dp2174
g7
I213
sg8
VP01579
p2175
sg10
I9
sg11
VIFN-Gamma
p2176
sg13
I1
sa(dp2177
g7
I69
sg8
VP01730
p2178
sg10
I4
sg11
VCD4+
p2179
sg13
I1
sa(dp2180
g7
I50
sg8
VP18621
p2181
sg10
I4
sg11
VPD-1
p2182
sg13
I1
sasg19
(lp2183
(dp2184
g7
I387
sg22
VC0854148
p2185
sg10
I14
sg11
Vcells in urine
p2186
sg13
I3
sasa(dp2187
g2
S'Our research demonstrated that the protective function of systemic activation of PD-1-PD-L1 axis with PD-L1-Ig attenuates the nephritis in SLE-prone mice, which facilitates us to understand the suppressive function of PD-1-PD-L1 axis in the pathogenesis and progress of the lupus nephritis, and to explore a possible effective therapeutic strategy to SLE.\n'
p2188
sg4
(lp2189
(dp2190
g7
I81
sg8
VP18621
p2191
sg10
I4
sg11
VPD-1
p2192
sg13
I1
sa(dp2193
g7
I81
sg8
VP18621
p2194
sg10
I10
sg11
VPD-1-PD-L1
p2195
sg13
I1
sasg19
(lp2196
(dp2197
g7
I139
sg22
VC0014060
p2198
sg10
I3
sg11
VSLE
p2199
sg13
I1
sa(dp2200
g7
I139
sg22
VC0014060
p2201
sg10
I3
sg11
VSLE
p2202
sg13
I1
sa(dp2203
g7
I274
sg22
VC0024143
p2204
sg10
I15
sg11
Vlupus nephritis
p2205
sg13
I2
sa(dp2206
g7
I126
sg22
VC0027697
p2207
sg10
I9
sg11
Vnephritis
p2208
sg13
I1
sa(dp2209
g7
I241
sg22
VC0699748
p2210
sg10
I12
sg11
Vpathogenesis
p2211
sg13
I1
sasa(dp2212
g2
S'Lastly, the protective effect of CD28 blockade was associated with increased intrarenal expression of the immunoregulatory molecule, Indoleamine 2, 3-dioxygenase, of the co-inhibitory receptor programmed cell-Death - 1 (PD-1) and of its ligand programmed death ligand - 1 (PDL-1).In conclusion, CD28 blockade prevented the development of lupus nephritis in NZB/NZW F1 mice.\n'
p2213
sg4
(lp2214
(dp2215
g7
I255
sg8
g15
sg10
I16
sg11
Vdeath ligand - 1
p2216
sg13
I4
sa(dp2217
g7
I33
sg8
VP33681
p2218
sg10
I4
sg11
VCD28
p2219
sg13
I1
sa(dp2220
g7
I33
sg8
VP33681
p2221
sg10
I4
sg11
VCD28
p2222
sg13
I1
sasg19
(lp2223
(dp2224
g7
I338
sg22
VC0024143
p2225
sg10
I15
sg11
Vlupus nephritis
p2226
sg13
I2
sasa(dp2227
g2
S'PD-L1 expression on tumor cells was higher in patients with preoperative chronic kidney disease (CKD) stage 4-5 than in those with no CKD or CKD stage 1-3 (P = 0.011).\n'
p2228
sg4
(lp2229
sg19
(lp2230
(dp2231
g7
I20
sg22
VC0027651
p2232
sg10
I5
sg11
Vtumor
p2233
sg13
I1
sa(dp2234
g7
I141
sg22
VC2316401
p2235
sg10
I11
sg11
VCKD stage 1
p2236
sg13
I3
sa(dp2237
g7
I97
sg22
VC1561643
p2238
sg10
I3
sg11
VCKD
p2239
sg13
I1
sa(dp2240
g7
I97
sg22
VC1561643
p2241
sg10
I3
sg11
VCKD
p2242
sg13
I1
sa(dp2243
g7
I73
sg22
VC1561643
p2244
sg10
I22
sg11
Vchronic kidney disease
p2245
sg13
I3
sasa(dp2246
g2
S'The occurrence of a major glomerulus-infiltrating CD11b+F4/80-I-A- macrophage population exhibiting the markers programmed death ligand-1 (PD-L1), Mac-2, and macrophage mannose receptor (CD206) and producing Klf4, Il10, Retnla, Tnf, and Il6 mRNA, which are known to be expressed by alternatively activated (M2b) macrophages, correlated with proteinuria status.\n'
p2247
sg4
(lp2248
(dp2249
g7
I214
sg8
VP22301
p2250
sg10
I4
sg11
VIl10
p2251
sg13
I1
sa(dp2252
g7
I208
sg8
g15
sg10
I4
sg11
VKlf4
p2253
sg13
I1
sa(dp2254
g7
I228
sg8
VP01375
p2255
sg10
I3
sg11
VTnf
p2256
sg13
I1
sa(dp2257
g7
I187
sg8
VP22897
p2258
sg10
I5
sg11
VCD206
p2259
sg13
I1
sa(dp2260
g7
I158
sg8
VP22897
p2261
sg10
I27
sg11
Vmacrophage mannose receptor
p2262
sg13
I3
sa(dp2263
g7
I147
sg8
VP17931
p2264
sg10
I5
sg11
VMac-2
p2265
sg13
I1
sa(dp2266
g7
I237
sg8
VP05231
p2267
sg10
I8
sg11
VIl6 mRNA
p2268
sg13
I2
sa(dp2269
g7
I123
sg8
g15
sg10
I14
sg11
Vdeath ligand-1
p2270
sg13
I2
sasg19
(lp2271
(dp2272
g7
I37
sg22
VC0332448
p2273
sg10
I12
sg11
Vinfiltrating
p2274
sg13
I1
sasa(dp2275
g2
S'The predominant and high expression of PD-L1 by CD11b+F4/80-I-A- glomerular macrophages in kidneys of mice with GN and the inhibition of proteinuria by anti-PD-L1 mAb supported the pathogenic role of these macrophages but not the PD-L1- PMN in GN development and in inducing podocyte damage.\n'
p2276
sg4
(lp2277
(dp2278
g7
I48
sg8
VP11215
p2279
sg10
I15
sg11
VCD11b+F4/80-I-A
p2280
sg13
I1
sasg19
(lp2281
sa(dp2282
g2
S'In order to elucidate the steroidogenesis of clinically nonfunctioning adrenocortical adenoma, we studied the aldosterone, cortisol (F) and dehydroepiandrosterone (DHEA) content and the expression of mRNA of cytochrome P450 for side chain cleavage (P450scc), 17 alpha-hydroxylase (P450c17).\n'
p2283
sg4
(lp2284
(dp2285
g7
I219
sg8
VP05108
p2286
sg10
I28
sg11
VP450 for side chain cleavage
p2287
sg13
I5
sa(dp2288
g7
I208
sg8
VP20853
p2289
sg10
I15
sg11
Vcytochrome P450
p2290
sg13
I2
sa(dp2291
g7
I249
sg8
VP05108
p2292
sg10
I7
sg11
VP450scc
p2293
sg13
I1
sa(dp2294
g7
I281
sg8
VP05093
p2295
sg10
I7
sg11
VP450c17
p2296
sg13
I1
sasg19
(lp2297
(dp2298
g7
I71
sg22
VC0206667
p2299
sg10
I22
sg11
Vadrenocortical adenoma
p2300
sg13
I2
sasa(dp2301
g2
S'To understand the molecular mechanism by which OCT4 and GDF3 function in tumorigenesis as well as stemness, we investigated the transcriptional regulation of GDF3 mediated by OCT4 in human embryonic carcinoma (EC) NCCIT cells, which are pluripotent stem cells of TGCTs.\n'
p2302
sg4
(lp2303
(dp2304
g7
I56
sg8
g15
sg10
I4
sg11
VGDF3
p2305
sg13
I1
sa(dp2306
g7
I56
sg8
g15
sg10
I4
sg11
VGDF3
p2307
sg13
I1
sasg19
(lp2308
(dp2309
g7
I73
sg22
VC0007621
p2310
sg10
I13
sg11
Vtumorigenesis
p2311
sg13
I1
sa(dp2312
g7
I199
sg22
VC0007097
p2313
sg10
I9
sg11
Vcarcinoma
p2314
sg13
I1
sasa(dp2315
g2
S'Comparative quantitative real-time PCR analysis of the expression of TGF@[beta] family factors in mouse embryonic stem, embryonic germ, and embryonic teratocarcinoma cells showed that embryonic teratocarcinoma cells express lower ActivinA than pluripotent stem cells but similar levels of factors Nodal, Lefty 1, TGFbeta1, BMP4, and GDF3.\n'
p2316
sg4
(lp2317
(dp2318
g7
I313
sg8
VP01137
p2319
sg10
I8
sg11
VTGFbeta1
p2320
sg13
I1
sa(dp2321
g7
I297
sg8
g15
sg10
I5
sg11
VNodal
p2322
sg13
I1
sa(dp2323
g7
I69
sg8
VP19883
p2324
sg10
I25
sg11
VTGF@[beta] family factors
p2325
sg13
I3
sa(dp2326
g7
I323
sg8
VP12644
p2327
sg10
I4
sg11
VBMP4
p2328
sg13
I1
sa(dp2329
g7
I333
sg8
g15
sg10
I4
sg11
VGDF3
p2330
sg13
I1
sasg19
(lp2331
(dp2332
g7
I150
sg22
VC0206664
p2333
sg10
I15
sg11
Vteratocarcinoma
p2334
sg13
I1
sa(dp2335
g7
I150
sg22
VC0206664
p2336
sg10
I15
sg11
Vteratocarcinoma
p2337
sg13
I1
sasa(dp2338
g2
S'In human nullipotent embryonic teratocarcinoma PA-1 cells, most factors of the TGFbeta family (ACTIVINA, NODAL, LEFTY 1, BMP4, and GDF3) are expressed at lower levels than in human embryonic stem cells: Thus, in mouse and human nullipotent teratocarcinoma cells, theexpression of ActivinA is significantly reduced com- pared ivith embryonic stem cells.\n'
p2339
sg4
(lp2340
(dp2341
g7
I79
sg8
VP01137
p2342
sg10
I14
sg11
VTGFbeta family
p2343
sg13
I2
sa(dp2344
g7
I131
sg8
g15
sg10
I4
sg11
VGDF3
p2345
sg13
I1
sa(dp2346
g7
I105
sg8
g15
sg10
I5
sg11
VNODAL
p2347
sg13
I1
sa(dp2348
g7
I121
sg8
VP12644
p2349
sg10
I4
sg11
VBMP4
p2350
sg13
I1
sasg19
(lp2351
(dp2352
g7
I31
sg22
VC0206664
p2353
sg10
I15
sg11
Vteratocarcinoma
p2354
sg13
I1
sa(dp2355
g7
I31
sg22
VC0206664
p2356
sg10
I15
sg11
Vteratocarcinoma
p2357
sg13
I1
sasa(dp2358
g2
S'GDF3 is a TGFB family member associated with pluripotency and differentiation during embryonic development that has been previously reported to be re-expressed in a number of cancer types.\n'
p2359
sg4
(lp2360
(dp2361
g7
I10
sg8
VP01137
p2362
sg10
I18
sg11
VTGFB family member
p2363
sg13
I3
sa(dp2364
g7
I0
sg8
g15
sg10
I4
sg11
VGDF3
p2365
sg13
I1
sasg19
(lp2366
(dp2367
g7
I175
sg22
VC0006826
p2368
sg10
I6
sg11
Vcancer
p2369
sg13
I1
sasa(dp2370
g2
S'In this study we decipher the role of GDF3 in an in vitro model of cancer stem cells, NCCIT cells.\n'
p2371
sg4
(lp2372
(dp2373
g7
I38
sg8
g15
sg10
I4
sg11
VGDF3
p2374
sg13
I1
sasg19
(lp2375
(dp2376
g7
I67
sg22
VC0006826
p2377
sg10
I6
sg11
Vcancer
p2378
sg13
I1
sasa(dp2379
g2
S'Our study implies that blocking of GDF3 combined with retinoic acid-treatment of solid cancers is a compelling direction for further investigations, which can lead to re-design of cancer differentiation therapies.\n'
p2380
sg4
(lp2381
(dp2382
g7
I35
sg8
g15
sg10
I4
sg11
VGDF3
p2383
sg13
I1
sasg19
(lp2384
(dp2385
g7
I87
sg22
VC0006826
p2386
sg10
I7
sg11
Vcancers
p2387
sg13
I1
sa(dp2388
g7
I23
sg22
VC0233660
p2389
sg10
I8
sg11
Vblocking
p2390
sg13
I1
sa(dp2391
g7
I87
sg22
VC0006826
p2392
sg10
I6
sg11
Vcancer
p2393
sg13
I1
sasa(dp2394
g2
S'This study provides the first evidence that NANOG is a transcriptional activator of the expression of the oncogenic growth factor GDF3 in embryonic carcinoma cells.\n'
p2395
sg4
(lp2396
(dp2397
g7
I106
sg8
g15
sg10
I28
sg11
Voncogenic growth factor GDF3
p2398
sg13
I4
sa(dp2399
g7
I44
sg8
g15
sg10
I5
sg11
VNANOG
p2400
sg13
I1
sasg19
(lp2401
(dp2402
g7
I148
sg22
VC0007097
p2403
sg10
I9
sg11
Vcarcinoma
p2404
sg13
I1
sasa(dp2405
g2
S'Thus any change of the CHH/CHG methylation pattern is a minor event in tumorigenesis, even if the stem cell markers OCT4, NANOG, STELLAR and GDF3 are expressed like in the MCF7 breast cancer cell line.\n'
p2406
sg4
(lp2407
(dp2408
g7
I122
sg8
g15
sg10
I5
sg11
VNANOG
p2409
sg13
I1
sa(dp2410
g7
I141
sg8
g15
sg10
I4
sg11
VGDF3
p2411
sg13
I1
sa(dp2412
g7
I129
sg8
g15
sg10
I7
sg11
VSTELLAR
p2413
sg13
I1
sasg19
(lp2414
(dp2415
g7
I23
sg22
VC0220748
p2416
sg10
I3
sg11
VCHH
p2417
sg13
I1
sa(dp2418
g7
I71
sg22
VC0007621
p2419
sg10
I13
sg11
Vtumorigenesis
p2420
sg13
I1
sa(dp2421
g7
I177
sg22
VC0678222
p2422
sg10
I13
sg11
Vbreast cancer
p2423
sg13
I2
sasa(dp2424
g2
S'The aim of this study is to investigate whether GDF3 is related to the progression of human breast cancer and the effects of GDF3 on breast cancer cells.\n'
p2425
sg4
(lp2426
(dp2427
g7
I48
sg8
g15
sg10
I4
sg11
VGDF3
p2428
sg13
I1
sa(dp2429
g7
I48
sg8
g15
sg10
I4
sg11
VGDF3
p2430
sg13
I1
sasg19
(lp2431
(dp2432
g7
I92
sg22
VC0678222
p2433
sg10
I13
sg11
Vbreast cancer
p2434
sg13
I2
sa(dp2435
g7
I92
sg22
VC0678222
p2436
sg10
I13
sg11
Vbreast cancer
p2437
sg13
I2
sasa(dp2438
g2
S'The expression of GDF3 in 24 breast cancer specimens paired with corresponding neighboring nontumorous tissue was studied by Western blot.\n'
p2439
sg4
(lp2440
(dp2441
g7
I18
sg8
g15
sg10
I4
sg11
VGDF3
p2442
sg13
I1
sasg19
(lp2443
(dp2444
g7
I29
sg22
VC0678222
p2445
sg10
I13
sg11
Vbreast cancer
p2446
sg13
I2
sasa(dp2447
g2
S'Breast cancer cells were treated with different concentrations of recombinant human GDF3 protein.\n'
p2448
sg4
(lp2449
(dp2450
g7
I66
sg8
g15
sg10
I30
sg11
Vrecombinant human GDF3 protein
p2451
sg13
I4
sasg19
(lp2452
(dp2453
g7
I0
sg22
VC0678222
p2454
sg10
I13
sg11
VBreast cancer
p2455
sg13
I2
sasa(dp2456
g2
S'We found that GDF3 expression level was significantly down-regulated in breast cancer tissues compared to the surrounding nontumorous tissues.\n'
p2457
sg4
(lp2458
(dp2459
g7
I14
sg8
g15
sg10
I4
sg11
VGDF3
p2460
sg13
I1
sasg19
(lp2461
(dp2462
g7
I72
sg22
VC0678222
p2463
sg10
I13
sg11
Vbreast cancer
p2464
sg13
I2
sasa(dp2465
g2
S'Our data indicated that GDF3 expression is significantly decreased in human breast cancer tissues, and reconstitution of GDF3 in breast cancer may be a potential therapeutic approach to inhibit aggressive growth of breast cancer.\n'
p2466
sg4
(lp2467
(dp2468
g7
I24
sg8
g15
sg10
I4
sg11
VGDF3
p2469
sg13
I1
sa(dp2470
g7
I24
sg8
g15
sg10
I4
sg11
VGDF3
p2471
sg13
I1
sasg19
(lp2472
(dp2473
g7
I76
sg22
VC0678222
p2474
sg10
I13
sg11
Vbreast cancer
p2475
sg13
I2
sa(dp2476
g7
I194
sg22
VC0001807
p2477
sg10
I10
sg11
Vaggressive
p2478
sg13
I1
sa(dp2479
g7
I76
sg22
VC0678222
p2480
sg10
I13
sg11
Vbreast cancer
p2481
sg13
I2
sa(dp2482
g7
I76
sg22
VC0678222
p2483
sg10
I13
sg11
Vbreast cancer
p2484
sg13
I2
sasa(dp2485
g2
S'The TRPV4-axonal neuropathy spectrum is a group of disorders presenting as a predominantly motor axonal peripheral neuropathy, frequently in association with vocal cord paralysis, and occasionally accompanied by sensorineural hearing loss and bladder urgency and incontinence.\n'
p2486
sg4
(lp2487
sg19
(lp2488
(dp2489
g7
I263
sg22
VC0021167
p2490
sg10
I12
sg11
Vincontinence
p2491
sg13
I1
sa(dp2492
g7
I10
sg22
VC0270921
p2493
sg10
I17
sg11
Vaxonal neuropathy
p2494
sg13
I2
sa(dp2495
g7
I97
sg22
VC1263857
p2496
sg10
I28
sg11
Vaxonal peripheral neuropathy
p2497
sg13
I3
sa(dp2498
g7
I212
sg22
VC0018784
p2499
sg10
I26
sg11
Vsensorineural hearing loss
p2500
sg13
I3
sa(dp2501
g7
I158
sg22
VC0042928
p2502
sg10
I20
sg11
Vvocal cord paralysis
p2503
sg13
I3
sasa(dp2504
g2
S"TRPV4 was also present in the endolymphatic sacs of patients with vestibular schwannoma and with Meniere's disease.\n"
p2505
sg4
(lp2506
sg19
(lp2507
(dp2508
g7
I66
sg22
VC0027859
p2509
sg10
I21
sg11
Vvestibular schwannoma
p2510
sg13
I2
sa(dp2511
g7
I97
sg22
VC0025281
p2512
sg10
I17
sg11
VMeniere's disease
p2513
sg13
I2
sa(dp2514
g7
I44
sg22
VC1849140
p2515
sg10
I4
sg11
Vsacs
p2516
sg13
I1
sasa(dp2517
g2
S'An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer.\n'
p2518
sg4
(lp2519
(dp2520
g7
I92
sg8
VP18621
p2521
sg10
I4
sg11
VPD-1
p2522
sg13
I1
sa(dp2523
g7
I3
sg8
VP14902
p2524
sg10
I4
sg11
VIDO1
p2525
sg13
I1
sasg19
(lp2526
(dp2527
g7
I152
sg22
VC0025202
p2528
sg10
I8
sg11
Vmelanoma
p2529
sg13
I1
sa(dp2530
g7
I210
sg22
VC0007131
p2531
sg10
I26
sg11
Vnon-small cell lung cancer
p2532
sg13
I4
sa(dp2533
g7
I173
sg22
VC0007097
p2534
sg10
I9
sg11
Vcarcinoma
p2535
sg13
I1
sa(dp2536
g7
I128
sg22
VC0280100
p2537
sg10
I12
sg11
Vsolid tumors
p2538
sg13
I2
sa(dp2539
g7
I173
sg22
VC0007134
p2540
sg10
I21
sg11
Vcarcinoma, renal cell
p2541
sg13
I3
sasa(dp2542
g2
S'To explore the role of indoleamine-pyrrole 2,3-dioxygenase (IDO), an immunomodulatory enzyme, in renal cell carcinoma (RCC).\n'
p2543
sg4
(lp2544
(dp2545
g7
I60
sg8
VP14902
p2546
sg10
I3
sg11
VIDO
p2547
sg13
I1
sa(dp2548
g7
I23
sg8
VP14902
p2549
sg10
I35
sg11
Vindoleamine-pyrrole 2,3-dioxygenase
p2550
sg13
I2
sasg19
(lp2551
(dp2552
g7
I119
sg22
VC0007134
p2553
sg10
I3
sg11
VRCC
p2554
sg13
I1
sa(dp2555
g7
I97
sg22
VC0007134
p2556
sg10
I20
sg11
Vrenal cell carcinoma
p2557
sg13
I3
sasa(dp2558
g2
S'Some of salivary glycoproteins, such as Alfa-amylase, clusterin, haptoglobin, heavy and light chains of immunoglobulins, and transferrin, seem to be worthy of detailed glycosylation analysis in the detection of alcohol dependence.\n'
p2559
sg4
(lp2560
(dp2561
g7
I40
sg8
VP04746
p2562
sg10
I12
sg11
VAlfa-amylase
p2563
sg13
I1
sa(dp2564
g7
I54
sg8
VP10909
p2565
sg10
I9
sg11
Vclusterin
p2566
sg13
I1
sa(dp2567
g7
I65
sg8
VP00738
p2568
sg10
I54
sg11
Vhaptoglobin, heavy and light chains of immunoglobulins
p2569
sg13
I7
sa(dp2570
g7
I8
sg8
VP04745
p2571
sg10
I22
sg11
Vsalivary glycoproteins
p2572
sg13
I2
sa(dp2573
g7
I125
sg8
VP02787
p2574
sg10
I11
sg11
Vtransferrin
p2575
sg13
I1
sasg19
(lp2576
(dp2577
g7
I211
sg22
VC0001973
p2578
sg10
I18
sg11
Valcohol dependence
p2579
sg13
I2
sasa(dp2580
g2
S'The presentations were (1) Introduction, by Raye Litten; (2) Direct Ethanol Metabolites--On the Threshold From Science to Routine Use, by Friedrich M. Wurst; (3) Sialic Acid Index of Plasma Apolipoprotein J (SIJ) as a Viable Marker for Chronic Alcohol Consumption, by Philippe Marmillot; (4) The Emergence of Ethyl Glucuronide (EtG) Testing as a Tool in Monitoring Healthcare Professionals, by Gregory E. Skipper; (5) Application of Biomarkers for Alcohol Use Disorders in Clinical Practice, by Tim Neumann; (6) Utility of Biomarkers in Assessing the Efficacy of Medications for Treating Alcoholism, by Marty Javors; and (7) Discussion, by Raye Litten.\n'
p2581
sg4
(lp2582
(dp2583
g7
I183
sg8
VP10909
p2584
sg10
I23
sg11
VPlasma Apolipoprotein J
p2585
sg13
I3
sasg19
(lp2586
(dp2587
g7
I588
sg22
VC0001973
p2588
sg10
I10
sg11
VAlcoholism
p2589
sg13
I1
sa(dp2590
g7
I448
sg22
VC0001956
p2591
sg10
I21
sg11
VAlcohol Use Disorders
p2592
sg13
I3
sasa(dp2593
g2
S'In contrast to CDG1, there was no decrease in clusterin or serum amyloid P in patients with alcoholism.\n'
p2594
sg4
(lp2595
(dp2596
g7
I15
sg8
g15
sg10
I4
sg11
VCDG1
p2597
sg13
I1
sasg19
(lp2598
(dp2599
g7
I65
sg22
VC0011560
p2600
sg10
I7
sg11
Vamyloid
p2601
sg13
I1
sa(dp2602
g7
I92
sg22
VC0001973
p2603
sg10
I10
sg11
Valcoholism
p2604
sg13
I1
sasa(dp2605
g2
S'The PID-IFB controller is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting.\n'
p2606
sg4
(lp2607
(dp2608
g7
I4
sg8
g15
sg10
I18
sg11
VPID-IFB controller
p2609
sg13
I2
sasg19
(lp2610
(dp2611
g7
I4
sg22
VC0242172
p2612
sg10
I3
sg11
VPID
p2613
sg13
I1
sa(dp2614
g7
I173
sg22
VC0011854
p2615
sg10
I15
sg11
Vtype 1 diabetes
p2616
sg13
I3
sa(dp2617
g7
I180
sg22
VC0011849
p2618
sg10
I8
sg11
Vdiabetes
p2619
sg13
I1
sa(dp2620
g7
I89
sg22
VC0342315
p2621
sg10
I22
sg11
Vnocturnal hypoglycemia
p2622
sg13
I2
sasa(dp2623
g2
S'To examine for the possibility that CD59 becomes detached from cell surfaces following cell injury, this study evaluated renal excretion of CD59 in patients with idiopathic membranous glomerulonephritis (MGN; N = 21), diabetic nephropathy (DNP; N = 15) and in healthy control subjects (N = 13).\n'
p2624
sg4
(lp2625
(dp2626
g7
I36
sg8
VP13987
p2627
sg10
I4
sg11
VCD59
p2628
sg13
I1
sa(dp2629
g7
I36
sg8
VP13987
p2630
sg10
I4
sg11
VCD59
p2631
sg13
I1
sasg19
(lp2632
(dp2633
g7
I218
sg22
VC0011881
p2634
sg10
I20
sg11
Vdiabetic nephropathy
p2635
sg13
I2
sa(dp2636
g7
I204
sg22
VC0017665
p2637
sg10
I3
sg11
VMGN
p2638
sg13
I1
sa(dp2639
g7
I162
sg22
VC0086445
p2640
sg10
I40
sg11
Vidiopathic membranous glomerulonephritis
p2641
sg13
I3
sa(dp2642
g7
I87
sg22
VC0599732
p2643
sg10
I11
sg11
Vcell injury
p2644
sg13
I2
sa(dp2645
g7
I240
sg22
VC0011881
p2646
sg10
I3
sg11
VDNP
p2647
sg13
I1
sasa(dp2648
g2
S"In normal kidneys and kidney specimens from the patients with minimal change nephrotic syndrome, membranous nephropathy, and IgA nephropathy, HRF20 was strongly localized in the peritubular capillaries and along Bowman's capsules.\n"
p2649
sg4
(lp2650
(dp2651
g7
I142
sg8
VP13987
p2652
sg10
I5
sg11
VHRF20
p2653
sg13
I1
sa(dp2654
g7
I125
sg8
VP11912
p2655
sg10
I3
sg11
VIgA
p2656
sg13
I1
sasg19
(lp2657
(dp2658
g7
I97
sg22
VC0017665
p2659
sg10
I22
sg11
Vmembranous nephropathy
p2660
sg13
I2
sa(dp2661
g7
I125
sg22
VC0017661
p2662
sg10
I15
sg11
VIgA nephropathy
p2663
sg13
I2
sa(dp2664
g7
I62
sg22
VC1704321
p2665
sg10
I33
sg11
Vminimal change nephrotic syndrome
p2666
sg13
I4
sasa(dp2667
g2
S'We investigated Beta-defensin family expression in liver cancer in publicly available datasets and found that among all the Beta-defensins tested, only Beta-defensin 1 was significantly downregulated, suggesting Beta-defensin 1 plays a crucial role in liver cancer development.\n'
p2668
sg4
(lp2669
(dp2670
g7
I152
sg8
VP60022
p2671
sg10
I15
sg11
VBeta-defensin 1
p2672
sg13
I2
sa(dp2673
g7
I124
sg8
g15
sg10
I14
sg11
VBeta-defensins
p2674
sg13
I1
sa(dp2675
g7
I152
sg8
VP60022
p2676
sg10
I15
sg11
VBeta-defensin 1
p2677
sg13
I2
sa(dp2678
g7
I16
sg8
VP59861
p2679
sg10
I20
sg11
VBeta-defensin family
p2680
sg13
I2
sasg19
(lp2681
(dp2682
g7
I51
sg22
VC0345904
p2683
sg10
I12
sg11
Vliver cancer
p2684
sg13
I2
sa(dp2685
g7
I51
sg22
VC0345904
p2686
sg10
I12
sg11
Vliver cancer
p2687
sg13
I2
sasa(dp2688
g2
S'Furthermore, the downregulation of Beta-defensin 1 and E-cadherin, and upregulation of hepatocyte growth factor-regulated tyrosine kinase substrate, were further confirmed in liver cancer and adjacent normal tissue collected from in-house Chinese liver cancer patients.\n'
p2689
sg4
(lp2690
(dp2691
g7
I87
sg8
VP29401
p2692
sg10
I50
sg11
Vhepatocyte growth factor-regulated tyrosine kinase
p2693
sg13
I5
sa(dp2694
g7
I35
sg8
VP60022
p2695
sg10
I15
sg11
VBeta-defensin 1
p2696
sg13
I2
sa(dp2697
g7
I55
sg8
VP12830
p2698
sg10
I10
sg11
VE-cadherin
p2699
sg13
I1
sasg19
(lp2700
(dp2701
g7
I175
sg22
VC0345904
p2702
sg10
I12
sg11
Vliver cancer
p2703
sg13
I2
sa(dp2704
g7
I175
sg22
VC0345904
p2705
sg10
I12
sg11
Vliver cancer
p2706
sg13
I2
sasa(dp2707
g2
S'Together, our results suggest Beta-defensin 1 plays an important role in protecting HCV progression and liver cancer development.\n'
p2708
sg4
(lp2709
(dp2710
g7
I30
sg8
VP60022
p2711
sg10
I15
sg11
VBeta-defensin 1
p2712
sg13
I2
sasg19
(lp2713
(dp2714
g7
I104
sg22
VC0345904
p2715
sg10
I12
sg11
Vliver cancer
p2716
sg13
I2
sasa(dp2717
g2
S'mRNA expression of the AMPs Alfa defensin (HNP-1); cathelicidin (LL-37); and Beta defensins (hBD-1, hBD-2, hBD-3, hBD-4) in human uveal and cutaneous melanoma cell lines, primary human uveal melanocytes, and primary human uveal melanoma cells was determined by reverse transcriptase polymerase chain reaction.\n'
p2718
sg4
(lp2719
(dp2720
g7
I107
sg8
VP81534
p2721
sg10
I5
sg11
VhBD-3
p2722
sg13
I1
sa(dp2723
g7
I93
sg8
VP60022
p2724
sg10
I5
sg11
VhBD-1
p2725
sg13
I1
sa(dp2726
g7
I23
sg8
VP30566
p2727
sg10
I18
sg11
VAMPs Alfa defensin
p2728
sg13
I3
sa(dp2729
g7
I77
sg8
VP59665
p2730
sg10
I14
sg11
VBeta defensins
p2731
sg13
I2
sa(dp2732
g7
I114
sg8
g15
sg10
I5
sg11
VhBD-4
p2733
sg13
I1
sa(dp2734
g7
I43
sg8
VP59665
p2735
sg10
I5
sg11
VHNP-1
p2736
sg13
I1
sa(dp2737
g7
I261
sg8
VP63136
p2738
sg10
I21
sg11
Vreverse transcriptase
p2739
sg13
I2
sa(dp2740
g7
I100
sg8
g15
sg10
I5
sg11
VhBD-2
p2741
sg13
I1
sasg19
(lp2742
(dp2743
g7
I140
sg22
VC0025202
p2744
sg10
I18
sg11
Vcutaneous melanoma
p2745
sg13
I2
sa(dp2746
g7
I93
sg22
VC1840321
p2747
sg10
I3
sg11
VhBD
p2748
sg13
I1
sa(dp2749
g7
I222
sg22
VC0220633
p2750
sg10
I14
sg11
Vuveal melanoma
p2751
sg13
I2
sa(dp2752
g7
I93
sg22
VC1840321
p2753
sg10
I3
sg11
VhBD
p2754
sg13
I1
sa(dp2755
g7
I93
sg22
VC1840321
p2756
sg10
I3
sg11
VhBD
p2757
sg13
I1
sa(dp2758
g7
I93
sg22
VC1840321
p2759
sg10
I3
sg11
VhBD
p2760
sg13
I1
sasa(dp2761
g2
S'Small molecular inhibitors targeting the first bromodomain of BRD4 (BRD4-BD1) have showed promising potentials in the therapies of BRD4-related cancers.\n'
p2762
sg4
(lp2763
(dp2764
g7
I68
sg8
g15
sg10
I8
sg11
VBRD4-BD1
p2765
sg13
I1
sa(dp2766
g7
I62
sg8
g15
sg10
I4
sg11
VBRD4
p2767
sg13
I1
sa(dp2768
g7
I62
sg8
g15
sg10
I4
sg11
VBRD4
p2769
sg13
I1
sasg19
(lp2770
(dp2771
g7
I144
sg22
VC0006826
p2772
sg10
I7
sg11
Vcancers
p2773
sg13
I1
sasa(dp2774
g2
S'The DEFB1 gene, which encodes human Beta-defensin-1 (HBD-1), contributes to innate immune responses and functions as a potential tumor suppressor in urological cancers.\n'
p2775
sg4
(lp2776
(dp2777
g7
I53
sg8
VP60022
p2778
sg10
I5
sg11
VHBD-1
p2779
sg13
I1
sa(dp2780
g7
I4
sg8
VP60022
p2781
sg10
I10
sg11
VDEFB1 gene
p2782
sg13
I2
sa(dp2783
g7
I30
sg8
VP60022
p2784
sg10
I21
sg11
Vhuman Beta-defensin-1
p2785
sg13
I2
sasg19
(lp2786
(dp2787
g7
I149
sg22
VC0751571
p2788
sg10
I18
sg11
Vurological cancers
p2789
sg13
I2
sa(dp2790
g7
I76
sg22
VC1155265
p2791
sg10
I23
sg11
Vinnate immune responses
p2792
sg13
I3
sa(dp2793
g7
I53
sg22
VC1840321
p2794
sg10
I3
sg11
VHBD
p2795
sg13
I1
sa(dp2796
g7
I129
sg22
VC0027651
p2797
sg10
I5
sg11
Vtumor
p2798
sg13
I1
sasa(dp2799
g2
S'Bromodomain-containing protein 4 (BRD4), a protein containing two BRDs termed BD1 and BD2, has emerged as an attractive candidate for the development of inhibitors targeting gene transcription in several types of cancers.\n'
p2800
sg4
(lp2801
(dp2802
g7
I34
sg8
g15
sg10
I4
sg11
VBRD4
p2803
sg13
I1
sa(dp2804
g7
I78
sg8
VP60022
p2805
sg10
I3
sg11
VBD1
p2806
sg13
I1
sa(dp2807
g7
I0
sg8
g15
sg10
I32
sg11
VBromodomain-containing protein 4
p2808
sg13
I3
sasg19
(lp2809
(dp2810
g7
I213
sg22
VC0006826
p2811
sg10
I7
sg11
Vcancers
p2812
sg13
I1
sasa(dp2813
g2
S'We discuss three hypothalamic mechanisms of fatigue in multiple sclerosis: (1) general hypothalamic-pituitary-adrenal axis hyperactivity, (2) disordered orexin neurotransmission, (3) abnormal cortisol secretion.\n'
p2814
sg4
(lp2815
sg19
(lp2816
(dp2817
g7
I55
sg22
VC0026769
p2818
sg10
I18
sg11
Vmultiple sclerosis
p2819
sg13
I2
sa(dp2820
g7
I44
sg22
VC0015672
p2821
sg10
I7
sg11
Vfatigue
p2822
sg13
I1
sasa(dp2823
g2
S'Elevation levels of OX1R and OX2R following EAE induction suggest that alteration in orexinergic system may involve in pathogenesis of multiple sclerosis.\n'
p2824
sg4
(lp2825
(dp2826
g7
I20
sg8
g15
sg10
I4
sg11
VOX1R
p2827
sg13
I1
sa(dp2828
g7
I29
sg8
g15
sg10
I4
sg11
VOX2R
p2829
sg13
I1
sasg19
(lp2830
(dp2831
g7
I119
sg22
VC0699748
p2832
sg10
I12
sg11
Vpathogenesis
p2833
sg13
I1
sa(dp2834
g7
I135
sg22
VC0026769
p2835
sg10
I18
sg11
Vmultiple sclerosis
p2836
sg13
I2
sasa(dp2837
g2
S'Narcolepsy with cataplexy is caused by a selective loss of hypocretin-producing neurons, but symptomatic narcolepsy can also result from hypothalamic and brainstem lesions caused by multiple sclerosis (MS).\n'
p2838
sg4
(lp2839
(dp2840
g7
I59
sg8
VP50336
p2841
sg10
I10
sg11
Vhypocretin
p2842
sg13
I1
sasg19
(lp2843
(dp2844
g7
I0
sg22
VC0751362
p2845
sg10
I25
sg11
VNarcolepsy with cataplexy
p2846
sg13
I3
sa(dp2847
g7
I182
sg22
VC0026769
p2848
sg10
I18
sg11
Vmultiple sclerosis
p2849
sg13
I2
sa(dp2850
g7
I202
sg22
VC0026769
p2851
sg10
I2
sg11
VMS
p2852
sg13
I1
sa(dp2853
g7
I105
sg22
VC0027404
p2854
sg10
I10
sg11
Vnarcolepsy
p2855
sg13
I1
sasa(dp2856
g2
S'Considering the multiplicity of symptoms associated with multiple sclerosis (MS), there is possibility that hypocretin system function might be involved in the pathogenesis of the disease.\n'
p2857
sg4
(lp2858
(dp2859
g7
I108
sg8
VP50336
p2860
sg10
I10
sg11
Vhypocretin
p2861
sg13
I1
sasg19
(lp2862
(dp2863
g7
I160
sg22
VC0699748
p2864
sg10
I12
sg11
Vpathogenesis
p2865
sg13
I1
sa(dp2866
g7
I57
sg22
VC0026769
p2867
sg10
I18
sg11
Vmultiple sclerosis
p2868
sg13
I2
sa(dp2869
g7
I77
sg22
VC0026769
p2870
sg10
I2
sg11
VMS
p2871
sg13
I1
sasa(dp2872
g2
S'The mass was then completely removed surgically using an NBI-assisted endoscopic technique, and a histopathological examination revealed it was a hemangiopericytoma-like (HPCL) tumor.\n'
p2873
sg4
(lp2874
sg19
(lp2875
(dp2876
g7
I177
sg22
VC0027651
p2877
sg10
I5
sg11
Vtumor
p2878
sg13
I1
sa(dp2879
g7
I146
sg22
VC0018922
p2880
sg10
I18
sg11
Vhemangiopericytoma
p2881
sg13
I1
sasa(dp2882
g2
S'Nasal hemangiopericytoma-like (HPCL) tumor is a rare vascular tumor and should be differentiated from typical hemangiopericytomas (HPCs).\n'
p2883
sg4
(lp2884
sg19
(lp2885
(dp2886
g7
I110
sg22
VC0018922
p2887
sg10
I19
sg11
Vhemangiopericytomas
p2888
sg13
I1
sa(dp2889
g7
I37
sg22
VC0027651
p2890
sg10
I5
sg11
Vtumor
p2891
sg13
I1
sa(dp2892
g7
I6
sg22
VC0018922
p2893
sg10
I18
sg11
Vhemangiopericytoma
p2894
sg13
I1
sa(dp2895
g7
I131
sg22
VC0018922
p2896
sg10
I4
sg11
VHPCs
p2897
sg13
I1
sa(dp2898
g7
I53
sg22
VC0282607
p2899
sg10
I14
sg11
Vvascular tumor
p2900
sg13
I2
sasa(dp2901
g2
S'These studies have identified four gene variants associated with restless legs syndrome (BTBD9, MEIS1, MAP2K5/LBXCOR1, and PTPRD) and two variants associated with narcolepsy (one in the T-cell receptor Alfa locus and another between CPT1B and CHKB).\n'
p2902
sg4
(lp2903
(dp2904
g7
I123
sg8
VP23468
p2905
sg10
I5
sg11
VPTPRD
p2906
sg13
I1
sa(dp2907
g7
I233
sg8
g15
sg10
I5
sg11
VCPT1B
p2908
sg13
I1
sa(dp2909
g7
I110
sg8
VP84550
p2910
sg10
I7
sg11
VLBXCOR1
p2911
sg13
I1
sa(dp2912
g7
I243
sg8
g15
sg10
I4
sg11
VCHKB
p2913
sg13
I1
sa(dp2914
g7
I103
sg8
g15
sg10
I6
sg11
VMAP2K5
p2915
sg13
I1
sa(dp2916
g7
I89
sg8
g15
sg10
I5
sg11
VBTBD9
p2917
sg13
I1
sa(dp2918
g7
I96
sg8
g15
sg10
I5
sg11
VMEIS1
p2919
sg13
I1
sa(dp2920
g7
I186
sg8
g15
sg10
I26
sg11
VT-cell receptor Alfa locus
p2921
sg13
I4
sasg19
(lp2922
(dp2923
g7
I65
sg22
VC0035258
p2924
sg10
I22
sg11
Vrestless legs syndrome
p2925
sg13
I3
sa(dp2926
g7
I163
sg22
VC0027404
p2927
sg10
I10
sg11
Vnarcolepsy
p2928
sg13
I1
sasa(dp2929
g2
S'In this study, the effect of therapeutic hypervolemia, hemodilution, and hypertension (HHH-therapy) on cerebral blood flow (CBF) was assessed by xenon-enhanced computerized tomography (XeCT) hypothesizing an increase in CBF in poorly perfused regions.\n'
p2930
sg4
(lp2931
sg19
(lp2932
(dp2933
g7
I87
sg22
VC0268540
p2934
sg10
I3
sg11
VHHH
p2935
sg13
I1
sa(dp2936
g7
I41
sg22
VC0546817
p2937
sg10
I12
sg11
Vhypervolemia
p2938
sg13
I1
sa(dp2939
g7
I73
sg22
VC0020538
p2940
sg10
I12
sg11
Vhypertension
p2941
sg13
I1
sasa(dp2942
g2
S'Surgical outcomes were improved by the introduction of the operative microscope in the 1960s and perioperative care utilizing induced hypertension, hypovolemia, and hemodilution ("HHH therapy").\n'
p2943
sg4
(lp2944
sg19
(lp2945
(dp2946
g7
I134
sg22
VC0020538
p2947
sg10
I12
sg11
Vhypertension
p2948
sg13
I1
sa(dp2949
g7
I180
sg22
VC0268540
p2950
sg10
I3
sg11
VHHH
p2951
sg13
I1
sasa(dp2952
g2
S'Hypertension, hypervolemia, and hemodilution [HHH] therapy is widely used for prophylactic and therapeutic means in the setting of angiographic or clinical cerebral vasospasm.\n'
p2953
sg4
(lp2954
sg19
(lp2955
(dp2956
g7
I46
sg22
VC0268540
p2957
sg10
I3
sg11
VHHH
p2958
sg13
I1
sa(dp2959
g7
I0
sg22
VC0020538
p2960
sg10
I12
sg11
VHypertension
p2961
sg13
I1
sa(dp2962
g7
I156
sg22
VC0265110
p2963
sg10
I18
sg11
Vcerebral vasospasm
p2964
sg13
I2
sa(dp2965
g7
I14
sg22
VC0546817
p2966
sg10
I12
sg11
Vhypervolemia
p2967
sg13
I1
sasa(dp2968
g2
S'This work presents a yet unreported CNS involvement pattern, notably multiple supratentorial stroke-like lesions in association with HHH syndrome.\n'
p2969
sg4
(lp2970
sg19
(lp2971
(dp2972
g7
I93
sg22
VC0038454
p2973
sg10
I6
sg11
Vstroke
p2974
sg13
I1
sa(dp2975
g7
I133
sg22
VC0268540
p2976
sg10
I12
sg11
VHHH syndrome
p2977
sg13
I2
sasa(dp2978
g2
S'We suggest including HHH syndrome in the differential diagnosis of patients found to have stroke-like lesions on brain MRI.\n'
p2979
sg4
(lp2980
sg19
(lp2981
(dp2982
g7
I90
sg22
VC0038454
p2983
sg10
I6
sg11
Vstroke
p2984
sg13
I1
sa(dp2985
g7
I21
sg22
VC0268540
p2986
sg10
I12
sg11
VHHH syndrome
p2987
sg13
I2
sasa(dp2988
g2
S'The induction of hypertension as part of HHH therapy for SAH-related cerebral vasospasm may result in RLS.\n'
p2989
sg4
(lp2990
sg19
(lp2991
(dp2992
g7
I69
sg22
VC0265110
p2993
sg10
I18
sg11
Vcerebral vasospasm
p2994
sg13
I2
sa(dp2995
g7
I41
sg22
VC0268540
p2996
sg10
I3
sg11
VHHH
p2997
sg13
I1
sa(dp2998
g7
I102
sg22
VC0035258
p2999
sg10
I3
sg11
VRLS
p3000
sg13
I1
sa(dp3001
g7
I17
sg22
VC0020538
p3002
sg10
I12
sg11
Vhypertension
p3003
sg13
I1
sasa(dp3004
g2
S'Therapeutic treatment with hypertension, hypervolemia and hemodilution (HHH) has a direct influence on cerebral vasospasm, ischemic sequelae and outcome, while prophylactic HHH leads to excess complications.\n'
p3005
sg4
(lp3006
sg19
(lp3007
(dp3008
g7
I27
sg22
VC0020538
p3009
sg10
I12
sg11
Vhypertension
p3010
sg13
I1
sa(dp3011
g7
I103
sg22
VC0265110
p3012
sg10
I18
sg11
Vcerebral vasospasm
p3013
sg13
I2
sa(dp3014
g7
I72
sg22
VC0268540
p3015
sg10
I3
sg11
VHHH
p3016
sg13
I1
sa(dp3017
g7
I41
sg22
VC0546817
p3018
sg10
I12
sg11
Vhypervolemia
p3019
sg13
I1
sa(dp3020
g7
I72
sg22
VC0268540
p3021
sg10
I3
sg11
VHHH
p3022
sg13
I1
sasa(dp3023
g2
S'The common therapeutic approach to patients, who develop vasospasm following subarachnoid hemorrhage, is usually composed of hypertension, hypervolemia, and hemodilution (HHH).\n'
p3024
sg4
(lp3025
sg19
(lp3026
(dp3027
g7
I125
sg22
VC0020538
p3028
sg10
I12
sg11
Vhypertension
p3029
sg13
I1
sa(dp3030
g7
I77
sg22
VC0038525
p3031
sg10
I23
sg11
Vsubarachnoid hemorrhage
p3032
sg13
I2
sa(dp3033
g7
I139
sg22
VC0546817
p3034
sg10
I12
sg11
Vhypervolemia
p3035
sg13
I1
sa(dp3036
g7
I171
sg22
VC0268540
p3037
sg10
I3
sg11
VHHH
p3038
sg13
I1
sa(dp3039
g7
I57
sg22
VC0085616
p3040
sg10
I9
sg11
Vvasospasm
p3041
sg13
I1
sasa(dp3042
g2
S'Elevated TCD velocities often initiate the use of triple-H (HHH: hypertension, hemodilution, and hypervolemia) therapy and subsequently guide it.\n'
p3043
sg4
(lp3044
(dp3045
g7
I60
sg8
g15
sg10
I3
sg11
VHHH
p3046
sg13
I1
sasg19
(lp3047
(dp3048
g7
I60
sg22
VC0268540
p3049
sg10
I3
sg11
VHHH
p3050
sg13
I1
sa(dp3051
g7
I9
sg22
VC0008525
p3052
sg10
I3
sg11
VTCD
p3053
sg13
I1
sa(dp3054
g7
I97
sg22
VC0546817
p3055
sg10
I12
sg11
Vhypervolemia
p3056
sg13
I1
sa(dp3057
g7
I65
sg22
VC0020538
p3058
sg10
I12
sg11
Vhypertension
p3059
sg13
I1
sasa(dp3060
g2
S'A significantly higher mRNA expression of CHST11, CHST12, and CHST15 was measured in ovarian cancer samples in comparison to non-malignant ones, and the same trend was observed for CHST13.\n'
p3061
sg4
(lp3062
(dp3063
g7
I42
sg8
g15
sg10
I6
sg11
VCHST11
p3064
sg13
I1
sa(dp3065
g7
I181
sg8
g15
sg10
I6
sg11
VCHST13
p3066
sg13
I1
sa(dp3067
g7
I50
sg8
g15
sg10
I6
sg11
VCHST12
p3068
sg13
I1
sasg19
(lp3069
(dp3070
g7
I85
sg22
VC1140680
p3071
sg10
I14
sg11
Vovarian cancer
p3072
sg13
I2
sasa(dp3073
g2
S'Here, we review the current evidence for mitochondrial dysfunction in neuronal models of seven LSD, including GM1-gangliosidosis, mucopolysaccharidosis IIIC, multiple sulfatase deficiency, Krabbe disease, Gaucher disease, Niemann Pick disease type C and the neural ceroid lipofuscinoses and outline current experimental therapies aimed at restoring mitochondrial function and neuroprotection in LSD.\n'
p3074
sg4
(lp3075
(dp3076
g7
I167
sg8
g15
sg10
I9
sg11
Vsulfatase
p3077
sg13
I1
sasg19
(lp3078
(dp3079
g7
I196
sg22
VC0017205
p3080
sg10
I16
sg11
Vdisease, Gaucher
p3081
sg13
I2
sa(dp3082
g7
I222
sg22
VC0028064
p3083
sg10
I20
sg11
VNiemann Pick disease
p3084
sg13
I3
sa(dp3085
g7
I158
sg22
VC0268263
p3086
sg10
I29
sg11
Vmultiple sulfatase deficiency
p3087
sg13
I3
sa(dp3088
g7
I114
sg22
VC0017083
p3089
sg10
I14
sg11
Vgangliosidosis
p3090
sg13
I1
sa(dp3091
g7
I130
sg22
VC0026703
p3092
sg10
I21
sg11
Vmucopolysaccharidosis
p3093
sg13
I1
sasa(dp3094
g2
S'Lysosomal storage disorder samples include; aspartylglucosaminuria, galactosialidosis, Gaucher disease, GM1 gangliosidosis, mucopolysaccharidosis types I, II, IIIC, IVA, VI, and VII, mucolipidosis type II, multiple sulfatase deficiency, and sialidosis type II.\n'
p3095
sg4
(lp3096
(dp3097
g7
I215
sg8
g15
sg10
I9
sg11
Vsulfatase
p3098
sg13
I1
sasg19
(lp3099
(dp3100
g7
I44
sg22
VC0268225
p3101
sg10
I22
sg11
Vaspartylglucosaminuria
p3102
sg13
I1
sa(dp3103
g7
I165
sg22
VC0268575
p3104
sg10
I3
sg11
VIVA
p3105
sg13
I1
sa(dp3106
g7
I0
sg22
VC0085078
p3107
sg10
I26
sg11
VLysosomal storage disorder
p3108
sg13
I3
sa(dp3109
g7
I183
sg22
VC0020725
p3110
sg10
I21
sg11
Vmucolipidosis type II
p3111
sg13
I3
sa(dp3112
g7
I206
sg22
VC0268263
p3113
sg10
I29
sg11
Vmultiple sulfatase deficiency
p3114
sg13
I3
sa(dp3115
g7
I124
sg22
VC0026703
p3116
sg10
I21
sg11
Vmucopolysaccharidosis
p3117
sg13
I1
sa(dp3118
g7
I104
sg22
VC0085131
p3119
sg10
I18
sg11
VGM1 gangliosidosis
p3120
sg13
I2
sa(dp3121
g7
I87
sg22
VC0017205
p3122
sg10
I15
sg11
VGaucher disease
p3123
sg13
I2
sa(dp3124
g7
I68
sg22
VC0268233
p3125
sg10
I17
sg11
Vgalactosialidosis
p3126
sg13
I1
sa(dp3127
g7
I75
sg22
VC0268226
p3128
sg10
I10
sg11
Vsialidosis
p3129
sg13
I1
sasa(dp3130
g2
S"There were 20 cases of metachromatic leukodystrophy (infantile,14; juvenile, 6), 12 cases of Tay-Sachs disease (infantile, 9; late G(M2-M3) gangliosidoses, 3), 8 cases of Sandhoff's disease, and 1 male case with multiple sulfatase deficiency.\n"
p3131
sg4
(lp3132
(dp3133
g7
I221
sg8
g15
sg10
I9
sg11
Vsulfatase
p3134
sg13
I1
sasg19
(lp3135
(dp3136
g7
I140
sg22
VC0017083
p3137
sg10
I14
sg11
Vgangliosidoses
p3138
sg13
I1
sa(dp3139
g7
I212
sg22
VC0268263
p3140
sg10
I29
sg11
Vmultiple sulfatase deficiency
p3141
sg13
I3
sa(dp3142
g7
I93
sg22
VC0039373
p3143
sg10
I17
sg11
VTay-Sachs disease
p3144
sg13
I2
sa(dp3145
g7
I171
sg22
VC0036161
p3146
sg10
I18
sg11
VSandhoff's disease
p3147
sg13
I2
sa(dp3148
g7
I23
sg22
VC0023522
p3149
sg10
I28
sg11
Vmetachromatic leukodystrophy
p3150
sg13
I2
sasa(dp3151
g2
S'The characteristic cytoplasmic inclusions were observed in the cultured cells of Fabry disease, Tay-Sachs disease, Sandhoff disease, generalized gangliosidosis, Niemann-Pick disease, metachromatic leukodystrophy, and multiple sulfatase deficiency, and differ in fine structure with these diseases.\n'
p3152
sg4
(lp3153
(dp3154
g7
I226
sg8
g15
sg10
I9
sg11
Vsulfatase
p3155
sg13
I1
sasg19
(lp3156
(dp3157
g7
I133
sg22
VC0268271
p3158
sg10
I26
sg11
Vgeneralized gangliosidosis
p3159
sg13
I2
sa(dp3160
g7
I161
sg22
VC0028064
p3161
sg10
I20
sg11
VNiemann-Pick disease
p3162
sg13
I2
sa(dp3163
g7
I87
sg22
VC0039373
p3164
sg10
I18
sg11
Vdisease, Tay-Sachs
p3165
sg13
I2
sa(dp3166
g7
I115
sg22
VC0036161
p3167
sg10
I16
sg11
VSandhoff disease
p3168
sg13
I2
sa(dp3169
g7
I183
sg22
VC0023522
p3170
sg10
I28
sg11
Vmetachromatic leukodystrophy
p3171
sg13
I2
sa(dp3172
g7
I217
sg22
VC0268263
p3173
sg10
I29
sg11
Vmultiple sulfatase deficiency
p3174
sg13
I3
sasa(dp3175
g2
S'Ultrastructurally, the cytoplasmic inclusions showed pleomorphic osmiophilic inclusions in Fabry disease, membranous cytoplasmic bodies (MCB) in Tay-Sachs disease and Sandhoff disease, MCB and vacuolar inclusions containing finely reticulogranular materials in generalized gangliosidosis, myelin-like inclusions in Niemann-Pick disease, concentric lamellar inclusions in metachromatic leukodystrophy, and polymorphic cytoplasmic inclusions in multiple sulfatase deficiency.\n'
p3176
sg4
(lp3177
(dp3178
g7
I452
sg8
g15
sg10
I9
sg11
Vsulfatase
p3179
sg13
I1
sasg19
(lp3180
(dp3181
g7
I371
sg22
VC0023522
p3182
sg10
I28
sg11
Vmetachromatic leukodystrophy
p3183
sg13
I2
sa(dp3184
g7
I145
sg22
VC0039373
p3185
sg10
I17
sg11
VTay-Sachs disease
p3186
sg13
I2
sa(dp3187
g7
I91
sg22
VC0002986
p3188
sg10
I13
sg11
VFabry disease
p3189
sg13
I2
sa(dp3190
g7
I315
sg22
VC0028064
p3191
sg10
I20
sg11
VNiemann-Pick disease
p3192
sg13
I2
sa(dp3193
g7
I261
sg22
VC0268271
p3194
sg10
I26
sg11
Vgeneralized gangliosidosis
p3195
sg13
I2
sa(dp3196
g7
I443
sg22
VC0268263
p3197
sg10
I29
sg11
Vmultiple sulfatase deficiency
p3198
sg13
I3
sa(dp3199
g7
I167
sg22
VC0036161
p3200
sg10
I16
sg11
VSandhoff disease
p3201
sg13
I2
sasa(dp3202
g2
S'Real-time reverse transcription polymerase chain reaction, in accordance with the microarray analysis, indicated that PEDF treatment caused an upregulation in the mRNA expression level of stanniocalcin 2, brain-specific angiogenesis inhibitor 2 and growth arrest, DNA-damage-inducible, alpha, and downregulation in the messenger ribonucleic acid level of fibroblast growth factor 3, teratocarcinoma-derived growth factor, neuropilin1, and endothelial Per/ARNT/Sim domain protein1, respectively.\n'
p3203
sg4
(lp3204
(dp3205
g7
I422
sg8
g15
sg10
I11
sg11
Vneuropilin1
p3206
sg13
I1
sa(dp3207
g7
I355
sg8
VP11487
p3208
sg10
I26
sg11
Vfibroblast growth factor 3
p3209
sg13
I4
sa(dp3210
g7
I455
sg8
VP27540
p3211
sg10
I4
sg11
VARNT
p3212
sg13
I1
sa(dp3213
g7
I460
sg8
g15
sg10
I3
sg11
VSim
p3214
sg13
I1
sa(dp3215
g7
I188
sg8
g15
sg10
I15
sg11
Vstanniocalcin 2
p3216
sg13
I2
sa(dp3217
g7
I118
sg8
VP36955
p3218
sg10
I4
sg11
VPEDF
p3219
sg13
I1
sa(dp3220
g7
I383
sg8
g15
sg10
I37
sg11
Vteratocarcinoma-derived growth factor
p3221
sg13
I3
sa(dp3222
g7
I205
sg8
g15
sg10
I39
sg11
Vbrain-specific angiogenesis inhibitor 2
p3223
sg13
I4
sasg19
(lp3224
(dp3225
g7
I383
sg22
VC0206664
p3226
sg10
I15
sg11
Vteratocarcinoma
p3227
sg13
I1
sa(dp3228
g7
I249
sg22
VC0333951
p3229
sg10
I13
sg11
Vgrowth arrest
p3230
sg13
I2
sasa(dp3231
g2
S'PSK reduced SMO, MAML3 and RBPJ expression in pancreatic cancer cells under hypoxia.\n'
p3232
sg4
(lp3233
(dp3234
g7
I17
sg8
g15
sg10
I5
sg11
VMAML3
p3235
sg13
I1
sa(dp3236
g7
I27
sg8
g15
sg10
I4
sg11
VRBPJ
p3237
sg13
I1
sa(dp3238
g7
I0
sg8
VP45877
p3239
sg10
I3
sg11
VPSK
p3240
sg13
I1
sa(dp3241
g7
I12
sg8
g15
sg10
I3
sg11
VSMO
p3242
sg13
I1
sasg19
(lp3243
(dp3244
g7
I76
sg22
VC0242184
p3245
sg10
I7
sg11
Vhypoxia
p3246
sg13
I1
sa(dp3247
g7
I46
sg22
VC0235974
p3248
sg10
I17
sg11
Vpancreatic cancer
p3249
sg13
I2
sasa(dp3250
g2
S'These results suggest that PSK suppresses Hedgehog signaling through down-regulation of MAML3 and RBPJ transcription under hypoxia, inhibiting the induction of a malignant phenotype in pancreatic cancer.\n'
p3251
sg4
(lp3252
(dp3253
g7
I88
sg8
g15
sg10
I5
sg11
VMAML3
p3254
sg13
I1
sa(dp3255
g7
I27
sg8
VP45877
p3256
sg10
I3
sg11
VPSK
p3257
sg13
I1
sa(dp3258
g7
I98
sg8
g15
sg10
I4
sg11
VRBPJ
p3259
sg13
I1
sasg19
(lp3260
(dp3261
g7
I123
sg22
VC0242184
p3262
sg10
I7
sg11
Vhypoxia
p3263
sg13
I1
sa(dp3264
g7
I185
sg22
VC0235974
p3265
sg10
I17
sg11
Vpancreatic cancer
p3266
sg13
I2
sasa(dp3267
g2
S'Our results suggest that hypoxia promotes SMO transcription through upregulation of MAML3 and RBPJ to induce proliferation, invasiveness and tumorigenesis in pancreatic cancer.\n'
p3268
sg4
(lp3269
(dp3270
g7
I84
sg8
g15
sg10
I5
sg11
VMAML3
p3271
sg13
I1
sa(dp3272
g7
I94
sg8
g15
sg10
I4
sg11
VRBPJ
p3273
sg13
I1
sa(dp3274
g7
I42
sg8
g15
sg10
I3
sg11
VSMO
p3275
sg13
I1
sasg19
(lp3276
(dp3277
g7
I25
sg22
VC0242184
p3278
sg10
I7
sg11
Vhypoxia
p3279
sg13
I1
sa(dp3280
g7
I109
sg22
VC0334094
p3281
sg10
I13
sg11
Vproliferation
p3282
sg13
I1
sa(dp3283
g7
I141
sg22
VC0007621
p3284
sg10
I13
sg11
Vtumorigenesis
p3285
sg13
I1
sa(dp3286
g7
I158
sg22
VC0235974
p3287
sg10
I17
sg11
Vpancreatic cancer
p3288
sg13
I2
sasa(dp3289
g2
S'A total of 75 anal lesions were retrieved from the files of the Department of Pathology of Barretos Cancer Hospital (Barretos, Brazil) in order to verify the human papillomavirus (HPV) statuses of these lesions and characterize the immunohistochemical expression levels of TOP2A and MCM2 in anal carcinoma, as these are important markers for cervical HPV-induced lesions; their expression was also compared with respect to p16 and Ki-67.\n'
p3290
sg4
(lp3291
(dp3292
g7
I423
sg8
VP42771
p3293
sg10
I3
sg11
Vp16
p3294
sg13
I1
sa(dp3295
g7
I273
sg8
g15
sg10
I5
sg11
VTOP2A
p3296
sg13
I1
sa(dp3297
g7
I283
sg8
VP33993
p3298
sg10
I4
sg11
VMCM2
p3299
sg13
I1
sa(dp3300
g7
I431
sg8
VP46013
p3301
sg10
I5
sg11
VKi-67
p3302
sg13
I1
sasg19
(lp3303
(dp3304
g7
I78
sg22
VC0677042
p3305
sg10
I9
sg11
VPathology
p3306
sg13
I1
sa(dp3307
g7
I291
sg22
VC0349534
p3308
sg10
I14
sg11
Vanal carcinoma
p3309
sg13
I2
sa(dp3310
g7
I100
sg22
VC0006826
p3311
sg10
I6
sg11
VCancer
p3312
sg13
I1
sasa(dp3313
g2
S'MCM2, TOP2A, p16 and Ki-67 exhibited intense positive staining in the anal lesions, indicating that these markers were significantly and constantly expressed in anal carcinoma.\n'
p3314
sg4
(lp3315
(dp3316
g7
I0
sg8
VP33993
p3317
sg10
I4
sg11
VMCM2
p3318
sg13
I1
sa(dp3319
g7
I21
sg8
VP46013
p3320
sg10
I5
sg11
VKi-67
p3321
sg13
I1
sa(dp3322
g7
I13
sg8
VP42771
p3323
sg10
I3
sg11
Vp16
p3324
sg13
I1
sa(dp3325
g7
I6
sg8
g15
sg10
I5
sg11
VTOP2A
p3326
sg13
I1
sasg19
(lp3327
(dp3328
g7
I161
sg22
VC0349534
p3329
sg10
I14
sg11
Vanal carcinoma
p3330
sg13
I2
sasa(dp3331
g2
S'Briefly, one cell proliferation marker, Ki-67 antigen (Ki-67), was upregulated in the cells with overexpressed GAS2, "Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer" [1].\n'
p3332
sg4
(lp3333
(dp3334
g7
I161
sg8
VP12004
p3335
sg10
I4
sg11
VPCNA
p3336
sg13
I1
sa(dp3337
g7
I40
sg8
VP46013
p3338
sg10
I5
sg11
VKi-67
p3339
sg13
I1
sa(dp3340
g7
I40
sg8
VP46013
p3341
sg10
I5
sg11
VKi-67
p3342
sg13
I1
sa(dp3343
g7
I111
sg8
g15
sg10
I4
sg11
VGAS2
p3344
sg13
I1
sa(dp3345
g7
I40
sg8
VP46013
p3346
sg10
I13
sg11
VKi-67 antigen
p3347
sg13
I2
sa(dp3348
g7
I184
sg8
VP10415
p3349
sg10
I27
sg11
Vantiapoptotic protein Bcl-2
p3350
sg13
I3
sasg19
(lp3351
(dp3352
g7
I18
sg22
VC0334094
p3353
sg10
I13
sg11
Vproliferation
p3354
sg13
I1
sa(dp3355
g7
I174
sg22
VC1865285
p3356
sg10
I3
sg11
VMCM
p3357
sg13
I1
sa(dp3358
g7
I215
sg22
VC1527249
p3359
sg10
I17
sg11
Vcolorectal cancer
p3360
sg13
I2
sa(dp3361
g7
I18
sg22
VC0334094
p3362
sg10
I13
sg11
Vproliferation
p3363
sg13
I1
sasa(dp3364
g2
S'RTKN could affect the proliferation and metastasis of colon cancer by reducing expression of MCM2/3/5, CDK1/2 and PCNA, suggesting that RTKN was a potential target for treating colon cancer.\n'
p3365
sg4
(lp3366
(dp3367
g7
I93
sg8
VP33993
p3368
sg10
I8
sg11
VMCM2/3/5
p3369
sg13
I1
sa(dp3370
g7
I0
sg8
g15
sg10
I4
sg11
VRTKN
p3371
sg13
I1
sa(dp3372
g7
I114
sg8
VP12004
p3373
sg10
I4
sg11
VPCNA
p3374
sg13
I1
sa(dp3375
g7
I103
sg8
VP06493
p3376
sg10
I6
sg11
VCDK1/2
p3377
sg13
I1
sa(dp3378
g7
I0
sg8
g15
sg10
I4
sg11
VRTKN
p3379
sg13
I1
sasg19
(lp3380
(dp3381
g7
I54
sg22
VC0699790
p3382
sg10
I12
sg11
Vcolon cancer
p3383
sg13
I2
sa(dp3384
g7
I22
sg22
VC0334094
p3385
sg10
I13
sg11
Vproliferation
p3386
sg13
I1
sa(dp3387
g7
I54
sg22
VC0699790
p3388
sg10
I12
sg11
Vcolon cancer
p3389
sg13
I2
sa(dp3390
g7
I40
sg22
VC0027627
p3391
sg10
I10
sg11
Vmetastasis
p3392
sg13
I1
sasa(dp3393
g2
S'We found that the expression of MCM7 is an independent risk factor for RFS in patients with Dukes C colorectal cancer.\n'
p3394
sg4
(lp3395
(dp3396
g7
I32
sg8
VP33993
p3397
sg10
I4
sg11
VMCM7
p3398
sg13
I1
sasg19
(lp3399
(dp3400
g7
I92
sg22
VC0677949
p3401
sg10
I25
sg11
VDukes C colorectal cancer
p3402
sg13
I4
sa(dp3403
g7
I71
sg22
VC0015624
p3404
sg10
I3
sg11
VRFS
p3405
sg13
I1
sasa(dp3406
g2
S'Further studies are required to investigate the validity of MCM7 protein expression for its potential clinical use in colorectal cancer therapy and prognosis.\n'
p3407
sg4
(lp3408
(dp3409
g7
I60
sg8
VP33993
p3410
sg10
I12
sg11
VMCM7 protein
p3411
sg13
I2
sasg19
(lp3412
(dp3413
g7
I118
sg22
VC1527249
p3414
sg10
I17
sg11
Vcolorectal cancer
p3415
sg13
I2
sasa(dp3416
g2
S'In 120 untreated patients (age: 53.5 +/- 11.2 years) with essential hypertension and 60 healthy controls, we measured (a) LV longitudinal, circumferential and radial strain (S), peak torsion and the percentage changes between peak twisting and untwisting at the end of early diastolic filling (%dpTw-UtwEDF) using speckle tracking echocardiography and (b) serum levels of ACE and NTproBNP.\n'
p3417
sg4
(lp3418
(dp3419
g7
I372
sg8
VP12821
p3420
sg10
I3
sg11
VACE
p3421
sg13
I1
sasg19
(lp3422
(dp3423
g7
I183
sg22
VC1265748
p3424
sg10
I7
sg11
Vtorsion
p3425
sg13
I1
sa(dp3426
g7
I58
sg22
VC0085580
p3427
sg10
I22
sg11
Vessential hypertension
p3428
sg13
I2
sasa(dp3429
g2
S'Plasma ADM, ANP and BNP concentrations were measured in 20 patients with AMH, 35 patients with essential hypertension (EH), and 40 healthy control subjects.\n'
p3430
sg4
(lp3431
(dp3432
g7
I0
sg8
VP35318
p3433
sg10
I10
sg11
VPlasma ADM
p3434
sg13
I2
sa(dp3435
g7
I20
sg8
VP16860
p3436
sg10
I3
sg11
VBNP
p3437
sg13
I1
sa(dp3438
g7
I12
sg8
VP16066
p3439
sg10
I3
sg11
VANP
p3440
sg13
I1
sasg19
(lp3441
(dp3442
g7
I119
sg22
VC0085580
p3443
sg10
I2
sg11
VEH
p3444
sg13
I1
sa(dp3445
g7
I95
sg22
VC0085580
p3446
sg10
I22
sg11
Vessential hypertension
p3447
sg13
I2
sasa(dp3448
g2
S'This study was designed to assess any changes in the plasma concentrations of adrenomedullin (ADM) and atrial and brain natriuretic peptide (ANP and BNP, respectively), and to investigate their pathophysiological roles in patients with essential hypertension (EH).\n'
p3449
sg4
(lp3450
(dp3451
g7
I114
sg8
VP16860
p3452
sg10
I25
sg11
Vbrain natriuretic peptide
p3453
sg13
I3
sa(dp3454
g7
I78
sg8
VP35318
p3455
sg10
I14
sg11
Vadrenomedullin
p3456
sg13
I1
sa(dp3457
g7
I141
sg8
VP16066
p3458
sg10
I3
sg11
VANP
p3459
sg13
I1
sa(dp3460
g7
I94
sg8
VP35318
p3461
sg10
I3
sg11
VADM
p3462
sg13
I1
sa(dp3463
g7
I149
sg8
VP16860
p3464
sg10
I3
sg11
VBNP
p3465
sg13
I1
sasg19
(lp3466
(dp3467
g7
I260
sg22
VC0085580
p3468
sg10
I2
sg11
VEH
p3469
sg13
I1
sa(dp3470
g7
I236
sg22
VC0085580
p3471
sg10
I22
sg11
Vessential hypertension
p3472
sg13
I2
sasa(dp3473
g2
S'Previously we demonstrated that a single intravenous injection of the myocardium-tropic adeno-associated virus (AAV) 9-based vector encoding for proBNP prevented the development of hypertensive heart disease (HHD) in spontaneously hypertensive rats (SHRs).\n'
p3474
sg4
(lp3475
sg19
(lp3476
(dp3477
g7
I181
sg22
VC0152105
p3478
sg10
I26
sg11
Vhypertensive heart disease
p3479
sg13
I3
sa(dp3480
g7
I209
sg22
VC0085106
p3481
sg10
I3
sg11
VHHD
p3482
sg13
I1
sasa(dp3483
g2
S'The current study was designed to determine the duration of cardiac transduction after a single AAV9 injection and to determine whether cardiac BNP overexpression can delay the progression of previously established HHD, and improve survival in aged SHRs with overt HHD.\n'
p3484
sg4
(lp3485
sg19
(lp3486
(dp3487
g7
I215
sg22
VC0085106
p3488
sg10
I3
sg11
VHHD
p3489
sg13
I1
sa(dp3490
g7
I215
sg22
VC0085106
p3491
sg10
I3
sg11
VHHD
p3492
sg13
I1
sasa(dp3493
g2
S'In aged SHRs (9-months of age), echocardiographic studies demonstrated progression of HHD in untreated controls, while AAV9-BNP vector treatment arrested the deterioration of cardiac function at six months post-injection (15-months of age).\n'
p3494
sg4
(lp3495
(dp3496
g7
I119
sg8
VP16860
p3497
sg10
I8
sg11
VAAV9-BNP
p3498
sg13
I1
sasg19
(lp3499
(dp3500
g7
I86
sg22
VC0085106
p3501
sg10
I3
sg11
VHHD
p3502
sg13
I1
sa(dp3503
g7
I145
sg22
VC0018790
p3504
sg10
I8
sg11
Varrested
p3505
sg13
I1
sasa(dp3506
g2
S'AAV9 induced cardiac BNP overexpression prevented development of congestive heart failure, and significantly prolonged the survival of aged SHRs with previously established overt HHD.\n'
p3507
sg4
(lp3508
(dp3509
g7
I21
sg8
VP16860
p3510
sg10
I3
sg11
VBNP
p3511
sg13
I1
sasg19
(lp3512
(dp3513
g7
I65
sg22
VC0018802
p3514
sg10
I24
sg11
Vcongestive heart failure
p3515
sg13
I3
sa(dp3516
g7
I179
sg22
VC0085106
p3517
sg10
I3
sg11
VHHD
p3518
sg13
I1
sasa(dp3519
g2
S'These findings support the beneficial effects of chronic supplementation of BNP in a frequent and highly morbid condition such as HHD.\n'
p3520
sg4
(lp3521
(dp3522
g7
I76
sg8
VP16860
p3523
sg10
I3
sg11
VBNP
p3524
sg13
I1
sasg19
(lp3525
(dp3526
g7
I112
sg22
VC0012634
p3527
sg10
I9
sg11
Vcondition
p3528
sg13
I1
sa(dp3529
g7
I130
sg22
VC0085106
p3530
sg10
I3
sg11
VHHD
p3531
sg13
I1
sasa(dp3532
g2
S'We measured urinary excretion of AQP2 and ENaC Beta-subunit corrected for creatinine (u-AQP2(CR), u-ENaC(Beta-CR)), prostaglandin E2 (u-PGE2) and cyclic AMP (u-cAMP), fractional sodium excretion (FE(Na)), free water clearance (C(H2O)), as well as plasma concentrations of vasopressin (AVP), renin (PRC), angiotensin II (Ang II), aldosterone (Aldo), and atrial and brain natriuretic peptide (ANP, BNP) in 21 patients with essential hypertension and 20 normotensive controls during 24-h urine collection (baseline), and after hypertonic saline infusion on a 4-day high sodium (HS) diet (300 mmol sodium/day) and a 4-day low sodium (LS) diet (30 mmol sodium/day).\n'
p3533
sg4
(lp3534
(dp3535
g7
I391
sg8
VP16066
p3536
sg10
I3
sg11
VANP
p3537
sg13
I1
sa(dp3538
g7
I33
sg8
VP41181
p3539
sg10
I4
sg11
VAQP2
p3540
sg13
I1
sa(dp3541
g7
I285
sg8
VP01185
p3542
sg10
I3
sg11
VAVP
p3543
sg13
I1
sa(dp3544
g7
I244
sg8
VP01185
p3545
sg10
I39
sg11
Vas plasma concentrations of vasopressin
p3546
sg13
I5
sa(dp3547
g7
I298
sg8
g15
sg10
I3
sg11
VPRC
p3548
sg13
I1
sa(dp3549
g7
I93
sg8
VP22676
p3550
sg10
I2
sg11
VCR
p3551
sg13
I1
sa(dp3552
g7
I98
sg8
VP37088
p3553
sg10
I6
sg11
Vu-ENaC
p3554
sg13
I1
sa(dp3555
g7
I360
sg8
VP16066
p3556
sg10
I29
sg11
Vand brain natriuretic peptide
p3557
sg13
I4
sa(dp3558
g7
I42
sg8
VP37088
p3559
sg10
I17
sg11
VENaC Beta-subunit
p3560
sg13
I2
sa(dp3561
g7
I291
sg8
VP00797
p3562
sg10
I5
sg11
Vrenin
p3563
sg13
I1
sa(dp3564
g7
I304
sg8
VP01019
p3565
sg10
I14
sg11
Vangiotensin II
p3566
sg13
I2
sa(dp3567
g7
I105
sg8
VP22676
p3568
sg10
I7
sg11
VBeta-CR
p3569
sg13
I1
sa(dp3570
g7
I320
sg8
VP01019
p3571
sg10
I6
sg11
VAng II
p3572
sg13
I2
sasg19
(lp3573
(dp3574
g7
I421
sg22
VC0085580
p3575
sg10
I22
sg11
Vessential hypertension
p3576
sg13
I2
sasa(dp3577
g2
S'SIRs of cancers having temporal overlap with the active phase of myositis [cancers concurrent with active myositis (CAM), n = 30] and cancers not having such temporal overlap [cancers non-concurrent with active myositis (CNM), n = 22] were compared in 281 patients.\n'
p3578
sg4
(lp3579
sg19
(lp3580
(dp3581
g7
I83
sg22
VC1861821
p3582
sg10
I31
sg11
Vconcurrent with active myositis
p3583
sg13
I4
sa(dp3584
g7
I83
sg22
VC1861821
p3585
sg10
I31
sg11
Vconcurrent with active myositis
p3586
sg13
I4
sa(dp3587
g7
I8
sg22
VC0006826
p3588
sg10
I7
sg11
Vcancers
p3589
sg13
I1
sa(dp3590
g7
I65
sg22
VC0027121
p3591
sg10
I8
sg11
Vmyositis
p3592
sg13
I1
sa(dp3593
g7
I8
sg22
VC0006826
p3594
sg10
I7
sg11
Vcancers
p3595
sg13
I1
sa(dp3596
g7
I116
sg22
VC1861821
p3597
sg10
I3
sg11
VCAM
p3598
sg13
I1
sa(dp3599
g7
I8
sg22
VC0006826
p3600
sg10
I7
sg11
Vcancers
p3601
sg13
I1
sa(dp3602
g7
I8
sg22
VC0006826
p3603
sg10
I7
sg11
Vcancers
p3604
sg13
I1
sa(dp3605
g7
I0
sg22
VC0242966
p3606
sg10
I4
sg11
VSIRs
p3607
sg13
I1
sasa(dp3608
g2
S'When stratified by myositis-cancer intervals, CAM SIR was 9.94 (6.43, 14.67) within 1 year of myositis diagnosis, whereas no temporal relationship was found for CNM.\n'
p3609
sg4
(lp3610
sg19
(lp3611
(dp3612
g7
I19
sg22
VC0027121
p3613
sg10
I8
sg11
Vmyositis
p3614
sg13
I1
sa(dp3615
g7
I28
sg22
VC0006826
p3616
sg10
I6
sg11
Vcancer
p3617
sg13
I1
sa(dp3618
g7
I19
sg22
VC0027121
p3619
sg10
I8
sg11
Vmyositis
p3620
sg13
I1
sa(dp3621
g7
I46
sg22
VC1861821
p3622
sg10
I3
sg11
VCAM
p3623
sg13
I1
sasa(dp3624
g2
S'The cancer stage at the time of diagnosis was more advanced in CAM than CNM (P &lt; 0.001), with a correspondingly increased hazard ratio of mortality [4.3 (1.5, 12.7)] in patients with CAM vs CNM.\n'
p3625
sg4
(lp3626
sg19
(lp3627
(dp3628
g7
I4
sg22
VC0006826
p3629
sg10
I6
sg11
Vcancer
p3630
sg13
I1
sa(dp3631
g7
I63
sg22
VC1861821
p3632
sg10
I3
sg11
VCAM
p3633
sg13
I1
sa(dp3634
g7
I63
sg22
VC1861821
p3635
sg10
I3
sg11
VCAM
p3636
sg13
I1
sasa(dp3637
g2
S'Multiple types of cancers showed elevated SIRs among CAM, but none among CNM.\n'
p3638
sg4
(lp3639
sg19
(lp3640
(dp3641
g7
I18
sg22
VC0006826
p3642
sg10
I7
sg11
Vcancers
p3643
sg13
I1
sa(dp3644
g7
I53
sg22
VC1861821
p3645
sg10
I3
sg11
VCAM
p3646
sg13
I1
sa(dp3647
g7
I42
sg22
VC0242966
p3648
sg10
I4
sg11
VSIRs
p3649
sg13
I1
sasa(dp3650
g2
S'We analyzed 15 conventional melanomas (CMs), 3 melanomas arising in congenital nevi (CNMs), and 5 spitzoid melanomas (SMs), using various platforms, including whole genome or exome sequencing, the molecular inversion probe assay, and/or targeted sequencing.\n'
p3651
sg4
(lp3652
sg19
(lp3653
(dp3654
g7
I28
sg22
VC0025202
p3655
sg10
I9
sg11
Vmelanomas
p3656
sg13
I1
sa(dp3657
g7
I28
sg22
VC0025202
p3658
sg10
I9
sg11
Vmelanomas
p3659
sg13
I1
sa(dp3660
g7
I207
sg22
VC0021943
p3661
sg10
I9
sg11
Vinversion
p3662
sg13
I1
sa(dp3663
g7
I118
sg22
VC0795864
p3664
sg10
I3
sg11
VSMs
p3665
sg13
I1
sa(dp3666
g7
I79
sg22
VC0027962
p3667
sg10
I4
sg11
Vnevi
p3668
sg13
I1
sa(dp3669
g7
I98
sg22
VC0795864
p3670
sg10
I18
sg11
Vspitzoid melanomas
p3671
sg13
I2
sasa(dp3672
g2
S'In the present study, we aimed to investigate the role of myotubularin-related phosphatase 3 (MTMR3) in CRC cell growth via lentivirus-mediated small interfering RNA (siRNA) transduction in human colon cancer cell lines HCT116 and SW1116.\n'
p3673
sg4
(lp3674
(dp3675
g7
I94
sg8
g15
sg10
I5
sg11
VMTMR3
p3676
sg13
I1
sa(dp3677
g7
I58
sg8
g15
sg10
I34
sg11
Vmyotubularin-related phosphatase 3
p3678
sg13
I3
sasg19
(lp3679
(dp3680
g7
I104
sg22
VC1527249
p3681
sg10
I3
sg11
VCRC
p3682
sg13
I1
sa(dp3683
g7
I196
sg22
VC0699790
p3684
sg10
I12
sg11
Vcolon cancer
p3685
sg13
I2
sasa(dp3686
g2
S'Type I CMN is the most common, usually, if not always, a single lesion, it consists of a plaque that involves only 1 anatomic region and does not go beyond it; type I CNM grows in proportion to the growth of the child, melanoma rarely develops from it, and when it does it usually arises at the dermoepidermal junction.\n'
p3687
sg4
(lp3688
sg19
(lp3689
(dp3690
g7
I219
sg22
VC0025202
p3691
sg10
I8
sg11
Vmelanoma
p3692
sg13
I1
sa(dp3693
g7
I89
sg22
VC0011389
p3694
sg10
I6
sg11
Vplaque
p3695
sg13
I1
sasa(dp3696
g2
S'Tamoxifen (Tmf), is a standard of care for women with estrogen receptor positive (ER+) breast cancer.\n'
p3697
sg4
(lp3698
(dp3699
g7
I54
sg8
VP03372
p3700
sg10
I17
sg11
Vestrogen receptor
p3701
sg13
I2
sa(dp3702
g7
I0
sg8
g15
sg10
I9
sg11
VTamoxifen
p3703
sg13
I1
sa(dp3704
g7
I11
sg8
VP82094
p3705
sg10
I3
sg11
VTmf
p3706
sg13
I1
sasg19
(lp3707
(dp3708
g7
I87
sg22
VC0678222
p3709
sg10
I13
sg11
Vbreast cancer
p3710
sg13
I2
sasa(dp3711
g2
S'In the group of breast cancer patients (P T0-2N0-1M0) who received adjuvant polychemotherapy (TMF, CMF schemes) the survival rates are higher by 12.0%-16.6% than in the control group during the sixth, seventh, and eighth years of the follow-up.\n'
p3712
sg4
(lp3713
sg19
(lp3714
(dp3715
g7
I16
sg22
VC0678222
p3716
sg10
I13
sg11
Vbreast cancer
p3717
sg13
I2
sasa(dp3718
g2
S'The study included myopic and hyperopic eyes with preoperative best corrected visual acuity (BCVA) = 1 (20/20), of the total number of 322 divided into 2 groups--1) myopic eyes (n = 241) which were divided into 4 subgroups according to the myopia strength: a) &lt; or = -1.75 D (n = 23), b) from -2 to -3.75 D (n = 81), c) from -4 to -6.75 D (n = 113), d) &gt; or = -7 D (n = 24); 2) hyperopic eyes (n = 81) which were divided into 3 subgroups according to the hyperopia strength: a) &lt; or = +1.75D (n = 10), b) from +2 to +3.75 D (n = 46), c) &gt; or = +4 D (n = 25).\n'
p3719
sg4
(lp3720
sg19
(lp3721
(dp3722
g7
I240
sg22
VC0027092
p3723
sg10
I6
sg11
Vmyopia
p3724
sg13
I1
sa(dp3725
g7
I461
sg22
VC0020490
p3726
sg10
I9
sg11
Vhyperopia
p3727
sg13
I1
sasa(dp3728
g2
S'However a very significant difference was found according to histotype: five year disease specific survival was 84% (CI 66-93) for the well- differentiated and only 35% (CI 20-51) for the dedifferentiated liposarcoma (p &lt; 0.0001).\n'
p3729
sg4
(lp3730
sg19
(lp3731
(dp3732
g7
I188
sg22
VC0205824
p3733
sg10
I28
sg11
Vdedifferentiated liposarcoma
p3734
sg13
I2
sasa(dp3735
g2
S'FDG-PET/CT had a sensitivity of 100% (95% CI 63-100) and specificity of 100% (95% CI 20-100) for the detection of recurrent uterine leiomyosarcomas.\n'
p3736
sg4
(lp3737
sg19
(lp3738
(dp3739
g7
I132
sg22
VC0023269
p3740
sg10
I15
sg11
Vleiomyosarcomas
p3741
sg13
I1
sasa(dp3742
g2
S'The NGF (angiogenesis) and VEGF-C (lymphangiogenesis) might play a crucial role in the pathogenesis of psoriasis vulgaris and could be researched further as potential new targeted therapies for psoriasis vulgaris.\n'
p3743
sg4
(lp3744
(dp3745
g7
I4
sg8
VP01138
p3746
sg10
I18
sg11
VNGF (angiogenesis)
p3747
sg13
I2
sa(dp3748
g7
I27
sg8
VP49767
p3749
sg10
I6
sg11
VVEGF-C
p3750
sg13
I1
sasg19
(lp3751
(dp3752
g7
I87
sg22
VC0699748
p3753
sg10
I12
sg11
Vpathogenesis
p3754
sg13
I1
sa(dp3755
g7
I103
sg22
VC0263361
p3756
sg10
I18
sg11
Vpsoriasis vulgaris
p3757
sg13
I2
sa(dp3758
g7
I103
sg22
VC0263361
p3759
sg10
I18
sg11
Vpsoriasis vulgaris
p3760
sg13
I2
sasa(dp3761
g2
S"Taken together, these findings suggested that crmp2 is a target of miR-181c and that the abnormally low expression of miR-181c in the hippocampus of SAMP8 mice could lead to an increase of the crmp2 protein level in AD mice, which might potentially play a role in the pathogenesis of Alzheimer's disease.\n"
p3762
sg4
(lp3763
(dp3764
g7
I67
sg8
g15
sg10
I8
sg11
VmiR-181c
p3765
sg13
I1
sa(dp3766
g7
I67
sg8
g15
sg10
I8
sg11
VmiR-181c
p3767
sg13
I1
sa(dp3768
g7
I46
sg8
g15
sg10
I5
sg11
Vcrmp2
p3769
sg13
I1
sa(dp3770
g7
I193
sg8
g15
sg10
I13
sg11
Vcrmp2 protein
p3771
sg13
I2
sasg19
(lp3772
(dp3773
g7
I284
sg22
VC1521724
p3774
sg10
I19
sg11
VAlzheimer's disease
p3775
sg13
I2
sa(dp3776
g7
I268
sg22
VC0699748
p3777
sg10
I12
sg11
Vpathogenesis
p3778
sg13
I1
sasa(dp3779
g2
S'The E3 ubiquitin ligase synoviolin (SYVN1) functions as an anti-apoptotic factor that is responsible for the outgrowth of synovial cells during the development of rheumatoid arthritis.\n'
p3780
sg4
(lp3781
(dp3782
g7
I36
sg8
g15
sg10
I5
sg11
VSYVN1
p3783
sg13
I1
sa(dp3784
g7
I7
sg8
g15
sg10
I27
sg11
Vubiquitin ligase synoviolin
p3785
sg13
I3
sasg19
(lp3786
(dp3787
g7
I163
sg22
VC0003873
p3788
sg10
I20
sg11
Vrheumatoid arthritis
p3789
sg13
I2
sasa(dp3790
g2
S'Here, we report that elevated SYVN1 expression correlates with decreased levels of the protein inositol-requiring enzyme 1 (IRE1)-a pro-apoptotic factor in the endoplasmic reticulum (ER)-stress-induced apoptosis pathway-in synovial fibroblasts from mice with collagen-induced arthritis (CIA).\n'
p3791
sg4
(lp3792
(dp3793
g7
I124
sg8
VP21399
p3794
sg10
I4
sg11
VIRE1
p3795
sg13
I1
sa(dp3796
g7
I95
sg8
VP21399
p3797
sg10
I27
sg11
Vinositol-requiring enzyme 1
p3798
sg13
I3
sa(dp3799
g7
I30
sg8
g15
sg10
I5
sg11
VSYVN1
p3800
sg13
I1
sasg19
(lp3801
(dp3802
g7
I276
sg22
VC0003864
p3803
sg10
I9
sg11
Varthritis
p3804
sg13
I1
sasa(dp3805
g2
S'Higher levels of insulin and glucose, lower levels of HDL, higher levels of TC/HDL and HOMA values, and different levels of some hormones were noted only in the women with abdominal, and not general obesity.\n'
p3806
sg4
(lp3807
(dp3808
g7
I17
sg8
VP01308
p3809
sg10
I7
sg11
Vinsulin
p3810
sg13
I1
sa(dp3811
g7
I54
sg8
VP28845
p3812
sg10
I3
sg11
VHDL
p3813
sg13
I1
sa(dp3814
g7
I54
sg8
VP28845
p3815
sg10
I3
sg11
VHDL
p3816
sg13
I1
sasg19
(lp3817
(dp3818
g7
I199
sg22
VC0028754
p3819
sg10
I7
sg11
Vobesity
p3820
sg13
I1
sasa(dp3821
g2
S'Abdominal obesity is associated with insulin resistance and with higher risks of metabolic syndrome and cardiovascular diseases, whereas general obesity is not.\n'
p3822
sg4
(lp3823
(dp3824
g7
I37
sg8
VP01308
p3825
sg10
I7
sg11
Vinsulin
p3826
sg13
I1
sasg19
(lp3827
(dp3828
g7
I37
sg22
VC0021655
p3829
sg10
I18
sg11
Vinsulin resistance
p3830
sg13
I2
sa(dp3831
g7
I104
sg22
VC0007222
p3832
sg10
I23
sg11
Vcardiovascular diseases
p3833
sg13
I2
sa(dp3834
g7
I10
sg22
VC0028754
p3835
sg10
I7
sg11
Vobesity
p3836
sg13
I1
sa(dp3837
g7
I0
sg22
VC0311277
p3838
sg10
I17
sg11
VAbdominal obesity
p3839
sg13
I2
sa(dp3840
g7
I81
sg22
VC0524620
p3841
sg10
I18
sg11
Vmetabolic syndrome
p3842
sg13
I2
sasa(dp3843
g2
S'The present study aims at examining the effects of argan oil on the three main cardiovascular risk factors associated with metabolic syndrome (hypertension, insulin resistance and obesity) and on one of its main complications, neuropathic pain.\n'
p3844
sg4
(lp3845
(dp3846
g7
I157
sg8
VP01308
p3847
sg10
I7
sg11
Vinsulin
p3848
sg13
I1
sasg19
(lp3849
(dp3850
g7
I123
sg22
VC0524620
p3851
sg10
I18
sg11
Vmetabolic syndrome
p3852
sg13
I2
sa(dp3853
g7
I143
sg22
VC0020538
p3854
sg10
I12
sg11
Vhypertension
p3855
sg13
I1
sa(dp3856
g7
I180
sg22
VC0028754
p3857
sg10
I7
sg11
Vobesity
p3858
sg13
I1
sa(dp3859
g7
I157
sg22
VC0021655
p3860
sg10
I18
sg11
Vinsulin resistance
p3861
sg13
I2
sa(dp3862
g7
I227
sg22
VC0027796
p3863
sg10
I16
sg11
Vneuropathic pain
p3864
sg13
I2
sasa(dp3865
g2
S'A total of 97 IDDs subjects including 51 MS and 46 neuromyelitis optica spectrum disorder (NMOSD) patients, and 34 healthy controls (HCs) were tested for the detection of IgG, IgM and IgA against mycobacterial antigens by indirect ELISA.\n'
p3866
sg4
(lp3867
(dp3868
g7
I176
sg8
VP29965
p3869
sg10
I3
sg11
VIgM
p3870
sg13
I1
sa(dp3871
g7
I184
sg8
VP11912
p3872
sg10
I3
sg11
VIgA
p3873
sg13
I1
sasg19
(lp3874
(dp3875
g7
I51
sg22
VC0027873
p3876
sg10
I20
sg11
Vneuromyelitis optica
p3877
sg13
I2
sasa(dp3878
g2
S'Cerebrospinal fluid (CSF) and serum sCD40L levels were measured in 29 multiple sclerosis (MS), 29 neuromyelitis optica spectrum disorder (NMOSD), and 27 disease control (DC) patients.\n'
p3879
sg4
(lp3880
sg19
(lp3881
(dp3882
g7
I70
sg22
VC0026769
p3883
sg10
I18
sg11
Vmultiple sclerosis
p3884
sg13
I2
sa(dp3885
g7
I90
sg22
VC0026769
p3886
sg10
I2
sg11
VMS
p3887
sg13
I1
sa(dp3888
g7
I98
sg22
VC0027873
p3889
sg10
I20
sg11
Vneuromyelitis optica
p3890
sg13
I2
sasa(dp3891
g2
S'Viral hepatitis markers, anti-HIV, toxoplasma-IgM, CMV-IgM, rubella-IgM, EBV-VCA-IgM, VDRL, Brucella tube agglutination, echinococcus antibody, autoantibody tests and neuromyelitis optica test were negative.\n'
p3892
sg4
(lp3893
(dp3894
g7
I51
sg8
VP29965
p3895
sg10
I7
sg11
VCMV-IgM
p3896
sg13
I1
sa(dp3897
g7
I25
sg8
VP29965
p3898
sg10
I24
sg11
Vanti-HIV, toxoplasma-IgM
p3899
sg13
I2
sa(dp3900
g7
I60
sg8
VP29965
p3901
sg10
I11
sg11
Vrubella-IgM
p3902
sg13
I1
sa(dp3903
g7
I73
sg8
VP29965
p3904
sg10
I11
sg11
VEBV-VCA-IgM
p3905
sg13
I1
sasg19
(lp3906
(dp3907
g7
I30
sg22
VC0019693
p3908
sg10
I3
sg11
VHIV
p3909
sg13
I1
sa(dp3910
g7
I167
sg22
VC0027873
p3911
sg10
I20
sg11
Vneuromyelitis optica
p3912
sg13
I2
sa(dp3913
g7
I0
sg22
VC0042721
p3914
sg10
I15
sg11
VViral hepatitis
p3915
sg13
I2
sa(dp3916
g7
I60
sg22
VC0035920
p3917
sg10
I7
sg11
Vrubella
p3918
sg13
I1
sasa(dp3919
g2
S'This study was undertaken to investigate the association of aldosterone synthase C-344T, angiotensin II type I receptor A1166C and 11- hydroxysteroid dehydrogenase type 2 G534A polymorphisms with essential hypertension in the population of Odisha, India.\n'
p3920
sg4
(lp3921
(dp3922
g7
I60
sg8
VP15538
p3923
sg10
I27
sg11
Valdosterone synthase C-344T
p3924
sg13
I3
sa(dp3925
g7
I89
sg8
VP01019
p3926
sg10
I37
sg11
Vangiotensin II type I receptor A1166C
p3927
sg13
I6
sa(dp3928
g7
I131
sg8
VP49366
p3929
sg10
I45
sg11
V11- hydroxysteroid dehydrogenase type 2 G534A
p3930
sg13
I6
sasg19
(lp3931
(dp3932
g7
I196
sg22
VC0085580
p3933
sg10
I22
sg11
Vessential hypertension
p3934
sg13
I2
sasa(dp3935
g2
S'The expression of PG-M1, the most specific histiocytic marker, has not yet been studied in granuloma annulare (GA) and other palisaded granulomas of the skin.\n'
p3936
sg4
(lp3937
sg19
(lp3938
(dp3939
g7
I91
sg22
VC0085074
p3940
sg10
I18
sg11
Vgranuloma annulare
p3941
sg13
I2
sa(dp3942
g7
I135
sg22
VC0018188
p3943
sg10
I10
sg11
Vgranulomas
p3944
sg13
I1
sa(dp3945
g7
I111
sg22
VC0085074
p3946
sg10
I2
sg11
VGA
p3947
sg13
I1
sasa(dp3948
g2
S'Because opioid peptides might be of importance in inflammatory skin diseases, for example psoriasis, sections of skin from psoriatic patients were immunohistochemically stained with antisera against methionine and leucine enkephalin, CD68 (KP1, PG-M1), calprotectin (M747), M130 (Ber-MAC3), CD1a and CD3.\n'
p3949
sg4
(lp3950
(dp3951
g7
I234
sg8
VP34810
p3952
sg10
I4
sg11
VCD68
p3953
sg13
I1
sa(dp3954
g7
I291
sg8
VP15813
p3955
sg10
I4
sg11
VCD1a
p3956
sg13
I1
sa(dp3957
g7
I274
sg8
g15
sg10
I4
sg11
VM130
p3958
sg13
I1
sa(dp3959
g7
I8
sg8
g15
sg10
I15
sg11
Vopioid peptides
p3960
sg13
I2
sa(dp3961
g7
I214
sg8
VP30740
p3962
sg10
I18
sg11
Vleucine enkephalin
p3963
sg13
I2
sasg19
(lp3964
(dp3965
g7
I90
sg22
VC0033860
p3966
sg10
I9
sg11
Vpsoriasis
p3967
sg13
I1
sa(dp3968
g7
I63
sg22
VC0037274
p3969
sg10
I13
sg11
Vskin diseases
p3970
sg13
I2
sasa(dp3971
g2
S"The resting plasma PGF2 alpha in ten 'aspirin-sensitive' urticaria patients (24.89 +/- 2.79 pg m-1) was significantly higher than the levels in ten normal subjects (6.75 +/- 1.1 pg ml-1) (P less than 0.01).\n"
p3972
sg4
(lp3973
sg19
(lp3974
(dp3975
g7
I57
sg22
VC0042109
p3976
sg10
I9
sg11
Vurticaria
p3977
sg13
I1
sasa(dp3978
g2
S'However, combining previously published data from various authors with our own, significant associations between this skin disease and genetic polymorphisms such as MN, Gc, Gm (2), red cell acid phosphatase, and red cell phosphoglucomutase (PGM1) were seen.\n'
p3979
sg4
(lp3980
(dp3981
g7
I241
sg8
VP36871
p3982
sg10
I4
sg11
VPGM1
p3983
sg13
I1
sa(dp3984
g7
I181
sg8
VP16435
p3985
sg10
I25
sg11
Vred cell acid phosphatase
p3986
sg13
I4
sa(dp3987
g7
I212
sg8
VP16435
p3988
sg10
I27
sg11
Vred cell phosphoglucomutase
p3989
sg13
I3
sasg19
(lp3990
(dp3991
g7
I118
sg22
VC0037274
p3992
sg10
I12
sg11
Vskin disease
p3993
sg13
I2
sasa(dp3994
g2
S'In 239 German patients with atopic conditions (atopic dermatitis, hay fever, allergic rhinitis, bronchial asthma, and acute urticaria) the phenotype and gene distribution of 15 genetic blood polymorphisms (ABO, MNSs, rhesus, P, Kell, Duffy, Kidd, Hp, Gc, Gm, Inv, aP, PGM1, EsD, and 6-PGD) were analyzed and compared with those in 151 selected controls (individuals clinically free of allergic conditions and without allergy in the family history).\n'
p3995
sg4
(lp3996
(dp3997
g7
I268
sg8
VP36871
p3998
sg10
I4
sg11
VPGM1
p3999
sg13
I1
sa(dp4000
g7
I274
sg8
VP10768
p4001
sg10
I3
sg11
VEsD
p4002
sg13
I1
sa(dp4003
g7
I259
sg8
g15
sg10
I3
sg11
VInv
p4004
sg13
I1
sasg19
(lp4005
(dp4006
g7
I77
sg22
VC2607914
p4007
sg10
I17
sg11
Vallergic rhinitis
p4008
sg13
I2
sa(dp4009
g7
I28
sg22
VC0392707
p4010
sg10
I6
sg11
Vatopic
p4011
sg13
I1
sa(dp4012
g7
I96
sg22
VC0004096
p4013
sg10
I16
sg11
Vbronchial asthma
p4014
sg13
I2
sa(dp4015
g7
I417
sg22
VC0020517
p4016
sg10
I7
sg11
Vallergy
p4017
sg13
I1
sa(dp4018
g7
I66
sg22
VC0018621
p4019
sg10
I9
sg11
Vhay fever
p4020
sg13
I2
sa(dp4021
g7
I118
sg22
VC0234935
p4022
sg10
I15
sg11
Vacute urticaria
p4023
sg13
I2
sa(dp4024
g7
I47
sg22
VC0011615
p4025
sg10
I17
sg11
Vatopic dermatitis
p4026
sg13
I2
sasa(dp4027
g2
S"To examine the relationship between HLA-DRB1 alleles and the clinical expression of the secondary form of Sjogren's syndrome (SS) in patients with rheumatoid arthritis (RA).\n"
p4028
sg4
(lp4029
(dp4030
g7
I36
sg8
VP20039
p4031
sg10
I16
sg11
VHLA-DRB1 alleles
p4032
sg13
I2
sasg19
(lp4033
(dp4034
g7
I106
sg22
VC1527336
p4035
sg10
I18
sg11
VSjogren's syndrome
p4036
sg13
I2
sa(dp4037
g7
I147
sg22
VC0003873
p4038
sg10
I20
sg11
Vrheumatoid arthritis
p4039
sg13
I2
sa(dp4040
g7
I126
sg22
VC1527336
p4041
sg10
I2
sg11
VSS
p4042
sg13
I1
sa(dp4043
g7
I169
sg22
VC0003873
p4044
sg10
I2
sg11
VRA
p4045
sg13
I1
sasa(dp4046
g2
S'Our identification and independent replication of variants in KCNK3, a gene implicated in primary hyperaldosteronism, as well as a variant in HOTTIP (HOXA-EVX1) suggest that further work to clarify the roles of these genes may be warranted.\n'
p4047
sg4
(lp4048
(dp4049
g7
I62
sg8
g15
sg10
I5
sg11
VKCNK3
p4050
sg13
I1
sa(dp4051
g7
I150
sg8
VP49640
p4052
sg10
I9
sg11
VHOXA-EVX1
p4053
sg13
I1
sasg19
(lp4054
(dp4055
g7
I90
sg22
VC1384514
p4056
sg10
I26
sg11
Vprimary hyperaldosteronism
p4057
sg13
I2
sasa(dp4058
g2
S'The role of the two-pore domain K+ (K2P) channel TASK-1 (KCNK3) in lung cancer is at present unknown.\n'
p4059
sg4
(lp4060
(dp4061
g7
I49
sg8
g15
sg10
I6
sg11
VTASK-1
p4062
sg13
I1
sa(dp4063
g7
I57
sg8
g15
sg10
I5
sg11
VKCNK3
p4064
sg13
I1
sasg19
(lp4065
(dp4066
g7
I67
sg22
VC0684249
p4067
sg10
I11
sg11
Vlung cancer
p4068
sg13
I2
sasa(dp4069
g2
S'We found that TASK-1 is expressed in non-small cell lung cancer (NSCLC) cell lines at variable levels.\n'
p4070
sg4
(lp4071
(dp4072
g7
I14
sg8
g15
sg10
I6
sg11
VTASK-1
p4073
sg13
I1
sasg19
(lp4074
(dp4075
g7
I37
sg22
VC0007131
p4076
sg10
I26
sg11
Vnon-small cell lung cancer
p4077
sg13
I4
sa(dp4078
g7
I65
sg22
VC0007131
p4079
sg10
I5
sg11
VNSCLC
p4080
sg13
I1
sasa(dp4081
g2
S'In a highly TASK-1 expressing NSCLC cell line, A549, a characteristic pH- and hypoxia-sensitive non-inactivating K+ current was measured, indicating the presence of functional TASK-1 channels.\n'
p4082
sg4
(lp4083
(dp4084
g7
I176
sg8
g15
sg10
I15
sg11
VTASK-1 channels
p4085
sg13
I2
sasg19
(lp4086
(dp4087
g7
I30
sg22
VC0007131
p4088
sg10
I5
sg11
VNSCLC
p4089
sg13
I1
sa(dp4090
g7
I78
sg22
VC0242184
p4091
sg10
I7
sg11
Vhypoxia
p4092
sg13
I1
sasa(dp4093
g2
S'In contrast to TASK-1, which was not differentially expressed in lung cancer vs. normal lung tissue, we found the Na+-coupled nutrient transporters, SLC5A3, SLC5A6, and SLC38A1, transporters for myo-inositol, biotin and glutamine, respectively, to be significantly overexpressed in lung adenocarcinomas.\n'
p4094
sg4
(lp4095
(dp4096
g7
I15
sg8
g15
sg10
I6
sg11
VTASK-1
p4097
sg13
I1
sa(dp4098
g7
I114
sg8
g15
sg10
I33
sg11
VNa+-coupled nutrient transporters
p4099
sg13
I3
sa(dp4100
g7
I157
sg8
g15
sg10
I6
sg11
VSLC5A6
p4101
sg13
I1
sa(dp4102
g7
I169
sg8
g15
sg10
I7
sg11
VSLC38A1
p4103
sg13
I1
sa(dp4104
g7
I149
sg8
VP53794
p4105
sg10
I6
sg11
VSLC5A3
p4106
sg13
I1
sasg19
(lp4107
(dp4108
g7
I65
sg22
VC0684249
p4109
sg10
I11
sg11
Vlung cancer
p4110
sg13
I2
sa(dp4111
g7
I287
sg22
VC0001418
p4112
sg10
I15
sg11
Vadenocarcinomas
p4113
sg13
I1
sasa(dp4114
g2
S'In summary, we show for the first time that the TASK-1 channel regulates apoptosis and proliferation in a subset of NSCLC.\n'
p4115
sg4
(lp4116
(dp4117
g7
I48
sg8
g15
sg10
I14
sg11
VTASK-1 channel
p4118
sg13
I2
sasg19
(lp4119
(dp4120
g7
I87
sg22
VC0334094
p4121
sg10
I13
sg11
Vproliferation
p4122
sg13
I1
sa(dp4123
g7
I116
sg22
VC0007131
p4124
sg10
I5
sg11
VNSCLC
p4125
sg13
I1
sasa(dp4126
g2
S'Three potassium channels have been associated with primary aldosteronism (PA) in rodents and humans: KCNK3 (TASK-1), KCNK9 (TASK-3), and KCNJ5 (Kir3.4).\n'
p4127
sg4
(lp4128
(dp4129
g7
I117
sg8
g15
sg10
I5
sg11
VKCNK9
p4130
sg13
I1
sa(dp4131
g7
I101
sg8
g15
sg10
I5
sg11
VKCNK3
p4132
sg13
I1
sa(dp4133
g7
I144
sg8
VP48544
p4134
sg10
I6
sg11
VKir3.4
p4135
sg13
I1
sa(dp4136
g7
I124
sg8
g15
sg10
I6
sg11
VTASK-3
p4137
sg13
I1
sa(dp4138
g7
I137
sg8
VP48544
p4139
sg10
I5
sg11
VKCNJ5
p4140
sg13
I1
sa(dp4141
g7
I108
sg8
g15
sg10
I6
sg11
VTASK-1
p4142
sg13
I1
sasg19
(lp4143
(dp4144
g7
I51
sg22
VC1384514
p4145
sg10
I21
sg11
Vprimary aldosteronism
p4146
sg13
I2
sa(dp4147
g7
I74
sg22
VC1384514
p4148
sg10
I2
sg11
VPA
p4149
sg13
I1
sasa(dp4150
g2
S'In the experiments here, the small interfering RNAs (siRNAs) targeted against TASK-1, an acid-sensitive member of two-pore domain K(+) (K2P) channel family, were transfected into mouse neuroblastoma N2A cells.\n'
p4151
sg4
(lp4152
(dp4153
g7
I136
sg8
g15
sg10
I3
sg11
VK2P
p4154
sg13
I1
sa(dp4155
g7
I78
sg8
g15
sg10
I6
sg11
VTASK-1
p4156
sg13
I1
sasg19
(lp4157
(dp4158
g7
I179
sg22
VC1524043
p4159
sg10
I19
sg11
Vmouse neuroblastoma
p4160
sg13
I2
sasa(dp4161
g2
S'In the present study, the expressions of two members of acid-sensitive TASK channels, TASK-1 and TASK-2, were detected in mouse neuroblastoma N2A cells by RT-PCR.\n'
p4162
sg4
(lp4163
(dp4164
g7
I86
sg8
g15
sg10
I6
sg11
VTASK-1
p4165
sg13
I1
sa(dp4166
g7
I97
sg8
g15
sg10
I6
sg11
VTASK-2
p4167
sg13
I1
sasg19
(lp4168
(dp4169
g7
I122
sg22
VC1524043
p4170
sg10
I19
sg11
Vmouse neuroblastoma
p4171
sg13
I2
sasa(dp4172
g2
S'Background Inherited deficiency of all vitamin K-dependent coagulant factors (VKCFD) is a rare autosomal recessive disorder caused by mutations in the Gamma-glutamyl carboxylase gene (GGCX) or the vitamin K epoxide reductase gene (VKORC1), with great heterogeneity in terms of both clinical presentation and response to treatment.\n'
p4173
sg4
(lp4174
(dp4175
g7
I59
sg8
VP19883
p4176
sg10
I17
sg11
Vcoagulant factors
p4177
sg13
I2
sa(dp4178
g7
I197
sg8
g15
sg10
I32
sg11
Vvitamin K epoxide reductase gene
p4179
sg13
I5
sa(dp4180
g7
I184
sg8
VP38435
p4181
sg10
I4
sg11
VGGCX
p4182
sg13
I1
sa(dp4183
g7
I78
sg8
VP38435
p4184
sg10
I5
sg11
VVKCFD
p4185
sg13
I1
sa(dp4186
g7
I231
sg8
g15
sg10
I6
sg11
VVKORC1
p4187
sg13
I1
sa(dp4188
g7
I151
sg8
VP38435
p4189
sg10
I31
sg11
VGamma-glutamyl carboxylase gene
p4190
sg13
I3
sasg19
(lp4191
(dp4192
g7
I78
sg22
VC1848534
p4193
sg10
I5
sg11
VVKCFD
p4194
sg13
I1
sasa(dp4195
g2
S'Biochemical and molecular studies identify two variants of this autosomal recessive disorder: VKCFD1, which is associated with point mutations in the gamma-glutamylcarboxylase gene (GGCX), and VKCFD2, which results from point mutations in the vitamin K epoxide reductase gene (VKOR).\n'
p4196
sg4
(lp4197
(dp4198
g7
I193
sg8
g15
sg10
I6
sg11
VVKCFD2
p4199
sg13
I1
sa(dp4200
g7
I94
sg8
VP38435
p4201
sg10
I6
sg11
VVKCFD1
p4202
sg13
I1
sa(dp4203
g7
I182
sg8
VP38435
p4204
sg10
I4
sg11
VGGCX
p4205
sg13
I1
sa(dp4206
g7
I277
sg8
g15
sg10
I4
sg11
VVKOR
p4207
sg13
I1
sa(dp4208
g7
I243
sg8
g15
sg10
I32
sg11
Vvitamin K epoxide reductase gene
p4209
sg13
I5
sa(dp4210
g7
I150
sg8
VP38435
p4211
sg10
I30
sg11
Vgamma-glutamylcarboxylase gene
p4212
sg13
I2
sasg19
(lp4213
(dp4214
g7
I193
sg22
VC1843832
p4215
sg10
I6
sg11
VVKCFD2
p4216
sg13
I1
sa(dp4217
g7
I94
sg22
VC1848534
p4218
sg10
I6
sg11
VVKCFD1
p4219
sg13
I1
sasa(dp4220
g2
S'PXE-like clinical findings have been encountered in association with vitamin K-dependent coagulation factor deficiency, an autosomal recessive disorder that is due to mutations in either the GGCX or VKORC1 genes.\n'
p4221
sg4
(lp4222
(dp4223
g7
I191
sg8
VP38435
p4224
sg10
I4
sg11
VGGCX
p4225
sg13
I1
sa(dp4226
g7
I89
sg8
VP80511
p4227
sg10
I18
sg11
Vcoagulation factor
p4228
sg13
I2
sa(dp4229
g7
I0
sg8
g15
sg10
I3
sg11
VPXE
p4230
sg13
I1
sa(dp4231
g7
I199
sg8
g15
sg10
I12
sg11
VVKORC1 genes
p4232
sg13
I2
sasg19
(lp4233
(dp4234
g7
I89
sg22
VC0849773
p4235
sg10
I29
sg11
Vcoagulation factor deficiency
p4236
sg13
I3
sa(dp4237
g7
I0
sg22
VC0033847
p4238
sg10
I3
sg11
VPXE
p4239
sg13
I1
sa(dp4240
g7
I9
sg22
VC0037088
p4241
sg10
I17
sg11
Vclinical findings
p4242
sg13
I2
sasa(dp4243
g2
S'However, the function and mechanism of KLF2 in colorectal cancer (CRC) is still unknown.\n'
p4244
sg4
(lp4245
(dp4246
g7
I39
sg8
g15
sg10
I4
sg11
VKLF2
p4247
sg13
I1
sasg19
(lp4248
(dp4249
g7
I66
sg22
VC1527249
p4250
sg10
I3
sg11
VCRC
p4251
sg13
I1
sa(dp4252
g7
I47
sg22
VC1527249
p4253
sg10
I17
sg11
Vcolorectal cancer
p4254
sg13
I2
sasa(dp4255
g2
S'To determine whether altered levels of apolipoprotein(a) [apo(a)], the plasminogenlike glycoprotein of the potentially atherogenic lipoprotein(a); contribute to the increased risk of atherosclerosis, apo(a) levels were measured in 107 patients with IDDM and compared with nondiabetic control subjects and male elective coronary artery graft patients.\n'
p4256
sg4
(lp4257
(dp4258
g7
I39
sg8
g15
sg10
I3
sg11
Vapo
p4259
sg13
I1
sa(dp4260
g7
I39
sg8
g15
sg10
I3
sg11
Vapo
p4261
sg13
I1
sa(dp4262
g7
I71
sg8
VP36222
p4263
sg10
I28
sg11
Vplasminogenlike glycoprotein
p4264
sg13
I2
sa(dp4265
g7
I39
sg8
VP02656
p4266
sg10
I17
sg11
Vapolipoprotein(a)
p4267
sg13
I1
sasg19
(lp4268
(dp4269
g7
I183
sg22
VC0004153
p4270
sg10
I15
sg11
Vatherosclerosis
p4271
sg13
I1
sa(dp4272
g7
I249
sg22
VC0011854
p4273
sg10
I4
sg11
VIDDM
p4274
sg13
I1
sasa(dp4275
g2
S'Screening for MYOC mutations was performed in 207 index patients: 96 with adult-onset primary open-angle glaucoma (POAG), 21 with primary congenital glaucoma (PCG), 18 with juvenile-onset open-angle glaucoma (JOAG), five with Axenfeld-Rieger syndrome (ARS), and 67 with other types of glaucoma.\n'
p4276
sg4
(lp4277
sg19
(lp4278
(dp4279
g7
I252
sg22
VC0265341
p4280
sg10
I3
sg11
VARS
p4281
sg13
I1
sa(dp4282
g7
I105
sg22
VC0017601
p4283
sg10
I8
sg11
Vglaucoma
p4284
sg13
I1
sa(dp4285
g7
I130
sg22
VC1533041
p4286
sg10
I27
sg11
Vprimary congenital glaucoma
p4287
sg13
I3
sa(dp4288
g7
I159
sg22
VC1533041
p4289
sg10
I3
sg11
VPCG
p4290
sg13
I1
sa(dp4291
g7
I226
sg22
VC0265341
p4292
sg10
I24
sg11
VAxenfeld-Rieger syndrome
p4293
sg13
I2
sa(dp4294
g7
I86
sg22
VC0339573
p4295
sg10
I27
sg11
Vprimary open-angle glaucoma
p4296
sg13
I3
sa(dp4297
g7
I94
sg22
VC0017612
p4298
sg10
I19
sg11
Vopen-angle glaucoma
p4299
sg13
I2
sa(dp4300
g7
I115
sg22
VC0339573
p4301
sg10
I4
sg11
VPOAG
p4302
sg13
I1
sasa(dp4303
g2
S'Immunohistochemistry was performed on 328 samples consisting of 256 clear cell/conventional, 27 papillary, 28 chromophobe, five collecting duct, five unclassified RCCs and seven renal oncocytomas using antibodies MOC31, BerEP4 and antibodies against cytokeratins (KL-1, CAM5.2, 34betaE12, cytokeratin 7), RCC Ma, epithelial membrane antigen, E-cadherin, CD10, CD15 and vimentin.\n'
p4304
sg4
(lp4305
(dp4306
g7
I342
sg8
VP12830
p4307
sg10
I10
sg11
VE-cadherin
p4308
sg13
I1
sa(dp4309
g7
I360
sg8
VP22083
p4310
sg10
I4
sg11
VCD15
p4311
sg13
I1
sa(dp4312
g7
I354
sg8
VP08473
p4313
sg10
I4
sg11
VCD10
p4314
sg13
I1
sa(dp4315
g7
I313
sg8
VP12830
p4316
sg10
I27
sg11
Vepithelial membrane antigen
p4317
sg13
I3
sa(dp4318
g7
I270
sg8
VP08729
p4319
sg10
I32
sg11
VCAM5.2, 34betaE12, cytokeratin 7
p4320
sg13
I4
sa(dp4321
g7
I213
sg8
VP16422
p4322
sg10
I5
sg11
VMOC31
p4323
sg13
I1
sa(dp4324
g7
I305
sg8
VP18887
p4325
sg10
I6
sg11
VRCC Ma
p4326
sg13
I2
sasg19
(lp4327
(dp4328
g7
I163
sg22
VC0007134
p4329
sg10
I3
sg11
VRCC
p4330
sg13
I1
sa(dp4331
g7
I163
sg22
VC0007134
p4332
sg10
I4
sg11
VRCCs
p4333
sg13
I1
sa(dp4334
g7
I184
sg22
VC0949541
p4335
sg10
I11
sg11
Voncocytomas
p4336
sg13
I1
sasa(dp4337
g2
S'Peripheral cell accentuation reactivity for cytokeratin KL1 was observed in 66% of the chromophobe cell carcinoma cases, and apical cytoplasmic positivity was observed in 37% of the renal oncocytoma cases (P = .01).\n'
p4338
sg4
(lp4339
(dp4340
g7
I44
sg8
g15
sg10
I15
sg11
Vcytokeratin KL1
p4341
sg13
I2
sasg19
(lp4342
(dp4343
g7
I104
sg22
VC0007097
p4344
sg10
I9
sg11
Vcarcinoma
p4345
sg13
I1
sa(dp4346
g7
I182
sg22
VC0346255
p4347
sg10
I16
sg11
Vrenal oncocytoma
p4348
sg13
I2
sasa(dp4349
g2
S'EMT was involved in the pathological process of diabetic pulmonary fibrosis, which was activated by LOX-1/TGF-Beta1/KLF6 signaling pathway.\n'
p4350
sg4
(lp4351
(dp4352
g7
I0
sg8
g15
sg10
I3
sg11
VEMT
p4353
sg13
I1
sa(dp4354
g7
I106
sg8
g15
sg10
I3
sg11
VTGF
p4355
sg13
I1
sa(dp4356
g7
I116
sg8
g15
sg10
I4
sg11
VKLF6
p4357
sg13
I1
sa(dp4358
g7
I100
sg8
VP78380
p4359
sg10
I5
sg11
VLOX-1
p4360
sg13
I1
sasg19
(lp4361
(dp4362
g7
I57
sg22
VC0034069
p4363
sg10
I18
sg11
Vpulmonary fibrosis
p4364
sg13
I2
sa(dp4365
g7
I24
sg22
VC0030660
p4366
sg10
I20
sg11
Vpathological process
p4367
sg13
I2
sasa(dp4368
g2
S'Lung lesion classifications were catarrhal-purulent bronchopneumonia (CPBP), pleuropneumonia (PLP) and pleuritis.\n'
p4369
sg4
(lp4370
(dp4371
g7
I33
sg8
g15
sg10
I35
sg11
Vcatarrhal-purulent bronchopneumonia
p4372
sg13
I2
sa(dp4373
g7
I70
sg8
g15
sg10
I4
sg11
VCPBP
p4374
sg13
I1
sasg19
(lp4375
(dp4376
g7
I94
sg22
VC0032241
p4377
sg10
I3
sg11
VPLP
p4378
sg13
I1
sa(dp4379
g7
I77
sg22
VC0032241
p4380
sg10
I15
sg11
Vpleuropneumonia
p4381
sg13
I1
sa(dp4382
g7
I103
sg22
VC0032231
p4383
sg10
I9
sg11
Vpleuritis
p4384
sg13
I1
sa(dp4385
g7
I52
sg22
VC0006285
p4386
sg10
I16
sg11
Vbronchopneumonia
p4387
sg13
I1
sasa(dp4388
g2
S'No respiratory failure occurred in group A; two patients experienced slow weaning from ventilation assistance and one died from that complication in group B. Myocardial revascularization without CPBP allows a better postoperative clinical course in patients with advanced pulmonary disease.\n'
p4389
sg4
(lp4390
(dp4391
g7
I195
sg8
g15
sg10
I4
sg11
VCPBP
p4392
sg13
I1
sasg19
(lp4393
(dp4394
g7
I149
sg22
VC0348801
p4395
sg10
I7
sg11
Vgroup B
p4396
sg13
I2
sa(dp4397
g7
I3
sg22
VC1145670
p4398
sg10
I19
sg11
Vrespiratory failure
p4399
sg13
I2
sa(dp4400
g7
I133
sg22
VC0009566
p4401
sg10
I12
sg11
Vcomplication
p4402
sg13
I1
sa(dp4403
g7
I272
sg22
VC0024115
p4404
sg10
I17
sg11
Vpulmonary disease
p4405
sg13
I2
sasa(dp4406
g2
S'Immunoexpression of galectin-1, galectin-3, galectin-7, and galectin-9 was semiquantitatively analyzed in 65 cases of actinic cheilitis graded as low risk (n = 40) or high risk (n = 25) of malignant transformation.\n'
p4407
sg4
(lp4408
(dp4409
g7
I32
sg8
VP17931
p4410
sg10
I10
sg11
Vgalectin-3
p4411
sg13
I1
sa(dp4412
g7
I44
sg8
VP47929
p4413
sg10
I10
sg11
Vgalectin-7
p4414
sg13
I1
sa(dp4415
g7
I60
sg8
g15
sg10
I10
sg11
Vgalectin-9
p4416
sg13
I1
sa(dp4417
g7
I20
sg8
VP09382
p4418
sg10
I10
sg11
Vgalectin-1
p4419
sg13
I1
sasg19
(lp4420
(dp4421
g7
I118
sg22
VC0267026
p4422
sg10
I17
sg11
Vactinic cheilitis
p4423
sg13
I2
sa(dp4424
g7
I189
sg22
VC1608408
p4425
sg10
I24
sg11
Vmalignant transformation
p4426
sg13
I2
sasa(dp4427
g2
S'Non-alcoholic fatty liver disease (NAFLD) affects 75 to 100% of the patients undergoing bariatric surgery (BSx), with non-alcoholic steatohepatitis (NASH) being present in 24 to 98% of the patients.\n'
p4428
sg4
(lp4429
sg19
(lp4430
(dp4431
g7
I118
sg22
VC3241937
p4432
sg10
I29
sg11
Vnon-alcoholic steatohepatitis
p4433
sg13
I2
sa(dp4434
g7
I0
sg22
VC0400966
p4435
sg10
I33
sg11
VNon-alcoholic fatty liver disease
p4436
sg13
I4
sa(dp4437
g7
I149
sg22
VC3241937
p4438
sg10
I4
sg11
VNASH
p4439
sg13
I1
sa(dp4440
g7
I35
sg22
VC0400966
p4441
sg10
I5
sg11
VNAFLD
p4442
sg13
I1
sasa(dp4443
g2
S'Bariatric surgery (BSx) is an approved therapeutic alternative for class II-III obesity, but little evidence focuses on older adults.\n'
p4444
sg4
(lp4445
sg19
(lp4446
(dp4447
g7
I80
sg22
VC0028754
p4448
sg10
I7
sg11
Vobesity
p4449
sg13
I1
sasa(dp4450
g2
S'We carried out a population-based, observational study from 1990-2009, of 40 consecutive elderly (age &gt;=60 years) residents of Olmsted County, MN, USA, with class II-III obesity treated with BSx at a University-based, academic health center.\n'
p4451
sg4
(lp4452
sg19
(lp4453
(dp4454
g7
I173
sg22
VC0028754
p4455
sg10
I7
sg11
Vobesity
p4456
sg13
I1
sasa(dp4457
g2
S'Prevalence 1 year after BSx decreased for diabetes (57.5% to 22.5%; P &lt; 0.03), hypertension 87.5% to 73.7% (P = 0.003), dyslipidemia (80% to 42.5%; P &lt; 0.001) and sleep apnea (62.5% to 23.7%; P &lt; 0.001).MetS prevalence decreased from 80% to 45% (P &lt; 0.002).\n'
p4458
sg4
(lp4459
(dp4460
g7
I212
sg8
VP41162
p4461
sg10
I4
sg11
VMetS
p4462
sg13
I1
sasg19
(lp4463
(dp4464
g7
I123
sg22
VC0242339
p4465
sg10
I12
sg11
Vdyslipidemia
p4466
sg13
I1
sa(dp4467
g7
I42
sg22
VC0011849
p4468
sg10
I8
sg11
Vdiabetes
p4469
sg13
I1
sa(dp4470
g7
I169
sg22
VC0037315
p4471
sg10
I11
sg11
Vsleep apnea
p4472
sg13
I2
sa(dp4473
g7
I82
sg22
VC0020538
p4474
sg10
I12
sg11
Vhypertension
p4475
sg13
I1
sasa(dp4476
g2
S'Accounting for the costs and risks associated with BSx, providing state and federal resources for lifestyle behavior change programs could provide a key opportunity for the war against obesity.\n'
p4477
sg4
(lp4478
sg19
(lp4479
(dp4480
g7
I185
sg22
VC0028754
p4481
sg10
I7
sg11
Vobesity
p4482
sg13
I1
sasa(dp4483
g2
S'We assessed the effects of bariatric surgery (BSx) compared to non-operative treatment for morbid obesity on overall quality of life (QoL), functional capacity, and symptoms in 13 HF patients undergoing BSx and six HF patients treated without surgery.\n'
p4484
sg4
(lp4485
sg19
(lp4486
(dp4487
g7
I91
sg22
VC0028756
p4488
sg10
I14
sg11
Vmorbid obesity
p4489
sg13
I2
sasa(dp4490
g2
S'At baseline, BSx subjects had a greater body mass index and greater prevalence of diabetes and depression.\n'
p4491
sg4
(lp4492
sg19
(lp4493
(dp4494
g7
I82
sg22
VC0011849
p4495
sg10
I8
sg11
Vdiabetes
p4496
sg13
I1
sa(dp4497
g7
I95
sg22
VC0011581
p4498
sg10
I10
sg11
Vdepression
p4499
sg13
I1
sasa(dp4500
g2
S'BSx subjects perceived obesity as a greater risk to their overall health than the surgical risk.\n'
p4501
sg4
(lp4502
(dp4503
g7
I0
sg8
g15
sg10
I3
sg11
VBSx
p4504
sg13
I1
sasg19
(lp4505
(dp4506
g7
I23
sg22
VC0028754
p4507
sg10
I7
sg11
Vobesity
p4508
sg13
I1
sasa(dp4509
g2
S'Those without a measurable decrease in CV risk had a greater tendency to perceive the risk of BSx as greater than that of obesity.\n'
p4510
sg4
(lp4511
(dp4512
g7
I94
sg8
g15
sg10
I3
sg11
VBSx
p4513
sg13
I1
sasg19
(lp4514
(dp4515
g7
I122
sg22
VC0028754
p4516
sg10
I7
sg11
Vobesity
p4517
sg13
I1
sasa(dp4518
g2
S'Obese subjects undergoing BSx are more likely than MM subjects to perceive obesity as a greater risk to their health than BSx.\n'
p4519
sg4
(lp4520
sg19
(lp4521
(dp4522
g7
I75
sg22
VC0028754
p4523
sg10
I7
sg11
Vobesity
p4524
sg13
I1
sa(dp4525
g7
I0
sg22
VC0028754
p4526
sg10
I5
sg11
VObese
p4527
sg13
I1
sasa(dp4528
g2
S"We collected functional magnetic resonance imaging data on 60 individuals of equivalent age and gender in each of three groups--20 BDD, 20 weight-restored AN, and 20 healthy controls (HC)--while they viewed images of others' faces that contained only high or low spatial frequency information (HSF or LSF).\n"
p4529
sg4
(lp4530
sg19
(lp4531
(dp4532
g7
I131
sg22
VC0220664
p4533
sg10
I3
sg11
VBDD
p4534
sg13
I1
sasa(dp4535
g2
S'The BDD group demonstrated increased functional connectivity compared to HC between left anterior occipital face area and right fusiform face area (FFA) for LSF faces, which was associated with symptom severity.\n'
p4536
sg4
(lp4537
sg19
(lp4538
(dp4539
g7
I194
sg22
VC1457887
p4540
sg10
I7
sg11
Vsymptom
p4541
sg13
I1
sa(dp4542
g7
I108
sg22
VC3160739
p4543
sg10
I4
sg11
Vface
p4544
sg13
I1
sa(dp4545
g7
I108
sg22
VC3160739
p4546
sg10
I4
sg11
Vface
p4547
sg13
I1
sa(dp4548
g7
I4
sg22
VC0220664
p4549
sg10
I3
sg11
VBDD
p4550
sg13
I1
sasa(dp4551
g2
S'Both BDD and AN groups had increased connectivity compared to HC between FFA and precuneous/posterior cingulate gyrus for LSF faces, and decreased connectivity between FFA and insula.\n'
p4552
sg4
(lp4553
sg19
(lp4554
(dp4555
g7
I5
sg22
VC0220664
p4556
sg10
I3
sg11
VBDD
p4557
sg13
I1
sasa(dp4558
g2
S'The BDD group showed lower activity in the parahippocampal gyrus, lingual gyrus and precuneus for LSF images.\n'
p4559
sg4
(lp4560
sg19
(lp4561
(dp4562
g7
I4
sg22
VC0220664
p4563
sg10
I3
sg11
VBDD
p4564
sg13
I1
sasa(dp4565
g2
S'Lymphoproliferative syndrome, production of anti-dsDNA Abs, lupus nephritis, and accumulation of CD3(+)B220(+)CD4(-)CD8(-) autoreactive T cells (in the peripheral blood and the spleen) were significantly increased in B6-MRL Fas lpr/j RAGE(-/-) mice compared with B6-MRL Fas lpr/j mice (respectively p &lt; 0.005, p &lt; 0.05, p &lt; 0.001, and p &lt; 0.001).\n'
p4566
sg4
(lp4567
(dp4568
g7
I97
sg8
VP08575
p4569
sg10
I22
sg11
VCD3(+)B220(+)CD4(-)CD8
p4570
sg13
I1
sasg19
(lp4571
(dp4572
g7
I224
sg22
VC0015923
p4573
sg10
I3
sg11
VFas
p4574
sg13
I1
sa(dp4575
g7
I20
sg22
VC0039082
p4576
sg10
I8
sg11
Vsyndrome
p4577
sg13
I1
sa(dp4578
g7
I60
sg22
VC0024143
p4579
sg10
I15
sg11
Vlupus nephritis
p4580
sg13
I2
sa(dp4581
g7
I224
sg22
VC0015923
p4582
sg10
I3
sg11
VFas
p4583
sg13
I1
sasa(dp4584
g2
S'It is suggested that, in essential hypertension, an increased cellular Ca2+ load or an enhanced external Ca2+ entry stimulate the NHE-1 through protein kinase/phosphatase and Ca2+/calmodulin systems, thereby increasing its activity.\n'
p4585
sg4
(lp4586
(dp4587
g7
I130
sg8
VP19634
p4588
sg10
I5
sg11
VNHE-1
p4589
sg13
I1
sa(dp4590
g7
I144
sg8
VP33981
p4591
sg10
I26
sg11
Vprotein kinase/phosphatase
p4592
sg13
I2
sa(dp4593
g7
I175
sg8
VP00918
p4594
sg10
I23
sg11
VCa2+/calmodulin systems
p4595
sg13
I2
sasg19
(lp4596
(dp4597
g7
I25
sg22
VC0085580
p4598
sg10
I22
sg11
Vessential hypertension
p4599
sg13
I2
sasa(dp4600
g2
S'In 15 patients with essential hypertension, 16 patients with renal hypertension and in 12 healthy subjects Ca2+ ATPase activity was determined in red blood cells both in the basal state and after maximal stimulation with calmodulin.\n'
p4601
sg4
(lp4602
(dp4603
g7
I112
sg8
VP38606
p4604
sg10
I6
sg11
VATPase
p4605
sg13
I1
sa(dp4606
g7
I221
sg8
g15
sg10
I10
sg11
Vcalmodulin
p4607
sg13
I1
sasg19
(lp4608
(dp4609
g7
I61
sg22
VC0020544
p4610
sg10
I18
sg11
Vrenal hypertension
p4611
sg13
I2
sa(dp4612
g7
I20
sg22
VC0085580
p4613
sg10
I22
sg11
Vessential hypertension
p4614
sg13
I2
sasa(dp4615
g2
S'Therefore, the aim of the present study was to evaluate basal and calmodulin-activated Ca(2+)-ATPase in red blood cells and its relationship to the insulin response during an intravenous glucose tolerance test in 27 normotensive adolescents with a family history of essential hypertension (F+) (mean age, 13.9 +/- 0.5 years) and in 10 control subjects matched for age and body mass index with no family history of hypertension (F-).\n'
p4616
sg4
(lp4617
(dp4618
g7
I148
sg8
VP01308
p4619
sg10
I7
sg11
Vinsulin
p4620
sg13
I1
sa(dp4621
g7
I87
sg8
VP38606
p4622
sg10
I13
sg11
VCa(2+)-ATPase
p4623
sg13
I1
sa(dp4624
g7
I66
sg8
g15
sg10
I10
sg11
Vcalmodulin
p4625
sg13
I1
sasg19
(lp4626
(dp4627
g7
I195
sg22
VC0020963
p4628
sg10
I9
sg11
Vtolerance
p4629
sg13
I1
sa(dp4630
g7
I266
sg22
VC0085580
p4631
sg10
I22
sg11
Vessential hypertension
p4632
sg13
I2
sa(dp4633
g7
I276
sg22
VC0020538
p4634
sg10
I12
sg11
Vhypertension
p4635
sg13
I1
sasa(dp4636
g2
S'Remarkably, pathogenic or likely pathogenic alleles in DNA repair/genomic instability genes (other than BRCA2, ATM and PALB2) accounted for at least 16.8, 11.1, 50 and 45.5% of mutation-positive breast, ovarian, thyroid and colorectal cancer patients, respectively.\n'
p4637
sg4
(lp4638
(dp4639
g7
I111
sg8
g15
sg10
I3
sg11
VATM
p4640
sg13
I1
sa(dp4641
g7
I119
sg8
g15
sg10
I5
sg11
VPALB2
p4642
sg13
I1
sa(dp4643
g7
I104
sg8
VP51587
p4644
sg10
I5
sg11
VBRCA2
p4645
sg13
I1
sasg19
(lp4646
(dp4647
g7
I66
sg22
VC0919532
p4648
sg10
I19
sg11
Vgenomic instability
p4649
sg13
I2
sa(dp4650
g7
I224
sg22
VC1527249
p4651
sg10
I17
sg11
Vcolorectal cancer
p4652
sg13
I2
sasa(dp4653
g2
S'Results Thirty-three (3.9%; 95% CI, 3.0% to 5.8%) of 854 patients with pancreatic cancer had a deleterious germline mutation, 31 (3.5%) of which affected known familial pancreatic cancer susceptibility genes: BRCA2 (12 patients), ATM (10 patients), BRCA1 (3 patients), PALB2 (2 patients), MLH1 (2 patients), CDKN2A (1 patient), and TP53 (1 patient).\n'
p4654
sg4
(lp4655
(dp4656
g7
I209
sg8
VP51587
p4657
sg10
I5
sg11
VBRCA2
p4658
sg13
I1
sa(dp4659
g7
I308
sg8
VP42771
p4660
sg10
I6
sg11
VCDKN2A
p4661
sg13
I1
sa(dp4662
g7
I289
sg8
VP40692
p4663
sg10
I4
sg11
VMLH1
p4664
sg13
I1
sasg19
(lp4665
(dp4666
g7
I71
sg22
VC0235974
p4667
sg10
I17
sg11
Vpancreatic cancer
p4668
sg13
I2
sa(dp4669
g7
I107
sg22
VC1705427
p4670
sg10
I17
sg11
Vgermline mutation
p4671
sg13
I2
sa(dp4672
g7
I160
sg22
VC2931038
p4673
sg10
I26
sg11
Vfamilial pancreatic cancer
p4674
sg13
I3
sasa(dp4675
g2
S'To evaluate the potential involvement of host lipoproteins and sPLA(2)s in malaria, we investigated the interactions between bee venom phospholipase A(2) (bvPLA(2)), human triglyceride-rich lipoproteins, and infected erythrocytes.\n'
p4676
sg4
(lp4677
(dp4678
g7
I155
sg8
g15
sg10
I8
sg11
VbvPLA(2)
p4679
sg13
I1
sa(dp4680
g7
I125
sg8
g15
sg10
I28
sg11
Vbee venom phospholipase A(2)
p4681
sg13
I4
sa(dp4682
g7
I166
sg8
g15
sg10
I36
sg11
Vhuman triglyceride-rich lipoproteins
p4683
sg13
I3
sasg19
(lp4684
(dp4685
g7
I75
sg22
VC0024530
p4686
sg10
I7
sg11
Vmalaria
p4687
sg13
I1
sasa(dp4688
g2
S'We demonstrate that HIPK1 is expressed in both androgen-dependent and androgen-independent prostate cancer (PCa) cells, whereas CLK2 and PAGE4 are expressed only in androgen-dependent cells.\n'
p4689
sg4
(lp4690
(dp4691
g7
I128
sg8
VP49760
p4692
sg10
I4
sg11
VCLK2
p4693
sg13
I1
sa(dp4694
g7
I137
sg8
g15
sg10
I5
sg11
VPAGE4
p4695
sg13
I1
sasg19
(lp4696
(dp4697
g7
I91
sg22
VC0600139
p4698
sg10
I15
sg11
Vprostate cancer
p4699
sg13
I2
sa(dp4700
g7
I108
sg22
VC0268398
p4701
sg10
I3
sg11
VPCa
p4702
sg13
I1
sasa(dp4703
g2
S'Emerging data point to the role of HIPK1 in cancer, but it is still not clear whether it acts as a tumor suppressor or promoter.\n'
p4704
sg4
(lp4705
sg19
(lp4706
(dp4707
g7
I99
sg22
VC0027651
p4708
sg10
I5
sg11
Vtumor
p4709
sg13
I1
sa(dp4710
g7
I44
sg22
VC0006826
p4711
sg10
I6
sg11
Vcancer
p4712
sg13
I1
sasa(dp4713
g2
S'Here we identified HIPK1 as a kinase that is significantly overexpressed in colorectal cancer (CRC) and whose expression is stage-dependent.\n'
p4714
sg4
(lp4715
sg19
(lp4716
(dp4717
g7
I95
sg22
VC1527249
p4718
sg10
I3
sg11
VCRC
p4719
sg13
I1
sa(dp4720
g7
I76
sg22
VC1527249
p4721
sg10
I17
sg11
Vcolorectal cancer
p4722
sg13
I2
sasa(dp4723
g2
S'This study investigated the incidence and clinical significance of homeodomain-interacting protein kinase 1 expression in breast cancer patients.\n'
p4724
sg4
(lp4725
(dp4726
g7
I67
sg8
g15
sg10
I40
sg11
Vhomeodomain-interacting protein kinase 1
p4727
sg13
I4
sasg19
(lp4728
(dp4729
g7
I122
sg22
VC0678222
p4730
sg10
I13
sg11
Vbreast cancer
p4731
sg13
I2
sasa(dp4732
g2
S'Non-cancerous breast tissue, pTis and pT1mic lesions did not show homeodomain-interacting protein kinase 1 expression at any sites.\n'
p4733
sg4
(lp4734
(dp4735
g7
I66
sg8
g15
sg10
I40
sg11
Vhomeodomain-interacting protein kinase 1
p4736
sg13
I4
sasg19
(lp4737
sa(dp4738
g2
S'Homeodomain-interacting protein kinase  1 expression was identified only in invasive breast cancer cells with three different patterns: cytoplasmic, nuclear, and both cytoplasmic and nuclear.\n'
p4739
sg4
(lp4740
(dp4741
g7
I0
sg8
g15
sg10
I41
sg11
VHomeodomain-interacting protein kinase  1
p4742
sg13
I5
sasg19
(lp4743
(dp4744
g7
I76
sg22
VC0853879
p4745
sg10
I22
sg11
Vinvasive breast cancer
p4746
sg13
I3
sasa(dp4747
g2
S'Quantitative PCR (qPCR) and antibody detection demonstrated that the mucus composition of pigs with swine dysentery was characterized by de novo expression of MUC5AC and increased expression of MUC2 in the colon.\n'
p4748
sg4
(lp4749
(dp4750
g7
I194
sg8
g15
sg10
I4
sg11
VMUC2
p4751
sg13
I1
sasg19
(lp4752
(dp4753
g7
I100
sg22
VC0275879
p4754
sg10
I15
sg11
Vswine dysentery
p4755
sg13
I2
sasa(dp4756
g2
S'WNT signaling-targeted therapeutics, such as anti-FZD1/2/5/7/8 monoclonal antibody (mAb) (vantictumab), anti-LGR5 antibody-drug conjugate (ADC) (mAb-mc-vc-PAB-MMAE), anti-PTK7 ADC (PF-06647020), anti-ROR1 mAb (cirmtuzumab), anti-RSPO3 mAb (rosmantuzumab), small-molecule porcupine inhibitors (ETC-159, WNT-C59 and WNT974), tankyrase inhibitors (AZ1366, G007-LK, NVP-TNKS656 and XAV939) and Beta-catenin inhibitors (BC2059, CWP232228, ICG-001 and PRI-724), are in clinical trials or preclinical studies for the treatment of patients with WNT-driven cancers.\n'
p4757
sg4
(lp4758
(dp4759
g7
I45
sg8
g15
sg10
I37
sg11
Vanti-FZD1/2/5/7/8 monoclonal antibody
p4760
sg13
I3
sa(dp4761
g7
I390
sg8
VP35222
p4762
sg10
I12
sg11
VBeta-catenin
p4763
sg13
I1
sa(dp4764
g7
I323
sg8
g15
sg10
I9
sg11
Vtankyrase
p4765
sg13
I1
sa(dp4766
g7
I104
sg8
g15
sg10
I18
sg11
Vanti-LGR5 antibody
p4767
sg13
I2
sa(dp4768
g7
I224
sg8
g15
sg10
I14
sg11
Vanti-RSPO3 mAb
p4769
sg13
I2
sa(dp4770
g7
I195
sg8
VP35398
p4771
sg10
I13
sg11
Vanti-ROR1 mAb
p4772
sg13
I2
sa(dp4773
g7
I166
sg8
VP20711
p4774
sg10
I13
sg11
Vanti-PTK7 ADC
p4775
sg13
I2
sasg19
(lp4776
(dp4777
g7
I548
sg22
VC0006826
p4778
sg10
I7
sg11
Vcancers
p4779
sg13
I1
sasa(dp4780
g2
S'Using a multivariate regression model, ADHD combined presentation [combined versus predominantly hyperactive/impulsive and unspecified OR 4.52 (1.23-16.55), p = 0.023], age [OR 1.46 (1.14-1.88), p = 0.003], ODD/CD [OR 5.53 (2.19-14.01), p &lt; 0.001], DCD [OR 4.22 (1.70-10.48), p = 0.002], PRI [OR 0.97 (0.94-0.99), p = 0.01] were significantly associated with recommendation of methylphenidate treatment.\n'
p4781
sg4
(lp4782
(dp4783
g7
I39
sg8
g15
sg10
I4
sg11
VADHD
p4784
sg13
I1
sa(dp4785
g7
I252
sg8
VP81605
p4786
sg10
I3
sg11
VDCD
p4787
sg13
I1
sa(dp4788
g7
I291
sg8
VP13489
p4789
sg10
I3
sg11
VPRI
p4790
sg13
I1
sasg19
(lp4791
(dp4792
g7
I39
sg22
VC1263846
p4793
sg10
I4
sg11
VADHD
p4794
sg13
I1
sasa(dp4795
g2
S'Bullying victimization and perpetration in children with ADHD having a low PRI and low executive function should be routinely surveyed.\n'
p4796
sg4
(lp4797
(dp4798
g7
I71
sg8
VP13489
p4799
sg10
I7
sg11
Vlow PRI
p4800
sg13
I2
sasg19
(lp4801
(dp4802
g7
I9
sg22
VC0474404
p4803
sg10
I13
sg11
Vvictimization
p4804
sg13
I1
sa(dp4805
g7
I57
sg22
VC1263846
p4806
sg10
I4
sg11
VADHD
p4807
sg13
I1
sa(dp4808
g7
I0
sg22
VC0424318
p4809
sg10
I8
sg11
VBullying
p4810
sg13
I1
sasa(dp4811
g2
S'The present study evaluates the use of curcumin (CC) and primaquine (PRI) as an anti-malarial combination, packaged within niosomes, in comparison to their respective monotherapy options.\n'
p4812
sg4
(lp4813
sg19
(lp4814
sa(dp4815
g2
S'It was observed that in Plasmodium berghei-infected mice, mice treated with a combination of 35 mg/kg of CC along with either 5 mg/kg or 1 mg/kg body weight of PRI demonstrated 100% anti-malarial activity and survivability beyond 20 days.\n'
p4816
sg4
(lp4817
sg19
(lp4818
sa(dp4819
g2
S'The findings of the study suggest that niosome-based PRI-CC combination therapy may be a promising approach in the treatment of malaria.\n'
p4820
sg4
(lp4821
sg19
(lp4822
(dp4823
g7
I128
sg22
VC0024530
p4824
sg10
I7
sg11
Vmalaria
p4825
sg13
I1
sasa(dp4826
g2
S'The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis.\n'
p4827
sg4
(lp4828
(dp4829
g7
I90
sg8
VP13489
p4830
sg10
I7
sg11
VPRI-724
p4831
sg13
I1
sasg19
(lp4832
(dp4833
g7
I165
sg22
VC0023890
p4834
sg10
I9
sg11
Vcirrhosis
p4835
sg13
I1
sasa(dp4836
g2
S'In this single-center, open-label, phase 1 trial, we sequentially enrolled patients with HCV cirrhosis who were classified as Child-Pugh (CP) class A or B. PRI-724 was administered as a continuous intravenous infusion of 10, 40, or 160mg/m2/day for six cycles of 1week on and 1week off.\n'
p4837
sg4
(lp4838
(dp4839
g7
I156
sg8
VP13489
p4840
sg10
I3
sg11
VPRI
p4841
sg13
I1
sasg19
(lp4842
(dp4843
g7
I93
sg22
VC0023890
p4844
sg10
I9
sg11
Vcirrhosis
p4845
sg13
I1
sasa(dp4846
g2
S'The secondary endpoint was efficacy of PRI-724 in treating cirrhosis based on CP score and liver biopsy.\n'
p4847
sg4
(lp4848
sg19
(lp4849
(dp4850
g7
I59
sg22
VC0023890
p4851
sg10
I9
sg11
Vcirrhosis
p4852
sg13
I1
sasa(dp4853
g2
S'This study showed that administration of 10 or 40mg/m2/day intravenous PRI-724 over 12weeks was well-tolerated by patients with HCV cirrhosis; however, liver injury as a possible related serious adverse event was observed in the 160mg/m2/day cohort.\n'
p4854
sg4
(lp4855
(dp4856
g7
I71
sg8
VP13489
p4857
sg10
I7
sg11
VPRI-724
p4858
sg13
I1
sasg19
(lp4859
(dp4860
g7
I132
sg22
VC0023890
p4861
sg10
I9
sg11
Vcirrhosis
p4862
sg13
I1
sasa(dp4863
g2
S'With regard to chiral inversion enzymes, adjuvant-induced arthritis decreased the messenger RNA levels of acyl-coenzyme A synthetase (ACS) isoforms, but not 2-arylpropionyl-CoA epimerase, compared with control rats.\n'
p4864
sg4
(lp4865
(dp4866
g7
I106
sg8
g15
sg10
I41
sg11
Vacyl-coenzyme A synthetase (ACS) isoforms
p4867
sg13
I5
sasg19
(lp4868
(dp4869
g7
I22
sg22
VC0021943
p4870
sg10
I9
sg11
Vinversion
p4871
sg13
I1
sa(dp4872
g7
I173
sg22
VC2678439
p4873
sg10
I3
sg11
VCoA
p4874
sg13
I1
sa(dp4875
g7
I58
sg22
VC0003864
p4876
sg10
I9
sg11
Varthritis
p4877
sg13
I1
sasa(dp4878
g2
S'administration at 20 mg/kg of body weight, but not 2 mg/kg, to male DBA/1J mice every 2 days for 12 days led to a marked decrease in type II collagen-induced arthritis by 45% (P &lt; 0.05).\n'
p4879
sg4
(lp4880
sg19
(lp4881
(dp4882
g7
I68
sg22
VC0398550
p4883
sg10
I3
sg11
VDBA
p4884
sg13
I1
sa(dp4885
g7
I158
sg22
VC0003864
p4886
sg10
I9
sg11
Varthritis
p4887
sg13
I1
sasa(dp4888
g2
S'1 but not 2 suppressed the chronic inflammation in the arthritis model but neither compound was active in the acute inflammation assay.\n'
p4889
sg4
(lp4890
sg19
(lp4891
(dp4892
g7
I55
sg22
VC0003864
p4893
sg10
I9
sg11
Varthritis
p4894
sg13
I1
sa(dp4895
g7
I35
sg22
VC0021368
p4896
sg10
I12
sg11
Vinflammation
p4897
sg13
I1
sa(dp4898
g7
I27
sg22
VC0021376
p4899
sg10
I20
sg11
Vchronic inflammation
p4900
sg13
I2
sasa(dp4901
g2
S'Exposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells.\n'
p4902
sg4
(lp4903
(dp4904
g7
I79
sg8
VP22083
p4905
sg10
I4
sg11
VCD15
p4906
sg13
I1
sa(dp4907
g7
I194
sg8
VP04198
p4908
sg10
I12
sg11
VNMYC protein
p4909
sg13
I2
sa(dp4910
g7
I17
sg8
VP18075
p4911
sg10
I29
sg11
Vmorphogenetic protein (BMP)-4
p4912
sg13
I3
sa(dp4913
g7
I85
sg8
VP61073
p4914
sg10
I5
sg11
VCD184
p4915
sg13
I1
sasg19
(lp4916
(dp4917
g7
I92
sg22
VC0027819
p4918
sg10
I13
sg11
Vneuroblastoma
p4919
sg13
I1
sasa(dp4920
g2
S'Recent studies indicate that C-X-C motif chemokine receptor 4 (CXCR4) and its ligand, C-X-C motif chemokine ligand 12 (CXCL12), stimulate expression of the cell cycle regulatory protein Cyclin D1 in neurofibromatosis 1-associated malignant peripheral nerve sheath tumor (MPNST) cells and promote their proliferation.\n'
p4921
sg4
(lp4922
(dp4923
g7
I29
sg8
VP51679
p4924
sg10
I32
sg11
VC-X-C motif chemokine receptor 4
p4925
sg13
I5
sa(dp4926
g7
I119
sg8
VP48061
p4927
sg10
I6
sg11
VCXCL12
p4928
sg13
I1
sa(dp4929
g7
I63
sg8
VP61073
p4930
sg10
I5
sg11
VCXCR4
p4931
sg13
I1
sa(dp4932
g7
I86
sg8
VP55773
p4933
sg10
I31
sg11
VC-X-C motif chemokine ligand 12
p4934
sg13
I5
sa(dp4935
g7
I186
sg8
VP24385
p4936
sg10
I9
sg11
VCyclin D1
p4937
sg13
I2
sasg19
(lp4938
(dp4939
g7
I230
sg22
VC0751690
p4940
sg10
I39
sg11
Vmalignant peripheral nerve sheath tumor
p4941
sg13
I5
sa(dp4942
g7
I199
sg22
VC0027831
p4943
sg10
I19
sg11
Vneurofibromatosis 1
p4944
sg13
I2
sa(dp4945
g7
I302
sg22
VC0334094
p4946
sg10
I13
sg11
Vproliferation
p4947
sg13
I1
sa(dp4948
g7
I271
sg22
VC0751690
p4949
sg10
I5
sg11
VMPNST
p4950
sg13
I1
sasa(dp4951
g2
S'Recent studies have independently implicated the chemokine CXCL12 and its receptors, CXCR4 and CXCR7, in the pathophysiology of Kaposi sarcoma (KS).\n'
p4952
sg4
(lp4953
(dp4954
g7
I95
sg8
VP25106
p4955
sg10
I5
sg11
VCXCR7
p4956
sg13
I1
sa(dp4957
g7
I85
sg8
VP61073
p4958
sg10
I5
sg11
VCXCR4
p4959
sg13
I1
sasg19
(lp4960
(dp4961
g7
I128
sg22
VC0036220
p4962
sg10
I14
sg11
VKaposi sarcoma
p4963
sg13
I2
sa(dp4964
g7
I144
sg22
VC0036220
p4965
sg10
I2
sg11
VKS
p4966
sg13
I1
sasa(dp4967
g2
S'Western blot analysis revealed the expression of multiple CXCR4 isoforms in neuroblastoma cells.\n'
p4968
sg4
(lp4969
(dp4970
g7
I58
sg8
VP61073
p4971
sg10
I14
sg11
VCXCR4 isoforms
p4972
sg13
I2
sasg19
(lp4973
(dp4974
g7
I76
sg22
VC0027819
p4975
sg10
I13
sg11
Vneuroblastoma
p4976
sg13
I1
sasa(dp4977
g2
S'Our data suggest a modulatory role of the MSC secretome on the expression of the 47 kDa CXCR4 isoform and invasion potential of the neuroblastoma cells to the bone marrow.\n'
p4978
sg4
(lp4979
(dp4980
g7
I81
sg8
VP61073
p4981
sg10
I20
sg11
V47 kDa CXCR4 isoform
p4982
sg13
I4
sasg19
(lp4983
(dp4984
g7
I132
sg22
VC0027819
p4985
sg10
I13
sg11
Vneuroblastoma
p4986
sg13
I1
sa(dp4987
g7
I106
sg22
VC2699153
p4988
sg10
I8
sg11
Vinvasion
p4989
sg13
I1
sasa(dp4990
g2
S'Finally, we identified seven MS indel driver hotspots: four in known cancer genes (ACVR2A, RNF43, JAK1, and MSH3) and three in genes not previously implicated as cancer drivers (ESRP1, PRDM2, and DOCK3).\n'
p4991
sg4
(lp4992
(dp4993
g7
I196
sg8
g15
sg10
I5
sg11
VDOCK3
p4994
sg13
I1
sa(dp4995
g7
I91
sg8
g15
sg10
I5
sg11
VRNF43
p4996
sg13
I1
sa(dp4997
g7
I108
sg8
VP20585
p4998
sg10
I4
sg11
VMSH3
p4999
sg13
I1
sa(dp5000
g7
I83
sg8
VP27037
p5001
sg10
I6
sg11
VACVR2A
p5002
sg13
I1
sa(dp5003
g7
I185
sg8
g15
sg10
I5
sg11
VPRDM2
p5004
sg13
I1
sa(dp5005
g7
I178
sg8
g15
sg10
I5
sg11
VESRP1
p5006
sg13
I1
sa(dp5007
g7
I98
sg8
VP23458
p5008
sg10
I4
sg11
VJAK1
p5009
sg13
I1
sasg19
(lp5010
(dp5011
g7
I69
sg22
VC0006826
p5012
sg10
I6
sg11
Vcancer
p5013
sg13
I1
sa(dp5014
g7
I69
sg22
VC0006826
p5015
sg10
I6
sg11
Vcancer
p5016
sg13
I1
sasa(dp5017
g2
S'In conclusion, our results supported that miR-512-3p could inhibit tumor cell adhesion, migration, and invasion by regulating the RAC1 activity via DOCK3 in NSCLC A549 and H1299 cell lines.\n'
p5018
sg4
(lp5019
(dp5020
g7
I148
sg8
g15
sg10
I5
sg11
VDOCK3
p5021
sg13
I1
sa(dp5022
g7
I130
sg8
VP63000
p5023
sg10
I4
sg11
VRAC1
p5024
sg13
I1
sa(dp5025
g7
I42
sg8
g15
sg10
I10
sg11
VmiR-512-3p
p5026
sg13
I1
sasg19
(lp5027
(dp5028
g7
I67
sg22
VC0027651
p5029
sg10
I5
sg11
Vtumor
p5030
sg13
I1
sa(dp5031
g7
I103
sg22
VC2699153
p5032
sg10
I8
sg11
Vinvasion
p5033
sg13
I1
sa(dp5034
g7
I78
sg22
VC0001511
p5035
sg10
I8
sg11
Vadhesion
p5036
sg13
I1
sa(dp5037
g7
I157
sg22
VC0007131
p5038
sg10
I5
sg11
VNSCLC
p5039
sg13
I1
sasa(dp5040
g2
S'Elongated mesenchymal migration of cancer cells is driven by Rac1 activation mediated by the adaptor NEDD9 and the exchange factor DOCK3.\n'
p5041
sg4
(lp5042
(dp5043
g7
I115
sg8
g15
sg10
I21
sg11
Vexchange factor DOCK3
p5044
sg13
I3
sa(dp5045
g7
I61
sg8
VP63000
p5046
sg10
I4
sg11
VRac1
p5047
sg13
I1
sasg19
(lp5048
(dp5049
g7
I35
sg22
VC0006826
p5050
sg10
I6
sg11
Vcancer
p5051
sg13
I1
sasa(dp5052
g2
S'NEDD9 interacts with the guanine nucleotide exchange factor DOCK3 to promote Rac activation and the elongated, mesenchymal-type of tumour cell invasion, but the molecular mechanisms through which NEDD9 promotes melanoma metastasis are not fully understood.\n'
p5053
sg4
(lp5054
(dp5055
g7
I0
sg8
g15
sg10
I5
sg11
VNEDD9
p5056
sg13
I1
sa(dp5057
g7
I60
sg8
g15
sg10
I5
sg11
VDOCK3
p5058
sg13
I1
sa(dp5059
g7
I25
sg8
g15
sg10
I34
sg11
Vguanine nucleotide exchange factor
p5060
sg13
I4
sa(dp5061
g7
I77
sg8
VP31749
p5062
sg10
I3
sg11
VRac
p5063
sg13
I1
sa(dp5064
g7
I0
sg8
g15
sg10
I5
sg11
VNEDD9
p5065
sg13
I1
sasg19
(lp5066
(dp5067
g7
I138
sg22
VC2699153
p5068
sg10
I13
sg11
Vcell invasion
p5069
sg13
I2
sa(dp5070
g7
I211
sg22
VC0025202
p5071
sg10
I8
sg11
Vmelanoma
p5072
sg13
I1
sa(dp5073
g7
I131
sg22
VC0027651
p5074
sg10
I6
sg11
Vtumour
p5075
sg13
I1
sa(dp5076
g7
I220
sg22
VC0027627
p5077
sg10
I10
sg11
Vmetastasis
p5078
sg13
I1
sasa(dp5079
g2
S'We show that mesenchymal-type movement in melanoma cells is driven by activation of the GTPase Rac through a complex containing NEDD9, a recently identified melanoma metastasis gene, and DOCK3, a Rac guanine nucleotide exchange factor.\n'
p5080
sg4
(lp5081
(dp5082
g7
I196
sg8
VP31749
p5083
sg10
I38
sg11
VRac guanine nucleotide exchange factor
p5084
sg13
I5
sa(dp5085
g7
I128
sg8
g15
sg10
I5
sg11
VNEDD9
p5086
sg13
I1
sa(dp5087
g7
I187
sg8
g15
sg10
I5
sg11
VDOCK3
p5088
sg13
I1
sa(dp5089
g7
I157
sg8
VP41162
p5090
sg10
I24
sg11
Vmelanoma metastasis gene
p5091
sg13
I3
sa(dp5092
g7
I88
sg8
VP84095
p5093
sg10
I10
sg11
VGTPase Rac
p5094
sg13
I2
sasg19
(lp5095
(dp5096
g7
I42
sg22
VC0025202
p5097
sg10
I8
sg11
Vmelanoma
p5098
sg13
I1
sa(dp5099
g7
I42
sg22
VC0025202
p5100
sg10
I8
sg11
Vmelanoma
p5101
sg13
I1
sa(dp5102
g7
I166
sg22
VC0027627
p5103
sg10
I10
sg11
Vmetastasis
p5104
sg13
I1
sasa(dp5105
g2
S'identify DOCK3, NEDD9, WAVE2, and ARHGAP22 as key molecules regulating Rac and Rho signaling that determine the mode of movement driving melanoma cell metastasis.\n'
p5106
sg4
(lp5107
(dp5108
g7
I71
sg8
VP31749
p5109
sg10
I3
sg11
VRac
p5110
sg13
I1
sa(dp5111
g7
I79
sg8
VP08100
p5112
sg10
I3
sg11
VRho
p5113
sg13
I1
sa(dp5114
g7
I23
sg8
g15
sg10
I5
sg11
VWAVE2
p5115
sg13
I1
sa(dp5116
g7
I34
sg8
g15
sg10
I8
sg11
VARHGAP22
p5117
sg13
I1
sa(dp5118
g7
I9
sg8
g15
sg10
I5
sg11
VDOCK3
p5119
sg13
I1
sa(dp5120
g7
I16
sg8
g15
sg10
I5
sg11
VNEDD9
p5121
sg13
I1
sasg19
(lp5122
(dp5123
g7
I137
sg22
VC0025202
p5124
sg10
I8
sg11
Vmelanoma
p5125
sg13
I1
sa(dp5126
g7
I151
sg22
VC0027627
p5127
sg10
I10
sg11
Vmetastasis
p5128
sg13
I1
sasa(dp5129
g2
S'Mechanisms, some involving established cancer-related signaling/transcription factor pathways (for example, Wnt, TGF-Beta, mir200, ZEB1, OVOL2, p63 and p300) and translational implications of the Grainyhead proteins in cancer are discussed in this review article.\n'
p5130
sg4
(lp5131
(dp5132
g7
I144
sg8
g15
sg10
I3
sg11
Vp63
p5133
sg13
I1
sa(dp5134
g7
I131
sg8
VP37275
p5135
sg10
I4
sg11
VZEB1
p5136
sg13
I1
sa(dp5137
g7
I196
sg8
VP02649
p5138
sg10
I19
sg11
VGrainyhead proteins
p5139
sg13
I2
sa(dp5140
g7
I113
sg8
VP18075
p5141
sg10
I8
sg11
VTGF-Beta
p5142
sg13
I1
sa(dp5143
g7
I137
sg8
g15
sg10
I5
sg11
VOVOL2
p5144
sg13
I1
sa(dp5145
g7
I152
sg8
g15
sg10
I4
sg11
Vp300
p5146
sg13
I1
sasg19
(lp5147
(dp5148
g7
I39
sg22
VC0006826
p5149
sg10
I6
sg11
Vcancer
p5150
sg13
I1
sa(dp5151
g7
I39
sg22
VC0006826
p5152
sg10
I6
sg11
Vcancer
p5153
sg13
I1
sasa(dp5154
g2
S'In the present study, we demonstrated that OVOL2, a zinc finger transcription factor, inhibits TGF-Beta signaling-induced EMT in mouse and human mammary tumor cells, as well as in mouse tumor models.\n'
p5155
sg4
(lp5156
(dp5157
g7
I43
sg8
g15
sg10
I5
sg11
VOVOL2
p5158
sg13
I1
sa(dp5159
g7
I52
sg8
g15
sg10
I32
sg11
Vzinc finger transcription factor
p5160
sg13
I4
sa(dp5161
g7
I95
sg8
VP18075
p5162
sg10
I8
sg11
VTGF-Beta
p5163
sg13
I1
sasg19
(lp5164
(dp5165
g7
I145
sg22
VC1458155
p5166
sg10
I13
sg11
Vmammary tumor
p5167
sg13
I2
sa(dp5168
g7
I153
sg22
VC0027651
p5169
sg10
I5
sg11
Vtumor
p5170
sg13
I1
sasa(dp5171
g2
S'Data from the Oncomine databases indicated a strong negative relationship between OVOL2 expression and breast cancer progression.\n'
p5172
sg4
(lp5173
(dp5174
g7
I82
sg8
g15
sg10
I5
sg11
VOVOL2
p5175
sg13
I1
sasg19
(lp5176
(dp5177
g7
I110
sg22
VC0178874
p5178
sg10
I18
sg11
Vcancer progression
p5179
sg13
I2
sasa(dp5180
g2
S'The modulation of these molecular processes may represent a strategy for inhibiting breast cancer invasion by restoring OVOL2 expression.\n'
p5181
sg4
(lp5182
(dp5183
g7
I120
sg8
g15
sg10
I5
sg11
VOVOL2
p5184
sg13
I1
sasg19
(lp5185
(dp5186
g7
I84
sg22
VC0678222
p5187
sg10
I13
sg11
Vbreast cancer
p5188
sg13
I2
sa(dp5189
g7
I98
sg22
VC2699153
p5190
sg10
I8
sg11
Vinvasion
p5191
sg13
I1
sasa(dp5192
g2
S"We previously reported that human OVOL1 and OVOL2 were preferentially expressed in the normal epidermis and hair follicles as well as their tumors, and found that OVOL1 is upregulated in Bowen's disease and downregulated in cutaneous squamous cell carcinoma.\n"
p5193
sg4
(lp5194
(dp5195
g7
I28
sg8
g15
sg10
I11
sg11
Vhuman OVOL1
p5196
sg13
I2
sa(dp5197
g7
I44
sg8
g15
sg10
I5
sg11
VOVOL2
p5198
sg13
I1
sa(dp5199
g7
I34
sg8
g15
sg10
I5
sg11
VOVOL1
p5200
sg13
I1
sasg19
(lp5201
(dp5202
g7
I224
sg22
VC0553723
p5203
sg10
I33
sg11
Vcutaneous squamous cell carcinoma
p5204
sg13
I4
sa(dp5205
g7
I187
sg22
VC0006079
p5206
sg10
I15
sg11
VBowen's disease
p5207
sg13
I2
sa(dp5208
g7
I140
sg22
VC0027651
p5209
sg10
I6
sg11
Vtumors
p5210
sg13
I1
sasa(dp5211
g2
S"The aims of this study were to elucidate the potential role of the OVOL1-OVOL2 axis in Bowen's disease and squamous cell carcinoma, and to reveal the relationship between OVOL and c-Myc, a proto-oncogene that plays a pivotal role in the malignancy of epithelial tumors.\n"
p5212
sg4
(lp5213
(dp5214
g7
I180
sg8
VP12524
p5215
sg10
I5
sg11
Vc-Myc
p5216
sg13
I1
sa(dp5217
g7
I73
sg8
g15
sg10
I5
sg11
VOVOL2
p5218
sg13
I1
sa(dp5219
g7
I67
sg8
g15
sg10
I5
sg11
VOVOL1
p5220
sg13
I1
sasg19
(lp5221
(dp5222
g7
I237
sg22
VC0006826
p5223
sg10
I10
sg11
Vmalignancy
p5224
sg13
I1
sa(dp5225
g7
I251
sg22
VC1368683
p5226
sg10
I17
sg11
Vepithelial tumors
p5227
sg13
I2
sa(dp5228
g7
I107
sg22
VC0007137
p5229
sg10
I23
sg11
Vsquamous cell carcinoma
p5230
sg13
I3
sa(dp5231
g7
I87
sg22
VC0006079
p5232
sg10
I15
sg11
VBowen's disease
p5233
sg13
I2
sasa(dp5234
g2
S"OVOL2 was markedly upregulated in the nucleus of Bowen's disease cells, but the distribution of OVOL2 expression in squamous cell carcinoma varied widely; OVOL2 was typically expressed in the cytoplasm, but only sporadically in the nucleus.\n"
p5235
sg4
(lp5236
(dp5237
g7
I0
sg8
g15
sg10
I5
sg11
VOVOL2
p5238
sg13
I1
sa(dp5239
g7
I0
sg8
g15
sg10
I5
sg11
VOVOL2
p5240
sg13
I1
sa(dp5241
g7
I0
sg8
g15
sg10
I5
sg11
VOVOL2
p5242
sg13
I1
sasg19
(lp5243
(dp5244
g7
I116
sg22
VC0007137
p5245
sg10
I23
sg11
Vsquamous cell carcinoma
p5246
sg13
I3
sa(dp5247
g7
I49
sg22
VC0006079
p5248
sg10
I15
sg11
VBowen's disease
p5249
sg13
I2
sasa(dp5250
g2
S'These results suggest that OVOL1 is an upstream suppressor of c-Myc and OVOL2, and the OVOL1-OVOL2 axis is a modulator of c-Myc, coordinately regulating the invasiveness of cutaneous squamous cell carcinoma.\n'
p5251
sg4
(lp5252
(dp5253
g7
I72
sg8
g15
sg10
I5
sg11
VOVOL2
p5254
sg13
I1
sa(dp5255
g7
I27
sg8
g15
sg10
I5
sg11
VOVOL1
p5256
sg13
I1
sa(dp5257
g7
I72
sg8
g15
sg10
I5
sg11
VOVOL2
p5258
sg13
I1
sa(dp5259
g7
I62
sg8
VP12524
p5260
sg10
I5
sg11
Vc-Myc
p5261
sg13
I1
sa(dp5262
g7
I62
sg8
VP12524
p5263
sg10
I5
sg11
Vc-Myc
p5264
sg13
I1
sa(dp5265
g7
I27
sg8
g15
sg10
I5
sg11
VOVOL1
p5266
sg13
I1
sasg19
(lp5267
(dp5268
g7
I173
sg22
VC0553723
p5269
sg10
I33
sg11
Vcutaneous squamous cell carcinoma
p5270
sg13
I4
sasa(dp5271
g2
S"Taken together, this study suggests that the OVOL1-OVOL2 axis is a key modulator of c-Myc expression in the shift from in situ epidermal malignancy (Bowen's disease) to invasive squamous cell carcinoma.\n"
p5272
sg4
(lp5273
(dp5274
g7
I51
sg8
g15
sg10
I5
sg11
VOVOL2
p5275
sg13
I1
sa(dp5276
g7
I45
sg8
g15
sg10
I5
sg11
VOVOL1
p5277
sg13
I1
sa(dp5278
g7
I84
sg8
VP12524
p5279
sg10
I5
sg11
Vc-Myc
p5280
sg13
I1
sasg19
(lp5281
(dp5282
g7
I178
sg22
VC0007137
p5283
sg10
I23
sg11
Vsquamous cell carcinoma
p5284
sg13
I3
sa(dp5285
g7
I137
sg22
VC0006826
p5286
sg10
I10
sg11
Vmalignancy
p5287
sg13
I1
sa(dp5288
g7
I149
sg22
VC0006079
p5289
sg10
I15
sg11
VBowen's disease
p5290
sg13
I2
sasa(dp5291
g2
S'In order to obtain some essential evidences for a potential targeted therapy in lung adenocarcinoma, the effects of Ovol2 gene on Epithelial-to-Mesenchymal Transition (EMT) was observed and the probable mechanisms were analyzed.\n'
p5292
sg4
(lp5293
(dp5294
g7
I116
sg8
g15
sg10
I10
sg11
VOvol2 gene
p5295
sg13
I2
sasg19
(lp5296
(dp5297
g7
I156
sg22
VC0599156
p5298
sg10
I10
sg11
VTransition
p5299
sg13
I1
sa(dp5300
g7
I80
sg22
VC0152013
p5301
sg10
I19
sg11
Vlung adenocarcinoma
p5302
sg13
I2
sasa(dp5303
g2
S'Ovol2 expression was previously evaluated by immunochemistry in lung adenocarcinoma tissue, and Ovol2 was overexpressed by lentivirus infection in A549 cells.\n'
p5304
sg4
(lp5305
(dp5306
g7
I0
sg8
g15
sg10
I5
sg11
VOvol2
p5307
sg13
I1
sa(dp5308
g7
I0
sg8
g15
sg10
I5
sg11
VOvol2
p5309
sg13
I1
sasg19
(lp5310
(dp5311
g7
I64
sg22
VC0152013
p5312
sg10
I19
sg11
Vlung adenocarcinoma
p5313
sg13
I2
sa(dp5314
g7
I123
sg22
VC0079680
p5315
sg10
I20
sg11
Vlentivirus infection
p5316
sg13
I2
sasa(dp5317
g2
S'Downregulated Ovol2 expression is involved in the invasion and metastasis of breast and prostate cancers, but little is known about its expression and prognostic value in other cancers, including hepatocellular carcinoma (HCC).\n'
p5318
sg4
(lp5319
(dp5320
g7
I14
sg8
g15
sg10
I5
sg11
VOvol2
p5321
sg13
I1
sasg19
(lp5322
(dp5323
g7
I63
sg22
VC0027627
p5324
sg10
I10
sg11
Vmetastasis
p5325
sg13
I1
sa(dp5326
g7
I88
sg22
VC0376358
p5327
sg10
I16
sg11
Vprostate cancers
p5328
sg13
I2
sa(dp5329
g7
I50
sg22
VC2699153
p5330
sg10
I8
sg11
Vinvasion
p5331
sg13
I1
sa(dp5332
g7
I222
sg22
VC2239176
p5333
sg10
I3
sg11
VHCC
p5334
sg13
I1
sa(dp5335
g7
I97
sg22
VC0006826
p5336
sg10
I7
sg11
Vcancers
p5337
sg13
I1
sa(dp5338
g7
I196
sg22
VC2239176
p5339
sg10
I24
sg11
Vhepatocellular carcinoma
p5340
sg13
I2
sasa(dp5341
g2
S'Ovol2 expression was significantly lower in HCC tissues than in adjacent noncancerous tissues.\n'
p5342
sg4
(lp5343
(dp5344
g7
I0
sg8
g15
sg10
I5
sg11
VOvol2
p5345
sg13
I1
sasg19
(lp5346
(dp5347
g7
I44
sg22
VC2239176
p5348
sg10
I3
sg11
VHCC
p5349
sg13
I1
sasa(dp5350
g2
S'OVOL2 was also expressed in pilomatricoma, with only partial expression of OVOL1.\n'
p5351
sg4
(lp5352
(dp5353
g7
I0
sg8
g15
sg10
I5
sg11
VOVOL2
p5354
sg13
I1
sa(dp5355
g7
I75
sg8
g15
sg10
I5
sg11
VOVOL1
p5356
sg13
I1
sasg19
(lp5357
(dp5358
g7
I28
sg22
VC0206711
p5359
sg10
I13
sg11
Vpilomatricoma
p5360
sg13
I1
sasa(dp5361
g2
S'These results indicated that the OVOL1-OVOL2 axis may actively contribute to cell differentiation and proliferation in the hair bulb, suggesting that the OVOL1 and OVOL2 may be therapeutic targets of hair disorders, including alopecia, and play important roles in the tumorigenesis of pilomatricoma.\n'
p5362
sg4
(lp5363
(dp5364
g7
I33
sg8
g15
sg10
I5
sg11
VOVOL1
p5365
sg13
I1
sa(dp5366
g7
I39
sg8
g15
sg10
I5
sg11
VOVOL2
p5367
sg13
I1
sa(dp5368
g7
I39
sg8
g15
sg10
I5
sg11
VOVOL2
p5369
sg13
I1
sa(dp5370
g7
I33
sg8
g15
sg10
I5
sg11
VOVOL1
p5371
sg13
I1
sasg19
(lp5372
(dp5373
g7
I102
sg22
VC0334094
p5374
sg10
I13
sg11
Vproliferation
p5375
sg13
I1
sa(dp5376
g7
I268
sg22
VC0007621
p5377
sg10
I13
sg11
Vtumorigenesis
p5378
sg13
I1
sa(dp5379
g7
I285
sg22
VC0206711
p5380
sg10
I13
sg11
Vpilomatricoma
p5381
sg13
I1
sa(dp5382
g7
I200
sg22
VC0018500
p5383
sg10
I14
sg11
Vhair disorders
p5384
sg13
I2
sasa(dp5385
g2
S'We studied the expression and function of OVOL2, a member of the Ovo family of conserved zinc-finger transcription factors regulated by the WNT signaling pathway, in intestinal tumors of mice and human beings.\n'
p5386
sg4
(lp5387
(dp5388
g7
I42
sg8
g15
sg10
I5
sg11
VOVOL2
p5389
sg13
I1
sa(dp5390
g7
I65
sg8
VP19883
p5391
sg10
I57
sg11
VOvo family of conserved zinc-finger transcription factors
p5392
sg13
I7
sasg19
(lp5393
(dp5394
g7
I166
sg22
VC0021841
p5395
sg10
I17
sg11
Vintestinal tumors
p5396
sg13
I2
sasa(dp5397
g2
S'Analysis of data from patients indicated that the levels of OVOL2 messenger RNA were significantly lower in colon carcinomas than adenomas, and decreased significantly as carcinomas progressed from grades 2 to 4.\n'
p5398
sg4
(lp5399
(dp5400
g7
I60
sg8
g15
sg10
I19
sg11
VOVOL2 messenger RNA
p5401
sg13
I3
sasg19
(lp5402
(dp5403
g7
I130
sg22
VC0001430
p5404
sg10
I8
sg11
Vadenomas
p5405
sg13
I1
sa(dp5406
g7
I114
sg22
VC0007097
p5407
sg10
I10
sg11
Vcarcinomas
p5408
sg13
I1
sa(dp5409
g7
I114
sg22
VC0007097
p5410
sg10
I10
sg11
Vcarcinomas
p5411
sg13
I1
sasa(dp5412
g2
S'Disruption of Ovol2 in Apc(min/+) mice increased WNT activity in intestinal tissues and the formation of invasive intestinal tumors.\n'
p5413
sg4
(lp5414
(dp5415
g7
I14
sg8
g15
sg10
I5
sg11
VOvol2
p5416
sg13
I1
sasg19
(lp5417
(dp5418
g7
I23
sg22
VC0033036
p5419
sg10
I3
sg11
VApc
p5420
sg13
I1
sa(dp5421
g7
I114
sg22
VC0021841
p5422
sg10
I17
sg11
Vintestinal tumors
p5423
sg13
I2
sasa(dp5424
g2
S'Furthermore, forced expression of the repressor isoform of Ovol2 is able to reprogram metastatic breast cancer cells from a mesenchymal to an epithelial state.\n'
p5425
sg4
(lp5426
(dp5427
g7
I59
sg8
g15
sg10
I5
sg11
VOvol2
p5428
sg13
I1
sasg19
(lp5429
(dp5430
g7
I86
sg22
VC0278488
p5431
sg10
I24
sg11
Vmetastatic breast cancer
p5432
sg13
I3
sasa(dp5433
g2
S'Here, we found that PCBP4-deficient mice are prone to lung adenocarcinoma, lymphoma, and kidney tumor and that PCBP4-deficient mouse embryo fibroblasts (MEFs) exhibit enhanced cell proliferation but decreased cellular senescence.\n'
p5434
sg4
(lp5435
(dp5436
g7
I20
sg8
VP57723
p5437
sg10
I5
sg11
VPCBP4
p5438
sg13
I1
sa(dp5439
g7
I20
sg8
VP57723
p5440
sg10
I5
sg11
VPCBP4
p5441
sg13
I1
sasg19
(lp5442
(dp5443
g7
I54
sg22
VC0152013
p5444
sg10
I19
sg11
Vlung adenocarcinoma
p5445
sg13
I2
sa(dp5446
g7
I181
sg22
VC0334094
p5447
sg10
I13
sg11
Vproliferation
p5448
sg13
I1
sa(dp5449
g7
I89
sg22
VC0022665
p5450
sg10
I12
sg11
Vkidney tumor
p5451
sg13
I2
sa(dp5452
g7
I75
sg22
VC0024299
p5453
sg10
I8
sg11
Vlymphoma
p5454
sg13
I1
sasa(dp5455
g2
S'PCBP4 plays important roles in the induction of cisplatin resistance in human maxillary cancers.\n'
p5456
sg4
(lp5457
(dp5458
g7
I0
sg8
VP57723
p5459
sg10
I5
sg11
VPCBP4
p5460
sg13
I1
sasg19
(lp5461
(dp5462
g7
I88
sg22
VC0006826
p5463
sg10
I7
sg11
Vcancers
p5464
sg13
I1
sasa(dp5465
g2
S'PCBP4 is a novel molecular target for the therapy of head and neck cancers, especially cisplatin-resistant cancers.\n'
p5466
sg4
(lp5467
(dp5468
g7
I0
sg8
VP57723
p5469
sg10
I5
sg11
VPCBP4
p5470
sg13
I1
sasg19
(lp5471
(dp5472
g7
I67
sg22
VC0006826
p5473
sg10
I7
sg11
Vcancers
p5474
sg13
I1
sa(dp5475
g7
I67
sg22
VC0006826
p5476
sg10
I7
sg11
Vcancers
p5477
sg13
I1
sasa(dp5478
g2
S'The protein alpha CP-4 (also known as hnRNP E4) is an RNA binding protein encoded by a gene at 3p21, one of the most common altered regions in lung cancer.\n'
p5479
sg4
(lp5480
(dp5481
g7
I38
sg8
VP57723
p5482
sg10
I8
sg11
VhnRNP E4
p5483
sg13
I2
sasg19
(lp5484
(dp5485
g7
I143
sg22
VC0684249
p5486
sg10
I11
sg11
Vlung cancer
p5487
sg13
I2
sasa(dp5488
g2
S'The aim of this study was to evaluate the effect of alpha CP-4 on the tumorigenic capacity of lung cancer cells.\n'
p5489
sg4
(lp5490
sg19
(lp5491
(dp5492
g7
I94
sg22
VC0684249
p5493
sg10
I11
sg11
Vlung cancer
p5494
sg13
I2
sasa(dp5495
g2
S'Induction of alpha CP-4 expression caused cell cycle arrest in G(2)/M in 3 out of the 7 lung cancer cell lines studied, while no effect on apoptosis was observed.\n'
p5496
sg4
(lp5497
sg19
(lp5498
(dp5499
g7
I88
sg22
VC0684249
p5500
sg10
I11
sg11
Vlung cancer
p5501
sg13
I2
sasa(dp5502
g2
S'In conclusion, expression of alpha CP-4 can inhibit proliferation and tumorigenesis of lung cancer cells, both in vivo and in vitro, by delaying the progression of the cell cycle.\n'
p5503
sg4
(lp5504
sg19
(lp5505
(dp5506
g7
I87
sg22
VC0684249
p5507
sg10
I11
sg11
Vlung cancer
p5508
sg13
I2
sa(dp5509
g7
I70
sg22
VC0007621
p5510
sg10
I13
sg11
Vtumorigenesis
p5511
sg13
I1
sa(dp5512
g7
I52
sg22
VC0334094
p5513
sg10
I13
sg11
Vproliferation
p5514
sg13
I1
sasa(dp5515
g2
S'alpha CP-4 is an RNA-binding protein coded by PCBP4, a gene mapped to 3p21, a common deleted region in lung cancer.\n'
p5516
sg4
(lp5517
(dp5518
g7
I46
sg8
VP57723
p5519
sg10
I5
sg11
VPCBP4
p5520
sg13
I1
sasg19
(lp5521
(dp5522
g7
I103
sg22
VC0684249
p5523
sg10
I11
sg11
Vlung cancer
p5524
sg13
I2
sasa(dp5525
g2
S'In this study we characterized the expression of alpha CP-4 and alpha CP-4a, an alternatively spliced variant of alpha CP-4, in lung cancer cell lines and non-small cell lung cancer (NSCLC) samples from early stage lung cancer patients.\n'
p5526
sg4
(lp5527
sg19
(lp5528
(dp5529
g7
I128
sg22
VC0684249
p5530
sg10
I11
sg11
Vlung cancer
p5531
sg13
I2
sa(dp5532
g7
I155
sg22
VC0007131
p5533
sg10
I26
sg11
Vnon-small cell lung cancer
p5534
sg13
I4
sa(dp5535
g7
I128
sg22
VC0684249
p5536
sg10
I11
sg11
Vlung cancer
p5537
sg13
I2
sa(dp5538
g7
I183
sg22
VC0007131
p5539
sg10
I5
sg11
VNSCLC
p5540
sg13
I1
sasa(dp5541
g2
S'In NSCLC biopsies, an immunocytochemical analysis showed cytoplasmic expression of alpha CP-4 and alpha CP-4a in normal lung bronchiolar epithelium.\n'
p5542
sg4
(lp5543
sg19
(lp5544
(dp5545
g7
I3
sg22
VC0007131
p5546
sg10
I5
sg11
VNSCLC
p5547
sg13
I1
sasa(dp5548
g2
S'In contrast, alpha CP-4 immunoreactivity was not found in 47% adenocarcinomas and 83% squamous cell carcinomas, whereas all of the tumors expressed alpha CP-4a.\n'
p5549
sg4
(lp5550
sg19
(lp5551
(dp5552
g7
I86
sg22
VC0007137
p5553
sg10
I24
sg11
Vsquamous cell carcinomas
p5554
sg13
I3
sa(dp5555
g7
I131
sg22
VC0027651
p5556
sg10
I6
sg11
Vtumors
p5557
sg13
I1
sa(dp5558
g7
I62
sg22
VC0001418
p5559
sg10
I15
sg11
Vadenocarcinomas
p5560
sg13
I1
sasa(dp5561
g2
S'By fluorescence in situ hybridization, &gt;30% of NSCLC cell lines and tumors showed allelic losses at PCBP4, correlating with the absence of the protein.\n'
p5562
sg4
(lp5563
(dp5564
g7
I103
sg8
VP57723
p5565
sg10
I5
sg11
VPCBP4
p5566
sg13
I1
sasg19
(lp5567
(dp5568
g7
I50
sg22
VC0007131
p5569
sg10
I5
sg11
VNSCLC
p5570
sg13
I1
sa(dp5571
g7
I71
sg22
VC0027651
p5572
sg10
I6
sg11
Vtumors
p5573
sg13
I1
sasa(dp5574
g2
S'By Northern blotting and real-time reverse transcription-PCR, we detected the expression of alpha CP-4 and alpha CP-4a messages in NSCLC and small cell lung cancer cell lines.\n'
p5575
sg4
(lp5576
sg19
(lp5577
(dp5578
g7
I141
sg22
VC0149925
p5579
sg10
I22
sg11
Vsmall cell lung cancer
p5580
sg13
I4
sa(dp5581
g7
I131
sg22
VC0007131
p5582
sg10
I5
sg11
VNSCLC
p5583
sg13
I1
sasa(dp5584
g2
S'Our data demonstrate an abnormal expression of alpha CP-4 in lung cancer, possibly associated with an altered processing of the alpha CP-4 mRNA leading to a predominant expression of alpha CP-4a.\n'
p5585
sg4
(lp5586
sg19
(lp5587
(dp5588
g7
I61
sg22
VC0684249
p5589
sg10
I11
sg11
Vlung cancer
p5590
sg13
I2
sasa(dp5591
g2
S'Many pediatric patients, particularly those with short bowel syndrome or intestinal failure, will eventually require home PN (HPN) therapy.\n'
p5592
sg4
(lp5593
sg19
(lp5594
(dp5595
g7
I49
sg22
VC0036992
p5596
sg10
I20
sg11
Vshort bowel syndrome
p5597
sg13
I3
sasa(dp5598
g2
S'The CD80/CD86-CD28 axis is a critical pathway for immuno-corrective therapy, and the cytotoxic T lymphocyte antigen 4 (CTLA4) is a promising immunosuppressor targeting the CD80/CD86-CD28 axis; however, its use for asthma therapy needs further optimization.\n'
p5599
sg4
(lp5600
(dp5601
g7
I9
sg8
VP42081
p5602
sg10
I4
sg11
VCD86
p5603
sg13
I1
sa(dp5604
g7
I4
sg8
VP33681
p5605
sg10
I4
sg11
VCD80
p5606
sg13
I1
sa(dp5607
g7
I119
sg8
VP16410
p5608
sg10
I5
sg11
VCTLA4
p5609
sg13
I1
sa(dp5610
g7
I9
sg8
VP42081
p5611
sg10
I4
sg11
VCD86
p5612
sg13
I1
sa(dp5613
g7
I14
sg8
VP33681
p5614
sg10
I4
sg11
VCD28
p5615
sg13
I1
sa(dp5616
g7
I85
sg8
VP16410
p5617
sg10
I32
sg11
Vcytotoxic T lymphocyte antigen 4
p5618
sg13
I5
sa(dp5619
g7
I14
sg8
VP33681
p5620
sg10
I4
sg11
VCD28
p5621
sg13
I1
sa(dp5622
g7
I4
sg8
VP33681
p5623
sg10
I4
sg11
VCD80
p5624
sg13
I1
sasg19
(lp5625
(dp5626
g7
I214
sg22
VC0004096
p5627
sg10
I6
sg11
Vasthma
p5628
sg13
I1
sasa(dp5629
g2
S'We assessed the roles of these inputs in DC10 reversal of OVA-associated asthma-like disease by treating affected mice with OVA-pulsed DC10 generated from wild-type or IL-10-sufficient MHCII(-/-) or CD80/CD86(-/-) mice, or with MHCII-intact IL-10-silenced DC10.\n'
p5630
sg4
(lp5631
(dp5632
g7
I204
sg8
VP42081
p5633
sg10
I4
sg11
VCD86
p5634
sg13
I1
sa(dp5635
g7
I199
sg8
VP33681
p5636
sg10
I4
sg11
VCD80
p5637
sg13
I1
sa(dp5638
g7
I228
sg8
g15
sg10
I32
sg11
VMHCII-intact IL-10-silenced DC10
p5639
sg13
I3
sasg19
(lp5640
(dp5641
g7
I73
sg22
VC0004096
p5642
sg10
I6
sg11
Vasthma
p5643
sg13
I1
sasa(dp5644
g2
S'MHCII(-/-) DC10 expressed normal levels of IL-10, but, nevertheless, were unable to induce allergen tolerance in asthma phenotype mice, while tolerance induced by CD80/CD86(-/-) DC10 was attenuated but not eliminated.\n'
p5645
sg4
(lp5646
(dp5647
g7
I163
sg8
VP33681
p5648
sg10
I4
sg11
VCD80
p5649
sg13
I1
sa(dp5650
g7
I168
sg8
VP42081
p5651
sg10
I4
sg11
VCD86
p5652
sg13
I1
sasg19
(lp5653
(dp5654
g7
I100
sg22
VC0020963
p5655
sg10
I9
sg11
Vtolerance
p5656
sg13
I1
sa(dp5657
g7
I100
sg22
VC0020963
p5658
sg10
I9
sg11
Vtolerance
p5659
sg13
I1
sa(dp5660
g7
I113
sg22
VC0004096
p5661
sg10
I6
sg11
Vasthma
p5662
sg13
I1
sasa(dp5663
g2
S"To further clarify the endocrine activities of GHS, in 9 obese patients, 9 patients with Cushing's disease and 14 controls we studied the ACTH, F, GH and PRL responses to hexarelin (HEX, 2.0 micrograms/kg i.v.\n"
p5664
sg4
(lp5665
(dp5666
g7
I138
sg8
VP01189
p5667
sg10
I4
sg11
VACTH
p5668
sg13
I1
sa(dp5669
g7
I154
sg8
VP01236
p5670
sg10
I3
sg11
VPRL
p5671
sg13
I1
sasg19
(lp5672
(dp5673
g7
I57
sg22
VC0028754
p5674
sg10
I5
sg11
Vobese
p5675
sg13
I1
sa(dp5676
g7
I89
sg22
VC0221406
p5677
sg10
I17
sg11
VCushing's disease
p5678
sg13
I2
sasa(dp5679
g2
S"Patients with Cushing's disease are known to have high ACTH/cortisol responses to desmopressin (DDAVP, a vasopressin analogue) and to hexarelin (HEX, a synthetic GH-releasing peptide).\n"
p5680
sg4
(lp5681
(dp5682
g7
I105
sg8
VP01185
p5683
sg10
I11
sg11
Vvasopressin
p5684
sg13
I1
sa(dp5685
g7
I55
sg8
VP01189
p5686
sg10
I4
sg11
VACTH
p5687
sg13
I1
sa(dp5688
g7
I162
sg8
g15
sg10
I20
sg11
VGH-releasing peptide
p5689
sg13
I2
sasg19
(lp5690
(dp5691
g7
I14
sg22
VC0221406
p5692
sg10
I17
sg11
VCushing's disease
p5693
sg13
I2
sasa(dp5694
g2
S"The ACTH and cortisol responses to Hexarelin (HEX), a peptidyl GHS, are abolished by low-dose dexamethasone pretreatment in normal subjects but are exaggerated and higher than those after hCRH in patients with pituitary ACTH-dependent Cushing's disease, in spite of their hypercortisolism.\n"
p5695
sg4
(lp5696
(dp5697
g7
I4
sg8
VP01189
p5698
sg10
I4
sg11
VACTH
p5699
sg13
I1
sa(dp5700
g7
I4
sg8
VP01189
p5701
sg10
I4
sg11
VACTH
p5702
sg13
I1
sa(dp5703
g7
I35
sg8
g15
sg10
I9
sg11
VHexarelin
p5704
sg13
I1
sa(dp5705
g7
I46
sg8
g15
sg10
I3
sg11
VHEX
p5706
sg13
I1
sasg19
(lp5707
(dp5708
g7
I272
sg22
VC0010481
p5709
sg10
I16
sg11
Vhypercortisolism
p5710
sg13
I1
sa(dp5711
g7
I235
sg22
VC0221406
p5712
sg10
I17
sg11
VCushing's disease
p5713
sg13
I2
sasa(dp5714
g2
S"The endocrine responses (mean +/- SEM) to HEX alone were also studied in 8 patients with Addison's disease (AD, 6 males, 2 females, age 30-77 years; last hydrocortisone administration the day before testing).\n"
p5715
sg4
(lp5716
(dp5717
g7
I42
sg8
g15
sg10
I3
sg11
VHEX
p5718
sg13
I1
sasg19
(lp5719
(dp5720
g7
I34
sg22
VC0432222
p5721
sg10
I3
sg11
VSEM
p5722
sg13
I1
sa(dp5723
g7
I89
sg22
VC0001403
p5724
sg10
I17
sg11
VAddison's disease
p5725
sg13
I2
sa(dp5726
g7
I108
sg22
VC0001403
p5727
sg10
I2
sg11
VAD
p5728
sg13
I1
sasa(dp5729
g2
S'In conclusion, our present data demonstrate that the ACTH-releasing activity of HEX is increased in primary hypoadrenalism as well as in normal subjects after metyrapone but not after RU-486 pretreatment.\n'
p5730
sg4
(lp5731
(dp5732
g7
I53
sg8
VP01189
p5733
sg10
I4
sg11
VACTH
p5734
sg13
I1
sa(dp5735
g7
I80
sg8
g15
sg10
I3
sg11
VHEX
p5736
sg13
I1
sasg19
(lp5737
(dp5738
g7
I100
sg22
VC0001403
p5739
sg10
I22
sg11
Vprimary hypoadrenalism
p5740
sg13
I2
sasa(dp5741
g2
S"Interestingly, the stimulatory effect of HEX on ACTH and cortisol release is exaggerated and higher than that of hCRH in patients with Cushing's disease (CD).\n"
p5742
sg4
(lp5743
(dp5744
g7
I41
sg8
g15
sg10
I3
sg11
VHEX
p5745
sg13
I1
sa(dp5746
g7
I48
sg8
VP01189
p5747
sg10
I4
sg11
VACTH
p5748
sg13
I1
sasg19
(lp5749
(dp5750
g7
I135
sg22
VC0221406
p5751
sg10
I17
sg11
VCushing's disease
p5752
sg13
I2
sa(dp5753
g7
I154
sg22
VC0221406
p5754
sg10
I2
sg11
VCD
p5755
sg13
I1
sasa(dp5756
g2
S"We previously reported that in Cushing's disease (CD) the ACTH- and cortisol (F)-releasing activity of Hexarelin (HEX), a GH secretagogue, is exaggerated with respect to that in normal subjects and is higher than that of human CRH (hCRH), but it is absent in Cushing's syndrome.\n"
p5757
sg4
(lp5758
(dp5759
g7
I58
sg8
VP01189
p5760
sg10
I4
sg11
VACTH
p5761
sg13
I1
sa(dp5762
g7
I232
sg8
VP06850
p5763
sg10
I4
sg11
VhCRH
p5764
sg13
I1
sa(dp5765
g7
I221
sg8
VP06850
p5766
sg10
I9
sg11
Vhuman CRH
p5767
sg13
I2
sa(dp5768
g7
I103
sg8
g15
sg10
I9
sg11
VHexarelin
p5769
sg13
I1
sa(dp5770
g7
I114
sg8
g15
sg10
I3
sg11
VHEX
p5771
sg13
I1
sasg19
(lp5772
(dp5773
g7
I31
sg22
VC0221406
p5774
sg10
I17
sg11
VCushing's disease
p5775
sg13
I2
sa(dp5776
g7
I259
sg22
VC0010481
p5777
sg10
I18
sg11
VCushing's syndrome
p5778
sg13
I2
sa(dp5779
g7
I50
sg22
VC0221406
p5780
sg10
I2
sg11
VCD
p5781
sg13
I1
sasa(dp5782
g2
S"In conclusion, our findings demonstrate that the ACTH and F hyperresponsiveness to HEX is present in Cushing's disease with micro-, but not macro- ACTH-secreting pituitary adenoma.\n"
p5783
sg4
(lp5784
(dp5785
g7
I49
sg8
VP01189
p5786
sg10
I4
sg11
VACTH
p5787
sg13
I1
sa(dp5788
g7
I83
sg8
g15
sg10
I3
sg11
VHEX
p5789
sg13
I1
sa(dp5790
g7
I49
sg8
VP01189
p5791
sg10
I4
sg11
VACTH
p5792
sg13
I1
sasg19
(lp5793
(dp5794
g7
I101
sg22
VC0221406
p5795
sg10
I17
sg11
VCushing's disease
p5796
sg13
I2
sa(dp5797
g7
I147
sg22
VC1306214
p5798
sg10
I32
sg11
VACTH-secreting pituitary adenoma
p5799
sg13
I3
sasa(dp5800
g2
S"To investigate the mechanism underlying the ACTH- and cortisol-releasing activity of GHRPs in man, we compared the ACTH- and cortisol-releasing activity of Hexarelin (HEX; 2.0 micrograms/kg, iv), a hexapeptide belonging to the GHRP family, with that of human CRH (hCRH; 2.0 micrograms/kg, iv) in normal subjects (6 men and 6 women, 24-68 yr old) and patients with Cushing's syndrome (2 men and 15 women, 16-68 yr old).\n"
p5801
sg4
(lp5802
(dp5803
g7
I264
sg8
VP06850
p5804
sg10
I4
sg11
VhCRH
p5805
sg13
I1
sa(dp5806
g7
I44
sg8
VP01189
p5807
sg10
I4
sg11
VACTH
p5808
sg13
I1
sa(dp5809
g7
I227
sg8
g15
sg10
I11
sg11
VGHRP family
p5810
sg13
I2
sa(dp5811
g7
I85
sg8
g15
sg10
I5
sg11
VGHRPs
p5812
sg13
I1
sa(dp5813
g7
I253
sg8
VP06850
p5814
sg10
I9
sg11
Vhuman CRH
p5815
sg13
I2
sa(dp5816
g7
I44
sg8
VP01189
p5817
sg10
I4
sg11
VACTH
p5818
sg13
I1
sasg19
(lp5819
(dp5820
g7
I364
sg22
VC0010481
p5821
sg10
I18
sg11
VCushing's syndrome
p5822
sg13
I2
sasa(dp5823
g2
S"The stimulatory effect of HEX, but not that of hCRH, on both ACTH and cortisol secretion in Cushing's disease was clearly higher (P &lt; 0.01) than that observed in normal subjects.\n"
p5824
sg4
(lp5825
(dp5826
g7
I26
sg8
g15
sg10
I3
sg11
VHEX
p5827
sg13
I1
sa(dp5828
g7
I61
sg8
VP01189
p5829
sg10
I4
sg11
VACTH
p5830
sg13
I1
sasg19
(lp5831
(dp5832
g7
I92
sg22
VC0221406
p5833
sg10
I17
sg11
VCushing's disease
p5834
sg13
I2
sasa(dp5835
g2
S"In fact, in Cushing's disease both HEX and hCRH elicited a clear increase in ACTH levels [381.1 +/- 350.0 vs. 52.4 +/- 25.0 (P &lt; 0.005) and 100.0 +/- 86.2 vs. 53.3 +/- 29.7 pg/mL (P &lt; 0.01), respectively but the ACTH increase induced by HEX was about 7-fold greater (P &lt; 0.02) than that induced by hCRH.\n"
p5836
sg4
(lp5837
(dp5838
g7
I77
sg8
VP01189
p5839
sg10
I4
sg11
VACTH
p5840
sg13
I1
sa(dp5841
g7
I77
sg8
VP01189
p5842
sg10
I4
sg11
VACTH
p5843
sg13
I1
sasg19
(lp5844
(dp5845
g7
I12
sg22
VC0221406
p5846
sg10
I17
sg11
VCushing's disease
p5847
sg13
I2
sasa(dp5848
g2
S"In patients with Cushing's syndrome due to adrenal adenoma or ectopic ACTH, no change in ACTH and cortisol levels was observed after either HEX or hCRH administration.\n"
p5849
sg4
(lp5850
(dp5851
g7
I70
sg8
VP01189
p5852
sg10
I4
sg11
VACTH
p5853
sg13
I1
sa(dp5854
g7
I70
sg8
VP01189
p5855
sg10
I4
sg11
VACTH
p5856
sg13
I1
sasg19
(lp5857
(dp5858
g7
I43
sg22
VC0206667
p5859
sg10
I15
sg11
Vadrenal adenoma
p5860
sg13
I2
sa(dp5861
g7
I17
sg22
VC0010481
p5862
sg10
I18
sg11
VCushing's syndrome
p5863
sg13
I2
sasa(dp5864
g2
S"In conclusion, the ACTH- and cortisol-releasing activity of HEX is similar to that of hCRH in normal subjects, whereas it is dramatically enhanced in patients with Cushing's disease.\n"
p5865
sg4
(lp5866
(dp5867
g7
I60
sg8
g15
sg10
I3
sg11
VHEX
p5868
sg13
I1
sa(dp5869
g7
I19
sg8
VP01189
p5870
sg10
I4
sg11
VACTH
p5871
sg13
I1
sasg19
(lp5872
(dp5873
g7
I164
sg22
VC0221406
p5874
sg10
I17
sg11
VCushing's disease
p5875
sg13
I2
sasa(dp5876
g2
S"As the stimulatory effect of HEX on ACTH and cortisol secretion is lost in patients with Cushing's syndrome due to adrenal adenoma or ectopic ACTH, these findings suggest the usefulness of GHRPs to investigate the activity of the hypothalamo-pituitary-adrenal axis in pathophysiological conditions and possibly to differentiate pituitary from ectopic ACTH-dependent Cushing's syndrome.\n"
p5877
sg4
(lp5878
(dp5879
g7
I36
sg8
VP01189
p5880
sg10
I4
sg11
VACTH
p5881
sg13
I1
sa(dp5882
g7
I189
sg8
g15
sg10
I5
sg11
VGHRPs
p5883
sg13
I1
sa(dp5884
g7
I29
sg8
g15
sg10
I3
sg11
VHEX
p5885
sg13
I1
sa(dp5886
g7
I36
sg8
VP01189
p5887
sg10
I4
sg11
VACTH
p5888
sg13
I1
sa(dp5889
g7
I36
sg8
VP01189
p5890
sg10
I4
sg11
VACTH
p5891
sg13
I1
sasg19
(lp5892
(dp5893
g7
I351
sg22
VC0342442
p5894
sg10
I33
sg11
VACTH-dependent Cushing's syndrome
p5895
sg13
I3
sa(dp5896
g7
I115
sg22
VC0206667
p5897
sg10
I15
sg11
Vadrenal adenoma
p5898
sg13
I2
sa(dp5899
g7
I89
sg22
VC0010481
p5900
sg10
I18
sg11
VCushing's syndrome
p5901
sg13
I2
sasa(dp5902
g2
S'Thus, the aim of this study was to detect FOXL1 expression in breast cancer and to analyze its role in the progression of breast cancer.\n'
p5903
sg4
(lp5904
(dp5905
g7
I42
sg8
VP55317
p5906
sg10
I5
sg11
VFOXL1
p5907
sg13
I1
sasg19
(lp5908
(dp5909
g7
I62
sg22
VC0678222
p5910
sg10
I13
sg11
Vbreast cancer
p5911
sg13
I2
sa(dp5912
g7
I62
sg22
VC0678222
p5913
sg10
I13
sg11
Vbreast cancer
p5914
sg13
I2
sasa(dp5915
g2
S'Our results demonstrated that FOXL1 expression at both the mRNA and protein levels was downregulated in breast cancer tissues and cell lines.\n'
p5916
sg4
(lp5917
(dp5918
g7
I30
sg8
VP55317
p5919
sg10
I5
sg11
VFOXL1
p5920
sg13
I1
sasg19
(lp5921
(dp5922
g7
I104
sg22
VC0678222
p5923
sg10
I13
sg11
Vbreast cancer
p5924
sg13
I2
sasa(dp5925
g2
S'Ectopic FOXL1 suppressed breast cancer cell proliferation, migration, and invasion in vitro.\n'
p5926
sg4
(lp5927
(dp5928
g7
I8
sg8
VP55317
p5929
sg10
I5
sg11
VFOXL1
p5930
sg13
I1
sasg19
(lp5931
(dp5932
g7
I25
sg22
VC0678222
p5933
sg10
I13
sg11
Vbreast cancer
p5934
sg13
I2
sa(dp5935
g7
I74
sg22
VC2699153
p5936
sg10
I8
sg11
Vinvasion
p5937
sg13
I1
sa(dp5938
g7
I44
sg22
VC0334094
p5939
sg10
I13
sg11
Vproliferation
p5940
sg13
I1
sasa(dp5941
g2
S'Taken together, the present study demonstrated that FOXL1 inhibited the proliferation, invasion, and migration of breast cancer in vitro and breast tumor growth in vivo through deactivating the Wnt/Beta-catenin signaling pathway.\n'
p5942
sg4
(lp5943
(dp5944
g7
I52
sg8
VP55317
p5945
sg10
I5
sg11
VFOXL1
p5946
sg13
I1
sasg19
(lp5947
(dp5948
g7
I114
sg22
VC0678222
p5949
sg10
I13
sg11
Vbreast cancer
p5950
sg13
I2
sa(dp5951
g7
I87
sg22
VC2699153
p5952
sg10
I8
sg11
Vinvasion
p5953
sg13
I1
sa(dp5954
g7
I148
sg22
VC0598934
p5955
sg10
I12
sg11
Vtumor growth
p5956
sg13
I2
sa(dp5957
g7
I72
sg22
VC0334094
p5958
sg10
I13
sg11
Vproliferation
p5959
sg13
I1
sasa(dp5960
g2
S'Thus, these findings suggest that FOXL1 may be a potential novel target for breast cancer therapy.\n'
p5961
sg4
(lp5962
(dp5963
g7
I34
sg8
VP55317
p5964
sg10
I5
sg11
VFOXL1
p5965
sg13
I1
sasg19
(lp5966
(dp5967
g7
I76
sg22
VC0678222
p5968
sg10
I13
sg11
Vbreast cancer
p5969
sg13
I2
sasa(dp5970
g2
S'Prolidase deficiency is a rare autosomal recessive disorder characterized by recurrent and nonhealing skin ulcers along with facial dysmorphism and mental retardation.\n'
p5971
sg4
(lp5972
(dp5973
g7
I0
sg8
VP12955
p5974
sg10
I9
sg11
VProlidase
p5975
sg13
I1
sasg19
(lp5976
(dp5977
g7
I0
sg22
VC0268532
p5978
sg10
I20
sg11
VProlidase deficiency
p5979
sg13
I2
sa(dp5980
g7
I102
sg22
VC0037299
p5981
sg10
I11
sg11
Vskin ulcers
p5982
sg13
I2
sa(dp5983
g7
I125
sg22
VC0266617
p5984
sg10
I18
sg11
Vfacial dysmorphism
p5985
sg13
I2
sa(dp5986
g7
I148
sg22
VC0025362
p5987
sg10
I18
sg11
Vmental retardation
p5988
sg13
I2
sasa(dp5989
g2
S'Prolidase deficiency is a rare autosomal recessive disease, in which pulmonary manifestations have been sporadically reported.\n'
p5990
sg4
(lp5991
(dp5992
g7
I0
sg8
VP12955
p5993
sg10
I9
sg11
VProlidase
p5994
sg13
I1
sasg19
(lp5995
(dp5996
g7
I0
sg22
VC0268532
p5997
sg10
I20
sg11
VProlidase deficiency
p5998
sg13
I2
sasa(dp5999
g2
S'Prolidase deficiency is an autosomal recessive disorder, which is associated with chronic skin ulcers, a characteristic facial appearance, mental retardation, and recurrent infections.\n'
p6000
sg4
(lp6001
(dp6002
g7
I0
sg8
VP12955
p6003
sg10
I9
sg11
VProlidase
p6004
sg13
I1
sasg19
(lp6005
(dp6006
g7
I173
sg22
VC0021311
p6007
sg10
I10
sg11
Vinfections
p6008
sg13
I1
sa(dp6009
g7
I0
sg22
VC0268532
p6010
sg10
I20
sg11
VProlidase deficiency
p6011
sg13
I2
sa(dp6012
g7
I82
sg22
VC0157738
p6013
sg10
I19
sg11
Vchronic skin ulcers
p6014
sg13
I3
sa(dp6015
g7
I139
sg22
VC0025362
p6016
sg10
I18
sg11
Vmental retardation
p6017
sg13
I2
sasa(dp6018
g2
S'The association of moderate to severe eczema and elevated plasma levels of immunoglobulin E is a characteristic not only of atopic dermatitis but also of various genodermatoses: hyperimmunoglobulin E syndromes, Omenn syndrome, Netherton syndrome, peeling skin syndrome type B, severe dermatitis, multiple allergies, and metabolic wasting syndrome, Wiskott-Aldrich syndrome, prolidase deficiency, Loeys-Dietz syndrome, IPEX syndrome, STAT5B deficiency, and pentasomy X.\n'
p6019
sg4
(lp6020
(dp6021
g7
I374
sg8
VP12955
p6022
sg10
I9
sg11
Vprolidase
p6023
sg13
I1
sa(dp6024
g7
I178
sg8
VP40763
p6025
sg10
I21
sg11
Vhyperimmunoglobulin E
p6026
sg13
I2
sa(dp6027
g7
I433
sg8
VP51692
p6028
sg10
I6
sg11
VSTAT5B
p6029
sg13
I1
sa(dp6030
g7
I75
sg8
VP01854
p6031
sg10
I16
sg11
Vimmunoglobulin E
p6032
sg13
I2
sasg19
(lp6033
(dp6034
g7
I396
sg22
VC2697932
p6035
sg10
I20
sg11
VLoeys-Dietz syndrome
p6036
sg13
I2
sa(dp6037
g7
I456
sg22
VC2937419
p6038
sg10
I11
sg11
Vpentasomy X
p6039
sg13
I2
sa(dp6040
g7
I131
sg22
VC0011603
p6041
sg10
I10
sg11
Vdermatitis
p6042
sg13
I1
sa(dp6043
g7
I200
sg22
VC0039082
p6044
sg10
I8
sg11
Vsyndrome
p6045
sg13
I1
sa(dp6046
g7
I374
sg22
VC0268532
p6047
sg10
I20
sg11
Vprolidase deficiency
p6048
sg13
I2
sa(dp6049
g7
I38
sg22
VC0013595
p6050
sg10
I6
sg11
Veczema
p6051
sg13
I1
sa(dp6052
g7
I296
sg22
VC0740281
p6053
sg10
I18
sg11
Vmultiple allergies
p6054
sg13
I2
sa(dp6055
g7
I247
sg22
VC1849193
p6056
sg10
I21
sg11
Vpeeling skin syndrome
p6057
sg13
I3
sa(dp6058
g7
I217
sg22
VC0265962
p6059
sg10
I19
sg11
Vsyndrome, Netherton
p6060
sg13
I2
sa(dp6061
g7
I200
sg22
VC0039082
p6062
sg10
I8
sg11
Vsyndrome
p6063
sg13
I1
sa(dp6064
g7
I200
sg22
VC0039082
p6065
sg10
I8
sg11
Vsyndrome
p6066
sg13
I1
sa(dp6067
g7
I418
sg22
VC0342288
p6068
sg10
I4
sg11
VIPEX
p6069
sg13
I1
sa(dp6070
g7
I211
sg22
VC1801959
p6071
sg10
I14
sg11
VOmenn syndrome
p6072
sg13
I2
sa(dp6073
g7
I338
sg22
VC0043194
p6074
sg10
I25
sg11
Vsyndrome, Wiskott-Aldrich
p6075
sg13
I2
sa(dp6076
g7
I200
sg22
VC0039082
p6077
sg10
I9
sg11
Vsyndromes
p6078
sg13
I1
sa(dp6079
g7
I124
sg22
VC0011615
p6080
sg10
I17
sg11
Vatopic dermatitis
p6081
sg13
I2
sasa(dp6082
g2
S'Prolidase deficiency (PD) is a rare autosomal recessive disorder that has symptoms such as skin ulcers, characteristic facies, mental retardation, skeletal deformities, hematological anomalies, splenomegaly, and chronic infections.\n'
p6083
sg4
(lp6084
(dp6085
g7
I0
sg8
VP12955
p6086
sg10
I9
sg11
VProlidase
p6087
sg13
I1
sasg19
(lp6088
(dp6089
g7
I22
sg22
VC0268532
p6090
sg10
I2
sg11
VPD
p6091
sg13
I1
sa(dp6092
g7
I127
sg22
VC0025362
p6093
sg10
I18
sg11
Vmental retardation
p6094
sg13
I2
sa(dp6095
g7
I0
sg22
VC0268532
p6096
sg10
I20
sg11
VProlidase deficiency
p6097
sg13
I2
sa(dp6098
g7
I212
sg22
VC0151317
p6099
sg10
I18
sg11
Vchronic infections
p6100
sg13
I2
sa(dp6101
g7
I156
sg22
VC0000768
p6102
sg10
I11
sg11
Vdeformities
p6103
sg13
I1
sa(dp6104
g7
I91
sg22
VC0037299
p6105
sg10
I11
sg11
Vskin ulcers
p6106
sg13
I2
sasa(dp6107
g2
S'Mutations in PEPD gene cause, in human, prolidase deficiency (PD), a rare autosomal recessive disorder.\n'
p6108
sg4
(lp6109
(dp6110
g7
I40
sg8
VP12955
p6111
sg10
I9
sg11
Vprolidase
p6112
sg13
I1
sa(dp6113
g7
I13
sg8
VP12955
p6114
sg10
I9
sg11
VPEPD gene
p6115
sg13
I2
sasg19
(lp6116
(dp6117
g7
I13
sg22
VC1833661
p6118
sg10
I4
sg11
VPEPD
p6119
sg13
I1
sa(dp6120
g7
I15
sg22
VC0268532
p6121
sg10
I2
sg11
VPD
p6122
sg13
I1
sa(dp6123
g7
I40
sg22
VC0268532
p6124
sg10
I20
sg11
Vprolidase deficiency
p6125
sg13
I2
sasa(dp6126
g2
S'Xaa-Pro dipeptidase (XPD; prolidase; EC 3.4.13.9) specifically hydrolyzes dipeptides with a prolyl residue at the carboxy-terminus.\n'
p6127
sg4
(lp6128
(dp6129
g7
I0
sg8
VP12955
p6130
sg10
I19
sg11
VXaa-Pro dipeptidase
p6131
sg13
I2
sa(dp6132
g7
I26
sg8
VP12955
p6133
sg10
I9
sg11
Vprolidase
p6134
sg13
I1
sa(dp6135
g7
I21
sg8
VP18074
p6136
sg10
I3
sg11
VXPD
p6137
sg13
I1
sasg19
(lp6138
(dp6139
g7
I0
sg22
VC0268138
p6140
sg10
I19
sg11
VXaa-Pro dipeptidase
p6141
sg13
I2
sa(dp6142
g7
I21
sg22
VC0268138
p6143
sg10
I3
sg11
VXPD
p6144
sg13
I1
sasa(dp6145
g2
S'Prolidase deficiency is a rare autosomal recessive disease in which one of the last steps of collagen metabolism, cleavage of proline-containing dipeptides, is impaired.\n'
p6146
sg4
(lp6147
(dp6148
g7
I0
sg8
VP12955
p6149
sg10
I9
sg11
VProlidase
p6150
sg13
I1
sasg19
(lp6151
(dp6152
g7
I0
sg22
VC0268532
p6153
sg10
I20
sg11
VProlidase deficiency
p6154
sg13
I2
sa(dp6155
g7
I160
sg22
VC0684336
p6156
sg10
I8
sg11
Vimpaired
p6157
sg13
I1
sasa(dp6158
g2
S'Prolidase deficiency (PD) is a rare autosomal recessive disorder which may have a wide spectrum of clinical features.\n'
p6159
sg4
(lp6160
(dp6161
g7
I0
sg8
VP12955
p6162
sg10
I9
sg11
VProlidase
p6163
sg13
I1
sasg19
(lp6164
(dp6165
g7
I22
sg22
VC0268532
p6166
sg10
I2
sg11
VPD
p6167
sg13
I1
sa(dp6168
g7
I0
sg22
VC0268532
p6169
sg10
I20
sg11
VProlidase deficiency
p6170
sg13
I2
sasa(dp6171
g2
S'Prolidase deficiency (PD), a rare autosomal recessive disorder in which mutations in the PEPD gene affect prolidase functionality, tends to have serious and sometimes life-threatening clinical symptoms.\n'
p6172
sg4
(lp6173
(dp6174
g7
I0
sg8
VP12955
p6175
sg10
I9
sg11
VProlidase
p6176
sg13
I1
sa(dp6177
g7
I106
sg8
VP12955
p6178
sg10
I9
sg11
Vprolidase
p6179
sg13
I1
sa(dp6180
g7
I89
sg8
VP12955
p6181
sg10
I9
sg11
VPEPD gene
p6182
sg13
I2
sasg19
(lp6183
(dp6184
g7
I22
sg22
VC0268532
p6185
sg10
I2
sg11
VPD
p6186
sg13
I1
sa(dp6187
g7
I0
sg22
VC0268532
p6188
sg10
I20
sg11
VProlidase deficiency
p6189
sg13
I2
sa(dp6190
g7
I89
sg22
VC1833661
p6191
sg10
I4
sg11
VPEPD
p6192
sg13
I1
sasa(dp6193
g2
S'The objective of this study was to determine whether diabetes mellitus (DM)-induced up-regulation of 14-3-3Beta (YWHAB) in endothelial cells enhances intimal hyperplasia in carotid artery-injured DM Sprague-Dawley (SD) rats.\n'
p6194
sg4
(lp6195
(dp6196
g7
I113
sg8
VP31946
p6197
sg10
I5
sg11
VYWHAB
p6198
sg13
I1
sasg19
(lp6199
(dp6200
g7
I72
sg22
VC0011849
p6201
sg10
I2
sg11
VDM
p6202
sg13
I1
sa(dp6203
g7
I72
sg22
VC0011849
p6204
sg10
I2
sg11
VDM
p6205
sg13
I1
sa(dp6206
g7
I53
sg22
VC0011849
p6207
sg10
I17
sg11
Vdiabetes mellitus
p6208
sg13
I2
sa(dp6209
g7
I158
sg22
VC0020507
p6210
sg10
I11
sg11
Vhyperplasia
p6211
sg13
I1
sasa(dp6212
g2
S'Objective: To investigate expression, clinical, pathologic and prognostic significances of G-protein-coupled receptor kinase 3 (GRK3) in hepatocellular carcinoma (HCC).\n'
p6213
sg4
(lp6214
(dp6215
g7
I91
sg8
VP35626
p6216
sg10
I35
sg11
VG-protein-coupled receptor kinase 3
p6217
sg13
I4
sa(dp6218
g7
I128
sg8
VP35626
p6219
sg10
I4
sg11
VGRK3
p6220
sg13
I1
sasg19
(lp6221
(dp6222
g7
I137
sg22
VC2239176
p6223
sg10
I24
sg11
Vhepatocellular carcinoma
p6224
sg13
I2
sa(dp6225
g7
I163
sg22
VC2239176
p6226
sg10
I3
sg11
VHCC
p6227
sg13
I1
sasa(dp6228
g2
S'We have reported that G protein-coupled receptor kinase 3 (GRK3, also called ADRBK2) promotes prostate cancer progression.\n'
p6229
sg4
(lp6230
(dp6231
g7
I22
sg8
VP43250
p6232
sg10
I35
sg11
VG protein-coupled receptor kinase 3
p6233
sg13
I5
sa(dp6234
g7
I59
sg8
VP35626
p6235
sg10
I4
sg11
VGRK3
p6236
sg13
I1
sa(dp6237
g7
I77
sg8
VP35626
p6238
sg10
I6
sg11
VADRBK2
p6239
sg13
I1
sasg19
(lp6240
(dp6241
g7
I103
sg22
VC0178874
p6242
sg10
I18
sg11
Vcancer progression
p6243
sg13
I2
sasa(dp6244
g2
S'We show GRK3 expression is higher in NEPC than in PAC cells and mouse models, and it positively correlates with the expression and activity of CREB in human prostate cancers.\n'
p6245
sg4
(lp6246
(dp6247
g7
I8
sg8
VP35626
p6248
sg10
I4
sg11
VGRK3
p6249
sg13
I1
sa(dp6250
g7
I143
sg8
VP16220
p6251
sg10
I4
sg11
VCREB
p6252
sg13
I1
sasg19
(lp6253
(dp6254
g7
I157
sg22
VC0376358
p6255
sg10
I16
sg11
Vprostate cancers
p6256
sg13
I2
sa(dp6257
g7
I50
sg22
VC0033036
p6258
sg10
I3
sg11
VPAC
p6259
sg13
I1
sasa(dp6260
g2
S'Taken together, these results indicate that GRK3 is a new critical activator of NE phenotypes and mediator of CREB activation in promoting NED of prostate cancer cells.\n'
p6261
sg4
(lp6262
(dp6263
g7
I44
sg8
VP35626
p6264
sg10
I4
sg11
VGRK3
p6265
sg13
I1
sa(dp6266
g7
I110
sg8
VP16220
p6267
sg10
I4
sg11
VCREB
p6268
sg13
I1
sasg19
(lp6269
(dp6270
g7
I146
sg22
VC0600139
p6271
sg10
I15
sg11
Vprostate cancer
p6272
sg13
I2
sasa(dp6273
g2
S'Using established human breast cancer cell lines and an immunocompetent in vivo mouse model, we further demonstrate that alterations in GRK3 expression levels in tumor cells directly affect migration and invasion in vitro and the establishment of distant metastasis in vivo.\n'
p6274
sg4
(lp6275
(dp6276
g7
I136
sg8
VP35626
p6277
sg10
I4
sg11
VGRK3
p6278
sg13
I1
sasg19
(lp6279
(dp6280
g7
I24
sg22
VC0678222
p6281
sg10
I13
sg11
Vbreast cancer
p6282
sg13
I2
sa(dp6283
g7
I204
sg22
VC2699153
p6284
sg10
I8
sg11
Vinvasion
p6285
sg13
I1
sa(dp6286
g7
I255
sg22
VC0027627
p6287
sg10
I10
sg11
Vmetastasis
p6288
sg13
I1
sa(dp6289
g7
I162
sg22
VC0027651
p6290
sg10
I5
sg11
Vtumor
p6291
sg13
I1
sasa(dp6292
g2
S'Furthermore, GRK3 was found to be overexpressed in human prostate cancers, especially in metastatic tumors.\n'
p6293
sg4
(lp6294
(dp6295
g7
I13
sg8
VP35626
p6296
sg10
I4
sg11
VGRK3
p6297
sg13
I1
sasg19
(lp6298
(dp6299
g7
I89
sg22
VC0027627
p6300
sg10
I17
sg11
Vmetastatic tumors
p6301
sg13
I2
sa(dp6302
g7
I57
sg22
VC0376358
p6303
sg10
I16
sg11
Vprostate cancers
p6304
sg13
I2
sasa(dp6305
g2
S'Taken together, these data suggest that GRK3 plays an important role in prostate cancer progression and metastasis.\n'
p6306
sg4
(lp6307
(dp6308
g7
I40
sg8
VP35626
p6309
sg10
I4
sg11
VGRK3
p6310
sg13
I1
sasg19
(lp6311
(dp6312
g7
I104
sg22
VC0027627
p6313
sg10
I10
sg11
Vmetastasis
p6314
sg13
I1
sa(dp6315
g7
I81
sg22
VC0178874
p6316
sg10
I18
sg11
Vcancer progression
p6317
sg13
I2
sasa(dp6318
g2
S'In an analysis of data from The Cancer Genome Atlas, we found that GRK3 expression is frequently decreased in glioblastoma (GBM) of the classical subtype, which possesses signature amplification or mutational activation of the epidermal growth factor (EGF) receptor.\n'
p6319
sg4
(lp6320
(dp6321
g7
I67
sg8
VP35626
p6322
sg10
I4
sg11
VGRK3
p6323
sg13
I1
sa(dp6324
g7
I227
sg8
VP04626
p6325
sg10
I38
sg11
Vepidermal growth factor (EGF) receptor
p6326
sg13
I5
sasg19
(lp6327
(dp6328
g7
I124
sg22
VC0017636
p6329
sg10
I3
sg11
VGBM
p6330
sg13
I1
sa(dp6331
g7
I181
sg22
VC1705759
p6332
sg10
I13
sg11
Vamplification
p6333
sg13
I1
sa(dp6334
g7
I161
sg22
VC0850310
p6335
sg10
I9
sg11
Vpossesses
p6336
sg13
I1
sa(dp6337
g7
I110
sg22
VC0017636
p6338
sg10
I12
sg11
Vglioblastoma
p6339
sg13
I1
sa(dp6340
g7
I32
sg22
VC0006826
p6341
sg10
I6
sg11
VCancer
p6342
sg13
I1
sasa(dp6343
g2
S'We tested the correlation between GRK3 expression and GBM subtypes, as well as the relationship between the activation of the EGF and other growth factor receptor pathways and GRK expression.\n'
p6344
sg4
(lp6345
(dp6346
g7
I126
sg8
VP01133
p6347
sg10
I3
sg11
VEGF
p6348
sg13
I1
sa(dp6349
g7
I34
sg8
VP35626
p6350
sg10
I4
sg11
VGRK3
p6351
sg13
I1
sa(dp6352
g7
I54
sg8
g15
sg10
I12
sg11
VGBM subtypes
p6353
sg13
I2
sa(dp6354
g7
I34
sg8
VP34947
p6355
sg10
I3
sg11
VGRK
p6356
sg13
I1
sa(dp6357
g7
I140
sg8
g15
sg10
I22
sg11
Vgrowth factor receptor
p6358
sg13
I3
sasg19
(lp6359
(dp6360
g7
I54
sg22
VC0017636
p6361
sg10
I3
sg11
VGBM
p6362
sg13
I1
sasa(dp6363
g2
S'In analyses of primary GBM tissue and RNA specimens, we found that GRK3 expression is correlated with established criteria for GBM subtyping including expression of EGF receptor, platelet-derived growth factor receptor (PDGFR)Alfa, NF1, PTEN, CDKN2A, and neurofilament.\n'
p6364
sg4
(lp6365
(dp6366
g7
I243
sg8
VP42771
p6367
sg10
I6
sg11
VCDKN2A
p6368
sg13
I1
sa(dp6369
g7
I220
sg8
VP09619
p6370
sg10
I5
sg11
VPDGFR
p6371
sg13
I1
sa(dp6372
g7
I232
sg8
VP21359
p6373
sg10
I3
sg11
VNF1
p6374
sg13
I1
sa(dp6375
g7
I179
sg8
VP09619
p6376
sg10
I39
sg11
Vplatelet-derived growth factor receptor
p6377
sg13
I4
sa(dp6378
g7
I237
sg8
VP60484
p6379
sg10
I4
sg11
VPTEN
p6380
sg13
I1
sa(dp6381
g7
I165
sg8
VP01133
p6382
sg10
I12
sg11
VEGF receptor
p6383
sg13
I2
sa(dp6384
g7
I67
sg8
VP35626
p6385
sg10
I4
sg11
VGRK3
p6386
sg13
I1
sasg19
(lp6387
(dp6388
g7
I23
sg22
VC0017636
p6389
sg10
I3
sg11
VGBM
p6390
sg13
I1
sa(dp6391
g7
I232
sg22
VC0027831
p6392
sg10
I3
sg11
VNF1
p6393
sg13
I1
sa(dp6394
g7
I23
sg22
VC0017636
p6395
sg10
I3
sg11
VGBM
p6396
sg13
I1
sasa(dp6397
g2
S'Together, these experiments show that GRK3 is a negative regulator of cell growth whose expression is preferentially reduced in GBM of the classical subtype as a consequence of activity in primary gliomagenic pathways.\n'
p6398
sg4
(lp6399
(dp6400
g7
I38
sg8
VP35626
p6401
sg10
I4
sg11
VGRK3
p6402
sg13
I1
sasg19
(lp6403
(dp6404
g7
I128
sg22
VC0017636
p6405
sg10
I3
sg11
VGBM
p6406
sg13
I1
sasa(dp6407
g2
S'Candidates include members of the pir superfamily found in the human parasite Plasmodium vivax (vir), in the simian pathogen Plasmodium knowlesi (kir) and in the rodent malarias Plasmodium yoelii (yir), Plasmodium berghei (bir) and Plasmodium chabaudi (cir).\n'
p6408
sg4
(lp6409
(dp6410
g7
I34
sg8
g15
sg10
I15
sg11
Vpir superfamily
p6411
sg13
I2
sasg19
(lp6412
(dp6413
g7
I169
sg22
VC0024530
p6414
sg10
I8
sg11
Vmalarias
p6415
sg13
I1
sasa(dp6416
g2
S'Immmunohistochemically, human kallikrein protein (hK9) was localized in the cytoplasm, but not in the nuclei, of the epithelial cells of ovarian cancer tissues.\n'
p6417
sg4
(lp6418
(dp6419
g7
I24
sg8
VP06870
p6420
sg10
I24
sg11
Vhuman kallikrein protein
p6421
sg13
I3
sasg19
(lp6422
(dp6423
g7
I137
sg22
VC1140680
p6424
sg10
I14
sg11
Vovarian cancer
p6425
sg13
I2
sasa(dp6426
g2
S'Epidermolytic palmoplantar keratosis (EPPK) cosegregates with breast and ovarian cancers in a large French pedigree, raising the possibility that a single genetic mutation might cause these conditions and offering a potential lead to the identification of a hereditary breast/ovarian cancer gene.\n'
p6427
sg4
(lp6428
sg19
(lp6429
(dp6430
g7
I73
sg22
VC1140680
p6431
sg10
I14
sg11
Vovarian cancer
p6432
sg13
I2
sa(dp6433
g7
I38
sg22
VC1721006
p6434
sg10
I4
sg11
VEPPK
p6435
sg13
I1
sa(dp6436
g7
I0
sg22
VC1721006
p6437
sg10
I36
sg11
VEpidermolytic palmoplantar keratosis
p6438
sg13
I3
sa(dp6439
g7
I73
sg22
VC1140680
p6440
sg10
I15
sg11
Vovarian cancers
p6441
sg13
I2
sasa(dp6442
g2
S'Although inheritance of this mutation is likely responsible for EPPK, it is unlikely to be the cause of the breast and ovarian cancer.\n'
p6443
sg4
(lp6444
(dp6445
g7
I64
sg8
VP35527
p6446
sg10
I4
sg11
VEPPK
p6447
sg13
I1
sasg19
(lp6448
(dp6449
g7
I64
sg22
VC1721006
p6450
sg10
I4
sg11
VEPPK
p6451
sg13
I1
sa(dp6452
g7
I119
sg22
VC1140680
p6453
sg10
I14
sg11
Vovarian cancer
p6454
sg13
I2
sasa(dp6455
g2
S'In contrast to the low expression of SRCL in the wild-type mouse brain, in a double transgenic mouse model of AD (Tg-APP/PS1), immunohistochemistry showed that SRCL was markedly induced in Abeta-positive astrocytes and Abeta-positive vascular/perivascular cells, which are associated closely with cerebral amyloid angiopathy.\n'
p6456
sg4
(lp6457
(dp6458
g7
I37
sg8
g15
sg10
I4
sg11
VSRCL
p6459
sg13
I1
sa(dp6460
g7
I189
sg8
g15
sg10
I5
sg11
VAbeta
p6461
sg13
I1
sa(dp6462
g7
I117
sg8
g15
sg10
I3
sg11
VAPP
p6463
sg13
I1
sa(dp6464
g7
I121
sg8
VP49768
p6465
sg10
I3
sg11
VPS1
p6466
sg13
I1
sa(dp6467
g7
I37
sg8
g15
sg10
I4
sg11
VSRCL
p6468
sg13
I1
sa(dp6469
g7
I189
sg8
g15
sg10
I5
sg11
VAbeta
p6470
sg13
I1
sasg19
(lp6471
(dp6472
g7
I297
sg22
VC0085220
p6473
sg10
I27
sg11
Vcerebral amyloid angiopathy
p6474
sg13
I3
sasa(dp6475
g2
S'This study aimed to determine whether plasma levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptor (sTNF-R) increases in rheumatic mitral stenosis (MS) patients with sinus rhythm and to examine the effect of percutaneous mitral balloon valvuloplasty (PMBV) on these parameters.\n'
p6476
sg4
(lp6477
(dp6478
g7
I121
sg8
g15
sg10
I6
sg11
VsTNF-R
p6479
sg13
I1
sa(dp6480
g7
I55
sg8
VP01375
p6481
sg10
I27
sg11
Vtumor necrosis factor-alpha
p6482
sg13
I3
sa(dp6483
g7
I84
sg8
VP01375
p6484
sg10
I9
sg11
VTNF-alpha
p6485
sg13
I1
sa(dp6486
g7
I99
sg8
g15
sg10
I20
sg11
Vsoluble TNF receptor
p6487
sg13
I3
sasg19
(lp6488
(dp6489
g7
I55
sg22
VC0333516
p6490
sg10
I14
sg11
Vtumor necrosis
p6491
sg13
I2
sa(dp6492
g7
I187
sg22
VC0016169
p6493
sg10
I5
sg11
Vsinus
p6494
sg13
I1
sa(dp6495
g7
I142
sg22
VC0264766
p6496
sg10
I25
sg11
Vrheumatic mitral stenosis
p6497
sg13
I3
sasa(dp6498
g2
S'Plasma concentrations of TNF-alpha and the extent of calcium deposits were significantly higher in patients with aortic valve stenosis compared with individuals with mitral valve stenosis.\n'
p6499
sg4
(lp6500
(dp6501
g7
I25
sg8
VP01375
p6502
sg10
I9
sg11
VTNF-alpha
p6503
sg13
I1
sasg19
(lp6504
(dp6505
g7
I166
sg22
VC0026269
p6506
sg10
I21
sg11
Vmitral valve stenosis
p6507
sg13
I3
sa(dp6508
g7
I113
sg22
VC0003507
p6509
sg10
I21
sg11
Vaortic valve stenosis
p6510
sg13
I3
sasa(dp6511
g2
S'In conclusion, the plasma concentrations of TNF-alpha of patients with rheumatic mitral stenosis were significantly higher than those of healthy volunteers.\n'
p6512
sg4
(lp6513
(dp6514
g7
I44
sg8
VP01375
p6515
sg10
I9
sg11
VTNF-alpha
p6516
sg13
I1
sasg19
(lp6517
(dp6518
g7
I71
sg22
VC0264766
p6519
sg10
I25
sg11
Vrheumatic mitral stenosis
p6520
sg13
I3
sasa(dp6521
g2
S'In addition, there was a significantly direct relationship between the soluble TNF-alpha and IL-10 concentrations in the atrial and peripheral venous blood, indicating a balance between circulating TNF-alpha and IL-10 levels in patients with rheumatic mitral stenosis.\n'
p6522
sg4
(lp6523
(dp6524
g7
I79
sg8
VP01375
p6525
sg10
I9
sg11
VTNF-alpha
p6526
sg13
I1
sa(dp6527
g7
I79
sg8
VP01375
p6528
sg10
I9
sg11
VTNF-alpha
p6529
sg13
I1
sasg19
(lp6530
(dp6531
g7
I242
sg22
VC0264766
p6532
sg10
I25
sg11
Vrheumatic mitral stenosis
p6533
sg13
I3
sasa(dp6534
g2
S'To ascertain whether elevated levels of circulating proinflammatory cytokines in patients with advanced heart failure are due to congestive heart failure or due to cachexia or infection complicating heart failure, we measured prospectively plasma concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interleukin 2 (IL-2), and interleukin-6 (IL-6) in 12 patients with mitral stenosis with moderate congestive heart failure, but not with cachexia or infection.\n'
p6535
sg4
(lp6536
(dp6537
g7
I353
sg8
VP60568
p6538
sg10
I4
sg11
VIL-2
p6539
sg13
I1
sa(dp6540
g7
I326
sg8
VP01584
p6541
sg10
I9
sg11
VIL-1 beta
p6542
sg13
I2
sa(dp6543
g7
I379
sg8
VP05231
p6544
sg10
I4
sg11
VIL-6
p6545
sg13
I1
sa(dp6546
g7
I265
sg8
VP01375
p6547
sg10
I27
sg11
Vtumor necrosis factor-alpha
p6548
sg13
I3
sa(dp6549
g7
I338
sg8
VP60568
p6550
sg10
I13
sg11
Vinterleukin 2
p6551
sg13
I2
sa(dp6552
g7
I364
sg8
VP05231
p6553
sg10
I13
sg11
Vinterleukin-6
p6554
sg13
I1
sa(dp6555
g7
I294
sg8
VP01375
p6556
sg10
I9
sg11
VTNF-alpha
p6557
sg13
I1
sa(dp6558
g7
I306
sg8
VP01584
p6559
sg10
I18
sg11
Vinterleukin-1 beta
p6560
sg13
I2
sasg19
(lp6561
(dp6562
g7
I176
sg22
VC0009450
p6563
sg10
I9
sg11
Vinfection
p6564
sg13
I1
sa(dp6565
g7
I164
sg22
VC0006625
p6566
sg10
I8
sg11
Vcachexia
p6567
sg13
I1
sa(dp6568
g7
I176
sg22
VC0009450
p6569
sg10
I9
sg11
Vinfection
p6570
sg13
I1
sa(dp6571
g7
I405
sg22
VC0026269
p6572
sg10
I15
sg11
Vmitral stenosis
p6573
sg13
I2
sa(dp6574
g7
I129
sg22
VC0018802
p6575
sg10
I24
sg11
Vcongestive heart failure
p6576
sg13
I3
sa(dp6577
g7
I104
sg22
VC0018802
p6578
sg10
I13
sg11
Vheart failure
p6579
sg13
I2
sa(dp6580
g7
I129
sg22
VC0018802
p6581
sg10
I24
sg11
Vcongestive heart failure
p6582
sg13
I3
sa(dp6583
g7
I104
sg22
VC0018802
p6584
sg10
I13
sg11
Vheart failure
p6585
sg13
I2
sa(dp6586
g7
I265
sg22
VC0333516
p6587
sg10
I14
sg11
Vtumor necrosis
p6588
sg13
I2
sa(dp6589
g7
I164
sg22
VC0006625
p6590
sg10
I8
sg11
Vcachexia
p6591
sg13
I1
sasa(dp6592
g2
S'Salivary inflammation was studied in an additional 86 age-matched subjects (43 controls/43 patients with cirrhosis); significantly higher interleukin (IL)-6/IL-1Beta, secretory IgA, and lower lysozyme, and histatins 1 and 5 were found in patients with cirrhosis, compared to controls.\n'
p6593
sg4
(lp6594
(dp6595
g7
I206
sg8
VP24821
p6596
sg10
I11
sg11
Vhistatins 1
p6597
sg13
I2
sa(dp6598
g7
I138
sg8
VP60568
p6599
sg10
I18
sg11
Vinterleukin (IL)-6
p6600
sg13
I2
sa(dp6601
g7
I157
sg8
VP01584
p6602
sg10
I8
sg11
VIL-1Beta
p6603
sg13
I1
sa(dp6604
g7
I167
sg8
VP11912
p6605
sg10
I33
sg11
Vsecretory IgA, and lower lysozyme
p6606
sg13
I5
sasg19
(lp6607
(dp6608
g7
I105
sg22
VC0023890
p6609
sg10
I9
sg11
Vcirrhosis
p6610
sg13
I1
sa(dp6611
g7
I9
sg22
VC0021368
p6612
sg10
I12
sg11
Vinflammation
p6613
sg13
I1
sa(dp6614
g7
I105
sg22
VC0023890
p6615
sg10
I9
sg11
Vcirrhosis
p6616
sg13
I1
sasa(dp6617
g2
S'In contrast, lysozyme was a marker of both brain and liver disease.\n'
p6618
sg4
(lp6619
(dp6620
g7
I13
sg8
VP61626
p6621
sg10
I8
sg11
Vlysozyme
p6622
sg13
I1
sasg19
(lp6623
(dp6624
g7
I53
sg22
VC0023895
p6625
sg10
I13
sg11
Vliver disease
p6626
sg13
I2
sasa(dp6627
g2
S'Myocardial infarction was induced in 8 dogs by ligation of the left anterior descending coronary artery, 4 of which were reperfused after 3 hr Gd-Mesoporphyrin (0.05 mmol/kg) was injected intravenously 210 min after the onset of ischemia (n = 6) or after 24 hr in 2 dogs with non-reperfused infarctions.\n'
p6628
sg4
(lp6629
sg19
(lp6630
(dp6631
g7
I291
sg22
VC0021308
p6632
sg10
I11
sg11
Vinfarctions
p6633
sg13
I1
sa(dp6634
g7
I229
sg22
VC0022116
p6635
sg10
I8
sg11
Vischemia
p6636
sg13
I1
sa(dp6637
g7
I0
sg22
VC0027051
p6638
sg10
I21
sg11
VMyocardial infarction
p6639
sg13
I2
sasa(dp6640
g2
S'Consistent with this, variola virus complement regulator SPICE (smallpox inhibitor of complement enzymes) exhibits selectivity in inhibiting the human alternative complement pathway and vaccinia virus complement regulator VCP (vaccinia virus complement control protein) displays selectivity in inhibiting the bovine alternative complement pathway.\n'
p6641
sg4
(lp6642
(dp6643
g7
I30
sg8
g15
sg10
I16
sg11
Vvirus complement
p6644
sg13
I2
sa(dp6645
g7
I227
sg8
g15
sg10
I41
sg11
Vvaccinia virus complement control protein
p6646
sg13
I5
sa(dp6647
g7
I145
sg8
g15
sg10
I36
sg11
Vhuman alternative complement pathway
p6648
sg13
I4
sa(dp6649
g7
I309
sg8
g15
sg10
I37
sg11
Vbovine alternative complement pathway
p6650
sg13
I4
sa(dp6651
g7
I186
sg8
g15
sg10
I39
sg11
Vvaccinia virus complement regulator VCP
p6652
sg13
I5
sasg19
(lp6653
(dp6654
g7
I186
sg22
VC0042214
p6655
sg10
I8
sg11
Vvaccinia
p6656
sg13
I1
sa(dp6657
g7
I64
sg22
VC0037354
p6658
sg10
I8
sg11
Vsmallpox
p6659
sg13
I1
sa(dp6660
g7
I22
sg22
VC0037354
p6661
sg10
I7
sg11
Vvariola
p6662
sg13
I1
sa(dp6663
g7
I186
sg22
VC0042214
p6664
sg10
I8
sg11
Vvaccinia
p6665
sg13
I1
sasa(dp6666
g2
S'One of the spice long pepper has been traditionally used to treat chronic bronchitis, asthma, constipation, gonorrhea, paralysis of the tongue, diarrhea, cholera, malaria, viral hepatitis, respiratory infections, stomach ache, diseases of the spleen, cough, and tumors.\n'
p6667
sg4
(lp6668
sg19
(lp6669
(dp6670
g7
I189
sg22
VC0035243
p6671
sg10
I22
sg11
Vrespiratory infections
p6672
sg13
I2
sa(dp6673
g7
I213
sg22
VC0221512
p6674
sg10
I12
sg11
Vstomach ache
p6675
sg13
I2
sa(dp6676
g7
I172
sg22
VC0042721
p6677
sg10
I15
sg11
Vviral hepatitis
p6678
sg13
I2
sa(dp6679
g7
I108
sg22
VC0018081
p6680
sg10
I9
sg11
Vgonorrhea
p6681
sg13
I1
sa(dp6682
g7
I227
sg22
VC0037997
p6683
sg10
I22
sg11
Vdiseases of the spleen
p6684
sg13
I4
sa(dp6685
g7
I163
sg22
VC0024530
p6686
sg10
I7
sg11
Vmalaria
p6687
sg13
I1
sa(dp6688
g7
I86
sg22
VC0004096
p6689
sg10
I6
sg11
Vasthma
p6690
sg13
I1
sa(dp6691
g7
I262
sg22
VC0027651
p6692
sg10
I6
sg11
Vtumors
p6693
sg13
I1
sa(dp6694
g7
I251
sg22
VC0010200
p6695
sg10
I5
sg11
Vcough
p6696
sg13
I1
sa(dp6697
g7
I66
sg22
VC0008677
p6698
sg10
I18
sg11
Vchronic bronchitis
p6699
sg13
I2
sa(dp6700
g7
I154
sg22
VC0008354
p6701
sg10
I7
sg11
Vcholera
p6702
sg13
I1
sa(dp6703
g7
I144
sg22
VC0011991
p6704
sg10
I8
sg11
Vdiarrhea
p6705
sg13
I1
sa(dp6706
g7
I94
sg22
VC0009806
p6707
sg10
I12
sg11
Vconstipation
p6708
sg13
I1
sasa(dp6709
g2
S'Dried plant parts used as culinary spices (CSs) in food are permitted as dietary ingredients in dietary supplements (DSs) within certain constraints in the United States.\n'
p6710
sg4
(lp6711
sg19
(lp6712
(dp6713
g7
I26
sg22
VC0265338
p6714
sg10
I15
sg11
Vculinary spices
p6715
sg13
I2
sa(dp6716
g7
I117
sg22
VC0011195
p6717
sg10
I3
sg11
VDSs
p6718
sg13
I1
sa(dp6719
g7
I43
sg22
VC0265338
p6720
sg10
I3
sg11
VCSs
p6721
sg13
I1
sa(dp6722
g7
I96
sg22
VC0011195
p6723
sg10
I19
sg11
Vdietary supplements
p6724
sg13
I2
sasa(dp6725
g2
S'Curcumin, a yellow pigment present in the spice turmeric (Curcuma longa), can be used for the treatment of several diseases including HIV-AIDS because of its antioxidant, anti-inflammatory, anticancer, antiviral, and antibacterial nature.\n'
p6726
sg4
(lp6727
sg19
(lp6728
(dp6729
g7
I134
sg22
VC0019693
p6730
sg10
I3
sg11
VHIV
p6731
sg13
I1
sasa(dp6732
g2
S'In their own right, urocortins may be clinically relevant molecules in the pathogenesis or management of many conditions, including congestive heart failure, hypertension, gastrointestinal and inflammatory disorders (irritable bowel syndrome, active gastritis, gastroparesis, and rheumatoid arthritis), atopic/allergic disorders (dermatitis, urticaria, and asthma), pregnancy and parturition (preeclampsia, spontaneous abortion, onset, and maintenance of effective labor), major depression and obesity.\n'
p6733
sg4
(lp6734
sg19
(lp6735
(dp6736
g7
I261
sg22
VC0152020
p6737
sg10
I13
sg11
Vgastroparesis
p6738
sg13
I1
sa(dp6739
g7
I132
sg22
VC0018802
p6740
sg10
I24
sg11
Vcongestive heart failure
p6741
sg13
I3
sa(dp6742
g7
I310
sg22
VC0020517
p6743
sg10
I18
sg11
Vallergic disorders
p6744
sg13
I2
sa(dp6745
g7
I407
sg22
VC0000786
p6746
sg10
I20
sg11
Vspontaneous abortion
p6747
sg13
I2
sa(dp6748
g7
I494
sg22
VC0028754
p6749
sg10
I7
sg11
Vobesity
p6750
sg13
I1
sa(dp6751
g7
I75
sg22
VC0699748
p6752
sg10
I12
sg11
Vpathogenesis
p6753
sg13
I1
sa(dp6754
g7
I250
sg22
VC0017152
p6755
sg10
I9
sg11
Vgastritis
p6756
sg13
I1
sa(dp6757
g7
I217
sg22
VC0022104
p6758
sg10
I24
sg11
Virritable bowel syndrome
p6759
sg13
I3
sa(dp6760
g7
I393
sg22
VC0032914
p6761
sg10
I12
sg11
Vpreeclampsia
p6762
sg13
I1
sa(dp6763
g7
I342
sg22
VC0042109
p6764
sg10
I9
sg11
Vurticaria
p6765
sg13
I1
sa(dp6766
g7
I303
sg22
VC0392707
p6767
sg10
I6
sg11
Vatopic
p6768
sg13
I1
sa(dp6769
g7
I280
sg22
VC0003873
p6770
sg10
I20
sg11
Vrheumatoid arthritis
p6771
sg13
I2
sa(dp6772
g7
I357
sg22
VC0004096
p6773
sg10
I6
sg11
Vasthma
p6774
sg13
I1
sa(dp6775
g7
I330
sg22
VC0011603
p6776
sg10
I10
sg11
Vdermatitis
p6777
sg13
I1
sa(dp6778
g7
I158
sg22
VC0020538
p6779
sg10
I12
sg11
Vhypertension
p6780
sg13
I1
sa(dp6781
g7
I473
sg22
VC1269683
p6782
sg10
I16
sg11
Vmajor depression
p6783
sg13
I2
sasa(dp6784
g2
S'This effect of Ucn may explain stress-induced disorders, such as atopic dermatitis or psoriasis, and may lead to new forms of treatment.\n'
p6785
sg4
(lp6786
(dp6787
g7
I15
sg8
VP55089
p6788
sg10
I3
sg11
VUcn
p6789
sg13
I1
sasg19
(lp6790
(dp6791
g7
I86
sg22
VC0033860
p6792
sg10
I9
sg11
Vpsoriasis
p6793
sg13
I1
sa(dp6794
g7
I65
sg22
VC0011615
p6795
sg10
I17
sg11
Vatopic dermatitis
p6796
sg13
I2
sasa(dp6797
g2
S'Inherited, autosomal dominant spinocerebellar ataxia type 11 (SCA11) is caused by loss of function mutations of TTBK2 (tau tubulin kinase 2).\n'
p6798
sg4
(lp6799
(dp6800
g7
I112
sg8
g15
sg10
I5
sg11
VTTBK2
p6801
sg13
I1
sa(dp6802
g7
I11
sg8
VP56715
p6803
sg10
I49
sg11
Vautosomal dominant spinocerebellar ataxia type 11
p6804
sg13
I6
sa(dp6805
g7
I119
sg8
g15
sg10
I20
sg11
Vtau tubulin kinase 2
p6806
sg13
I4
sa(dp6807
g7
I62
sg8
g15
sg10
I5
sg11
VSCA11
p6808
sg13
I1
sasg19
(lp6809
(dp6810
g7
I30
sg22
VC1858351
p6811
sg10
I30
sg11
Vspinocerebellar ataxia type 11
p6812
sg13
I4
sa(dp6813
g7
I62
sg22
VC1858351
p6814
sg10
I5
sg11
VSCA11
p6815
sg13
I1
sasa(dp6816
g2
S'Spinocerebellar ataxia type 11 (SCA11) is rare and has previously been described in four families worldwide.\n'
p6817
sg4
(lp6818
(dp6819
g7
I0
sg8
g15
sg10
I30
sg11
VSpinocerebellar ataxia type 11
p6820
sg13
I4
sa(dp6821
g7
I32
sg8
g15
sg10
I5
sg11
VSCA11
p6822
sg13
I1
sasg19
(lp6823
(dp6824
g7
I0
sg22
VC1858351
p6825
sg10
I30
sg11
VSpinocerebellar ataxia type 11
p6826
sg13
I4
sa(dp6827
g7
I32
sg22
VC1858351
p6828
sg10
I5
sg11
VSCA11
p6829
sg13
I1
sasa(dp6830
g2
S'Mutations of TTBK2 are associated with spinocerebellar ataxia type 11.\n'
p6831
sg4
(lp6832
(dp6833
g7
I13
sg8
g15
sg10
I5
sg11
VTTBK2
p6834
sg13
I1
sasg19
(lp6835
(dp6836
g7
I39
sg22
VC0087012
p6837
sg10
I22
sg11
Vspinocerebellar ataxia
p6838
sg13
I2
sasa(dp6839
g2
S'TTBK2 is ubiquitously expressed in multiple tissues and genetically linked to spinocerebellar ataxia type 11.\n'
p6840
sg4
(lp6841
(dp6842
g7
I0
sg8
g15
sg10
I5
sg11
VTTBK2
p6843
sg13
I1
sasg19
(lp6844
(dp6845
g7
I78
sg22
VC0087012
p6846
sg10
I22
sg11
Vspinocerebellar ataxia
p6847
sg13
I2
sasa(dp6848
g2
S'Loss of function mutations of TTBK2 lead to autosomal dominant spinocerebellar ataxia type 11 (SCA11).\n'
p6849
sg4
(lp6850
(dp6851
g7
I95
sg8
g15
sg10
I5
sg11
VSCA11
p6852
sg13
I1
sa(dp6853
g7
I30
sg8
g15
sg10
I5
sg11
VTTBK2
p6854
sg13
I1
sa(dp6855
g7
I54
sg8
g15
sg10
I39
sg11
Vdominant spinocerebellar ataxia type 11
p6856
sg13
I5
sasg19
(lp6857
(dp6858
g7
I95
sg22
VC1858351
p6859
sg10
I5
sg11
VSCA11
p6860
sg13
I1
sa(dp6861
g7
I63
sg22
VC1858351
p6862
sg10
I30
sg11
Vspinocerebellar ataxia type 11
p6863
sg13
I4
sasa(dp6864
g2
S'ADCA Type III consists of six subtypes, SCA5, SCA6, SCA11, SCA26, SCA30, and SCA31.\n'
p6865
sg4
(lp6866
(dp6867
g7
I77
sg8
g15
sg10
I5
sg11
VSCA31
p6868
sg13
I1
sa(dp6869
g7
I52
sg8
g15
sg10
I5
sg11
VSCA11
p6870
sg13
I1
sa(dp6871
g7
I40
sg8
g15
sg10
I4
sg11
VSCA5
p6872
sg13
I1
sasg19
(lp6873
(dp6874
g7
I46
sg22
VC0752124
p6875
sg10
I4
sg11
VSCA6
p6876
sg13
I1
sa(dp6877
g7
I66
sg22
VC2936793
p6878
sg10
I5
sg11
VSCA30
p6879
sg13
I1
sa(dp6880
g7
I40
sg22
VC0752123
p6881
sg10
I4
sg11
VSCA5
p6882
sg13
I1
sa(dp6883
g7
I59
sg22
VC1836395
p6884
sg10
I5
sg11
VSCA26
p6885
sg13
I1
sa(dp6886
g7
I52
sg22
VC1858351
p6887
sg10
I5
sg11
VSCA11
p6888
sg13
I1
sa(dp6889
g7
I77
sg22
VC1861736
p6890
sg10
I5
sg11
VSCA31
p6891
sg13
I1
sasa(dp6892
g2
S'Dominant truncating mutations in human TTBK2 cause spinocerebellar ataxia type 11 (SCA11); these mutant proteins do not promote ciliogenesis and inhibit ciliogenesis in wild-type cells.\n'
p6893
sg4
(lp6894
(dp6895
g7
I83
sg8
g15
sg10
I5
sg11
VSCA11
p6896
sg13
I1
sa(dp6897
g7
I33
sg8
g15
sg10
I11
sg11
Vhuman TTBK2
p6898
sg13
I2
sa(dp6899
g7
I51
sg8
g15
sg10
I30
sg11
Vspinocerebellar ataxia type 11
p6900
sg13
I4
sasg19
(lp6901
(dp6902
g7
I83
sg22
VC1858351
p6903
sg10
I5
sg11
VSCA11
p6904
sg13
I1
sa(dp6905
g7
I51
sg22
VC1858351
p6906
sg10
I30
sg11
Vspinocerebellar ataxia type 11
p6907
sg13
I4
sa(dp6908
g7
I97
sg22
VC0596988
p6909
sg10
I6
sg11
Vmutant
p6910
sg13
I1
sasa(dp6911
g2
S'Subsequently, point and Indel (Insertion/deletion) mutation analyses of SCA5, SCA11, SCA13, SCA14, SCA15/16/29, SCA27, SCA31 and SCA35 were detected in 91 families with ADCA and 196 patients with sporadic ataxias excluded from SCA1, 2, 3, 6, 7, 8, 10, 12, 17 and DRPLA genotypes via PCR and Denaturing High Performance Liquid Chromatography (PCR-DHPLC), Multiplex ligation-dependent probe amplification and DNA direct sequencing analysis.\n'
p6912
sg4
(lp6913
(dp6914
g7
I112
sg8
g15
sg10
I5
sg11
VSCA27
p6915
sg13
I1
sa(dp6916
g7
I85
sg8
g15
sg10
I5
sg11
VSCA13
p6917
sg13
I1
sa(dp6918
g7
I99
sg8
g15
sg10
I11
sg11
VSCA15/16/29
p6919
sg13
I1
sa(dp6920
g7
I119
sg8
g15
sg10
I5
sg11
VSCA31
p6921
sg13
I1
sa(dp6922
g7
I72
sg8
g15
sg10
I4
sg11
VSCA5
p6923
sg13
I1
sa(dp6924
g7
I78
sg8
g15
sg10
I5
sg11
VSCA11
p6925
sg13
I1
sa(dp6926
g7
I78
sg8
VP54253
p6927
sg10
I4
sg11
VSCA1
p6928
sg13
I1
sa(dp6929
g7
I92
sg8
VP05129
p6930
sg10
I5
sg11
VSCA14
p6931
sg13
I1
sasg19
(lp6932
(dp6933
g7
I112
sg22
VC1836383
p6934
sg10
I5
sg11
VSCA27
p6935
sg13
I1
sa(dp6936
g7
I389
sg22
VC1705759
p6937
sg10
I13
sg11
Vamplification
p6938
sg13
I1
sa(dp6939
g7
I263
sg22
VC0751781
p6940
sg10
I5
sg11
VDRPLA
p6941
sg13
I1
sa(dp6942
g7
I99
sg22
VC1847725
p6943
sg10
I5
sg11
VSCA15
p6944
sg13
I1
sa(dp6945
g7
I205
sg22
VC0004134
p6946
sg10
I7
sg11
Vataxias
p6947
sg13
I1
sa(dp6948
g7
I85
sg22
VC1854488
p6949
sg10
I5
sg11
VSCA13
p6950
sg13
I1
sa(dp6951
g7
I119
sg22
VC1861736
p6952
sg10
I5
sg11
VSCA31
p6953
sg13
I1
sa(dp6954
g7
I72
sg22
VC0752123
p6955
sg10
I4
sg11
VSCA5
p6956
sg13
I1
sa(dp6957
g7
I78
sg22
VC1858351
p6958
sg10
I5
sg11
VSCA11
p6959
sg13
I1
sa(dp6960
g7
I78
sg22
VC0752120
p6961
sg10
I4
sg11
VSCA1
p6962
sg13
I1
sa(dp6963
g7
I92
sg22
VC1854369
p6964
sg10
I5
sg11
VSCA14
p6965
sg13
I1
sasa(dp6966
g2
S'While SCA12, SCA17 and SCA35 are seldom found, SCA5, SCA8, SCA10, SCA11, SCA13, SCA27, SCA31 and DRPLA are very rare.\n'
p6967
sg4
(lp6968
(dp6969
g7
I53
sg8
g15
sg10
I4
sg11
VSCA8
p6970
sg13
I1
sa(dp6971
g7
I80
sg8
g15
sg10
I5
sg11
VSCA27
p6972
sg13
I1
sa(dp6973
g7
I47
sg8
g15
sg10
I4
sg11
VSCA5
p6974
sg13
I1
sa(dp6975
g7
I97
sg8
VP54259
p6976
sg10
I5
sg11
VDRPLA
p6977
sg13
I1
sa(dp6978
g7
I13
sg8
VP20226
p6979
sg10
I5
sg11
VSCA17
p6980
sg13
I1
sa(dp6981
g7
I87
sg8
g15
sg10
I5
sg11
VSCA31
p6982
sg13
I1
sa(dp6983
g7
I66
sg8
g15
sg10
I5
sg11
VSCA11
p6984
sg13
I1
sa(dp6985
g7
I6
sg8
g15
sg10
I5
sg11
VSCA12
p6986
sg13
I1
sa(dp6987
g7
I59
sg8
g15
sg10
I5
sg11
VSCA10
p6988
sg13
I1
sa(dp6989
g7
I73
sg8
g15
sg10
I5
sg11
VSCA13
p6990
sg13
I1
sasg19
(lp6991
(dp6992
g7
I53
sg22
VC1837454
p6993
sg10
I4
sg11
VSCA8
p6994
sg13
I1
sa(dp6995
g7
I80
sg22
VC1836383
p6996
sg10
I5
sg11
VSCA27
p6997
sg13
I1
sa(dp6998
g7
I47
sg22
VC0752123
p6999
sg10
I4
sg11
VSCA5
p7000
sg13
I1
sa(dp7001
g7
I97
sg22
VC0751781
p7002
sg10
I5
sg11
VDRPLA
p7003
sg13
I1
sa(dp7004
g7
I13
sg22
VC1846707
p7005
sg10
I5
sg11
VSCA17
p7006
sg13
I1
sa(dp7007
g7
I87
sg22
VC1861736
p7008
sg10
I5
sg11
VSCA31
p7009
sg13
I1
sa(dp7010
g7
I66
sg22
VC1858351
p7011
sg10
I5
sg11
VSCA11
p7012
sg13
I1
sa(dp7013
g7
I6
sg22
VC1858501
p7014
sg10
I5
sg11
VSCA12
p7015
sg13
I1
sa(dp7016
g7
I59
sg22
VC1963674
p7017
sg10
I5
sg11
VSCA10
p7018
sg13
I1
sa(dp7019
g7
I73
sg22
VC1854488
p7020
sg10
I5
sg11
VSCA13
p7021
sg13
I1
sasa(dp7022
g2
S'Mutations that truncate the C-terminal non-catalytic moiety of TTBK2 (tau tubulin kinase 2) cause the inherited, autosomal dominant, SCA11 (spinocerebellar ataxia type 11) movement disorder.\n'
p7023
sg4
(lp7024
(dp7025
g7
I70
sg8
g15
sg10
I20
sg11
Vtau tubulin kinase 2
p7026
sg13
I4
sa(dp7027
g7
I133
sg8
g15
sg10
I5
sg11
VSCA11
p7028
sg13
I1
sa(dp7029
g7
I140
sg8
g15
sg10
I30
sg11
Vspinocerebellar ataxia type 11
p7030
sg13
I4
sa(dp7031
g7
I63
sg8
g15
sg10
I5
sg11
VTTBK2
p7032
sg13
I1
sasg19
(lp7033
(dp7034
g7
I133
sg22
VC1858351
p7035
sg10
I5
sg11
VSCA11
p7036
sg13
I1
sa(dp7037
g7
I140
sg22
VC1858351
p7038
sg10
I30
sg11
Vspinocerebellar ataxia type 11
p7039
sg13
I4
sa(dp7040
g7
I172
sg22
VC0026650
p7041
sg10
I17
sg11
Vmovement disorder
p7042
sg13
I2
sasa(dp7043
g2
S'In addition, miR-940 may modulate the suppressive effects of fetal KCson the cell proliferation, differentiation and extracellular matrix synthesis of HSFbs by directly targeting transforming growth factor-Beta1.\n'
p7044
sg4
(lp7045
sg19
(lp7046
(dp7047
g7
I82
sg22
VC0334094
p7048
sg10
I13
sg11
Vproliferation
p7049
sg13
I1
sasa(dp7050
g2
S'Target genes (e.g., cyclin-dependent kinase 6) of hsa-miR-942-5p were mainly enriched in cancer-related pathways, whereas target genes (e.g., CRK-Like Proto-Oncogene, Adaptor Protein) of hsa-miR-940 were enriched in the ErbB signaling pathway.\n'
p7051
sg4
(lp7052
(dp7053
g7
I142
sg8
VP46108
p7054
sg10
I40
sg11
VCRK-Like Proto-Oncogene, Adaptor Protein
p7055
sg13
I4
sa(dp7056
g7
I187
sg8
g15
sg10
I11
sg11
Vhsa-miR-940
p7057
sg13
I1
sa(dp7058
g7
I50
sg8
g15
sg10
I14
sg11
Vhsa-miR-942-5p
p7059
sg13
I1
sa(dp7060
g7
I220
sg8
g15
sg10
I4
sg11
VErbB
p7061
sg13
I1
sa(dp7062
g7
I20
sg8
g15
sg10
I25
sg11
Vcyclin-dependent kinase 6
p7063
sg13
I3
sasg19
(lp7064
(dp7065
g7
I89
sg22
VC0006826
p7066
sg10
I6
sg11
Vcancer
p7067
sg13
I1
sa(dp7068
g7
I50
sg22
VC0393754
p7069
sg10
I3
sg11
Vhsa
p7070
sg13
I1
sa(dp7071
g7
I50
sg22
VC0393754
p7072
sg10
I3
sg11
Vhsa
p7073
sg13
I1
sasa(dp7074
g2
S'Herein, we demonstrated that hypoxia induces the high expression of microRNA-940 (miR-940) in exosomes derived from epithelial ovarian cancer (EOC).\n'
p7075
sg4
(lp7076
sg19
(lp7077
(dp7078
g7
I143
sg22
VC0677886
p7079
sg10
I3
sg11
VEOC
p7080
sg13
I1
sa(dp7081
g7
I29
sg22
VC0242184
p7082
sg10
I7
sg11
Vhypoxia
p7083
sg13
I1
sa(dp7084
g7
I116
sg22
VC0677886
p7085
sg10
I25
sg11
Vepithelial ovarian cancer
p7086
sg13
I3
sasa(dp7087
g2
S'Results: Expressions of hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all up regulated in high invasion capable cell lines (SNU423, SNU449) and vascular invasion patients with hepatocellular carcinoma (logFC&gt;1, P&lt;0.05).\n'
p7088
sg4
(lp7089
(dp7090
g7
I24
sg8
g15
sg10
I3
sg11
Vhsa
p7091
sg13
I1
sa(dp7092
g7
I38
sg8
g15
sg10
I11
sg11
Vhsa-mir-149
p7093
sg13
I1
sa(dp7094
g7
I51
sg8
g15
sg10
I11
sg11
Vhsa-mir-744
p7095
sg13
I1
sa(dp7096
g7
I24
sg8
g15
sg10
I12
sg11
Vhsa-mir-1180
p7097
sg13
I1
sasg19
(lp7098
(dp7099
g7
I24
sg22
VC0393754
p7100
sg10
I3
sg11
Vhsa
p7101
sg13
I1
sa(dp7102
g7
I24
sg22
VC0393754
p7103
sg10
I3
sg11
Vhsa
p7104
sg13
I1
sa(dp7105
g7
I24
sg22
VC0393754
p7106
sg10
I3
sg11
Vhsa
p7107
sg13
I1
sa(dp7108
g7
I24
sg22
VC0393754
p7109
sg10
I3
sg11
Vhsa
p7110
sg13
I1
sa(dp7111
g7
I109
sg22
VC2699153
p7112
sg10
I8
sg11
Vinvasion
p7113
sg13
I1
sa(dp7114
g7
I190
sg22
VC1512411
p7115
sg10
I24
sg11
Vhepatocellular carcinoma
p7116
sg13
I2
sa(dp7117
g7
I109
sg22
VC2699153
p7118
sg10
I8
sg11
Vinvasion
p7119
sg13
I1
sasa(dp7120
g2
S'Results from the Survival analysis showed that hsa-mir-1180 (HR=1.623, 95% CI: 1.114-2.365, P=0.012), hsa-mir-149 (HR=2.400, 95% CI: 1.639-3.514) and hsa-mir-940 (HR=1.704, 95%CI: 1.188-2.443, P=0.004) were independent risk factors on the prognosis of patients with hepatocellular carcinoma (P&lt;0.05).\n'
p7121
sg4
(lp7122
(dp7123
g7
I47
sg8
g15
sg10
I3
sg11
Vhsa
p7124
sg13
I1
sa(dp7125
g7
I47
sg8
g15
sg10
I3
sg11
Vhsa
p7126
sg13
I1
sa(dp7127
g7
I47
sg8
g15
sg10
I3
sg11
Vhsa
p7128
sg13
I1
sasg19
(lp7129
(dp7130
g7
I47
sg22
VC0393754
p7131
sg10
I3
sg11
Vhsa
p7132
sg13
I1
sa(dp7133
g7
I47
sg22
VC0393754
p7134
sg10
I3
sg11
Vhsa
p7135
sg13
I1
sa(dp7136
g7
I266
sg22
VC1512411
p7137
sg10
I24
sg11
Vhepatocellular carcinoma
p7138
sg13
I2
sa(dp7139
g7
I47
sg22
VC0393754
p7140
sg10
I3
sg11
Vhsa
p7141
sg13
I1
sasa(dp7142
g2
S'Conclusion: With TCGA and GEO data mining, we found that hsa-mir-1180, hsa-mir-149, hsa-mir-744 and hsa-mir-940 were all highly related to the prognosis of hepatocellular carcinoma, that enabled it to be used to further study the biomarkers related to the prognosis of hepatocellular carcinoma.\n'
p7143
sg4
(lp7144
(dp7145
g7
I57
sg8
g15
sg10
I12
sg11
Vhsa-mir-1180
p7146
sg13
I1
sa(dp7147
g7
I71
sg8
g15
sg10
I11
sg11
Vhsa-mir-149
p7148
sg13
I1
sa(dp7149
g7
I84
sg8
g15
sg10
I11
sg11
Vhsa-mir-744
p7150
sg13
I1
sa(dp7151
g7
I57
sg8
g15
sg10
I3
sg11
Vhsa
p7152
sg13
I1
sasg19
(lp7153
(dp7154
g7
I57
sg22
VC0393754
p7155
sg10
I3
sg11
Vhsa
p7156
sg13
I1
sa(dp7157
g7
I156
sg22
VC1512411
p7158
sg10
I24
sg11
Vhepatocellular carcinoma
p7159
sg13
I2
sa(dp7160
g7
I156
sg22
VC1512411
p7161
sg10
I24
sg11
Vhepatocellular carcinoma
p7162
sg13
I2
sa(dp7163
g7
I57
sg22
VC0393754
p7164
sg10
I3
sg11
Vhsa
p7165
sg13
I1
sa(dp7166
g7
I57
sg22
VC0393754
p7167
sg10
I3
sg11
Vhsa
p7168
sg13
I1
sa(dp7169
g7
I57
sg22
VC0393754
p7170
sg10
I3
sg11
Vhsa
p7171
sg13
I1
sasa(dp7172
g2
S'### ###GEO (Gene Expression Omnibus) #TCGA (The Cancer Genome Atlas) #####, ###########microRNA, ############ ### ##GEO###########microRNA#### (GSE67140) , #5########### (SNU423#SNU449#HepG2#Hep3B#SNU398) #########, ##81############91#######################TCGA####362############, ##microRNA########GO#KEGG### ### hsa-mir-1180#hsa-mir-149#hsa-mir-744#hsa-mir-940########################### (logFC&gt;1, P&lt;0.05) #######, hsa-mir-1180 (HR=1.623, 95%CI#1.114~2.365, P=0.012) #hsa-mir-149 (HR=2.400, 95% CI#1.639~3.514, P&lt;0.001) #hsa-mir-744 (HR=1.679, 95%CI#1.161~2.427, P=0.006) #hsa-mir-940 (HR=1.704, 95%CI#1.188~2.443, P=0.004) #############, ############### (P&lt;0.05) #GO#KEGG############################## ### ###TCGA#GEO######, ####hsa-mir-1180#hsa-mir-149#hsa-mir-744#hsa-mir-940#########, ##############.\n'
p7173
sg4
(lp7174
(dp7175
g7
I315
sg8
g15
sg10
I3
sg11
Vhsa
p7176
sg13
I1
sa(dp7177
g7
I315
sg8
g15
sg10
I3
sg11
Vhsa
p7178
sg13
I1
sa(dp7179
g7
I315
sg8
g15
sg10
I3
sg11
Vhsa
p7180
sg13
I1
sasg19
(lp7181
(dp7182
g7
I315
sg22
VC0393754
p7183
sg10
I3
sg11
Vhsa
p7184
sg13
I1
sa(dp7185
g7
I315
sg22
VC0393754
p7186
sg10
I3
sg11
Vhsa
p7187
sg13
I1
sa(dp7188
g7
I315
sg22
VC0393754
p7189
sg10
I3
sg11
Vhsa
p7190
sg13
I1
sa(dp7191
g7
I315
sg22
VC0393754
p7192
sg10
I3
sg11
Vhsa
p7193
sg13
I1
sa(dp7194
g7
I315
sg22
VC0393754
p7195
sg10
I3
sg11
Vhsa
p7196
sg13
I1
sa(dp7197
g7
I315
sg22
VC0393754
p7198
sg10
I3
sg11
Vhsa
p7199
sg13
I1
sa(dp7200
g7
I315
sg22
VC0393754
p7201
sg10
I3
sg11
Vhsa
p7202
sg13
I1
sa(dp7203
g7
I48
sg22
VC0006826
p7204
sg10
I6
sg11
VCancer
p7205
sg13
I1
sa(dp7206
g7
I315
sg22
VC0393754
p7207
sg10
I3
sg11
Vhsa
p7208
sg13
I1
sa(dp7209
g7
I315
sg22
VC0393754
p7210
sg10
I3
sg11
Vhsa
p7211
sg13
I1
sa(dp7212
g7
I315
sg22
VC0393754
p7213
sg10
I3
sg11
Vhsa
p7214
sg13
I1
sa(dp7215
g7
I315
sg22
VC0393754
p7216
sg10
I3
sg11
Vhsa
p7217
sg13
I1
sa(dp7218
g7
I315
sg22
VC0393754
p7219
sg10
I3
sg11
Vhsa
p7220
sg13
I1
sasa(dp7221
g2
S'The high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma.\n'
p7222
sg4
(lp7223
(dp7224
g7
I23
sg8
g15
sg10
I7
sg11
VmiR-940
p7225
sg13
I1
sasg19
(lp7226
(dp7227
g7
I83
sg22
VC0279663
p7228
sg10
I33
sg11
Vovarian serous cystadenocarcinoma
p7229
sg13
I3
sasa(dp7230
g2
S'In our study, real-time (RT) quantitative PCR indicated that miR-940 levels were upregulated in human cervical cancer tissue samples and cell lines.\n'
p7231
sg4
(lp7232
sg19
(lp7233
(dp7234
g7
I102
sg22
VC0302592
p7235
sg10
I15
sg11
Vcervical cancer
p7236
sg13
I2
sasa(dp7237
g2
S'Ectopic miR-940 accelerated cervical cancer cell growth, proliferation and cell cycle arrest in vitro as well as tumor formation in vivo.\n'
p7238
sg4
(lp7239
sg19
(lp7240
(dp7241
g7
I37
sg22
VC1516170
p7242
sg10
I18
sg11
Vcancer cell growth
p7243
sg13
I3
sa(dp7244
g7
I113
sg22
VC0027651
p7245
sg10
I5
sg11
Vtumor
p7246
sg13
I1
sa(dp7247
g7
I57
sg22
VC0334094
p7248
sg10
I13
sg11
Vproliferation
p7249
sg13
I1
sasa(dp7250
g2
S'p27 and PTEN were evidenced as direct targets for miR-940 and inhibition of p27 and PTEN recovered the suppressive function of miR-940-silenced cell towards to proliferation and tumorigenicity in cervical cancer cells.\n'
p7251
sg4
(lp7252
(dp7253
g7
I0
sg8
VP40305
p7254
sg10
I3
sg11
Vp27
p7255
sg13
I1
sa(dp7256
g7
I8
sg8
VP60484
p7257
sg10
I4
sg11
VPTEN
p7258
sg13
I1
sa(dp7259
g7
I0
sg8
VP40305
p7260
sg10
I3
sg11
Vp27
p7261
sg13
I1
sa(dp7262
g7
I8
sg8
VP60484
p7263
sg10
I4
sg11
VPTEN
p7264
sg13
I1
sasg19
(lp7265
(dp7266
g7
I196
sg22
VC0302592
p7267
sg10
I15
sg11
Vcervical cancer
p7268
sg13
I2
sa(dp7269
g7
I160
sg22
VC0334094
p7270
sg10
I13
sg11
Vproliferation
p7271
sg13
I1
sa(dp7272
g7
I178
sg22
VC1519697
p7273
sg10
I14
sg11
Vtumorigenicity
p7274
sg13
I1
sasa(dp7275
g2
S'In addition, miR-940 expression was inversely associated with p27 and PTEN expression levels and actively with cyclin D1 in cervical cancer specimens.\n'
p7276
sg4
(lp7277
(dp7278
g7
I111
sg8
VP24385
p7279
sg10
I9
sg11
Vcyclin D1
p7280
sg13
I2
sa(dp7281
g7
I62
sg8
VP40305
p7282
sg10
I3
sg11
Vp27
p7283
sg13
I1
sa(dp7284
g7
I70
sg8
VP60484
p7285
sg10
I4
sg11
VPTEN
p7286
sg13
I1
sasg19
(lp7287
(dp7288
g7
I124
sg22
VC0302592
p7289
sg10
I15
sg11
Vcervical cancer
p7290
sg13
I2
sasa(dp7291
g2
S'The results from our study demonstrated that miR-940 regulated p27 and PTEN post-transcriptionally and might play a significant role in cervical cancer development and progression.\n'
p7292
sg4
(lp7293
(dp7294
g7
I45
sg8
g15
sg10
I7
sg11
VmiR-940
p7295
sg13
I1
sa(dp7296
g7
I71
sg8
VP60484
p7297
sg10
I4
sg11
VPTEN
p7298
sg13
I1
sa(dp7299
g7
I63
sg8
VP40305
p7300
sg10
I3
sg11
Vp27
p7301
sg13
I1
sasg19
(lp7302
(dp7303
g7
I136
sg22
VC0302592
p7304
sg10
I15
sg11
Vcervical cancer
p7305
sg13
I2
sasa(dp7306
g2
S'Thus, miR-940 might provide a potential value as therapeutic target for cervical cancer treatment in future.\n'
p7307
sg4
(lp7308
(dp7309
g7
I6
sg8
g15
sg10
I7
sg11
VmiR-940
p7310
sg13
I1
sasg19
(lp7311
(dp7312
g7
I72
sg22
VC0302592
p7313
sg10
I15
sg11
Vcervical cancer
p7314
sg13
I2
sasa(dp7315
g2
S'We aimed to explore the roles and regulatory mechanism of microRNA-940 (miR-940) in bladder cancer development.\n'
p7316
sg4
(lp7317
sg19
(lp7318
(dp7319
g7
I84
sg22
VC0699885
p7320
sg10
I14
sg11
Vbladder cancer
p7321
sg13
I2
sasa(dp7322
g2
S'The expressions of miR-940 in bladder cancer tissues and cells were measured.\n'
p7323
sg4
(lp7324
sg19
(lp7325
(dp7326
g7
I30
sg22
VC0699885
p7327
sg10
I14
sg11
Vbladder cancer
p7328
sg13
I2
sasa(dp7329
g2
S'miR-940 was up-regulated in bladder cancer tissues and cells.\n'
p7330
sg4
(lp7331
sg19
(lp7332
(dp7333
g7
I28
sg22
VC0699885
p7334
sg10
I14
sg11
Vbladder cancer
p7335
sg13
I2
sasa(dp7336
g2
S'Overexpression of miR-940 significantly increased bladder cancer cell proliferation, promoted migration and invasion, and inhibited cell apoptosis.\n'
p7337
sg4
(lp7338
sg19
(lp7339
(dp7340
g7
I108
sg22
VC2699153
p7341
sg10
I8
sg11
Vinvasion
p7342
sg13
I1
sa(dp7343
g7
I50
sg22
VC0699885
p7344
sg10
I14
sg11
Vbladder cancer
p7345
sg13
I2
sa(dp7346
g7
I70
sg22
VC0334094
p7347
sg10
I13
sg11
Vproliferation
p7348
sg13
I1
sasa(dp7349
g2
S'INPP4A and GSK3Beta were the direct targets of miR-940, and knockdown of INPP4A or GSK3Beta significantly increased cancer cell proliferation, migration and invasion, and inhibited cell apoptosis.\n'
p7350
sg4
(lp7351
(dp7352
g7
I0
sg8
g15
sg10
I6
sg11
VINPP4A
p7353
sg13
I1
sa(dp7354
g7
I0
sg8
g15
sg10
I6
sg11
VINPP4A
p7355
sg13
I1
sasg19
(lp7356
(dp7357
g7
I128
sg22
VC0334094
p7358
sg10
I13
sg11
Vproliferation
p7359
sg13
I1
sa(dp7360
g7
I157
sg22
VC2699153
p7361
sg10
I8
sg11
Vinvasion
p7362
sg13
I1
sa(dp7363
g7
I116
sg22
VC0006826
p7364
sg10
I6
sg11
Vcancer
p7365
sg13
I1
sasa(dp7366
g2
S'Our results indicate that overexpression of miR-940 may promote bladder cancer cell proliferation, migration and invasion, and inhibited cell apoptosis via targeting INPP4A or GSK3Beta and activating Wnt/Beta-catenin pathway.\n'
p7367
sg4
(lp7368
(dp7369
g7
I44
sg8
g15
sg10
I7
sg11
VmiR-940
p7370
sg13
I1
sa(dp7371
g7
I166
sg8
g15
sg10
I6
sg11
VINPP4A
p7372
sg13
I1
sasg19
(lp7373
(dp7374
g7
I113
sg22
VC2699153
p7375
sg10
I8
sg11
Vinvasion
p7376
sg13
I1
sa(dp7377
g7
I64
sg22
VC0699885
p7378
sg10
I14
sg11
Vbladder cancer
p7379
sg13
I2
sa(dp7380
g7
I84
sg22
VC0334094
p7381
sg10
I13
sg11
Vproliferation
p7382
sg13
I1
sasa(dp7383
g2
S'We investigated the expressions of miR-940, miR-15a, miR-16 and IL-23 in plasma and thyroid tissues of PTC, nodular goiter and healthy people with qRT-PCR, and further analyzed the associations between their levels and the clinical characteristics of PTC.\n'
p7384
sg4
(lp7385
(dp7386
g7
I35
sg8
g15
sg10
I7
sg11
VmiR-940
p7387
sg13
I1
sa(dp7388
g7
I64
sg8
g15
sg10
I5
sg11
VIL-23
p7389
sg13
I1
sa(dp7390
g7
I44
sg8
g15
sg10
I7
sg11
VmiR-15a
p7391
sg13
I1
sa(dp7392
g7
I53
sg8
g15
sg10
I6
sg11
VmiR-16
p7393
sg13
I1
sasg19
(lp7394
(dp7395
g7
I108
sg22
VC1318500
p7396
sg10
I14
sg11
Vnodular goiter
p7397
sg13
I2
sa(dp7398
g7
I103
sg22
VC0238463
p7399
sg10
I3
sg11
VPTC
p7400
sg13
I1
sa(dp7401
g7
I103
sg22
VC0238463
p7402
sg10
I3
sg11
VPTC
p7403
sg13
I1
sasa(dp7404
g2
S'Level of IL-23 expression was higher while levels of miR-940, miR-15a and miR-16 expression in the PTC tissues were lower compared with the nodular goiter tissues and perineoplastic thyroid tissues.\n'
p7405
sg4
(lp7406
(dp7407
g7
I53
sg8
g15
sg10
I7
sg11
VmiR-940
p7408
sg13
I1
sa(dp7409
g7
I74
sg8
g15
sg10
I6
sg11
VmiR-16
p7410
sg13
I1
sa(dp7411
g7
I62
sg8
g15
sg10
I7
sg11
VmiR-15a
p7412
sg13
I1
sa(dp7413
g7
I9
sg8
g15
sg10
I5
sg11
VIL-23
p7414
sg13
I1
sasg19
(lp7415
(dp7416
g7
I99
sg22
VC0238463
p7417
sg10
I3
sg11
VPTC
p7418
sg13
I1
sa(dp7419
g7
I140
sg22
VC1318500
p7420
sg10
I14
sg11
Vnodular goiter
p7421
sg13
I2
sasa(dp7422
g2
S'Expressions of miR-940, miR-15a, miR-16 and IL-23 in PTC tissues might be useful biomarkers and promising targets in the diagnosis of papillary thyroid carcinoma.\n'
p7423
sg4
(lp7424
(dp7425
g7
I24
sg8
g15
sg10
I7
sg11
VmiR-15a
p7426
sg13
I1
sa(dp7427
g7
I44
sg8
g15
sg10
I5
sg11
VIL-23
p7428
sg13
I1
sa(dp7429
g7
I15
sg8
g15
sg10
I7
sg11
VmiR-940
p7430
sg13
I1
sa(dp7431
g7
I33
sg8
g15
sg10
I6
sg11
VmiR-16
p7432
sg13
I1
sa(dp7433
g7
I53
sg8
g15
sg10
I3
sg11
VPTC
p7434
sg13
I1
sasg19
(lp7435
(dp7436
g7
I134
sg22
VC0238463
p7437
sg10
I27
sg11
Vpapillary thyroid carcinoma
p7438
sg13
I3
sa(dp7439
g7
I53
sg22
VC0238463
p7440
sg10
I3
sg11
VPTC
p7441
sg13
I1
sasa(dp7442
g2
S'This study investigated the pivotal role of miR-940 in the progression of ovarian cancer and to reveal the possible molecular mechanism of its action.\n'
p7443
sg4
(lp7444
sg19
(lp7445
(dp7446
g7
I74
sg22
VC1140680
p7447
sg10
I14
sg11
Vovarian cancer
p7448
sg13
I2
sasa(dp7449
g2
S'Ovarian cancer OVCAR3 cells were transfected with the miR-940 vector, miR-940 inhibitor, and/or small interfering RNA (siRNA) targeting PKC-Delta (si-PKC-Delta), respectively.\n'
p7450
sg4
(lp7451
(dp7452
g7
I147
sg8
VP17252
p7453
sg10
I12
sg11
Vsi-PKC-Delta
p7454
sg13
I1
sa(dp7455
g7
I136
sg8
VP17252
p7456
sg10
I9
sg11
VPKC-Delta
p7457
sg13
I1
sasg19
(lp7458
(dp7459
g7
I0
sg22
VC1140680
p7460
sg10
I14
sg11
VOvarian cancer
p7461
sg13
I2
sa(dp7462
g7
I136
sg22
VC1868682
p7463
sg10
I3
sg11
VPKC
p7464
sg13
I1
sa(dp7465
g7
I136
sg22
VC1868682
p7466
sg10
I3
sg11
VPKC
p7467
sg13
I1
sasa(dp7468
g2
S'Taken together, the results of our study suggest that upregulation of miR-940 may function as a suppressor in the progression of ovarian cancer by inhibiting cell proliferation and inducing apoptosis by targeting PKC-Delta.\n'
p7469
sg4
(lp7470
(dp7471
g7
I213
sg8
VP17252
p7472
sg10
I9
sg11
VPKC-Delta
p7473
sg13
I1
sa(dp7474
g7
I70
sg8
g15
sg10
I7
sg11
VmiR-940
p7475
sg13
I1
sasg19
(lp7476
(dp7477
g7
I129
sg22
VC1140680
p7478
sg10
I14
sg11
Vovarian cancer
p7479
sg13
I2
sa(dp7480
g7
I213
sg22
VC1868682
p7481
sg10
I3
sg11
VPKC
p7482
sg13
I1
sa(dp7483
g7
I163
sg22
VC0334094
p7484
sg10
I13
sg11
Vproliferation
p7485
sg13
I1
sasa(dp7486
g2
S'This study may provide a basis for the possible application of miR-940 in illustrating the molecular pathogenic mechanism of ovarian cancer.\n'
p7487
sg4
(lp7488
sg19
(lp7489
(dp7490
g7
I125
sg22
VC1140680
p7491
sg10
I14
sg11
Vovarian cancer
p7492
sg13
I2
sasa(dp7493
g2
S'A case-control study of 266 patients (133 cases of leptospirosis and 133 controls) was constructed to evaluate the diagnostic sensitivity and specificity (DSe &amp; DSp) of both PCR assays.\n'
p7494
sg4
(lp7495
sg19
(lp7496
(dp7497
g7
I51
sg22
VC0023364
p7498
sg10
I13
sg11
Vleptospirosis
p7499
sg13
I1
sasa(dp7500
g2
S'To determine the diagnostic sensitivity (DSe) and specificity (DSp), clinical blood samples from 26 laboratory-confirmed and 107 negative patients suspected of leptospirosis were enrolled as a prospective consecutive cohort.\n'
p7501
sg4
(lp7502
(dp7503
g7
I63
sg8
VP15924
p7504
sg10
I3
sg11
VDSp
p7505
sg13
I1
sasg19
(lp7506
(dp7507
g7
I160
sg22
VC0023364
p7508
sg10
I13
sg11
Vleptospirosis
p7509
sg13
I1
sasa(dp7510
g2
S'A group of unrelated patients (n=82), characterized by short stature, dysmorphology and X-ray abnormalities, of which mucopolysacharidoses, GM1 gangliosidosis, mucolipidosis type II/III and achondroplasia owing to FGFR3 G380R mutation had been excluded, were recruited in this study.\n'
p7511
sg4
(lp7512
(dp7513
g7
I214
sg8
VP22607
p7514
sg10
I20
sg11
VFGFR3 G380R mutation
p7515
sg13
I3
sasg19
(lp7516
(dp7517
g7
I55
sg22
VC0013336
p7518
sg10
I13
sg11
Vshort stature
p7519
sg13
I2
sa(dp7520
g7
I190
sg22
VC0001080
p7521
sg10
I14
sg11
Vachondroplasia
p7522
sg13
I1
sa(dp7523
g7
I140
sg22
VC0085131
p7524
sg10
I18
sg11
VGM1 gangliosidosis
p7525
sg13
I2
sa(dp7526
g7
I160
sg22
VC0020725
p7527
sg10
I21
sg11
Vmucolipidosis type II
p7528
sg13
I3
sasa(dp7529
g2
S'The various encephalopathies that are reviewed in this article include the following: early infantile epileptic encephalopathy or Ohtahara syndrome, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, West syndrome, severe myoclonic epilepsy in infancy (Dravet syndrome), Landau-Kleffner syndrome, Lennox-Gastaut syndrome, and epileptic encephalopathy with continuous spike-and-wave during sleep.\n'
p7530
sg4
(lp7531
sg19
(lp7532
(dp7533
g7
I232
sg22
VC0037769
p7534
sg10
I13
sg11
VWest syndrome
p7535
sg13
I2
sa(dp7536
g7
I181
sg22
VC0014544
p7537
sg10
I8
sg11
Vepilepsy
p7538
sg13
I1
sa(dp7539
g7
I12
sg22
VC0085584
p7540
sg10
I16
sg11
Vencephalopathies
p7541
sg13
I1
sa(dp7542
g7
I102
sg22
VC0543888
p7543
sg10
I24
sg11
Vepileptic encephalopathy
p7544
sg13
I2
sa(dp7545
g7
I247
sg22
VC0751122
p7546
sg10
I36
sg11
Vsevere myoclonic epilepsy in infancy
p7547
sg13
I5
sa(dp7548
g7
I329
sg22
VC0238111
p7549
sg10
I23
sg11
VLennox-Gastaut syndrome
p7550
sg13
I2
sa(dp7551
g7
I149
sg22
VC0270855
p7552
sg10
I30
sg11
Vearly myoclonic encephalopathy
p7553
sg13
I3
sa(dp7554
g7
I130
sg22
VC0393706
p7555
sg10
I17
sg11
VOhtahara syndrome
p7556
sg13
I2
sa(dp7557
g7
I303
sg22
VC0282512
p7558
sg10
I24
sg11
VLandau-Kleffner syndrome
p7559
sg13
I2
sa(dp7560
g7
I285
sg22
VC0751122
p7561
sg10
I15
sg11
VDravet syndrome
p7562
sg13
I2
sa(dp7563
g7
I216
sg22
VC0751495
p7564
sg10
I14
sg11
Vfocal seizures
p7565
sg13
I2
sa(dp7566
g7
I102
sg22
VC0543888
p7567
sg10
I24
sg11
Vepileptic encephalopathy
p7568
sg13
I2
sasa(dp7569
g2
S'Mutations in the SCN1A gene are found in up to 80% of individuals with severe myoclonic epilepsy of infancy (SMEI), and mutations in KCNQ2 and KCNQ3 were identified in benign familial neonatal convulsions (BFNC) as well as in single families with Rolandic epilepsy (RE) and idiopathic generalized epilepsies (IGE).\n'
p7570
sg4
(lp7571
(dp7572
g7
I168
sg8
VP43681
p7573
sg10
I36
sg11
Vbenign familial neonatal convulsions
p7574
sg13
I4
sa(dp7575
g7
I206
sg8
VP43681
p7576
sg10
I4
sg11
VBFNC
p7577
sg13
I1
sa(dp7578
g7
I17
sg8
VP35498
p7579
sg10
I10
sg11
VSCN1A gene
p7580
sg13
I2
sa(dp7581
g7
I143
sg8
g15
sg10
I5
sg11
VKCNQ3
p7582
sg13
I1
sa(dp7583
g7
I133
sg8
g15
sg10
I5
sg11
VKCNQ2
p7584
sg13
I1
sasg19
(lp7585
(dp7586
g7
I309
sg22
VC0270850
p7587
sg10
I3
sg11
VIGE
p7588
sg13
I1
sa(dp7589
g7
I71
sg22
VC0751122
p7590
sg10
I36
sg11
Vsevere myoclonic epilepsy of infancy
p7591
sg13
I5
sa(dp7592
g7
I206
sg22
VC0220669
p7593
sg10
I4
sg11
VBFNC
p7594
sg13
I1
sa(dp7595
g7
I266
sg22
VC0376532
p7596
sg10
I2
sg11
VRE
p7597
sg13
I1
sa(dp7598
g7
I274
sg22
VC0270850
p7599
sg10
I33
sg11
Vidiopathic generalized epilepsies
p7600
sg13
I3
sa(dp7601
g7
I109
sg22
VC0751122
p7602
sg10
I4
sg11
VSMEI
p7603
sg13
I1
sa(dp7604
g7
I168
sg22
VC0220669
p7605
sg10
I36
sg11
Vbenign familial neonatal convulsions
p7606
sg13
I4
sa(dp7607
g7
I247
sg22
VC0376532
p7608
sg10
I17
sg11
VRolandic epilepsy
p7609
sg13
I2
sasa(dp7610
g2
S'Sequence analysis of the KCNQ2, Q3, and Q5 coding regions was performed in a screening sample consisting of 58 nuclear families with rolandic epilepsy.\n'
p7611
sg4
(lp7612
(dp7613
g7
I25
sg8
g15
sg10
I5
sg11
VKCNQ2
p7614
sg13
I1
sasg19
(lp7615
(dp7616
g7
I133
sg22
VC0376532
p7617
sg10
I17
sg11
Vrolandic epilepsy
p7618
sg13
I2
sasa(dp7619
g2
S'An in-frame deletion of codon 116 in KCNQ2 (p.Lys116del) and a missense mutation in KCNQ3 (p.Glu299Lys) were detected in two index cases exhibiting rolandic epilepsy and benign neonatal convulsions.\n'
p7620
sg4
(lp7621
(dp7622
g7
I84
sg8
g15
sg10
I5
sg11
VKCNQ3
p7623
sg13
I1
sa(dp7624
g7
I37
sg8
g15
sg10
I5
sg11
VKCNQ2
p7625
sg13
I1
sasg19
(lp7626
(dp7627
g7
I170
sg22
VC0270851
p7628
sg10
I27
sg11
Vbenign neonatal convulsions
p7629
sg13
I3
sa(dp7630
g7
I148
sg22
VC0376532
p7631
sg10
I17
sg11
Vrolandic epilepsy
p7632
sg13
I2
sasa(dp7633
g2
S'Mutation analysis of families with rolandic epilepsy without neonatal seizures discovered three novel missense variations (KCNQ2 p.Ile592Met, KCNQ3 p.Ala381Val, KCNQ3 p.Pro574Ser).\n'
p7634
sg4
(lp7635
(dp7636
g7
I142
sg8
g15
sg10
I7
sg11
VKCNQ3 p
p7637
sg13
I2
sa(dp7638
g7
I142
sg8
g15
sg10
I7
sg11
VKCNQ3 p
p7639
sg13
I2
sa(dp7640
g7
I123
sg8
g15
sg10
I17
sg11
VKCNQ2 p.Ile592Met
p7641
sg13
I2
sasg19
(lp7642
(dp7643
g7
I61
sg22
VC0159020
p7644
sg10
I17
sg11
Vneonatal seizures
p7645
sg13
I2
sa(dp7646
g7
I35
sg22
VC0376532
p7647
sg10
I17
sg11
Vrolandic epilepsy
p7648
sg13
I2
sasa(dp7649
g2
S'early myoclonic encephalopathy to West syndrome 1, early infantile epileptic encephalopathy to West syndrome 1, West syndrome to Lennox-Gastaut syndrome 2.\n'
p7650
sg4
(lp7651
sg19
(lp7652
(dp7653
g7
I34
sg22
VC0037769
p7654
sg10
I13
sg11
VWest syndrome
p7655
sg13
I2
sa(dp7656
g7
I34
sg22
VC0037769
p7657
sg10
I13
sg11
VWest syndrome
p7658
sg13
I2
sa(dp7659
g7
I67
sg22
VC0543888
p7660
sg10
I24
sg11
Vepileptic encephalopathy
p7661
sg13
I2
sa(dp7662
g7
I0
sg22
VC0270855
p7663
sg10
I30
sg11
Vearly myoclonic encephalopathy
p7664
sg13
I3
sa(dp7665
g7
I129
sg22
VC0238111
p7666
sg10
I23
sg11
VLennox-Gastaut syndrome
p7667
sg13
I2
sa(dp7668
g7
I34
sg22
VC0037769
p7669
sg10
I13
sg11
VWest syndrome
p7670
sg13
I2
sasa(dp7671
g2
S'We identified 421 genes that were differentially expressed between histologically normal thyroid tissues and all follicular neoplasms (P &lt; 0.01; fold-change &gt;2), 94 genes that distinguished follicular carcinomas from follicular adenomas (including PBP and CKS2), and 4 genes that distinguished aggressive follicular carcinomas from nonaggressive follicular carcinomas (NID2, TM7SF2, TRIM2, and GLTSCR2).\n'
p7672
sg4
(lp7673
(dp7674
g7
I389
sg8
g15
sg10
I5
sg11
VTRIM2
p7675
sg13
I1
sa(dp7676
g7
I381
sg8
g15
sg10
I6
sg11
VTM7SF2
p7677
sg13
I1
sa(dp7678
g7
I262
sg8
VP33552
p7679
sg10
I4
sg11
VCKS2
p7680
sg13
I1
sa(dp7681
g7
I254
sg8
VP02775
p7682
sg10
I3
sg11
VPBP
p7683
sg13
I1
sa(dp7684
g7
I375
sg8
g15
sg10
I4
sg11
VNID2
p7685
sg13
I1
sa(dp7686
g7
I400
sg8
g15
sg10
I7
sg11
VGLTSCR2
p7687
sg13
I1
sasg19
(lp7688
(dp7689
g7
I223
sg22
VC0205647
p7690
sg10
I19
sg11
Vfollicular adenomas
p7691
sg13
I2
sa(dp7692
g7
I300
sg22
VC0001807
p7693
sg10
I10
sg11
Vaggressive
p7694
sg13
I1
sa(dp7695
g7
I207
sg22
VC0007097
p7696
sg10
I10
sg11
Vcarcinomas
p7697
sg13
I1
sa(dp7698
g7
I207
sg22
VC0007097
p7699
sg10
I10
sg11
Vcarcinomas
p7700
sg13
I1
sa(dp7701
g7
I113
sg22
VC0474808
p7702
sg10
I20
sg11
Vfollicular neoplasms
p7703
sg13
I2
sa(dp7704
g7
I207
sg22
VC0007097
p7705
sg10
I10
sg11
Vcarcinomas
p7706
sg13
I1
sasa(dp7707
g2
S'These segments are replicated and transcribed by a viral RNA-dependent RNA polymerase (RdRp) that is made up of the influenza virus proteins PB1, PB2 and PA. To copy the viral RNA (vRNA) genome segments and the complementary RNA (cRNA) segments, the replicative intermediate of viral replication, the RdRp must use two promoters and two different de novo initiation mechanisms.\n'
p7708
sg4
(lp7709
(dp7710
g7
I51
sg8
VP19525
p7711
sg10
I34
sg11
Vviral RNA-dependent RNA polymerase
p7712
sg13
I4
sasg19
(lp7713
(dp7714
g7
I116
sg22
VC0021400
p7715
sg10
I9
sg11
Vinfluenza
p7716
sg13
I1
sasa(dp7717
g2
S'Taken together, our genome-wide study of NP-vRNA interaction has implications for the understanding of influenza vRNA architecture and genome packaging.\n'
p7718
sg4
(lp7719
sg19
(lp7720
(dp7721
g7
I103
sg22
VC0021400
p7722
sg10
I9
sg11
Vinfluenza
p7723
sg13
I1
sasa(dp7724
g2
S"Twelve nucleotides located at the 3' end of viral genomic RNA (vRNA) are conserved among influenza A viruses (IAV) and have a promoter function.\n"
p7725
sg4
(lp7726
sg19
(lp7727
(dp7728
g7
I89
sg22
VC0021400
p7729
sg10
I9
sg11
Vinfluenza
p7730
sg13
I1
sasa(dp7731
g2
S'Influenza A virus (IAV) consists of eight viral RNA (vRNA) segments that are replicated in the host cell nucleus and transported to the plasma membrane for packaging into progeny virions.\n'
p7732
sg4
(lp7733
sg19
(lp7734
(dp7735
g7
I0
sg22
VC0021400
p7736
sg10
I9
sg11
VInfluenza
p7737
sg13
I1
sasa(dp7738
g2
S'Taken together, our data suggest that cytoplasmic transport of influenza vRNA may include a Rab11A RE-independent mechanism.IMPORTANCE IAV infections cause a large public health burden through seasonal epidemics and sporadic pandemics.\n'
p7739
sg4
(lp7740
(dp7741
g7
I92
sg8
VP62491
p7742
sg10
I9
sg11
VRab11A RE
p7743
sg13
I2
sasg19
(lp7744
(dp7745
g7
I139
sg22
VC0021311
p7746
sg10
I10
sg11
Vinfections
p7747
sg13
I1
sa(dp7748
g7
I63
sg22
VC0021400
p7749
sg10
I9
sg11
Vinfluenza
p7750
sg13
I1
sasa(dp7751
g2
S'Double immunofluorescent analyses revealed nuclear retention and apparent colocalization of RanGap1 with Nup205, Gp210 with Nup205, and partial colocalization of Nup205 with Nup107; most of the ischemic changes above were similar to those observed in patients with C9orf72-genetic amyotrophic lateral sclerosis.\n'
p7752
sg4
(lp7753
(dp7754
g7
I105
sg8
g15
sg10
I6
sg11
VNup205
p7755
sg13
I1
sa(dp7756
g7
I92
sg8
VP46060
p7757
sg10
I7
sg11
VRanGap1
p7758
sg13
I1
sa(dp7759
g7
I174
sg8
VP57740
p7760
sg10
I6
sg11
VNup107
p7761
sg13
I1
sa(dp7762
g7
I105
sg8
g15
sg10
I6
sg11
VNup205
p7763
sg13
I1
sa(dp7764
g7
I105
sg8
g15
sg10
I6
sg11
VNup205
p7765
sg13
I1
sa(dp7766
g7
I113
sg8
g15
sg10
I5
sg11
VGp210
p7767
sg13
I1
sasg19
(lp7768
(dp7769
g7
I281
sg22
VC0002736
p7770
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p7771
sg13
I3
sasa(dp7772
g2
S'Polymorphisms of PDGFRB, MMP-3, TIMP-2, RNF213, TGFB1, Raptor and eNOS genes have been associated with Moyamoya disease (MMD) separately in studies, but their interactions on MMD have never been evaluated in one study.\n'
p7773
sg4
(lp7774
(dp7775
g7
I17
sg8
VP09619
p7776
sg10
I6
sg11
VPDGFRB
p7777
sg13
I1
sa(dp7778
g7
I40
sg8
g15
sg10
I6
sg11
VRNF213
p7779
sg13
I1
sa(dp7780
g7
I66
sg8
VP01893
p7781
sg10
I10
sg11
VeNOS genes
p7782
sg13
I2
sa(dp7783
g7
I55
sg8
g15
sg10
I6
sg11
VRaptor
p7784
sg13
I1
sa(dp7785
g7
I25
sg8
VP08254
p7786
sg10
I5
sg11
VMMP-3
p7787
sg13
I1
sa(dp7788
g7
I32
sg8
VP16035
p7789
sg10
I6
sg11
VTIMP-2
p7790
sg13
I1
sa(dp7791
g7
I48
sg8
VP01137
p7792
sg10
I5
sg11
VTGFB1
p7793
sg13
I1
sasg19
(lp7794
(dp7795
g7
I103
sg22
VC0026654
p7796
sg10
I16
sg11
VMoyamoya disease
p7797
sg13
I2
sa(dp7798
g7
I121
sg22
VC0026654
p7799
sg10
I3
sg11
VMMD
p7800
sg13
I1
sa(dp7801
g7
I121
sg22
VC0026654
p7802
sg10
I3
sg11
VMMD
p7803
sg13
I1
sasa(dp7804
g2
S'We genotyped 17 SNPs in or adjacent to 11 genes (ELN, LIMK1, CDKN2A/B, CXCL12, Pseudogene ENSG00000197218, PSRC1, MTHFD1L, SMAD3, MIA3, PDGF-B, TIMP2) comparing 40 DNA samples of Moyamoya disease patients to 68 healthy controls from central Europe.\n'
p7805
sg4
(lp7806
(dp7807
g7
I144
sg8
VP16035
p7808
sg10
I5
sg11
VTIMP2
p7809
sg13
I1
sa(dp7810
g7
I136
sg8
VP01127
p7811
sg10
I6
sg11
VPDGF-B
p7812
sg13
I1
sa(dp7813
g7
I114
sg8
g15
sg10
I7
sg11
VMTHFD1L
p7814
sg13
I1
sa(dp7815
g7
I49
sg8
g15
sg10
I3
sg11
VELN
p7816
sg13
I1
sa(dp7817
g7
I107
sg8
g15
sg10
I5
sg11
VPSRC1
p7818
sg13
I1
sa(dp7819
g7
I61
sg8
VP42771
p7820
sg10
I6
sg11
VCDKN2A
p7821
sg13
I1
sa(dp7822
g7
I54
sg8
VP53667
p7823
sg10
I5
sg11
VLIMK1
p7824
sg13
I1
sa(dp7825
g7
I71
sg8
VP48061
p7826
sg10
I6
sg11
VCXCL12
p7827
sg13
I1
sa(dp7828
g7
I79
sg8
VP01893
p7829
sg10
I26
sg11
VPseudogene ENSG00000197218
p7830
sg13
I2
sasg19
(lp7831
(dp7832
g7
I179
sg22
VC0026654
p7833
sg10
I16
sg11
VMoyamoya disease
p7834
sg13
I2
sasa(dp7835
g2
S'The genes encoding tissue inhibitor of metalloproteinase (TIMP) 4 and TIMP2 span chromosomes 3p24.2-p26 and 17q25, respectively, which are the locations of familial moyamoya disease (FMMD) genes.\n'
p7836
sg4
(lp7837
(dp7838
g7
I70
sg8
VP16035
p7839
sg10
I5
sg11
VTIMP2
p7840
sg13
I1
sa(dp7841
g7
I19
sg8
VP52888
p7842
sg10
I46
sg11
Vtissue inhibitor of metalloproteinase (TIMP) 4
p7843
sg13
I6
sasg19
(lp7844
(dp7845
g7
I165
sg22
VC0026654
p7846
sg10
I16
sg11
Vmoyamoya disease
p7847
sg13
I2
sasa(dp7848
g2
S'We report the first case of trisomy 18 with truncus arteriosus type II.\n'
p7849
sg4
(lp7850
sg19
(lp7851
(dp7852
g7
I44
sg22
VC0041207
p7853
sg10
I18
sg11
Vtruncus arteriosus
p7854
sg13
I2
sa(dp7855
g7
I28
sg22
VC0152096
p7856
sg10
I10
sg11
Vtrisomy 18
p7857
sg13
I2
sasa(dp7858
g2
S'Loss of immunohistochemical staining for the protein product of the SMAD4 gene and positive staining for mesothelin support a diagnosis of ductal adenocarcinoma.\n'
p7859
sg4
(lp7860
(dp7861
g7
I68
sg8
g15
sg10
I10
sg11
VSMAD4 gene
p7862
sg13
I2
sasg19
(lp7863
(dp7864
g7
I139
sg22
VC1527349
p7865
sg10
I21
sg11
Vductal adenocarcinoma
p7866
sg13
I2
sasa(dp7867
g2
S'Loss of immunohistochemical staining for the protein product of the SMAD4 gene and positive staining for mesothelin support a diagnosis of ductal adenocarcinoma.\n'
p7868
sg4
(lp7869
(dp7870
g7
I68
sg8
g15
sg10
I10
sg11
VSMAD4 gene
p7871
sg13
I2
sasg19
(lp7872
(dp7873
g7
I139
sg22
VC1527349
p7874
sg10
I21
sg11
Vductal adenocarcinoma
p7875
sg13
I2
sasa(dp7876
g2
S'To evaluate the diagnostic and prognostic significance of mesothelin, immunohistochemistry was used to assess the level of mesothelin  protein in surgically resected, formalin-fixed, paraffin-embedded invasive breast carcinoma specimens.\n'
p7877
sg4
(lp7878
sg19
(lp7879
(dp7880
g7
I201
sg22
VC0853879
p7881
sg10
I25
sg11
Vinvasive breast carcinoma
p7882
sg13
I3
sasa(dp7883
g2
S'To investigate the utility of 26 immunohistochemical markers (CAM 5.2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas.\n'
p7884
sg4
(lp7885
(dp7886
g7
I135
sg8
g15
sg10
I4
sg11
VMUC6
p7887
sg13
I1
sa(dp7888
g7
I220
sg8
VP25815
p7889
sg10
I5
sg11
VS100P
p7890
sg13
I1
sa(dp7891
g7
I328
sg8
VP56856
p7892
sg10
I10
sg11
Vclaudin 18
p7893
sg13
I2
sa(dp7894
g7
I91
sg8
VP35900
p7895
sg10
I4
sg11
VCK20
p7896
sg13
I1
sa(dp7897
g7
I151
sg8
g15
sg10
I5
sg11
VSMAD4
p7898
sg13
I1
sa(dp7899
g7
I158
sg8
g15
sg10
I4
sg11
VCDX2
p7900
sg13
I1
sa(dp7901
g7
I317
sg8
g15
sg10
I9
sg11
Vclaudin 4
p7902
sg13
I2
sa(dp7903
g7
I227
sg8
g15
sg10
I5
sg11
VIMP-3
p7904
sg13
I1
sa(dp7905
g7
I115
sg8
g15
sg10
I4
sg11
VMUC2
p7906
sg13
I1
sa(dp7907
g7
I164
sg8
VP40337
p7908
sg10
I4
sg11
VpVHL
p7909
sg13
I1
sa(dp7910
g7
I402
sg8
VP40198
p7911
sg10
I3
sg11
VCEA
p7912
sg13
I1
sa(dp7913
g7
I352
sg8
g15
sg10
I6
sg11
Vfascin
p7914
sg13
I1
sa(dp7915
g7
I395
sg8
VP16422
p7916
sg10
I5
sg11
VMOC31
p7917
sg13
I1
sa(dp7918
g7
I340
sg8
VP13928
p7919
sg10
I10
sg11
Vannexin A8
p7920
sg13
I2
sa(dp7921
g7
I360
sg8
g15
sg10
I4
sg11
VPSCA
p7922
sg13
I1
sa(dp7923
g7
I62
sg8
VP01768
p7924
sg10
I7
sg11
VCAM 5.2
p7925
sg13
I2
sa(dp7926
g7
I297
sg8
VP36952
p7927
sg10
I6
sg11
Vmaspin
p7928
sg13
I1
sa(dp7929
g7
I141
sg8
VP42771
p7930
sg10
I3
sg11
Vp53
p7931
sg13
I1
sa(dp7932
g7
I234
sg8
VP01308
p7933
sg10
I60
sg11
Vinsulin-like growth factor 2 messenger RNA binding protein 3
p7934
sg13
I9
sa(dp7935
g7
I71
sg8
g15
sg10
I18
sg11
VCK [cytokeratin] 7
p7936
sg13
I3
sa(dp7937
g7
I146
sg8
g15
sg10
I4
sg11
VDPC4
p7938
sg13
I1
sasg19
(lp7939
(dp7940
g7
I446
sg22
VC0006826
p7941
sg10
I6
sg11
Vcancer
p7942
sg13
I1
sa(dp7943
g7
I62
sg22
VC1861821
p7944
sg10
I3
sg11
VCAM
p7945
sg13
I1
sa(dp7946
g7
I488
sg22
VC1335302
p7947
sg10
I37
sg11
Vductal adenocarcinoma of the pancreas
p7948
sg13
I5
sa(dp7949
g7
I188
sg22
VC0027651
p7950
sg10
I5
sg11
Vtumor
p7951
sg13
I1
sasa(dp7952
g2
S'The results demonstrated that (1) more than 90% of cases of ductal adenocarcinoma were positive for maspin, S100P, and IMP-3; (2) nearly all adenocarcinoma cases were negative for pVHL, whereas nonneoplastic ducts and acini were positive for pVHL in all cases; (3) normal/reactive pancreatic ducts were frequently positive for CK7, CK19, MUC1, MUC6, CA19-9, MOC31, PSCA, mesothelin, annexin A8, claudin 4, and claudin 18; (4) normal pancreatic ducts were usually negative for IMP-3, maspin, S100P, CK17, MUC2, MUC4, and MUC5AC; (5) 60% of adenocarcinomas were negative for DPC4/SMAD4; and (6) strong background staining was frequently seen with fascin, PSCA, and annexin A8.\n'
p7953
sg4
(lp7954
(dp7955
g7
I578
sg8
g15
sg10
I5
sg11
VSMAD4
p7956
sg13
I1
sa(dp7957
g7
I108
sg8
VP25815
p7958
sg10
I5
sg11
VS100P
p7959
sg13
I1
sa(dp7960
g7
I108
sg8
VP25815
p7961
sg10
I5
sg11
VS100P
p7962
sg13
I1
sa(dp7963
g7
I573
sg8
g15
sg10
I4
sg11
VDPC4
p7964
sg13
I1
sa(dp7965
g7
I358
sg8
VP16422
p7966
sg10
I5
sg11
VMOC31
p7967
sg13
I1
sa(dp7968
g7
I100
sg8
VP36952
p7969
sg10
I6
sg11
Vmaspin
p7970
sg13
I1
sa(dp7971
g7
I327
sg8
VP08729
p7972
sg10
I3
sg11
VCK7
p7973
sg13
I1
sa(dp7974
g7
I645
sg8
g15
sg10
I6
sg11
Vfascin
p7975
sg13
I1
sa(dp7976
g7
I383
sg8
VP13928
p7977
sg10
I21
sg11
Vannexin A8, claudin 4
p7978
sg13
I4
sa(dp7979
g7
I344
sg8
g15
sg10
I4
sg11
VMUC6
p7980
sg13
I1
sa(dp7981
g7
I365
sg8
g15
sg10
I4
sg11
VPSCA
p7982
sg13
I1
sa(dp7983
g7
I100
sg8
VP36952
p7984
sg10
I6
sg11
Vmaspin
p7985
sg13
I1
sa(dp7986
g7
I119
sg8
g15
sg10
I5
sg11
VIMP-3
p7987
sg13
I1
sa(dp7988
g7
I180
sg8
VP40337
p7989
sg10
I4
sg11
VpVHL
p7990
sg13
I1
sa(dp7991
g7
I180
sg8
VP40337
p7992
sg10
I4
sg11
VpVHL
p7993
sg13
I1
sa(dp7994
g7
I383
sg8
VP13928
p7995
sg10
I10
sg11
Vannexin A8
p7996
sg13
I2
sa(dp7997
g7
I504
sg8
g15
sg10
I4
sg11
VMUC2
p7998
sg13
I1
sa(dp7999
g7
I410
sg8
VP56856
p8000
sg10
I10
sg11
Vclaudin 18
p8001
sg13
I2
sa(dp8002
g7
I365
sg8
g15
sg10
I4
sg11
VPSCA
p8003
sg13
I1
sasg19
(lp8004
(dp8005
g7
I67
sg22
VC0001418
p8006
sg10
I14
sg11
Vadenocarcinoma
p8007
sg13
I1
sa(dp8008
g7
I539
sg22
VC0001418
p8009
sg10
I15
sg11
Vadenocarcinomas
p8010
sg13
I1
sa(dp8011
g7
I60
sg22
VC1527349
p8012
sg10
I21
sg11
Vductal adenocarcinoma
p8013
sg13
I2
sasa(dp8014
g2
S'This study evaluated the utility of mesothelin and mammaglobin antibodies in differentiating breast carcinoma (particularly those with a papillary morphology) from Mullerian serous carcinomas.\n'
p8015
sg4
(lp8016
(dp8017
g7
I51
sg8
g15
sg10
I22
sg11
Vmammaglobin antibodies
p8018
sg13
I2
sasg19
(lp8019
(dp8020
g7
I93
sg22
VC0678222
p8021
sg10
I16
sg11
Vbreast carcinoma
p8022
sg13
I2
sa(dp8023
g7
I181
sg22
VC0007097
p8024
sg10
I10
sg11
Vcarcinomas
p8025
sg13
I1
sasa(dp8026
g2
S'Formalin-fixed, paraffin-embedded archival tissue from 21 breast carcinomas (10 micropapillary, 11 usual type ductal carcinomas) and 20 serous carcinomas (12 ovarian and 8 uterine) in addition to 6 cases of metastatic breast cancer to the ovary (5 cases) and cervix (1 case) were evaluated for the pattern and intensity of reactivity to antibodies to mesothelin, mammaglobin, and GCDFP-15.\n'
p8027
sg4
(lp8028
(dp8029
g7
I363
sg8
g15
sg10
I11
sg11
Vmammaglobin
p8030
sg13
I1
sasg19
(lp8031
(dp8032
g7
I65
sg22
VC0007097
p8033
sg10
I10
sg11
Vcarcinomas
p8034
sg13
I1
sa(dp8035
g7
I110
sg22
VC1176475
p8036
sg10
I17
sg11
Vductal carcinomas
p8037
sg13
I2
sa(dp8038
g7
I58
sg22
VC0678222
p8039
sg10
I17
sg11
Vbreast carcinomas
p8040
sg13
I2
sa(dp8041
g7
I207
sg22
VC0278488
p8042
sg10
I24
sg11
Vmetastatic breast cancer
p8043
sg13
I3
sasa(dp8044
g2
S'None of the breast carcinomas stained for mesothelin, whereas 8/12 and 3/8 ovarian and uterine serous carcinomas were positive; however, 7 of these had less than 10% positivity.\n'
p8045
sg4
(lp8046
sg19
(lp8047
(dp8048
g7
I12
sg22
VC0678222
p8049
sg10
I17
sg11
Vbreast carcinomas
p8050
sg13
I2
sa(dp8051
g7
I19
sg22
VC0007097
p8052
sg10
I10
sg11
Vcarcinomas
p8053
sg13
I1
sasa(dp8054
g2
S'We investigated HLA-class I APM components (Delta, LMP-7/10, TAP-1, Calnexin, Tapasin, Beta2-microglobulin and HLA-A,B,C) in LCs from healthy donors skin and melanoma patients SLN.\n'
p8055
sg4
(lp8056
(dp8057
g7
I16
sg8
VP30486
p8058
sg10
I3
sg11
VHLA
p8059
sg13
I1
sa(dp8060
g7
I61
sg8
g15
sg10
I5
sg11
VTAP-1
p8061
sg13
I1
sa(dp8062
g7
I68
sg8
VP27824
p8063
sg10
I8
sg11
VCalnexin
p8064
sg13
I1
sa(dp8065
g7
I51
sg8
VP11279
p8066
sg10
I8
sg11
VLMP-7/10
p8067
sg13
I1
sa(dp8068
g7
I111
sg8
VP30447
p8069
sg10
I5
sg11
VHLA-A
p8070
sg13
I1
sa(dp8071
g7
I87
sg8
VP61769
p8072
sg10
I19
sg11
VBeta2-microglobulin
p8073
sg13
I1
sasg19
(lp8074
(dp8075
g7
I125
sg22
VC0268314
p8076
sg10
I3
sg11
VLCs
p8077
sg13
I1
sa(dp8078
g7
I158
sg22
VC0025202
p8079
sg10
I8
sg11
Vmelanoma
p8080
sg13
I1
sasa(dp8081
g2
S'Recently, expression of the immunoproteasome subunits low molecular protein (LMP) 2 or LMP7 was shown to reduce the presentation of certain major histocompatibility complex (MHC) class I-restricted tumour peptide epitopes in renal cell carcinoma and melanoma cells.\n'
p8082
sg4
(lp8083
(dp8084
g7
I54
sg8
VP11279
p8085
sg10
I29
sg11
Vlow molecular protein (LMP) 2
p8086
sg13
I5
sa(dp8087
g7
I140
sg8
VP18464
p8088
sg10
I72
sg11
Vmajor histocompatibility complex (MHC) class I-restricted tumour peptide
p8089
sg13
I8
sa(dp8090
g7
I87
sg8
VP28062
p8091
sg10
I4
sg11
VLMP7
p8092
sg13
I1
sasg19
(lp8093
(dp8094
g7
I225
sg22
VC0007134
p8095
sg10
I20
sg11
Vrenal cell carcinoma
p8096
sg13
I3
sa(dp8097
g7
I198
sg22
VC0027651
p8098
sg10
I6
sg11
Vtumour
p8099
sg13
I1
sa(dp8100
g7
I250
sg22
VC0025202
p8101
sg10
I8
sg11
Vmelanoma
p8102
sg13
I1
sasa(dp8103
g2
S'Immunohistochemical staining with anti-LMP2 and anti-LMP7 xenoantibodies showed a significantly higher expression of these immunoproteasome subunits in primary melanoma lesions exhibiting histological signs of tumour regression than in primary melanoma lesions without regression phenomena.\n'
p8104
sg4
(lp8105
(dp8106
g7
I34
sg8
VP28065
p8107
sg10
I9
sg11
Vanti-LMP2
p8108
sg13
I1
sa(dp8109
g7
I48
sg8
VP28062
p8110
sg10
I24
sg11
Vanti-LMP7 xenoantibodies
p8111
sg13
I2
sasg19
(lp8112
(dp8113
g7
I160
sg22
VC0025202
p8114
sg10
I8
sg11
Vmelanoma
p8115
sg13
I1
sa(dp8116
g7
I160
sg22
VC0025202
p8117
sg10
I8
sg11
Vmelanoma
p8118
sg13
I1
sa(dp8119
g7
I210
sg22
VC0027651
p8120
sg10
I6
sg11
Vtumour
p8121
sg13
I1
sasa(dp8122
g2
S'In spontaneously regressing melanoma lesions, LMP2 and LMP7 expression was significantly associated with the presence of tumour-infiltrating lymphocytes.\n'
p8123
sg4
(lp8124
(dp8125
g7
I46
sg8
VP28065
p8126
sg10
I4
sg11
VLMP2
p8127
sg13
I1
sa(dp8128
g7
I55
sg8
VP28062
p8129
sg10
I4
sg11
VLMP7
p8130
sg13
I1
sasg19
(lp8131
(dp8132
g7
I121
sg22
VC0027651
p8133
sg10
I6
sg11
Vtumour
p8134
sg13
I1
sa(dp8135
g7
I17
sg22
VC0334427
p8136
sg10
I19
sg11
Vregressing melanoma
p8137
sg13
I2
sa(dp8138
g7
I128
sg22
VC0332448
p8139
sg10
I12
sg11
Vinfiltrating
p8140
sg13
I1
sasa(dp8141
g2
S'Our results are compatible with the possibility that the expression of the immunoproteasome subunits LMP2 and LMP7 rather than their downregulation in melanoma cells is associated with the presence of a successful anti-melanoma immune response.\n'
p8142
sg4
(lp8143
(dp8144
g7
I110
sg8
VP28062
p8145
sg10
I4
sg11
VLMP7
p8146
sg13
I1
sa(dp8147
g7
I101
sg8
VP28065
p8148
sg10
I4
sg11
VLMP2
p8149
sg13
I1
sasg19
(lp8150
(dp8151
g7
I151
sg22
VC0025202
p8152
sg10
I8
sg11
Vmelanoma
p8153
sg13
I1
sa(dp8154
g7
I151
sg22
VC0025202
p8155
sg10
I8
sg11
Vmelanoma
p8156
sg13
I1
sasa(dp8157
g2
S'Seventeen formalin-fixed, paraffin-embedded primary melanomas thinner than 0.76 mm and 21 thicker than 1.50 mm were stained with anti-LMP2, -LMP7, -TAP1, -TAP2, -HLA class I and -beta2-microglobulin monoclonal antibodies.\n'
p8158
sg4
(lp8159
(dp8160
g7
I162
sg8
VP61769
p8161
sg10
I36
sg11
VHLA class I and -beta2-microglobulin
p8162
sg13
I5
sa(dp8163
g7
I129
sg8
VP28065
p8164
sg10
I16
sg11
Vanti-LMP2, -LMP7
p8165
sg13
I2
sa(dp8166
g7
I155
sg8
g15
sg10
I4
sg11
VTAP2
p8167
sg13
I1
sa(dp8168
g7
I148
sg8
g15
sg10
I4
sg11
VTAP1
p8169
sg13
I1
sasg19
(lp8170
(dp8171
g7
I52
sg22
VC0025202
p8172
sg10
I9
sg11
Vmelanomas
p8173
sg13
I1
sasa(dp8174
g2
S'We postulate here that the MHC class I-deficient phenotype of B16 melanoma cells is attributable to down-regulation or the loss of the expression and function of multiple components of the MHC class I antigen-processing pathway, including the peptide transporter associated with antigen processing, the proteasome subunits LMP2, LMP7, and LMP10, PA28alpha and -beta, and the chaperone tapasin.\n'
p8175
sg4
(lp8176
(dp8177
g7
I339
sg8
VP40313
p8178
sg10
I5
sg11
VLMP10
p8179
sg13
I1
sa(dp8180
g7
I323
sg8
VP28065
p8181
sg10
I4
sg11
VLMP2
p8182
sg13
I1
sa(dp8183
g7
I329
sg8
VP28062
p8184
sg10
I4
sg11
VLMP7
p8185
sg13
I1
sa(dp8186
g7
I189
sg8
VP30461
p8187
sg10
I19
sg11
VMHC class I antigen
p8188
sg13
I4
sa(dp8189
g7
I27
sg8
VP30486
p8190
sg10
I11
sg11
VMHC class I
p8191
sg13
I3
sa(dp8192
g7
I346
sg8
g15
sg10
I19
sg11
VPA28alpha and -beta
p8193
sg13
I3
sasg19
(lp8194
(dp8195
g7
I62
sg22
VC0004565
p8196
sg10
I12
sg11
VB16 melanoma
p8197
sg13
I2
sasa(dp8198
g2
S'Primary aldosteronism (PA) caused by aldosterone-producing adenoma (APA), but not by bilateral hyperplasia (BAH), has somatic mutations in KCNJ5 gene.\n'
p8199
sg4
(lp8200
(dp8201
g7
I139
sg8
VP48544
p8202
sg10
I10
sg11
VKCNJ5 gene
p8203
sg13
I2
sasg19
(lp8204
(dp8205
g7
I118
sg22
VC0544886
p8206
sg10
I17
sg11
Vsomatic mutations
p8207
sg13
I2
sa(dp8208
g7
I59
sg22
VC0001430
p8209
sg10
I7
sg11
Vadenoma
p8210
sg13
I1
sa(dp8211
g7
I23
sg22
VC1384514
p8212
sg10
I2
sg11
VPA
p8213
sg13
I1
sa(dp8214
g7
I0
sg22
VC1384514
p8215
sg10
I21
sg11
VPrimary aldosteronism
p8216
sg13
I2
sa(dp8217
g7
I85
sg22
VC0333976
p8218
sg10
I21
sg11
Vbilateral hyperplasia
p8219
sg13
I2
sa(dp8220
g7
I108
sg22
VC0333976
p8221
sg10
I3
sg11
VBAH
p8222
sg13
I1
sasa(dp8223
g2
S'A correct diagnosis of primary aldosteronism (PA) requires adrenal venous sampling (AVS) for the classification of subtypes (bilateral hyperplasia, BAH, or adenoma, APA).\n'
p8224
sg4
(lp8225
sg19
(lp8226
(dp8227
g7
I46
sg22
VC1384514
p8228
sg10
I2
sg11
VPA
p8229
sg13
I1
sa(dp8230
g7
I23
sg22
VC1384514
p8231
sg10
I21
sg11
Vprimary aldosteronism
p8232
sg13
I2
sa(dp8233
g7
I156
sg22
VC0001430
p8234
sg10
I7
sg11
Vadenoma
p8235
sg13
I1
sa(dp8236
g7
I125
sg22
VC0333976
p8237
sg10
I21
sg11
Vbilateral hyperplasia
p8238
sg13
I2
sasa(dp8239
g2
S'The detection of primary aldosteronism is of particular importance, not only because it provides an opportunity for a targeted treatment (surgical for APA and medical with mineralocorticoid receptor antagonists for BAH), but also because it has been extensively demonstrated that patients affected by PA are more prone to cardiovascular events and target organ damage than essential hypertensives.\n'
p8240
sg4
(lp8241
sg19
(lp8242
(dp8243
g7
I17
sg22
VC1384514
p8244
sg10
I21
sg11
Vprimary aldosteronism
p8245
sg13
I2
sasa(dp8246
g2
S'This retrospective study was aimed 1) to compare the difference of the findings between adrenal CT scan and adrenal venous sampling (AVS) in 35 cases with definite primary aldosteronism (PA) for assessment of the diagnostic efficacy of PA subgroup (unilateral and bilateral adrenal hypersecretion: UAH and BAH), and 2) to determine the clinical and biochemical parameters as potential predictors for PA subgroup.\n'
p8247
sg4
(lp8248
sg19
(lp8249
(dp8250
g7
I164
sg22
VC1384514
p8251
sg10
I21
sg11
Vprimary aldosteronism
p8252
sg13
I2
sa(dp8253
g7
I187
sg22
VC1384514
p8254
sg10
I2
sg11
VPA
p8255
sg13
I1
sa(dp8256
g7
I187
sg22
VC1384514
p8257
sg10
I2
sg11
VPA
p8258
sg13
I1
sa(dp8259
g7
I187
sg22
VC1384514
p8260
sg10
I2
sg11
VPA
p8261
sg13
I1
sasa(dp8262
g2
S'The expression of SLC4A11 in the corneal endothelium and inner ear patterns the deficits seen in CHED with corneal edema and hearing loss (Harboyan syndrome).\n'
p8263
sg4
(lp8264
(dp8265
g7
I18
sg8
g15
sg10
I7
sg11
VSLC4A11
p8266
sg13
I1
sasg19
(lp8267
(dp8268
g7
I97
sg22
VC1852555
p8269
sg10
I4
sg11
VCHED
p8270
sg13
I1
sa(dp8271
g7
I139
sg22
VC1857572
p8272
sg10
I17
sg11
VHarboyan syndrome
p8273
sg13
I2
sa(dp8274
g7
I125
sg22
VC0011053
p8275
sg10
I12
sg11
Vhearing loss
p8276
sg13
I2
sa(dp8277
g7
I107
sg22
VC0010037
p8278
sg10
I13
sg11
Vcorneal edema
p8279
sg13
I2
sasa(dp8280
g2
S'Slc4a11(-/-) mice manifest corneal oedema and distorted endothelial cells, consistent with loss of a water-flux.\n'
p8281
sg4
(lp8282
(dp8283
g7
I0
sg8
g15
sg10
I7
sg11
VSlc4a11
p8284
sg13
I1
sasg19
(lp8285
(dp8286
g7
I27
sg22
VC0010037
p8287
sg10
I14
sg11
Vcorneal oedema
p8288
sg13
I2
sasa(dp8289
g2
S'Geographically different strains of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto Ir 105, B. burgdorferi s.s. + B. afzelii V 123, B. garinii Ir 112 - isolates from eastern Slovakia, B. garinii K24 - isolate from western Slovakia and B. burgdorferi s.s. B 31 - American strain) were compared as antigens for serological study of Lyme borreliosis by IgG ELISA on a group of horses from eastern Slovakia.\n'
p8290
sg4
(lp8291
sg19
(lp8292
(dp8293
g7
I36
sg22
VC0024198
p8294
sg10
I8
sg11
VBorrelia
p8295
sg13
I1
sa(dp8296
g7
I344
sg22
VC0024198
p8297
sg10
I16
sg11
VLyme borreliosis
p8298
sg13
I2
sasa(dp8299
g2
S'It is genetically different from the B-31 reference strain of B. burgdorferi sensu stricto that is typical of strains causing Lyme borreliosis in North America.\n'
p8300
sg4
(lp8301
sg19
(lp8302
(dp8303
g7
I126
sg22
VC0024198
p8304
sg10
I16
sg11
VLyme borreliosis
p8305
sg13
I2
sasa(dp8306
g2
S'On the other hand Contactin 1 drives Notch signalling activation via the Hes pathway, which could be consistent with its ability to modulate neuroinflammation events, and with the possibility that Contactin 1-dependent interactions may participate to the pathogenesis of the Multiple Sclerosis and of other inflammatory disorders.\n'
p8307
sg4
(lp8308
(dp8309
g7
I18
sg8
g15
sg10
I11
sg11
VContactin 1
p8310
sg13
I2
sa(dp8311
g7
I18
sg8
g15
sg10
I11
sg11
VContactin 1
p8312
sg13
I2
sasg19
(lp8313
(dp8314
g7
I73
sg22
VC0206141
p8315
sg10
I3
sg11
VHes
p8316
sg13
I1
sa(dp8317
g7
I275
sg22
VC0026769
p8318
sg10
I18
sg11
VMultiple Sclerosis
p8319
sg13
I2
sa(dp8320
g7
I255
sg22
VC0699748
p8321
sg10
I12
sg11
Vpathogenesis
p8322
sg13
I1
sasa(dp8323
g2
S"To illustrate this approach, and to serve as 'proof-of-principle', we used 3 late-onset Alzheimer's disease GWAS datasets to explore SNP-disease associations in 4 new candidate genes encoding cerebro-spinal fluid biomarkers for Alzheimer's disease; Fibrinogen Gamma-chain (FGG), SPARC-like1 (SPARCL1), Contactin-1 (CNTN1) and Contactin-2 (CNTN2).\n"
p8324
sg4
(lp8325
(dp8326
g7
I315
sg8
g15
sg10
I5
sg11
VCNTN1
p8327
sg13
I1
sa(dp8328
g7
I273
sg8
VP22087
p8329
sg10
I3
sg11
VFGG
p8330
sg13
I1
sa(dp8331
g7
I279
sg8
VP09486
p8332
sg10
I11
sg11
VSPARC-like1
p8333
sg13
I1
sa(dp8334
g7
I302
sg8
g15
sg10
I11
sg11
VContactin-1
p8335
sg13
I1
sa(dp8336
g7
I339
sg8
g15
sg10
I5
sg11
VCNTN2
p8337
sg13
I1
sa(dp8338
g7
I249
sg8
VP22087
p8339
sg10
I22
sg11
VFibrinogen Gamma-chain
p8340
sg13
I2
sa(dp8341
g7
I326
sg8
g15
sg10
I11
sg11
VContactin-2
p8342
sg13
I1
sa(dp8343
g7
I292
sg8
g15
sg10
I7
sg11
VSPARCL1
p8344
sg13
I1
sasg19
(lp8345
(dp8346
g7
I88
sg22
VC1521724
p8347
sg10
I19
sg11
VAlzheimer's disease
p8348
sg13
I2
sa(dp8349
g7
I88
sg22
VC1521724
p8350
sg10
I19
sg11
VAlzheimer's disease
p8351
sg13
I2
sasa(dp8352
g2
S'In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects.\n'
p8353
sg4
(lp8354
(dp8355
g7
I74
sg8
VP02765
p8356
sg10
I8
sg11
Vfetuin A
p8357
sg13
I2
sa(dp8358
g7
I61
sg8
g15
sg10
I11
sg11
Vcontactin 1
p8359
sg13
I2
sa(dp8360
g7
I84
sg8
VP02774
p8361
sg10
I25
sg11
Vvitamin D binding protein
p8362
sg13
I4
sa(dp8363
g7
I114
sg8
VP01019
p8364
sg10
I22
sg11
Vangiotensinogen (ANGT)
p8365
sg13
I2
sasg19
(lp8366
sa(dp8367
g2
S'A series of triblock (TB, polycaprolac- tone-polyethylene glycol-polycaprolactone (PCL-PEG-PCL), B-A-B) and pentablock copolymers (PBCs) (polylactic acid (PLA)-PCL-PEG-PCL-PLA (C-B-A-B-C) and PEG-PCL-PLA-PCL-PEG (A-B-C-B-A)) were synthesized and evaluated for their thermosensitive behavior.\n'
p8368
sg4
(lp8369
(dp8370
g7
I87
sg8
VP09466
p8371
sg10
I3
sg11
VPEG
p8372
sg13
I1
sa(dp8373
g7
I83
sg8
VP35916
p8374
sg10
I3
sg11
VPCL
p8375
sg13
I1
sa(dp8376
g7
I83
sg8
VP35916
p8377
sg10
I3
sg11
VPCL
p8378
sg13
I1
sa(dp8379
g7
I155
sg8
g15
sg10
I3
sg11
VPLA
p8380
sg13
I1
sa(dp8381
g7
I83
sg8
VP35916
p8382
sg10
I3
sg11
VPCL
p8383
sg13
I1
sa(dp8384
g7
I87
sg8
VP09466
p8385
sg10
I3
sg11
VPEG
p8386
sg13
I1
sa(dp8387
g7
I83
sg8
VP35916
p8388
sg10
I3
sg11
VPCL
p8389
sg13
I1
sa(dp8390
g7
I87
sg8
VP09466
p8391
sg10
I3
sg11
VPEG
p8392
sg13
I1
sa(dp8393
g7
I155
sg8
g15
sg10
I3
sg11
VPLA
p8394
sg13
I1
sasg19
(lp8395
(dp8396
g7
I83
sg22
VC1704423
p8397
sg10
I3
sg11
VPCL
p8398
sg13
I1
sa(dp8399
g7
I83
sg22
VC1704423
p8400
sg10
I3
sg11
VPCL
p8401
sg13
I1
sa(dp8402
g7
I83
sg22
VC1704423
p8403
sg10
I3
sg11
VPCL
p8404
sg13
I1
sa(dp8405
g7
I83
sg22
VC1704423
p8406
sg10
I3
sg11
VPCL
p8407
sg13
I1
sa(dp8408
g7
I83
sg22
VC1704423
p8409
sg10
I3
sg11
VPCL
p8410
sg13
I1
sa(dp8411
g7
I83
sg22
VC1704423
p8412
sg10
I3
sg11
VPCL
p8413
sg13
I1
sasa(dp8414
g2
S'Moreover, kinematic viscosity of aqueous solution at 25C for A-B-C-B-A type of PBCs was noticeably lower than the TB (B-A-B) copolymers and other PBCs with C-B-A-B-C block arrangements suggesting desired syringe- ability.\n'
p8415
sg4
(lp8416
sg19
(lp8417
sa(dp8418
g2
S'The presence of PLA blocks in PBCs (C-B-A-B-C and A-B-C-B-A) significantly reduces crystallinity.\n'
p8419
sg4
(lp8420
sg19
(lp8421
sa(dp8422
g2
S"In the study cohort of 145 patients implanted with DDD pacemakers with a programmable rest rate (RR) feature, the BR/RR settings were sequentially but randomly adjusted as follows: 60 bpm/Off for the baseline quarter (initial 3 months) and then to either 'A-B-C' or 'C-B-A' settings (A = 70/65 bpm, B = 70/Off, C = 80/65 bpm) for the subsequent quarters each of 3 months duration.\n"
p8423
sg4
(lp8424
sg19
(lp8425
(dp8426
g7
I51
sg22
VC0406811
p8427
sg10
I3
sg11
VDDD
p8428
sg13
I1
sasa(dp8429
g2
S'The treatment sequences were A-B-C; A-C-B; B-A-C; B-C-A; C-A-B; and C-B-A.\n'
p8430
sg4
(lp8431
sg19
(lp8432
sa(dp8433
g2
S'We could also show a physical association of Arc35p with subunits of CKII, Cmd1p, and Tub4p.\n'
p8434
sg4
(lp8435
(dp8436
g7
I69
sg8
VP68400
p8437
sg10
I4
sg11
VCKII
p8438
sg13
I1
sa(dp8439
g7
I75
sg8
VP26678
p8440
sg10
I5
sg11
VCmd1p
p8441
sg13
I1
sasg19
(lp8442
(dp8443
g7
I75
sg22
VC1835928
p8444
sg10
I5
sg11
VCmd1p
p8445
sg13
I1
sasa(dp8446
g2
S'Our results suggest that B7-H1, B7-H3 and B7-H4 may be potential biomarkers to identify LCS, and a clear understanding of their functional roles may further elucidate the pathogenesis of this carcinoma and potentially contribute to the development of novel immunotherapeutic strategies.\n'
p8447
sg4
(lp8448
(dp8449
g7
I42
sg8
g15
sg10
I5
sg11
VB7-H4
p8450
sg13
I1
sa(dp8451
g7
I32
sg8
g15
sg10
I5
sg11
VB7-H3
p8452
sg13
I1
sa(dp8453
g7
I25
sg8
g15
sg10
I5
sg11
VB7-H1
p8454
sg13
I1
sasg19
(lp8455
(dp8456
g7
I88
sg22
VC0268314
p8457
sg10
I3
sg11
VLCS
p8458
sg13
I1
sa(dp8459
g7
I192
sg22
VC0007097
p8460
sg10
I9
sg11
Vcarcinoma
p8461
sg13
I1
sa(dp8462
g7
I171
sg22
VC0699748
p8463
sg10
I12
sg11
Vpathogenesis
p8464
sg13
I1
sasa(dp8465
g2
S'We conclude that both GCDH activity and GCDH mutation analysis should be considered in the differential diagnosis of progressive forms of early-onset generalized dystonia and that mitochondrial fatty acid metabolism is one important pathway in the development of dystonia.\n'
p8466
sg4
(lp8467
(dp8468
g7
I22
sg8
g15
sg10
I4
sg11
VGCDH
p8469
sg13
I1
sa(dp8470
g7
I22
sg8
g15
sg10
I4
sg11
VGCDH
p8471
sg13
I1
sasg19
(lp8472
(dp8473
g7
I150
sg22
VC1848954
p8474
sg10
I20
sg11
Vgeneralized dystonia
p8475
sg13
I2
sa(dp8476
g7
I162
sg22
VC0393593
p8477
sg10
I8
sg11
Vdystonia
p8478
sg13
I1
sasa(dp8479
g2
S'As lysine restriction and L: -carnitine supplementation are important treatments for GCDH deficiency, identification of this deficiency in patients with progressive forms of early-onset generalized dystonia has potential treatment implications.\n'
p8480
sg4
(lp8481
(dp8482
g7
I85
sg8
g15
sg10
I4
sg11
VGCDH
p8483
sg13
I1
sasg19
(lp8484
(dp8485
g7
I186
sg22
VC1848954
p8486
sg10
I20
sg11
Vgeneralized dystonia
p8487
sg13
I2
sasa(dp8488
g2
S'SUCLA2 defects have been associated with mitochondrial DNA (mtDNA) depletion and the triad of hypotonia, dystonia/Leigh-like syndrome, and deafness.\n'
p8489
sg4
(lp8490
(dp8491
g7
I0
sg8
g15
sg10
I6
sg11
VSUCLA2
p8492
sg13
I1
sasg19
(lp8493
(dp8494
g7
I139
sg22
VC0011053
p8495
sg10
I8
sg11
Vdeafness
p8496
sg13
I1
sa(dp8497
g7
I105
sg22
VC0393593
p8498
sg10
I8
sg11
Vdystonia
p8499
sg13
I1
sa(dp8500
g7
I94
sg22
VC0026827
p8501
sg10
I9
sg11
Vhypotonia
p8502
sg13
I1
sa(dp8503
g7
I125
sg22
VC0039082
p8504
sg10
I8
sg11
Vsyndrome
p8505
sg13
I1
sasa(dp8506
g2
S'The findings indicate the importance of screening for mitochondrial dysfunction in patients with complex movement disorders without brain MRI lesions and further investigation for potential secondary CoQ10 deficiency in patients with SUCLA2 mutations.\n'
p8507
sg4
(lp8508
sg19
(lp8509
(dp8510
g7
I105
sg22
VC0026650
p8511
sg10
I18
sg11
Vmovement disorders
p8512
sg13
I2
sasa(dp8513
g2
S'SUCLA2 mutations result in a mitochondrial disorder that manifests as deafness, lesions in the basal ganglia, and encephalomyopathy accompanied by dystonia.\n'
p8514
sg4
(lp8515
(dp8516
g7
I0
sg8
g15
sg10
I6
sg11
VSUCLA2
p8517
sg13
I1
sasg19
(lp8518
(dp8519
g7
I29
sg22
VC0751651
p8520
sg10
I22
sg11
Vmitochondrial disorder
p8521
sg13
I2
sa(dp8522
g7
I70
sg22
VC0011053
p8523
sg10
I8
sg11
Vdeafness
p8524
sg13
I1
sa(dp8525
g7
I147
sg22
VC0393593
p8526
sg10
I8
sg11
Vdystonia
p8527
sg13
I1
sasa(dp8528
g2
S'Hypertrophic cardiomyopathy and liver involvement was exclusively found in patients with SUCLG1 mutations, whereas epilepsy was much more frequent in patients with SUCLA2 mutations compared to patients with SUCLG1 mutations.\n'
p8529
sg4
(lp8530
(dp8531
g7
I89
sg8
VP53597
p8532
sg10
I16
sg11
VSUCLG1 mutations
p8533
sg13
I2
sa(dp8534
g7
I89
sg8
VP53597
p8535
sg10
I16
sg11
VSUCLG1 mutations
p8536
sg13
I2
sasg19
(lp8537
(dp8538
g7
I115
sg22
VC0014544
p8539
sg10
I8
sg11
Vepilepsy
p8540
sg13
I1
sa(dp8541
g7
I0
sg22
VC0007194
p8542
sg10
I27
sg11
VHypertrophic cardiomyopathy
p8543
sg13
I2
sasa(dp8544
g2
S'Mutations in SUCLA2 lead to a mitochondrial disorder manifesting as encephalomyopathy with dystonia, deafness and lesions in the basal ganglia.\n'
p8545
sg4
(lp8546
(dp8547
g7
I13
sg8
g15
sg10
I6
sg11
VSUCLA2
p8548
sg13
I1
sasg19
(lp8549
(dp8550
g7
I30
sg22
VC0751651
p8551
sg10
I22
sg11
Vmitochondrial disorder
p8552
sg13
I2
sa(dp8553
g7
I91
sg22
VC0393593
p8554
sg10
I8
sg11
Vdystonia
p8555
sg13
I1
sa(dp8556
g7
I101
sg22
VC0011053
p8557
sg10
I8
sg11
Vdeafness
p8558
sg13
I1
sasa(dp8559
g2
S'Recent studies reported aberrant expression of placenta-specific microRNAs (miRNAs) in preeclampsia including miR-517a/b and miR-517c.\n'
p8560
sg4
(lp8561
(dp8562
g7
I110
sg8
g15
sg10
I10
sg11
VmiR-517a/b
p8563
sg13
I1
sa(dp8564
g7
I125
sg8
g15
sg10
I8
sg11
VmiR-517c
p8565
sg13
I1
sasg19
(lp8566
(dp8567
g7
I87
sg22
VC0032914
p8568
sg10
I12
sg11
Vpreeclampsia
p8569
sg13
I1
sasa(dp8570
g2
S'Using placental biopsies from a preeclampsia case-control study, we found increased expression of miR-517a/b in term and preterm preeclampsia vs controls, while, miR-517c was increased only in preterm preeclampsia vs controls.\n'
p8571
sg4
(lp8572
(dp8573
g7
I162
sg8
g15
sg10
I8
sg11
VmiR-517c
p8574
sg13
I1
sa(dp8575
g7
I98
sg8
g15
sg10
I10
sg11
VmiR-517a/b
p8576
sg13
I1
sasg19
(lp8577
(dp8578
g7
I32
sg22
VC0032914
p8579
sg10
I12
sg11
Vpreeclampsia
p8580
sg13
I1
sa(dp8581
g7
I32
sg22
VC0032914
p8582
sg10
I12
sg11
Vpreeclampsia
p8583
sg13
I1
sa(dp8584
g7
I32
sg22
VC0032914
p8585
sg10
I12
sg11
Vpreeclampsia
p8586
sg13
I1
sasa(dp8587
g2
S'In summary, we demonstrate that miR-517a/b and miR-517c contribute to the development of preeclampsia and suggest that these miRNAs play a critical role in regulating trophoblast and placental function.\n'
p8588
sg4
(lp8589
(dp8590
g7
I47
sg8
g15
sg10
I8
sg11
VmiR-517c
p8591
sg13
I1
sa(dp8592
g7
I32
sg8
g15
sg10
I10
sg11
VmiR-517a/b
p8593
sg13
I1
sasg19
(lp8594
(dp8595
g7
I89
sg22
VC0032914
p8596
sg10
I12
sg11
Vpreeclampsia
p8597
sg13
I1
sasa(dp8598
g2
S'We tested initially microRNAs (mir-135b and miR-517a) which presence in maternal circulation had been previously demonstrated and those microRNAs (miR-518b and miR-517a) with up-regulated expression profile in placentas derived from pregnancies during the onset of preeclampsia.\n'
p8599
sg4
(lp8600
(dp8601
g7
I44
sg8
g15
sg10
I8
sg11
VmiR-517a
p8602
sg13
I1
sa(dp8603
g7
I147
sg8
g15
sg10
I8
sg11
VmiR-518b
p8604
sg13
I1
sa(dp8605
g7
I44
sg8
g15
sg10
I8
sg11
VmiR-517a
p8606
sg13
I1
sa(dp8607
g7
I31
sg8
g15
sg10
I8
sg11
Vmir-135b
p8608
sg13
I1
sasg19
(lp8609
(dp8610
g7
I265
sg22
VC0032914
p8611
sg10
I12
sg11
Vpreeclampsia
p8612
sg13
I1
sasa(dp8613
g2
S'The observed phenotypes for these recessive variants were novel (e.g., FBN2-related myopathy and CSF1R-related brain malformation and osteopetrosis), typical (e.g., ACTG2-related visceral myopathy), or an apparently healthy state (e.g., PDE11A), consistent with the corresponding mouse knockout phenotypes.\n'
p8614
sg4
(lp8615
(dp8616
g7
I165
sg8
VP63267
p8617
sg10
I5
sg11
VACTG2
p8618
sg13
I1
sa(dp8619
g7
I237
sg8
g15
sg10
I6
sg11
VPDE11A
p8620
sg13
I1
sa(dp8621
g7
I97
sg8
VP09619
p8622
sg10
I5
sg11
VCSF1R
p8623
sg13
I1
sa(dp8624
g7
I71
sg8
VP35556
p8625
sg10
I21
sg11
VFBN2-related myopathy
p8626
sg13
I2
sasg19
(lp8627
(dp8628
g7
I84
sg22
VC0026848
p8629
sg10
I8
sg11
Vmyopathy
p8630
sg13
I1
sa(dp8631
g7
I111
sg22
VC0266449
p8632
sg10
I18
sg11
Vbrain malformation
p8633
sg13
I2
sa(dp8634
g7
I179
sg22
VC0042781
p8635
sg10
I17
sg11
Vvisceral myopathy
p8636
sg13
I2
sa(dp8637
g7
I134
sg22
VC0029454
p8638
sg10
I13
sg11
Vosteopetrosis
p8639
sg13
I1
sasa(dp8640
g2
S"One of these, located in the phosphodiesterase 11A (PDE11A) gene (R307X), has previously been reported to cause loss of PDE11A function and Cushing's syndrome in female carriers.\n"
p8641
sg4
(lp8642
(dp8643
g7
I52
sg8
g15
sg10
I6
sg11
VPDE11A
p8644
sg13
I1
sa(dp8645
g7
I29
sg8
g15
sg10
I35
sg11
Vphosphodiesterase 11A (PDE11A) gene
p8646
sg13
I4
sasg19
(lp8647
(dp8648
g7
I140
sg22
VC0010481
p8649
sg10
I18
sg11
VCushing's syndrome
p8650
sg13
I2
sasa(dp8651
g2
S'One percent of the Swedish population carries a PDE11A loss-of-function mutation associated with elevated BP, abdominal obesity, and risk of ischemic stroke.\n'
p8652
sg4
(lp8653
(dp8654
g7
I48
sg8
g15
sg10
I32
sg11
VPDE11A loss-of-function mutation
p8655
sg13
I3
sasg19
(lp8656
(dp8657
g7
I110
sg22
VC0311277
p8658
sg10
I17
sg11
Vabdominal obesity
p8659
sg13
I2
sa(dp8660
g7
I141
sg22
VC3272363
p8661
sg10
I15
sg11
Vischemic stroke
p8662
sg13
I2
sasa(dp8663
g2
S'Recently, important mechanisms underlying the pathogenesis of adrenal hypercortisolism have been elucidated with the discovery of mutations in cyclic AMP signalling (PRKACA, PRKAR1A, GNAS, PDE11A, PDE8B), armadillo repeat containing 5 gene (ARMC5) a putative tumour suppressor gene, aberrant G-protein-coupled receptors, and intra-adrenal secretion of ACTH.\n'
p8664
sg4
(lp8665
(dp8666
g7
I205
sg8
g15
sg10
I34
sg11
Varmadillo repeat containing 5 gene
p8667
sg13
I5
sa(dp8668
g7
I183
sg8
VP84996
p8669
sg10
I4
sg11
VGNAS
p8670
sg13
I1
sa(dp8671
g7
I143
sg8
VP49913
p8672
sg10
I21
sg11
Vcyclic AMP signalling
p8673
sg13
I3
sa(dp8674
g7
I292
sg8
g15
sg10
I27
sg11
VG-protein-coupled receptors
p8675
sg13
I2
sa(dp8676
g7
I166
sg8
VP17252
p8677
sg10
I6
sg11
VPRKACA
p8678
sg13
I1
sa(dp8679
g7
I197
sg8
g15
sg10
I5
sg11
VPDE8B
p8680
sg13
I1
sa(dp8681
g7
I174
sg8
VP10644
p8682
sg10
I7
sg11
VPRKAR1A
p8683
sg13
I1
sa(dp8684
g7
I241
sg8
g15
sg10
I5
sg11
VARMC5
p8685
sg13
I1
sa(dp8686
g7
I189
sg8
g15
sg10
I6
sg11
VPDE11A
p8687
sg13
I1
sa(dp8688
g7
I352
sg8
VP01189
p8689
sg10
I4
sg11
VACTH
p8690
sg13
I1
sasg19
(lp8691
(dp8692
g7
I70
sg22
VC0010481
p8693
sg10
I16
sg11
Vhypercortisolism
p8694
sg13
I1
sa(dp8695
g7
I259
sg22
VC0027651
p8696
sg10
I6
sg11
Vtumour
p8697
sg13
I1
sa(dp8698
g7
I46
sg22
VC0699748
p8699
sg10
I12
sg11
Vpathogenesis
p8700
sg13
I1
sasa(dp8701
g2
S'Recently, important mechanisms underlying the pathogenesis of adrenal hypercortisolism have been elucidated with the discovery of mutations in cyclic AMP signalling (PRKACA, PRKAR1A, GNAS, PDE11A, PDE8B), armadillo repeat containing 5 gene (ARMC5) a putative tumour suppressor gene, aberrant G-protein-coupled receptors, and intra-adrenal secretion of ACTH.\n'
p8702
sg4
(lp8703
(dp8704
g7
I205
sg8
g15
sg10
I34
sg11
Varmadillo repeat containing 5 gene
p8705
sg13
I5
sa(dp8706
g7
I183
sg8
VP84996
p8707
sg10
I4
sg11
VGNAS
p8708
sg13
I1
sa(dp8709
g7
I143
sg8
VP49913
p8710
sg10
I21
sg11
Vcyclic AMP signalling
p8711
sg13
I3
sa(dp8712
g7
I292
sg8
g15
sg10
I27
sg11
VG-protein-coupled receptors
p8713
sg13
I2
sa(dp8714
g7
I166
sg8
VP17252
p8715
sg10
I6
sg11
VPRKACA
p8716
sg13
I1
sa(dp8717
g7
I197
sg8
g15
sg10
I5
sg11
VPDE8B
p8718
sg13
I1
sa(dp8719
g7
I174
sg8
VP10644
p8720
sg10
I7
sg11
VPRKAR1A
p8721
sg13
I1
sa(dp8722
g7
I241
sg8
g15
sg10
I5
sg11
VARMC5
p8723
sg13
I1
sa(dp8724
g7
I189
sg8
g15
sg10
I6
sg11
VPDE11A
p8725
sg13
I1
sa(dp8726
g7
I352
sg8
VP01189
p8727
sg10
I4
sg11
VACTH
p8728
sg13
I1
sasg19
(lp8729
(dp8730
g7
I70
sg22
VC0010481
p8731
sg10
I16
sg11
Vhypercortisolism
p8732
sg13
I1
sa(dp8733
g7
I259
sg22
VC0027651
p8734
sg10
I6
sg11
Vtumour
p8735
sg13
I1
sa(dp8736
g7
I46
sg22
VC0699748
p8737
sg10
I12
sg11
Vpathogenesis
p8738
sg13
I1
sasa(dp8739
g2
S'Seven members of her family were screened for Cushing syndrome and Carney complex, and their blood DNA was extracted and sequenced for PRKAR1A, PDE11A, PDE8B and CTNNB1 mutations with ABI3730.\n'
p8740
sg4
(lp8741
(dp8742
g7
I144
sg8
g15
sg10
I6
sg11
VPDE11A
p8743
sg13
I1
sa(dp8744
g7
I135
sg8
VP10644
p8745
sg10
I7
sg11
VPRKAR1A
p8746
sg13
I1
sa(dp8747
g7
I162
sg8
VP35222
p8748
sg10
I16
sg11
VCTNNB1 mutations
p8749
sg13
I2
sa(dp8750
g7
I152
sg8
g15
sg10
I5
sg11
VPDE8B
p8751
sg13
I1
sasg19
(lp8752
(dp8753
g7
I46
sg22
VC0010481
p8754
sg10
I16
sg11
VCushing syndrome
p8755
sg13
I2
sa(dp8756
g7
I67
sg22
VC0406810
p8757
sg10
I14
sg11
VCarney complex
p8758
sg13
I2
sasa(dp8759
g2
S'We report one case with affectation of jugular foramen which clinically debuted as a peripheral vertigo and the diagnosis was made by CT, IRM and angiography.\n'
p8760
sg4
(lp8761
sg19
(lp8762
(dp8763
g7
I85
sg22
VC0155501
p8764
sg10
I18
sg11
Vperipheral vertigo
p8765
sg13
I2
sasa(dp8766
g2
S'In patients with indolent systemic mastocytosis with a history of Hymenoptera venom exposure after age 15 years or greater (n = 152), MIMA and age at the most recent Hymenoptera sting were independent predictors for HVAn (odds ratios of 0.723 [P = .001] and 1.062 [P &lt; .001], respectively).\n'
p8767
sg4
(lp8768
sg19
(lp8769
(dp8770
g7
I17
sg22
VC0272203
p8771
sg10
I30
sg11
Vindolent systemic mastocytosis
p8772
sg13
I3
sasa(dp8773
g2
S'The excretion of MH but not MIMA increased in four patients (ages 37, 45, 61 and 65 years) and decreased in two patients (ages 26 and 48 years), including the only patient with paediatric-onset cutaneous mastocytosis.\n'
p8774
sg4
(lp8775
sg19
(lp8776
(dp8777
g7
I194
sg22
VC1136033
p8778
sg10
I22
sg11
Vcutaneous mastocytosis
p8779
sg13
I2
sasa(dp8780
g2
S'Our data show that the activity of adult-onset indolent mastocytosis, as measured by urinary excretion of MH and MIMA and clinical signs and symptoms, can substantially decline, especially in older patients.\n'
p8781
sg4
(lp8782
sg19
(lp8783
(dp8784
g7
I131
sg22
VC0037088
p8785
sg10
I18
sg11
Vsigns and symptoms
p8786
sg13
I3
sa(dp8787
g7
I56
sg22
VC0042111
p8788
sg10
I12
sg11
Vmastocytosis
p8789
sg13
I1
sasa(dp8790
g2
S'ADAM10 (A Disintegrin and Metalloprotease Domain 10) affects the pathophysiology of various cancers, and we had shown that inhibition of ADAM10 sensitizes pancreatic cancer cells to gemcitabine.\n'
p8791
sg4
(lp8792
(dp8793
g7
I22
sg8
g15
sg10
I29
sg11
Vand Metalloprotease Domain 10
p8794
sg13
I4
sa(dp8795
g7
I0
sg8
g15
sg10
I6
sg11
VADAM10
p8796
sg13
I1
sa(dp8797
g7
I0
sg8
g15
sg10
I6
sg11
VADAM10
p8798
sg13
I1
sasg19
(lp8799
(dp8800
g7
I92
sg22
VC0006826
p8801
sg10
I7
sg11
Vcancers
p8802
sg13
I1
sa(dp8803
g7
I155
sg22
VC0235974
p8804
sg10
I17
sg11
Vpancreatic cancer
p8805
sg13
I2
sasa(dp8806
g2
S'ADAM10 is activated in response to calcium influx, and here we examined if calcium channel blockers (CCB) would impede ADAM10 activation and affect biology of pancreatic cancer cells.\n'
p8807
sg4
(lp8808
(dp8809
g7
I0
sg8
g15
sg10
I6
sg11
VADAM10
p8810
sg13
I1
sa(dp8811
g7
I0
sg8
g15
sg10
I6
sg11
VADAM10
p8812
sg13
I1
sasg19
(lp8813
(dp8814
g7
I159
sg22
VC0235974
p8815
sg10
I17
sg11
Vpancreatic cancer
p8816
sg13
I2
sasa(dp8817
g2
S'Furthermore, analysis of human pancreatic tumor tissue microarrays and lysates showed elevated levels of ADAM10, suggesting that aberrant activation of ADAM10 plays a fundamental role in growth and metastasis of PDACs and inhibiting this pathway might be a viable strategy to combat PDACs.\n'
p8818
sg4
(lp8819
(dp8820
g7
I105
sg8
g15
sg10
I6
sg11
VADAM10
p8821
sg13
I1
sa(dp8822
g7
I105
sg8
g15
sg10
I6
sg11
VADAM10
p8823
sg13
I1
sasg19
(lp8824
(dp8825
g7
I31
sg22
VC0030297
p8826
sg10
I16
sg11
Vpancreatic tumor
p8827
sg13
I2
sa(dp8828
g7
I198
sg22
VC0027627
p8829
sg10
I10
sg11
Vmetastasis
p8830
sg13
I1
sasa(dp8831
g2
S'In the present report we describe the release of high levels of the ectodomain of Fat1 cadherin into the secretomes of human pancreatic cancer cells in vitro, a process that is mediated by ADAM10.\n'
p8832
sg4
(lp8833
(dp8834
g7
I189
sg8
g15
sg10
I6
sg11
VADAM10
p8835
sg13
I1
sa(dp8836
g7
I82
sg8
g15
sg10
I13
sg11
VFat1 cadherin
p8837
sg13
I2
sasg19
(lp8838
(dp8839
g7
I125
sg22
VC0235974
p8840
sg10
I17
sg11
Vpancreatic cancer
p8841
sg13
I2
sasa(dp8842
g2
S'Fat1 and its sheddase ADAM10 are overexpressed in pancreatic adenocarcinomas and ectodomain shedding is also recapitulated in vivo leading to increased Fat1 serum levels in some pancreatic cancer patients.\n'
p8843
sg4
(lp8844
(dp8845
g7
I22
sg8
g15
sg10
I6
sg11
VADAM10
p8846
sg13
I1
sa(dp8847
g7
I0
sg8
g15
sg10
I4
sg11
VFat1
p8848
sg13
I1
sa(dp8849
g7
I0
sg8
g15
sg10
I4
sg11
VFat1
p8850
sg13
I1
sasg19
(lp8851
(dp8852
g7
I178
sg22
VC0235974
p8853
sg10
I17
sg11
Vpancreatic cancer
p8854
sg13
I2
sa(dp8855
g7
I61
sg22
VC0001418
p8856
sg10
I15
sg11
Vadenocarcinomas
p8857
sg13
I1
sasa(dp8858
g2
S'Therefore, the aim of our study was to evaluate the expression and potential function of ADAM10 in the pathophysiology of pancreatic cancer (PDAC).\n'
p8859
sg4
(lp8860
(dp8861
g7
I89
sg8
g15
sg10
I6
sg11
VADAM10
p8862
sg13
I1
sasg19
(lp8863
(dp8864
g7
I122
sg22
VC0235974
p8865
sg10
I17
sg11
Vpancreatic cancer
p8866
sg13
I2
sasa(dp8867
g2
S'The homogeneous reactivity for CD99, the negativity for Bcl-2 and lack of the honeycomb infiltration of the subcutis help to rule out myxoid dermatofibrosarcoma protuberans, whereas the negativity for MUC4 and Bcl-2 are helpful tools to rule out low-grade fibromyxoid sarcoma and spindled-cell lipoma, respectively.\n'
p8868
sg4
(lp8869
(dp8870
g7
I31
sg8
VP14209
p8871
sg10
I4
sg11
VCD99
p8872
sg13
I1
sa(dp8873
g7
I56
sg8
VP10415
p8874
sg10
I5
sg11
VBcl-2
p8875
sg13
I1
sa(dp8876
g7
I56
sg8
VP10415
p8877
sg10
I5
sg11
VBcl-2
p8878
sg13
I1
sasg19
(lp8879
(dp8880
g7
I88
sg22
VC0332448
p8881
sg10
I12
sg11
Vinfiltration
p8882
sg13
I1
sa(dp8883
g7
I246
sg22
VC1275282
p8884
sg10
I29
sg11
Vlow-grade fibromyxoid sarcoma
p8885
sg13
I3
sa(dp8886
g7
I134
sg22
VC0334454
p8887
sg10
I38
sg11
Vmyxoid dermatofibrosarcoma protuberans
p8888
sg13
I3
sa(dp8889
g7
I294
sg22
VC3489413
p8890
sg10
I6
sg11
Vlipoma
p8891
sg13
I1
sasa(dp8892
g2
S'In process, we have identified chromosomal aberration in 1p, 7, 10, 13 and 17q, high frequency of functional germline SNP of the T gene, rs2305089 (P = 0.0038) and several recurrent alterations including MUC4, NBPF1, NPIPB15 mutations and novel gene fusion of SAMD5-SASH1 for the first time in skull base chordoma.\n'
p8893
sg4
(lp8894
(dp8895
g7
I210
sg8
g15
sg10
I5
sg11
VNBPF1
p8896
sg13
I1
sa(dp8897
g7
I260
sg8
g15
sg10
I11
sg11
VSAMD5-SASH1
p8898
sg13
I1
sasg19
(lp8899
(dp8900
g7
I31
sg22
VC0008625
p8901
sg10
I22
sg11
Vchromosomal aberration
p8902
sg13
I2
sa(dp8903
g7
I294
sg22
VC1335975
p8904
sg10
I19
sg11
Vskull base chordoma
p8905
sg13
I3
sa(dp8906
g7
I245
sg22
VC1705736
p8907
sg10
I11
sg11
Vgene fusion
p8908
sg13
I2
sasa(dp8909
g2
S'We confirm in our two cases that the distinct pattern of immunohistochemical staining for MUC4, associated with the absence of staining for both SATB2, a marker of osteoblastic differentiation, and pan-cytokeratin, allows differentiating between sclerosing epithelioid fibrosarcoma and metastatic carcinoma or osteosarcoma.\n'
p8910
sg4
(lp8911
(dp8912
g7
I198
sg8
g15
sg10
I15
sg11
Vpan-cytokeratin
p8913
sg13
I1
sa(dp8914
g7
I145
sg8
g15
sg10
I5
sg11
VSATB2
p8915
sg13
I1
sasg19
(lp8916
(dp8917
g7
I286
sg22
VC1384494
p8918
sg10
I20
sg11
Vmetastatic carcinoma
p8919
sg13
I2
sa(dp8920
g7
I310
sg22
VC0029463
p8921
sg10
I12
sg11
Vosteosarcoma
p8922
sg13
I1
sa(dp8923
g7
I246
sg22
VC1710026
p8924
sg10
I35
sg11
Vsclerosing epithelioid fibrosarcoma
p8925
sg13
I3
sasa(dp8926
g2
S'Significantly higher levels of interleukin (IL)-8 (p &lt; 0.001), eotaxin (p &lt; 0.001), interferon gamma-induced protein (IP)-10 (p &lt; 0.001) and macrophage inflammatory protein-1-beta (MIP-1Beta; p &lt; 0.001) were observed in aqueous of chronic PACG patients compared to controls.\n'
p8927
sg4
(lp8928
(dp8929
g7
I90
sg8
VP01579
p8930
sg10
I16
sg11
Vinterferon gamma
p8931
sg13
I2
sa(dp8932
g7
I31
sg8
VP60568
p8933
sg10
I18
sg11
Vinterleukin (IL)-8
p8934
sg13
I2
sa(dp8935
g7
I150
sg8
VP09603
p8936
sg10
I38
sg11
Vmacrophage inflammatory protein-1-beta
p8937
sg13
I3
sa(dp8938
g7
I190
sg8
g15
sg10
I9
sg11
VMIP-1Beta
p8939
sg13
I1
sasg19
(lp8940
(dp8941
g7
I190
sg22
VC1851100
p8942
sg10
I3
sg11
VMIP
p8943
sg13
I1
sasa(dp8944
g2
S'This is the first study reporting significantly increased levels of eotaxin, MIP-1Beta, and IP-10 and lower levels of TNF-Alfa, IL-5, IL-9, IL-17, and GM-CSF in chronic PACG patients, suggesting a plausible role of these inflammatory cytokines in its pathogenesis.\n'
p8945
sg4
(lp8946
(dp8947
g7
I77
sg8
g15
sg10
I9
sg11
VMIP-1Beta
p8948
sg13
I1
sa(dp8949
g7
I92
sg8
VP02778
p8950
sg10
I5
sg11
VIP-10
p8951
sg13
I1
sa(dp8952
g7
I151
sg8
VP04141
p8953
sg10
I6
sg11
VGM-CSF
p8954
sg13
I1
sa(dp8955
g7
I128
sg8
VP05113
p8956
sg10
I4
sg11
VIL-5
p8957
sg13
I1
sa(dp8958
g7
I118
sg8
VP01375
p8959
sg10
I8
sg11
VTNF-Alfa
p8960
sg13
I1
sa(dp8961
g7
I134
sg8
VP15248
p8962
sg10
I4
sg11
VIL-9
p8963
sg13
I1
sa(dp8964
g7
I68
sg8
VP51671
p8965
sg10
I7
sg11
Veotaxin
p8966
sg13
I1
sasg19
(lp8967
(dp8968
g7
I77
sg22
VC1851100
p8969
sg10
I3
sg11
VMIP
p8970
sg13
I1
sa(dp8971
g7
I251
sg22
VC0699748
p8972
sg10
I12
sg11
Vpathogenesis
p8973
sg13
I1
sasa(dp8974
g2
S'Concentrations were as follows: IL-8, IP-10, MCP-1, and MIP-1Beta: POAG and NVG higher than cataract; IL-9: POAG lower than NVG; IL-12: POAG lower than cataract or NVG; and VEGF: NVG higher than cataract or POAG and POAG lower than cataract.\n'
p8975
sg4
(lp8976
(dp8977
g7
I38
sg8
VP02778
p8978
sg10
I5
sg11
VIP-10
p8979
sg13
I1
sa(dp8980
g7
I45
sg8
VP41597
p8981
sg10
I5
sg11
VMCP-1
p8982
sg13
I1
sa(dp8983
g7
I102
sg8
VP15248
p8984
sg10
I4
sg11
VIL-9
p8985
sg13
I1
sa(dp8986
g7
I56
sg8
g15
sg10
I9
sg11
VMIP-1Beta
p8987
sg13
I1
sasg19
(lp8988
(dp8989
g7
I92
sg22
VC0086543
p8990
sg10
I8
sg11
Vcataract
p8991
sg13
I1
sa(dp8992
g7
I67
sg22
VC0339573
p8993
sg10
I4
sg11
VPOAG
p8994
sg13
I1
sa(dp8995
g7
I67
sg22
VC0339573
p8996
sg10
I4
sg11
VPOAG
p8997
sg13
I1
sa(dp8998
g7
I67
sg22
VC0339573
p8999
sg10
I4
sg11
VPOAG
p9000
sg13
I1
sa(dp9001
g7
I67
sg22
VC0339573
p9002
sg10
I4
sg11
VPOAG
p9003
sg13
I1
sa(dp9004
g7
I92
sg22
VC0086543
p9005
sg10
I8
sg11
Vcataract
p9006
sg13
I1
sa(dp9007
g7
I92
sg22
VC0086543
p9008
sg10
I8
sg11
Vcataract
p9009
sg13
I1
sa(dp9010
g7
I56
sg22
VC1851100
p9011
sg10
I3
sg11
VMIP
p9012
sg13
I1
sa(dp9013
g7
I67
sg22
VC0339573
p9014
sg10
I4
sg11
VPOAG
p9015
sg13
I1
sa(dp9016
g7
I92
sg22
VC0086543
p9017
sg10
I8
sg11
Vcataract
p9018
sg13
I1
sasa(dp9019
g2
S'In zone1, lower concentration of IP-10 compared to baseline or higher concentration of macrophage inflammatory protein (MIP) -Alfa, and in zone 2, lower concentration of IL-5 compared to baseline, IL-8, and IP-10 or higher concentration of eotaxin-1 and MIP-1Beta were associated with improved DME.\n'
p9020
sg4
(lp9021
(dp9022
g7
I240
sg8
VP51671
p9023
sg10
I9
sg11
Veotaxin-1
p9024
sg13
I1
sa(dp9025
g7
I170
sg8
VP05113
p9026
sg10
I4
sg11
VIL-5
p9027
sg13
I1
sa(dp9028
g7
I254
sg8
g15
sg10
I9
sg11
VMIP-1Beta
p9029
sg13
I1
sa(dp9030
g7
I33
sg8
VP02778
p9031
sg10
I5
sg11
VIP-10
p9032
sg13
I1
sasg19
(lp9033
(dp9034
g7
I120
sg22
VC1851100
p9035
sg10
I3
sg11
VMIP
p9036
sg13
I1
sa(dp9037
g7
I120
sg22
VC1851100
p9038
sg10
I3
sg11
VMIP
p9039
sg13
I1
sa(dp9040
g7
I87
sg22
VC1851100
p9041
sg10
I31
sg11
Vmacrophage inflammatory protein
p9042
sg13
I3
sasa(dp9043
g2
S"Among BK eyes, the IL-6 and IFN-Gamma levels were elevated in eyes with pseudophakic BK (PBK), Fuchs' endothelial corneal dystrophy (FECD), postkeratoplasty, posttrabeculectomy, and postlaser iridotomy (LI) (all, P &lt; 0.04), whereas IL-1Alfa, IL-10, IL-17A, MIP-1Beta, and sICAM-1 levels were elevated only in PBK, postkeratoplasty, posttrabeculectomy, and post-LI eyes (all, P &lt; 0.05).\n"
p9044
sg4
(lp9045
(dp9046
g7
I72
sg8
g15
sg10
I15
sg11
Vpseudophakic BK
p9047
sg13
I2
sa(dp9048
g7
I28
sg8
VP01579
p9049
sg10
I9
sg11
VIFN-Gamma
p9050
sg13
I1
sa(dp9051
g7
I89
sg8
g15
sg10
I3
sg11
VPBK
p9052
sg13
I1
sa(dp9053
g7
I260
sg8
g15
sg10
I9
sg11
VMIP-1Beta
p9054
sg13
I1
sa(dp9055
g7
I19
sg8
VP05231
p9056
sg10
I4
sg11
VIL-6
p9057
sg13
I1
sasg19
(lp9058
(dp9059
g7
I102
sg22
VC0544008
p9060
sg10
I29
sg11
Vendothelial corneal dystrophy
p9061
sg13
I3
sa(dp9062
g7
I260
sg22
VC1851100
p9063
sg10
I3
sg11
VMIP
p9064
sg13
I1
sasa(dp9065
g2
S'Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.\n'
p9066
sg4
(lp9067
(dp9068
g7
I59
sg8
g15
sg10
I126
sg11
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p9069
sg13
I12
sa(dp9070
g7
I527
sg8
g15
sg10
I5
sg11
VAP3B2
p9071
sg13
I1
sa(dp9072
g7
I247
sg8
VP05129
p9073
sg10
I61
sg11
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p9074
sg13
I7
sa(dp9075
g7
I18
sg8
VP42261
p9076
sg10
I38
sg11
Vanti-metabotropic glutamate receptor 1
p9077
sg13
I4
sa(dp9078
g7
I356
sg8
g15
sg10
I49
sg11
Vanti-voltage-gated calcium channel-associated ACA
p9079
sg13
I4
sa(dp9080
g7
I476
sg8
VP01133
p9081
sg10
I40
sg11
Vepidermal growth factor-related receptor
p9082
sg13
I4
sasg19
(lp9083
(dp9084
g7
I227
sg22
VC0007758
p9085
sg10
I3
sg11
VACA
p9086
sg13
I1
sa(dp9087
g7
I227
sg22
VC0007758
p9088
sg10
I3
sg11
VACA
p9089
sg13
I1
sa(dp9090
g7
I227
sg22
VC0007758
p9091
sg10
I3
sg11
VACA
p9092
sg13
I1
sa(dp9093
g7
I197
sg22
VC0007758
p9094
sg10
I28
sg11
Vautoimmune cerebellar ataxia
p9095
sg13
I3
sa(dp9096
g7
I543
sg22
VC0262404
p9097
sg10
I23
sg11
Vcerebellar degeneration
p9098
sg13
I2
sasa(dp9099
g2
S'Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects, and provides a summary and outlook.\n'
p9100
sg4
(lp9101
(dp9102
g7
I59
sg8
g15
sg10
I126
sg11
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p9103
sg13
I12
sa(dp9104
g7
I527
sg8
g15
sg10
I5
sg11
VAP3B2
p9105
sg13
I1
sa(dp9106
g7
I247
sg8
VP05129
p9107
sg10
I61
sg11
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p9108
sg13
I7
sa(dp9109
g7
I18
sg8
VP42261
p9110
sg10
I38
sg11
Vanti-metabotropic glutamate receptor 1
p9111
sg13
I4
sa(dp9112
g7
I356
sg8
g15
sg10
I49
sg11
Vanti-voltage-gated calcium channel-associated ACA
p9113
sg13
I4
sa(dp9114
g7
I476
sg8
VP01133
p9115
sg10
I40
sg11
Vepidermal growth factor-related receptor
p9116
sg13
I4
sasg19
(lp9117
(dp9118
g7
I227
sg22
VC0007758
p9119
sg10
I3
sg11
VACA
p9120
sg13
I1
sa(dp9121
g7
I227
sg22
VC0007758
p9122
sg10
I3
sg11
VACA
p9123
sg13
I1
sa(dp9124
g7
I227
sg22
VC0007758
p9125
sg10
I3
sg11
VACA
p9126
sg13
I1
sa(dp9127
g7
I197
sg22
VC0007758
p9128
sg10
I28
sg11
Vautoimmune cerebellar ataxia
p9129
sg13
I3
sa(dp9130
g7
I543
sg22
VC0262404
p9131
sg10
I23
sg11
Vcerebellar degeneration
p9132
sg13
I2
sasa(dp9133
g2
S'Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.\n'
p9134
sg4
(lp9135
(dp9136
g7
I59
sg8
g15
sg10
I126
sg11
Vanti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII
p9137
sg13
I12
sa(dp9138
g7
I527
sg8
g15
sg10
I5
sg11
VAP3B2
p9139
sg13
I1
sa(dp9140
g7
I247
sg8
VP05129
p9141
sg10
I61
sg11
Vanti-protein kinase C gamma-, anti-glutamate receptor delta-2
p9142
sg13
I7
sa(dp9143
g7
I18
sg8
VP42261
p9144
sg10
I38
sg11
Vanti-metabotropic glutamate receptor 1
p9145
sg13
I4
sa(dp9146
g7
I356
sg8
g15
sg10
I49
sg11
Vanti-voltage-gated calcium channel-associated ACA
p9147
sg13
I4
sa(dp9148
g7
I476
sg8
VP01133
p9149
sg10
I40
sg11
Vepidermal growth factor-related receptor
p9150
sg13
I4
sasg19
(lp9151
(dp9152
g7
I227
sg22
VC0007758
p9153
sg10
I3
sg11
VACA
p9154
sg13
I1
sa(dp9155
g7
I227
sg22
VC0007758
p9156
sg10
I3
sg11
VACA
p9157
sg13
I1
sa(dp9158
g7
I227
sg22
VC0007758
p9159
sg10
I3
sg11
VACA
p9160
sg13
I1
sa(dp9161
g7
I197
sg22
VC0007758
p9162
sg10
I28
sg11
Vautoimmune cerebellar ataxia
p9163
sg13
I3
sa(dp9164
g7
I543
sg22
VC0262404
p9165
sg10
I23
sg11
Vcerebellar degeneration
p9166
sg13
I2
sasa(dp9167
g2
S"Lastly, a recent study identified delta/notch-like epidermal growth factor-related receptor (DNER) as the target antigen of Tr antibodies, a marker of cerebellar ataxia and Hodgkin's lymphoma.\n"
p9168
sg4
(lp9169
(dp9170
g7
I51
sg8
VP01133
p9171
sg10
I40
sg11
Vepidermal growth factor-related receptor
p9172
sg13
I4
sasg19
(lp9173
(dp9174
g7
I173
sg22
VC0019829
p9175
sg10
I18
sg11
VHodgkin's lymphoma
p9176
sg13
I2
sa(dp9177
g7
I151
sg22
VC0007758
p9178
sg10
I17
sg11
Vcerebellar ataxia
p9179
sg13
I2
sasa(dp9180
g2
S'A total of 835 RCCs, 143 chronic nephritis, 170 kidney stones and 415 health controls were collected for qRT-PCR, immunohistochemistry and Western blot analysis of CCP6 expression and mass spectrometry of DNAJC7 and polyglutamylated DNAJC7.\n'
p9181
sg4
(lp9182
(dp9183
g7
I164
sg8
g15
sg10
I4
sg11
VCCP6
p9184
sg13
I1
sasg19
(lp9185
(dp9186
g7
I48
sg22
VC0022650
p9187
sg10
I13
sg11
Vkidney stones
p9188
sg13
I2
sa(dp9189
g7
I15
sg22
VC0007134
p9190
sg10
I4
sg11
VRCCs
p9191
sg13
I1
sa(dp9192
g7
I25
sg22
VC2364010
p9193
sg10
I17
sg11
Vchronic nephritis
p9194
sg13
I2
sasa(dp9195
g2
S'hnRNPA2B1 and hnRNPA1 mutations have been recently identified by exome sequencing in three families presenting with multisystem proteinopathy (MSP), a rare complex phenotype associating frontotemporal lobar degeneration (FTLD), Paget disease of bone (PDB), inclusion body myopathy (IBM), and amyotrophic lateral sclerosis (ALS).\n'
p9196
sg4
(lp9197
(dp9198
g7
I0
sg8
VP22626
p9199
sg10
I9
sg11
VhnRNPA2B1
p9200
sg13
I1
sa(dp9201
g7
I14
sg8
VP09651
p9202
sg10
I7
sg11
VhnRNPA1
p9203
sg13
I1
sasg19
(lp9204
(dp9205
g7
I272
sg22
VC0026848
p9206
sg10
I8
sg11
Vmyopathy
p9207
sg13
I1
sa(dp9208
g7
I282
sg22
VC0238190
p9209
sg10
I3
sg11
VIBM
p9210
sg13
I1
sa(dp9211
g7
I228
sg22
VC0029401
p9212
sg10
I21
sg11
VPaget disease of bone
p9213
sg13
I4
sa(dp9214
g7
I251
sg22
VC0029401
p9215
sg10
I3
sg11
VPDB
p9216
sg13
I1
sa(dp9217
g7
I323
sg22
VC0002736
p9218
sg10
I3
sg11
VALS
p9219
sg13
I1
sa(dp9220
g7
I221
sg22
VC0751072
p9221
sg10
I4
sg11
VFTLD
p9222
sg13
I1
sa(dp9223
g7
I186
sg22
VC0751072
p9224
sg10
I33
sg11
Vfrontotemporal lobar degeneration
p9225
sg13
I3
sa(dp9226
g7
I292
sg22
VC0002736
p9227
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p9228
sg13
I3
sasa(dp9229
g2
S'Mutations in the prion-like domain (PrLD) of hnRNPA1 and A2/B1 genes were recently identified in 2 families with inclusion body myopathy associated with Paget disease of bone, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis, and in ALS patients.\n'
p9230
sg4
(lp9231
(dp9232
g7
I45
sg8
VP09651
p9233
sg10
I7
sg11
VhnRNPA1
p9234
sg13
I1
sa(dp9235
g7
I57
sg8
VP01893
p9236
sg10
I11
sg11
VA2/B1 genes
p9237
sg13
I2
sasg19
(lp9238
(dp9239
g7
I249
sg22
VC0002736
p9240
sg10
I3
sg11
VALS
p9241
sg13
I1
sa(dp9242
g7
I128
sg22
VC0026848
p9243
sg10
I8
sg11
Vmyopathy
p9244
sg13
I1
sa(dp9245
g7
I201
sg22
VC0338451
p9246
sg10
I3
sg11
VFTD
p9247
sg13
I1
sa(dp9248
g7
I176
sg22
VC0338451
p9249
sg10
I23
sg11
Vfrontotemporal dementia
p9250
sg13
I2
sa(dp9251
g7
I153
sg22
VC0029401
p9252
sg10
I21
sg11
VPaget disease of bone
p9253
sg13
I4
sa(dp9254
g7
I211
sg22
VC0002736
p9255
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p9256
sg13
I3
sasa(dp9257
g2
S'Patients with spring catarrh (vernal conjunctivitis) were studied for blood histamine (36) and plasma histaminase (16), and were compared with control histamine (22) and histaminase (19) levels.\n'
p9258
sg4
(lp9259
(dp9260
g7
I102
sg8
VP19801
p9261
sg10
I11
sg11
Vhistaminase
p9262
sg13
I1
sa(dp9263
g7
I95
sg8
VP19801
p9264
sg10
I18
sg11
Vplasma histaminase
p9265
sg13
I2
sasg19
(lp9266
(dp9267
g7
I21
sg22
VC1384493
p9268
sg10
I7
sg11
Vcatarrh
p9269
sg13
I1
sa(dp9270
g7
I30
sg22
VC0009773
p9271
sg10
I21
sg11
Vvernal conjunctivitis
p9272
sg13
I2
sasa(dp9273
g2
S'Atp10c is a strong candidate gene for diet-induced obesity and type 2 diabetes.\n'
p9274
sg4
(lp9275
(dp9276
g7
I0
sg8
g15
sg10
I6
sg11
VAtp10c
p9277
sg13
I1
sasg19
(lp9278
(dp9279
g7
I63
sg22
VC0011860
p9280
sg10
I15
sg11
Vtype 2 diabetes
p9281
sg13
I3
sa(dp9282
g7
I51
sg22
VC0028754
p9283
sg10
I7
sg11
Vobesity
p9284
sg13
I1
sasa(dp9285
g2
S'Furthermore, a role for Atp8b3 in mouse sperm cell capacitation has been suggested, whereas deficiency of Atp10a and Atp10d leads to insulin resistance and obesity in mice.\n'
p9286
sg4
(lp9287
(dp9288
g7
I117
sg8
g15
sg10
I6
sg11
VAtp10d
p9289
sg13
I1
sa(dp9290
g7
I133
sg8
VP01308
p9291
sg10
I7
sg11
Vinsulin
p9292
sg13
I1
sa(dp9293
g7
I24
sg8
g15
sg10
I6
sg11
VAtp8b3
p9294
sg13
I1
sa(dp9295
g7
I106
sg8
g15
sg10
I6
sg11
VAtp10a
p9296
sg13
I1
sasg19
(lp9297
(dp9298
g7
I133
sg22
VC0021655
p9299
sg10
I18
sg11
Vinsulin resistance
p9300
sg13
I2
sa(dp9301
g7
I156
sg22
VC0028754
p9302
sg10
I7
sg11
Vobesity
p9303
sg13
I1
sasa(dp9304
g2
S'Simulations of maternal deletion of ATP10A indicated an anabolic metabolism consistent with the known clinical phenotypes of obesity.\n'
p9305
sg4
(lp9306
(dp9307
g7
I36
sg8
g15
sg10
I6
sg11
VATP10A
p9308
sg13
I1
sasg19
(lp9309
(dp9310
g7
I125
sg22
VC0028754
p9311
sg10
I7
sg11
Vobesity
p9312
sg13
I1
sasa(dp9313
g2
S'The purpose of this study was to assess the overall effect of the heterozygous deletion of Atp10c on obesity-related phenotypes and metabolic abnormalities in mice fed a high-fat diet.\n'
p9314
sg4
(lp9315
(dp9316
g7
I91
sg8
g15
sg10
I6
sg11
VAtp10c
p9317
sg13
I1
sasg19
(lp9318
(dp9319
g7
I101
sg22
VC0028754
p9320
sg10
I7
sg11
Vobesity
p9321
sg13
I1
sasa(dp9322
g2
S'Although sex differences were observed, our data suggest that heterozygous deletion along with an unusual pattern of maternal inheritance of the chromosomal region containing the single gene, Atp10c, causes obesity, type 2 diabetes, and nonalcoholic fatty liver disease in these mice.\n'
p9323
sg4
(lp9324
(dp9325
g7
I192
sg8
g15
sg10
I6
sg11
VAtp10c
p9326
sg13
I1
sasg19
(lp9327
(dp9328
g7
I237
sg22
VC0400966
p9329
sg10
I32
sg11
Vnonalcoholic fatty liver disease
p9330
sg13
I4
sa(dp9331
g7
I216
sg22
VC0011860
p9332
sg10
I15
sg11
Vtype 2 diabetes
p9333
sg13
I3
sa(dp9334
g7
I207
sg22
VC0028754
p9335
sg10
I7
sg11
Vobesity
p9336
sg13
I1
sasa(dp9337
g2
S'The localization of Atp10a neighboring the maternally expressed gene Ube3a in the imprinted domain and an unusual inheritance pattern of the obesity phenotype with a p-locus deletion have suggested that Atp10a might be imprinted and associated with body fat.\n'
p9338
sg4
(lp9339
(dp9340
g7
I20
sg8
g15
sg10
I6
sg11
VAtp10a
p9341
sg13
I1
sa(dp9342
g7
I20
sg8
g15
sg10
I6
sg11
VAtp10a
p9343
sg13
I1
sasg19
(lp9344
(dp9345
g7
I141
sg22
VC0028754
p9346
sg10
I7
sg11
Vobesity
p9347
sg13
I1
sasa(dp9348
g2
S'Notably, transfer of cells from DNA-HSP65- or CpG/CFP-immunized MyD88(-/-) mice failed to reduce allergy.\n'
p9349
sg4
(lp9350
(dp9351
g7
I36
sg8
VP10809
p9352
sg10
I5
sg11
VHSP65
p9353
sg13
I1
sasg19
(lp9354
(dp9355
g7
I97
sg22
VC0020517
p9356
sg10
I7
sg11
Vallergy
p9357
sg13
I1
sasa(dp9358
g2
S'However, the roles of other genes, such as CSF3 (colony stimulating factor 3 receptor), CD40, TNFSF14 (tumor necrosis factor receptor superfamily, member 14), IFNB1 (interferon-Beta1), TIRAP (toll-interleukin 1 receptor domain containing adaptor protein), IL2RA (interleukin 2 receptor Alfa), ETS1 (v-ets avian erythroblastosis virus E26 oncogene homolog 1), GADD45B (growth arrest and DNA-damage-inducible 45 Beta), BIRC3 (baculoviral IAP repeat containing 3), VAV1 (vav 1 guanine nucleotide exchange factor), COL5A1 (collagen, type V, Alfa1), and C3 (complement component 3), have not been investigated thoroughly in the process of periodontitis.\n'
p9359
sg4
(lp9360
(dp9361
g7
I159
sg8
VP01574
p9362
sg10
I5
sg11
VIFNB1
p9363
sg13
I1
sa(dp9364
g7
I103
sg8
VP01375
p9365
sg10
I42
sg11
Vtumor necrosis factor receptor superfamily
p9366
sg13
I5
sa(dp9367
g7
I468
sg8
VP15498
p9368
sg10
I40
sg11
Vvav 1 guanine nucleotide exchange factor
p9369
sg13
I6
sa(dp9370
g7
I256
sg8
VP01589
p9371
sg10
I5
sg11
VIL2RA
p9372
sg13
I1
sa(dp9373
g7
I192
sg8
VP14778
p9374
sg10
I61
sg11
Vtoll-interleukin 1 receptor domain containing adaptor protein
p9375
sg13
I7
sa(dp9376
g7
I166
sg8
VP01563
p9377
sg10
I16
sg11
Vinterferon-Beta1
p9378
sg13
I1
sa(dp9379
g7
I293
sg8
VP14921
p9380
sg10
I4
sg11
VETS1
p9381
sg13
I1
sa(dp9382
g7
I311
sg8
VP35125
p9383
sg10
I45
sg11
Verythroblastosis virus E26 oncogene homolog 1
p9384
sg13
I6
sa(dp9385
g7
I368
sg8
g15
sg10
I46
sg11
Vgrowth arrest and DNA-damage-inducible 45 Beta
p9386
sg13
I6
sa(dp9387
g7
I263
sg8
VP01589
p9388
sg10
I27
sg11
Vinterleukin 2 receptor Alfa
p9389
sg13
I4
sa(dp9390
g7
I185
sg8
VP58753
p9391
sg10
I5
sg11
VTIRAP
p9392
sg13
I1
sa(dp9393
g7
I511
sg8
VP20908
p9394
sg10
I6
sg11
VCOL5A1
p9395
sg13
I1
sa(dp9396
g7
I359
sg8
g15
sg10
I7
sg11
VGADD45B
p9397
sg13
I1
sa(dp9398
g7
I94
sg8
g15
sg10
I7
sg11
VTNFSF14
p9399
sg13
I1
sa(dp9400
g7
I88
sg8
VP25942
p9401
sg10
I4
sg11
VCD40
p9402
sg13
I1
sa(dp9403
g7
I49
sg8
g15
sg10
I36
sg11
Vcolony stimulating factor 3 receptor
p9404
sg13
I5
sa(dp9405
g7
I462
sg8
VP15498
p9406
sg10
I4
sg11
VVAV1
p9407
sg13
I1
sa(dp9408
g7
I43
sg8
VP09919
p9409
sg10
I4
sg11
VCSF3
p9410
sg13
I1
sasg19
(lp9411
(dp9412
g7
I368
sg22
VC0333951
p9413
sg10
I13
sg11
Vgrowth arrest
p9414
sg13
I2
sa(dp9415
g7
I634
sg22
VC0031099
p9416
sg10
I13
sg11
Vperiodontitis
p9417
sg13
I1
sa(dp9418
g7
I311
sg22
VC0272138
p9419
sg10
I16
sg11
Verythroblastosis
p9420
sg13
I1
sa(dp9421
g7
I103
sg22
VC0333516
p9422
sg10
I14
sg11
Vtumor necrosis
p9423
sg13
I2
sasa(dp9424
g2
S'Compared with the normal controls, the levels of BMP4 in amniotic fluid and serum from the woman with a fetus with myelomeningocele were increased, whereas levels of Shh were increased in the woman pregnant with a fetus displaying anencephaly.\n'
p9425
sg4
(lp9426
(dp9427
g7
I49
sg8
VP12644
p9428
sg10
I4
sg11
VBMP4
p9429
sg13
I1
sa(dp9430
g7
I166
sg8
g15
sg10
I3
sg11
VShh
p9431
sg13
I1
sasg19
(lp9432
(dp9433
g7
I115
sg22
VC0025312
p9434
sg10
I16
sg11
Vmyelomeningocele
p9435
sg13
I1
sa(dp9436
g7
I231
sg22
VC0002902
p9437
sg10
I11
sg11
Vanencephaly
p9438
sg13
I1
sasa(dp9439
g2
S'Absence of the sonic hedgehog (shh) ligand is associated with the midline defect holoprosencephaly, whereas increased Shh signaling is associated with exencephaly and spina bifida.\n'
p9440
sg4
(lp9441
(dp9442
g7
I31
sg8
g15
sg10
I3
sg11
Vshh
p9443
sg13
I1
sa(dp9444
g7
I118
sg8
g15
sg10
I3
sg11
VShh
p9445
sg13
I1
sa(dp9446
g7
I15
sg8
g15
sg10
I14
sg11
Vsonic hedgehog
p9447
sg13
I2
sasg19
(lp9448
(dp9449
g7
I151
sg22
VC0266453
p9450
sg10
I11
sg11
Vexencephaly
p9451
sg13
I1
sa(dp9452
g7
I81
sg22
VC0079541
p9453
sg10
I17
sg11
Vholoprosencephaly
p9454
sg13
I1
sa(dp9455
g7
I167
sg22
VC0080178
p9456
sg10
I12
sg11
Vspina bifida
p9457
sg13
I2
sasa(dp9458
g2
S'Large tumour suppressor kinase 2 (LATS2) was confirmed as a direct target of miR-372 using luciferase assays in these two prostate cancer cell lines.\n'
p9459
sg4
(lp9460
(dp9461
g7
I0
sg8
VP43146
p9462
sg10
I32
sg11
VLarge tumour suppressor kinase 2
p9463
sg13
I5
sa(dp9464
g7
I34
sg8
g15
sg10
I5
sg11
VLATS2
p9465
sg13
I1
sa(dp9466
g7
I77
sg8
g15
sg10
I7
sg11
VmiR-372
p9467
sg13
I1
sasg19
(lp9468
(dp9469
g7
I122
sg22
VC0600139
p9470
sg10
I15
sg11
Vprostate cancer
p9471
sg13
I2
sa(dp9472
g7
I6
sg22
VC0027651
p9473
sg10
I6
sg11
Vtumour
p9474
sg13
I1
sasa(dp9475
g2
S'Down-regulation of LATS2 could promote prostate cancer cell proliferation and migration just as overexpression of miR-372 did and overexpression of LATS2 could reverse this effect of miR-372.\n'
p9476
sg4
(lp9477
(dp9478
g7
I19
sg8
g15
sg10
I5
sg11
VLATS2
p9479
sg13
I1
sa(dp9480
g7
I19
sg8
g15
sg10
I5
sg11
VLATS2
p9481
sg13
I1
sa(dp9482
g7
I114
sg8
g15
sg10
I7
sg11
VmiR-372
p9483
sg13
I1
sasg19
(lp9484
(dp9485
g7
I39
sg22
VC0600139
p9486
sg10
I15
sg11
Vprostate cancer
p9487
sg13
I2
sa(dp9488
g7
I60
sg22
VC0334094
p9489
sg10
I13
sg11
Vproliferation
p9490
sg13
I1
sasa(dp9491
g2
S'Altogether, our data showed evidence that repressing the overexpression of miR-372 by As4 S4 could inhibit prostate cancer cell proliferation and migration by targeting LATS2.\n'
p9492
sg4
(lp9493
(dp9494
g7
I169
sg8
g15
sg10
I5
sg11
VLATS2
p9495
sg13
I1
sa(dp9496
g7
I75
sg8
g15
sg10
I7
sg11
VmiR-372
p9497
sg13
I1
sasg19
(lp9498
(dp9499
g7
I128
sg22
VC0334094
p9500
sg10
I13
sg11
Vproliferation
p9501
sg13
I1
sa(dp9502
g7
I107
sg22
VC0600139
p9503
sg10
I15
sg11
Vprostate cancer
p9504
sg13
I2
sasa(dp9505
g2
S'Defective expression of LATS2, a negative regulator of YAP oncoprotein, has been reported in cancer of prostate, breast, liver, brain, and blood origins.\n'
p9506
sg4
(lp9507
(dp9508
g7
I55
sg8
VP46937
p9509
sg10
I15
sg11
VYAP oncoprotein
p9510
sg13
I2
sa(dp9511
g7
I24
sg8
g15
sg10
I5
sg11
VLATS2
p9512
sg13
I1
sasg19
(lp9513
(dp9514
g7
I93
sg22
VC0600139
p9515
sg10
I18
sg11
Vcancer of prostate
p9516
sg13
I3
sasa(dp9517
g2
S'In support of these results, reduced expression and somatic mutations of FOXP3 correlated strongly with defective LATS2 expression in microdissected prostate cancer tissues.\n'
p9518
sg4
(lp9519
(dp9520
g7
I114
sg8
g15
sg10
I5
sg11
VLATS2
p9521
sg13
I1
sa(dp9522
g7
I73
sg8
g15
sg10
I5
sg11
VFOXP3
p9523
sg13
I1
sasg19
(lp9524
(dp9525
g7
I52
sg22
VC0544886
p9526
sg10
I17
sg11
Vsomatic mutations
p9527
sg13
I2
sa(dp9528
g7
I149
sg22
VC0600139
p9529
sg10
I15
sg11
Vprostate cancer
p9530
sg13
I2
sasa(dp9531
g2
S'The results suggest that LATS2 may play a role in AR-mediated transcription and contribute to the development of prostate cancer.\n'
p9532
sg4
(lp9533
(dp9534
g7
I25
sg8
g15
sg10
I5
sg11
VLATS2
p9535
sg13
I1
sasg19
(lp9536
(dp9537
g7
I113
sg22
VC0600139
p9538
sg10
I15
sg11
Vprostate cancer
p9539
sg13
I2
sasa(dp9540
g2
S'In conclusion, BM ameliorated tubulointerstitial damage in the Ald- and salt-induced hypertension model through suppression of both ROS production and intrarenal renin-angiotensin system activation.\n'
p9541
sg4
(lp9542
(dp9543
g7
I162
sg8
VP00797
p9544
sg10
I5
sg11
Vrenin
p9545
sg13
I1
sa(dp9546
g7
I168
sg8
VP21549
p9547
sg10
I11
sg11
Vangiotensin
p9548
sg13
I1
sasg19
(lp9549
(dp9550
g7
I63
sg22
VC0162309
p9551
sg10
I3
sg11
VAld
p9552
sg13
I1
sa(dp9553
g7
I112
sg22
VC0221103
p9554
sg10
I11
sg11
Vsuppression
p9555
sg13
I1
sa(dp9556
g7
I85
sg22
VC0020538
p9557
sg10
I12
sg11
Vhypertension
p9558
sg13
I1
sasa(dp9559
g2
S'Migraine and arterial hypertension may share common mechanisms like endothelial dysfunction, deficiency of autonomic cardiovascular regulation and renin angiotensin system involvement.\n'
p9560
sg4
(lp9561
(dp9562
g7
I147
sg8
VP00797
p9563
sg10
I17
sg11
Vrenin angiotensin
p9564
sg13
I2
sasg19
(lp9565
(dp9566
g7
I68
sg22
VC0856169
p9567
sg10
I23
sg11
Vendothelial dysfunction
p9568
sg13
I2
sa(dp9569
g7
I13
sg22
VC0020538
p9570
sg10
I21
sg11
Varterial hypertension
p9571
sg13
I2
sa(dp9572
g7
I0
sg22
VC0149931
p9573
sg10
I8
sg11
VMigraine
p9574
sg13
I1
sasa(dp9575
g2
S'He was tentatively diagnosed as having idiopathic intracranial hypertension, and was later found to have atherosclerotic unilateral renovascular hypertension (RVH) based upon the extremely high plasma renin activity together with the radiological image tests.\n'
p9576
sg4
(lp9577
(dp9578
g7
I201
sg8
VP00797
p9579
sg10
I5
sg11
Vrenin
p9580
sg13
I1
sasg19
(lp9581
(dp9582
g7
I132
sg22
VC0020545
p9583
sg10
I25
sg11
Vrenovascular hypertension
p9584
sg13
I2
sa(dp9585
g7
I159
sg22
VC0162770
p9586
sg10
I3
sg11
VRVH
p9587
sg13
I1
sa(dp9588
g7
I39
sg22
VC0033845
p9589
sg10
I36
sg11
Vidiopathic intracranial hypertension
p9590
sg13
I3
sasa(dp9591
g2
S'Plasma angiotensin I (Ang I), angiotensin II (Ang II), plasma renin activity (PRA), aldosterone (Ald), creatinine, epinephrine, and norepinephrine (NE) were determined before and after treatments.\n'
p9592
sg4
(lp9593
(dp9594
g7
I7
sg8
VP01019
p9595
sg10
I13
sg11
Vangiotensin I
p9596
sg13
I2
sa(dp9597
g7
I46
sg8
VP01019
p9598
sg10
I6
sg11
VAng II
p9599
sg13
I2
sa(dp9600
g7
I55
sg8
VP00797
p9601
sg10
I12
sg11
Vplasma renin
p9602
sg13
I2
sa(dp9603
g7
I30
sg8
VP01019
p9604
sg10
I14
sg11
Vangiotensin II
p9605
sg13
I2
sa(dp9606
g7
I22
sg8
VP01019
p9607
sg10
I5
sg11
VAng I
p9608
sg13
I2
sasg19
(lp9609
(dp9610
g7
I84
sg22
VC0162309
p9611
sg10
I11
sg11
Valdosterone
p9612
sg13
I1
sa(dp9613
g7
I97
sg22
VC0162309
p9614
sg10
I3
sg11
VAld
p9615
sg13
I1
sasa(dp9616
g2
S'To investigate the regulatory effects of activation of the B7-H4 pathway on the function of activated T cells of patients with type 1 diabetes (T1D), we have used our in vitro human experimental system, including human Beta-cell antigen-specific T-cell clones and human Beta-cell lines CM and HP62, as well as primary islet cells.\n'
p9617
sg4
(lp9618
(dp9619
g7
I219
sg8
VP14209
p9620
sg10
I17
sg11
VBeta-cell antigen
p9621
sg13
I2
sasg19
(lp9622
(dp9623
g7
I144
sg22
VC0011854
p9624
sg10
I3
sg11
VT1D
p9625
sg13
I1
sa(dp9626
g7
I127
sg22
VC0011854
p9627
sg10
I15
sg11
Vtype 1 diabetes
p9628
sg13
I3
sasa(dp9629
g2
S'Recently, we demonstrated that the phenotype of impaired negative costimulation, due to reduced levels of V-set domain-containing T cell activation inhibitor 1 (VTCN1) protein on APCs, is shared between diabetes-susceptible NOD mice and human T1D patients.\n'
p9630
sg4
(lp9631
(dp9632
g7
I106
sg8
g15
sg10
I53
sg11
VV-set domain-containing T cell activation inhibitor 1
p9633
sg13
I7
sa(dp9634
g7
I179
sg8
VP02743
p9635
sg10
I4
sg11
VAPCs
p9636
sg13
I1
sa(dp9637
g7
I161
sg8
g15
sg10
I5
sg11
VVTCN1
p9638
sg13
I1
sasg19
(lp9639
(dp9640
g7
I48
sg22
VC0684336
p9641
sg10
I8
sg11
Vimpaired
p9642
sg13
I1
sa(dp9643
g7
I224
sg22
VC0751781
p9644
sg10
I3
sg11
VNOD
p9645
sg13
I1
sa(dp9646
g7
I179
sg22
VC0033036
p9647
sg10
I4
sg11
VAPCs
p9648
sg13
I1
sa(dp9649
g7
I203
sg22
VC0011849
p9650
sg10
I8
sg11
Vdiabetes
p9651
sg13
I1
sasa(dp9652
g2
S'In this study, we show that a similar process takes place in the target organ, as both Alfa and Beta cells within pancreatic islets gradually lose their VTCN1 protein during autoimmune diabetes development despite upregulation of the VTCN1 gene.\n'
p9653
sg4
(lp9654
(dp9655
g7
I234
sg8
g15
sg10
I10
sg11
VVTCN1 gene
p9656
sg13
I2
sa(dp9657
g7
I153
sg8
g15
sg10
I13
sg11
VVTCN1 protein
p9658
sg13
I2
sasg19
(lp9659
(dp9660
g7
I174
sg22
VC0205734
p9661
sg10
I19
sg11
Vautoimmune diabetes
p9662
sg13
I2
sasa(dp9663
g2
S'In this review we outline the protective effect of B7-H4 in the contexts of T1D, islet cell transplantation, and potentially type 2 diabetes.\n'
p9664
sg4
(lp9665
(dp9666
g7
I51
sg8
g15
sg10
I5
sg11
VB7-H4
p9667
sg13
I1
sasg19
(lp9668
(dp9669
g7
I125
sg22
VC0011860
p9670
sg10
I15
sg11
Vtype 2 diabetes
p9671
sg13
I3
sasa(dp9672
g2
S'Current evidence offers encouraging data regarding the role of B7-H4 in reversal of autoimmune diabetes and donor-specific islet allograft tolerance.\n'
p9673
sg4
(lp9674
(dp9675
g7
I63
sg8
g15
sg10
I5
sg11
VB7-H4
p9676
sg13
I1
sasg19
(lp9677
(dp9678
g7
I84
sg22
VC0205734
p9679
sg10
I19
sg11
Vautoimmune diabetes
p9680
sg13
I2
sa(dp9681
g7
I139
sg22
VC0020963
p9682
sg10
I9
sg11
Vtolerance
p9683
sg13
I1
sasa(dp9684
g2
S'Here, we unravel a general deficiency within the VTCN1 pathway that is shared between diabetes-prone mice and a subset of T1D patients.\n'
p9685
sg4
(lp9686
(dp9687
g7
I49
sg8
g15
sg10
I5
sg11
VVTCN1
p9688
sg13
I1
sasg19
(lp9689
(dp9690
g7
I86
sg22
VC0011849
p9691
sg10
I8
sg11
Vdiabetes
p9692
sg13
I1
sasa(dp9693
g2
S'We study here B7-H4 expression and its possible role in diabetes and cancer development.\n'
p9694
sg4
(lp9695
sg19
(lp9696
(dp9697
g7
I69
sg22
VC0006826
p9698
sg10
I6
sg11
Vcancer
p9699
sg13
I1
sa(dp9700
g7
I56
sg22
VC0011849
p9701
sg10
I8
sg11
Vdiabetes
p9702
sg13
I1
sasa(dp9703
g2
S'Formalin-fixed, paraffin-processed pancreas samples from patients with type 1 diabetes (T1D), insulinoma, pancreatic ductal adenocarcinoma (PDAC), and normal organ donors were studied by bright-field and multifluorescence immunohistochemistry to examine B7-H4 expression and its colocalization with islet endocrine hormones.\n'
p9704
sg4
(lp9705
sg19
(lp9706
(dp9707
g7
I106
sg22
VC1335302
p9708
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p9709
sg13
I3
sa(dp9710
g7
I88
sg22
VC0011854
p9711
sg10
I3
sg11
VT1D
p9712
sg13
I1
sa(dp9713
g7
I94
sg22
VC0021670
p9714
sg10
I10
sg11
Vinsulinoma
p9715
sg13
I1
sa(dp9716
g7
I71
sg22
VC0011854
p9717
sg10
I15
sg11
Vtype 1 diabetes
p9718
sg13
I3
sa(dp9719
g7
I140
sg22
VC1335302
p9720
sg10
I4
sg11
VPDAC
p9721
sg13
I1
sasa(dp9722
g2
S'We have previously shown that the administration of B7-H4-immunoglobulin fusion protein (B7-H4.Ig), a newly identified T-cell co-inhibitory signaling molecule, blocks the onset of diabetes in NOD mice.\n'
p9723
sg4
(lp9724
(dp9725
g7
I119
sg8
VP35555
p9726
sg10
I39
sg11
VT-cell co-inhibitory signaling molecule
p9727
sg13
I4
sa(dp9728
g7
I52
sg8
g15
sg10
I5
sg11
VB7-H4
p9729
sg13
I1
sa(dp9730
g7
I58
sg8
VP35637
p9731
sg10
I29
sg11
Vimmunoglobulin fusion protein
p9732
sg13
I3
sasg19
(lp9733
(dp9734
g7
I192
sg22
VC0751781
p9735
sg10
I3
sg11
VNOD
p9736
sg13
I1
sa(dp9737
g7
I180
sg22
VC0011849
p9738
sg10
I8
sg11
Vdiabetes
p9739
sg13
I1
sasa(dp9740
g2
S'Variants originally associated with juvenile idiopathic arthritis (VTCN1 gene), sarcoidosis (ANXA11 gene), primary biliary cirrhosis (IL12RB2 gene) and celiac disease (LPP gene) were not associated with type 1 diabetes in our dataset.\n'
p9741
sg4
(lp9742
(dp9743
g7
I93
sg8
VP50995
p9744
sg10
I11
sg11
VANXA11 gene
p9745
sg13
I2
sa(dp9746
g7
I67
sg8
g15
sg10
I10
sg11
VVTCN1 gene
p9747
sg13
I2
sa(dp9748
g7
I134
sg8
g15
sg10
I12
sg11
VIL12RB2 gene
p9749
sg13
I2
sasg19
(lp9750
(dp9751
g7
I36
sg22
VC0553662
p9752
sg10
I29
sg11
Vjuvenile idiopathic arthritis
p9753
sg13
I3
sa(dp9754
g7
I203
sg22
VC0011854
p9755
sg10
I15
sg11
Vtype 1 diabetes
p9756
sg13
I3
sa(dp9757
g7
I107
sg22
VC0008312
p9758
sg10
I25
sg11
Vprimary biliary cirrhosis
p9759
sg13
I3
sa(dp9760
g7
I152
sg22
VC0007570
p9761
sg10
I14
sg11
Vceliac disease
p9762
sg13
I2
sa(dp9763
g7
I80
sg22
VC0036202
p9764
sg10
I11
sg11
Vsarcoidosis
p9765
sg13
I1
sasa(dp9766
g2
S'Because B7x protein is expressed in some peripheral cells such as pancreatic Beta cells, we used a CD8 T cell-mediated diabetes model (AI4AlfaBeta) in which CD8 T cells recognize an endogenous self-Ag, and found that mice lacking B7x developed more severe diabetes than control AI4AlfaBeta mice.\n'
p9767
sg4
(lp9768
(dp9769
g7
I99
sg8
VP01732
p9770
sg10
I5
sg11
VCD8 T
p9771
sg13
I2
sa(dp9772
g7
I8
sg8
g15
sg10
I3
sg11
VB7x
p9773
sg13
I1
sa(dp9774
g7
I8
sg8
g15
sg10
I11
sg11
VB7x protein
p9775
sg13
I2
sa(dp9776
g7
I99
sg8
VP01732
p9777
sg10
I5
sg11
VCD8 T
p9778
sg13
I2
sasg19
(lp9779
(dp9780
g7
I119
sg22
VC0011849
p9781
sg10
I8
sg11
Vdiabetes
p9782
sg13
I1
sa(dp9783
g7
I119
sg22
VC0011849
p9784
sg10
I8
sg11
Vdiabetes
p9785
sg13
I1
sasa(dp9786
g2
S'Conversely, mice overexpressing B7x in the Beta cells (Rip-B7xAI4AlfaBeta) were diabetes free.\n'
p9787
sg4
(lp9788
(dp9789
g7
I32
sg8
g15
sg10
I3
sg11
VB7x
p9790
sg13
I1
sa(dp9791
g7
I55
sg8
VP52594
p9792
sg10
I18
sg11
VRip-B7xAI4AlfaBeta
p9793
sg13
I1
sasg19
(lp9794
(dp9795
g7
I80
sg22
VC0011849
p9796
sg10
I8
sg11
Vdiabetes
p9797
sg13
I1
sasa(dp9798
g2
S'Furthermore, adoptive transfer of effector AI4AlfaBeta CD8 T cells induced diabetes in control mice, but not in Rip-B7xAI4AlfaBeta mice.\n'
p9799
sg4
(lp9800
(dp9801
g7
I55
sg8
VP01732
p9802
sg10
I5
sg11
VCD8 T
p9803
sg13
I2
sa(dp9804
g7
I112
sg8
VP52594
p9805
sg10
I18
sg11
VRip-B7xAI4AlfaBeta
p9806
sg13
I1
sasg19
(lp9807
(dp9808
g7
I75
sg22
VC0011849
p9809
sg10
I8
sg11
Vdiabetes
p9810
sg13
I1
sasa(dp9811
g2
S'These results suggest that B7x in nonlymphoid organs prevents peripheral autoimmunity partially through inhibiting proliferation of tissue-specific CD8 T cells, and that local overexpression of B7x on pancreatic Beta cells is sufficient to abolish CD8 T cell-induced diabetes.\n'
p9812
sg4
(lp9813
(dp9814
g7
I148
sg8
VP01732
p9815
sg10
I5
sg11
VCD8 T
p9816
sg13
I2
sa(dp9817
g7
I27
sg8
g15
sg10
I3
sg11
VB7x
p9818
sg13
I1
sa(dp9819
g7
I148
sg8
VP01732
p9820
sg10
I5
sg11
VCD8 T
p9821
sg13
I2
sa(dp9822
g7
I27
sg8
g15
sg10
I3
sg11
VB7x
p9823
sg13
I1
sasg19
(lp9824
(dp9825
g7
I73
sg22
VC0004368
p9826
sg10
I12
sg11
Vautoimmunity
p9827
sg13
I1
sa(dp9828
g7
I267
sg22
VC0011849
p9829
sg10
I8
sg11
Vdiabetes
p9830
sg13
I1
sa(dp9831
g7
I115
sg22
VC0334094
p9832
sg10
I13
sg11
Vproliferation
p9833
sg13
I1
sasa(dp9834
g2
S"In Alzheimer's disease, the expression of SCGN in the hippocampus can boycott neurodegeneration.\n"
p9835
sg4
(lp9836
(dp9837
g7
I42
sg8
g15
sg10
I4
sg11
VSCGN
p9838
sg13
I1
sasg19
(lp9839
(dp9840
g7
I78
sg22
VC0027746
p9841
sg10
I17
sg11
Vneurodegeneration
p9842
sg13
I1
sa(dp9843
g7
I3
sg22
VC1521724
p9844
sg10
I19
sg11
VAlzheimer's disease
p9845
sg13
I2
sasa(dp9846
g2
S"In this article, we review the recent research progress of secretagogin, focus on its distribution and functions in various tumorous diseases and non-tumorous diseases, such as Alzheimer's disease.\n"
p9847
sg4
(lp9848
(dp9849
g7
I59
sg8
g15
sg10
I12
sg11
Vsecretagogin
p9850
sg13
I1
sasg19
(lp9851
(dp9852
g7
I177
sg22
VC1521724
p9853
sg10
I19
sg11
VAlzheimer's disease
p9854
sg13
I2
sasa(dp9855
g2
S"Secretagogin has been hypothesized to exert a neuroprotective role in neurodegenerative diseases like Alzheimer's disease.\n"
p9856
sg4
(lp9857
(dp9858
g7
I0
sg8
g15
sg10
I12
sg11
VSecretagogin
p9859
sg13
I1
sasg19
(lp9860
(dp9861
g7
I70
sg22
VC0524851
p9862
sg10
I26
sg11
Vneurodegenerative diseases
p9863
sg13
I2
sa(dp9864
g7
I102
sg22
VC1521724
p9865
sg10
I19
sg11
VAlzheimer's disease
p9866
sg13
I2
sasa(dp9867
g2
S"Indeed, the density, but not the morphological or neurochemical integrity, of secretagogin-positive neurons selectively decreases in the olfactory tract in Alzheimer's disease.\n"
p9868
sg4
(lp9869
(dp9870
g7
I78
sg8
g15
sg10
I12
sg11
Vsecretagogin
p9871
sg13
I1
sasg19
(lp9872
(dp9873
g7
I156
sg22
VC1521724
p9874
sg10
I19
sg11
VAlzheimer's disease
p9875
sg13
I2
sasa(dp9876
g2
S'Our findings demonstrated for the first time the association of TAU and the calcium-binding protein SCGN and support earlier results implicating that beta-cells might represent an extra cerebral site of tauopathy.\n'
p9877
sg4
(lp9878
sg19
(lp9879
(dp9880
g7
I203
sg22
VC0949664
p9881
sg10
I9
sg11
Vtauopathy
p9882
sg13
I1
sasa(dp9883
g2
S'The aim of our study was to characterize the association of clinicopathological variables and the SLC19A1/RFC-1 G80A polymorphism in methotrexate (MTX)-related toxicity in Portuguese patients with rheumatoid arthritis.\n'
p9884
sg4
(lp9885
(dp9886
g7
I98
sg8
VP41440
p9887
sg10
I7
sg11
VSLC19A1
p9888
sg13
I1
sa(dp9889
g7
I106
sg8
VP41440
p9890
sg10
I5
sg11
VRFC-1
p9891
sg13
I1
sasg19
(lp9892
(dp9893
g7
I197
sg22
VC0003873
p9894
sg10
I20
sg11
Vrheumatoid arthritis
p9895
sg13
I2
sasa(dp9896
g2
S'The current study was conducted to elucidate the effect of genetic variations in one-carbon metabolism on the epigenetic regulation of major histocompatibility complex II transactivator (MHC2TA), reduced folate carrier 1 (RFC1/SLC19A1) and human leukocyte antigen (HLA)-DR in systemic lupus erythematosus (SLE).\n'
p9897
sg4
(lp9898
(dp9899
g7
I222
sg8
VP41440
p9900
sg10
I4
sg11
VRFC1
p9901
sg13
I1
sa(dp9902
g7
I240
sg8
VP05534
p9903
sg10
I23
sg11
Vhuman leukocyte antigen
p9904
sg13
I3
sa(dp9905
g7
I187
sg8
VP33076
p9906
sg10
I6
sg11
VMHC2TA
p9907
sg13
I1
sa(dp9908
g7
I227
sg8
VP41440
p9909
sg10
I7
sg11
VSLC19A1
p9910
sg13
I1
sa(dp9911
g7
I135
sg8
VP18464
p9912
sg10
I50
sg11
Vmajor histocompatibility complex II transactivator
p9913
sg13
I5
sa(dp9914
g7
I196
sg8
VP41440
p9915
sg10
I24
sg11
Vreduced folate carrier 1
p9916
sg13
I4
sa(dp9917
g7
I265
sg8
VP30486
p9918
sg10
I3
sg11
VHLA
p9919
sg13
I1
sasg19
(lp9920
(dp9921
g7
I306
sg22
VC0024141
p9922
sg10
I3
sg11
VSLE
p9923
sg13
I1
sa(dp9924
g7
I276
sg22
VC0024141
p9925
sg10
I28
sg11
Vsystemic lupus erythematosus
p9926
sg13
I3
sasa(dp9927
g2
S'The majority of familial ALS (FALS) cases follow an autosomal dominant inheritance pattern, and include the following mutations: ALS1, Cu/Zn superoxide dismutase (SOD1); ALS3; ALS4, senataxin; ALS6, fused in sarcoma (FUS); ALS7; ALS8, vesicle-associated membrane protein; ALS9, angiogenin; ALS10, TAR DNA-binding protein (TARDBP); and ALS11/FIG4.\n'
p9928
sg4
(lp9929
(dp9930
g7
I229
sg8
g15
sg10
I4
sg11
VALS8
p9931
sg13
I1
sa(dp9932
g7
I322
sg8
g15
sg10
I6
sg11
VTARDBP
p9933
sg13
I1
sa(dp9934
g7
I272
sg8
VP03950
p9935
sg10
I4
sg11
VALS9
p9936
sg13
I1
sa(dp9937
g7
I335
sg8
g15
sg10
I5
sg11
VALS11
p9938
sg13
I1
sa(dp9939
g7
I193
sg8
VP35637
p9940
sg10
I4
sg11
VALS6
p9941
sg13
I1
sa(dp9942
g7
I163
sg8
VP00441
p9943
sg10
I4
sg11
VSOD1
p9944
sg13
I1
sa(dp9945
g7
I129
sg8
VP00441
p9946
sg10
I4
sg11
VALS1
p9947
sg13
I1
sa(dp9948
g7
I341
sg8
g15
sg10
I4
sg11
VFIG4
p9949
sg13
I1
sa(dp9950
g7
I290
sg8
g15
sg10
I5
sg11
VALS10
p9951
sg13
I1
sa(dp9952
g7
I278
sg8
VP03950
p9953
sg10
I10
sg11
Vangiogenin
p9954
sg13
I1
sa(dp9955
g7
I135
sg8
VP00441
p9956
sg10
I26
sg11
VCu/Zn superoxide dismutase
p9957
sg13
I3
sa(dp9958
g7
I297
sg8
g15
sg10
I23
sg11
VTAR DNA-binding protein
p9959
sg13
I3
sasg19
(lp9960
(dp9961
g7
I208
sg22
VC1261473
p9962
sg10
I7
sg11
Vsarcoma
p9963
sg13
I1
sa(dp9964
g7
I16
sg22
VC1862939
p9965
sg10
I12
sg11
Vfamilial ALS
p9966
sg13
I2
sa(dp9967
g7
I30
sg22
VC1862939
p9968
sg10
I4
sg11
VFALS
p9969
sg13
I1
sa(dp9970
g7
I170
sg22
VC1847735
p9971
sg10
I4
sg11
VALS3
p9972
sg13
I1
sa(dp9973
g7
I223
sg22
VC1842674
p9974
sg10
I4
sg11
VALS7
p9975
sg13
I1
sa(dp9976
g7
I193
sg22
VC1842675
p9977
sg10
I4
sg11
VALS6
p9978
sg13
I1
sa(dp9979
g7
I129
sg22
VC1862939
p9980
sg10
I4
sg11
VALS1
p9981
sg13
I1
sa(dp9982
g7
I229
sg22
VC1837728
p9983
sg10
I4
sg11
VALS8
p9984
sg13
I1
sa(dp9985
g7
I176
sg22
VC1865409
p9986
sg10
I4
sg11
VALS4
p9987
sg13
I1
sa(dp9988
g7
I272
sg22
VC2678468
p9989
sg10
I4
sg11
VALS9
p9990
sg13
I1
sa(dp9991
g7
I297
sg22
VC0175703
p9992
sg10
I3
sg11
VTAR
p9993
sg13
I1
sa(dp9994
g7
I235
sg22
VC0333262
p9995
sg10
I7
sg11
Vvesicle
p9996
sg13
I1
sa(dp9997
g7
I335
sg22
VC2675491
p9998
sg10
I5
sg11
VALS11
p9999
sg13
I1
sa(dp10000
g7
I290
sg22
VC2677565
p10001
sg10
I5
sg11
VALS10
p10002
sg13
I1
sasa(dp10003
g2
S'To clarify the role of cell adhesion molecules in cutaneous sarcoidosis, we induced sarcoid-like granulomatosis in mice deficient of intercellular adhesion molecule (ICAM)-1, L-selectin, P-selectin, or E-selectin via repeated P. acnes injection.\n'
p10004
sg4
(lp10005
(dp10006
g7
I187
sg8
VP16109
p10007
sg10
I10
sg11
VP-selectin
p10008
sg13
I1
sa(dp10009
g7
I202
sg8
VP16581
p10010
sg10
I10
sg11
VE-selectin
p10011
sg13
I1
sa(dp10012
g7
I133
sg8
VP01185
p10013
sg10
I40
sg11
Vintercellular adhesion molecule (ICAM)-1
p10014
sg13
I4
sa(dp10015
g7
I175
sg8
VP14151
p10016
sg10
I10
sg11
VL-selectin
p10017
sg13
I1
sasg19
(lp10018
(dp10019
g7
I28
sg22
VC0001511
p10020
sg10
I8
sg11
Vadhesion
p10021
sg13
I1
sa(dp10022
g7
I60
sg22
VC0036202
p10023
sg10
I7
sg11
Vsarcoid
p10024
sg13
I1
sa(dp10025
g7
I97
sg22
VC0521173
p10026
sg10
I14
sg11
Vgranulomatosis
p10027
sg13
I1
sa(dp10028
g7
I28
sg22
VC0001511
p10029
sg10
I8
sg11
Vadhesion
p10030
sg13
I1
sa(dp10031
g7
I50
sg22
VC0036203
p10032
sg10
I21
sg11
Vcutaneous sarcoidosis
p10033
sg13
I2
sasa(dp10034
g2
S'In this study, we evaluated the role of L-selectin in T lymphocyte alveolitis in patients with active pulmonary sarcoidosis.\n'
p10035
sg4
(lp10036
(dp10037
g7
I40
sg8
VP14151
p10038
sg10
I10
sg11
VL-selectin
p10039
sg13
I1
sasg19
(lp10040
(dp10041
g7
I67
sg22
VC0549493
p10042
sg10
I10
sg11
Valveolitis
p10043
sg13
I1
sa(dp10044
g7
I102
sg22
VC0036205
p10045
sg10
I21
sg11
Vpulmonary sarcoidosis
p10046
sg13
I2
sasa(dp10047
g2
S'Serum and BALF concentrations of sL-selectin were significantly elevated in patients with sarcoidosis compared with control healthy subjects and idiopathic pulmonary fibrosis (IPF) patients (P &lt; 0.05 and P &lt; 0.\n'
p10048
sg4
(lp10049
sg19
(lp10050
(dp10051
g7
I90
sg22
VC0036202
p10052
sg10
I11
sg11
Vsarcoidosis
p10053
sg13
I1
sa(dp10054
g7
I176
sg22
VC3161101
p10055
sg10
I3
sg11
VIPF
p10056
sg13
I1
sa(dp10057
g7
I145
sg22
VC3161101
p10058
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p10059
sg13
I3
sasa(dp10060
g2
S'The percentage of CD3+CD62L+ cells (L-selectin-bearing T lymphocytes) was significantly lower in peripheral blood of sarcoidosis than in that of healthy subjects (P &lt; 0.01).\n'
p10061
sg4
(lp10062
(dp10063
g7
I36
sg8
VP14151
p10064
sg10
I10
sg11
VL-selectin
p10065
sg13
I1
sasg19
(lp10066
(dp10067
g7
I117
sg22
VC0036202
p10068
sg10
I11
sg11
Vsarcoidosis
p10069
sg13
I1
sasa(dp10070
g2
S'In contrast, the percentage of CD3+CD62L- cells (L-selectin-negative T lymphocytes) in BALF of patients with sarcoidosis was significantly higher than in healthy subjects (P &lt; 0.05) and IPF patients (P &lt; 0.01).\n'
p10071
sg4
(lp10072
(dp10073
g7
I49
sg8
VP14151
p10074
sg10
I10
sg11
VL-selectin
p10075
sg13
I1
sasg19
(lp10076
(dp10077
g7
I109
sg22
VC0036202
p10078
sg10
I11
sg11
Vsarcoidosis
p10079
sg13
I1
sasa(dp10080
g2
S'Our results suggest that L-selectin may be involved in T lymphocyte alveolitis in patients with active pulmonary sarcoidosis.\n'
p10081
sg4
(lp10082
(dp10083
g7
I25
sg8
VP14151
p10084
sg10
I10
sg11
VL-selectin
p10085
sg13
I1
sasg19
(lp10086
(dp10087
g7
I68
sg22
VC0549493
p10088
sg10
I10
sg11
Valveolitis
p10089
sg13
I1
sa(dp10090
g7
I103
sg22
VC0036205
p10091
sg10
I21
sg11
Vpulmonary sarcoidosis
p10092
sg13
I2
sasa(dp10093
g2
S'In a cross-sectional study in patients with active and inactive sarcoidosis and in healthy volunteers, we examined, in serum and in BAL fluid, the soluble adhesion molecules, VCAM-1, ICAM-1, and P-, E- and L-selectin.\n'
p10094
sg4
(lp10095
(dp10096
g7
I183
sg8
VP05362
p10097
sg10
I6
sg11
VICAM-1
p10098
sg13
I1
sa(dp10099
g7
I175
sg8
VP19320
p10100
sg10
I6
sg11
VVCAM-1
p10101
sg13
I1
sa(dp10102
g7
I147
sg8
VP35558
p10103
sg10
I26
sg11
Vsoluble adhesion molecules
p10104
sg13
I3
sa(dp10105
g7
I195
sg8
VP14151
p10106
sg10
I21
sg11
VP-, E- and L-selectin
p10107
sg13
I4
sasg19
(lp10108
(dp10109
g7
I155
sg22
VC0001511
p10110
sg10
I8
sg11
Vadhesion
p10111
sg13
I1
sa(dp10112
g7
I64
sg22
VC0036202
p10113
sg10
I11
sg11
Vsarcoidosis
p10114
sg13
I1
sasa(dp10115
g2
S'A significant correlation was observed between serum soluble L-selectin levels and the number of lymphocytes in the bronchoalveolar lavage fluid of patients with sarcoidosis.\n'
p10116
sg4
(lp10117
(dp10118
g7
I61
sg8
VP14151
p10119
sg10
I10
sg11
VL-selectin
p10120
sg13
I1
sasg19
(lp10121
(dp10122
g7
I162
sg22
VC0036202
p10123
sg10
I11
sg11
Vsarcoidosis
p10124
sg13
I1
sasa(dp10125
g2
S'Endogenous ligands for tumor antigen may outperform single-chain variable fragments to serve as a component of CARs with high cancer recognition efficacy and minimized immunogenicity.\n'
p10126
sg4
(lp10127
(dp10128
g7
I111
sg8
VP49589
p10129
sg10
I4
sg11
VCARs
p10130
sg13
I1
sasg19
(lp10131
(dp10132
g7
I23
sg22
VC0027651
p10133
sg10
I5
sg11
Vtumor
p10134
sg13
I1
sa(dp10135
g7
I126
sg22
VC0006826
p10136
sg10
I6
sg11
Vcancer
p10137
sg13
I1
sasa(dp10138
g2
S'CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.\n'
p10139
sg4
(lp10140
(dp10141
g7
I15
sg8
VP15391
p10142
sg10
I4
sg11
VCD19
p10143
sg13
I1
sa(dp10144
g7
I0
sg8
VP49589
p10145
sg10
I4
sg11
VCARs
p10146
sg13
I1
sasg19
(lp10147
(dp10148
g7
I73
sg22
VC0024299
p10149
sg10
I9
sg11
Vlymphomas
p10150
sg13
I1
sa(dp10151
g7
I244
sg22
VC0024305
p10152
sg10
I20
sg11
Vnon-Hodgkin lymphoma
p10153
sg13
I2
sa(dp10154
g7
I59
sg22
VC0023418
p10155
sg10
I9
sg11
Vleukemias
p10156
sg13
I1
sa(dp10157
g7
I152
sg22
VC0277556
p10158
sg10
I16
sg11
Vrelapsed disease
p10159
sg13
I2
sa(dp10160
g7
I218
sg22
VC0023448
p10161
sg10
I20
sg11
Vlymphocytic leukemia
p10162
sg13
I2
sa(dp10163
g7
I186
sg22
VC0023434
p10164
sg10
I31
sg11
Vlymphoblastic leukemia, chronic
p10165
sg13
I3
sa(dp10166
g7
I102
sg22
VC0687702
p10167
sg10
I9
sg11
Vremission
p10168
sg13
I1
sasa(dp10169
g2
S'Congenital malformations of the central nervous system are related to alterations in neural tube formation, including most of the neurosurgical management entities, dysraphism and craniosynostosis; alterations of neuronal proliferation; megalencefaly and microcephaly; abnormal neuronal migration, lissencephaly, pachygyria, schizencephaly, agenesis of the corpus callosum, heterotopia and cortical dysplasia, spinal malformations and spinal dysraphism.\n'
p10170
sg4
(lp10171
sg19
(lp10172
(dp10173
g7
I298
sg22
VC0266463
p10174
sg10
I13
sg11
Vlissencephaly
p10175
sg13
I1
sa(dp10176
g7
I180
sg22
VC0010278
p10177
sg10
I16
sg11
Vcraniosynostosis
p10178
sg13
I1
sa(dp10179
g7
I341
sg22
VC0175754
p10180
sg10
I31
sg11
Vagenesis of the corpus callosum
p10181
sg13
I5
sa(dp10182
g7
I255
sg22
VC0025958
p10183
sg10
I12
sg11
Vmicrocephaly
p10184
sg13
I1
sa(dp10185
g7
I325
sg22
VC0266484
p10186
sg10
I14
sg11
Vschizencephaly
p10187
sg13
I1
sa(dp10188
g7
I11
sg22
VC0000768
p10189
sg10
I13
sg11
Vmalformations
p10190
sg13
I1
sa(dp10191
g7
I165
sg22
VC0332915
p10192
sg10
I10
sg11
Vdysraphism
p10193
sg13
I1
sa(dp10194
g7
I40
sg22
VC0027769
p10195
sg10
I7
sg11
Vnervous
p10196
sg13
I1
sa(dp10197
g7
I374
sg22
VC0008519
p10198
sg10
I11
sg11
Vheterotopia
p10199
sg13
I1
sa(dp10200
g7
I0
sg22
VC0000768
p10201
sg10
I24
sg11
VCongenital malformations
p10202
sg13
I2
sa(dp10203
g7
I390
sg22
VC0431380
p10204
sg10
I18
sg11
Vcortical dysplasia
p10205
sg13
I2
sa(dp10206
g7
I435
sg22
VC0080178
p10207
sg10
I17
sg11
Vspinal dysraphism
p10208
sg13
I2
sa(dp10209
g7
I313
sg22
VC0266483
p10210
sg10
I10
sg11
Vpachygyria
p10211
sg13
I1
sa(dp10212
g7
I222
sg22
VC0334094
p10213
sg10
I13
sg11
Vproliferation
p10214
sg13
I1
sasa(dp10215
g2
S'Compound mutants carrying mutations in both, the Reelin pathway and Lis1 exhibit hydrocephalus, a phenotype that is suppressed by mutations in the gene encoding the Alpha2 subunit of Pafah1b.\n'
p10216
sg4
(lp10217
(dp10218
g7
I68
sg8
VP43034
p10219
sg10
I4
sg11
VLis1
p10220
sg13
I1
sa(dp10221
g7
I49
sg8
VP78509
p10222
sg10
I6
sg11
VReelin
p10223
sg13
I1
sasg19
(lp10224
(dp10225
g7
I68
sg22
VC1843916
p10226
sg10
I4
sg11
VLis1
p10227
sg13
I1
sa(dp10228
g7
I81
sg22
VC0020255
p10229
sg10
I13
sg11
Vhydrocephalus
p10230
sg13
I1
sasa(dp10231
g2
S'We previously demonstrated that compound mutations of Pafah1b1 with genes in Reelin pathway result in layering defects and the appearance of hydrocephalus in double mutant mice.\n'
p10232
sg4
(lp10233
(dp10234
g7
I54
sg8
VP43034
p10235
sg10
I8
sg11
VPafah1b1
p10236
sg13
I1
sa(dp10237
g7
I77
sg8
VP78509
p10238
sg10
I6
sg11
VReelin
p10239
sg13
I1
sasg19
(lp10240
(dp10241
g7
I141
sg22
VC0020255
p10242
sg10
I13
sg11
Vhydrocephalus
p10243
sg13
I1
sa(dp10244
g7
I165
sg22
VC0596988
p10245
sg10
I6
sg11
Vmutant
p10246
sg13
I1
sasa(dp10247
g2
S'On an inbred genetic background, 20% of Lis1+/- mice develop hydrocephalus and die prematurely.\n'
p10248
sg4
(lp10249
sg19
(lp10250
(dp10251
g7
I61
sg22
VC0020255
p10252
sg10
I13
sg11
Vhydrocephalus
p10253
sg13
I1
sasa(dp10254
g2
S'However, the presence of the APC mutation increases the migration deficit and the incidence of hydrocephalus in Lis1+/- animals.\n'
p10255
sg4
(lp10256
(dp10257
g7
I29
sg8
VP25054
p10258
sg10
I12
sg11
VAPC mutation
p10259
sg13
I2
sasg19
(lp10260
(dp10261
g7
I95
sg22
VC0020255
p10262
sg10
I13
sg11
Vhydrocephalus
p10263
sg13
I1
sa(dp10264
g7
I29
sg22
VC0033036
p10265
sg10
I3
sg11
VAPC
p10266
sg13
I1
sa(dp10267
g7
I66
sg22
VC0162429
p10268
sg10
I7
sg11
Vdeficit
p10269
sg13
I1
sasa(dp10270
g2
S'Compound mutant mice with disruptions in the Reln pathway and heterozygous Pafah1b1 mutations had a higher incidence of hydrocephalus and enhanced cortical and hippocampal layering defects.\n'
p10271
sg4
(lp10272
(dp10273
g7
I45
sg8
VP78509
p10274
sg10
I4
sg11
VReln
p10275
sg13
I1
sa(dp10276
g7
I75
sg8
VP43034
p10277
sg10
I18
sg11
VPafah1b1 mutations
p10278
sg13
I2
sasg19
(lp10279
(dp10280
g7
I9
sg22
VC0596988
p10281
sg10
I6
sg11
Vmutant
p10282
sg13
I1
sa(dp10283
g7
I120
sg22
VC0020255
p10284
sg10
I13
sg11
Vhydrocephalus
p10285
sg13
I1
sasa(dp10286
g2
S'For example, holoprosencephaly is associated with HPE genes, hydrocephalus with L1-CAM and lissencephaly with LIS-1.\n'
p10287
sg4
(lp10288
(dp10289
g7
I80
sg8
VP01768
p10290
sg10
I6
sg11
VL1-CAM
p10291
sg13
I1
sasg19
(lp10292
(dp10293
g7
I61
sg22
VC0020255
p10294
sg10
I13
sg11
Vhydrocephalus
p10295
sg13
I1
sa(dp10296
g7
I13
sg22
VC0079541
p10297
sg10
I17
sg11
Vholoprosencephaly
p10298
sg13
I1
sa(dp10299
g7
I91
sg22
VC0266463
p10300
sg10
I13
sg11
Vlissencephaly
p10301
sg13
I1
sa(dp10302
g7
I83
sg22
VC1861821
p10303
sg10
I3
sg11
VCAM
p10304
sg13
I1
sasa(dp10305
g2
S'A genetic association study was then conducted on 146 multiplex families of the Collaborative study on Genetics of Alcoholism, in which seven single nucleotide polymorphisms located in the NTNG1 gene were genotyped.\n'
p10306
sg4
(lp10307
(dp10308
g7
I189
sg8
g15
sg10
I10
sg11
VNTNG1 gene
p10309
sg13
I2
sasg19
(lp10310
(dp10311
g7
I115
sg22
VC0001973
p10312
sg10
I10
sg11
VAlcoholism
p10313
sg13
I1
sasa(dp10314
g2
S'Smith-Lemli-Opitz syndrome is a recessive disorder caused by mutations in 7-dehydrocholesterol reductase (DHCR)7 with a heterozygous (HET) carrier frequency of 1-3%.\n'
p10315
sg4
(lp10316
(dp10317
g7
I134
sg8
g15
sg10
I3
sg11
VHET
p10318
sg13
I1
sa(dp10319
g7
I120
sg8
g15
sg10
I12
sg11
Vheterozygous
p10320
sg13
I1
sa(dp10321
g7
I106
sg8
g15
sg10
I4
sg11
VDHCR
p10322
sg13
I1
sa(dp10323
g7
I74
sg8
g15
sg10
I30
sg11
V7-dehydrocholesterol reductase
p10324
sg13
I2
sasg19
(lp10325
(dp10326
g7
I0
sg22
VC0175694
p10327
sg10
I26
sg11
VSmith-Lemli-Opitz syndrome
p10328
sg13
I2
sasa(dp10329
g2
S'Loss-of-function mutations in the enzyme 7-dehydrocholesterol reductase are responsible for the Smith-Lemli-Opitz syndrome, in which 7-dehydrocholesterol (7-DHC) levels are markedly increased in the plasma and tissues of patients.\n'
p10330
sg4
(lp10331
(dp10332
g7
I34
sg8
g15
sg10
I37
sg11
Venzyme 7-dehydrocholesterol reductase
p10333
sg13
I3
sasg19
(lp10334
(dp10335
g7
I96
sg22
VC0175694
p10336
sg10
I26
sg11
VSmith-Lemli-Opitz syndrome
p10337
sg13
I2
sasa(dp10338
g2
S'Smith-Lemli-Opitz syndrome is an autosomal recessive disease caused by mutations in 7-dehydrocholesterol reductase (DHCR7), which is rarely observed in Japan.\n'
p10339
sg4
(lp10340
(dp10341
g7
I84
sg8
g15
sg10
I30
sg11
V7-dehydrocholesterol reductase
p10342
sg13
I2
sa(dp10343
g7
I116
sg8
g15
sg10
I5
sg11
VDHCR7
p10344
sg13
I1
sasg19
(lp10345
(dp10346
g7
I0
sg22
VC0175694
p10347
sg10
I26
sg11
VSmith-Lemli-Opitz syndrome
p10348
sg13
I2
sasa(dp10349
g2
S'In Dhcr7-deficient Neuro2a cells or fibroblasts from SLOS patients, the biosynthetic transformation was interrupted at the penultimate step and alkynyl-7-DHC (a-7-DHC) was the major product formed.\n'
p10350
sg4
(lp10351
(dp10352
g7
I3
sg8
g15
sg10
I5
sg11
VDhcr7
p10353
sg13
I1
sasg19
(lp10354
(dp10355
g7
I85
sg22
VC1510411
p10356
sg10
I14
sg11
Vtransformation
p10357
sg13
I1
sa(dp10358
g7
I53
sg22
VC0175694
p10359
sg10
I4
sg11
VSLOS
p10360
sg13
I1
sasa(dp10361
g2
S'Smith-Lemli-Opitz syndrome is an inherited monogenic disorder in which mutations to the 7-dehydrocholesterol (7-DHC) reductase (Dhcr7) gene lead to deficits in cholesterol synthesis.\n'
p10362
sg4
(lp10363
(dp10364
g7
I88
sg8
g15
sg10
I38
sg11
V7-dehydrocholesterol (7-DHC) reductase
p10365
sg13
I3
sa(dp10366
g7
I128
sg8
g15
sg10
I5
sg11
VDhcr7
p10367
sg13
I1
sasg19
(lp10368
(dp10369
g7
I0
sg22
VC0175694
p10370
sg10
I26
sg11
VSmith-Lemli-Opitz syndrome
p10371
sg13
I2
sasa(dp10372
g2
S'The purpose of this study was to identify a potential abnormal behavioral phenotype in a compound mutant mouse model for Smith-Lemli-Opitz disease (Dhcr7 Delta3-5/T93M ) to further validate the model and to provide potential targets for future therapeutic interventions.\n'
p10373
sg4
(lp10374
(dp10375
g7
I154
sg8
g15
sg10
I13
sg11
VDelta3-5/T93M
p10376
sg13
I1
sa(dp10377
g7
I148
sg8
g15
sg10
I5
sg11
VDhcr7
p10378
sg13
I1
sasg19
(lp10379
(dp10380
g7
I98
sg22
VC0596988
p10381
sg10
I6
sg11
Vmutant
p10382
sg13
I1
sasa(dp10383
g2
S'Homozygous or compound heterozygous mutations in DHCR7 lead to the developmental disease Smith-Lemli-Opitz syndrome, which can also result in fetal mortality, highlighting the importance of this enzyme in human development and survival.\n'
p10384
sg4
(lp10385
(dp10386
g7
I49
sg8
g15
sg10
I5
sg11
VDHCR7
p10387
sg13
I1
sasg19
(lp10388
(dp10389
g7
I89
sg22
VC0175694
p10390
sg10
I26
sg11
VSmith-Lemli-Opitz syndrome
p10391
sg13
I2
sasa(dp10392
g2
S'Smith-Lemli-Opitz Syndrome (SLOS) is a rare hereditary autosomal recessive disorder with broken cholesterol synthesis causing by 7-dehydrocholesterol reductase deficiency.\n'
p10393
sg4
(lp10394
(dp10395
g7
I129
sg8
g15
sg10
I30
sg11
V7-dehydrocholesterol reductase
p10396
sg13
I2
sasg19
(lp10397
(dp10398
g7
I28
sg22
VC0175694
p10399
sg10
I4
sg11
VSLOS
p10400
sg13
I1
sa(dp10401
g7
I129
sg22
VC0175694
p10402
sg10
I41
sg11
V7-dehydrocholesterol reductase deficiency
p10403
sg13
I3
sa(dp10404
g7
I0
sg22
VC0175694
p10405
sg10
I26
sg11
VSmith-Lemli-Opitz Syndrome
p10406
sg13
I2
sasa(dp10407
g2
S'Largely, DHCR7 research is associated with the developmental disease Smith-Lemli-Opitz syndrome, which is caused by mutations in the DHCR7 gene.\n'
p10408
sg4
(lp10409
(dp10410
g7
I9
sg8
g15
sg10
I5
sg11
VDHCR7
p10411
sg13
I1
sa(dp10412
g7
I133
sg8
g15
sg10
I10
sg11
VDHCR7 gene
p10413
sg13
I2
sasg19
(lp10414
(dp10415
g7
I69
sg22
VC0175694
p10416
sg10
I26
sg11
VSmith-Lemli-Opitz syndrome
p10417
sg13
I2
sasa(dp10418
g2
S'In addition, an upregulation of E-selectin, ICAM-1 and VCAM-1 is also detected in liver biopsies obtained from patients with alcoholic hepatitis and cirrhosis.\n'
p10419
sg4
(lp10420
(dp10421
g7
I55
sg8
VP19320
p10422
sg10
I6
sg11
VVCAM-1
p10423
sg13
I1
sa(dp10424
g7
I44
sg8
VP05362
p10425
sg10
I6
sg11
VICAM-1
p10426
sg13
I1
sa(dp10427
g7
I32
sg8
VP16581
p10428
sg10
I10
sg11
VE-selectin
p10429
sg13
I1
sasg19
(lp10430
(dp10431
g7
I125
sg22
VC0019187
p10432
sg10
I19
sg11
Valcoholic hepatitis
p10433
sg13
I2
sa(dp10434
g7
I149
sg22
VC0023890
p10435
sg10
I9
sg11
Vcirrhosis
p10436
sg13
I1
sasa(dp10437
g2
S'In alcoholic hepatitis (AH), enhanced expression of intercellular adhesion molecule-1 (ICAM-1) correlates to neutrophil infiltration and histology.\n'
p10438
sg4
(lp10439
(dp10440
g7
I87
sg8
VP05362
p10441
sg10
I6
sg11
VICAM-1
p10442
sg13
I1
sa(dp10443
g7
I52
sg8
VP05362
p10444
sg10
I33
sg11
Vintercellular adhesion molecule-1
p10445
sg13
I3
sasg19
(lp10446
(dp10447
g7
I120
sg22
VC0332448
p10448
sg10
I12
sg11
Vinfiltration
p10449
sg13
I1
sa(dp10450
g7
I3
sg22
VC0019187
p10451
sg10
I19
sg11
Valcoholic hepatitis
p10452
sg13
I2
sa(dp10453
g7
I66
sg22
VC0001511
p10454
sg10
I8
sg11
Vadhesion
p10455
sg13
I1
sa(dp10456
g7
I24
sg22
VC0019187
p10457
sg10
I2
sg11
VAH
p10458
sg13
I1
sasa(dp10459
g2
S'The aim of this study was to clarify the role of soluble intercellular adhesion molecule-1 (sICAM-1) and interleukin-8 (IL-8) in the development of severe alcoholic hepatitis.\n'
p10460
sg4
(lp10461
(dp10462
g7
I57
sg8
VP05362
p10463
sg10
I33
sg11
Vintercellular adhesion molecule-1
p10464
sg13
I3
sa(dp10465
g7
I105
sg8
VP60568
p10466
sg10
I13
sg11
Vinterleukin-8
p10467
sg13
I1
sa(dp10468
g7
I120
sg8
VP60568
p10469
sg10
I4
sg11
VIL-8
p10470
sg13
I1
sasg19
(lp10471
(dp10472
g7
I155
sg22
VC0019187
p10473
sg10
I19
sg11
Valcoholic hepatitis
p10474
sg13
I2
sa(dp10475
g7
I71
sg22
VC0001511
p10476
sg10
I8
sg11
Vadhesion
p10477
sg13
I1
sasa(dp10478
g2
S'The overexpression of intercellular adhesion molecule-1 (ICAM-1) has been shown to be involved in the pathogenesis of various necroinflammatory diseases, including alcoholic hepatitis.\n'
p10479
sg4
(lp10480
(dp10481
g7
I57
sg8
VP05362
p10482
sg10
I6
sg11
VICAM-1
p10483
sg13
I1
sa(dp10484
g7
I22
sg8
VP05362
p10485
sg10
I33
sg11
Vintercellular adhesion molecule-1
p10486
sg13
I3
sasg19
(lp10487
(dp10488
g7
I164
sg22
VC0019187
p10489
sg10
I19
sg11
Valcoholic hepatitis
p10490
sg13
I2
sa(dp10491
g7
I102
sg22
VC0699748
p10492
sg10
I12
sg11
Vpathogenesis
p10493
sg13
I1
sa(dp10494
g7
I36
sg22
VC0001511
p10495
sg10
I8
sg11
Vadhesion
p10496
sg13
I1
sasa(dp10497
g2
S'Moreover, 19 common DEGs (including upregulated BCL9L, PER2 and TSPAN33, and downregulated GMPS and HES1) associated with both OLP and OSCC were identified.\n'
p10498
sg4
(lp10499
(dp10500
g7
I100
sg8
g15
sg10
I4
sg11
VHES1
p10501
sg13
I1
sa(dp10502
g7
I64
sg8
g15
sg10
I7
sg11
VTSPAN33
p10503
sg13
I1
sa(dp10504
g7
I48
sg8
g15
sg10
I5
sg11
VBCL9L
p10505
sg13
I1
sa(dp10506
g7
I55
sg8
g15
sg10
I4
sg11
VPER2
p10507
sg13
I1
sasg19
(lp10508
sa(dp10509
g2
S'These findings indicated that BCL9L, GMPS, HES1, PER2 and TSPAN33 affected the transformation of OLP to OSCC.\n'
p10510
sg4
(lp10511
(dp10512
g7
I30
sg8
g15
sg10
I5
sg11
VBCL9L
p10513
sg13
I1
sa(dp10514
g7
I43
sg8
g15
sg10
I4
sg11
VHES1
p10515
sg13
I1
sa(dp10516
g7
I37
sg8
VP49915
p10517
sg10
I4
sg11
VGMPS
p10518
sg13
I1
sa(dp10519
g7
I58
sg8
g15
sg10
I7
sg11
VTSPAN33
p10520
sg13
I1
sa(dp10521
g7
I49
sg8
g15
sg10
I4
sg11
VPER2
p10522
sg13
I1
sasg19
(lp10523
(dp10524
g7
I79
sg22
VC1510411
p10525
sg10
I14
sg11
Vtransformation
p10526
sg13
I1
sasa(dp10527
g2
S'Through genomic analysis of colorectal cancers and cell lines, we find frequent loss of heterozygosity and mutations in BCL9L in aneuploid tumors.\n'
p10528
sg4
(lp10529
(dp10530
g7
I120
sg8
g15
sg10
I5
sg11
VBCL9L
p10531
sg13
I1
sasg19
(lp10532
(dp10533
g7
I139
sg22
VC0027651
p10534
sg10
I6
sg11
Vtumors
p10535
sg13
I1
sa(dp10536
g7
I129
sg22
VC0002938
p10537
sg10
I9
sg11
Vaneuploid
p10538
sg13
I1
sa(dp10539
g7
I28
sg22
VC1527249
p10540
sg10
I18
sg11
Vcolorectal cancers
p10541
sg13
I2
sasa(dp10542
g2
S'Plumbagin (1) was found to downregulate Wnt signaling when assessed by a TOPFlash/FOPFlash reporter activity assay and also decreased the expression of several coactivators and downstream targets of Wnt signaling such as Beta-catenin, TCF7L2, p300, Bcl9l, c-Myc, vimentin, and cyclinD1 in SW620 colorectal cancer cells.\n'
p10543
sg4
(lp10544
(dp10545
g7
I221
sg8
VP35222
p10546
sg10
I12
sg11
VBeta-catenin
p10547
sg13
I1
sa(dp10548
g7
I243
sg8
g15
sg10
I4
sg11
Vp300
p10549
sg13
I1
sa(dp10550
g7
I256
sg8
VP12524
p10551
sg10
I5
sg11
Vc-Myc
p10552
sg13
I1
sa(dp10553
g7
I249
sg8
g15
sg10
I5
sg11
VBcl9l
p10554
sg13
I1
sasg19
(lp10555
(dp10556
g7
I295
sg22
VC1527249
p10557
sg10
I17
sg11
Vcolorectal cancer
p10558
sg13
I2
sasa(dp10559
g2
S'Recently, we could distinguished patients with major depressive disorder (MDD) from nonpsychiatric controls with high accuracy using a panel of five gene expression markers (ARHGAP24, HDAC5, PDGFC, PRNP, and SLC6A4) in leukocyte.\n'
p10560
sg4
(lp10561
(dp10562
g7
I191
sg8
g15
sg10
I5
sg11
VPDGFC
p10563
sg13
I1
sa(dp10564
g7
I184
sg8
g15
sg10
I5
sg11
VHDAC5
p10565
sg13
I1
sa(dp10566
g7
I198
sg8
g15
sg10
I4
sg11
VPRNP
p10567
sg13
I1
sa(dp10568
g7
I174
sg8
g15
sg10
I8
sg11
VARHGAP24
p10569
sg13
I1
sa(dp10570
g7
I208
sg8
VP31645
p10571
sg10
I6
sg11
VSLC6A4
p10572
sg13
I1
sasg19
(lp10573
(dp10574
g7
I74
sg22
VC1269683
p10575
sg10
I3
sg11
VMDD
p10576
sg13
I1
sa(dp10577
g7
I47
sg22
VC1269683
p10578
sg10
I25
sg11
Vmajor depressive disorder
p10579
sg13
I3
sasa(dp10580
g2
S'Thus, PP2A can shift myeloma cells from apoptosis to autophagic cell death.\n'
p10581
sg4
(lp10582
(dp10583
g7
I6
sg8
g15
sg10
I4
sg11
VPP2A
p10584
sg13
I1
sasg19
(lp10585
(dp10586
g7
I21
sg22
VC0026764
p10587
sg10
I7
sg11
Vmyeloma
p10588
sg13
I1
sasa(dp10589
g2
S'Given the central role of PP2A in regulating diverse biological functions and its dysregulation in many diseases, including cancer, PP2A directed therapeutics have become of great interest.\n'
p10590
sg4
(lp10591
(dp10592
g7
I26
sg8
g15
sg10
I4
sg11
VPP2A
p10593
sg13
I1
sa(dp10594
g7
I26
sg8
g15
sg10
I4
sg11
VPP2A
p10595
sg13
I1
sasg19
(lp10596
(dp10597
g7
I124
sg22
VC0006826
p10598
sg10
I6
sg11
Vcancer
p10599
sg13
I1
sasa(dp10600
g2
S'Here, we investigated the radiosensitizing effects of digoxin as a PP2A inhibitor in two non-small cell lung cancer cell types (H460 and A549) with differential sensitivity to radiation.\n'
p10601
sg4
(lp10602
(dp10603
g7
I67
sg8
g15
sg10
I4
sg11
VPP2A
p10604
sg13
I1
sasg19
(lp10605
(dp10606
g7
I89
sg22
VC0007131
p10607
sg10
I26
sg11
Vnon-small cell lung cancer
p10608
sg13
I4
sasa(dp10609
g2
S'In conclusion, digoxin has a novel function as a PP2A inhibitor, and combined with IR produces a synergistic effect of radiosensitizing cells, thereby indicating a potentially promising therapeutic approach to radioresistant lung cancer treatment.\n'
p10610
sg4
(lp10611
(dp10612
g7
I49
sg8
g15
sg10
I4
sg11
VPP2A
p10613
sg13
I1
sasg19
(lp10614
(dp10615
g7
I225
sg22
VC0684249
p10616
sg10
I11
sg11
Vlung cancer
p10617
sg13
I2
sasa(dp10618
g2
S'Therefore, it has been noted that PP2A could be a promising target for cancer therapy.\n'
p10619
sg4
(lp10620
(dp10621
g7
I34
sg8
g15
sg10
I4
sg11
VPP2A
p10622
sg13
I1
sasg19
(lp10623
(dp10624
g7
I71
sg22
VC0006826
p10625
sg10
I6
sg11
Vcancer
p10626
sg13
I1
sasa(dp10627
g2
S'We conclude that PP2A might contribute to an early stage of chemical carcinogenesis, suggesting that PP2A could be a molecular target of primary cancer prevention.\n'
p10628
sg4
(lp10629
(dp10630
g7
I17
sg8
g15
sg10
I4
sg11
VPP2A
p10631
sg13
I1
sa(dp10632
g7
I17
sg8
g15
sg10
I4
sg11
VPP2A
p10633
sg13
I1
sasg19
(lp10634
(dp10635
g7
I60
sg22
VC0596321
p10636
sg10
I23
sg11
Vchemical carcinogenesis
p10637
sg13
I2
sa(dp10638
g7
I145
sg22
VC0006826
p10639
sg10
I6
sg11
Vcancer
p10640
sg13
I1
sasa(dp10641
g2
S'In cancer cells, PP2A function can be compromised by several mechanisms, including sporadic mutations in its scaffolding A and regulatory B subunits or more frequently through overexpression of cellular PP2A inhibitors.\n'
p10642
sg4
(lp10643
(dp10644
g7
I17
sg8
g15
sg10
I4
sg11
VPP2A
p10645
sg13
I1
sa(dp10646
g7
I17
sg8
g15
sg10
I4
sg11
VPP2A
p10647
sg13
I1
sasg19
(lp10648
(dp10649
g7
I3
sg22
VC0006826
p10650
sg10
I6
sg11
Vcancer
p10651
sg13
I1
sasa(dp10652
g2
S'Here we identify a novel genetic mechanism by which PP2A function is recurrently affected in human cancer, involving haploinsufficiency of PPP2R4, a gene encoding the cellular PP2A activator PTPA.\n'
p10653
sg4
(lp10654
(dp10655
g7
I176
sg8
g15
sg10
I19
sg11
VPP2A activator PTPA
p10656
sg13
I3
sa(dp10657
g7
I52
sg8
g15
sg10
I4
sg11
VPP2A
p10658
sg13
I1
sasg19
(lp10659
(dp10660
g7
I99
sg22
VC0006826
p10661
sg10
I6
sg11
Vcancer
p10662
sg13
I1
sasa(dp10663
g2
S'Notably, up to 70% of cancer patients showed a heterozygous deletion or missense mutations in PPP2R4 Cancer-associated PTPA mutants exhibited decreased abilities to bind the PP2A-C subunit or activate PP2A and failed to reverse the tumorigenic phenotype induced by PTPA suppression, indicating they function as null alleles.\n'
p10664
sg4
(lp10665
(dp10666
g7
I174
sg8
g15
sg10
I4
sg11
VPP2A
p10667
sg13
I1
sa(dp10668
g7
I119
sg8
VP18433
p10669
sg10
I4
sg11
VPTPA
p10670
sg13
I1
sa(dp10671
g7
I174
sg8
VP67775
p10672
sg10
I14
sg11
VPP2A-C subunit
p10673
sg13
I2
sa(dp10674
g7
I94
sg8
VP18433
p10675
sg10
I37
sg11
VPPP2R4 Cancer-associated PTPA mutants
p10676
sg13
I4
sasg19
(lp10677
(dp10678
g7
I22
sg22
VC0006826
p10679
sg10
I6
sg11
Vcancer
p10680
sg13
I1
sa(dp10681
g7
I270
sg22
VC0221103
p10682
sg10
I11
sg11
Vsuppression
p10683
sg13
I1
sa(dp10684
g7
I101
sg22
VC0006826
p10685
sg10
I6
sg11
VCancer
p10686
sg13
I1
sasa(dp10687
g2
S'Our results provide evidence for PPP2R4 as a haploinsufficient tumor suppressor gene, defining a high-penetrance genetic mechanism for PP2A inhibition in human cancer.\n'
p10688
sg4
(lp10689
(dp10690
g7
I135
sg8
g15
sg10
I4
sg11
VPP2A
p10691
sg13
I1
sasg19
(lp10692
(dp10693
g7
I160
sg22
VC0006826
p10694
sg10
I6
sg11
Vcancer
p10695
sg13
I1
sa(dp10696
g7
I63
sg22
VC0027651
p10697
sg10
I5
sg11
Vtumor
p10698
sg13
I1
sasa(dp10699
g2
S'CIP2A inactivates protein phosphatase 2A (PP2A) which down-regulates Akt (Protein Kinase B) phosphorylation and stabilizes c-Myc (c-Myc oncogene product) in cancer cells.\n'
p10700
sg4
(lp10701
(dp10702
g7
I130
sg8
VP01106
p10703
sg10
I22
sg11
Vc-Myc oncogene product
p10704
sg13
I3
sa(dp10705
g7
I69
sg8
g15
sg10
I3
sg11
VAkt
p10706
sg13
I1
sa(dp10707
g7
I42
sg8
g15
sg10
I4
sg11
VPP2A
p10708
sg13
I1
sa(dp10709
g7
I0
sg8
g15
sg10
I5
sg11
VCIP2A
p10710
sg13
I1
sa(dp10711
g7
I123
sg8
VP12524
p10712
sg10
I5
sg11
Vc-Myc
p10713
sg13
I1
sa(dp10714
g7
I74
sg8
VP31749
p10715
sg10
I16
sg11
VProtein Kinase B
p10716
sg13
I3
sa(dp10717
g7
I18
sg8
g15
sg10
I22
sg11
Vprotein phosphatase 2A
p10718
sg13
I3
sasg19
(lp10719
(dp10720
g7
I157
sg22
VC0006826
p10721
sg10
I6
sg11
Vcancer
p10722
sg13
I1
sasa(dp10723
g2
S'At both sites, chronic kidney disease significantly lowered this TTR.\n'
p10724
sg4
(lp10725
sg19
(lp10726
(dp10727
g7
I15
sg22
VC1561643
p10728
sg10
I22
sg11
Vchronic kidney disease
p10729
sg13
I3
sasa(dp10730
g2
S'Multiple linear regression analysis showed CKD as an independent predictor of time in therapeutic range (TTR).\n'
p10731
sg4
(lp10732
sg19
(lp10733
sa(dp10734
g2
S'In the subgroup of patients with CKD, the SAMe-TT2 R2 (&gt;2 points) showed no significant predictive capacity for TTR (AUC 0.528, P = .354).\n'
p10735
sg4
(lp10736
sg19
(lp10737
sa(dp10738
g2
S'The SAMe-TT2 R2 score was not predictive of poor TTR in the subgroup with CKD, although a modest predictive value for poor TTR was found in those without CKD.\n'
p10739
sg4
(lp10740
sg19
(lp10741
sa(dp10742
g2
S'Hereditary transthyretin-related amyloidosis (ATTR-FAP) is characterized by a progressive neuropathy, cardiomyopathy, nephropathy and ocular disease.\n'
p10743
sg4
(lp10744
sg19
(lp10745
(dp10746
g7
I118
sg22
VC0022658
p10747
sg10
I11
sg11
Vnephropathy
p10748
sg13
I1
sa(dp10749
g7
I102
sg22
VC0878544
p10750
sg10
I14
sg11
Vcardiomyopathy
p10751
sg13
I1
sa(dp10752
g7
I51
sg22
VC0032580
p10753
sg10
I3
sg11
VFAP
p10754
sg13
I1
sa(dp10755
g7
I90
sg22
VC0442874
p10756
sg10
I10
sg11
Vneuropathy
p10757
sg13
I1
sa(dp10758
g7
I33
sg22
VC0002726
p10759
sg10
I11
sg11
Vamyloidosis
p10760
sg13
I1
sasa(dp10761
g2
S'Men showed increased levels of albumin and prealbumin, and women showed decreased proteinuria levels.\n'
p10762
sg4
(lp10763
(dp10764
g7
I43
sg8
VP31025
p10765
sg10
I10
sg11
Vprealbumin
p10766
sg13
I1
sa(dp10767
g7
I31
sg8
VP00441
p10768
sg10
I7
sg11
Valbumin
p10769
sg13
I1
sasg19
(lp10770
sa(dp10771
g2
S'Here, the authors describe a 59-year-old woman harboring a purely intrapelvic sciatic notch schwannoma extrinsic to the sciatic nerve, which was totally removed via the infragluteal approach preserving sciatic function.\n'
p10772
sg4
(lp10773
sg19
(lp10774
(dp10775
g7
I92
sg22
VC0027809
p10776
sg10
I10
sg11
Vschwannoma
p10777
sg13
I1
sasa(dp10778
g2
S'We describe a sciatic schwannoma spanning the sciatic notch in a 39-year-old woman with persistent pelvic pain after caesarean delivery.\n'
p10779
sg4
(lp10780
sg19
(lp10781
(dp10782
g7
I22
sg22
VC0027809
p10783
sg10
I10
sg11
Vschwannoma
p10784
sg13
I1
sa(dp10785
g7
I99
sg22
VC0030794
p10786
sg10
I11
sg11
Vpelvic pain
p10787
sg13
I2
sasa(dp10788
g2
S'A case is reported of schwannoma of the right masseteric nerve, invading the pterygopalatine fossa and the parapharyngeal space through the mandibular notch in a 61-year-old woman.\n'
p10789
sg4
(lp10790
sg19
(lp10791
(dp10792
g7
I22
sg22
VC0027809
p10793
sg10
I10
sg11
Vschwannoma
p10794
sg13
I1
sasa(dp10795
g2
S'The most important aspects of this case are the anatomic site of the schwannoma and its uncommon clinicopathologic manifestations; this tumor originated from the masseteric nerve and is the first case reported to straddle the mandibular notch.\n'
p10796
sg4
(lp10797
sg19
(lp10798
(dp10799
g7
I136
sg22
VC0027651
p10800
sg10
I5
sg11
Vtumor
p10801
sg13
I1
sa(dp10802
g7
I69
sg22
VC0027809
p10803
sg10
I10
sg11
Vschwannoma
p10804
sg13
I1
sasa(dp10805
g2
S'Tissue inhibitor of metalloproteinase 3 (TIMP3) is an extracellular matrix (ECM) bound protein, which has been shown to be downregulated in human subjects and experimental models with cardiometabolic disorders, including type 2 diabetes mellitus, hypertension and atherosclerosis.\n'
p10806
sg4
(lp10807
(dp10808
g7
I0
sg8
VP35625
p10809
sg10
I39
sg11
VTissue inhibitor of metalloproteinase 3
p10810
sg13
I5
sa(dp10811
g7
I41
sg8
VP35625
p10812
sg10
I5
sg11
VTIMP3
p10813
sg13
I1
sasg19
(lp10814
(dp10815
g7
I221
sg22
VC0011860
p10816
sg10
I24
sg11
Vtype 2 diabetes mellitus
p10817
sg13
I4
sa(dp10818
g7
I247
sg22
VC0020538
p10819
sg10
I12
sg11
Vhypertension
p10820
sg13
I1
sa(dp10821
g7
I264
sg22
VC0004153
p10822
sg10
I15
sg11
Vatherosclerosis
p10823
sg13
I1
sasa(dp10824
g2
S'The aim of this study was to investigate whether polymorphisms in the tissue inhibitor of metalloproteinase 3 gene (TIMP3) are associated with the risk of preeclampsia (PE) in Han Chinese women.\n'
p10825
sg4
(lp10826
(dp10827
g7
I116
sg8
VP35625
p10828
sg10
I5
sg11
VTIMP3
p10829
sg13
I1
sa(dp10830
g7
I70
sg8
VP35625
p10831
sg10
I44
sg11
Vtissue inhibitor of metalloproteinase 3 gene
p10832
sg13
I6
sasg19
(lp10833
(dp10834
g7
I155
sg22
VC0032914
p10835
sg10
I12
sg11
Vpreeclampsia
p10836
sg13
I1
sa(dp10837
g7
I169
sg22
VC0032914
p10838
sg10
I2
sg11
VPE
p10839
sg13
I1
sasa(dp10840
g2
S'In 1996 a large Dutch family with an autosomal-dominant syndrome ("limb mammary syndrome", LMS, MIM *603543) characterized by hypoplasia/aplasia of mammary glands and nipples, ectrodactyly, other hand/foot anomalies, lacrimal-duct atresia, nail dysplasia, hypohidrosis, cleft palate/bifid uvula, hypodontia was reported.\n'
p10841
sg4
(lp10842
sg19
(lp10843
(dp10844
g7
I56
sg22
VC0039082
p10845
sg10
I8
sg11
Vsyndrome
p10846
sg13
I1
sa(dp10847
g7
I126
sg22
VC0243069
p10848
sg10
I10
sg11
Vhypoplasia
p10849
sg13
I1
sa(dp10850
g7
I91
sg22
VC1851710
p10851
sg10
I3
sg11
VLMS
p10852
sg13
I1
sa(dp10853
g7
I137
sg22
VC0243065
p10854
sg10
I7
sg11
Vaplasia
p10855
sg13
I1
sa(dp10856
g7
I256
sg22
VC0020620
p10857
sg10
I12
sg11
Vhypohidrosis
p10858
sg13
I1
sa(dp10859
g7
I283
sg22
VC0266122
p10860
sg10
I11
sg11
Vbifid uvula
p10861
sg13
I2
sa(dp10862
g7
I240
sg22
VC3279947
p10863
sg10
I14
sg11
Vnail dysplasia
p10864
sg13
I2
sa(dp10865
g7
I270
sg22
VC0008925
p10866
sg10
I12
sg11
Vcleft palate
p10867
sg13
I2
sa(dp10868
g7
I231
sg22
VC0243066
p10869
sg10
I7
sg11
Vatresia
p10870
sg13
I1
sa(dp10871
g7
I56
sg22
VC0039082
p10872
sg10
I8
sg11
Vsyndrome
p10873
sg13
I1
sa(dp10874
g7
I176
sg22
VC0265554
p10875
sg10
I12
sg11
Vectrodactyly
p10876
sg13
I1
sa(dp10877
g7
I296
sg22
VC0020608
p10878
sg10
I10
sg11
Vhypodontia
p10879
sg13
I1
sasa(dp10880
g2
S'Bone-acting factors were present in serum and RANKL, PTHrP and DKK1, key mediators of hypercalcemia and bone loss, were upregulated in Gzmb-HBZ T cells.\n'
p10881
sg4
(lp10882
(dp10883
g7
I46
sg8
g15
sg10
I5
sg11
VRANKL
p10884
sg13
I1
sa(dp10885
g7
I53
sg8
VP12272
p10886
sg10
I5
sg11
VPTHrP
p10887
sg13
I1
sa(dp10888
g7
I135
sg8
VP10144
p10889
sg10
I8
sg11
VGzmb-HBZ
p10890
sg13
I1
sa(dp10891
g7
I63
sg8
g15
sg10
I4
sg11
VDKK1
p10892
sg13
I1
sasg19
(lp10893
(dp10894
g7
I86
sg22
VC0020437
p10895
sg10
I13
sg11
Vhypercalcemia
p10896
sg13
I1
sa(dp10897
g7
I104
sg22
VC0029453
p10898
sg10
I9
sg11
Vbone loss
p10899
sg13
I2
sasa(dp10900
g2
S'The seminal observations leading to these discoveries were the following: 1) mutations in FGF23 cause ADHR by limiting cleavage of the bioactive intact molecule, at a subtilisin-like protein convertase (SPC) site, resulting in increased circulating FGF23 levels and hypophosphatemia; 2) mutations in DMP1 cause ARHR, not only by increasing serum FGF23, albeit by enhanced production and not limited cleavage, but also by limiting production of the active DMP1 component, the C-terminal fragment, resulting in dysregulated production of DKK1 and Beta-catenin, which contributes to impaired bone mineralization; and 3) mutations in PHEX cause XLH both by altering FGF23 proteolysis and production and causing dysregulated production of DKK1 and Beta-catenin, similar to abnormalities in ADHR and ARHR, but secondary to different central pathophysiological events.\n'
p10901
sg4
(lp10902
(dp10903
g7
I536
sg8
g15
sg10
I4
sg11
VDKK1
p10904
sg13
I1
sa(dp10905
g7
I102
sg8
VP30518
p10906
sg10
I4
sg11
VADHR
p10907
sg13
I1
sa(dp10908
g7
I90
sg8
g15
sg10
I5
sg11
VFGF23
p10909
sg13
I1
sa(dp10910
g7
I641
sg8
VP78562
p10911
sg10
I3
sg11
VXLH
p10912
sg13
I1
sa(dp10913
g7
I545
sg8
VP35222
p10914
sg10
I12
sg11
VBeta-catenin
p10915
sg13
I1
sa(dp10916
g7
I630
sg8
VP78562
p10917
sg10
I4
sg11
VPHEX
p10918
sg13
I1
sa(dp10919
g7
I90
sg8
g15
sg10
I5
sg11
VFGF23
p10920
sg13
I1
sa(dp10921
g7
I102
sg8
VP30518
p10922
sg10
I4
sg11
VADHR
p10923
sg13
I1
sa(dp10924
g7
I340
sg8
g15
sg10
I11
sg11
Vserum FGF23
p10925
sg13
I2
sa(dp10926
g7
I167
sg8
VP11686
p10927
sg10
I34
sg11
Vsubtilisin-like protein convertase
p10928
sg13
I3
sa(dp10929
g7
I545
sg8
VP35222
p10930
sg10
I12
sg11
VBeta-catenin
p10931
sg13
I1
sa(dp10932
g7
I90
sg8
g15
sg10
I5
sg11
VFGF23
p10933
sg13
I1
sa(dp10934
g7
I203
sg8
VP11686
p10935
sg10
I3
sg11
VSPC
p10936
sg13
I1
sa(dp10937
g7
I311
sg8
g15
sg10
I4
sg11
VARHR
p10938
sg13
I1
sa(dp10939
g7
I300
sg8
g15
sg10
I15
sg11
VDMP1 cause ARHR
p10940
sg13
I3
sa(dp10941
g7
I300
sg8
g15
sg10
I4
sg11
VDMP1
p10942
sg13
I1
sa(dp10943
g7
I536
sg8
g15
sg10
I4
sg11
VDKK1
p10944
sg13
I1
sasg19
(lp10945
(dp10946
g7
I102
sg22
VC0342642
p10947
sg10
I4
sg11
VADHR
p10948
sg13
I1
sa(dp10949
g7
I641
sg22
VC0733682
p10950
sg10
I3
sg11
VXLH
p10951
sg13
I1
sa(dp10952
g7
I311
sg22
VC0342643
p10953
sg10
I4
sg11
VARHR
p10954
sg13
I1
sa(dp10955
g7
I102
sg22
VC0342642
p10956
sg10
I4
sg11
VADHR
p10957
sg13
I1
sa(dp10958
g7
I580
sg22
VC0684336
p10959
sg10
I8
sg11
Vimpaired
p10960
sg13
I1
sa(dp10961
g7
I266
sg22
VC0085682
p10962
sg10
I16
sg11
Vhypophosphatemia
p10963
sg13
I1
sa(dp10964
g7
I311
sg22
VC0342643
p10965
sg10
I4
sg11
VARHR
p10966
sg13
I1
sasa(dp10967
g2
S"The aim of this study was therefore to explore serum levels of DKK-1 and to evaluate DKK-1's association with the severity of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH).\n"
p10968
sg4
(lp10969
(dp10970
g7
I63
sg8
g15
sg10
I5
sg11
VDKK-1
p10971
sg13
I1
sasg19
(lp10972
(dp10973
g7
I148
sg22
VC0020498
p10974
sg10
I40
sg11
Vdiffuse idiopathic skeletal hyperostosis
p10975
sg13
I4
sa(dp10976
g7
I190
sg22
VC0020498
p10977
sg10
I4
sg11
VDISH
p10978
sg13
I1
sasa(dp10979
g2
S'To evaluate the plasma levels of CCL2, CCL3, CCL11, CCL24, tumor necrosis factor alpha, sTNFR1, and sTNFR2 in subjects exposed to silica (SES) with and without silicosis compared with unexposed reference control group, and their associations with the radiological severity and duration of exposure to silica.\n'
p10980
sg4
(lp10981
(dp10982
g7
I39
sg8
VP10147
p10983
sg10
I4
sg11
VCCL3
p10984
sg13
I1
sa(dp10985
g7
I45
sg8
VP51671
p10986
sg10
I5
sg11
VCCL11
p10987
sg13
I1
sa(dp10988
g7
I33
sg8
VP13500
p10989
sg10
I4
sg11
VCCL2
p10990
sg13
I1
sa(dp10991
g7
I59
sg8
VP01375
p10992
sg10
I27
sg11
Vtumor necrosis factor alpha
p10993
sg13
I4
sa(dp10994
g7
I52
sg8
g15
sg10
I5
sg11
VCCL24
p10995
sg13
I1
sasg19
(lp10996
(dp10997
g7
I59
sg22
VC0333516
p10998
sg10
I14
sg11
Vtumor necrosis
p10999
sg13
I2
sa(dp11000
g7
I160
sg22
VC0037116
p11001
sg10
I9
sg11
Vsilicosis
p11002
sg13
I1
sasa(dp11003
g2
S'CCL3, CCL24, sTNFR1, and sTNFR2 were increased in SES and in SES with silicosis than in controls.\n'
p11004
sg4
(lp11005
(dp11006
g7
I6
sg8
g15
sg10
I5
sg11
VCCL24
p11007
sg13
I1
sa(dp11008
g7
I0
sg8
VP10147
p11009
sg10
I4
sg11
VCCL3
p11010
sg13
I1
sasg19
(lp11011
(dp11012
g7
I70
sg22
VC0037116
p11013
sg10
I9
sg11
Vsilicosis
p11014
sg13
I1
sasa(dp11015
g2
S'One hundred and sixty four cases were diagnosed as amino acid metabolic disorders with a prevalence of 1:11 349, including 83 with hyperphenylalaninaemia (1:22 400), 29 with neonatal intrahepatic cholestasis caused by citrin deficiency (1:64 138), 16 with methionine S-adenosyltransferase deficiency (1:116 250), 9 with maple syrup urine disease (1:206 667), 8 with argininemia (1:232 500), 7 with citrullinemia type I (1:265 700), 6 with hyperprolinemia type I (1:310 000), and 2 with carbamylphosphate synthetase I deficiency(1:930 000).\n'
p11016
sg4
(lp11017
(dp11018
g7
I218
sg8
g15
sg10
I6
sg11
Vcitrin
p11019
sg13
I1
sa(dp11020
g7
I256
sg8
VP41162
p11021
sg10
I32
sg11
Vmethionine S-adenosyltransferase
p11022
sg13
I2
sasg19
(lp11023
(dp11024
g7
I320
sg22
VC0024776
p11025
sg10
I25
sg11
Vmaple syrup urine disease
p11026
sg13
I4
sa(dp11027
g7
I398
sg22
VC0175683
p11028
sg10
I13
sg11
Vcitrullinemia
p11029
sg13
I1
sa(dp11030
g7
I366
sg22
VC0268548
p11031
sg10
I11
sg11
Vargininemia
p11032
sg13
I1
sa(dp11033
g7
I62
sg22
VC0025517
p11034
sg10
I19
sg11
Vmetabolic disorders
p11035
sg13
I2
sa(dp11036
g7
I439
sg22
VC0268529
p11037
sg10
I22
sg11
Vhyperprolinemia type I
p11038
sg13
I3
sa(dp11039
g7
I131
sg22
VC0751435
p11040
sg10
I22
sg11
Vhyperphenylalaninaemia
p11041
sg13
I1
sa(dp11042
g7
I174
sg22
VC1853942
p11043
sg10
I61
sg11
Vneonatal intrahepatic cholestasis caused by citrin deficiency
p11044
sg13
I7
sasa(dp11045
g2
S'The simultaneous analysis and identification of &gt;400 metabolites in &gt;130 types of IMD was possible from the GC/MS results, where the IMDs included phenylketonuria, ornithine transcarbamylase deficiency, neonatal intrahepatic cholestasis caused by citrin deficiency, Beta-ureidopropionase deficiency and mitochondrial metabolic disorders.\n'
p11046
sg4
(lp11047
(dp11048
g7
I253
sg8
g15
sg10
I6
sg11
Vcitrin
p11049
sg13
I1
sa(dp11050
g7
I170
sg8
VP00480
p11051
sg10
I26
sg11
Vornithine transcarbamylase
p11052
sg13
I2
sa(dp11053
g7
I272
sg8
g15
sg10
I21
sg11
VBeta-ureidopropionase
p11054
sg13
I1
sa(dp11055
g7
I139
sg8
g15
sg10
I4
sg11
VIMDs
p11056
sg13
I1
sasg19
(lp11057
(dp11058
g7
I272
sg22
VC1291512
p11059
sg10
I32
sg11
VBeta-ureidopropionase deficiency
p11060
sg13
I2
sa(dp11061
g7
I153
sg22
VC0031485
p11062
sg10
I15
sg11
Vphenylketonuria
p11063
sg13
I1
sa(dp11064
g7
I209
sg22
VC1853942
p11065
sg10
I61
sg11
Vneonatal intrahepatic cholestasis caused by citrin deficiency
p11066
sg13
I7
sa(dp11067
g7
I170
sg22
VC0268542
p11068
sg10
I37
sg11
Vornithine transcarbamylase deficiency
p11069
sg13
I3
sa(dp11070
g7
I323
sg22
VC0025517
p11071
sg10
I19
sg11
Vmetabolic disorders
p11072
sg13
I2
sasa(dp11073
g2
S'We checked blood amino acids and acylcarnitines in 38 patients, which revealed phenylketonuria (PKU) in 2 patients, and one with suspected citrin deficiency.\n'
p11074
sg4
(lp11075
(dp11076
g7
I139
sg8
g15
sg10
I6
sg11
Vcitrin
p11077
sg13
I1
sasg19
(lp11078
(dp11079
g7
I139
sg22
VC1997910
p11080
sg10
I17
sg11
Vcitrin deficiency
p11081
sg13
I2
sa(dp11082
g7
I96
sg22
VC0031485
p11083
sg10
I3
sg11
VPKU
p11084
sg13
I1
sa(dp11085
g7
I79
sg22
VC0031485
p11086
sg10
I15
sg11
Vphenylketonuria
p11087
sg13
I1
sasa(dp11088
g2
S'Mutations in SLC25A13 cause citrin deficiency, which has three phenotypes: neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), failure to thrive and dyslipidemia caused by citrin deficiency (FTTDCD) and adult-onset type 2 citrullinemia (CTLN2).\n'
p11089
sg4
(lp11090
(dp11091
g7
I28
sg8
g15
sg10
I6
sg11
Vcitrin
p11092
sg13
I1
sa(dp11093
g7
I13
sg8
g15
sg10
I8
sg11
VSLC25A13
p11094
sg13
I1
sa(dp11095
g7
I28
sg8
g15
sg10
I6
sg11
Vcitrin
p11096
sg13
I1
sa(dp11097
g7
I28
sg8
g15
sg10
I6
sg11
Vcitrin
p11098
sg13
I1
sasg19
(lp11099
(dp11100
g7
I168
sg22
VC0242339
p11101
sg10
I12
sg11
Vdyslipidemia
p11102
sg13
I1
sa(dp11103
g7
I241
sg22
VC0175683
p11104
sg10
I13
sg11
Vcitrullinemia
p11105
sg13
I1
sa(dp11106
g7
I146
sg22
VC0015544
p11107
sg10
I17
sg11
Vfailure to thrive
p11108
sg13
I3
sa(dp11109
g7
I138
sg22
VC1853942
p11110
sg10
I5
sg11
VNICCD
p11111
sg13
I1
sa(dp11112
g7
I28
sg22
VC1863844
p11113
sg10
I17
sg11
Vcitrin deficiency
p11114
sg13
I2
sa(dp11115
g7
I28
sg22
VC1863844
p11116
sg10
I17
sg11
Vcitrin deficiency
p11117
sg13
I2
sa(dp11118
g7
I75
sg22
VC1853942
p11119
sg10
I61
sg11
Vneonatal intrahepatic cholestasis caused by citrin deficiency
p11120
sg13
I7
sa(dp11121
g7
I256
sg22
VC1863844
p11122
sg10
I5
sg11
VCTLN2
p11123
sg13
I1
sasa(dp11124
g2
S'Citrullinemia type II is an autosomal recessive urea cycle disorder and a subtype of citrin deficiency.\n'
p11125
sg4
(lp11126
(dp11127
g7
I85
sg8
g15
sg10
I6
sg11
Vcitrin
p11128
sg13
I1
sasg19
(lp11129
(dp11130
g7
I85
sg22
VC1997910
p11131
sg10
I17
sg11
Vcitrin deficiency
p11132
sg13
I2
sa(dp11133
g7
I0
sg22
VC0175683
p11134
sg10
I13
sg11
VCitrullinemia
p11135
sg13
I1
sa(dp11136
g7
I48
sg22
VC0154246
p11137
sg10
I19
sg11
Vurea cycle disorder
p11138
sg13
I3
sasa(dp11139
g2
S'However, the management of recurrent hyperammonemia with neurologic symptoms in patients with citrullinemia type II is quite different from the management of other types of urea cycle disorders.\n'
p11140
sg4
(lp11141
sg19
(lp11142
(dp11143
g7
I94
sg22
VC0175683
p11144
sg10
I13
sg11
Vcitrullinemia
p11145
sg13
I1
sa(dp11146
g7
I37
sg22
VC0220994
p11147
sg10
I14
sg11
Vhyperammonemia
p11148
sg13
I1
sa(dp11149
g7
I173
sg22
VC0154246
p11150
sg10
I20
sg11
Vurea cycle disorders
p11151
sg13
I3
sa(dp11152
g7
I57
sg22
VC0235031
p11153
sg10
I19
sg11
Vneurologic symptoms
p11154
sg13
I2
sasa(dp11155
g2
S'In pats with citrullinemia type II, regional anesthesia might be a good choice for the early detection of hyperammonemic symptoms and addressing psychic stress.\n'
p11156
sg4
(lp11157
sg19
(lp11158
(dp11159
g7
I13
sg22
VC0175683
p11160
sg10
I13
sg11
Vcitrullinemia
p11161
sg13
I1
sa(dp11162
g7
I45
sg22
VC0278134
p11163
sg10
I10
sg11
Vanesthesia
p11164
sg13
I1
sasa(dp11165
g2
S'A 48-year-old male with adult onset citrullinemia type II was scheduled for urethral scrotal fistula repair.\n'
p11166
sg4
(lp11167
sg19
(lp11168
(dp11169
g7
I36
sg22
VC0175683
p11170
sg10
I13
sg11
Vcitrullinemia
p11171
sg13
I1
sa(dp11172
g7
I85
sg22
VC0574041
p11173
sg10
I15
sg11
Vscrotal fistula
p11174
sg13
I2
sasa(dp11175
g2
S'For anesthesia of patients with adult onset citrullinemia type II, close monitoring of neurologic signs and serum ammonia are important to reduce neurologic complications induced by hyperammonemia.\n'
p11176
sg4
(lp11177
sg19
(lp11178
(dp11179
g7
I182
sg22
VC0220994
p11180
sg10
I14
sg11
Vhyperammonemia
p11181
sg13
I1
sa(dp11182
g7
I4
sg22
VC0278134
p11183
sg10
I10
sg11
Vanesthesia
p11184
sg13
I1
sa(dp11185
g7
I87
sg22
VC0751378
p11186
sg10
I16
sg11
Vneurologic signs
p11187
sg13
I2
sa(dp11188
g7
I44
sg22
VC0175683
p11189
sg10
I13
sg11
Vcitrullinemia
p11190
sg13
I1
sasa(dp11191
g2
S'Genetic causes of hypermethioninemia include mitochondrial depletion syndromes caused by mutations in the MPV17 and DGUOK genes and deficiencies of cystathionine Beta-synthase, methionine adenosyltransferase types I and III, glycine N-methyltransferase, S-adenosylhomocysteine hydrolase, citrin, fumarylacetoacetate hydrolase, and adenosine kinase.\n'
p11192
sg4
(lp11193
(dp11194
g7
I148
sg8
VP35520
p11195
sg10
I27
sg11
Vcystathionine Beta-synthase
p11196
sg13
I2
sa(dp11197
g7
I177
sg8
VP31153
p11198
sg10
I46
sg11
Vmethionine adenosyltransferase types I and III
p11199
sg13
I6
sa(dp11200
g7
I256
sg8
VP23526
p11201
sg10
I30
sg11
Vadenosylhomocysteine hydrolase
p11202
sg13
I2
sa(dp11203
g7
I296
sg8
VP16930
p11204
sg10
I29
sg11
Vfumarylacetoacetate hydrolase
p11205
sg13
I2
sa(dp11206
g7
I331
sg8
VP55263
p11207
sg10
I16
sg11
Vadenosine kinase
p11208
sg13
I2
sa(dp11209
g7
I225
sg8
g15
sg10
I27
sg11
Vglycine N-methyltransferase
p11210
sg13
I2
sa(dp11211
g7
I116
sg8
g15
sg10
I11
sg11
VDGUOK genes
p11212
sg13
I2
sa(dp11213
g7
I288
sg8
g15
sg10
I6
sg11
Vcitrin
p11214
sg13
I1
sa(dp11215
g7
I106
sg8
VP39210
p11216
sg10
I5
sg11
VMPV17
p11217
sg13
I1
sasg19
(lp11218
(dp11219
g7
I69
sg22
VC0039082
p11220
sg10
I9
sg11
Vsyndromes
p11221
sg13
I1
sa(dp11222
g7
I18
sg22
VC0268621
p11223
sg10
I18
sg11
Vhypermethioninemia
p11224
sg13
I1
sasa(dp11225
g2
S'These include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]).\n'
p11226
sg4
(lp11227
(dp11228
g7
I407
sg8
g15
sg10
I37
sg11
Vmitochondrial ornithine transporter 1
p11229
sg13
I4
sa(dp11230
g7
I61
sg8
g15
sg10
I31
sg11
VCarbamyl phosphate synthetase 1
p11231
sg13
I4
sa(dp11232
g7
I223
sg8
VP04424
p11233
sg10
I23
sg11
VArgininosuccinate lyase
p11234
sg13
I2
sa(dp11235
g7
I294
sg8
VP05089
p11236
sg10
I8
sg11
VArginase
p11237
sg13
I1
sa(dp11238
g7
I113
sg8
VP00480
p11239
sg10
I26
sg11
VOrnithine transcarbamylase
p11240
sg13
I2
sa(dp11241
g7
I159
sg8
VP00966
p11242
sg10
I28
sg11
VArgininosuccinate synthetase
p11243
sg13
I2
sa(dp11244
g7
I14
sg8
g15
sg10
I26
sg11
VN-acetylglutamate synthase
p11245
sg13
I2
sa(dp11246
g7
I494
sg8
g15
sg10
I61
sg11
Vmitochondrial aspartate/glutamate carrier deficiency [CITRIN]
p11247
sg13
I5
sasg19
(lp11248
(dp11249
g7
I389
sg22
VC0268540
p11250
sg10
I3
sg11
VHHH
p11251
sg13
I1
sa(dp11252
g7
I335
sg22
VC0599035
p11253
sg10
I17
sg11
VHyperornithinemia
p11254
sg13
I1
sa(dp11255
g7
I394
sg22
VC0039082
p11256
sg10
I8
sg11
Vsyndrome
p11257
sg13
I1
sa(dp11258
g7
I159
sg22
VC0175683
p11259
sg10
I39
sg11
VArgininosuccinate synthetase deficiency
p11260
sg13
I3
sa(dp11261
g7
I14
sg22
VC0268543
p11262
sg10
I37
sg11
VN-acetylglutamate synthase deficiency
p11263
sg13
I3
sa(dp11264
g7
I315
sg22
VC0268548
p11265
sg10
I4
sg11
VARGD
p11266
sg13
I1
sa(dp11267
g7
I223
sg22
VC0268547
p11268
sg10
I34
sg11
VArgininosuccinate lyase deficiency
p11269
sg13
I3
sa(dp11270
g7
I207
sg22
VC0175683
p11271
sg10
I13
sg11
VCitrullinemia
p11272
sg13
I1
sa(dp11273
g7
I152
sg22
VC0268542
p11274
sg10
I4
sg11
VOTCD
p11275
sg13
I1
sa(dp11276
g7
I53
sg22
VC0268543
p11277
sg10
I5
sg11
VNAGSD
p11278
sg13
I1
sa(dp11279
g7
I200
sg22
VC0175683
p11280
sg10
I4
sg11
VASSD
p11281
sg13
I1
sa(dp11282
g7
I259
sg22
VC0268547
p11283
sg10
I4
sg11
VASLD
p11284
sg13
I1
sa(dp11285
g7
I207
sg22
VC0175683
p11286
sg10
I13
sg11
VCitrullinemia
p11287
sg13
I1
sa(dp11288
g7
I321
sg22
VC0268548
p11289
sg10
I11
sg11
VArgininemia
p11290
sg13
I1
sa(dp11291
g7
I266
sg22
VC0268547
p11292
sg10
I25
sg11
VArgininosuccinic aciduria
p11293
sg13
I2
sa(dp11294
g7
I354
sg22
VC0220994
p11295
sg10
I14
sg11
Vhyperammonemia
p11296
sg13
I1
sa(dp11297
g7
I113
sg22
VC0268542
p11298
sg10
I37
sg11
VOrnithine transcarbamylase deficiency
p11299
sg13
I3
sa(dp11300
g7
I294
sg22
VC0268548
p11301
sg10
I19
sg11
VArginase deficiency
p11302
sg13
I2
sasa(dp11303
g2
S'We report the first Turkish patient with citrin deficiency detected incidentally by phenylketonuria screening.\n'
p11304
sg4
(lp11305
(dp11306
g7
I41
sg8
g15
sg10
I6
sg11
Vcitrin
p11307
sg13
I1
sasg19
(lp11308
(dp11309
g7
I84
sg22
VC0031485
p11310
sg10
I15
sg11
Vphenylketonuria
p11311
sg13
I1
sa(dp11312
g7
I41
sg22
VC1997910
p11313
sg10
I17
sg11
Vcitrin deficiency
p11314
sg13
I2
sasa(dp11315
g2
S'Genes that have been implicated in monogenic CVID include ICOS, TNFRSF13B (TACI), TNFRSF13C (BAFF-R), TNFSF12 (TWEAK), CD19, CD81, CR2 (CD21), MS4A1 (CD20), TNFRSF7 (CD27), IL21, IL21R, LRBA, CTLA4, PRKCD, PLCG2, NFKB1, NFKB2, PIK3CD, PIK3R1, VAV1, RAC2, BLK, IKZF1 (IKAROS) and IRF2BP2 With the increasing number of disease genes identified in CVID, it has become clear that CVID is an umbrella diagnosis and that many of these genetic defects cause distinct disease entities.\n'
p11316
sg4
(lp11317
(dp11318
g7
I111
sg8
g15
sg10
I5
sg11
VTWEAK
p11319
sg13
I1
sa(dp11320
g7
I82
sg8
g15
sg10
I9
sg11
VTNFRSF13C
p11321
sg13
I1
sa(dp11322
g7
I75
sg8
g15
sg10
I4
sg11
VTACI
p11323
sg13
I1
sa(dp11324
g7
I186
sg8
VP50851
p11325
sg10
I4
sg11
VLRBA
p11326
sg13
I1
sa(dp11327
g7
I213
sg8
VP19838
p11328
sg10
I5
sg11
VNFKB1
p11329
sg13
I1
sa(dp11330
g7
I235
sg8
VP27986
p11331
sg10
I6
sg11
VPIK3R1
p11332
sg13
I1
sa(dp11333
g7
I206
sg8
VP16885
p11334
sg10
I5
sg11
VPLCG2
p11335
sg13
I1
sa(dp11336
g7
I125
sg8
VP60033
p11337
sg10
I4
sg11
VCD81
p11338
sg13
I1
sa(dp11339
g7
I220
sg8
g15
sg10
I5
sg11
VNFKB2
p11340
sg13
I1
sa(dp11341
g7
I93
sg8
g15
sg10
I6
sg11
VBAFF-R
p11342
sg13
I1
sa(dp11343
g7
I279
sg8
g15
sg10
I7
sg11
VIRF2BP2
p11344
sg13
I1
sa(dp11345
g7
I119
sg8
VP15391
p11346
sg10
I4
sg11
VCD19
p11347
sg13
I1
sa(dp11348
g7
I45
sg8
g15
sg10
I4
sg11
VCVID
p11349
sg13
I1
sa(dp11350
g7
I45
sg8
g15
sg10
I4
sg11
VCVID
p11351
sg13
I1
sa(dp11352
g7
I227
sg8
g15
sg10
I6
sg11
VPIK3CD
p11353
sg13
I1
sa(dp11354
g7
I136
sg8
VP20023
p11355
sg10
I4
sg11
VCD21
p11356
sg13
I1
sa(dp11357
g7
I102
sg8
g15
sg10
I7
sg11
VTNFSF12
p11358
sg13
I1
sa(dp11359
g7
I58
sg8
VP16410
p11360
sg10
I4
sg11
VICOS
p11361
sg13
I1
sa(dp11362
g7
I249
sg8
VP15153
p11363
sg10
I4
sg11
VRAC2
p11364
sg13
I1
sa(dp11365
g7
I64
sg8
g15
sg10
I9
sg11
VTNFRSF13B
p11366
sg13
I1
sa(dp11367
g7
I243
sg8
VP15498
p11368
sg10
I4
sg11
VVAV1
p11369
sg13
I1
sa(dp11370
g7
I157
sg8
VP26842
p11371
sg10
I7
sg11
VTNFRSF7
p11372
sg13
I1
sa(dp11373
g7
I173
sg8
g15
sg10
I4
sg11
VIL21
p11374
sg13
I1
sa(dp11375
g7
I179
sg8
g15
sg10
I5
sg11
VIL21R
p11376
sg13
I1
sa(dp11377
g7
I166
sg8
VP26842
p11378
sg10
I4
sg11
VCD27
p11379
sg13
I1
sa(dp11380
g7
I260
sg8
g15
sg10
I5
sg11
VIKZF1
p11381
sg13
I1
sa(dp11382
g7
I150
sg8
VP35900
p11383
sg10
I4
sg11
VCD20
p11384
sg13
I1
sa(dp11385
g7
I192
sg8
VP16410
p11386
sg10
I5
sg11
VCTLA4
p11387
sg13
I1
sa(dp11388
g7
I267
sg8
g15
sg10
I6
sg11
VIKAROS
p11389
sg13
I1
sa(dp11390
g7
I143
sg8
VP11836
p11391
sg10
I5
sg11
VMS4A1
p11392
sg13
I1
sa(dp11393
g7
I199
sg8
g15
sg10
I5
sg11
VPRKCD
p11394
sg13
I1
sa(dp11395
g7
I131
sg8
VP20023
p11396
sg10
I3
sg11
VCR2
p11397
sg13
I1
sa(dp11398
g7
I255
sg8
VP51451
p11399
sg10
I3
sg11
VBLK
p11400
sg13
I1
sasg19
(lp11401
(dp11402
g7
I45
sg22
VC0009447
p11403
sg10
I4
sg11
VCVID
p11404
sg13
I1
sa(dp11405
g7
I45
sg22
VC0009447
p11406
sg10
I4
sg11
VCVID
p11407
sg13
I1
sa(dp11408
g7
I45
sg22
VC0009447
p11409
sg10
I4
sg11
VCVID
p11410
sg13
I1
sasa(dp11411
g2
S'To examine whether anti-TG2 immunohistochemical (IHC) staining can be of diagnostic value in identifying extraintestinal involvement in CeD, tissue blocks of patients with IgA nephropathies (IgAN), minimal change disease, membranous glomerulonephritis, membrano-proliferative glomerulonephritis, normal kidney, intestinal biopsies from CeD, tropical sprue, nonspecific duodenitis, and inflammatory bowel disease; liver biopsies from patients with chronic hepatitis B and C, acute liver failure (ALF), and CeD-associated liver diseases were retrieved and subjected to IHC staining for anti-tissue transglutaminase 2 enzyme.\n'
p11412
sg4
(lp11413
(dp11414
g7
I172
sg8
VP11912
p11415
sg10
I3
sg11
VIgA
p11416
sg13
I1
sa(dp11417
g7
I584
sg8
VP21980
p11418
sg10
I37
sg11
Vanti-tissue transglutaminase 2 enzyme
p11419
sg13
I4
sa(dp11420
g7
I136
sg8
VP01137
p11421
sg10
I3
sg11
VCeD
p11422
sg13
I1
sa(dp11423
g7
I136
sg8
VP01137
p11424
sg10
I3
sg11
VCeD
p11425
sg13
I1
sasg19
(lp11426
(dp11427
g7
I222
sg22
VC0017665
p11428
sg10
I29
sg11
Vmembranous glomerulonephritis
p11429
sg13
I2
sa(dp11430
g7
I136
sg22
VC0011989
p11431
sg10
I3
sg11
VCeD
p11432
sg13
I1
sa(dp11433
g7
I357
sg22
VC0341248
p11434
sg10
I22
sg11
Vnonspecific duodenitis
p11435
sg13
I2
sa(dp11436
g7
I136
sg22
VC0011989
p11437
sg10
I3
sg11
VCeD
p11438
sg13
I1
sa(dp11439
g7
I341
sg22
VC0038054
p11440
sg10
I14
sg11
Vtropical sprue
p11441
sg13
I2
sa(dp11442
g7
I520
sg22
VC0023895
p11443
sg10
I14
sg11
Vliver diseases
p11444
sg13
I2
sa(dp11445
g7
I385
sg22
VC0021390
p11446
sg10
I26
sg11
Vinflammatory bowel disease
p11447
sg13
I3
sa(dp11448
g7
I447
sg22
VC0524909
p11449
sg10
I19
sg11
Vchronic hepatitis B
p11450
sg13
I3
sa(dp11451
g7
I495
sg22
VC0162557
p11452
sg10
I3
sg11
VALF
p11453
sg13
I1
sa(dp11454
g7
I198
sg22
VC1704320
p11455
sg10
I22
sg11
Vminimal change disease
p11456
sg13
I3
sa(dp11457
g7
I136
sg22
VC0011989
p11458
sg10
I3
sg11
VCeD
p11459
sg13
I1
sa(dp11460
g7
I262
sg22
VC0235618
p11461
sg10
I32
sg11
Vproliferative glomerulonephritis
p11462
sg13
I2
sa(dp11463
g7
I176
sg22
VC0022658
p11464
sg10
I13
sg11
Vnephropathies
p11465
sg13
I1
sa(dp11466
g7
I474
sg22
VC0162557
p11467
sg10
I19
sg11
Vacute liver failure
p11468
sg13
I3
sasa(dp11469
g2
S'Transglutaminase-2 (TG2) is a new anti-fibrotic target for chronic kidney disease, for its role in altering the extracellular homeostatic balance leading to excessive build-up of matrix in kidney.\n'
p11470
sg4
(lp11471
(dp11472
g7
I20
sg8
VP21980
p11473
sg10
I3
sg11
VTG2
p11474
sg13
I1
sa(dp11475
g7
I0
sg8
VP21980
p11476
sg10
I18
sg11
VTransglutaminase-2
p11477
sg13
I1
sasg19
(lp11478
(dp11479
g7
I59
sg22
VC1561643
p11480
sg10
I22
sg11
Vchronic kidney disease
p11481
sg13
I3
sasa(dp11482
g2
S'Upregulated TG2 and impaired renal function were apparent with EST delivery combined with folic acid-induced nephropathy.\n'
p11483
sg4
(lp11484
(dp11485
g7
I12
sg8
VP21980
p11486
sg10
I3
sg11
VTG2
p11487
sg13
I1
sasg19
(lp11488
(dp11489
g7
I20
sg22
VC0341697
p11490
sg10
I23
sg11
Vimpaired renal function
p11491
sg13
I3
sa(dp11492
g7
I109
sg22
VC0022658
p11493
sg10
I11
sg11
Vnephropathy
p11494
sg13
I1
sasa(dp11495
g2
S'The CD89xTG2 formula had a high ability to discriminate active from inactive IgAN/HSPN in both situations: CD89xTG2/proteinuria ratio (AUC: 0.84, P &lt; 0.001, sensitivity: 76%, specificity: 74%) and CD89xTG2/urinary creatinine ratio (AUC: 0.82, P &lt; 0.001, sensitivity: 75%, specificity: 74%).\n'
p11496
sg4
(lp11497
(dp11498
g7
I77
sg8
VP07900
p11499
sg10
I9
sg11
VIgAN/HSPN
p11500
sg13
I1
sasg19
(lp11501
sa(dp11502
g2
S'Significant correlations between urinary CD89 and TG2 (r = 0.711, P &lt; 0.001), proteinuria and urinary CD89 (r = - 0.585, P &lt; 0.001), and proteinuria and urinary TG2 (r = - 0.620, P &lt; 0.001) were observed.\n'
p11503
sg4
(lp11504
(dp11505
g7
I41
sg8
VP21980
p11506
sg10
I12
sg11
VCD89 and TG2
p11507
sg13
I3
sasg19
(lp11508
sa(dp11509
g2
S'Mutations in ADP-ribosylation factor guanine nucleotide-exchange factor 2 (ARFGEF2) gene was recently recognized to cause bilateral periventricular nodular heterotopia, putaminal hyperintensity and movement disorder.\n'
p11510
sg4
(lp11511
(dp11512
g7
I75
sg8
g15
sg10
I7
sg11
VARFGEF2
p11513
sg13
I1
sa(dp11514
g7
I13
sg8
g15
sg10
I60
sg11
VADP-ribosylation factor guanine nucleotide-exchange factor 2
p11515
sg13
I6
sasg19
(lp11516
(dp11517
g7
I198
sg22
VC0026650
p11518
sg10
I17
sg11
Vmovement disorder
p11519
sg13
I2
sa(dp11520
g7
I122
sg22
VC1848213
p11521
sg10
I45
sg11
Vbilateral periventricular nodular heterotopia
p11522
sg13
I4
sasa(dp11523
g2
S'Mutations in the ARFGEF2 gene must be considered in the presence of bilateral periventricular nodular heterotopia and putaminal hyperintensity in children presenting with movement disorder, severe developmental delay and microcephaly.\n'
p11524
sg4
(lp11525
(dp11526
g7
I17
sg8
g15
sg10
I12
sg11
VARFGEF2 gene
p11527
sg13
I2
sasg19
(lp11528
(dp11529
g7
I221
sg22
VC0025958
p11530
sg10
I12
sg11
Vmicrocephaly
p11531
sg13
I1
sa(dp11532
g7
I171
sg22
VC0026650
p11533
sg10
I17
sg11
Vmovement disorder
p11534
sg13
I2
sa(dp11535
g7
I68
sg22
VC1848213
p11536
sg10
I45
sg11
Vbilateral periventricular nodular heterotopia
p11537
sg13
I4
sa(dp11538
g7
I197
sg22
VC0424605
p11539
sg10
I19
sg11
Vdevelopmental delay
p11540
sg13
I2
sasa(dp11541
g2
S'We report a child with a severe choreadystonic movement disorder, bilateral periventricular nodular heterotopia (BPNH), and secondary microcephaly based on compound heterozygosity for two new ARFGEF2 mutations (c.2031_2038dup and c.3798_3802del), changing the limited knowledge about the phenotype.\n'
p11542
sg4
(lp11543
(dp11544
g7
I192
sg8
g15
sg10
I7
sg11
VARFGEF2
p11545
sg13
I1
sasg19
(lp11546
(dp11547
g7
I47
sg22
VC0026650
p11548
sg10
I17
sg11
Vmovement disorder
p11549
sg13
I2
sa(dp11550
g7
I66
sg22
VC1848213
p11551
sg10
I45
sg11
Vbilateral periventricular nodular heterotopia
p11552
sg13
I4
sa(dp11553
g7
I113
sg22
VC1848213
p11554
sg10
I4
sg11
VBPNH
p11555
sg13
I1
sa(dp11556
g7
I124
sg22
VC0431352
p11557
sg10
I22
sg11
Vsecondary microcephaly
p11558
sg13
I2
sasa(dp11559
g2
S'Sections from 21 tumours diagnosed as primary or metastatic rhabdomyosarcoma were stained for alpha and beta enolase.\n'
p11560
sg4
(lp11561
(dp11562
g7
I104
sg8
VP13929
p11563
sg10
I12
sg11
Vbeta enolase
p11564
sg13
I2
sasg19
(lp11565
(dp11566
g7
I17
sg22
VC0027651
p11567
sg10
I7
sg11
Vtumours
p11568
sg13
I1
sa(dp11569
g7
I60
sg22
VC0035412
p11570
sg10
I16
sg11
Vrhabdomyosarcoma
p11571
sg13
I1
sasa(dp11572
g2
S'The results show that beta enolase is a sensitive marker of muscular differentiation in rhabdomyosarcoma.\n'
p11573
sg4
(lp11574
(dp11575
g7
I22
sg8
VP13929
p11576
sg10
I12
sg11
Vbeta enolase
p11577
sg13
I2
sasg19
(lp11578
(dp11579
g7
I88
sg22
VC0035412
p11580
sg10
I16
sg11
Vrhabdomyosarcoma
p11581
sg13
I1
sasa(dp11582
g2
S'Before treatment, a serum sample from a patient with rhabdomyosarcoma contained a high level of beta enolase and serum samples from patients with (ganglio)neuroblastoma contained high levels of gamma enolase.\n'
p11583
sg4
(lp11584
(dp11585
g7
I194
sg8
VP09104
p11586
sg10
I13
sg11
Vgamma enolase
p11587
sg13
I2
sa(dp11588
g7
I96
sg8
VP13929
p11589
sg10
I12
sg11
Vbeta enolase
p11590
sg13
I2
sasg19
(lp11591
(dp11592
g7
I155
sg22
VC0027819
p11593
sg10
I13
sg11
Vneuroblastoma
p11594
sg13
I1
sa(dp11595
g7
I53
sg22
VC0035412
p11596
sg10
I16
sg11
Vrhabdomyosarcoma
p11597
sg13
I1
sasa(dp11598
g2
S'A comparative study of beta enolase and myoglobin as markers of muscle differentiation in rhabdomyosarcoma was carried out, using an immunoperoxidase peroxidase antiperoxidase technique.\n'
p11599
sg4
(lp11600
(dp11601
g7
I139
sg8
VP05164
p11602
sg10
I10
sg11
Vperoxidase
p11603
sg13
I1
sa(dp11604
g7
I133
sg8
g15
sg10
I16
sg11
Vimmunoperoxidase
p11605
sg13
I1
sa(dp11606
g7
I40
sg8
VP02144
p11607
sg10
I9
sg11
Vmyoglobin
p11608
sg13
I1
sa(dp11609
g7
I23
sg8
VP13929
p11610
sg10
I12
sg11
Vbeta enolase
p11611
sg13
I2
sasg19
(lp11612
(dp11613
g7
I90
sg22
VC0035412
p11614
sg10
I16
sg11
Vrhabdomyosarcoma
p11615
sg13
I1
sasa(dp11616
g2
S'beta Enolase and myoglobin are useful in the histological diagnosis of rhabdomyosarcoma, and of the two, beta enolase seems to be the more sensitive.\n'
p11617
sg4
(lp11618
(dp11619
g7
I17
sg8
VP02144
p11620
sg10
I9
sg11
Vmyoglobin
p11621
sg13
I1
sa(dp11622
g7
I0
sg8
VP13929
p11623
sg10
I12
sg11
Vbeta Enolase
p11624
sg13
I2
sa(dp11625
g7
I105
sg8
VP13929
p11626
sg10
I12
sg11
Vbeta enolase
p11627
sg13
I2
sasg19
(lp11628
(dp11629
g7
I71
sg22
VC0035412
p11630
sg10
I16
sg11
Vrhabdomyosarcoma
p11631
sg13
I1
sasa(dp11632
g2
S'The major observed phenotypes in Tmem218(-/-) mice were progressive cystic kidney disease and retinal degeneration.\n'
p11633
sg4
(lp11634
sg19
(lp11635
(dp11636
g7
I68
sg22
VC1691228
p11637
sg10
I21
sg11
Vcystic kidney disease
p11638
sg13
I3
sa(dp11639
g7
I94
sg22
VC0035304
p11640
sg10
I20
sg11
Vretinal degeneration
p11641
sg13
I2
sasa(dp11642
g2
S'Certain patients with lymphoma may harbor mutations in perforin 1 (PRF1), unc-13 homolog D (UNC13D), syntaxin 11 (STX11), STXBP2 (syntaxin binding protein 2) or SH2 domain containing 1A (SH2D1A), which causes functional defects of cytotoxic lymphocytes.\n'
p11643
sg4
(lp11644
(dp11645
g7
I67
sg8
VP14222
p11646
sg10
I4
sg11
VPRF1
p11647
sg13
I1
sa(dp11648
g7
I122
sg8
g15
sg10
I6
sg11
VSTXBP2
p11649
sg13
I1
sa(dp11650
g7
I101
sg8
g15
sg10
I11
sg11
Vsyntaxin 11
p11651
sg13
I2
sa(dp11652
g7
I92
sg8
g15
sg10
I6
sg11
VUNC13D
p11653
sg13
I1
sa(dp11654
g7
I130
sg8
g15
sg10
I26
sg11
Vsyntaxin binding protein 2
p11655
sg13
I4
sa(dp11656
g7
I55
sg8
VP14222
p11657
sg10
I10
sg11
Vperforin 1
p11658
sg13
I2
sa(dp11659
g7
I114
sg8
g15
sg10
I5
sg11
VSTX11
p11660
sg13
I1
sa(dp11661
g7
I161
sg8
g15
sg10
I24
sg11
VSH2 domain containing 1A
p11662
sg13
I4
sa(dp11663
g7
I74
sg8
g15
sg10
I16
sg11
Vunc-13 homolog D
p11664
sg13
I3
sa(dp11665
g7
I187
sg8
g15
sg10
I6
sg11
VSH2D1A
p11666
sg13
I1
sasg19
(lp11667
(dp11668
g7
I22
sg22
VC0024299
p11669
sg10
I8
sg11
Vlymphoma
p11670
sg13
I1
sasa(dp11671
g2
S'In the present study, 90 patients with lymphoma were analyzed for UNC13D, PRF1, STXBP2, STX11, SH2D1A and X-linked inhibitor of apoptosis.\n'
p11672
sg4
(lp11673
(dp11674
g7
I80
sg8
g15
sg10
I6
sg11
VSTXBP2
p11675
sg13
I1
sa(dp11676
g7
I88
sg8
g15
sg10
I5
sg11
VSTX11
p11677
sg13
I1
sa(dp11678
g7
I95
sg8
g15
sg10
I6
sg11
VSH2D1A
p11679
sg13
I1
sa(dp11680
g7
I66
sg8
g15
sg10
I6
sg11
VUNC13D
p11681
sg13
I1
sa(dp11682
g7
I74
sg8
VP14222
p11683
sg10
I4
sg11
VPRF1
p11684
sg13
I1
sasg19
(lp11685
(dp11686
g7
I39
sg22
VC0024299
p11687
sg10
I8
sg11
Vlymphoma
p11688
sg13
I1
sasa(dp11689
g2
S'Therefore, genes involved in these steps play important roles in the pathogenesis of HLH disease which include PRF1, UNC13D (MUNC13-4), STX11, and STXBP2 (MUNC18-2).\n'
p11690
sg4
(lp11691
(dp11692
g7
I155
sg8
g15
sg10
I8
sg11
VMUNC18-2
p11693
sg13
I1
sa(dp11694
g7
I125
sg8
g15
sg10
I8
sg11
VMUNC13-4
p11695
sg13
I1
sa(dp11696
g7
I147
sg8
g15
sg10
I6
sg11
VSTXBP2
p11697
sg13
I1
sa(dp11698
g7
I136
sg8
g15
sg10
I5
sg11
VSTX11
p11699
sg13
I1
sa(dp11700
g7
I111
sg8
VP14222
p11701
sg10
I4
sg11
VPRF1
p11702
sg13
I1
sa(dp11703
g7
I117
sg8
g15
sg10
I6
sg11
VUNC13D
p11704
sg13
I1
sasg19
(lp11705
(dp11706
g7
I85
sg22
VC0024291
p11707
sg10
I3
sg11
VHLH
p11708
sg13
I1
sa(dp11709
g7
I69
sg22
VC0699748
p11710
sg10
I12
sg11
Vpathogenesis
p11711
sg13
I1
sasa(dp11712
g2
S'In the present study, we used exome sequencing to analyze PRF1, UNC13D, STX11, and STXBP2, as well as genes associated with primary immunodeficiency disease (RAB27A, LYST, AP3B1, SH2D1A, ITK, CD27, XIAP, and MAGT1) in Thai children with hemophagocytic lymphohistiocytosis (HLH).\n'
p11713
sg4
(lp11714
(dp11715
g7
I72
sg8
g15
sg10
I5
sg11
VSTX11
p11716
sg13
I1
sa(dp11717
g7
I179
sg8
g15
sg10
I6
sg11
VSH2D1A
p11718
sg13
I1
sa(dp11719
g7
I208
sg8
g15
sg10
I5
sg11
VMAGT1
p11720
sg13
I1
sa(dp11721
g7
I83
sg8
g15
sg10
I6
sg11
VSTXBP2
p11722
sg13
I1
sa(dp11723
g7
I187
sg8
VP19823
p11724
sg10
I3
sg11
VITK
p11725
sg13
I1
sa(dp11726
g7
I166
sg8
g15
sg10
I4
sg11
VLYST
p11727
sg13
I1
sa(dp11728
g7
I192
sg8
VP26842
p11729
sg10
I4
sg11
VCD27
p11730
sg13
I1
sa(dp11731
g7
I158
sg8
VP51159
p11732
sg10
I6
sg11
VRAB27A
p11733
sg13
I1
sa(dp11734
g7
I172
sg8
g15
sg10
I5
sg11
VAP3B1
p11735
sg13
I1
sa(dp11736
g7
I58
sg8
VP14222
p11737
sg10
I4
sg11
VPRF1
p11738
sg13
I1
sa(dp11739
g7
I198
sg8
VP98170
p11740
sg10
I4
sg11
VXIAP
p11741
sg13
I1
sa(dp11742
g7
I64
sg8
g15
sg10
I6
sg11
VUNC13D
p11743
sg13
I1
sasg19
(lp11744
(dp11745
g7
I132
sg22
VC0021051
p11746
sg10
I24
sg11
Vimmunodeficiency disease
p11747
sg13
I2
sa(dp11748
g7
I273
sg22
VC0024291
p11749
sg10
I3
sg11
VHLH
p11750
sg13
I1
sa(dp11751
g7
I237
sg22
VC0024291
p11752
sg10
I34
sg11
Vhemophagocytic lymphohistiocytosis
p11753
sg13
I2
sasa(dp11754
g2
S'mRNA expression of VDR and the metabolizing enzymes 1Alfa-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24A1) were examined in BAT of mice models of obesity and during brown adipocyte differentiation.\n'
p11755
sg4
(lp11756
(dp11757
g7
I19
sg8
VP11473
p11758
sg10
I3
sg11
VVDR
p11759
sg13
I1
sa(dp11760
g7
I71
sg8
g15
sg10
I7
sg11
VCYP27B1
p11761
sg13
I1
sa(dp11762
g7
I100
sg8
g15
sg10
I7
sg11
VCYP24A1
p11763
sg13
I1
sasg19
(lp11764
(dp11765
g7
I148
sg22
VC0028754
p11766
sg10
I7
sg11
Vobesity
p11767
sg13
I1
sasa(dp11768
g2
S'We undertook a comprehensive analysis between 100 tagging single nucleotide polymorphisms (tagSNPs) in genes encoding for DHCR7, CYP2R1, VDBP, CYP27B1, CYP27A1, CYP24A1, VDR and RXRG, and obesity traits in 5224 participants (aged 45 years) in the 1958 British birth cohort (1958BC).\n'
p11769
sg4
(lp11770
(dp11771
g7
I178
sg8
VP48443
p11772
sg10
I4
sg11
VRXRG
p11773
sg13
I1
sa(dp11774
g7
I161
sg8
g15
sg10
I7
sg11
VCYP24A1
p11775
sg13
I1
sa(dp11776
g7
I152
sg8
g15
sg10
I7
sg11
VCYP27A1
p11777
sg13
I1
sa(dp11778
g7
I137
sg8
VP02774
p11779
sg10
I4
sg11
VVDBP
p11780
sg13
I1
sa(dp11781
g7
I143
sg8
g15
sg10
I7
sg11
VCYP27B1
p11782
sg13
I1
sa(dp11783
g7
I129
sg8
g15
sg10
I6
sg11
VCYP2R1
p11784
sg13
I1
sa(dp11785
g7
I122
sg8
g15
sg10
I5
sg11
VDHCR7
p11786
sg13
I1
sa(dp11787
g7
I170
sg8
VP11473
p11788
sg10
I3
sg11
VVDR
p11789
sg13
I1
sasg19
(lp11790
(dp11791
g7
I188
sg22
VC0028754
p11792
sg10
I7
sg11
Vobesity
p11793
sg13
I1
sasa(dp11794
g2
S'In the 1958BC (n=5224), after Bonferroni correction, none of the tagSNPs were associated with obesity traits except for one tagSNP from CYP24A1 that was associated with waist-hip ratio (WHR) (rs2296239, P=0.001).\n'
p11795
sg4
(lp11796
(dp11797
g7
I136
sg8
g15
sg10
I7
sg11
VCYP24A1
p11798
sg13
I1
sasg19
(lp11799
(dp11800
g7
I94
sg22
VC0028754
p11801
sg10
I7
sg11
Vobesity
p11802
sg13
I1
sasa(dp11803
g2
S'Obesity is characterized by a decreased expression of the 25-hydroxylase CYP2J2 and the 1Alfa-hydroxylase CYP27B1 in SAT, whereas the catabolic CYP24A1 does not differ between lean and obese women.\n'
p11804
sg4
(lp11805
(dp11806
g7
I88
sg8
g15
sg10
I25
sg11
V1Alfa-hydroxylase CYP27B1
p11807
sg13
I2
sa(dp11808
g7
I134
sg8
g15
sg10
I17
sg11
Vcatabolic CYP24A1
p11809
sg13
I2
sa(dp11810
g7
I58
sg8
VP51589
p11811
sg10
I21
sg11
V25-hydroxylase CYP2J2
p11812
sg13
I2
sasg19
(lp11813
(dp11814
g7
I0
sg22
VC0028754
p11815
sg10
I7
sg11
VObesity
p11816
sg13
I1
sa(dp11817
g7
I185
sg22
VC0028754
p11818
sg10
I5
sg11
Vobese
p11819
sg13
I1
sasa(dp11820
g2
S'These coumarins thus act as isoform-selective CA inhibitors with the possibility to target isoforms involved in pathologies such as obesity (CA VA/VB) or cancer (CA IX and XII) without inhibiting the physiologically dominant, highly abundant hCA I and II.\n'
p11821
sg4
(lp11822
(dp11823
g7
I28
sg8
VP38606
p11824
sg10
I20
sg11
Visoform-selective CA
p11825
sg13
I2
sa(dp11826
g7
I141
sg8
VP35218
p11827
sg10
I5
sg11
VCA VA
p11828
sg13
I2
sa(dp11829
g7
I162
sg8
g15
sg10
I5
sg11
VCA IX
p11830
sg13
I2
sasg19
(lp11831
(dp11832
g7
I132
sg22
VC0028754
p11833
sg10
I7
sg11
Vobesity
p11834
sg13
I1
sa(dp11835
g7
I154
sg22
VC0006826
p11836
sg10
I6
sg11
Vcancer
p11837
sg13
I1
sasa(dp11838
g2
S'Specifically, FGFR loss of function counteracts renal FGF-23/Klotho signaling, leading to deregulation of Cyp27b1 and Cyp24a1 and the induction of hypervitaminosis D and hyperphosphatemia.\n'
p11839
sg4
(lp11840
(dp11841
g7
I106
sg8
g15
sg10
I7
sg11
VCyp27b1
p11842
sg13
I1
sa(dp11843
g7
I54
sg8
g15
sg10
I6
sg11
VFGF-23
p11844
sg13
I1
sa(dp11845
g7
I61
sg8
g15
sg10
I6
sg11
VKlotho
p11846
sg13
I1
sa(dp11847
g7
I118
sg8
g15
sg10
I7
sg11
VCyp24a1
p11848
sg13
I1
sasg19
(lp11849
(dp11850
g7
I147
sg22
VC1442839
p11851
sg10
I18
sg11
Vhypervitaminosis D
p11852
sg13
I2
sa(dp11853
g7
I170
sg22
VC0085681
p11854
sg10
I17
sg11
Vhyperphosphatemia
p11855
sg13
I1
sasa(dp11856
g2
S'Here, we identify a significant decrease in PLOD3 expression and its encoded protein, the collagen modifying enzyme lysyl hydroxylase 3 (LH3), in RDEB.\n'
p11857
sg4
(lp11858
(dp11859
g7
I44
sg8
g15
sg10
I5
sg11
VPLOD3
p11860
sg13
I1
sa(dp11861
g7
I109
sg8
g15
sg10
I26
sg11
Venzyme lysyl hydroxylase 3
p11862
sg13
I4
sa(dp11863
g7
I146
sg8
g15
sg10
I4
sg11
VRDEB
p11864
sg13
I1
sa(dp11865
g7
I137
sg8
g15
sg10
I3
sg11
VLH3
p11866
sg13
I1
sasg19
(lp11867
(dp11868
g7
I146
sg22
VC0079474
p11869
sg10
I4
sg11
VRDEB
p11870
sg13
I1
sasa(dp11871
g2
S'Although NMZL shared with SMZL a common mutation profile, NMZL harbored PTPRD lesions that were otherwise absent in SMZL.\n'
p11872
sg4
(lp11873
sg19
(lp11874
sa(dp11875
g2
S'Collectively, these findings provide new insights into the genetics of NMZL, identify PTPRD lesions as a novel marker for this lymphoma across mature B-cell tumors, and support the distinction of NMZL as an independent clinicopathologic entity within the current lymphoma classification.\n'
p11876
sg4
(lp11877
(dp11878
g7
I86
sg8
VP23468
p11879
sg10
I5
sg11
VPTPRD
p11880
sg13
I1
sasg19
(lp11881
(dp11882
g7
I127
sg22
VC0024299
p11883
sg10
I8
sg11
Vlymphoma
p11884
sg13
I1
sa(dp11885
g7
I127
sg22
VC0024299
p11886
sg10
I8
sg11
Vlymphoma
p11887
sg13
I1
sa(dp11888
g7
I157
sg22
VC0027651
p11889
sg10
I6
sg11
Vtumors
p11890
sg13
I1
sasa(dp11891
g2
S'Together with mutations affecting CSMD2, CSMD3, and PTPRD, these findings may suggest that alterations in genes having a role in CNS development may facilitate diffuse large B-cell lymphoma manifestation in the CNS.\n'
p11892
sg4
(lp11893
(dp11894
g7
I41
sg8
g15
sg10
I5
sg11
VCSMD3
p11895
sg13
I1
sa(dp11896
g7
I52
sg8
VP23468
p11897
sg10
I5
sg11
VPTPRD
p11898
sg13
I1
sasg19
(lp11899
(dp11900
g7
I160
sg22
VC0079744
p11901
sg10
I29
sg11
Vdiffuse large B-cell lymphoma
p11902
sg13
I4
sasa(dp11903
g2
S'We have attempted to find out any relationships between circulating tumor necrosis factor (TNF)-alpha levels and Epstein-Barr virus (EBV) associated peripheral T-cell and NK-cell proliferative disease/lymphoma (PTPD/L) status.\n'
p11904
sg4
(lp11905
(dp11906
g7
I149
sg8
VP23468
p11907
sg10
I60
sg11
Vperipheral T-cell and NK-cell proliferative disease/lymphoma
p11908
sg13
I6
sa(dp11909
g7
I68
sg8
VP01375
p11910
sg10
I33
sg11
Vtumor necrosis factor (TNF)-alpha
p11911
sg13
I4
sa(dp11912
g7
I211
sg8
VP23468
p11913
sg10
I6
sg11
VPTPD/L
p11914
sg13
I1
sasg19
(lp11915
(dp11916
g7
I68
sg22
VC0333516
p11917
sg10
I14
sg11
Vtumor necrosis
p11918
sg13
I2
sa(dp11919
g7
I201
sg22
VC0024299
p11920
sg10
I8
sg11
Vlymphoma
p11921
sg13
I1
sa(dp11922
g7
I179
sg22
VC0334094
p11923
sg10
I13
sg11
Vproliferative
p11924
sg13
I1
sasa(dp11925
g2
S'Nineteen newly recruited patients of pemphigus vulgaris (PV) received monthly DCPs in phase I and were then randomized into two groups.\n'
p11926
sg4
(lp11927
sg19
(lp11928
(dp11929
g7
I37
sg22
VC0030809
p11930
sg10
I18
sg11
Vpemphigus vulgaris
p11931
sg13
I2
sa(dp11932
g7
I57
sg22
VC0030809
p11933
sg10
I2
sg11
VPV
p11934
sg13
I1
sasa(dp11935
g2
S'Although the DCP regimen is the standard therapy for pemphigus in India, we found no difference in the clinical outcome between patients receiving nine DCPs in phase II and patients shifted directly from phase I to III.\n'
p11936
sg4
(lp11937
sg19
(lp11938
(dp11939
g7
I53
sg22
VC0030807
p11940
sg10
I9
sg11
Vpemphigus
p11941
sg13
I1
sasa(dp11942
g2
S'Satisfactory results were obtained in 22 of 27 cases of seborrhea, usually within the 1st 4 cycles.\n'
p11943
sg4
(lp11944
sg19
(lp11945
(dp11946
g7
I56
sg22
VC0234927
p11947
sg10
I9
sg11
Vseborrhea
p11948
sg13
I1
sasa(dp11949
g2
S'After having received a total of 14 to 48 DCPS, further treatment for pemphigus was withdrawn.\n'
p11950
sg4
(lp11951
sg19
(lp11952
(dp11953
g7
I84
sg22
VC2825032
p11954
sg10
I9
sg11
Vwithdrawn
p11955
sg13
I1
sa(dp11956
g7
I70
sg22
VC0030807
p11957
sg10
I9
sg11
Vpemphigus
p11958
sg13
I1
sasa(dp11959
g2
S'The expression of polySia in metastatic and non-metastatic primary laryngeal squamous cell carcinoma (LSCC) tumor biopsy specimens was investigated by immunohistochemistry, while the expression of polysialyltransferase IV (ST8SiaIV)(), fibroblast growth factor receptor 1 (FGFR1), extracellular signal regulated kinases 1 and 2 (Erk 1/2) and c-Raf was tested in metastatic and non-metastatic primary tumor tissues (including the corresponding non-tumor control tissues) by Western blot analysis.\n'
p11960
sg4
(lp11961
(dp11962
g7
I281
sg8
g15
sg10
I46
sg11
Vextracellular signal regulated kinases 1 and 2
p11963
sg13
I7
sa(dp11964
g7
I223
sg8
g15
sg10
I8
sg11
VST8SiaIV
p11965
sg13
I1
sa(dp11966
g7
I273
sg8
VP20930
p11967
sg10
I5
sg11
VFGFR1
p11968
sg13
I1
sa(dp11969
g7
I197
sg8
g15
sg10
I24
sg11
Vpolysialyltransferase IV
p11970
sg13
I2
sa(dp11971
g7
I342
sg8
VP04049
p11972
sg10
I5
sg11
Vc-Raf
p11973
sg13
I1
sa(dp11974
g7
I236
sg8
g15
sg10
I35
sg11
Vfibroblast growth factor receptor 1
p11975
sg13
I5
sa(dp11976
g7
I329
sg8
VP29323
p11977
sg10
I7
sg11
VErk 1/2
p11978
sg13
I2
sasg19
(lp11979
(dp11980
g7
I392
sg22
VC0677930
p11981
sg10
I13
sg11
Vprimary tumor
p11982
sg13
I2
sa(dp11983
g7
I108
sg22
VC0027651
p11984
sg10
I5
sg11
Vtumor
p11985
sg13
I1
sa(dp11986
g7
I67
sg22
VC0280324
p11987
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p11988
sg13
I4
sa(dp11989
g7
I102
sg22
VC0280324
p11990
sg10
I4
sg11
VLSCC
p11991
sg13
I1
sa(dp11992
g7
I108
sg22
VC0027651
p11993
sg10
I5
sg11
Vtumor
p11994
sg13
I1
sasa(dp11995
g2
S'We previously reported that antisense human c-raf-1 cDNA transfection results in reduction of the endogenous c-raf-1 transcript, decreased tumor growth rate, and enhanced radiation sensitivity of SQ-20B tumor cells established from a radiation-resistant laryngeal squamous cell carcinoma.\n'
p11996
sg4
(lp11997
(dp11998
g7
I109
sg8
VP04049
p11999
sg10
I18
sg11
Vc-raf-1 transcript
p12000
sg13
I2
sa(dp12001
g7
I28
sg8
VP04049
p12002
sg10
I28
sg11
Vantisense human c-raf-1 cDNA
p12003
sg13
I4
sasg19
(lp12004
(dp12005
g7
I139
sg22
VC0027651
p12006
sg10
I5
sg11
Vtumor
p12007
sg13
I1
sa(dp12008
g7
I139
sg22
VC0598934
p12009
sg10
I12
sg11
Vtumor growth
p12010
sg13
I2
sa(dp12011
g7
I254
sg22
VC0280324
p12012
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p12013
sg13
I4
sasa(dp12014
g2
S'Conclusion: In a GPA33-positive human colorectal cancer xenograft mouse model, we validated a SPECT/CT-based theranostic PRIT regimen that led to 100% complete responses and 100% cures without any treatment-related toxicities, based on high TIs for radiosensitive tissues.\n'
p12015
sg4
(lp12016
(dp12017
g7
I17
sg8
g15
sg10
I5
sg11
VGPA33
p12018
sg13
I1
sasg19
(lp12019
(dp12020
g7
I38
sg22
VC1527249
p12021
sg10
I17
sg11
Vcolorectal cancer
p12022
sg13
I2
sasa(dp12023
g2
S'These studies support the view that anti-GPA33 DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.\n'
p12024
sg4
(lp12025
(dp12026
g7
I41
sg8
g15
sg10
I5
sg11
VGPA33
p12027
sg13
I1
sa(dp12028
g7
I36
sg8
g15
sg10
I20
sg11
Vanti-GPA33 DOTA-PRIT
p12029
sg13
I2
sasg19
(lp12030
(dp12031
g7
I138
sg22
VC0027651
p12032
sg10
I6
sg11
Vtumors
p12033
sg13
I1
sa(dp12034
g7
I120
sg22
VC1527249
p12035
sg10
I17
sg11
Vcolorectal cancer
p12036
sg13
I2
sasa(dp12037
g2
S'GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting.\n'
p12038
sg4
(lp12039
(dp12040
g7
I0
sg8
g15
sg10
I5
sg11
VGPA33
p12041
sg13
I1
sa(dp12042
g7
I11
sg8
VP31749
p12043
sg10
I31
sg11
Vcolorectal cancer (CRC) antigen
p12044
sg13
I4
sasg19
(lp12045
(dp12046
g7
I30
sg22
VC1527249
p12047
sg10
I3
sg11
VCRC
p12048
sg13
I1
sa(dp12049
g7
I11
sg22
VC1527249
p12050
sg10
I17
sg11
Vcolorectal cancer
p12051
sg13
I2
sa(dp12052
g7
I97
sg22
VC0027651
p12053
sg10
I5
sg11
Vtumor
p12054
sg13
I1
sasa(dp12055
g2
S'Furthermore, 19% of all heterozygous and 37% of all homozygous gpA33(DeltaN-Bcat) mice spontaneously developed aberrant crypt foci and adenomatous polyps, at frequencies and latencies akin to those observed in sporadic colon cancer in humans.\n'
p12056
sg4
(lp12057
sg19
(lp12058
(dp12059
g7
I219
sg22
VC0699790
p12060
sg10
I12
sg11
Vcolon cancer
p12061
sg13
I2
sa(dp12062
g7
I135
sg22
VC0206677
p12063
sg10
I18
sg11
Vadenomatous polyps
p12064
sg13
I2
sasa(dp12065
g2
S'GPA33 is highly expressed in most human colorectal cancers and has been verified as a diagnostic and therapeutic target.\n'
p12066
sg4
(lp12067
(dp12068
g7
I0
sg8
g15
sg10
I5
sg11
VGPA33
p12069
sg13
I1
sasg19
(lp12070
(dp12071
g7
I40
sg22
VC1527249
p12072
sg10
I18
sg11
Vcolorectal cancers
p12073
sg13
I2
sasa(dp12074
g2
S'The A33scFv-Fc specifically binds GPA33-positive colorectal cancer cells and tumor tissues.\n'
p12075
sg4
(lp12076
(dp12077
g7
I34
sg8
g15
sg10
I5
sg11
VGPA33
p12078
sg13
I1
sasg19
(lp12079
(dp12080
g7
I49
sg22
VC1527249
p12081
sg10
I17
sg11
Vcolorectal cancer
p12082
sg13
I2
sa(dp12083
g7
I77
sg22
VC0027651
p12084
sg10
I5
sg11
Vtumor
p12085
sg13
I1
sasa(dp12086
g2
S'These results indicate that CF750-A33scFv-Fc can target GPA33, suggesting the potential of CF750-A33scFv-Fc as an imaging agent for the diagnosis of colorectal cancer.\n'
p12087
sg4
(lp12088
(dp12089
g7
I56
sg8
g15
sg10
I5
sg11
VGPA33
p12090
sg13
I1
sasg19
(lp12091
(dp12092
g7
I149
sg22
VC1527249
p12093
sg10
I17
sg11
Vcolorectal cancer
p12094
sg13
I2
sasa(dp12095
g2
S'A recombinant single-chain immunotoxin based on the ribotoxin Alfa-sarcin (IMTXA33AlfaS), produced in the generally regarded as safe (GRAS) yeast Pichia pastoris, has been recently described as a promising candidate for the treatment of colorectal cancer cells expressing the glycoprotein A33 (GPA33) antigen, due to its high specific and effective cytotoxic effect on in vitro assays against targeted cells.\n'
p12096
sg4
(lp12097
(dp12098
g7
I294
sg8
g15
sg10
I5
sg11
VGPA33
p12099
sg13
I1
sa(dp12100
g7
I134
sg8
VP15538
p12101
sg10
I4
sg11
VGRAS
p12102
sg13
I1
sa(dp12103
g7
I276
sg8
g15
sg10
I16
sg11
Vglycoprotein A33
p12104
sg13
I2
sa(dp12105
g7
I106
sg8
VP15538
p12106
sg10
I26
sg11
Vgenerally regarded as safe
p12107
sg13
I4
sasg19
(lp12108
(dp12109
g7
I237
sg22
VC1527249
p12110
sg10
I17
sg11
Vcolorectal cancer
p12111
sg13
I2
sasa(dp12112
g2
S'Here we report the in vivo antitumor effectiveness of this immunotoxin on nude mice bearing GPA33-positive human colon cancer xenografts.\n'
p12113
sg4
(lp12114
(dp12115
g7
I92
sg8
g15
sg10
I44
sg11
VGPA33-positive human colon cancer xenografts
p12116
sg13
I5
sasg19
(lp12117
(dp12118
g7
I113
sg22
VC0699790
p12119
sg10
I12
sg11
Vcolon cancer
p12120
sg13
I2
sasa(dp12121
g2
S'Thus, the genes contained in this ABCB1 amplicon including ABCB4, SRI, DBF4, TMEM243, and RUNDC3B are overexpressed in many cancers, and especially in MDR tumors, while TP53TG1 and DMTF1 are bona fide tumor suppressors.\n'
p12122
sg4
(lp12123
(dp12124
g7
I90
sg8
g15
sg10
I7
sg11
VRUNDC3B
p12125
sg13
I1
sa(dp12126
g7
I34
sg8
VP08183
p12127
sg10
I14
sg11
VABCB1 amplicon
p12128
sg13
I2
sa(dp12129
g7
I181
sg8
g15
sg10
I5
sg11
VDMTF1
p12130
sg13
I1
sa(dp12131
g7
I71
sg8
g15
sg10
I4
sg11
VDBF4
p12132
sg13
I1
sa(dp12133
g7
I59
sg8
VP21439
p12134
sg10
I5
sg11
VABCB4
p12135
sg13
I1
sa(dp12136
g7
I169
sg8
g15
sg10
I7
sg11
VTP53TG1
p12137
sg13
I1
sa(dp12138
g7
I66
sg8
VP30626
p12139
sg10
I3
sg11
VSRI
p12140
sg13
I1
sasg19
(lp12141
(dp12142
g7
I155
sg22
VC0027651
p12143
sg10
I5
sg11
Vtumor
p12144
sg13
I1
sa(dp12145
g7
I155
sg22
VC0027651
p12146
sg10
I6
sg11
Vtumors
p12147
sg13
I1
sa(dp12148
g7
I124
sg22
VC0006826
p12149
sg10
I7
sg11
Vcancers
p12150
sg13
I1
sasa(dp12151
g2
S'In this study, we investigated the role of lncRNA-TP53TG1 in response to glucose deprivation in human gliomas.\n'
p12152
sg4
(lp12153
(dp12154
g7
I43
sg8
g15
sg10
I14
sg11
VlncRNA-TP53TG1
p12155
sg13
I1
sasg19
(lp12156
(dp12157
g7
I102
sg22
VC0017638
p12158
sg10
I7
sg11
Vgliomas
p12159
sg13
I1
sasa(dp12160
g2
S'The expression levels of TP53TG1 in glioma tissues and cells were analyzed by qRT-PCR.\n'
p12161
sg4
(lp12162
(dp12163
g7
I25
sg8
g15
sg10
I7
sg11
VTP53TG1
p12164
sg13
I1
sasg19
(lp12165
(dp12166
g7
I36
sg22
VC0017638
p12167
sg10
I6
sg11
Vglioma
p12168
sg13
I1
sasa(dp12169
g2
S'The expression of TP53TG1 was significantly higher in human glioma tissues or cell lines compared with normal brain tissue or NHA.\n'
p12170
sg4
(lp12171
(dp12172
g7
I18
sg8
g15
sg10
I7
sg11
VTP53TG1
p12173
sg13
I1
sasg19
(lp12174
(dp12175
g7
I60
sg22
VC0017638
p12176
sg10
I6
sg11
Vglioma
p12177
sg13
I1
sasa(dp12178
g2
S'Our data showed that TP53TG1 under glucose deprivation may promote cell proliferation and migration by influencing the expression of glucose metabolism related genes in glioma.\n'
p12179
sg4
(lp12180
(dp12181
g7
I21
sg8
g15
sg10
I7
sg11
VTP53TG1
p12182
sg13
I1
sasg19
(lp12183
(dp12184
g7
I72
sg22
VC0334094
p12185
sg10
I13
sg11
Vproliferation
p12186
sg13
I1
sa(dp12187
g7
I169
sg22
VC0017638
p12188
sg10
I6
sg11
Vglioma
p12189
sg13
I1
sasa(dp12190
g2
S'Herein, we have identified a p53-induced lncRNA, TP53TG1, that undergoes cancer-specific promoter hypermethylation-associated silencing.\n'
p12191
sg4
(lp12192
(dp12193
g7
I29
sg8
VP42771
p12194
sg10
I3
sg11
Vp53
p12195
sg13
I1
sa(dp12196
g7
I49
sg8
g15
sg10
I7
sg11
VTP53TG1
p12197
sg13
I1
sasg19
(lp12198
(dp12199
g7
I73
sg22
VC0006826
p12200
sg10
I6
sg11
Vcancer
p12201
sg13
I1
sasa(dp12202
g2
S'TP53TG1 epigenetic inactivation in cancer cells releases the transcriptional repression of YBX1-targeted growth-promoting genes and creates a chemoresistant tumor.\n'
p12203
sg4
(lp12204
(dp12205
g7
I91
sg8
VP67809
p12206
sg10
I4
sg11
VYBX1
p12207
sg13
I1
sa(dp12208
g7
I0
sg8
g15
sg10
I7
sg11
VTP53TG1
p12209
sg13
I1
sasg19
(lp12210
(dp12211
g7
I35
sg22
VC0006826
p12212
sg10
I6
sg11
Vcancer
p12213
sg13
I1
sa(dp12214
g7
I19
sg22
VC0544461
p12215
sg10
I12
sg11
Vinactivation
p12216
sg13
I1
sa(dp12217
g7
I157
sg22
VC0027651
p12218
sg10
I5
sg11
Vtumor
p12219
sg13
I1
sasa(dp12220
g2
S'The epigenetic loss of TP53TG1 therefore represents an altered event in an lncRNA that is linked to classical tumoral pathways, such as p53 signaling, but is also connected to regulatory networks of the cancer cell.\n'
p12221
sg4
(lp12222
(dp12223
g7
I136
sg8
VP42771
p12224
sg10
I3
sg11
Vp53
p12225
sg13
I1
sa(dp12226
g7
I23
sg8
g15
sg10
I7
sg11
VTP53TG1
p12227
sg13
I1
sasg19
(lp12228
(dp12229
g7
I203
sg22
VC0006826
p12230
sg10
I6
sg11
Vcancer
p12231
sg13
I1
sasa(dp12232
g2
S'RNA expression analysis of 11 adenocarcinomas by reverse-transcription polymerase chain reaction was performed for cancer-related genes residing at 7q21 (ABCB1, ABCB4, CDK6, HGF, DMTF1, SRI, TP53AP1) and 20q13 (ZNF217, BCAS1, CYP24, TNFRSF6B).\n'
p12233
sg4
(lp12234
(dp12235
g7
I179
sg8
g15
sg10
I5
sg11
VDMTF1
p12236
sg13
I1
sa(dp12237
g7
I168
sg8
g15
sg10
I4
sg11
VCDK6
p12238
sg13
I1
sa(dp12239
g7
I174
sg8
VP05231
p12240
sg10
I3
sg11
VHGF
p12241
sg13
I1
sa(dp12242
g7
I219
sg8
g15
sg10
I5
sg11
VBCAS1
p12243
sg13
I1
sa(dp12244
g7
I161
sg8
VP21439
p12245
sg10
I5
sg11
VABCB4
p12246
sg13
I1
sa(dp12247
g7
I154
sg8
VP08183
p12248
sg10
I5
sg11
VABCB1
p12249
sg13
I1
sa(dp12250
g7
I226
sg8
g15
sg10
I5
sg11
VCYP24
p12251
sg13
I1
sa(dp12252
g7
I191
sg8
g15
sg10
I7
sg11
VTP53AP1
p12253
sg13
I1
sa(dp12254
g7
I233
sg8
g15
sg10
I8
sg11
VTNFRSF6B
p12255
sg13
I1
sa(dp12256
g7
I186
sg8
VP30626
p12257
sg10
I3
sg11
VSRI
p12258
sg13
I1
sa(dp12259
g7
I211
sg8
g15
sg10
I6
sg11
VZNF217
p12260
sg13
I1
sasg19
(lp12261
(dp12262
g7
I174
sg22
VC0399440
p12263
sg10
I3
sg11
VHGF
p12264
sg13
I1
sa(dp12265
g7
I30
sg22
VC0001418
p12266
sg10
I15
sg11
Vadenocarcinomas
p12267
sg13
I1
sa(dp12268
g7
I115
sg22
VC0006826
p12269
sg10
I6
sg11
Vcancer
p12270
sg13
I1
sasa(dp12271
g2
S'(2004) originally reported a significant association between TD and the NADPH quinine oxidoreductase 1 (NQO1) gene Pro187Ser (C609T, rs1800566) polymorphism in Korean schizophrenia patients; however, subsequent studies have not consistently replicated these findings.\n'
p12272
sg4
(lp12273
(dp12274
g7
I72
sg8
VP30043
p12275
sg10
I30
sg11
VNADPH quinine oxidoreductase 1
p12276
sg13
I4
sa(dp12277
g7
I104
sg8
VP15559
p12278
sg10
I4
sg11
VNQO1
p12279
sg13
I1
sasg19
(lp12280
(dp12281
g7
I167
sg22
VC0036341
p12282
sg10
I13
sg11
Vschizophrenia
p12283
sg13
I1
sasa(dp12284
g2
S'Western blot analysis showed that compound 3 significantly down-regulated the expression of phosphorylated STAT3 in both human and mouse colon cancer cells indicating that the mechanism of action for compound 3 may involve the inhibition of JAK3/STAT3 signaling pathways.\n'
p12285
sg4
(lp12286
(dp12287
g7
I107
sg8
VP40763
p12288
sg10
I5
sg11
VSTAT3
p12289
sg13
I1
sa(dp12290
g7
I107
sg8
VP40763
p12291
sg10
I5
sg11
VSTAT3
p12292
sg13
I1
sa(dp12293
g7
I241
sg8
VP52333
p12294
sg10
I4
sg11
VJAK3
p12295
sg13
I1
sasg19
(lp12296
(dp12297
g7
I137
sg22
VC0699790
p12298
sg10
I12
sg11
Vcolon cancer
p12299
sg13
I2
sasa(dp12300
g2
S'In the present study, the expression of IL-1Beta, IL-2, IL-4, IFNGamma, TNF-Alfa, iNOS, COX-2, Jak3, Stat3 and NF-KB were increased in the early stages of experimental colorectal cancer.\n'
p12301
sg4
(lp12302
(dp12303
g7
I82
sg8
g15
sg10
I4
sg11
ViNOS
p12304
sg13
I1
sa(dp12305
g7
I40
sg8
VP01584
p12306
sg10
I8
sg11
VIL-1Beta
p12307
sg13
I1
sa(dp12308
g7
I101
sg8
VP40763
p12309
sg10
I5
sg11
VStat3
p12310
sg13
I1
sa(dp12311
g7
I56
sg8
VP05112
p12312
sg10
I4
sg11
VIL-4
p12313
sg13
I1
sa(dp12314
g7
I50
sg8
VP60568
p12315
sg10
I4
sg11
VIL-2
p12316
sg13
I1
sa(dp12317
g7
I72
sg8
VP01375
p12318
sg10
I8
sg11
VTNF-Alfa
p12319
sg13
I1
sa(dp12320
g7
I95
sg8
VP52333
p12321
sg10
I4
sg11
VJak3
p12322
sg13
I1
sa(dp12323
g7
I88
sg8
VP35354
p12324
sg10
I5
sg11
VCOX-2
p12325
sg13
I1
sasg19
(lp12326
(dp12327
g7
I168
sg22
VC1527249
p12328
sg10
I17
sg11
Vcolorectal cancer
p12329
sg13
I2
sasa(dp12330
g2
S'JAK3 inhibitors may, therefore, be useful in the chemoprevention of colorectal cancer.\n'
p12331
sg4
(lp12332
(dp12333
g7
I0
sg8
VP52333
p12334
sg10
I4
sg11
VJAK3
p12335
sg13
I1
sasg19
(lp12336
(dp12337
g7
I68
sg22
VC1527249
p12338
sg10
I17
sg11
Vcolorectal cancer
p12339
sg13
I2
sasa(dp12340
g2
S'JAK3 inhibitors may therefore be useful in the prevention of colorectal cancer in individuals with FAP.\n'
p12341
sg4
(lp12342
(dp12343
g7
I99
sg8
VP25054
p12344
sg10
I3
sg11
VFAP
p12345
sg13
I1
sa(dp12346
g7
I0
sg8
VP52333
p12347
sg10
I4
sg11
VJAK3
p12348
sg13
I1
sasg19
(lp12349
(dp12350
g7
I99
sg22
VC0032580
p12351
sg10
I3
sg11
VFAP
p12352
sg13
I1
sa(dp12353
g7
I61
sg22
VC1527249
p12354
sg10
I17
sg11
Vcolorectal cancer
p12355
sg13
I2
sasa(dp12356
g2
S'Placenta praevia complicated 2.54% of cases with a previous caesarean section compared with 0.44% of cases with no scar--a 5-fold increase.\n'
p12357
sg4
(lp12358
sg19
(lp12359
(dp12360
g7
I115
sg22
VC2004491
p12361
sg10
I4
sg11
Vscar
p12362
sg13
I1
sa(dp12363
g7
I0
sg22
VC0032046
p12364
sg10
I16
sg11
VPlacenta praevia
p12365
sg13
I2
sasa(dp12366
g2
S'Thus, modulating DDAH1 activity through FXR receptor agonists such as UDCA could be a therapeutic target for treating reduced nitric oxide bioavailability in congestive heart failure and other cardiovascular diseases.\n'
p12367
sg4
(lp12368
(dp12369
g7
I17
sg8
g15
sg10
I5
sg11
VDDAH1
p12370
sg13
I1
sa(dp12371
g7
I40
sg8
VP23945
p12372
sg10
I12
sg11
VFXR receptor
p12373
sg13
I2
sasg19
(lp12374
(dp12375
g7
I193
sg22
VC0007222
p12376
sg10
I23
sg11
Vcardiovascular diseases
p12377
sg13
I2
sa(dp12378
g7
I158
sg22
VC0018802
p12379
sg10
I24
sg11
Vcongestive heart failure
p12380
sg13
I3
sasa(dp12381
g2
S'The aim of this study was to investigate the effect of pharmacological treatment on symmetric dimethylarginine (SDMA), ADMA and arginine plasma concentrations in patients with acute congestive heart failure (ACHF) through the evaluation of type-1 system cationic amino acid transporter-1/type 1 dimethylarginine dimethylaminohydrolases-1 (CAT-1/DDAH-1).\n'
p12382
sg4
(lp12383
(dp12384
g7
I274
sg8
g15
sg10
I63
sg11
Vtransporter-1/type 1 dimethylarginine dimethylaminohydrolases-1
p12385
sg13
I4
sa(dp12386
g7
I339
sg8
VP04040
p12387
sg10
I5
sg11
VCAT-1
p12388
sg13
I1
sa(dp12389
g7
I345
sg8
g15
sg10
I6
sg11
VDDAH-1
p12390
sg13
I1
sasg19
(lp12391
(dp12392
g7
I208
sg22
VC0264719
p12393
sg10
I4
sg11
VACHF
p12394
sg13
I1
sa(dp12395
g7
I176
sg22
VC0264719
p12396
sg10
I30
sg11
Vacute congestive heart failure
p12397
sg13
I4
sasa(dp12398
g2
S'In patients with ACHF, acute renal impairment function and the modulation of metabolism and extracellular transport by the DDAH-1/CAT-1 system determine high ADMA and SDMA levels after therapy for acute congestive heart failure.\n'
p12399
sg4
(lp12400
(dp12401
g7
I130
sg8
VP04040
p12402
sg10
I5
sg11
VCAT-1
p12403
sg13
I1
sa(dp12404
g7
I123
sg8
g15
sg10
I6
sg11
VDDAH-1
p12405
sg13
I1
sasg19
(lp12406
(dp12407
g7
I197
sg22
VC0264719
p12408
sg10
I30
sg11
Vacute congestive heart failure
p12409
sg13
I4
sa(dp12410
g7
I23
sg22
VC0403446
p12411
sg10
I22
sg11
Vacute renal impairment
p12412
sg13
I3
sasa(dp12413
g2
S'Mutations in the ASS1 gene cause citrullinemia type I, a rare autosomal recessive disorder characterized by neonatal hyperammonemia, elevated citrulline levels, and early neonatal death.\n'
p12414
sg4
(lp12415
(dp12416
g7
I17
sg8
VP00966
p12417
sg10
I9
sg11
VASS1 gene
p12418
sg13
I2
sasg19
(lp12419
(dp12420
g7
I33
sg22
VC0175683
p12421
sg10
I13
sg11
Vcitrullinemia
p12422
sg13
I1
sa(dp12423
g7
I171
sg22
VC0410916
p12424
sg10
I14
sg11
Vneonatal death
p12425
sg13
I2
sa(dp12426
g7
I117
sg22
VC0220994
p12427
sg10
I14
sg11
Vhyperammonemia
p12428
sg13
I1
sasa(dp12429
g2
S'Citrullinemia type I is an autosomal recessive disorder caused by mutation of the gene expressing ASS1 argininosuccinate synthetase, limiting enzyme of the urea cycle.\n'
p12430
sg4
(lp12431
(dp12432
g7
I98
sg8
VP00966
p12433
sg10
I33
sg11
VASS1 argininosuccinate synthetase
p12434
sg13
I3
sasg19
(lp12435
(dp12436
g7
I0
sg22
VC0175683
p12437
sg10
I13
sg11
VCitrullinemia
p12438
sg13
I1
sasa(dp12439
g2
S'We show that two ASS1 genomic variants (namely, rs10901080 and rs10793902) can serve as pharmacogenomic biomarkers to predict hydroxyurea treatment efficacy in sickle cell disease/Beta-thalassemia compound heterozygous patients.\n'
p12440
sg4
(lp12441
(dp12442
g7
I17
sg8
VP00966
p12443
sg10
I4
sg11
VASS1
p12444
sg13
I1
sasg19
(lp12445
(dp12446
g7
I180
sg22
VC0005283
p12447
sg10
I16
sg11
VBeta-thalassemia
p12448
sg13
I1
sa(dp12449
g7
I160
sg22
VC0002895
p12450
sg10
I19
sg11
Vsickle cell disease
p12451
sg13
I3
sasa(dp12452
g2
S'Citrullinemia type 1 (CTLN1) is an autosomal recessive disorder of metabolism caused by a deficiency of argininosuccinate synthetase.\n'
p12453
sg4
(lp12454
(dp12455
g7
I0
sg8
VP00966
p12456
sg10
I20
sg11
VCitrullinemia type 1
p12457
sg13
I3
sa(dp12458
g7
I22
sg8
VP00966
p12459
sg10
I5
sg11
VCTLN1
p12460
sg13
I1
sa(dp12461
g7
I104
sg8
VP00966
p12462
sg10
I28
sg11
Vargininosuccinate synthetase
p12463
sg13
I2
sasg19
(lp12464
(dp12465
g7
I0
sg22
VC0175683
p12466
sg10
I20
sg11
VCitrullinemia type 1
p12467
sg13
I3
sa(dp12468
g7
I22
sg22
VC0175683
p12469
sg10
I5
sg11
VCTLN1
p12470
sg13
I1
sasa(dp12471
g2
S'Argininosuccinate synthetase deficiency (citrullinemia type 1) is a rare autosomal recessive disorder of the urea cycle characterized by elevated concentrations of citrulline, ammonia, and orotic acid, manifesting with acute hyperammonemic crises, usually early in life, with concurrent neurologic deterioration.\n'
p12472
sg4
(lp12473
(dp12474
g7
I0
sg8
VP00966
p12475
sg10
I28
sg11
VArgininosuccinate synthetase
p12476
sg13
I2
sasg19
(lp12477
(dp12478
g7
I0
sg22
VC0175683
p12479
sg10
I39
sg11
VArgininosuccinate synthetase deficiency
p12480
sg13
I3
sa(dp12481
g7
I41
sg22
VC0175683
p12482
sg10
I20
sg11
Vcitrullinemia type 1
p12483
sg13
I3
sasa(dp12484
g2
S'Classical citrullinemia type I (CTLN1) is an autosomal recessive disorder encoded by the ASS1 gene, which codes for argininosuccinate synthetase (ASS), the rate-limiting enzyme in the urea cycle.\n'
p12485
sg4
(lp12486
(dp12487
g7
I89
sg8
VP00966
p12488
sg10
I3
sg11
VASS
p12489
sg13
I1
sa(dp12490
g7
I89
sg8
VP00966
p12491
sg10
I9
sg11
VASS1 gene
p12492
sg13
I2
sa(dp12493
g7
I116
sg8
VP00966
p12494
sg10
I28
sg11
Vargininosuccinate synthetase
p12495
sg13
I2
sasg19
(lp12496
(dp12497
g7
I0
sg22
VC0751751
p12498
sg10
I23
sg11
VClassical citrullinemia
p12499
sg13
I2
sa(dp12500
g7
I32
sg22
VC0175683
p12501
sg10
I5
sg11
VCTLN1
p12502
sg13
I1
sasa(dp12503
g2
S'CTLN2 is an autosomal recessive disorder characterized by recurrent encephalopathy with hyperammonemia due to highly elevated plasma levels of citrulline and ammonia, caused by a deficiency of argininosuccinate synthetase in the liver.\n'
p12504
sg4
(lp12505
(dp12506
g7
I193
sg8
VP00966
p12507
sg10
I28
sg11
Vargininosuccinate synthetase
p12508
sg13
I2
sa(dp12509
g7
I0
sg8
g15
sg10
I5
sg11
VCTLN2
p12510
sg13
I1
sasg19
(lp12511
(dp12512
g7
I68
sg22
VC0085584
p12513
sg10
I14
sg11
Vencephalopathy
p12514
sg13
I1
sa(dp12515
g7
I0
sg22
VC1863844
p12516
sg10
I5
sg11
VCTLN2
p12517
sg13
I1
sa(dp12518
g7
I88
sg22
VC0220994
p12519
sg10
I14
sg11
Vhyperammonemia
p12520
sg13
I1
sasa(dp12521
g2
S'Citrullinemia type I is an autosomal recessive disorder that is caused by a deficiency of the urea cycle enzyme argininosuccinate synthetase (ASS1).\n'
p12522
sg4
(lp12523
(dp12524
g7
I142
sg8
VP00966
p12525
sg10
I4
sg11
VASS1
p12526
sg13
I1
sa(dp12527
g7
I94
sg8
VP00966
p12528
sg10
I46
sg11
Vurea cycle enzyme argininosuccinate synthetase
p12529
sg13
I5
sasg19
(lp12530
(dp12531
g7
I0
sg22
VC0175683
p12532
sg10
I13
sg11
VCitrullinemia
p12533
sg13
I1
sasa(dp12534
g2
S'Classical citrullinemia (CTLN1), a rare autosomal recessive disorder, is caused by mutations of the argininosuccinate synthetase (ASS) gene, localized on chromosome 9q34.1.\n'
p12535
sg4
(lp12536
(dp12537
g7
I100
sg8
VP00966
p12538
sg10
I28
sg11
Vargininosuccinate synthetase
p12539
sg13
I2
sa(dp12540
g7
I130
sg8
VP00966
p12541
sg10
I3
sg11
VASS
p12542
sg13
I1
sasg19
(lp12543
(dp12544
g7
I0
sg22
VC0751751
p12545
sg10
I23
sg11
VClassical citrullinemia
p12546
sg13
I2
sa(dp12547
g7
I25
sg22
VC0175683
p12548
sg10
I5
sg11
VCTLN1
p12549
sg13
I1
sasa(dp12550
g2
S'We studied the expression of BMPR-IA, -IB, and -II, ActR-I, ActR-II, and OP-1/BMP-7 by immunohistochemistry in ossified ligament tissues of patients with OPLL and control ligament tissues from patients with cervical disc herniation.\n'
p12551
sg4
(lp12552
(dp12553
g7
I73
sg8
VP18075
p12554
sg10
I4
sg11
VOP-1
p12555
sg13
I1
sa(dp12556
g7
I29
sg8
VP36894
p12557
sg10
I7
sg11
VBMPR-IA
p12558
sg13
I1
sa(dp12559
g7
I78
sg8
VP18075
p12560
sg10
I5
sg11
VBMP-7
p12561
sg13
I1
sa(dp12562
g7
I52
sg8
g15
sg10
I6
sg11
VActR-I
p12563
sg13
I1
sa(dp12564
g7
I60
sg8
VP27037
p12565
sg10
I7
sg11
VActR-II
p12566
sg13
I1
sasg19
(lp12567
(dp12568
g7
I207
sg22
VC0410619
p12569
sg10
I24
sg11
Vcervical disc herniation
p12570
sg13
I3
sa(dp12571
g7
I154
sg22
VC1865343
p12572
sg10
I4
sg11
VOPLL
p12573
sg13
I1
sasa(dp12574
g2
S'Genes that have been implicated in monogenic CVID include ICOS, TNFRSF13B (TACI), TNFRSF13C (BAFF-R), TNFSF12 (TWEAK), CD19, CD81, CR2 (CD21), MS4A1 (CD20), TNFRSF7 (CD27), IL21, IL21R, LRBA, CTLA4, PRKCD, PLCG2, NFKB1, NFKB2, PIK3CD, PIK3R1, VAV1, RAC2, BLK, IKZF1 (IKAROS) and IRF2BP2 With the increasing number of disease genes identified in CVID, it has become clear that CVID is an umbrella diagnosis and that many of these genetic defects cause distinct disease entities.\n'
p12575
sg4
(lp12576
(dp12577
g7
I111
sg8
g15
sg10
I5
sg11
VTWEAK
p12578
sg13
I1
sa(dp12579
g7
I82
sg8
g15
sg10
I9
sg11
VTNFRSF13C
p12580
sg13
I1
sa(dp12581
g7
I75
sg8
g15
sg10
I4
sg11
VTACI
p12582
sg13
I1
sa(dp12583
g7
I186
sg8
VP50851
p12584
sg10
I4
sg11
VLRBA
p12585
sg13
I1
sa(dp12586
g7
I213
sg8
VP19838
p12587
sg10
I5
sg11
VNFKB1
p12588
sg13
I1
sa(dp12589
g7
I235
sg8
VP27986
p12590
sg10
I6
sg11
VPIK3R1
p12591
sg13
I1
sa(dp12592
g7
I206
sg8
VP16885
p12593
sg10
I5
sg11
VPLCG2
p12594
sg13
I1
sa(dp12595
g7
I125
sg8
VP60033
p12596
sg10
I4
sg11
VCD81
p12597
sg13
I1
sa(dp12598
g7
I220
sg8
g15
sg10
I5
sg11
VNFKB2
p12599
sg13
I1
sa(dp12600
g7
I93
sg8
g15
sg10
I6
sg11
VBAFF-R
p12601
sg13
I1
sa(dp12602
g7
I279
sg8
g15
sg10
I7
sg11
VIRF2BP2
p12603
sg13
I1
sa(dp12604
g7
I119
sg8
VP15391
p12605
sg10
I4
sg11
VCD19
p12606
sg13
I1
sa(dp12607
g7
I45
sg8
g15
sg10
I4
sg11
VCVID
p12608
sg13
I1
sa(dp12609
g7
I45
sg8
g15
sg10
I4
sg11
VCVID
p12610
sg13
I1
sa(dp12611
g7
I227
sg8
g15
sg10
I6
sg11
VPIK3CD
p12612
sg13
I1
sa(dp12613
g7
I136
sg8
VP20023
p12614
sg10
I4
sg11
VCD21
p12615
sg13
I1
sa(dp12616
g7
I102
sg8
g15
sg10
I7
sg11
VTNFSF12
p12617
sg13
I1
sa(dp12618
g7
I58
sg8
VP16410
p12619
sg10
I4
sg11
VICOS
p12620
sg13
I1
sa(dp12621
g7
I249
sg8
VP15153
p12622
sg10
I4
sg11
VRAC2
p12623
sg13
I1
sa(dp12624
g7
I64
sg8
g15
sg10
I9
sg11
VTNFRSF13B
p12625
sg13
I1
sa(dp12626
g7
I243
sg8
VP15498
p12627
sg10
I4
sg11
VVAV1
p12628
sg13
I1
sa(dp12629
g7
I157
sg8
VP26842
p12630
sg10
I7
sg11
VTNFRSF7
p12631
sg13
I1
sa(dp12632
g7
I173
sg8
g15
sg10
I4
sg11
VIL21
p12633
sg13
I1
sa(dp12634
g7
I179
sg8
g15
sg10
I5
sg11
VIL21R
p12635
sg13
I1
sa(dp12636
g7
I166
sg8
VP26842
p12637
sg10
I4
sg11
VCD27
p12638
sg13
I1
sa(dp12639
g7
I260
sg8
g15
sg10
I5
sg11
VIKZF1
p12640
sg13
I1
sa(dp12641
g7
I150
sg8
VP35900
p12642
sg10
I4
sg11
VCD20
p12643
sg13
I1
sa(dp12644
g7
I192
sg8
VP16410
p12645
sg10
I5
sg11
VCTLA4
p12646
sg13
I1
sa(dp12647
g7
I267
sg8
g15
sg10
I6
sg11
VIKAROS
p12648
sg13
I1
sa(dp12649
g7
I143
sg8
VP11836
p12650
sg10
I5
sg11
VMS4A1
p12651
sg13
I1
sa(dp12652
g7
I199
sg8
g15
sg10
I5
sg11
VPRKCD
p12653
sg13
I1
sa(dp12654
g7
I131
sg8
VP20023
p12655
sg10
I3
sg11
VCR2
p12656
sg13
I1
sa(dp12657
g7
I255
sg8
VP51451
p12658
sg10
I3
sg11
VBLK
p12659
sg13
I1
sasg19
(lp12660
(dp12661
g7
I45
sg22
VC0009447
p12662
sg10
I4
sg11
VCVID
p12663
sg13
I1
sa(dp12664
g7
I45
sg22
VC0009447
p12665
sg10
I4
sg11
VCVID
p12666
sg13
I1
sa(dp12667
g7
I45
sg22
VC0009447
p12668
sg10
I4
sg11
VCVID
p12669
sg13
I1
sasa(dp12670
g2
S'Second, patients presenting with cold-induced urticaria, granulomatous rash, autoantibodies, and common variable immunodeficiency, or with blistering skin lesions, bronchiolitis, enterocolitis, ocular inflammation, and mild immunodeficiency harbor distinct mutations in phospholipase CGamma2, encoding a signaling molecule expressed in natural killer cells, mast cells, and B lymphocytes.\n'
p12671
sg4
(lp12672
(dp12673
g7
I270
sg8
VP04054
p12674
sg10
I21
sg11
Vphospholipase CGamma2
p12675
sg13
I2
sasg19
(lp12676
(dp12677
g7
I33
sg22
VC0221207
p12678
sg10
I22
sg11
Vcold-induced urticaria
p12679
sg13
I2
sa(dp12680
g7
I71
sg22
VC0015230
p12681
sg10
I4
sg11
Vrash
p12682
sg13
I1
sa(dp12683
g7
I139
sg22
VC0005758
p12684
sg10
I10
sg11
Vblistering
p12685
sg13
I1
sa(dp12686
g7
I179
sg22
VC0014356
p12687
sg10
I13
sg11
Venterocolitis
p12688
sg13
I1
sa(dp12689
g7
I113
sg22
VC0021051
p12690
sg10
I16
sg11
Vimmunodeficiency
p12691
sg13
I1
sa(dp12692
g7
I97
sg22
VC0009447
p12693
sg10
I32
sg11
Vcommon variable immunodeficiency
p12694
sg13
I3
sa(dp12695
g7
I201
sg22
VC0021368
p12696
sg10
I12
sg11
Vinflammation
p12697
sg13
I1
sa(dp12698
g7
I164
sg22
VC0006271
p12699
sg10
I13
sg11
Vbronchiolitis
p12700
sg13
I1
sasa(dp12701
g2
S'An age and gender-matched cohort of THAs performed for non-traumatic osteoarthritis (OA) or avascular necrosis (AVN) (n = 98) were used to compare complications and patient-reported outcome measures (PROMs).\n'
p12702
sg4
(lp12703
sg19
(lp12704
(dp12705
g7
I36
sg22
VC0559483
p12706
sg10
I4
sg11
VTHAs
p12707
sg13
I1
sa(dp12708
g7
I85
sg22
VC0029408
p12709
sg10
I2
sg11
VOA
p12710
sg13
I1
sa(dp12711
g7
I69
sg22
VC0029408
p12712
sg10
I14
sg11
Vosteoarthritis
p12713
sg13
I1
sa(dp12714
g7
I112
sg22
VC0027543
p12715
sg10
I3
sg11
VAVN
p12716
sg13
I1
sa(dp12717
g7
I92
sg22
VC0027543
p12718
sg10
I18
sg11
Vavascular necrosis
p12719
sg13
I2
sasa(dp12720
g2
S'Our systematic review investigates whether THAs for acetabular fractures should be performed acutely, with a short delay, or as a late procedure for posttraumatic osteoarthritis (PTOA) if it develops.\n'
p12721
sg4
(lp12722
sg19
(lp12723
(dp12724
g7
I43
sg22
VC0559483
p12725
sg10
I4
sg11
VTHAs
p12726
sg13
I1
sa(dp12727
g7
I163
sg22
VC0029408
p12728
sg10
I14
sg11
Vosteoarthritis
p12729
sg13
I1
sasa(dp12730
g2
S'In a retrospective analysis of over 1000 MIS THAs from our institutional joint registry, operative time, complication rates, patient reported outcome measures (Western Ontario and McMaster Universities Arthritis Index [WOMAC] and Euro-Qol 5D-5L [EQ-5D]) within the first year and responder rates for positive outcome as defined by the Outcome Measures in Rheumatology and Osteoarthritis Research Society International consensus responder (OMERACT-OARSI) criteria were compared between trainee and senior surgeons.\n'
p12731
sg4
(lp12732
sg19
(lp12733
(dp12734
g7
I372
sg22
VC0029408
p12735
sg10
I14
sg11
VOsteoarthritis
p12736
sg13
I1
sa(dp12737
g7
I202
sg22
VC0003864
p12738
sg10
I9
sg11
VArthritis
p12739
sg13
I1
sa(dp12740
g7
I105
sg22
VC0009566
p12741
sg10
I12
sg11
Vcomplication
p12742
sg13
I1
sa(dp12743
g7
I45
sg22
VC0559483
p12744
sg10
I4
sg11
VTHAs
p12745
sg13
I1
sasa(dp12746
g2
S'To determine corneal topography parameters of myopia in Chinese and help for studies of causes of myopia, distingiush other corneal diseases (such as early keratoconus), further explore the accurateness and safeness of the clinical effects of radil keratotomy (RK) or photorefractive keratectomy (PRK).\n'
p12747
sg4
(lp12748
sg19
(lp12749
(dp12750
g7
I46
sg22
VC0027092
p12751
sg10
I6
sg11
Vmyopia
p12752
sg13
I1
sa(dp12753
g7
I46
sg22
VC0027092
p12754
sg10
I6
sg11
Vmyopia
p12755
sg13
I1
sa(dp12756
g7
I124
sg22
VC0010034
p12757
sg10
I16
sg11
Vcorneal diseases
p12758
sg13
I2
sa(dp12759
g7
I156
sg22
VC0022578
p12760
sg10
I11
sg11
Vkeratoconus
p12761
sg13
I1
sasa(dp12762
g2
S"Markedly reduced ecto-5'-nucleotidase activity was found in peripheral blood lymphocytes from 27 out of 30 homosexual men with the acquired immune deficiency syndrome (AIDS) in association with Kaposi's sarcoma (AIDS-KS; 2.67 +/- 1.70 U/10(6) cells; n = 13), opportunistic infections (AIDS-OI; 9.29 +/- 7.32; n = 7), or the AIDS-related complex (ARC; 9.82 +/- 6.12; n = 10).\n"
p12763
sg4
(lp12764
sg19
(lp12765
(dp12766
g7
I131
sg22
VC0001175
p12767
sg10
I35
sg11
Vacquired immune deficiency syndrome
p12768
sg13
I4
sa(dp12769
g7
I168
sg22
VC0001175
p12770
sg10
I4
sg11
VAIDS
p12771
sg13
I1
sa(dp12772
g7
I168
sg22
VC0001175
p12773
sg10
I4
sg11
VAIDS
p12774
sg13
I1
sa(dp12775
g7
I324
sg22
VC0001857
p12776
sg10
I20
sg11
VAIDS-related complex
p12777
sg13
I2
sa(dp12778
g7
I346
sg22
VC0001857
p12779
sg10
I3
sg11
VARC
p12780
sg13
I1
sa(dp12781
g7
I194
sg22
VC0036220
p12782
sg10
I16
sg11
VKaposi's sarcoma
p12783
sg13
I2
sa(dp12784
g7
I168
sg22
VC0001175
p12785
sg10
I4
sg11
VAIDS
p12786
sg13
I1
sa(dp12787
g7
I259
sg22
VC0029118
p12788
sg10
I24
sg11
Vopportunistic infections
p12789
sg13
I2
sasa(dp12790
g2
S'This study aimed to determine circulating levels of polyunsaturated fatty acids (PUFAs), secretory phospholipase A2 (sPLA2), lipoprotein lipase (LPL) and measure circulating protein levels of angiopoietin-like protein 3 (ANGPTL3), ANGPTL4, cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) in patients with acne vulgaris.\n'
p12791
sg4
(lp12792
(dp12793
g7
I240
sg8
VP35354
p12794
sg10
I16
sg11
Vcyclooxygenase-2
p12795
sg13
I1
sa(dp12796
g7
I125
sg8
VP06858
p12797
sg10
I18
sg11
Vlipoprotein lipase
p12798
sg13
I2
sa(dp12799
g7
I192
sg8
g15
sg10
I27
sg11
Vangiopoietin-like protein 3
p12800
sg13
I3
sa(dp12801
g7
I145
sg8
VP06858
p12802
sg10
I3
sg11
VLPL
p12803
sg13
I1
sa(dp12804
g7
I221
sg8
g15
sg10
I7
sg11
VANGPTL3
p12805
sg13
I1
sa(dp12806
g7
I117
sg8
VP14555
p12807
sg10
I5
sg11
VsPLA2
p12808
sg13
I1
sa(dp12809
g7
I89
sg8
VP14555
p12810
sg10
I26
sg11
Vsecretory phospholipase A2
p12811
sg13
I3
sa(dp12812
g7
I258
sg8
VP35354
p12813
sg10
I5
sg11
VCOX-2
p12814
sg13
I1
sa(dp12815
g7
I231
sg8
g15
sg10
I7
sg11
VANGPTL4
p12816
sg13
I1
sasg19
(lp12817
(dp12818
g7
I310
sg22
VC0001144
p12819
sg10
I13
sg11
Vacne vulgaris
p12820
sg13
I2
sasa(dp12821
g2
S'We identified patient-specific genetic alterations in candidate driving genes: RASA2 and NF1 (prostate cancer), TP53 and CDKN2C (olfactory neuroblastoma), FAT1, NOTCH1, and SMAD4 (head and neck cancer), KRAS (urachal carcinoma), EML4-ALK (lung cancer), and MDM2 and PTEN (liposarcoma).\n'
p12822
sg4
(lp12823
(dp12824
g7
I79
sg8
g15
sg10
I5
sg11
VRASA2
p12825
sg13
I1
sa(dp12826
g7
I234
sg8
g15
sg10
I3
sg11
VALK
p12827
sg13
I1
sa(dp12828
g7
I229
sg8
g15
sg10
I4
sg11
VEML4
p12829
sg13
I1
sa(dp12830
g7
I155
sg8
g15
sg10
I4
sg11
VFAT1
p12831
sg13
I1
sa(dp12832
g7
I89
sg8
VP21359
p12833
sg10
I27
sg11
VNF1 (prostate cancer), TP53
p12834
sg13
I4
sa(dp12835
g7
I266
sg8
VP60484
p12836
sg10
I4
sg11
VPTEN
p12837
sg13
I1
sa(dp12838
g7
I203
sg8
VP01116
p12839
sg10
I4
sg11
VKRAS
p12840
sg13
I1
sa(dp12841
g7
I161
sg8
VP46531
p12842
sg10
I6
sg11
VNOTCH1
p12843
sg13
I1
sa(dp12844
g7
I173
sg8
g15
sg10
I5
sg11
VSMAD4
p12845
sg13
I1
sa(dp12846
g7
I121
sg8
VP42773
p12847
sg10
I6
sg11
VCDKN2C
p12848
sg13
I1
sasg19
(lp12849
(dp12850
g7
I239
sg22
VC0684249
p12851
sg10
I11
sg11
Vlung cancer
p12852
sg13
I2
sa(dp12853
g7
I272
sg22
VC0023827
p12854
sg10
I11
sg11
Vliposarcoma
p12855
sg13
I1
sa(dp12856
g7
I89
sg22
VC0027831
p12857
sg10
I3
sg11
VNF1
p12858
sg13
I1
sa(dp12859
g7
I94
sg22
VC0600139
p12860
sg10
I15
sg11
Vprostate cancer
p12861
sg13
I2
sa(dp12862
g7
I180
sg22
VC0278996
p12863
sg10
I20
sg11
Vhead and neck cancer
p12864
sg13
I4
sa(dp12865
g7
I129
sg22
VC0206717
p12866
sg10
I23
sg11
Volfactory neuroblastoma
p12867
sg13
I2
sa(dp12868
g7
I209
sg22
VC2931202
p12869
sg10
I17
sg11
Vurachal carcinoma
p12870
sg13
I2
sasa(dp12871
g2
S'However, these profiles did not segregate by histology (lung adenocarcinoma-appendiceal cancer (KRAS G12D and GNAS R201C), and lung adenocarcinoma-liposarcoma (CDK4 and MDM2 amplification pairs)).\n'
p12872
sg4
(lp12873
(dp12874
g7
I96
sg8
VP01116
p12875
sg10
I9
sg11
VKRAS G12D
p12876
sg13
I2
sa(dp12877
g7
I160
sg8
VP11802
p12878
sg10
I4
sg11
VCDK4
p12879
sg13
I1
sa(dp12880
g7
I110
sg8
VP84996
p12881
sg10
I10
sg11
VGNAS R201C
p12882
sg13
I2
sasg19
(lp12883
(dp12884
g7
I76
sg22
VC0496779
p12885
sg10
I18
sg11
Vappendiceal cancer
p12886
sg13
I2
sa(dp12887
g7
I96
sg22
VC3274016
p12888
sg10
I9
sg11
VKRAS G12D
p12889
sg13
I2
sa(dp12890
g7
I56
sg22
VC0152013
p12891
sg10
I19
sg11
Vlung adenocarcinoma
p12892
sg13
I2
sa(dp12893
g7
I174
sg22
VC1705759
p12894
sg10
I13
sg11
Vamplification
p12895
sg13
I1
sa(dp12896
g7
I147
sg22
VC0023827
p12897
sg10
I11
sg11
Vliposarcoma
p12898
sg13
I1
sa(dp12899
g7
I56
sg22
VC0152013
p12900
sg10
I19
sg11
Vlung adenocarcinoma
p12901
sg13
I2
sasa(dp12902
g2
S'We report that FUS-CHOP, a hallmark fusion gene in mixoid liposarcoma (MLS), has an instructive role in lineage commitment, and its expression in hMSC sequentially immortalized/transformed with up to five oncogenic hits (p53 and Rb deficiency, hTERT over-expression, c-myc stabilization, and H-RAS(v12) mutation) drives the formation of serially transplantable MLS.\n'
p12903
sg4
(lp12904
(dp12905
g7
I244
sg8
g15
sg10
I5
sg11
VhTERT
p12906
sg13
I1
sa(dp12907
g7
I294
sg8
VP01116
p12908
sg10
I3
sg11
VRAS
p12909
sg13
I1
sa(dp12910
g7
I221
sg8
VP42771
p12911
sg10
I3
sg11
Vp53
p12912
sg13
I1
sa(dp12913
g7
I267
sg8
VP12524
p12914
sg10
I5
sg11
Vc-myc
p12915
sg13
I1
sa(dp12916
g7
I15
sg8
VP35637
p12917
sg10
I8
sg11
VFUS-CHOP
p12918
sg13
I1
sasg19
(lp12919
(dp12920
g7
I71
sg22
VC0023827
p12921
sg10
I3
sg11
VMLS
p12922
sg13
I1
sa(dp12923
g7
I51
sg22
VC0023827
p12924
sg10
I18
sg11
Vmixoid liposarcoma
p12925
sg13
I2
sa(dp12926
g7
I71
sg22
VC0023827
p12927
sg10
I3
sg11
VMLS
p12928
sg13
I1
sasa(dp12929
g2
S'TSLP, IL-25, and IL-33 concentrations were measured in bronchoalveolar lavage fluids obtained from normal controls (NCs; n = 40) and from patients with idiopathic pulmonary fibrosis (IPF; n = 100), non-specific interstitial pneumonia (NSIP; n = 22), hypersensitivity pneumonitis (HP; n = 20), and sarcoidosis (n = 19).\n'
p12930
sg4
(lp12931
(dp12932
g7
I0
sg8
g15
sg10
I4
sg11
VTSLP
p12933
sg13
I1
sa(dp12934
g7
I6
sg8
g15
sg10
I5
sg11
VIL-25
p12935
sg13
I1
sasg19
(lp12936
(dp12937
g7
I211
sg22
VC0206061
p12938
sg10
I22
sg11
Vinterstitial pneumonia
p12939
sg13
I2
sa(dp12940
g7
I183
sg22
VC3161101
p12941
sg10
I3
sg11
VIPF
p12942
sg13
I1
sa(dp12943
g7
I152
sg22
VC3161101
p12944
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p12945
sg13
I3
sa(dp12946
g7
I297
sg22
VC0036202
p12947
sg10
I11
sg11
Vsarcoidosis
p12948
sg13
I1
sa(dp12949
g7
I280
sg22
VC0002390
p12950
sg10
I2
sg11
VHP
p12951
sg13
I1
sa(dp12952
g7
I250
sg22
VC0002390
p12953
sg10
I28
sg11
Vhypersensitivity pneumonitis
p12954
sg13
I2
sasa(dp12955
g2
S'The TSLP and IL-33 levels were significantly higher in patients with IPF relative to the NCs (p = 0.01 and p = 0.0001, respectively), NSIP (p = 4.95E - 7 and p = 0.0002, respectively), HP (p = 0.00003 and p = 0.000005, respectively), and sarcoidosis groups (p = 0.003 and p = 0.0001, respectively).\n'
p12956
sg4
(lp12957
(dp12958
g7
I4
sg8
g15
sg10
I4
sg11
VTSLP
p12959
sg13
I1
sasg19
(lp12960
(dp12961
g7
I238
sg22
VC0036202
p12962
sg10
I11
sg11
Vsarcoidosis
p12963
sg13
I1
sasa(dp12964
g2
S'Recently, thymic stromal lymphopoietin (TSLP), which is well studied in allergic diseases, has been reported in fibrotic diseases, including idiopathic pulmonary fibrosis and atopic dermatitis fibrosis.\n'
p12965
sg4
(lp12966
(dp12967
g7
I40
sg8
g15
sg10
I4
sg11
VTSLP
p12968
sg13
I1
sa(dp12969
g7
I10
sg8
g15
sg10
I28
sg11
Vthymic stromal lymphopoietin
p12970
sg13
I3
sasg19
(lp12971
(dp12972
g7
I175
sg22
VC0011615
p12973
sg10
I17
sg11
Vatopic dermatitis
p12974
sg13
I2
sa(dp12975
g7
I141
sg22
VC3161101
p12976
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p12977
sg13
I3
sa(dp12978
g7
I162
sg22
VC0016059
p12979
sg10
I8
sg11
Vfibrosis
p12980
sg13
I1
sasa(dp12981
g2
S'Thymic stromal lymphopoietin (TSLP) has been found at high levels in patients with asthma and idiopathic pulmonary fibrosis, and TSLP has been proposed as a primary driver of lung fibrotic disease.\n'
p12982
sg4
(lp12983
(dp12984
g7
I30
sg8
g15
sg10
I4
sg11
VTSLP
p12985
sg13
I1
sa(dp12986
g7
I30
sg8
g15
sg10
I4
sg11
VTSLP
p12987
sg13
I1
sa(dp12988
g7
I0
sg8
g15
sg10
I28
sg11
VThymic stromal lymphopoietin
p12989
sg13
I3
sasg19
(lp12990
(dp12991
g7
I83
sg22
VC0004096
p12992
sg10
I6
sg11
Vasthma
p12993
sg13
I1
sa(dp12994
g7
I94
sg22
VC3161101
p12995
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p12996
sg13
I3
sasa(dp12997
g2
S'In addition, in a model of influenza-induced exacerbation of atopic airway inflammation, the absence of TSLPR signaling also led to exaggerated neutrophilic inflammation.\n'
p12998
sg4
(lp12999
(dp13000
g7
I104
sg8
g15
sg10
I5
sg11
VTSLPR
p13001
sg13
I1
sasg19
(lp13002
(dp13003
g7
I61
sg22
VC0392707
p13004
sg10
I6
sg11
Vatopic
p13005
sg13
I1
sa(dp13006
g7
I75
sg22
VC0021368
p13007
sg10
I12
sg11
Vinflammation
p13008
sg13
I1
sa(dp13009
g7
I75
sg22
VC0021368
p13010
sg10
I12
sg11
Vinflammation
p13011
sg13
I1
sa(dp13012
g7
I27
sg22
VC0021400
p13013
sg10
I9
sg11
Vinfluenza
p13014
sg13
I1
sasa(dp13015
g2
S'In this study, we demonstrate that influenza infection induces the early expression of TSLP by lung epithelial cells with multiple consequences.\n'
p13016
sg4
(lp13017
(dp13018
g7
I87
sg8
g15
sg10
I4
sg11
VTSLP
p13019
sg13
I1
sasg19
(lp13020
(dp13021
g7
I45
sg22
VC0009450
p13022
sg10
I9
sg11
Vinfection
p13023
sg13
I1
sa(dp13024
g7
I35
sg22
VC0021400
p13025
sg10
I9
sg11
Vinfluenza
p13026
sg13
I1
sasa(dp13027
g2
S'The aim of this study was to examine whether TSLP may be involved in the pathogenesis of a proto-typical fibrotic disease, idiopathic pulmonary fibrosis (IPF).\n'
p13028
sg4
(lp13029
sg19
(lp13030
(dp13031
g7
I154
sg22
VC3161101
p13032
sg10
I3
sg11
VIPF
p13033
sg13
I1
sa(dp13034
g7
I123
sg22
VC3161101
p13035
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p13036
sg13
I3
sa(dp13037
g7
I73
sg22
VC0699748
p13038
sg10
I12
sg11
Vpathogenesis
p13039
sg13
I1
sasa(dp13040
g2
S'We have previously reported that human CAP10-like protein 46 kDa (hCLP46) is overexpressed in human acute myelogenous leukemia, T acute lymphoblastic leukemia, and leukemia cell lines.\n'
p13041
sg4
(lp13042
(dp13043
g7
I33
sg8
g15
sg10
I40
sg11
Vhuman CAP10-like protein 46 kDa (hCLP46)
p13044
sg13
I6
sasg19
(lp13045
(dp13046
g7
I100
sg22
VC0023467
p13047
sg10
I26
sg11
Vacute myelogenous leukemia
p13048
sg13
I3
sa(dp13049
g7
I118
sg22
VC0023418
p13050
sg10
I8
sg11
Vleukemia
p13051
sg13
I1
sa(dp13052
g7
I128
sg22
VC1961099
p13053
sg10
I30
sg11
VT acute lymphoblastic leukemia
p13054
sg13
I4
sasa(dp13055
g2
S'Protein O-glucosyltransferase 1 (POGLUT1) is a novel gene that was initially isolated and identified from the bone marrow cells of patients with myelodysplastic syndrome/acute myeloid leukemia.\n'
p13056
sg4
(lp13057
(dp13058
g7
I33
sg8
g15
sg10
I7
sg11
VPOGLUT1
p13059
sg13
I1
sa(dp13060
g7
I0
sg8
g15
sg10
I31
sg11
VProtein O-glucosyltransferase 1
p13061
sg13
I3
sasg19
(lp13062
(dp13063
g7
I145
sg22
VC0033027
p13064
sg10
I24
sg11
Vmyelodysplastic syndrome
p13065
sg13
I2
sa(dp13066
g7
I170
sg22
VC0023467
p13067
sg10
I22
sg11
Vacute myeloid leukemia
p13068
sg13
I3
sasa(dp13069
g2
S'We showed that lack of hCLP46 results in impaired ligand induced Notch activation in mammalian cell, and hCLP46 regulates the proliferation of U937 cell through CDKI-RB signaling pathway, which may be important for the pathogenesis of leukemia.\n'
p13070
sg4
(lp13071
(dp13072
g7
I23
sg8
g15
sg10
I6
sg11
VhCLP46
p13073
sg13
I1
sa(dp13074
g7
I23
sg8
g15
sg10
I6
sg11
VhCLP46
p13075
sg13
I1
sasg19
(lp13076
(dp13077
g7
I41
sg22
VC0684336
p13078
sg10
I8
sg11
Vimpaired
p13079
sg13
I1
sa(dp13080
g7
I219
sg22
VC0699748
p13081
sg10
I12
sg11
Vpathogenesis
p13082
sg13
I1
sa(dp13083
g7
I126
sg22
VC0334094
p13084
sg10
I13
sg11
Vproliferation
p13085
sg13
I1
sa(dp13086
g7
I235
sg22
VC0023418
p13087
sg10
I8
sg11
Vleukemia
p13088
sg13
I1
sasa(dp13089
g2
S'We earlier identified a novel gene human CAP10-like protein 46 KD (hCLP46) from human acute myelogenous leukemia (AML) transformed from myelodysplastic syndrome CD34(+) cells, but the function of this gene remains unclear.\n'
p13090
sg4
(lp13091
(dp13092
g7
I35
sg8
g15
sg10
I30
sg11
Vhuman CAP10-like protein 46 KD
p13093
sg13
I5
sa(dp13094
g7
I67
sg8
g15
sg10
I6
sg11
VhCLP46
p13095
sg13
I1
sasg19
(lp13096
(dp13097
g7
I86
sg22
VC0023467
p13098
sg10
I26
sg11
Vacute myelogenous leukemia
p13099
sg13
I3
sa(dp13100
g7
I114
sg22
VC0023467
p13101
sg10
I3
sg11
VAML
p13102
sg13
I1
sa(dp13103
g7
I136
sg22
VC0033027
p13104
sg10
I24
sg11
Vmyelodysplastic syndrome
p13105
sg13
I2
sasa(dp13106
g2
S'In this study, a real-time polymerase chain reaction-based assay was developed to quantify expression of hCLP46 in the peripheral blood of AML and T-acute lymphoblastic leukemia (T-ALL) primary samples and in six leukemic cell lines.\n'
p13107
sg4
(lp13108
(dp13109
g7
I105
sg8
g15
sg10
I6
sg11
VhCLP46
p13110
sg13
I1
sasg19
(lp13111
(dp13112
g7
I139
sg22
VC0023467
p13113
sg10
I3
sg11
VAML
p13114
sg13
I1
sa(dp13115
g7
I179
sg22
VC1961099
p13116
sg10
I5
sg11
VT-ALL
p13117
sg13
I1
sa(dp13118
g7
I147
sg22
VC1961099
p13119
sg10
I30
sg11
VT-acute lymphoblastic leukemia
p13120
sg13
I3
sasa(dp13121
g2
S'A novel human gene, named as human CAP10-like protein 46 kDa (hCLP46), was isolated and identified from human acute myeloid leukemia transformed from myelodysplastic syndrome (MDS-AML) CD34(+) cells.\n'
p13122
sg4
(lp13123
(dp13124
g7
I29
sg8
g15
sg10
I31
sg11
Vhuman CAP10-like protein 46 kDa
p13125
sg13
I5
sa(dp13126
g7
I185
sg8
VP28906
p13127
sg10
I4
sg11
VCD34
p13128
sg13
I1
sa(dp13129
g7
I176
sg8
VP62258
p13130
sg10
I7
sg11
VMDS-AML
p13131
sg13
I1
sa(dp13132
g7
I62
sg8
g15
sg10
I6
sg11
VhCLP46
p13133
sg13
I1
sasg19
(lp13134
(dp13135
g7
I180
sg22
VC0023467
p13136
sg10
I3
sg11
VAML
p13137
sg13
I1
sa(dp13138
g7
I150
sg22
VC3463824
p13139
sg10
I24
sg11
Vmyelodysplastic syndrome
p13140
sg13
I2
sa(dp13141
g7
I110
sg22
VC0023467
p13142
sg10
I22
sg11
Vacute myeloid leukemia
p13143
sg13
I3
sa(dp13144
g7
I176
sg22
VC0265219
p13145
sg10
I3
sg11
VMDS
p13146
sg13
I1
sasa(dp13147
g2
S'In vivo, RGC-32-/- mice display an attenuated experimental autoimmune encephalomyelitis phenotype accompanied by decreased CNS inflammation and reduced frequency of IL-17- and GM-CSF-producing CD4+ T cells.\n'
p13148
sg4
(lp13149
(dp13150
g7
I176
sg8
VP04141
p13151
sg10
I6
sg11
VGM-CSF
p13152
sg13
I1
sa(dp13153
g7
I9
sg8
g15
sg10
I6
sg11
VRGC-32
p13154
sg13
I1
sa(dp13155
g7
I193
sg8
VP01730
p13156
sg10
I4
sg11
VCD4+
p13157
sg13
I1
sasg19
(lp13158
(dp13159
g7
I59
sg22
VC0443146
p13160
sg10
I10
sg11
Vautoimmune
p13161
sg13
I1
sa(dp13162
g7
I70
sg22
VC0014070
p13163
sg10
I17
sg11
Vencephalomyelitis
p13164
sg13
I1
sa(dp13165
g7
I127
sg22
VC0021368
p13166
sg10
I12
sg11
Vinflammation
p13167
sg13
I1
sasa(dp13168
g2
S'Collectively, our results identify RGC-32 as a novel regulator of Th17 cell differentiation in vitro and in vivo and suggest that RGC-32 is a potential therapeutic target in multiple sclerosis and other Th17-mediated autoimmune diseases.\n'
p13169
sg4
(lp13170
(dp13171
g7
I35
sg8
g15
sg10
I6
sg11
VRGC-32
p13172
sg13
I1
sa(dp13173
g7
I35
sg8
g15
sg10
I6
sg11
VRGC-32
p13174
sg13
I1
sasg19
(lp13175
(dp13176
g7
I217
sg22
VC0004364
p13177
sg10
I19
sg11
Vautoimmune diseases
p13178
sg13
I2
sa(dp13179
g7
I174
sg22
VC0026769
p13180
sg10
I18
sg11
Vmultiple sclerosis
p13181
sg13
I2
sasa(dp13182
g2
S'qRT-PCR confirmed the changes of six lncRNAs (RP11-517C16.2-001, FR271872, LOC283352, RP11-401E9.3, FGFR3P, and XXbac-BPG16N22.5) and nine mRNAs (NOS2, C13orf15, FOS, FCN2, SPINT1, PLAC8, BIRC5, NOS2, and COL19A1).\n'
p13183
sg4
(lp13184
(dp13185
g7
I181
sg8
g15
sg10
I5
sg11
VPLAC8
p13186
sg13
I1
sa(dp13187
g7
I146
sg8
VP60321
p13188
sg10
I4
sg11
VNOS2
p13189
sg13
I1
sa(dp13190
g7
I162
sg8
VP01100
p13191
sg10
I3
sg11
VFOS
p13192
sg13
I1
sa(dp13193
g7
I152
sg8
g15
sg10
I8
sg11
VC13orf15
p13194
sg13
I1
sa(dp13195
g7
I86
sg8
g15
sg10
I12
sg11
VRP11-401E9.3
p13196
sg13
I1
sa(dp13197
g7
I146
sg8
VP60321
p13198
sg10
I4
sg11
VNOS2
p13199
sg13
I1
sa(dp13200
g7
I173
sg8
g15
sg10
I6
sg11
VSPINT1
p13201
sg13
I1
sa(dp13202
g7
I167
sg8
g15
sg10
I4
sg11
VFCN2
p13203
sg13
I1
sasg19
(lp13204
(dp13205
g7
I46
sg22
VC1838601
p13206
sg10
I4
sg11
VRP11
p13207
sg13
I1
sa(dp13208
g7
I46
sg22
VC1838601
p13209
sg10
I4
sg11
VRP11
p13210
sg13
I1
sasa(dp13211
g2
S'We investigated the combined roles of Response Gene to Complement 32 (RGC-32), FasL, CDC2, AKT, and IL-21 as possible biomarkers of relapse and response to glatiramer acetate (GA) treatment in relapsing-remitting MS (RRMS) patients.\n'
p13212
sg4
(lp13213
(dp13214
g7
I85
sg8
VP06493
p13215
sg10
I4
sg11
VCDC2
p13216
sg13
I1
sa(dp13217
g7
I91
sg8
g15
sg10
I3
sg11
VAKT
p13218
sg13
I1
sa(dp13219
g7
I38
sg8
g15
sg10
I30
sg11
VResponse Gene to Complement 32
p13220
sg13
I5
sa(dp13221
g7
I79
sg8
VP48023
p13222
sg10
I4
sg11
VFasL
p13223
sg13
I1
sa(dp13224
g7
I70
sg8
g15
sg10
I6
sg11
VRGC-32
p13225
sg13
I1
sasg19
(lp13226
(dp13227
g7
I132
sg22
VC0277556
p13228
sg10
I7
sg11
Vrelapse
p13229
sg13
I1
sasa(dp13230
g2
S'The development of psoriatic-like lesions is attributable to 1) the spontaneously tuning up of psoriasis signatures in keratinocytes through JNK pathway; and 2) neutrophil accumulation caused by the enhanced leukocyte-recruiting capacity associated with overexpression of S100A7-9 and CXCL-1, 8 in keratinocytes with impaired galectin-3 expression.\n'
p13231
sg4
(lp13232
(dp13233
g7
I326
sg8
VP17931
p13234
sg10
I10
sg11
Vgalectin-3
p13235
sg13
I1
sa(dp13236
g7
I141
sg8
VP53779
p13237
sg10
I3
sg11
VJNK
p13238
sg13
I1
sa(dp13239
g7
I272
sg8
VP31151
p13240
sg10
I8
sg11
VS100A7-9
p13241
sg13
I1
sasg19
(lp13242
(dp13243
g7
I317
sg22
VC0684336
p13244
sg10
I8
sg11
Vimpaired
p13245
sg13
I1
sa(dp13246
g7
I95
sg22
VC0033860
p13247
sg10
I9
sg11
Vpsoriasis
p13248
sg13
I1
sasa(dp13249
g2
S'CXCL1 was associated with atopic dermatitis, a highly pruritic skin disease, but it is not clear what is its mechanism of action, while for CXCL2 there are no data about an association with itch sensitivity.\n'
p13250
sg4
(lp13251
(dp13252
g7
I140
sg8
VP19875
p13253
sg10
I5
sg11
VCXCL2
p13254
sg13
I1
sa(dp13255
g7
I0
sg8
VP09341
p13256
sg10
I5
sg11
VCXCL1
p13257
sg13
I1
sasg19
(lp13258
(dp13259
g7
I26
sg22
VC0011615
p13260
sg10
I17
sg11
Vatopic dermatitis
p13261
sg13
I2
sa(dp13262
g7
I63
sg22
VC0037274
p13263
sg10
I12
sg11
Vskin disease
p13264
sg13
I2
sa(dp13265
g7
I190
sg22
VC0033774
p13266
sg10
I4
sg11
Vitch
p13267
sg13
I1
sasa(dp13268
g2
S'Hypothesizing that the IL-22/IL-22BP expression ratio reflects the level of bioactive IL-22 in psoriasis skin, we found positive correlations with the expression of IL-22-inducible molecules (IL-20, IL-24, IL-36Gamma, CXCL1, and BD2) in keratinocytes.\n'
p13269
sg4
(lp13270
(dp13271
g7
I218
sg8
VP09341
p13272
sg10
I5
sg11
VCXCL1
p13273
sg13
I1
sa(dp13274
g7
I199
sg8
g15
sg10
I5
sg11
VIL-24
p13275
sg13
I1
sa(dp13276
g7
I29
sg8
g15
sg10
I7
sg11
VIL-22BP
p13277
sg13
I1
sa(dp13278
g7
I165
sg8
g15
sg10
I25
sg11
VIL-22-inducible molecules
p13279
sg13
I2
sa(dp13280
g7
I23
sg8
g15
sg10
I5
sg11
VIL-22
p13281
sg13
I1
sa(dp13282
g7
I23
sg8
g15
sg10
I5
sg11
VIL-22
p13283
sg13
I1
sa(dp13284
g7
I192
sg8
g15
sg10
I5
sg11
VIL-20
p13285
sg13
I1
sasg19
(lp13286
(dp13287
g7
I95
sg22
VC0033860
p13288
sg10
I9
sg11
Vpsoriasis
p13289
sg13
I1
sasa(dp13290
g2
S'UVB irradiation inhibits IL-17A/TNF-Alfa-induced IL-6, IL-8, and CXCL-1 production in HDFs by decreasing the expression of IL-17RA and IL-17RC on fibroblasts through TGF-Beta1/Smad3 signaling pathway, which reveals a new mechanism of the therapeutic action of UVB on psoriasis.\n'
p13291
sg4
(lp13292
(dp13293
g7
I32
sg8
VP01375
p13294
sg10
I3
sg11
VTNF
p13295
sg13
I1
sa(dp13296
g7
I49
sg8
VP05231
p13297
sg10
I4
sg11
VIL-6
p13298
sg13
I1
sa(dp13299
g7
I166
sg8
VP01137
p13300
sg10
I9
sg11
VTGF-Beta1
p13301
sg13
I1
sasg19
(lp13302
(dp13303
g7
I267
sg22
VC0033860
p13304
sg10
I9
sg11
Vpsoriasis
p13305
sg13
I1
sasa(dp13306
g2
S'Increased IL-4 expression in human colorectal cancer tissue and growth of colon cancer cell lines implied that IL-4-induced Stat6-mediated tumorigenic signaling likely contributes to intestinal tumor progression in ApcMin/+ mice.\n'
p13307
sg4
(lp13308
(dp13309
g7
I10
sg8
VP05112
p13310
sg10
I4
sg11
VIL-4
p13311
sg13
I1
sa(dp13312
g7
I124
sg8
VP42226
p13313
sg10
I5
sg11
VStat6
p13314
sg13
I1
sa(dp13315
g7
I10
sg8
VP05112
p13316
sg10
I4
sg11
VIL-4
p13317
sg13
I1
sasg19
(lp13318
(dp13319
g7
I35
sg22
VC1527249
p13320
sg10
I17
sg11
Vcolorectal cancer
p13321
sg13
I2
sa(dp13322
g7
I194
sg22
VC0178874
p13323
sg10
I17
sg11
Vtumor progression
p13324
sg13
I2
sa(dp13325
g7
I74
sg22
VC0699790
p13326
sg10
I12
sg11
Vcolon cancer
p13327
sg13
I2
sasa(dp13328
g2
S'ALDH, aldehyde dehydrogenase; APC, antigen-presenting cells; APM, antigen-processing machinery; CAR: chimeric antigen receptor; CHK1, checkpoint serine/threonine protein kinase; CIC, cancer-initiating cell; CRC, colorectal cancer; CTLA-4, cytotoxic T lymphocyte antigen-4; GBM, glioblastoma multiforme; GDF-15, growth differentiation factor-15; CSPG4: chondroitin sulfate proteoglycan-4; IFN, interferon; IL-4, interleukin-4; IL-10, interleukin-10; IL-13, interleukin-13; IL-13Alfa2, Alfa2 chain of IL-13 receptor; mAb, monoclonal antibody; MDSC, myeloid-derived suppressor cell; MHC, major histocompatibility complex; PD-1, programmed death-1; PD-L1 programmed death ligand-1; PDK, 3-phosphoinositide-dependent protein kinase-1; PGE2, prostaglandin E2; STAT3, signal transducer and activator of transcription 3; TGFB-1, transforming growth factor beta-1; Treg, T regulatory cell.\n'
p13329
sg4
(lp13330
(dp13331
g7
I411
sg8
VP05112
p13332
sg10
I13
sg11
Vinterleukin-4
p13333
sg13
I1
sa(dp13334
g7
I231
sg8
VP16410
p13335
sg10
I6
sg11
VCTLA-4
p13336
sg13
I1
sa(dp13337
g7
I499
sg8
VP35225
p13338
sg10
I14
sg11
VIL-13 receptor
p13339
sg13
I2
sa(dp13340
g7
I761
sg8
VP40763
p13341
sg10
I50
sg11
Vsignal transducer and activator of transcription 3
p13342
sg13
I7
sa(dp13343
g7
I0
sg8
VP00352
p13344
sg10
I4
sg11
VALDH
p13345
sg13
I1
sa(dp13346
g7
I134
sg8
VP51812
p13347
sg10
I42
sg11
Vcheckpoint serine/threonine protein kinase
p13348
sg13
I4
sa(dp13349
g7
I678
sg8
g15
sg10
I3
sg11
VPDK
p13350
sg13
I1
sa(dp13351
g7
I683
sg8
VP19525
p13352
sg10
I45
sg11
V3-phosphoinositide-dependent protein kinase-1
p13353
sg13
I3
sa(dp13354
g7
I449
sg8
VP35225
p13355
sg10
I5
sg11
VIL-13
p13356
sg13
I1
sa(dp13357
g7
I821
sg8
VP01137
p13358
sg10
I33
sg11
Vtransforming growth factor beta-1
p13359
sg13
I4
sa(dp13360
g7
I813
sg8
VP01137
p13361
sg10
I6
sg11
VTGFB-1
p13362
sg13
I1
sa(dp13363
g7
I456
sg8
VP35225
p13364
sg10
I14
sg11
Vinterleukin-13
p13365
sg13
I1
sa(dp13366
g7
I405
sg8
VP05112
p13367
sg10
I4
sg11
VIL-4
p13368
sg13
I1
sa(dp13369
g7
I619
sg8
VP18621
p13370
sg10
I4
sg11
VPD-1
p13371
sg13
I1
sa(dp13372
g7
I433
sg8
VP22301
p13373
sg10
I14
sg11
Vinterleukin-10
p13374
sg13
I1
sa(dp13375
g7
I345
sg8
g15
sg10
I5
sg11
VCSPG4
p13376
sg13
I1
sa(dp13377
g7
I388
sg8
VP01562
p13378
sg10
I3
sg11
VIFN
p13379
sg13
I1
sa(dp13380
g7
I101
sg8
VP14209
p13381
sg10
I25
sg11
Vchimeric antigen receptor
p13382
sg13
I3
sa(dp13383
g7
I754
sg8
VP40763
p13384
sg10
I5
sg11
VSTAT3
p13385
sg13
I1
sa(dp13386
g7
I563
sg8
VP13747
p13387
sg10
I54
sg11
Vsuppressor cell; MHC, major histocompatibility complex
p13388
sg13
I6
sa(dp13389
g7
I662
sg8
g15
sg10
I14
sg11
Vdeath ligand-1
p13390
sg13
I2
sa(dp13391
g7
I128
sg8
g15
sg10
I4
sg11
VCHK1
p13392
sg13
I1
sa(dp13393
g7
I393
sg8
VP01563
p13394
sg10
I10
sg11
Vinterferon
p13395
sg13
I1
sa(dp13396
g7
I30
sg8
VP25054
p13397
sg10
I3
sg11
VAPC
p13398
sg13
I1
sa(dp13399
g7
I303
sg8
g15
sg10
I37
sg11
VGDF-15, growth differentiation factor
p13400
sg13
I4
sa(dp13401
g7
I6
sg8
VP49366
p13402
sg10
I22
sg11
Valdehyde dehydrogenase
p13403
sg13
I2
sasg19
(lp13404
(dp13405
g7
I207
sg22
VC1527249
p13406
sg10
I3
sg11
VCRC
p13407
sg13
I1
sa(dp13408
g7
I96
sg22
VC2607929
p13409
sg10
I3
sg11
VCAR
p13410
sg13
I1
sa(dp13411
g7
I278
sg22
VC1621958
p13412
sg10
I23
sg11
Vglioblastoma multiforme
p13413
sg13
I2
sa(dp13414
g7
I212
sg22
VC1527249
p13415
sg10
I17
sg11
Vcolorectal cancer
p13416
sg13
I2
sa(dp13417
g7
I273
sg22
VC1621958
p13418
sg10
I3
sg11
VGBM
p13419
sg13
I1
sa(dp13420
g7
I30
sg22
VC0033036
p13421
sg10
I3
sg11
VAPC
p13422
sg13
I1
sa(dp13423
g7
I183
sg22
VC0006826
p13424
sg10
I6
sg11
Vcancer
p13425
sg13
I1
sasa(dp13426
g2
S'A few studies suggested that matrix metalloproteinase 1 (MMP-1) rs1799750 polymorphism was associated with nasopharyngeal carcinoma (NPC) risk.\n'
p13427
sg4
(lp13428
(dp13429
g7
I57
sg8
VP03956
p13430
sg10
I5
sg11
VMMP-1
p13431
sg13
I1
sa(dp13432
g7
I29
sg8
VP03956
p13433
sg10
I26
sg11
Vmatrix metalloproteinase 1
p13434
sg13
I3
sasg19
(lp13435
(dp13436
g7
I107
sg22
VC2931822
p13437
sg10
I24
sg11
Vnasopharyngeal carcinoma
p13438
sg13
I2
sa(dp13439
g7
I133
sg22
VC2931822
p13440
sg10
I3
sg11
VNPC
p13441
sg13
I1
sasa(dp13442
g2
S'However, the contribution of MMP1 genotype to hepatocellular carcinoma (HCC) has not been well studied.\n'
p13443
sg4
(lp13444
(dp13445
g7
I29
sg8
VP03956
p13446
sg10
I13
sg11
VMMP1 genotype
p13447
sg13
I2
sasg19
(lp13448
(dp13449
g7
I46
sg22
VC2239176
p13450
sg10
I24
sg11
Vhepatocellular carcinoma
p13451
sg13
I2
sa(dp13452
g7
I72
sg22
VC2239176
p13453
sg10
I3
sg11
VHCC
p13454
sg13
I1
sasa(dp13455
g2
S'M3 muscarinic receptor (M3R) expression is increased in colon cancer; M3R activation stimulates colon cancer cell invasion via cross-talk with epidermal growth factor receptors (EGFR), post-EGFR activation of mitogen-activated protein kinase (MAPK) extracellular signal-related kinase 1/2 (ERK1/2), and induction of matrix metalloproteinase-1 (MMP1) expression.\n'
p13456
sg4
(lp13457
(dp13458
g7
I178
sg8
VP01133
p13459
sg10
I4
sg11
VEGFR
p13460
sg13
I1
sa(dp13461
g7
I24
sg8
VP20309
p13462
sg10
I3
sg11
VM3R
p13463
sg13
I1
sa(dp13464
g7
I344
sg8
VP03956
p13465
sg10
I4
sg11
VMMP1
p13466
sg13
I1
sa(dp13467
g7
I24
sg8
VP20309
p13468
sg10
I3
sg11
VM3R
p13469
sg13
I1
sa(dp13470
g7
I209
sg8
VP53779
p13471
sg10
I32
sg11
Vmitogen-activated protein kinase
p13472
sg13
I3
sa(dp13473
g7
I243
sg8
VP53779
p13474
sg10
I4
sg11
VMAPK
p13475
sg13
I1
sa(dp13476
g7
I290
sg8
VP27361
p13477
sg10
I6
sg11
VERK1/2
p13478
sg13
I1
sa(dp13479
g7
I143
sg8
VP01133
p13480
sg10
I33
sg11
Vepidermal growth factor receptors
p13481
sg13
I4
sa(dp13482
g7
I0
sg8
VP20309
p13483
sg10
I22
sg11
VM3 muscarinic receptor
p13484
sg13
I3
sa(dp13485
g7
I178
sg8
VP01133
p13486
sg10
I4
sg11
VEGFR
p13487
sg13
I1
sa(dp13488
g7
I249
sg8
VP27361
p13489
sg10
I39
sg11
Vextracellular signal-related kinase 1/2
p13490
sg13
I4
sa(dp13491
g7
I316
sg8
VP03956
p13492
sg10
I26
sg11
Vmatrix metalloproteinase-1
p13493
sg13
I2
sasg19
(lp13494
(dp13495
g7
I109
sg22
VC2699153
p13496
sg10
I13
sg11
Vcell invasion
p13497
sg13
I2
sa(dp13498
g7
I56
sg22
VC0699790
p13499
sg10
I12
sg11
Vcolon cancer
p13500
sg13
I2
sa(dp13501
g7
I56
sg22
VC0699790
p13502
sg10
I12
sg11
Vcolon cancer
p13503
sg13
I2
sasa(dp13504
g2
S'Collectively, these studies uncover novel functional interactions between post-muscarinic receptor signaling pathways that augment MMP1 expression and drive colon cancer cell invasion; targeting these potentiating interactions has therapeutic potential.\n'
p13505
sg4
(lp13506
(dp13507
g7
I131
sg8
VP03956
p13508
sg10
I4
sg11
VMMP1
p13509
sg13
I1
sasg19
(lp13510
(dp13511
g7
I157
sg22
VC0699790
p13512
sg10
I12
sg11
Vcolon cancer
p13513
sg13
I2
sa(dp13514
g7
I170
sg22
VC2699153
p13515
sg10
I13
sg11
Vcell invasion
p13516
sg13
I2
sasa(dp13517
g2
S'HAS2 is one of the key regulators responsible for CAF-mediated OSCC progression and acts by modulating the balance of MMP1 and TIMP1.\n'
p13518
sg4
(lp13519
(dp13520
g7
I0
sg8
g15
sg10
I4
sg11
VHAS2
p13521
sg13
I1
sa(dp13522
g7
I118
sg8
VP03956
p13523
sg10
I4
sg11
VMMP1
p13524
sg13
I1
sa(dp13525
g7
I127
sg8
VP01033
p13526
sg10
I5
sg11
VTIMP1
p13527
sg13
I1
sasg19
(lp13528
sa(dp13529
g2
S'It was further demonstrated that olomoucine blocks SpH2B and SpH1 phosphorylation.\n'
p13530
sg4
(lp13531
(dp13532
g7
I61
sg8
VP16157
p13533
sg10
I4
sg11
VSpH1
p13534
sg13
I1
sasg19
(lp13535
(dp13536
g7
I61
sg22
VC2674218
p13537
sg10
I4
sg11
VSpH1
p13538
sg13
I1
sasa(dp13539
g2
S'We found that olomoucine blocks SpH1 and SpH2B phosphorylation and inhibits male pronucleus decondensation in vivo.\n'
p13540
sg4
(lp13541
(dp13542
g7
I14
sg8
VP16157
p13543
sg10
I22
sg11
Volomoucine blocks SpH1
p13544
sg13
I3
sasg19
(lp13545
(dp13546
g7
I32
sg22
VC2674218
p13547
sg10
I4
sg11
VSpH1
p13548
sg13
I1
sasa(dp13549
g2
S'From these results, it also emerges that the phosphorylation of SpH2B and SpH1 is not required for the degradation of the SpH that is concurrent to male chromatin remodeling.\n'
p13550
sg4
(lp13551
(dp13552
g7
I74
sg8
VP16157
p13553
sg10
I4
sg11
VSpH1
p13554
sg13
I1
sasg19
(lp13555
(dp13556
g7
I74
sg22
VC2674218
p13557
sg10
I4
sg11
VSpH1
p13558
sg13
I1
sa(dp13559
g7
I64
sg22
VC2674218
p13560
sg10
I3
sg11
VSpH
p13561
sg13
I1
sasa(dp13562
g2
S'In T. niger, as well as in P. angulosus, a single form of SpH1 and SpH2A were found.\n'
p13563
sg4
(lp13564
(dp13565
g7
I58
sg8
VP16157
p13566
sg10
I4
sg11
VSpH1
p13567
sg13
I1
sasg19
(lp13568
(dp13569
g7
I58
sg22
VC2674218
p13570
sg10
I4
sg11
VSpH1
p13571
sg13
I1
sasa(dp13572
g2
S'From the results obtained, it emerged that histone SpH2A was the more closely related protein between these two species, followed by histone SpH1.\n'
p13573
sg4
(lp13574
(dp13575
g7
I43
sg8
VP62805
p13576
sg10
I13
sg11
Vhistone SpH2A
p13577
sg13
I2
sa(dp13578
g7
I133
sg8
VP62805
p13579
sg10
I12
sg11
Vhistone SpH1
p13580
sg13
I2
sasg19
(lp13581
(dp13582
g7
I141
sg22
VC2674218
p13583
sg10
I4
sg11
VSpH1
p13584
sg13
I1
sasa(dp13585
g2
S'At intermediate stages of male pronucleus formation, sperm-derived chromatin is composed of hybrid nucleoprotein particles formed by sperm H1 (SpH1), dimers of sperm H2A-H2B (SpH2A-SpH2B), and a subset of maternal cleavage stage (CS) histone variants.\n'
p13586
sg4
(lp13587
(dp13588
g7
I133
sg8
VP16157
p13589
sg10
I8
sg11
Vsperm H1
p13590
sg13
I2
sa(dp13591
g7
I143
sg8
VP16157
p13592
sg10
I4
sg11
VSpH1
p13593
sg13
I1
sa(dp13594
g7
I170
sg8
VP62807
p13595
sg10
I3
sg11
VH2B
p13596
sg13
I1
sa(dp13597
g7
I205
sg8
VP62805
p13598
sg10
I45
sg11
Vmaternal cleavage stage (CS) histone variants
p13599
sg13
I6
sa(dp13600
g7
I166
sg8
VP04908
p13601
sg10
I3
sg11
VH2A
p13602
sg13
I1
sasg19
(lp13603
(dp13604
g7
I133
sg22
VC2674218
p13605
sg10
I8
sg11
Vsperm H1
p13606
sg13
I2
sa(dp13607
g7
I143
sg22
VC2674218
p13608
sg10
I4
sg11
VSpH1
p13609
sg13
I1
sasa(dp13610
g2
S'At this stage in vivo, the CS histone variants are poly(ADP-ribosylated), while SpH2B and SpH1 are phosphorylated.\n'
p13611
sg4
(lp13612
(dp13613
g7
I90
sg8
VP16157
p13614
sg10
I4
sg11
VSpH1
p13615
sg13
I1
sa(dp13616
g7
I27
sg8
VP62805
p13617
sg10
I19
sg11
VCS histone variants
p13618
sg13
I3
sasg19
(lp13619
(dp13620
g7
I90
sg22
VC2674218
p13621
sg10
I4
sg11
VSpH1
p13622
sg13
I1
sasa(dp13623
g2
S'Consequently, we have investigated the phosphorylation state of SpH1 and SpH2B in relation to the possible protection of these proteins from proteolytic degradation.\n'
p13624
sg4
(lp13625
(dp13626
g7
I64
sg8
VP16157
p13627
sg10
I4
sg11
VSpH1
p13628
sg13
I1
sasg19
(lp13629
(dp13630
g7
I64
sg22
VC2674218
p13631
sg10
I4
sg11
VSpH1
p13632
sg13
I1
sasa(dp13633
g2
S'The phosphorylated forms of SpH1 and SpH2B were found to remain unaltered, while the nonphosphorylated forms were degraded.\n'
p13634
sg4
(lp13635
(dp13636
g7
I28
sg8
VP16157
p13637
sg10
I4
sg11
VSpH1
p13638
sg13
I1
sasg19
(lp13639
(dp13640
g7
I28
sg22
VC2674218
p13641
sg10
I4
sg11
VSpH1
p13642
sg13
I1
sasa(dp13643
g2
S'On the basis of this result, we postulate a novel role for the phosphorylation of SpH1 and SpH2B that occurs in vivo after fertilization, namely to protect these histones against degradation at intermediate stages of male chromatin remodeling.\n'
p13644
sg4
(lp13645
(dp13646
g7
I82
sg8
VP16157
p13647
sg10
I4
sg11
VSpH1
p13648
sg13
I1
sasg19
(lp13649
(dp13650
g7
I82
sg22
VC2674218
p13651
sg10
I4
sg11
VSpH1
p13652
sg13
I1
sasa(dp13653
g2
S'The disappearance of SpH is not coincidental for the five histone classes: SpH4 and SpH3 are lost 5-15 min post insemination (p.i.\n'
p13654
sg4
(lp13655
(dp13656
g7
I75
sg8
VP02730
p13657
sg10
I4
sg11
VSpH4
p13658
sg13
I1
sa(dp13659
g7
I84
sg8
VP02549
p13660
sg10
I4
sg11
VSpH3
p13661
sg13
I1
sa(dp13662
g7
I58
sg8
VP62805
p13663
sg10
I15
sg11
Vhistone classes
p13664
sg13
I2
sasg19
(lp13665
(dp13666
g7
I21
sg22
VC2674218
p13667
sg10
I3
sg11
VSpH
p13668
sg13
I1
sa(dp13669
g7
I75
sg22
VC2675212
p13670
sg10
I4
sg11
VSpH4
p13671
sg13
I1
sa(dp13672
g7
I84
sg22
VC2678338
p13673
sg10
I4
sg11
VSpH3
p13674
sg13
I1
sasa(dp13675
g2
S'), SpH2B and SpH2A disappear 20-40 min p.i., and SpH1 is progressively diminished up to 30 min p.i.\n'
p13676
sg4
(lp13677
(dp13678
g7
I49
sg8
VP16157
p13679
sg10
I4
sg11
VSpH1
p13680
sg13
I1
sasg19
(lp13681
(dp13682
g7
I49
sg22
VC2674218
p13683
sg10
I4
sg11
VSpH1
p13684
sg13
I1
sasa(dp13685
g2
S'We report a case of adult polycystic kidney disease (ADPKD) with end stage renal disease and episodes of fever and cervical lymphadenopathy.\n'
p13686
sg4
(lp13687
sg19
(lp13688
(dp13689
g7
I53
sg22
VC0085413
p13690
sg10
I5
sg11
VADPKD
p13691
sg13
I1
sa(dp13692
g7
I65
sg22
VC0022661
p13693
sg10
I23
sg11
Vend stage renal disease
p13694
sg13
I4
sa(dp13695
g7
I20
sg22
VC0085413
p13696
sg10
I31
sg11
Vadult polycystic kidney disease
p13697
sg13
I4
sa(dp13698
g7
I115
sg22
VC0235592
p13699
sg10
I24
sg11
Vcervical lymphadenopathy
p13700
sg13
I2
sasa(dp13701
g2
S'Use of the focused approach resulted in fewer false-positive diagnoses, but five malignant tumors of the breast, 88 lung infiltrates, 43 cases of adenopathy, two cases of polycystic kidney disease, one breast abscess, and one case of splenic flexure diverticulitis were missed.\n'
p13702
sg4
(lp13703
sg19
(lp13704
(dp13705
g7
I250
sg22
VC0012813
p13706
sg10
I14
sg11
Vdiverticulitis
p13707
sg13
I1
sa(dp13708
g7
I121
sg22
VC0332448
p13709
sg10
I11
sg11
Vinfiltrates
p13710
sg13
I1
sa(dp13711
g7
I171
sg22
VC0022680
p13712
sg10
I25
sg11
Vpolycystic kidney disease
p13713
sg13
I3
sa(dp13714
g7
I81
sg22
VC0006826
p13715
sg10
I16
sg11
Vmalignant tumors
p13716
sg13
I2
sa(dp13717
g7
I202
sg22
VC0151463
p13718
sg10
I14
sg11
Vbreast abscess
p13719
sg13
I2
sasa(dp13720
g2
S'Heritable disorders of connective tissue (marfan syndrome, Ehlers-Danlos syndrome, adult polycystic kidney disease, floppy mitral valve/mitral valve prolapse); congenital heart disease (bicuspid aortic valve); inflammatory/immunologic disorders (rheumatic fever, AIDS, Kawasaki disease, syphilis, seronegative spondyloarthropathies, systemic lupus erythematosus, antiphospholipid syndrome); endocardial disorders (nonbacteremic thrombotic endocarditis, infective endocarditis, endomyocardial fibroelastosis); myocardial dysfunction (ischemic heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy); diseases and disorders of other organs (chronic renal failure, carcinoid heart disease); aging (calcific aortic stenosis, mitral annular calcification); postinterventional valvular disease; drugs and physical agents are all clinical entities associated with VHD.\n'
p13721
sg4
(lp13722
sg19
(lp13723
(dp13724
g7
I136
sg22
VC0026267
p13725
sg10
I21
sg11
Vmitral valve prolapse
p13726
sg13
I3
sa(dp13727
g7
I533
sg22
VC0151744
p13728
sg10
I22
sg11
Vischemic heart disease
p13729
sg13
I3
sa(dp13730
g7
I116
sg22
VC0026267
p13731
sg10
I19
sg11
Vfloppy mitral valve
p13732
sg13
I3
sa(dp13733
g7
I160
sg22
VC0152021
p13734
sg10
I24
sg11
Vcongenital heart disease
p13735
sg13
I3
sa(dp13736
g7
I565
sg22
VC0878544
p13737
sg10
I14
sg11
Vcardiomyopathy
p13738
sg13
I1
sa(dp13739
g7
I186
sg22
VC0149630
p13740
sg10
I21
sg11
Vbicuspid aortic valve
p13741
sg13
I3
sa(dp13742
g7
I223
sg22
VC0021053
p13743
sg10
I21
sg11
Vimmunologic disorders
p13744
sg13
I2
sa(dp13745
g7
I611
sg22
VC0012634
p13746
sg10
I22
sg11
Vdiseases and disorders
p13747
sg13
I3
sa(dp13748
g7
I477
sg22
VC0014117
p13749
sg10
I29
sg11
Vendomyocardial fibroelastosis
p13750
sg13
I2
sa(dp13751
g7
I333
sg22
VC0024141
p13752
sg10
I28
sg11
Vsystemic lupus erythematosus
p13753
sg13
I3
sa(dp13754
g7
I674
sg22
VC0007093
p13755
sg10
I23
sg11
Vcarcinoid heart disease
p13756
sg13
I3
sa(dp13757
g7
I565
sg22
VC0007194
p13758
sg10
I28
sg11
Vcardiomyopathy, hypertrophic
p13759
sg13
I2
sa(dp13760
g7
I723
sg22
VC0026269
p13761
sg10
I16
sg11
Vstenosis, mitral
p13762
sg13
I2
sa(dp13763
g7
I439
sg22
VC1541923
p13764
sg10
I23
sg11
Vendocarditis, infective
p13765
sg13
I2
sa(dp13766
g7
I310
sg22
VC0949691
p13767
sg10
I21
sg11
Vspondyloarthropathies
p13768
sg13
I1
sa(dp13769
g7
I246
sg22
VC0035436
p13770
sg10
I15
sg11
Vrheumatic fever
p13771
sg13
I2
sa(dp13772
g7
I439
sg22
VC0014118
p13773
sg10
I12
sg11
Vendocarditis
p13774
sg13
I1
sa(dp13775
g7
I49
sg22
VC0013720
p13776
sg10
I23
sg11
Vsyndrome, Ehlers-Danlos
p13777
sg13
I2
sa(dp13778
g7
I509
sg22
VC0340515
p13779
sg10
I22
sg11
Vmyocardial dysfunction
p13780
sg13
I2
sa(dp13781
g7
I269
sg22
VC0026691
p13782
sg10
I16
sg11
VKawasaki disease
p13783
sg13
I2
sa(dp13784
g7
I83
sg22
VC0085413
p13785
sg10
I31
sg11
Vadult polycystic kidney disease
p13786
sg13
I4
sa(dp13787
g7
I651
sg22
VC0022661
p13788
sg10
I21
sg11
Vchronic renal failure
p13789
sg13
I3
sa(dp13790
g7
I49
sg22
VC0039082
p13791
sg10
I8
sg11
Vsyndrome
p13792
sg13
I1
sa(dp13793
g7
I363
sg22
VC0085278
p13794
sg10
I25
sg11
Vantiphospholipid syndrome
p13795
sg13
I2
sa(dp13796
g7
I287
sg22
VC0039128
p13797
sg10
I8
sg11
Vsyphilis
p13798
sg13
I1
sasa(dp13799
g2
S'The animal models of chronic gastritis in rats were established, and the surface damage of gastric mucosa was observed by gross anatomy; the changes of gastric mucosal tissue and surface morphology were observed by pathological sections of gastric mucosal tissues; the expressions of heme oxygenase-1 (HO-1) and nuclear factor E2-related factor 2 (Nrf-2) proteins of gastric mucosal tissues in each group were detected by western blot analysis; the activities of superoxide dismutase (SOD) and catalase (CAT) as well as the contents of reduced glutathione (GSH) and malondialdehyde (MDA) in gastric mucosal tissues were detected by kits.\n'
p13800
sg4
(lp13801
(dp13802
g7
I504
sg8
VP04040
p13803
sg10
I3
sg11
VCAT
p13804
sg13
I1
sa(dp13805
g7
I494
sg8
VP04040
p13806
sg10
I8
sg11
Vcatalase
p13807
sg13
I1
sa(dp13808
g7
I312
sg8
VP01160
p13809
sg10
I34
sg11
Vnuclear factor E2-related factor 2
p13810
sg13
I5
sa(dp13811
g7
I463
sg8
VP00441
p13812
sg10
I20
sg11
Vsuperoxide dismutase
p13813
sg13
I2
sa(dp13814
g7
I485
sg8
VP00441
p13815
sg10
I3
sg11
VSOD
p13816
sg13
I1
sa(dp13817
g7
I348
sg8
g15
sg10
I5
sg11
VNrf-2
p13818
sg13
I1
sa(dp13819
g7
I284
sg8
VP09601
p13820
sg10
I16
sg11
Vheme oxygenase-1
p13821
sg13
I2
sa(dp13822
g7
I302
sg8
VP09601
p13823
sg10
I4
sg11
VHO-1
p13824
sg13
I1
sasg19
(lp13825
(dp13826
g7
I21
sg22
VC0085695
p13827
sg10
I17
sg11
Vchronic gastritis
p13828
sg13
I2
sa(dp13829
g7
I557
sg22
VC1260386
p13830
sg10
I3
sg11
VGSH
p13831
sg13
I1
sasa(dp13832
g2
S'RE control rats exhibited the down-regulation of antioxidant-related proteins, such as nuclear factor-erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) expression levels, in the presence of esophagitis; however, the levels with Rhei Rhizoma treatment were significantly higher than those in RE control rats.\n'
p13833
sg4
(lp13834
(dp13835
g7
I87
sg8
g15
sg10
I43
sg11
Vnuclear factor-erythroid 2-related factor 2
p13836
sg13
I5
sa(dp13837
g7
I160
sg8
VP09601
p13838
sg10
I4
sg11
VHO-1
p13839
sg13
I1
sa(dp13840
g7
I132
sg8
g15
sg10
I4
sg11
VNrf2
p13841
sg13
I1
sa(dp13842
g7
I142
sg8
VP09601
p13843
sg10
I16
sg11
Vheme oxygenase-1
p13844
sg13
I2
sasg19
(lp13845
(dp13846
g7
I204
sg22
VC0014868
p13847
sg10
I11
sg11
Vesophagitis
p13848
sg13
I1
sasa(dp13849
g2
S'Genetic ablation of hmox-1 in H. pylori-infected mice increased histologic gastritis, which was associated with enhanced M1/Th1/Th17 responses, decreased regulatory macrophage (Mreg) response, and reduced H. pylori colonization.\n'
p13850
sg4
(lp13851
sg19
(lp13852
(dp13853
g7
I75
sg22
VC0017152
p13854
sg10
I9
sg11
Vgastritis
p13855
sg13
I1
sasa(dp13856
g2
S'More rarely, germline mutations predisposing to pituitary adenomas -as part of a syndrome (eg, MEN1 or Carney complex), or isolated to the pituitary (AIP or GPR101) can be identified.\n'
p13857
sg4
(lp13858
(dp13859
g7
I139
sg8
VP18509
p13860
sg10
I25
sg11
Vpituitary (AIP or GPR101)
p13861
sg13
I4
sa(dp13862
g7
I95
sg8
g15
sg10
I4
sg11
VMEN1
p13863
sg13
I1
sasg19
(lp13864
(dp13865
g7
I81
sg22
VC0039082
p13866
sg10
I8
sg11
Vsyndrome
p13867
sg13
I1
sa(dp13868
g7
I150
sg22
VC0162565
p13869
sg10
I3
sg11
VAIP
p13870
sg13
I1
sa(dp13871
g7
I48
sg22
VC0032000
p13872
sg10
I18
sg11
Vpituitary adenomas
p13873
sg13
I2
sa(dp13874
g7
I103
sg22
VC0406810
p13875
sg10
I14
sg11
VCarney complex
p13876
sg13
I2
sa(dp13877
g7
I95
sg22
VC0025267
p13878
sg10
I4
sg11
VMEN1
p13879
sg13
I1
sasa(dp13880
g2
S'Particularly, the variants of GPR101, GPR161, and GPR88 are related to the genetic diseases: growth hormone-secreting pituitary adenoma 2, pituitary stalk interruption syndrome (not confirmed), and childhood-onset chorea with psychomotor retardation, respectively.\n'
p13881
sg4
(lp13882
(dp13883
g7
I30
sg8
g15
sg10
I6
sg11
VGPR101
p13884
sg13
I1
sa(dp13885
g7
I50
sg8
g15
sg10
I5
sg11
VGPR88
p13886
sg13
I1
sa(dp13887
g7
I38
sg8
g15
sg10
I6
sg11
VGPR161
p13888
sg13
I1
sasg19
(lp13889
(dp13890
g7
I149
sg22
VC0935572
p13891
sg10
I5
sg11
Vstalk
p13892
sg13
I1
sa(dp13893
g7
I214
sg22
VC0008489
p13894
sg10
I6
sg11
Vchorea
p13895
sg13
I1
sa(dp13896
g7
I168
sg22
VC0039082
p13897
sg10
I8
sg11
Vsyndrome
p13898
sg13
I1
sa(dp13899
g7
I93
sg22
VC0346302
p13900
sg10
I42
sg11
Vgrowth hormone-secreting pituitary adenoma
p13901
sg13
I4
sasa(dp13902
g2
S'In addition to mutations or deletions, copy number variation at the GPR101 locus may also lead to mixed GH and prolactin secreting pituitary adenomas in the setting of X-linked acrogigantism (X-LAG syndrome).\n'
p13903
sg4
(lp13904
(dp13905
g7
I111
sg8
VP01236
p13906
sg10
I9
sg11
Vprolactin
p13907
sg13
I1
sa(dp13908
g7
I68
sg8
g15
sg10
I12
sg11
VGPR101 locus
p13909
sg13
I2
sasg19
(lp13910
(dp13911
g7
I131
sg22
VC0032000
p13912
sg10
I18
sg11
Vpituitary adenomas
p13913
sg13
I2
sa(dp13914
g7
I198
sg22
VC0039082
p13915
sg10
I8
sg11
Vsyndrome
p13916
sg13
I1
sasa(dp13917
g2
S'In this review, we summarise the published evidence on XLAG and GPR101 and discuss the results of recent studies that have investigated the potential role of GPR101 variants in the pathogenesis of pituitary adenomas.\n'
p13918
sg4
(lp13919
(dp13920
g7
I55
sg8
g15
sg10
I4
sg11
VXLAG
p13921
sg13
I1
sa(dp13922
g7
I64
sg8
g15
sg10
I6
sg11
VGPR101
p13923
sg13
I1
sa(dp13924
g7
I158
sg8
g15
sg10
I15
sg11
VGPR101 variants
p13925
sg13
I2
sasg19
(lp13926
(dp13927
g7
I197
sg22
VC0032000
p13928
sg10
I18
sg11
Vpituitary adenomas
p13929
sg13
I2
sa(dp13930
g7
I55
sg22
VC1846171
p13931
sg10
I4
sg11
VXLAG
p13932
sg13
I1
sa(dp13933
g7
I181
sg22
VC0699748
p13934
sg10
I12
sg11
Vpathogenesis
p13935
sg13
I1
sasa(dp13936
g2
S'It has been suggested that medulloblastomas be categorized into 4 distinct molecular subgroups- WNT (DKK1), SHH (SFRP1), Group 3 (NPR3), or Group 4 (KCNA1)-since each subgroup is distinct and there is no overlap.\n'
p13937
sg4
(lp13938
(dp13939
g7
I108
sg8
g15
sg10
I3
sg11
VSHH
p13940
sg13
I1
sa(dp13941
g7
I121
sg8
VP00390
p13942
sg10
I7
sg11
VGroup 3
p13943
sg13
I2
sa(dp13944
g7
I149
sg8
g15
sg10
I5
sg11
VKCNA1
p13945
sg13
I1
sa(dp13946
g7
I140
sg8
VP00390
p13947
sg10
I7
sg11
VGroup 4
p13948
sg13
I2
sa(dp13949
g7
I113
sg8
g15
sg10
I5
sg11
VSFRP1
p13950
sg13
I1
sa(dp13951
g7
I101
sg8
g15
sg10
I4
sg11
VDKK1
p13952
sg13
I1
sa(dp13953
g7
I130
sg8
VP17342
p13954
sg10
I4
sg11
VNPR3
p13955
sg13
I1
sasg19
(lp13956
(dp13957
g7
I27
sg22
VC0025149
p13958
sg10
I16
sg11
Vmedulloblastomas
p13959
sg13
I1
sasa(dp13960
g2
S'Immunohistochemistry for DKK1 (WNT), SFRP1 (SHH), NPR3 (group C), and KCNA1 (group D) could reliably and uniquely classify formalin-fixed medulloblastomas in approximately 98% of patients.\n'
p13961
sg4
(lp13962
(dp13963
g7
I70
sg8
g15
sg10
I5
sg11
VKCNA1
p13964
sg13
I1
sa(dp13965
g7
I44
sg8
g15
sg10
I3
sg11
VSHH
p13966
sg13
I1
sa(dp13967
g7
I37
sg8
g15
sg10
I5
sg11
VSFRP1
p13968
sg13
I1
sa(dp13969
g7
I25
sg8
g15
sg10
I4
sg11
VDKK1
p13970
sg13
I1
sa(dp13971
g7
I50
sg8
VP17342
p13972
sg10
I4
sg11
VNPR3
p13973
sg13
I1
sasg19
(lp13974
(dp13975
g7
I138
sg22
VC0025149
p13976
sg10
I16
sg11
Vmedulloblastomas
p13977
sg13
I1
sasa(dp13978
g2
S'We examined DKK1 expression in primary medulloblastoma cells and patient samples by reverse transcriptase PCR and found it to be significantly down-regulated relative to normal cerebellum.\n'
p13979
sg4
(lp13980
(dp13981
g7
I84
sg8
VP63136
p13982
sg10
I21
sg11
Vreverse transcriptase
p13983
sg13
I2
sa(dp13984
g7
I12
sg8
g15
sg10
I4
sg11
VDKK1
p13985
sg13
I1
sasg19
(lp13986
(dp13987
g7
I39
sg22
VC0025149
p13988
sg10
I15
sg11
Vmedulloblastoma
p13989
sg13
I1
sasa(dp13990
g2
S'Transfection of a DKK1 gene construct into D283 cell lines suppressed medulloblastoma tumor growth in colony focus assays by 60% (P &lt; 0.001).\n'
p13991
sg4
(lp13992
(dp13993
g7
I18
sg8
g15
sg10
I19
sg11
VDKK1 gene construct
p13994
sg13
I3
sasg19
(lp13995
(dp13996
g7
I86
sg22
VC0598934
p13997
sg10
I12
sg11
Vtumor growth
p13998
sg13
I2
sa(dp13999
g7
I70
sg22
VC0025149
p14000
sg10
I15
sg11
Vmedulloblastoma
p14001
sg13
I1
sasa(dp14002
g2
S'In addition, adenoviral vector-mediated expression of DKK1 in medulloblastoma cells increased apoptosis fourfold (P &lt; 0.001).\n'
p14003
sg4
(lp14004
(dp14005
g7
I54
sg8
g15
sg10
I4
sg11
VDKK1
p14006
sg13
I1
sasg19
(lp14007
(dp14008
g7
I62
sg22
VC0025149
p14009
sg10
I15
sg11
Vmedulloblastoma
p14010
sg13
I1
sasa(dp14011
g2
S'These data reveal that inappropriate histone modifications might deregulate DKK1 expression in medulloblastoma tumorigenesis and block its tumor-suppressive activity.\n'
p14012
sg4
(lp14013
(dp14014
g7
I37
sg8
VP62805
p14015
sg10
I7
sg11
Vhistone
p14016
sg13
I1
sa(dp14017
g7
I76
sg8
g15
sg10
I4
sg11
VDKK1
p14018
sg13
I1
sasg19
(lp14019
(dp14020
g7
I111
sg22
VC0027651
p14021
sg10
I5
sg11
Vtumor
p14022
sg13
I1
sa(dp14023
g7
I95
sg22
VC0025149
p14024
sg10
I15
sg11
Vmedulloblastoma
p14025
sg13
I1
sa(dp14026
g7
I111
sg22
VC0007621
p14027
sg10
I13
sg11
Vtumorigenesis
p14028
sg13
I1
sasa(dp14029
g2
S'Gene profiling analyses identified several deregulated genes reported as being also deregulated in psoriasis skin in vivo (S100A12, IL-8, DEFB4A and KYNU).\n'
p14030
sg4
(lp14031
(dp14032
g7
I123
sg8
VP80511
p14033
sg10
I7
sg11
VS100A12
p14034
sg13
I1
sa(dp14035
g7
I138
sg8
g15
sg10
I6
sg11
VDEFB4A
p14036
sg13
I1
sa(dp14037
g7
I149
sg8
g15
sg10
I4
sg11
VKYNU
p14038
sg13
I1
sasg19
(lp14039
(dp14040
g7
I99
sg22
VC0033860
p14041
sg10
I9
sg11
Vpsoriasis
p14042
sg13
I1
sasa(dp14043
g2
S'However, in patients with chronic inflammatory skin disease, such as psoriasis and atopic dermatitis (AD), another tryptophan metabolism enzyme downstream of IDO, L-kynureninase (KYNU), is heavily upregulated.\n'
p14044
sg4
(lp14045
(dp14046
g7
I179
sg8
g15
sg10
I4
sg11
VKYNU
p14047
sg13
I1
sa(dp14048
g7
I163
sg8
g15
sg10
I14
sg11
VL-kynureninase
p14049
sg13
I1
sa(dp14050
g7
I158
sg8
VP14902
p14051
sg10
I3
sg11
VIDO
p14052
sg13
I1
sasg19
(lp14053
(dp14054
g7
I83
sg22
VC0011615
p14055
sg10
I17
sg11
Vatopic dermatitis
p14056
sg13
I2
sa(dp14057
g7
I69
sg22
VC0033860
p14058
sg10
I9
sg11
Vpsoriasis
p14059
sg13
I1
sa(dp14060
g7
I102
sg22
VC0011615
p14061
sg10
I2
sg11
VAD
p14062
sg13
I1
sa(dp14063
g7
I47
sg22
VC0037274
p14064
sg10
I12
sg11
Vskin disease
p14065
sg13
I2
sasa(dp14066
g2
S'The role of KYNU has not been explored in patients with these skin diseases or in general human immunology.\n'
p14067
sg4
(lp14068
(dp14069
g7
I12
sg8
g15
sg10
I4
sg11
VKYNU
p14070
sg13
I1
sasg19
(lp14071
(dp14072
g7
I62
sg22
VC0037274
p14073
sg10
I13
sg11
Vskin diseases
p14074
sg13
I2
sasa(dp14075
g2
S'We sought to explore the expression and potential immunologic function of the tryptophan metabolism enzyme KYNU in inflammatory skin disease and its potential contribution to general human immunology.\n'
p14076
sg4
(lp14077
sg19
(lp14078
(dp14079
g7
I128
sg22
VC0037274
p14080
sg10
I12
sg11
Vskin disease
p14081
sg13
I2
sasa(dp14082
g2
S'KYNU expression positively correlates with disease severity and inflammation and is reduced on successful treatment of psoriasis or AD.\n'
p14083
sg4
(lp14084
(dp14085
g7
I0
sg8
g15
sg10
I4
sg11
VKYNU
p14086
sg13
I1
sasg19
(lp14087
(dp14088
g7
I64
sg22
VC0021368
p14089
sg10
I12
sg11
Vinflammation
p14090
sg13
I1
sa(dp14091
g7
I119
sg22
VC0033860
p14092
sg10
I9
sg11
Vpsoriasis
p14093
sg13
I1
sasa(dp14094
g2
S'Recently, global CpG methylation changes have been identified in psoriatic skin in comparison to normal skin, particularly near genes known to be upregulated in psoriasis such as KYNU, OAS2, and SERPINB3.\n'
p14095
sg4
(lp14096
(dp14097
g7
I179
sg8
g15
sg10
I4
sg11
VKYNU
p14098
sg13
I1
sa(dp14099
g7
I185
sg8
VP29728
p14100
sg10
I4
sg11
VOAS2
p14101
sg13
I1
sasg19
(lp14102
(dp14103
g7
I161
sg22
VC0033860
p14104
sg10
I9
sg11
Vpsoriasis
p14105
sg13
I1
sasa(dp14106
g2
S'Sites with inverse correlations between methylation and nearby gene expression include those of KYNU, OAS2, S100A12, and SERPINB3, whose strong transcriptional upregulation is an important discriminator of psoriasis.\n'
p14107
sg4
(lp14108
(dp14109
g7
I102
sg8
VP29728
p14110
sg10
I4
sg11
VOAS2
p14111
sg13
I1
sa(dp14112
g7
I108
sg8
VP80511
p14113
sg10
I7
sg11
VS100A12
p14114
sg13
I1
sa(dp14115
g7
I96
sg8
g15
sg10
I4
sg11
VKYNU
p14116
sg13
I1
sasg19
(lp14117
(dp14118
g7
I206
sg22
VC0033860
p14119
sg10
I9
sg11
Vpsoriasis
p14120
sg13
I1
sasa(dp14121
g2
S'KCNJ2 gain-of-function mutations V93I and D172N associate with increased IK1, short QT syndrome type 3 and congenital atrial fibrillation.\n'
p14122
sg4
(lp14123
(dp14124
g7
I73
sg8
g15
sg10
I3
sg11
VIK1
p14125
sg13
I1
sa(dp14126
g7
I0
sg8
VP63252
p14127
sg10
I5
sg11
VKCNJ2
p14128
sg13
I1
sasg19
(lp14129
(dp14130
g7
I118
sg22
VC0004238
p14131
sg10
I19
sg11
Vatrial fibrillation
p14132
sg13
I2
sa(dp14133
g7
I78
sg22
VC2348199
p14134
sg10
I17
sg11
Vshort QT syndrome
p14135
sg13
I3
sasa(dp14136
g2
S'Gain-of-function mutations in KCNJ2-encoded Kir2.1 channels underlie variant 3 (SQT3) of the short QT syndrome, which is associated with atrial fibrillation (AF).\n'
p14137
sg4
(lp14138
(dp14139
g7
I30
sg8
VP63252
p14140
sg10
I5
sg11
VKCNJ2
p14141
sg13
I1
sa(dp14142
g7
I44
sg8
VP63252
p14143
sg10
I34
sg11
VKir2.1 channels underlie variant 3
p14144
sg13
I5
sa(dp14145
g7
I80
sg8
VP63252
p14146
sg10
I4
sg11
VSQT3
p14147
sg13
I1
sasg19
(lp14148
(dp14149
g7
I158
sg22
VC0004238
p14150
sg10
I2
sg11
VAF
p14151
sg13
I1
sa(dp14152
g7
I93
sg22
VC2348199
p14153
sg10
I17
sg11
Vshort QT syndrome
p14154
sg13
I3
sa(dp14155
g7
I137
sg22
VC0004238
p14156
sg10
I19
sg11
Vatrial fibrillation
p14157
sg13
I2
sa(dp14158
g7
I80
sg22
VC1865018
p14159
sg10
I4
sg11
VSQT3
p14160
sg13
I1
sasa(dp14161
g2
S'Mutations of Kir2.1, such as D172N or E299V, inducing gain-of-function, can cause type3 short QT syndrome (SQT3) due to the enlarged outward currents.\n'
p14162
sg4
(lp14163
(dp14164
g7
I13
sg8
VP63252
p14165
sg10
I6
sg11
VKir2.1
p14166
sg13
I1
sasg19
(lp14167
(dp14168
g7
I107
sg22
VC1865018
p14169
sg10
I4
sg11
VSQT3
p14170
sg13
I1
sa(dp14171
g7
I88
sg22
VC2348199
p14172
sg10
I17
sg11
Vshort QT syndrome
p14173
sg13
I3
sasa(dp14174
g2
S'Methods In this context, a search was undertaken for mutations in LMNA, encoding Lamins A/C, and ZMPSTE24, LBR, LMNB1, LMNB2, MAN1, SYNE1a and LAP2, encoding Lamins A/C molecular partners, in a Caucasian woman affected with Reynolds syndrome, a particular nosologic entity specifically associating limited cutaneous SSc and primary biliary cirrhosis.\n'
p14175
sg4
(lp14176
(dp14177
g7
I126
sg8
g15
sg10
I4
sg11
VMAN1
p14178
sg13
I1
sa(dp14179
g7
I112
sg8
VP20700
p14180
sg10
I5
sg11
VLMNB1
p14181
sg13
I1
sa(dp14182
g7
I97
sg8
g15
sg10
I8
sg11
VZMPSTE24
p14183
sg13
I1
sa(dp14184
g7
I119
sg8
g15
sg10
I5
sg11
VLMNB2
p14185
sg13
I1
sa(dp14186
g7
I107
sg8
g15
sg10
I3
sg11
VLBR
p14187
sg13
I1
sa(dp14188
g7
I143
sg8
VP42166
p14189
sg10
I4
sg11
VLAP2
p14190
sg13
I1
sa(dp14191
g7
I81
sg8
VP49815
p14192
sg10
I10
sg11
VLamins A/C
p14193
sg13
I2
sa(dp14194
g7
I81
sg8
VP49815
p14195
sg10
I10
sg11
VLamins A/C
p14196
sg13
I2
sa(dp14197
g7
I66
sg8
VP02545
p14198
sg10
I4
sg11
VLMNA
p14199
sg13
I1
sasg19
(lp14200
(dp14201
g7
I324
sg22
VC0008312
p14202
sg10
I25
sg11
Vprimary biliary cirrhosis
p14203
sg13
I3
sa(dp14204
g7
I224
sg22
VC0748397
p14205
sg10
I17
sg11
VReynolds syndrome
p14206
sg13
I2
sasa(dp14207
g2
S'In particular, lamin B1 may be considered as a marker for cirrhosis, because its expression level changes considerably in cirrhotic tissue compared with normal tissue.\n'
p14208
sg4
(lp14209
(dp14210
g7
I15
sg8
VP20700
p14211
sg10
I8
sg11
Vlamin B1
p14212
sg13
I2
sasg19
(lp14213
(dp14214
g7
I58
sg22
VC0023890
p14215
sg10
I9
sg11
Vcirrhosis
p14216
sg13
I1
sasa(dp14217
g2
S'A cross-sectional study of anti-lamin B1 autoantibodies, as measured by enzyme-linked immunosorbent assay using human recombinant lamin B1 autoantigen, was performed on serum samples obtained at first evaluation of 238 consecutive French Canadian adults: 61 healthy control subjects, 20 patients with osteoarthritis, 22 with ankylosing spondylitis, 11 with autoimmune hepatitis, 30 with rheumatoid arthritis, and 94 with SLE.\n'
p14218
sg4
(lp14219
(dp14220
g7
I27
sg8
VP20700
p14221
sg10
I28
sg11
Vanti-lamin B1 autoantibodies
p14222
sg13
I3
sa(dp14223
g7
I112
sg8
VP20700
p14224
sg10
I38
sg11
Vhuman recombinant lamin B1 autoantigen
p14225
sg13
I5
sasg19
(lp14226
(dp14227
g7
I301
sg22
VC0029408
p14228
sg10
I14
sg11
Vosteoarthritis
p14229
sg13
I1
sa(dp14230
g7
I357
sg22
VC0241910
p14231
sg10
I20
sg11
Vautoimmune hepatitis
p14232
sg13
I2
sa(dp14233
g7
I325
sg22
VC0038013
p14234
sg10
I22
sg11
Vankylosing spondylitis
p14235
sg13
I2
sa(dp14236
g7
I387
sg22
VC0003873
p14237
sg10
I20
sg11
Vrheumatoid arthritis
p14238
sg13
I2
sa(dp14239
g7
I421
sg22
VC0014060
p14240
sg10
I3
sg11
VSLE
p14241
sg13
I1
sasa(dp14242
g2
S'EGR3 is considered as a potential candidate gene for schizophrenia.\n'
p14243
sg4
(lp14244
(dp14245
g7
I0
sg8
g15
sg10
I4
sg11
VEGR3
p14246
sg13
I1
sasg19
(lp14247
(dp14248
g7
I53
sg22
VC0036341
p14249
sg10
I13
sg11
Vschizophrenia
p14250
sg13
I1
sasa(dp14251
g2
S'We conducted in vitro DNA methylation reaction, Lucia luciferase activity assay, and pyrosequencing assay to assess the DNA methylation of the EGR3 expression underlying the pathophysiology of schizophrenia.\n'
p14252
sg4
(lp14253
(dp14254
g7
I143
sg8
g15
sg10
I4
sg11
VEGR3
p14255
sg13
I1
sasg19
(lp14256
(dp14257
g7
I193
sg22
VC0036341
p14258
sg10
I13
sg11
Vschizophrenia
p14259
sg13
I1
sasa(dp14260
g2
S'Our data suggest that DNA methylation regulated the expression of EGR3 might not be associated with schizophrenia.\n'
p14261
sg4
(lp14262
(dp14263
g7
I66
sg8
g15
sg10
I4
sg11
VEGR3
p14264
sg13
I1
sasg19
(lp14265
(dp14266
g7
I100
sg22
VC0036341
p14267
sg10
I13
sg11
Vschizophrenia
p14268
sg13
I1
sasa(dp14269
g2
S'Accordingly, variations in the immediate early gene EGR3, and its target ARC, should influence schizophrenia susceptibility.\n'
p14270
sg4
(lp14271
(dp14272
g7
I31
sg8
g15
sg10
I25
sg11
Vimmediate early gene EGR3
p14273
sg13
I4
sasg19
(lp14274
(dp14275
g7
I95
sg22
VC0036341
p14276
sg10
I13
sg11
Vschizophrenia
p14277
sg13
I1
sa(dp14278
g7
I73
sg22
VC0001857
p14279
sg10
I3
sg11
VARC
p14280
sg13
I1
sasa(dp14281
g2
S'In the EU group of 386 schizophrenia cases and 150 controls EGR3 SNP rs1877670 and ARC SNP rs35900184 showed significant associations (p = 0.0078 and p = 0.0275, respectively).\n'
p14282
sg4
(lp14283
(dp14284
g7
I60
sg8
g15
sg10
I18
sg11
VEGR3 SNP rs1877670
p14285
sg13
I3
sa(dp14286
g7
I83
sg8
g15
sg10
I18
sg11
VARC SNP rs35900184
p14287
sg13
I3
sasg19
(lp14288
(dp14289
g7
I23
sg22
VC0036341
p14290
sg10
I13
sg11
Vschizophrenia
p14291
sg13
I1
sa(dp14292
g7
I83
sg22
VC0001857
p14293
sg10
I3
sg11
VARC
p14294
sg13
I1
sasa(dp14295
g2
S'These findings support previously reported associations between EGR3 and schizophrenia.\n'
p14296
sg4
(lp14297
(dp14298
g7
I64
sg8
g15
sg10
I4
sg11
VEGR3
p14299
sg13
I1
sasg19
(lp14300
(dp14301
g7
I73
sg22
VC0036341
p14302
sg10
I13
sg11
Vschizophrenia
p14303
sg13
I1
sasa(dp14304
g2
S'In this study, we aimed to investigate the white matter connection in schizophrenia susceptible brain regions of early growth response factor 3 (EGR3) expressing rats.\n'
p14305
sg4
(lp14306
(dp14307
g7
I113
sg8
g15
sg10
I30
sg11
Vearly growth response factor 3
p14308
sg13
I5
sa(dp14309
g7
I145
sg8
g15
sg10
I4
sg11
VEGR3
p14310
sg13
I1
sasg19
(lp14311
(dp14312
g7
I70
sg22
VC0036341
p14313
sg10
I13
sg11
Vschizophrenia
p14314
sg13
I1
sasa(dp14315
g2
S'A rat model of schizophrenia was created by the transfection of the EGR3 gene into rat hippocampus.\n'
p14316
sg4
(lp14317
(dp14318
g7
I68
sg8
g15
sg10
I9
sg11
VEGR3 gene
p14319
sg13
I2
sasg19
(lp14320
(dp14321
g7
I15
sg22
VC0036341
p14322
sg10
I13
sg11
Vschizophrenia
p14323
sg13
I1
sasa(dp14324
g2
S'The volume of hippocampus and the number of fiber bundles were reduced in EGR3 transgenic schizophrenia rats, and are the most sensitive indicators in schizophrenia.\n'
p14325
sg4
(lp14326
(dp14327
g7
I74
sg8
g15
sg10
I4
sg11
VEGR3
p14328
sg13
I1
sasg19
(lp14329
(dp14330
g7
I90
sg22
VC0036341
p14331
sg10
I13
sg11
Vschizophrenia
p14332
sg13
I1
sa(dp14333
g7
I90
sg22
VC0036341
p14334
sg10
I13
sg11
Vschizophrenia
p14335
sg13
I1
sasa(dp14336
g2
S'In this study, we successfully created a rat model of schizophrenia by the transfection of EGR3 gene into rat brain.\n'
p14337
sg4
(lp14338
(dp14339
g7
I91
sg8
g15
sg10
I9
sg11
VEGR3 gene
p14340
sg13
I2
sasg19
(lp14341
(dp14342
g7
I54
sg22
VC0036341
p14343
sg10
I13
sg11
Vschizophrenia
p14344
sg13
I1
sasa(dp14345
g2
S'The transcription factor early growth response protein 3 (EGR3) is involved in schizophrenia.\n'
p14346
sg4
(lp14347
(dp14348
g7
I4
sg8
g15
sg10
I52
sg11
Vtranscription factor early growth response protein 3
p14349
sg13
I7
sa(dp14350
g7
I58
sg8
g15
sg10
I4
sg11
VEGR3
p14351
sg13
I1
sasg19
(lp14352
(dp14353
g7
I79
sg22
VC0036341
p14354
sg10
I13
sg11
Vschizophrenia
p14355
sg13
I1
sasa(dp14356
g2
S'We developed a putative rat model of schizophrenia by transfecting lentiviral particles carrying the Egr3 gene into bilateral hippocampal dentate gyrus.\n'
p14357
sg4
(lp14358
(dp14359
g7
I101
sg8
g15
sg10
I9
sg11
VEgr3 gene
p14360
sg13
I2
sasg19
(lp14361
(dp14362
g7
I37
sg22
VC0036341
p14363
sg10
I13
sg11
Vschizophrenia
p14364
sg13
I1
sasa(dp14365
g2
S'This study is the first to report evaluation of brain metabolites using 3.0 T proton magnetic resonance spectroscopy in rats transfected with Egr3, and reveals metabolic abnormalities in the hippocampus and thalamus in this putative model of schizophrenia.\n'
p14366
sg4
(lp14367
(dp14368
g7
I142
sg8
g15
sg10
I4
sg11
VEgr3
p14369
sg13
I1
sasg19
(lp14370
(dp14371
g7
I242
sg22
VC0036341
p14372
sg10
I13
sg11
Vschizophrenia
p14373
sg13
I1
sasa(dp14374
g2
S'The early growth response 3 (EGR3) gene is an immediate early gene that is expressed throughout the brain and has been suggested as a potential susceptibility gene for schizophrenia (SZ).\n'
p14375
sg4
(lp14376
(dp14377
g7
I4
sg8
g15
sg10
I23
sg11
Vearly growth response 3
p14378
sg13
I4
sa(dp14379
g7
I29
sg8
g15
sg10
I4
sg11
VEGR3
p14380
sg13
I1
sasg19
(lp14381
(dp14382
g7
I168
sg22
VC0036341
p14383
sg10
I13
sg11
Vschizophrenia
p14384
sg13
I1
sa(dp14385
g7
I183
sg22
VC0036341
p14386
sg10
I2
sg11
VSZ
p14387
sg13
I1
sasa(dp14388
g2
S"The immediate-early gene early growth response 3 (Egr3) is associated with schizophrenia and expressed at reduced levels in postmortem patients' brains.\n"
p14389
sg4
(lp14390
(dp14391
g7
I20
sg8
g15
sg10
I28
sg11
Vgene early growth response 3
p14392
sg13
I5
sa(dp14393
g7
I50
sg8
g15
sg10
I4
sg11
VEgr3
p14394
sg13
I1
sasg19
(lp14395
(dp14396
g7
I75
sg22
VC0036341
p14397
sg10
I13
sg11
Vschizophrenia
p14398
sg13
I1
sasa(dp14399
g2
S'We have previously reported that Egr3-deficient (Egr3(-/-)) mice display reduced sensitivity to the sedating effects of clozapine compared with wild-type (WT) littermates, paralleling the heightened tolerance of schizophrenia patients to antipsychotic side effects.\n'
p14400
sg4
(lp14401
(dp14402
g7
I33
sg8
g15
sg10
I4
sg11
VEgr3
p14403
sg13
I1
sa(dp14404
g7
I33
sg8
g15
sg10
I4
sg11
VEgr3
p14405
sg13
I1
sasg19
(lp14406
(dp14407
g7
I212
sg22
VC0036341
p14408
sg10
I13
sg11
Vschizophrenia
p14409
sg13
I1
sa(dp14410
g7
I199
sg22
VC0020963
p14411
sg10
I9
sg11
Vtolerance
p14412
sg13
I1
sasa(dp14413
g2
S'Moreover, as the deficit in cortical 5HT(2A)R in Egr3(-/-) mice aligns with numerous studies reporting decreased 5HT(2A)R levels in the brains of schizophrenia patients, and the gene encoding the 5HT(2A)R is itself a leading schizophrenia candidate gene, these findings suggest a potential mechanism by which putative dysfunction in EGR3 in humans may influence risk for schizophrenia.\n'
p14414
sg4
(lp14415
(dp14416
g7
I49
sg8
g15
sg10
I4
sg11
VEgr3
p14417
sg13
I1
sa(dp14418
g7
I333
sg8
g15
sg10
I4
sg11
VEGR3
p14419
sg13
I1
sasg19
(lp14420
(dp14421
g7
I17
sg22
VC0162429
p14422
sg10
I7
sg11
Vdeficit
p14423
sg13
I1
sa(dp14424
g7
I146
sg22
VC0036341
p14425
sg10
I13
sg11
Vschizophrenia
p14426
sg13
I1
sa(dp14427
g7
I146
sg22
VC0036341
p14428
sg10
I13
sg11
Vschizophrenia
p14429
sg13
I1
sa(dp14430
g7
I146
sg22
VC0036341
p14431
sg10
I13
sg11
Vschizophrenia
p14432
sg13
I1
sasa(dp14433
g2
S'Previous studies showed that EGR3 gene located in chromosome 8p21.3 was involved in the etiology of schizophrenia.\n'
p14434
sg4
(lp14435
(dp14436
g7
I29
sg8
g15
sg10
I9
sg11
VEGR3 gene
p14437
sg13
I2
sasg19
(lp14438
(dp14439
g7
I100
sg22
VC0036341
p14440
sg10
I13
sg11
Vschizophrenia
p14441
sg13
I1
sasa(dp14442
g2
S'Overall, the results suggested that EGR3 gene may play an important role in schizophrenia susceptibility in the Han Chinese population, and further functional exploration of the EGR3 gene will contribute to the underlying molecular mechanism for schizophrenia pathogenesis.\n'
p14443
sg4
(lp14444
(dp14445
g7
I36
sg8
g15
sg10
I9
sg11
VEGR3 gene
p14446
sg13
I2
sa(dp14447
g7
I36
sg8
g15
sg10
I9
sg11
VEGR3 gene
p14448
sg13
I2
sasg19
(lp14449
(dp14450
g7
I76
sg22
VC0036341
p14451
sg10
I13
sg11
Vschizophrenia
p14452
sg13
I1
sa(dp14453
g7
I76
sg22
VC0036341
p14454
sg10
I13
sg11
Vschizophrenia
p14455
sg13
I1
sa(dp14456
g7
I260
sg22
VC0699748
p14457
sg10
I12
sg11
Vpathogenesis
p14458
sg13
I1
sasa(dp14459
g2
S'The early growth response 3 (EGR3) gene located in chromosome 8p21.3 was also found to be involved in the etiology of schizophrenia.\n'
p14460
sg4
(lp14461
(dp14462
g7
I4
sg8
g15
sg10
I23
sg11
Vearly growth response 3
p14463
sg13
I4
sa(dp14464
g7
I29
sg8
g15
sg10
I4
sg11
VEGR3
p14465
sg13
I1
sasg19
(lp14466
(dp14467
g7
I118
sg22
VC0036341
p14468
sg10
I13
sg11
Vschizophrenia
p14469
sg13
I1
sasa(dp14470
g2
S'To investigate the genetic role of EGR3 in Chinese patients, we genotyped four SNPs (average interval ~2.3 kb) in the chromosome region of EGR3 in 470 Chinese schizophrenia patients and 480 healthy control subjects.\n'
p14471
sg4
(lp14472
(dp14473
g7
I35
sg8
g15
sg10
I4
sg11
VEGR3
p14474
sg13
I1
sa(dp14475
g7
I35
sg8
g15
sg10
I4
sg11
VEGR3
p14476
sg13
I1
sasg19
(lp14477
(dp14478
g7
I159
sg22
VC0036341
p14479
sg10
I13
sg11
Vschizophrenia
p14480
sg13
I1
sasa(dp14481
g2
S'In summary, our study supports the association of EGR3 with schizophrenia in our Han Chinese sample, and further functional exploration of the EGR3 gene will contribute to the molecular basis for the complex network underlying schizophrenia pathogenesis.\n'
p14482
sg4
(lp14483
(dp14484
g7
I50
sg8
g15
sg10
I4
sg11
VEGR3
p14485
sg13
I1
sa(dp14486
g7
I143
sg8
g15
sg10
I9
sg11
VEGR3 gene
p14487
sg13
I2
sasg19
(lp14488
(dp14489
g7
I241
sg22
VC0699748
p14490
sg10
I12
sg11
Vpathogenesis
p14491
sg13
I1
sa(dp14492
g7
I60
sg22
VC0036341
p14493
sg10
I13
sg11
Vschizophrenia
p14494
sg13
I1
sa(dp14495
g7
I60
sg22
VC0036341
p14496
sg10
I13
sg11
Vschizophrenia
p14497
sg13
I1
sasa(dp14498
g2
S'Serum xylosyltransferase I (XT-I) is a marker for the determination of tissue remodeling in systemic sclerosis.\n'
p14499
sg4
(lp14500
(dp14501
g7
I28
sg8
g15
sg10
I4
sg11
VXT-I
p14502
sg13
I1
sa(dp14503
g7
I0
sg8
g15
sg10
I26
sg11
VSerum xylosyltransferase I
p14504
sg13
I3
sasg19
(lp14505
(dp14506
g7
I92
sg22
VC0036421
p14507
sg10
I18
sg11
Vsystemic sclerosis
p14508
sg13
I2
sasa(dp14509
g2
S'Since PEComa is associated with upregulation of mammalian target of rapamycin (mTOR) pathway which controls Glut-1 (glucose transporter) function, increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake may indicate the over activation of mTOR pathway and may guide selectively inhibiting mTOR pathway treatment.\n'
p14510
sg4
(lp14511
(dp14512
g7
I79
sg8
VP42345
p14513
sg10
I4
sg11
VmTOR
p14514
sg13
I1
sa(dp14515
g7
I79
sg8
VP42345
p14516
sg10
I4
sg11
VmTOR
p14517
sg13
I1
sa(dp14518
g7
I79
sg8
VP42345
p14519
sg10
I4
sg11
VmTOR
p14520
sg13
I1
sa(dp14521
g7
I48
sg8
VP42345
p14522
sg10
I29
sg11
Vmammalian target of rapamycin
p14523
sg13
I4
sasg19
(lp14524
(dp14525
g7
I6
sg22
VC1300127
p14526
sg10
I6
sg11
VPEComa
p14527
sg13
I1
sasa(dp14528
g2
S'We report a malignant PEComa patient who presented for (18)F-FDG positron emission tomography/computed tomography (PET/CT) restaging.\n'
p14529
sg4
(lp14530
sg19
(lp14531
(dp14532
g7
I22
sg22
VC1300127
p14533
sg10
I6
sg11
VPEComa
p14534
sg13
I1
sasa(dp14535
g2
S'Therefore, (18)F-FDG PET/CT is helpful in restaging and guiding treatment for malignant PEComa with mTOR inhibitors.\n'
p14536
sg4
(lp14537
(dp14538
g7
I100
sg8
VP42345
p14539
sg10
I4
sg11
VmTOR
p14540
sg13
I1
sasg19
(lp14541
(dp14542
g7
I88
sg22
VC1300127
p14543
sg10
I6
sg11
VPEComa
p14544
sg13
I1
sasa(dp14545
g2
S'We present a case of a 40-year old patient who was incidentally diagnosed of a uterine PEComa and serial studies of PET-CT with FDG were performed for staging and therapeutic response assessment.\n'
p14546
sg4
(lp14547
sg19
(lp14548
(dp14549
g7
I87
sg22
VC1300127
p14550
sg10
I6
sg11
VPEComa
p14551
sg13
I1
sasa(dp14552
g2
S'This pilot study suggests that FDG-PET scans are negative in patients with benign PEComas and therefore are not likely to be useful for estimating the burden of disease in patients with TSC or LAM, but that FDG-PET scans can be used to identify or exclude other neoplasms in these patients.\n'
p14553
sg4
(lp14554
sg19
(lp14555
(dp14556
g7
I82
sg22
VC1300127
p14557
sg10
I7
sg11
VPEComas
p14558
sg13
I1
sa(dp14559
g7
I193
sg22
VC0751674
p14560
sg10
I3
sg11
VLAM
p14561
sg13
I1
sa(dp14562
g7
I186
sg22
VC0041341
p14563
sg10
I3
sg11
VTSC
p14564
sg13
I1
sa(dp14565
g7
I262
sg22
VC0027651
p14566
sg10
I9
sg11
Vneoplasms
p14567
sg13
I1
sasa(dp14568
g2
S'Complete deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity causes Lesch Nyhan disease (LND), characterized by hyperuricemia, severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit and self-injurious behavior.\n'
p14569
sg4
(lp14570
(dp14571
g7
I23
sg8
VP00492
p14572
sg10
I46
sg11
Vhypoxanthine-guanine phosphoribosyltransferase
p14573
sg13
I2
sa(dp14574
g7
I71
sg8
VP00492
p14575
sg10
I4
sg11
VHPRT
p14576
sg13
I1
sasg19
(lp14577
(dp14578
g7
I176
sg22
VC0085583
p14579
sg10
I15
sg11
Vchoreoathetosis
p14580
sg13
I1
sa(dp14581
g7
I137
sg22
VC0740394
p14582
sg10
I13
sg11
Vhyperuricemia
p14583
sg13
I1
sa(dp14584
g7
I218
sg22
VC0041671
p14585
sg10
I17
sg11
Vattention deficit
p14586
sg13
I2
sa(dp14587
g7
I193
sg22
VC0752196
p14588
sg10
I9
sg11
Vballismus
p14589
sg13
I1
sa(dp14590
g7
I240
sg22
VC0085271
p14591
sg10
I23
sg11
Vself-injurious behavior
p14592
sg13
I2
sa(dp14593
g7
I9
sg22
VC0023374
p14594
sg10
I60
sg11
Vdeficiency of hypoxanthine-guanine phosphoribosyltransferase
p14595
sg13
I4
sa(dp14596
g7
I93
sg22
VC0023374
p14597
sg10
I19
sg11
VLesch Nyhan disease
p14598
sg13
I3
sa(dp14599
g7
I166
sg22
VC0393593
p14600
sg10
I8
sg11
Vdystonia
p14601
sg13
I1
sa(dp14602
g7
I114
sg22
VC0023374
p14603
sg10
I3
sg11
VLND
p14604
sg13
I1
sasa(dp14605
g2
S'The current investigation also identified an unexpected and unique behavior of the knee in children with dystonic cerebral palsy (CP) that was noticed while administering the Pendulum Knee Drop test (PKD) at approximately 0.4 rad (a mid-angle between full extension and zero vertical).\n'
p14606
sg4
(lp14607
sg19
(lp14608
(dp14609
g7
I105
sg22
VC2875324
p14610
sg10
I23
sg11
Vdystonic cerebral palsy
p14611
sg13
I3
sa(dp14612
g7
I200
sg22
VC1868682
p14613
sg10
I3
sg11
VPKD
p14614
sg13
I1
sa(dp14615
g7
I130
sg22
VC0007789
p14616
sg10
I2
sg11
VCP
p14617
sg13
I1
sa(dp14618
g7
I175
sg22
VC1868682
p14619
sg10
I23
sg11
VPendulum Knee Drop test
p14620
sg13
I4
sasa(dp14621
g2
S'Gprt also showed slightly stronger correlations than Hprt with 13 of 14 measures of the clinical phenotype, including the severity of dystonia, cognitive impairment, and behavioral abnormalities.\n'
p14622
sg4
(lp14623
sg19
(lp14624
(dp14625
g7
I134
sg22
VC0393593
p14626
sg10
I8
sg11
Vdystonia
p14627
sg13
I1
sa(dp14628
g7
I144
sg22
VC0338656
p14629
sg10
I20
sg11
Vcognitive impairment
p14630
sg13
I2
sasa(dp14631
g2
S'To observe the effect of garlicin on adhension molecules CD11a and deformability of peripheral neutrophil in patients with acute cerebral infarction (ACI).\n'
p14632
sg4
(lp14633
(dp14634
g7
I57
sg8
VP20701
p14635
sg10
I5
sg11
VCD11a
p14636
sg13
I1
sasg19
(lp14637
(dp14638
g7
I129
sg22
VC0038454
p14639
sg10
I19
sg11
Vcerebral infarction
p14640
sg13
I2
sasa(dp14641
g2
S'We examined in 19 subjects with acute ischaemic stroke (AIS) the PMN integrin pattern (CD11a, CD11b, CD11c, CD18), using indirect immunofluorescence and adopting a flow cytometer, at baseline and during activation, prolonged for 5 and 15 min, with 4-phorbol 12-myristate 13-acetate (PMA).\n'
p14642
sg4
(lp14643
(dp14644
g7
I108
sg8
VP05107
p14645
sg10
I4
sg11
VCD18
p14646
sg13
I1
sa(dp14647
g7
I87
sg8
VP20701
p14648
sg10
I5
sg11
VCD11a
p14649
sg13
I1
sa(dp14650
g7
I65
sg8
VP48556
p14651
sg10
I20
sg11
VPMN integrin pattern
p14652
sg13
I3
sa(dp14653
g7
I94
sg8
VP11215
p14654
sg10
I5
sg11
VCD11b
p14655
sg13
I1
sa(dp14656
g7
I101
sg8
VP20702
p14657
sg10
I5
sg11
VCD11c
p14658
sg13
I1
sasg19
(lp14659
(dp14660
g7
I32
sg22
VC0039585
p14661
sg10
I22
sg11
Vacute ischaemic stroke
p14662
sg13
I3
sa(dp14663
g7
I56
sg22
VC0039585
p14664
sg10
I3
sg11
VAIS
p14665
sg13
I1
sasa(dp14666
g2
S'We report, here, the establishment of an in vitro lung             cancer microenvironment by co-incubation of seminaphtharhodafluor (SNARF) labeled             Lewis lung cancer (LLC) cells, carboxyfluorescein succinimidyl ester (CFSE) labeled             fibroblasts and 4-chloromethyl-7-hydroxycoumarin (CMHC) labeled DCs.\n'
p14667
sg4
(lp14668
sg19
(lp14669
(dp14670
g7
I67
sg22
VC0006826
p14671
sg10
I6
sg11
Vcancer
p14672
sg13
I1
sa(dp14673
g7
I167
sg22
VC0684249
p14674
sg10
I11
sg11
Vlung cancer
p14675
sg13
I2
sa(dp14676
g7
I321
sg22
VC0268238
p14677
sg10
I3
sg11
VDCs
p14678
sg13
I1
sasa(dp14679
g2
S'Blasts from 38 children with acute leukemia (31 with ALL and 7 with AML) were tested for apoptotic index (Annexin V) and intracellular pH (SNARF).\n'
p14680
sg4
(lp14681
sg19
(lp14682
(dp14683
g7
I68
sg22
VC0023467
p14684
sg10
I3
sg11
VAML
p14685
sg13
I1
sa(dp14686
g7
I29
sg22
VC0085669
p14687
sg10
I14
sg11
Vacute leukemia
p14688
sg13
I2
sasa(dp14689
g2
S'In congenital heart block association with HLA-B27 and HLA-DR3 is a possible prerequisite in the pathophysiology of the disease, although transplacental passage of various antibodies and immune complexes is widely recognized.\n'
p14690
sg4
(lp14691
(dp14692
g7
I55
sg8
VP30486
p14693
sg10
I7
sg11
VHLA-DR3
p14694
sg13
I1
sa(dp14695
g7
I43
sg8
VP30486
p14696
sg10
I7
sg11
VHLA-B27
p14697
sg13
I1
sasg19
(lp14698
(dp14699
g7
I3
sg22
VC0149530
p14700
sg10
I22
sg11
Vcongenital heart block
p14701
sg13
I3
sasa(dp14702
g2
S'The occurrence of complete congenital heart block has been shown to be associated with the presence of SS-A/Ro antibodies as well as the MHC-haplotype DR3.\n'
p14703
sg4
(lp14704
(dp14705
g7
I137
sg8
VP13747
p14706
sg10
I17
sg11
VMHC-haplotype DR3
p14707
sg13
I2
sa(dp14708
g7
I103
sg8
VP37268
p14709
sg10
I18
sg11
VSS-A/Ro antibodies
p14710
sg13
I2
sasg19
(lp14711
(dp14712
g7
I27
sg22
VC0149530
p14713
sg10
I22
sg11
Vcongenital heart block
p14714
sg13
I3
sasa(dp14715
g2
S'We identified 16 miRNAs for colon and 17 miRNAs for rectal carcinoma that appear to differentiate between carcinoma and normal mucosa; of these, 12 were important for both colon and rectal cancer, hsa-miR-663b, hsa-miR-4539, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-4506, hsa-miR-92a-3p, hsa-miR-93-5p, hsa-miR-145-5p, hsa-miR-3651, hsa-miR-378a-3p, and hsa-miR-378i.\n'
p14716
sg4
(lp14717
(dp14718
g7
I301
sg8
g15
sg10
I13
sg11
Vhsa-miR-93-5p
p14719
sg13
I1
sa(dp14720
g7
I256
sg8
g15
sg10
I13
sg11
Vhsa-miR-21-5p
p14721
sg13
I1
sa(dp14722
g7
I285
sg8
g15
sg10
I14
sg11
Vhsa-miR-92a-3p
p14723
sg13
I1
sa(dp14724
g7
I332
sg8
g15
sg10
I12
sg11
Vhsa-miR-3651
p14725
sg13
I1
sa(dp14726
g7
I316
sg8
g15
sg10
I14
sg11
Vhsa-miR-145-5p
p14727
sg13
I1
sa(dp14728
g7
I271
sg8
g15
sg10
I12
sg11
Vhsa-miR-4506
p14729
sg13
I1
sa(dp14730
g7
I17
sg8
g15
sg10
I3
sg11
VmiR
p14731
sg13
I1
sa(dp14732
g7
I197
sg8
g15
sg10
I3
sg11
Vhsa
p14733
sg13
I1
sa(dp14734
g7
I346
sg8
g15
sg10
I15
sg11
Vhsa-miR-378a-3p
p14735
sg13
I1
sa(dp14736
g7
I17
sg8
g15
sg10
I3
sg11
VmiR
p14737
sg13
I1
sa(dp14738
g7
I197
sg8
g15
sg10
I3
sg11
Vhsa
p14739
sg13
I1
sa(dp14740
g7
I240
sg8
g15
sg10
I14
sg11
Vhsa-miR-20a-5p
p14741
sg13
I1
sa(dp14742
g7
I211
sg8
g15
sg10
I12
sg11
Vhsa-miR-4539
p14743
sg13
I1
sa(dp14744
g7
I225
sg8
g15
sg10
I13
sg11
Vhsa-miR-17-5p
p14745
sg13
I1
sasg19
(lp14746
(dp14747
g7
I197
sg22
VC0393754
p14748
sg10
I3
sg11
Vhsa
p14749
sg13
I1
sa(dp14750
g7
I197
sg22
VC0393754
p14751
sg10
I3
sg11
Vhsa
p14752
sg13
I1
sa(dp14753
g7
I182
sg22
VC0007113
p14754
sg10
I13
sg11
Vrectal cancer
p14755
sg13
I2
sa(dp14756
g7
I197
sg22
VC0393754
p14757
sg10
I3
sg11
Vhsa
p14758
sg13
I1
sa(dp14759
g7
I52
sg22
VC0007113
p14760
sg10
I16
sg11
Vrectal carcinoma
p14761
sg13
I2
sa(dp14762
g7
I197
sg22
VC0393754
p14763
sg10
I3
sg11
Vhsa
p14764
sg13
I1
sa(dp14765
g7
I197
sg22
VC0393754
p14766
sg10
I3
sg11
Vhsa
p14767
sg13
I1
sa(dp14768
g7
I197
sg22
VC0393754
p14769
sg10
I3
sg11
Vhsa
p14770
sg13
I1
sa(dp14771
g7
I197
sg22
VC0393754
p14772
sg10
I3
sg11
Vhsa
p14773
sg13
I1
sa(dp14774
g7
I197
sg22
VC0393754
p14775
sg10
I3
sg11
Vhsa
p14776
sg13
I1
sa(dp14777
g7
I197
sg22
VC0393754
p14778
sg10
I3
sg11
Vhsa
p14779
sg13
I1
sa(dp14780
g7
I197
sg22
VC0393754
p14781
sg10
I3
sg11
Vhsa
p14782
sg13
I1
sa(dp14783
g7
I59
sg22
VC0007097
p14784
sg10
I9
sg11
Vcarcinoma
p14785
sg13
I1
sa(dp14786
g7
I197
sg22
VC0393754
p14787
sg10
I3
sg11
Vhsa
p14788
sg13
I1
sa(dp14789
g7
I197
sg22
VC0393754
p14790
sg10
I3
sg11
Vhsa
p14791
sg13
I1
sasa(dp14792
g2
S'We confirmed that Sp1 is overexpressed in castration-resistant prostate cancer (CRPC) cells.\n'
p14793
sg4
(lp14794
(dp14795
g7
I18
sg8
VP08047
p14796
sg10
I3
sg11
VSp1
p14797
sg13
I1
sasg19
(lp14798
(dp14799
g7
I63
sg22
VC0600139
p14800
sg10
I15
sg11
Vprostate cancer
p14801
sg13
I2
sasa(dp14802
g2
S'The finding of an ERE overlapping with the Sp1-binding site affected by SNP285, taken together with the significant impact of SNP285 on the risk of breast, ovarian and now endometrial cancer but not prostatic cancer, suggests a gender specific effect of SNP285C on cancer risk.\n'
p14803
sg4
(lp14804
(dp14805
g7
I43
sg8
VP08047
p14806
sg10
I16
sg11
VSp1-binding site
p14807
sg13
I2
sasg19
(lp14808
(dp14809
g7
I199
sg22
VC0376358
p14810
sg10
I16
sg11
Vprostatic cancer
p14811
sg13
I2
sa(dp14812
g7
I184
sg22
VC0006826
p14813
sg10
I6
sg11
Vcancer
p14814
sg13
I1
sa(dp14815
g7
I172
sg22
VC0476089
p14816
sg10
I18
sg11
Vendometrial cancer
p14817
sg13
I2
sasa(dp14818
g2
S'Taken together, our results demonstrate that a key event in the artemisinin anti-proliferative effects in prostate cancer cells is the transcriptional down-regulation of CDK4 expression by disruption of Sp1 interactions with the CDK4 promoter.\n'
p14819
sg4
(lp14820
(dp14821
g7
I170
sg8
VP11802
p14822
sg10
I4
sg11
VCDK4
p14823
sg13
I1
sa(dp14824
g7
I203
sg8
VP08047
p14825
sg10
I3
sg11
VSp1
p14826
sg13
I1
sa(dp14827
g7
I229
sg8
VP11802
p14828
sg10
I13
sg11
VCDK4 promoter
p14829
sg13
I2
sasg19
(lp14830
(dp14831
g7
I106
sg22
VC0600139
p14832
sg10
I15
sg11
Vprostate cancer
p14833
sg13
I2
sa(dp14834
g7
I81
sg22
VC0334094
p14835
sg10
I13
sg11
Vproliferative
p14836
sg13
I1
sasa(dp14837
g2
S'Recently, miR-33b has been reported to be involved in multiple types of human cancer, including hepatocellular carcinoma (HCC).\n'
p14838
sg4
(lp14839
(dp14840
g7
I10
sg8
g15
sg10
I7
sg11
VmiR-33b
p14841
sg13
I1
sasg19
(lp14842
(dp14843
g7
I78
sg22
VC0006826
p14844
sg10
I6
sg11
Vcancer
p14845
sg13
I1
sa(dp14846
g7
I122
sg22
VC2239176
p14847
sg10
I3
sg11
VHCC
p14848
sg13
I1
sa(dp14849
g7
I96
sg22
VC2239176
p14850
sg10
I24
sg11
Vhepatocellular carcinoma
p14851
sg13
I2
sasa(dp14852
g2
S'To investigate the expression of miR-33b in hepatocellular carcinoma (HCC) and to explore regulatory mechanism of miR-33b for cell proliferation of HCC.\n'
p14853
sg4
(lp14854
(dp14855
g7
I33
sg8
g15
sg10
I7
sg11
VmiR-33b
p14856
sg13
I1
sasg19
(lp14857
(dp14858
g7
I44
sg22
VC2239176
p14859
sg10
I24
sg11
Vhepatocellular carcinoma
p14860
sg13
I2
sa(dp14861
g7
I70
sg22
VC2239176
p14862
sg10
I3
sg11
VHCC
p14863
sg13
I1
sa(dp14864
g7
I70
sg22
VC2239176
p14865
sg10
I3
sg11
VHCC
p14866
sg13
I1
sa(dp14867
g7
I131
sg22
VC0334094
p14868
sg10
I13
sg11
Vproliferation
p14869
sg13
I1
sasa(dp14870
g2
S'#######RNA-33b(micro RNA-33b, miR-33b)#####(hepatocellular carcinoma, HCC)#######HCC####################HCC#####32#, ########## PCR#Western##############4(Sal-like 4, SALL4)RNA#####,  MTT####HCC####, ############miR-33b#SALL4###########MiR-33b#HCC##############(P&lt;0.001)####miR-33b#####HCC LH86######SALL4#miR-33b####, ######miR-33b#######SALL4###miR-33b#LH86##########SALL4#HCC##############(P&lt;0.001)####MiR-33b#HCC###############SALL4#######.\n'
p14871
sg4
(lp14872
(dp14873
g7
I167
sg8
g15
sg10
I5
sg11
VSALL4
p14874
sg13
I1
sa(dp14875
g7
I167
sg8
g15
sg10
I5
sg11
VSALL4
p14876
sg13
I1
sa(dp14877
g7
I167
sg8
g15
sg10
I5
sg11
VSALL4
p14878
sg13
I1
sa(dp14879
g7
I167
sg8
g15
sg10
I5
sg11
VSALL4
p14880
sg13
I1
sa(dp14881
g7
I30
sg8
g15
sg10
I7
sg11
VmiR-33b
p14882
sg13
I1
sa(dp14883
g7
I155
sg8
g15
sg10
I10
sg11
VSal-like 4
p14884
sg13
I2
sa(dp14885
g7
I167
sg8
g15
sg10
I5
sg11
VSALL4
p14886
sg13
I1
sa(dp14887
g7
I167
sg8
g15
sg10
I5
sg11
VSALL4
p14888
sg13
I1
sasg19
(lp14889
(dp14890
g7
I70
sg22
VC2239176
p14891
sg10
I3
sg11
VHCC
p14892
sg13
I1
sa(dp14893
g7
I70
sg22
VC2239176
p14894
sg10
I3
sg11
VHCC
p14895
sg13
I1
sa(dp14896
g7
I70
sg22
VC2239176
p14897
sg10
I3
sg11
VHCC
p14898
sg13
I1
sa(dp14899
g7
I70
sg22
VC2239176
p14900
sg10
I3
sg11
VHCC
p14901
sg13
I1
sa(dp14902
g7
I70
sg22
VC2239176
p14903
sg10
I3
sg11
VHCC
p14904
sg13
I1
sa(dp14905
g7
I70
sg22
VC2239176
p14906
sg10
I3
sg11
VHCC
p14907
sg13
I1
sa(dp14908
g7
I70
sg22
VC2239176
p14909
sg10
I3
sg11
VHCC
p14910
sg13
I1
sa(dp14911
g7
I44
sg22
VC2239176
p14912
sg10
I24
sg11
Vhepatocellular carcinoma
p14913
sg13
I2
sa(dp14914
g7
I70
sg22
VC2239176
p14915
sg10
I3
sg11
VHCC
p14916
sg13
I1
sasa(dp14917
g2
S'Analysis using a Cox proportional hazard regression model showed that MAPK8IP1 and SH3GLB1, two autophagy-related genes, were associated with the prognostic signature for glioma.\n'
p14918
sg4
(lp14919
(dp14920
g7
I70
sg8
g15
sg10
I8
sg11
VMAPK8IP1
p14921
sg13
I1
sa(dp14922
g7
I83
sg8
g15
sg10
I7
sg11
VSH3GLB1
p14923
sg13
I1
sa(dp14924
g7
I96
sg8
VP01893
p14925
sg10
I23
sg11
Vautophagy-related genes
p14926
sg13
I2
sasg19
(lp14927
(dp14928
g7
I171
sg22
VC0017638
p14929
sg10
I6
sg11
Vglioma
p14930
sg13
I1
sasa(dp14931
g2
S'Glioma patients from the CGGA batches 1 and 2, GSE4412 and TCGA datasets could be divided into high- and low-risk groups with different survival times based on levels of MAPK8IP1 and SH3GLB1 expression.\n'
p14932
sg4
(lp14933
(dp14934
g7
I170
sg8
g15
sg10
I8
sg11
VMAPK8IP1
p14935
sg13
I1
sa(dp14936
g7
I183
sg8
g15
sg10
I7
sg11
VSH3GLB1
p14937
sg13
I1
sasg19
(lp14938
(dp14939
g7
I0
sg22
VC0017638
p14940
sg10
I6
sg11
VGlioma
p14941
sg13
I1
sasa(dp14942
g2
S'MAPK8IP1 overexpression and SH3GLB1 knockdown inhibited glioma cell proliferation, migration and invasion, and improved Temozolomide sensitivity.\n'
p14943
sg4
(lp14944
(dp14945
g7
I0
sg8
g15
sg10
I8
sg11
VMAPK8IP1
p14946
sg13
I1
sa(dp14947
g7
I28
sg8
g15
sg10
I7
sg11
VSH3GLB1
p14948
sg13
I1
sasg19
(lp14949
(dp14950
g7
I97
sg22
VC2699153
p14951
sg10
I8
sg11
Vinvasion
p14952
sg13
I1
sa(dp14953
g7
I56
sg22
VC0017638
p14954
sg10
I6
sg11
Vglioma
p14955
sg13
I1
sa(dp14956
g7
I68
sg22
VC0334094
p14957
sg10
I13
sg11
Vproliferation
p14958
sg13
I1
sasa(dp14959
g2
S'These findings suggest autophagy-related genes like MAPK8IP1 and SH3GLB1 could be potential therapeutic targets in glioma.\n'
p14960
sg4
(lp14961
(dp14962
g7
I52
sg8
g15
sg10
I8
sg11
VMAPK8IP1
p14963
sg13
I1
sa(dp14964
g7
I65
sg8
g15
sg10
I7
sg11
VSH3GLB1
p14965
sg13
I1
sasg19
(lp14966
(dp14967
g7
I115
sg22
VC0017638
p14968
sg10
I6
sg11
Vglioma
p14969
sg13
I1
sasa(dp14970
g2
S'In the present study, we demonstrated that endophilin B1 expression was inhibited and EGFR expression was significantly increased in prostate cancer cell lines.\n'
p14971
sg4
(lp14972
(dp14973
g7
I43
sg8
g15
sg10
I13
sg11
Vendophilin B1
p14974
sg13
I2
sasg19
(lp14975
(dp14976
g7
I133
sg22
VC0600139
p14977
sg10
I15
sg11
Vprostate cancer
p14978
sg13
I2
sasa(dp14979
g2
S'Endophilin B1 decreased also sustained EGFR downstream signaling such as Erk1/2 phosphorylation in response to EGF stimulation and promoted prostate cancer cell proliferation which is EGF independent.\n'
p14980
sg4
(lp14981
(dp14982
g7
I39
sg8
VP01133
p14983
sg10
I3
sg11
VEGF
p14984
sg13
I1
sa(dp14985
g7
I73
sg8
VP27361
p14986
sg10
I6
sg11
VErk1/2
p14987
sg13
I1
sa(dp14988
g7
I0
sg8
g15
sg10
I13
sg11
VEndophilin B1
p14989
sg13
I2
sa(dp14990
g7
I39
sg8
VP01133
p14991
sg10
I3
sg11
VEGF
p14992
sg13
I1
sasg19
(lp14993
(dp14994
g7
I161
sg22
VC0334094
p14995
sg10
I13
sg11
Vproliferation
p14996
sg13
I1
sa(dp14997
g7
I140
sg22
VC0600139
p14998
sg10
I15
sg11
Vprostate cancer
p14999
sg13
I2
sasa(dp15000
g2
S'Our data indicated that endophilin B1 mediated the biological function of EGFR in cancer cell proliferation through regulating the EGFR endocytic trafficking and downstream signaling.\n'
p15001
sg4
(lp15002
(dp15003
g7
I24
sg8
g15
sg10
I13
sg11
Vendophilin B1
p15004
sg13
I2
sasg19
(lp15005
(dp15006
g7
I94
sg22
VC0334094
p15007
sg10
I13
sg11
Vproliferation
p15008
sg13
I1
sa(dp15009
g7
I82
sg22
VC0006826
p15010
sg10
I6
sg11
Vcancer
p15011
sg13
I1
sasa(dp15012
g2
S'Dominant overexpression of Sh3glb1, Tm4sf1 or Csf1 in chromosome 3 of TCs is mainly associated with tumour promotion in lung cancer, while most down-expression of Pde5 may be involved in the development of pulmonary fibrosis and other acute and chronic interstitial lung disease.\n'
p15013
sg4
(lp15014
(dp15015
g7
I27
sg8
g15
sg10
I7
sg11
VSh3glb1
p15016
sg13
I1
sa(dp15017
g7
I46
sg8
VP09919
p15018
sg10
I4
sg11
VCsf1
p15019
sg13
I1
sa(dp15020
g7
I163
sg8
g15
sg10
I4
sg11
VPde5
p15021
sg13
I1
sa(dp15022
g7
I36
sg8
VP30408
p15023
sg10
I6
sg11
VTm4sf1
p15024
sg13
I1
sasg19
(lp15025
(dp15026
g7
I120
sg22
VC0684249
p15027
sg10
I11
sg11
Vlung cancer
p15028
sg13
I2
sa(dp15029
g7
I70
sg22
VC0242387
p15030
sg10
I3
sg11
VTCs
p15031
sg13
I1
sa(dp15032
g7
I253
sg22
VC0034069
p15033
sg10
I25
sg11
Vinterstitial lung disease
p15034
sg13
I3
sa(dp15035
g7
I100
sg22
VC0027651
p15036
sg10
I6
sg11
Vtumour
p15037
sg13
I1
sa(dp15038
g7
I206
sg22
VC0034069
p15039
sg10
I18
sg11
Vpulmonary fibrosis
p15040
sg13
I2
sasa(dp15041
g2
S'We have recently reported that SH3GLB1/Bif-1 functions as a haploinsufficient tumor suppressor to prevent the acquisition of apoptosis resistance and malignant transformation during Myc-driven lymphomagenesis.\n'
p15042
sg4
(lp15043
(dp15044
g7
I182
sg8
VP12524
p15045
sg10
I3
sg11
VMyc
p15046
sg13
I1
sa(dp15047
g7
I31
sg8
g15
sg10
I7
sg11
VSH3GLB1
p15048
sg13
I1
sa(dp15049
g7
I39
sg8
g15
sg10
I5
sg11
VBif-1
p15050
sg13
I1
sasg19
(lp15051
(dp15052
g7
I150
sg22
VC1608408
p15053
sg10
I24
sg11
Vmalignant transformation
p15054
sg13
I2
sa(dp15055
g7
I78
sg22
VC0027651
p15056
sg10
I5
sg11
Vtumor
p15057
sg13
I1
sa(dp15058
g7
I193
sg22
VC0598766
p15059
sg10
I15
sg11
Vlymphomagenesis
p15060
sg13
I1
sasa(dp15061
g2
S'Notably, we found that Sh3glb1 haploinsufficiency increases mitochondrial mass in overproliferated prelymphomatous Emy-Myc cells.\n'
p15062
sg4
(lp15063
(dp15064
g7
I23
sg8
g15
sg10
I7
sg11
VSh3glb1
p15065
sg13
I1
sasg19
(lp15066
sa(dp15067
g2
S'In the present study, we report that Bif-1 (Sh3glb1), a gene encoding a membrane curvature-driving endophilin protein, is a haploinsufficient tumor suppressor that plays a key role in the prevention of chromosomal instability and suppresses the acquisition of apoptosis resistance during Myc-driven lymphomagenesis.\n'
p15068
sg4
(lp15069
(dp15070
g7
I44
sg8
g15
sg10
I7
sg11
VSh3glb1
p15071
sg13
I1
sa(dp15072
g7
I37
sg8
g15
sg10
I5
sg11
VBif-1
p15073
sg13
I1
sasg19
(lp15074
(dp15075
g7
I202
sg22
VC1257806
p15076
sg10
I23
sg11
Vchromosomal instability
p15077
sg13
I2
sa(dp15078
g7
I299
sg22
VC0598766
p15079
sg10
I15
sg11
Vlymphomagenesis
p15080
sg13
I1
sa(dp15081
g7
I142
sg22
VC0027651
p15082
sg10
I5
sg11
Vtumor
p15083
sg13
I1
sasa(dp15084
g2
S'Although a large portion of Bif-1-deficient mice harboring an Emy-Myc transgene displayed embryonic lethality, allelic loss of Bif-1 dramatically accelerated the onset of Myc-induced lymphoma.\n'
p15085
sg4
(lp15086
(dp15087
g7
I28
sg8
g15
sg10
I5
sg11
VBif-1
p15088
sg13
I1
sa(dp15089
g7
I28
sg8
g15
sg10
I5
sg11
VBif-1
p15090
sg13
I1
sa(dp15091
g7
I66
sg8
VP12524
p15092
sg10
I3
sg11
VMyc
p15093
sg13
I1
sa(dp15094
g7
I66
sg8
VP12524
p15095
sg10
I3
sg11
VMyc
p15096
sg13
I1
sasg19
(lp15097
(dp15098
g7
I183
sg22
VC0024299
p15099
sg10
I8
sg11
Vlymphoma
p15100
sg13
I1
sasa(dp15101
g2
S'Consistently, allelic loss of Bif-1 suppressed the activation of caspase-3 in Myc-induced lymphoma cells.\n'
p15102
sg4
(lp15103
(dp15104
g7
I78
sg8
VP12524
p15105
sg10
I3
sg11
VMyc
p15106
sg13
I1
sa(dp15107
g7
I65
sg8
VP42574
p15108
sg10
I9
sg11
Vcaspase-3
p15109
sg13
I1
sa(dp15110
g7
I30
sg8
g15
sg10
I5
sg11
VBif-1
p15111
sg13
I1
sasg19
(lp15112
(dp15113
g7
I90
sg22
VC0024299
p15114
sg10
I8
sg11
Vlymphoma
p15115
sg13
I1
sasa(dp15116
g2
S'With the use of tissue microarrays comprising 50 matched cases of invasive and metastatic lesions, the expression profiles of SH3GLB1 and SUB1, SND1, TRIM28 were validated to be down- and up-regulated, respectively, during clinical progression of carcinoma in situ to invasive and metastatic carcinomas.\n'
p15117
sg4
(lp15118
(dp15119
g7
I126
sg8
g15
sg10
I7
sg11
VSH3GLB1
p15120
sg13
I1
sa(dp15121
g7
I150
sg8
g15
sg10
I6
sg11
VTRIM28
p15122
sg13
I1
sa(dp15123
g7
I138
sg8
VP53999
p15124
sg10
I4
sg11
VSUB1
p15125
sg13
I1
sa(dp15126
g7
I144
sg8
g15
sg10
I4
sg11
VSND1
p15127
sg13
I1
sasg19
(lp15128
(dp15129
g7
I292
sg22
VC0007097
p15130
sg10
I10
sg11
Vcarcinomas
p15131
sg13
I1
sa(dp15132
g7
I247
sg22
VC0007099
p15133
sg10
I17
sg11
Vcarcinoma in situ
p15134
sg13
I3
sasa(dp15135
g2
S'The human aminopeptidase XPNPEP3 is associated with cystic kidney disease and TNF-TNFR2 cellular signaling.\n'
p15136
sg4
(lp15137
(dp15138
g7
I4
sg8
VP55786
p15139
sg10
I28
sg11
Vhuman aminopeptidase XPNPEP3
p15140
sg13
I3
sa(dp15141
g7
I82
sg8
VP20333
p15142
sg10
I5
sg11
VTNFR2
p15143
sg13
I1
sa(dp15144
g7
I78
sg8
VP01375
p15145
sg10
I3
sg11
VTNF
p15146
sg13
I1
sasg19
(lp15147
(dp15148
g7
I52
sg22
VC1691228
p15149
sg10
I21
sg11
Vcystic kidney disease
p15150
sg13
I3
sasa(dp15151
g2
S'High circulating levels of soluble tumor necrosis factor receptors (TNFRs: TNFR1, TNFR2) predict renal function decline in a variety of kidney diseases.\n'
p15152
sg4
(lp15153
(dp15154
g7
I75
sg8
VP20333
p15155
sg10
I5
sg11
VTNFR1
p15156
sg13
I1
sa(dp15157
g7
I82
sg8
VP20333
p15158
sg10
I5
sg11
VTNFR2
p15159
sg13
I1
sa(dp15160
g7
I35
sg8
VP01375
p15161
sg10
I31
sg11
Vtumor necrosis factor receptors
p15162
sg13
I4
sa(dp15163
g7
I68
sg8
VP19438
p15164
sg10
I5
sg11
VTNFRs
p15165
sg13
I1
sasg19
(lp15166
(dp15167
g7
I136
sg22
VC0022658
p15168
sg10
I15
sg11
Vkidney diseases
p15169
sg13
I2
sa(dp15170
g7
I35
sg22
VC0333516
p15171
sg10
I14
sg11
Vtumor necrosis
p15172
sg13
I2
sasa(dp15173
g2
S'Analyses carried out by broadening the panic disorder phenotype to include agoraphobia continued to support linkage to ADORA2A.\n'
p15174
sg4
(lp15175
(dp15176
g7
I119
sg8
VP29274
p15177
sg10
I7
sg11
VADORA2A
p15178
sg13
I1
sasg19
(lp15179
(dp15180
g7
I39
sg22
VC1868649
p15181
sg10
I14
sg11
Vpanic disorder
p15182
sg13
I2
sa(dp15183
g7
I75
sg22
VC0001818
p15184
sg10
I11
sg11
Vagoraphobia
p15185
sg13
I1
sasa(dp15186
g2
S'Our findings provide evidence for a susceptibility locus for panic disorder, and possibly including agoraphobia, either within the ADORA2A gene or in a nearby region of chromosome 22, and serves as the first successful candidate gene replication study in panic disorder.\n'
p15187
sg4
(lp15188
(dp15189
g7
I131
sg8
VP29274
p15190
sg10
I12
sg11
VADORA2A gene
p15191
sg13
I2
sasg19
(lp15192
(dp15193
g7
I100
sg22
VC0001818
p15194
sg10
I11
sg11
Vagoraphobia
p15195
sg13
I1
sa(dp15196
g7
I61
sg22
VC1868649
p15197
sg10
I14
sg11
Vpanic disorder
p15198
sg13
I2
sa(dp15199
g7
I61
sg22
VC1868649
p15200
sg10
I14
sg11
Vpanic disorder
p15201
sg13
I2
sasa(dp15202
g2
S'Although MUC13, a transmembrane mucin, is aberrantly expressed in pancreatic ductal adenocarcinoma (PDAC) and generally correlates with increased expression of HER2, the underlying mechanism remains poorly understood.\n'
p15203
sg4
(lp15204
(dp15205
g7
I9
sg8
g15
sg10
I28
sg11
VMUC13, a transmembrane mucin
p15206
sg13
I4
sa(dp15207
g7
I160
sg8
VP04626
p15208
sg10
I4
sg11
VHER2
p15209
sg13
I1
sasg19
(lp15210
(dp15211
g7
I100
sg22
VC1335302
p15212
sg10
I4
sg11
VPDAC
p15213
sg13
I1
sa(dp15214
g7
I66
sg22
VC1335302
p15215
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p15216
sg13
I3
sasa(dp15217
g2
S"However, to date, we still have no outlined knowledges about the pharmacological effects of TSG, though the role of TSG in aging and Alzheimer's disease has been reviewed in recent years.\n"
p15218
sg4
(lp15219
(dp15220
g7
I92
sg8
g15
sg10
I3
sg11
VTSG
p15221
sg13
I1
sasg19
(lp15222
(dp15223
g7
I133
sg22
VC1521724
p15224
sg10
I19
sg11
VAlzheimer's disease
p15225
sg13
I2
sasa(dp15226
g2
S"2,3,4',5-tetrahydroxystilbene 2-O-Beta-D-glucoside (TSG), a monomer of stilbene from polygonummultiflorum, exerts neuroprotection in a range of experimental models such as Alzheimer's disease and brain ischemia.\n"
p15227
sg4
(lp15228
sg19
(lp15229
(dp15230
g7
I172
sg22
VC1521724
p15231
sg10
I19
sg11
VAlzheimer's disease
p15232
sg13
I2
sa(dp15233
g7
I196
sg22
VC0007786
p15234
sg10
I14
sg11
Vbrain ischemia
p15235
sg13
I2
sasa(dp15236
g2
S"The efficacy of 2, 3, 5, 4'-tetrahydroxystilbene-2-O-Beta-D-glucoside (TSG) treatment on cognitive decline in individuals with Alzheimer's disease (AD) has not been investigated.\n"
p15237
sg4
(lp15238
sg19
(lp15239
(dp15240
g7
I148
sg22
VC1521724
p15241
sg10
I2
sg11
VAD
p15242
sg13
I1
sa(dp15243
g7
I127
sg22
VC1521724
p15244
sg10
I19
sg11
VAlzheimer's disease
p15245
sg13
I2
sa(dp15246
g7
I89
sg22
VC0338656
p15247
sg10
I17
sg11
Vcognitive decline
p15248
sg13
I2
sasa(dp15249
g2
S"As erythropoietin cannot freely cross the blood-brain barrier, we tested EH-201 (2,3,5,4'-tetrahydroxystilbene-2-O-Beta-d-glucoside, also known as TSG), a low MW inducer of erythropoietin, for its therapeutic effects on memory impairment in models of neurodegenerative diseases, physiological ageing or brain injury.\n"
p15250
sg4
(lp15251
(dp15252
g7
I147
sg8
g15
sg10
I3
sg11
VTSG
p15253
sg13
I1
sa(dp15254
g7
I3
sg8
VP01588
p15255
sg10
I14
sg11
Verythropoietin
p15256
sg13
I1
sa(dp15257
g7
I3
sg8
VP01588
p15258
sg10
I14
sg11
Verythropoietin
p15259
sg13
I1
sasg19
(lp15260
(dp15261
g7
I220
sg22
VC0233794
p15262
sg10
I17
sg11
Vmemory impairment
p15263
sg13
I2
sa(dp15264
g7
I251
sg22
VC0524851
p15265
sg10
I26
sg11
Vneurodegenerative diseases
p15266
sg13
I2
sasa(dp15267
g2
S"This study was aimed to investigate the potential neuroprotective effect of TSG in 1-methyl-4-phenyl-1,2,3,6-tetrahydropypridine (MPTP)-treated mouse model of Parkinson's disease (PD).\n"
p15268
sg4
(lp15269
sg19
(lp15270
(dp15271
g7
I180
sg22
VC0030567
p15272
sg10
I2
sg11
VPD
p15273
sg13
I1
sa(dp15274
g7
I159
sg22
VC0030567
p15275
sg10
I19
sg11
VParkinson's disease
p15276
sg13
I2
sasa(dp15277
g2
S"The aim of this study was to evaluate the protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-Beta-D-glucoside (TSG), an active component extracted from Polygonum multiflorum, on learning/memory deficits in Alzheimer's disease (AD).\n"
p15278
sg4
(lp15279
sg19
(lp15280
(dp15281
g7
I192
sg22
VC0233794
p15282
sg10
I15
sg11
Vmemory deficits
p15283
sg13
I2
sa(dp15284
g7
I232
sg22
VC1521724
p15285
sg10
I2
sg11
VAD
p15286
sg13
I1
sa(dp15287
g7
I211
sg22
VC1521724
p15288
sg10
I19
sg11
VAlzheimer's disease
p15289
sg13
I2
sasa(dp15290
g2
S"To investigate the mRNA and protein alterations of Alfa-synuclein in the brain of Alzheimer's disease-like mouse model at the different ages, and to evaluate the effects of 2,3,5,4'-tetrahydroxy stilbene-2-O-Beta-D-glucoside (TSG) on Alfa-synuclein expression.\n"
p15291
sg4
(lp15292
(dp15293
g7
I51
sg8
VP37840
p15294
sg10
I14
sg11
VAlfa-synuclein
p15295
sg13
I1
sa(dp15296
g7
I51
sg8
VP37840
p15297
sg10
I14
sg11
VAlfa-synuclein
p15298
sg13
I1
sasg19
(lp15299
(dp15300
g7
I82
sg22
VC1521724
p15301
sg10
I19
sg11
VAlzheimer's disease
p15302
sg13
I2
sasa(dp15303
g2
S"TSG may have potential to the prevention and treatment of Alzheimer's diseases.\n"
p15304
sg4
(lp15305
(dp15306
g7
I0
sg8
g15
sg10
I3
sg11
VTSG
p15307
sg13
I1
sasg19
(lp15308
(dp15309
g7
I58
sg22
VC0002395
p15310
sg10
I20
sg11
VAlzheimer's diseases
p15311
sg13
I2
sasa(dp15312
g2
S'Familial tumoral calcinosis (FTC)/hyperostosis-hyperphosphatemia syndrome (HHS) is a rare disorder caused by mutations in the genes encoding fibroblast growth factor-23 (FGF23), N-acetylgalactosaminyltransferase 3 (GALNT3), or KLOTHO.\n'
p15313
sg4
(lp15314
(dp15315
g7
I170
sg8
g15
sg10
I5
sg11
VFGF23
p15316
sg13
I1
sa(dp15317
g7
I227
sg8
g15
sg10
I6
sg11
VKLOTHO
p15318
sg13
I1
sa(dp15319
g7
I215
sg8
g15
sg10
I6
sg11
VGALNT3
p15320
sg13
I1
sa(dp15321
g7
I141
sg8
g15
sg10
I27
sg11
Vfibroblast growth factor-23
p15322
sg13
I3
sa(dp15323
g7
I178
sg8
g15
sg10
I35
sg11
VN-acetylgalactosaminyltransferase 3
p15324
sg13
I2
sasg19
(lp15325
(dp15326
g7
I29
sg22
VC0206682
p15327
sg10
I3
sg11
VFTC
p15328
sg13
I1
sa(dp15329
g7
I33
sg22
VC0265354
p15330
sg10
I40
sg11
V/hyperostosis-hyperphosphatemia syndrome
p15331
sg13
I2
sa(dp15332
g7
I85
sg22
VC0678236
p15333
sg10
I13
sg11
Vrare disorder
p15334
sg13
I2
sa(dp15335
g7
I0
sg22
VC0206682
p15336
sg10
I27
sg11
VFamilial tumoral calcinosis
p15337
sg13
I3
sa(dp15338
g7
I75
sg22
VC0265354
p15339
sg10
I3
sg11
VHHS
p15340
sg13
I1
sasa(dp15341
g2
S'Mutations of any of FGF23, Klotho or GALnT3 genes can lead to a syndrome characterized by hyperphosphatemia, ectopic calcifications and recurrent long bone lesions with hyperostosis.\n'
p15342
sg4
(lp15343
(dp15344
g7
I37
sg8
g15
sg10
I12
sg11
VGALnT3 genes
p15345
sg13
I2
sa(dp15346
g7
I27
sg8
g15
sg10
I6
sg11
VKlotho
p15347
sg13
I1
sa(dp15348
g7
I20
sg8
g15
sg10
I5
sg11
VFGF23
p15349
sg13
I1
sasg19
(lp15350
(dp15351
g7
I151
sg22
VC0238792
p15352
sg10
I12
sg11
Vbone lesions
p15353
sg13
I2
sa(dp15354
g7
I169
sg22
VC0020492
p15355
sg10
I12
sg11
Vhyperostosis
p15356
sg13
I1
sa(dp15357
g7
I64
sg22
VC0039082
p15358
sg10
I8
sg11
Vsyndrome
p15359
sg13
I1
sa(dp15360
g7
I90
sg22
VC0085681
p15361
sg10
I17
sg11
Vhyperphosphatemia
p15362
sg13
I1
sasa(dp15363
g2
S'The EAD amplitude (EADA) in the dauricine group (26% +/- 9% of MAPA) was smaller than that in the control group (52% +/- 5% of MAPA, P &lt; 0.05) and the incidence of arrhythmias in dauricine group (28%) was lower than that in control group (80%, P &lt; 0.05).\n'
p15364
sg4
(lp15365
sg19
(lp15366
(dp15367
g7
I4
sg22
VC1864233
p15368
sg10
I3
sg11
VEAD
p15369
sg13
I1
sa(dp15370
g7
I167
sg22
VC0003811
p15371
sg10
I11
sg11
Varrhythmias
p15372
sg13
I1
sasa(dp15373
g2
S'The pre-dietary rehabilitation levels of acute phase proteins (APP) namely, alpha-1-antitrypsin (AAT), orosomucoid (ORO), haptoglobin (HAP), fibrinogen (FIB) and C-reactive protein (CRP) in the plasma of Sudanese children with severe protein energy malnutrition (PEM) were compared with those of normal controls, and with the levels after dietary rehabilitation.\n'
p15374
sg4
(lp15375
(dp15376
g7
I135
sg8
VP10826
p15377
sg10
I3
sg11
VHAP
p15378
sg13
I1
sa(dp15379
g7
I97
sg8
VP17174
p15380
sg10
I3
sg11
VAAT
p15381
sg13
I1
sa(dp15382
g7
I182
sg8
VP02741
p15383
sg10
I3
sg11
VCRP
p15384
sg13
I1
sa(dp15385
g7
I41
sg8
g15
sg10
I20
sg11
Vacute phase proteins
p15386
sg13
I3
sa(dp15387
g7
I141
sg8
VP22087
p15388
sg10
I10
sg11
Vfibrinogen
p15389
sg13
I1
sa(dp15390
g7
I76
sg8
VP25100
p15391
sg10
I19
sg11
Valpha-1-antitrypsin
p15392
sg13
I1
sa(dp15393
g7
I153
sg8
VP22087
p15394
sg10
I3
sg11
VFIB
p15395
sg13
I1
sa(dp15396
g7
I122
sg8
VP00738
p15397
sg10
I11
sg11
Vhaptoglobin
p15398
sg13
I1
sa(dp15399
g7
I162
sg8
VP02741
p15400
sg10
I18
sg11
VC-reactive protein
p15401
sg13
I2
sa(dp15402
g7
I63
sg8
g15
sg10
I3
sg11
VAPP
p15403
sg13
I1
sasg19
(lp15404
(dp15405
g7
I263
sg22
VC0270700
p15406
sg10
I3
sg11
VPEM
p15407
sg13
I1
sa(dp15408
g7
I234
sg22
VC0033677
p15409
sg10
I27
sg11
Vprotein energy malnutrition
p15410
sg13
I3
sasa(dp15411
g2
S'A commercially available radial immunodiffusion assay was used to measure serum and faecal alpha 1-antitrypsin concentrations as well as alpha 1-antitrypsin clearance in 17 children with kwashiorkor, 11 children with marasmic kwashiorkor, 10 children with marasmus, and 16 normal children.\n'
p15412
sg4
(lp15413
(dp15414
g7
I91
sg8
VP25100
p15415
sg10
I19
sg11
Valpha 1-antitrypsin
p15416
sg13
I2
sa(dp15417
g7
I84
sg8
VP25100
p15418
sg10
I26
sg11
Vfaecal alpha 1-antitrypsin
p15419
sg13
I3
sasg19
(lp15420
(dp15421
g7
I217
sg22
VC0342914
p15422
sg10
I20
sg11
Vmarasmic kwashiorkor
p15423
sg13
I2
sa(dp15424
g7
I187
sg22
VC0022806
p15425
sg10
I11
sg11
Vkwashiorkor
p15426
sg13
I1
sa(dp15427
g7
I256
sg22
VC0086588
p15428
sg10
I8
sg11
Vmarasmus
p15429
sg13
I1
sasa(dp15430
g2
S'Serum alpha 1-antitrypsin concentrations were significantly higher than normal in the marasmus and marasmic kwashiorkor groups, and significantly lower than normal in the kwashiorkor group.\n'
p15431
sg4
(lp15432
(dp15433
g7
I0
sg8
g15
sg10
I25
sg11
VSerum alpha 1-antitrypsin
p15434
sg13
I3
sasg19
(lp15435
(dp15436
g7
I99
sg22
VC0342914
p15437
sg10
I20
sg11
Vmarasmic kwashiorkor
p15438
sg13
I2
sa(dp15439
g7
I108
sg22
VC0022806
p15440
sg10
I11
sg11
Vkwashiorkor
p15441
sg13
I1
sa(dp15442
g7
I86
sg22
VC0086588
p15443
sg10
I8
sg11
Vmarasmus
p15444
sg13
I1
sasa(dp15445
g2
S'The intestinal clearance of alpha 1-antitrypsin was significantly higher than normal in the marasmus and marasmic kwashiorkor groups, and significantly lower than normal in the kwashiorkor group.\n'
p15446
sg4
(lp15447
(dp15448
g7
I28
sg8
VP25100
p15449
sg10
I19
sg11
Valpha 1-antitrypsin
p15450
sg13
I2
sasg19
(lp15451
(dp15452
g7
I114
sg22
VC0022806
p15453
sg10
I11
sg11
Vkwashiorkor
p15454
sg13
I1
sa(dp15455
g7
I92
sg22
VC0086588
p15456
sg10
I8
sg11
Vmarasmus
p15457
sg13
I1
sa(dp15458
g7
I105
sg22
VC0342914
p15459
sg10
I20
sg11
Vmarasmic kwashiorkor
p15460
sg13
I2
sasa(dp15461
g2
S'There was a significant inverse correlation between the alpha 1-antitrypsin clearance and serum albumin concentration in the marasmus and marasmic kwashiorkor groups.\n'
p15462
sg4
(lp15463
(dp15464
g7
I90
sg8
g15
sg10
I13
sg11
Vserum albumin
p15465
sg13
I2
sa(dp15466
g7
I56
sg8
VP25100
p15467
sg10
I19
sg11
Valpha 1-antitrypsin
p15468
sg13
I2
sasg19
(lp15469
(dp15470
g7
I138
sg22
VC0342914
p15471
sg10
I20
sg11
Vmarasmic kwashiorkor
p15472
sg13
I2
sa(dp15473
g7
I125
sg22
VC0086588
p15474
sg10
I8
sg11
Vmarasmus
p15475
sg13
I1
sasa(dp15476
g2
S'The concentrations of serum protein albumin, prealbumin and transferrin were determined in twenty-eight cases of protein-energy malnutrition (PEM) with infection, together with the levels of serum proteinase inhibitors (PI), alpha1-antitrypsin (AT), alpha1-antichymotrypsin (Ach), alpha2-macroglobulin (alpha2M) and inter-alpha-trypsin inhibitor (IalphaI).\n'
p15477
sg4
(lp15478
(dp15479
g7
I191
sg8
VP63123
p15480
sg10
I16
sg11
Vserum proteinase
p15481
sg13
I2
sa(dp15482
g7
I245
sg8
VP25100
p15483
sg10
I2
sg11
VAT
p15484
sg13
I1
sa(dp15485
g7
I45
sg8
VP31025
p15486
sg10
I10
sg11
Vprealbumin
p15487
sg13
I1
sa(dp15488
g7
I303
sg8
VP01023
p15489
sg10
I7
sg11
Valpha2M
p15490
sg13
I1
sa(dp15491
g7
I275
sg8
VP22607
p15492
sg10
I3
sg11
VAch
p15493
sg13
I1
sa(dp15494
g7
I316
sg8
VP35030
p15495
sg10
I19
sg11
Vinter-alpha-trypsin
p15496
sg13
I1
sa(dp15497
g7
I60
sg8
VP02787
p15498
sg10
I11
sg11
Vtransferrin
p15499
sg13
I1
sa(dp15500
g7
I225
sg8
VP25100
p15501
sg10
I18
sg11
Valpha1-antitrypsin
p15502
sg13
I1
sa(dp15503
g7
I36
sg8
VP00441
p15504
sg10
I7
sg11
Valbumin
p15505
sg13
I1
sa(dp15506
g7
I281
sg8
VP01023
p15507
sg10
I20
sg11
Valpha2-macroglobulin
p15508
sg13
I1
sa(dp15509
g7
I250
sg8
VP25100
p15510
sg10
I23
sg11
Valpha1-antichymotrypsin
p15511
sg13
I1
sasg19
(lp15512
(dp15513
g7
I275
sg22
VC0234238
p15514
sg10
I3
sg11
VAch
p15515
sg13
I1
sa(dp15516
g7
I250
sg22
VC0234238
p15517
sg10
I23
sg11
Valpha1-antichymotrypsin
p15518
sg13
I1
sa(dp15519
g7
I142
sg22
VC0270700
p15520
sg10
I3
sg11
VPEM
p15521
sg13
I1
sa(dp15522
g7
I113
sg22
VC0033677
p15523
sg10
I27
sg11
Vprotein-energy malnutrition
p15524
sg13
I2
sa(dp15525
g7
I152
sg22
VC0009450
p15526
sg10
I9
sg11
Vinfection
p15527
sg13
I1
sasa(dp15528
g2
S'Compared to the control, cirrhosis group demonstrated lower mRNA levels of OATP1 (0.038 +/- 0.020 vs. 0.232 +/- 0.0979; p = 0.004), MRP2 (0.201 +/- 0.084 vs. 0.7567 +/- 0.254; p = 0.002), and OATP1/MRP2 mRNA ratio (0.193 +/- 0.065 vs. 0.342 +/- 0.206; p = 0.032).\n'
p15529
sg4
(lp15530
(dp15531
g7
I75
sg8
VP46721
p15532
sg10
I5
sg11
VOATP1
p15533
sg13
I1
sa(dp15534
g7
I75
sg8
VP46721
p15535
sg10
I5
sg11
VOATP1
p15536
sg13
I1
sa(dp15537
g7
I132
sg8
g15
sg10
I4
sg11
VMRP2
p15538
sg13
I1
sa(dp15539
g7
I132
sg8
g15
sg10
I4
sg11
VMRP2
p15540
sg13
I1
sasg19
(lp15541
(dp15542
g7
I25
sg22
VC0023890
p15543
sg10
I9
sg11
Vcirrhosis
p15544
sg13
I1
sasa(dp15545
g2
S'In the cirrhosis group, there was an inverse correlation between the ratios of OATP1/MRP2 mRNA and DSR (R = -0.709, p = 0.01).\n'
p15546
sg4
(lp15547
(dp15548
g7
I85
sg8
g15
sg10
I4
sg11
VMRP2
p15549
sg13
I1
sa(dp15550
g7
I79
sg8
VP46721
p15551
sg10
I5
sg11
VOATP1
p15552
sg13
I1
sasg19
(lp15553
(dp15554
g7
I7
sg22
VC0023890
p15555
sg10
I9
sg11
Vcirrhosis
p15556
sg13
I1
sasa(dp15557
g2
S'In the present study, we investigated the WIF1 expression level by immuno-histochemical staining and semi-quantitative RT-PCR in normal oral, OSF and OSCC tissues, as well as the methylation status by methylation-specific PCR and bisulfite genomic sequencing.\n'
p15558
sg4
(lp15559
(dp15560
g7
I42
sg8
g15
sg10
I4
sg11
VWIF1
p15561
sg13
I1
sasg19
(lp15562
sa(dp15563
g2
S'The results showed that WIF1 was readily expressed in normal oral mucous tissues, but decreased gradually in OSF early, moderately advanced and advanced tissues, and was less expressed in OSCC tissues.\n'
p15564
sg4
(lp15565
(dp15566
g7
I24
sg8
g15
sg10
I4
sg11
VWIF1
p15567
sg13
I1
sasg19
(lp15568
sa(dp15569
g2
S'Moreover, WIF1 was able to translocate from the nuclear to cytoplasm in OSF and OSCC tissues.\n'
p15570
sg4
(lp15571
(dp15572
g7
I10
sg8
g15
sg10
I4
sg11
VWIF1
p15573
sg13
I1
sasg19
(lp15574
sa(dp15575
g2
S'Furthermore, WIF1 was frequently methylated in OSCC cases with betel quid chewing habit, but not in normal oral mucous and different stages of OSF tissues, suggesting WIF1 methylation is tumor-specific in the development of OSF.\n'
p15576
sg4
(lp15577
(dp15578
g7
I13
sg8
g15
sg10
I4
sg11
VWIF1
p15579
sg13
I1
sa(dp15580
g7
I13
sg8
g15
sg10
I4
sg11
VWIF1
p15581
sg13
I1
sasg19
(lp15582
(dp15583
g7
I187
sg22
VC0027651
p15584
sg10
I5
sg11
Vtumor
p15585
sg13
I1
sasa(dp15586
g2
S'Thus, the results demonstrated that WIF1 is frequently downregulated or silenced by promoter methylation in the carcinogenesis of OSF, which serves as a potential epigenetic biomarker for the early detection of OSCC.\n'
p15587
sg4
(lp15588
(dp15589
g7
I36
sg8
g15
sg10
I4
sg11
VWIF1
p15590
sg13
I1
sasg19
(lp15591
(dp15592
g7
I112
sg22
VC0596263
p15593
sg10
I14
sg11
Vcarcinogenesis
p15594
sg13
I1
sasa(dp15595
g2
S'Here we report for the first time that downregulation of the Wnt inhibitory factor 1 (WIF1) is a widespread event in salivary gland carcinoma ex-pleomorphic adenoma (CaExPA).\n'
p15596
sg4
(lp15597
(dp15598
g7
I86
sg8
g15
sg10
I4
sg11
VWIF1
p15599
sg13
I1
sa(dp15600
g7
I61
sg8
g15
sg10
I23
sg11
VWnt inhibitory factor 1
p15601
sg13
I4
sasg19
(lp15602
(dp15603
g7
I145
sg22
VC0026277
p15604
sg10
I19
sg11
Vpleomorphic adenoma
p15605
sg13
I2
sa(dp15606
g7
I117
sg22
VC0948750
p15607
sg10
I24
sg11
Vsalivary gland carcinoma
p15608
sg13
I3
sasa(dp15609
g2
S'Most importantly, WIF1 significantly diminished the number of salivary gland cancer stem cells and the anchorage-independent cell growth.\n'
p15610
sg4
(lp15611
(dp15612
g7
I18
sg8
g15
sg10
I4
sg11
VWIF1
p15613
sg13
I1
sasg19
(lp15614
(dp15615
g7
I62
sg22
VC0220636
p15616
sg10
I21
sg11
Vsalivary gland cancer
p15617
sg13
I3
sasa(dp15618
g2
S'Antagomir and miRNA-mimic transfections in neuroblastoma cell lines confirmed that DKK3 secretion to the culture media is regulated by mir-92.\n'
p15619
sg4
(lp15620
(dp15621
g7
I83
sg8
g15
sg10
I4
sg11
VDKK3
p15622
sg13
I1
sasg19
(lp15623
(dp15624
g7
I43
sg22
VC0027819
p15625
sg10
I13
sg11
Vneuroblastoma
p15626
sg13
I1
sasa(dp15627
g2
S'We showed that the repressor REST inhibits the activity of the miR-9-2 promoter in undifferentiated neuroblastoma cells, whereas REST dismissal and phosphorylation of CREB trigger transcription in differentiating cells.\n'
p15628
sg4
(lp15629
(dp15630
g7
I167
sg8
VP16220
p15631
sg10
I4
sg11
VCREB
p15632
sg13
I1
sa(dp15633
g7
I63
sg8
g15
sg10
I16
sg11
VmiR-9-2 promoter
p15634
sg13
I2
sasg19
(lp15635
(dp15636
g7
I83
sg22
VC1519787
p15637
sg10
I30
sg11
Vundifferentiated neuroblastoma
p15638
sg13
I2
sasa(dp15639
g2
S'To explore the effect and molecular mechanism of the unconventional prefoldin RPB5 interactor (URI) in hepatocellular carcinoma HepG2 cells.\n'
p15640
sg4
(lp15641
(dp15642
g7
I53
sg8
g15
sg10
I40
sg11
Vunconventional prefoldin RPB5 interactor
p15643
sg13
I4
sa(dp15644
g7
I95
sg8
g15
sg10
I3
sg11
VURI
p15645
sg13
I1
sasg19
(lp15646
(dp15647
g7
I103
sg22
VC1512411
p15648
sg10
I24
sg11
Vhepatocellular carcinoma
p15649
sg13
I2
sasa(dp15650
g2
S'In this issue of Cancer Cell, Tummala and colleagues demonstrate that unconventional prefoldin RPB5 interactor (URI) expression in hepatocytes leads to hepatocellular carcinoma (HCC) development by interacting with L-tryptophan/kynurenine/nicotinamide adenine dinucleotide (NAD(+)) metabolism.\n'
p15651
sg4
(lp15652
(dp15653
g7
I70
sg8
g15
sg10
I40
sg11
Vunconventional prefoldin RPB5 interactor
p15654
sg13
I4
sa(dp15655
g7
I112
sg8
g15
sg10
I3
sg11
VURI
p15656
sg13
I1
sasg19
(lp15657
(dp15658
g7
I274
sg22
VC1850380
p15659
sg10
I3
sg11
VNAD
p15660
sg13
I1
sa(dp15661
g7
I17
sg22
VC0006826
p15662
sg10
I6
sg11
VCancer
p15663
sg13
I1
sa(dp15664
g7
I152
sg22
VC2239176
p15665
sg10
I24
sg11
Vhepatocellular carcinoma
p15666
sg13
I2
sa(dp15667
g7
I178
sg22
VC2239176
p15668
sg10
I3
sg11
VHCC
p15669
sg13
I1
sasa(dp15670
g2
S'Peginterferon/ribavirin has been the standard-of-care for chronic hepatitis C virus (HCV) infections: 48 weeks for genotype 1 or 4 (HCV-1/4) and 24 weeks for HCV-2/3.\n'
p15671
sg4
(lp15672
sg19
(lp15673
(dp15674
g7
I90
sg22
VC0021311
p15675
sg10
I10
sg11
Vinfections
p15676
sg13
I1
sa(dp15677
g7
I58
sg22
VC0524910
p15678
sg10
I19
sg11
Vchronic hepatitis C
p15679
sg13
I3
sasa(dp15680
g2
S'Our recent studies implicated key and distinct roles for the highly related RalA and RalB small GTPases (82% sequence identity) in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis and invasive and metastatic growth, respectively.\n'
p15681
sg4
(lp15682
(dp15683
g7
I85
sg8
VP11234
p15684
sg10
I18
sg11
VRalB small GTPases
p15685
sg13
I3
sa(dp15686
g7
I76
sg8
VP11233
p15687
sg10
I4
sg11
VRalA
p15688
sg13
I1
sasg19
(lp15689
(dp15690
g7
I131
sg22
VC1335302
p15691
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p15692
sg13
I3
sa(dp15693
g7
I171
sg22
VC0007621
p15694
sg10
I13
sg11
Vtumorigenesis
p15695
sg13
I1
sa(dp15696
g7
I165
sg22
VC1335302
p15697
sg10
I4
sg11
VPDAC
p15698
sg13
I1
sasa(dp15699
g2
S'Our recent studies established essential and distinct roles for RalA and RalB small GTPase activation in K-Ras mutant pancreatic ductal adenocarcinoma (PDAC) cell line tumorigencity, invasion, and metastasis.\n'
p15700
sg4
(lp15701
(dp15702
g7
I64
sg8
VP11233
p15703
sg10
I4
sg11
VRalA
p15704
sg13
I1
sa(dp15705
g7
I73
sg8
VP11234
p15706
sg10
I33
sg11
VRalB small GTPase activation in K
p15707
sg13
I6
sa(dp15708
g7
I107
sg8
VP01116
p15709
sg10
I3
sg11
VRas
p15710
sg13
I1
sasg19
(lp15711
(dp15712
g7
I111
sg22
VC0596988
p15713
sg10
I6
sg11
Vmutant
p15714
sg13
I1
sa(dp15715
g7
I118
sg22
VC1335302
p15716
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p15717
sg13
I3
sa(dp15718
g7
I183
sg22
VC2699153
p15719
sg10
I8
sg11
Vinvasion
p15720
sg13
I1
sa(dp15721
g7
I152
sg22
VC1335302
p15722
sg10
I4
sg11
VPDAC
p15723
sg13
I1
sa(dp15724
g7
I197
sg22
VC0027627
p15725
sg10
I10
sg11
Vmetastasis
p15726
sg13
I1
sasa(dp15727
g2
S'RalA, RalB, and their major effectors RalBP1 and Sec5 were knocked down by stable expression of short hairpin RNAs in the K-Ras-dependent pancreatic cancer-derived cell line MIA PaCa-2.\n'
p15728
sg4
(lp15729
(dp15730
g7
I0
sg8
VP11233
p15731
sg10
I4
sg11
VRalA
p15732
sg13
I1
sa(dp15733
g7
I122
sg8
VP01116
p15734
sg10
I5
sg11
VK-Ras
p15735
sg13
I1
sa(dp15736
g7
I38
sg8
g15
sg10
I6
sg11
VRalBP1
p15737
sg13
I1
sa(dp15738
g7
I6
sg8
VP11234
p15739
sg10
I4
sg11
VRalB
p15740
sg13
I1
sa(dp15741
g7
I49
sg8
g15
sg10
I4
sg11
VSec5
p15742
sg13
I1
sasg19
(lp15743
(dp15744
g7
I138
sg22
VC0235974
p15745
sg10
I17
sg11
Vpancreatic cancer
p15746
sg13
I2
sa(dp15747
g7
I178
sg22
VC1836780
p15748
sg10
I4
sg11
VPaCa
p15749
sg13
I1
sasa(dp15750
g2
S'In the present study, we determined whether RalA and RalB also had divergent roles in promoting the aberrant growth of pancreatic cancers, which are characterized by the highest occurrence of Ras mutations.\n'
p15751
sg4
(lp15752
(dp15753
g7
I53
sg8
VP11234
p15754
sg10
I4
sg11
VRalB
p15755
sg13
I1
sa(dp15756
g7
I44
sg8
VP11233
p15757
sg10
I4
sg11
VRalA
p15758
sg13
I1
sa(dp15759
g7
I192
sg8
VP01116
p15760
sg10
I3
sg11
VRas
p15761
sg13
I1
sasg19
(lp15762
(dp15763
g7
I119
sg22
VC0346647
p15764
sg10
I18
sg11
Vpancreatic cancers
p15765
sg13
I2
sasa(dp15766
g2
S'We now show that inhibition of RalA but not RalB expression universally reduced the transformed and tumorigenic growth in a panel of ten genetically diverse human pancreatic cancer cell lines.\n'
p15767
sg4
(lp15768
(dp15769
g7
I44
sg8
VP11234
p15770
sg10
I4
sg11
VRalB
p15771
sg13
I1
sa(dp15772
g7
I31
sg8
VP11233
p15773
sg10
I4
sg11
VRalA
p15774
sg13
I1
sasg19
(lp15775
(dp15776
g7
I163
sg22
VC0235974
p15777
sg10
I17
sg11
Vpancreatic cancer
p15778
sg13
I2
sasa(dp15779
g2
S'Despite the apparent unimportant role of RalB in tumorigenic growth, it was nevertheless critical for invasion in seven of nine pancreatic cancer cell lines and for metastasis as assessed by tail-vein injection of three different tumorigenic cell lines tested.\n'
p15780
sg4
(lp15781
(dp15782
g7
I41
sg8
VP11234
p15783
sg10
I4
sg11
VRalB
p15784
sg13
I1
sasg19
(lp15785
(dp15786
g7
I102
sg22
VC2699153
p15787
sg10
I8
sg11
Vinvasion
p15788
sg13
I1
sa(dp15789
g7
I128
sg22
VC0235974
p15790
sg10
I17
sg11
Vpancreatic cancer
p15791
sg13
I2
sa(dp15792
g7
I165
sg22
VC0027627
p15793
sg10
I10
sg11
Vmetastasis
p15794
sg13
I1
sasa(dp15795
g2
S'Moreover, both RalA and RalB were more commonly activated in pancreatic tumor tissue than other Ras effector pathways.\n'
p15796
sg4
(lp15797
(dp15798
g7
I96
sg8
VP01116
p15799
sg10
I3
sg11
VRas
p15800
sg13
I1
sa(dp15801
g7
I24
sg8
VP11234
p15802
sg10
I4
sg11
VRalB
p15803
sg13
I1
sa(dp15804
g7
I15
sg8
VP11233
p15805
sg10
I4
sg11
VRalA
p15806
sg13
I1
sasg19
(lp15807
(dp15808
g7
I61
sg22
VC0030297
p15809
sg10
I16
sg11
Vpancreatic tumor
p15810
sg13
I2
sasa(dp15811
g2
S'RalA function is critical to tumor initiation, whereas RalB function is more important for tumor metastasis in the tested cell lines and thus argues for critical, but distinct, roles of Ral proteins during the dynamic progression of Ras-driven pancreatic cancers.\n'
p15812
sg4
(lp15813
(dp15814
g7
I0
sg8
VP11233
p15815
sg10
I4
sg11
VRalA
p15816
sg13
I1
sa(dp15817
g7
I55
sg8
VP11234
p15818
sg10
I4
sg11
VRalB
p15819
sg13
I1
sa(dp15820
g7
I186
sg8
VP11233
p15821
sg10
I12
sg11
VRal proteins
p15822
sg13
I2
sa(dp15823
g7
I233
sg8
VP01116
p15824
sg10
I3
sg11
VRas
p15825
sg13
I1
sasg19
(lp15826
(dp15827
g7
I244
sg22
VC0346647
p15828
sg10
I18
sg11
Vpancreatic cancers
p15829
sg13
I2
sa(dp15830
g7
I91
sg22
VC0027627
p15831
sg10
I16
sg11
Vtumor metastasis
p15832
sg13
I2
sa(dp15833
g7
I29
sg22
VC0598935
p15834
sg10
I16
sg11
Vtumor initiation
p15835
sg13
I2
sasa(dp15836
g2
S'The mutations of keratin 1 gene (KRT1) were reported to associate with skin diseases.\n'
p15837
sg4
(lp15838
(dp15839
g7
I17
sg8
VP04264
p15840
sg10
I14
sg11
Vkeratin 1 gene
p15841
sg13
I3
sa(dp15842
g7
I33
sg8
VP02533
p15843
sg10
I4
sg11
VKRT1
p15844
sg13
I1
sasg19
(lp15845
(dp15846
g7
I71
sg22
VC0037274
p15847
sg10
I13
sg11
Vskin diseases
p15848
sg13
I2
sasa(dp15849
g2
S'We speculate the effects of KRT10 and LHON mutations influence each other-skin inflammatory reaction due to severe ichthyosis might trigger the development of psychoneurological abnormalities whereas the mitochondrial mutation may reduce revertant mosaicism phenomenon resulting in the lack of confetti-like spots characteristic for IWC.\n'
p15850
sg4
(lp15851
(dp15852
g7
I28
sg8
VP13645
p15853
sg10
I5
sg11
VKRT10
p15854
sg13
I1
sasg19
(lp15855
(dp15856
g7
I308
sg22
VC0015230
p15857
sg10
I5
sg11
Vspots
p15858
sg13
I1
sa(dp15859
g7
I115
sg22
VC0020758
p15860
sg10
I10
sg11
Vichthyosis
p15861
sg13
I1
sa(dp15862
g7
I248
sg22
VC0392053
p15863
sg10
I9
sg11
Vmosaicism
p15864
sg13
I1
sa(dp15865
g7
I333
sg22
VC1836681
p15866
sg10
I3
sg11
VIWC
p15867
sg13
I1
sa(dp15868
g7
I79
sg22
VC0021368
p15869
sg10
I21
sg11
Vinflammatory reaction
p15870
sg13
I2
sa(dp15871
g7
I38
sg22
VC0917796
p15872
sg10
I4
sg11
VLHON
p15873
sg13
I1
sasa(dp15874
g2
S'Specific regions of Kaposi\'s sarcoma-associated herpesvirus (KSHV) latent episomes are "poised" to be activated by the KSHV replication and transcription activator (K-Rta).\n'
p15875
sg4
(lp15876
sg19
(lp15877
(dp15878
g7
I20
sg22
VC0036220
p15879
sg10
I16
sg11
VKaposi's sarcoma
p15880
sg13
I2
sa(dp15881
g7
I167
sg22
VC0001126
p15882
sg10
I3
sg11
VRta
p15883
sg13
I1
sasa(dp15884
g2
S'UFS features incomplete urinary bladder emptying and vesicoureteric reflux, with a high risk of recurrent urosepsis and end-stage renal disease.\n'
p15885
sg4
(lp15886
sg19
(lp15887
(dp15888
g7
I53
sg22
VC0042580
p15889
sg10
I21
sg11
Vvesicoureteric reflux
p15890
sg13
I2
sa(dp15891
g7
I0
sg22
VC0403555
p15892
sg10
I3
sg11
VUFS
p15893
sg13
I1
sa(dp15894
g7
I120
sg22
VC0022661
p15895
sg10
I23
sg11
Vend-stage renal disease
p15896
sg13
I3
sa(dp15897
g7
I106
sg22
VC0149801
p15898
sg10
I9
sg11
Vurosepsis
p15899
sg13
I1
sasa(dp15900
g2
S'Non-neurogenic neurogenic bladder (NNNB) has a bladder identical to UFS without typical facial features.\n'
p15901
sg4
(lp15902
sg19
(lp15903
(dp15904
g7
I68
sg22
VC0403555
p15905
sg10
I3
sg11
VUFS
p15906
sg13
I1
sa(dp15907
g7
I15
sg22
VC0005697
p15908
sg10
I18
sg11
Vneurogenic bladder
p15909
sg13
I2
sasa(dp15910
g2
S'HPSE2 mutations were absent in 23 non-neurogenic neurogenic bladder probands and, of 439 families with nonsyndromic vesicoureteric reflux, only one carried a putative pathogenic HPSE2 variant.\n'
p15911
sg4
(lp15912
(dp15913
g7
I0
sg8
g15
sg10
I5
sg11
VHPSE2
p15914
sg13
I1
sa(dp15915
g7
I0
sg8
g15
sg10
I5
sg11
VHPSE2
p15916
sg13
I1
sasg19
(lp15917
(dp15918
g7
I49
sg22
VC0005697
p15919
sg10
I18
sg11
Vneurogenic bladder
p15920
sg13
I2
sa(dp15921
g7
I116
sg22
VC0042580
p15922
sg10
I21
sg11
Vvesicoureteric reflux
p15923
sg13
I2
sasa(dp15924
g2
S'Urofacial syndrome (UFS) (or Ochoa syndrome) is an autosomal-recessive disease characterized by congenital urinary bladder dysfunction, associated with a significant risk of kidney failure, and an abnormal facial expression upon smiling, laughing, and crying.\n'
p15925
sg4
(lp15926
sg19
(lp15927
(dp15928
g7
I174
sg22
VC0035078
p15929
sg10
I14
sg11
Vkidney failure
p15930
sg13
I2
sa(dp15931
g7
I115
sg22
VC0232841
p15932
sg10
I19
sg11
Vbladder dysfunction
p15933
sg13
I2
sa(dp15934
g7
I20
sg22
VC0403555
p15935
sg10
I3
sg11
VUFS
p15936
sg13
I1
sa(dp15937
g7
I0
sg22
VC0403555
p15938
sg10
I18
sg11
VUrofacial syndrome
p15939
sg13
I2
sa(dp15940
g7
I29
sg22
VC0403555
p15941
sg10
I14
sg11
VOchoa syndrome
p15942
sg13
I2
sasa(dp15943
g2
S'UFS individuals often have reflux of infected urine from the bladder to the upper renal tract, with a risk of kidney damage and renal failure.\n'
p15944
sg4
(lp15945
sg19
(lp15946
(dp15947
g7
I128
sg22
VC0035078
p15948
sg10
I13
sg11
Vrenal failure
p15949
sg13
I2
sa(dp15950
g7
I0
sg22
VC0403555
p15951
sg10
I3
sg11
VUFS
p15952
sg13
I1
sa(dp15953
g7
I27
sg22
VC0017168
p15954
sg10
I6
sg11
Vreflux
p15955
sg13
I1
sasa(dp15956
g2
S'Soluble VEGFC was detected in the plasma and ascites of patients with ovarian carcinoma, and VEGFR3 expression was found in their tumor tissues.\n'
p15957
sg4
(lp15958
(dp15959
g7
I8
sg8
VP49767
p15960
sg10
I5
sg11
VVEGFC
p15961
sg13
I1
sa(dp15962
g7
I93
sg8
VP35916
p15963
sg10
I6
sg11
VVEGFR3
p15964
sg13
I1
sasg19
(lp15965
(dp15966
g7
I130
sg22
VC0027651
p15967
sg10
I5
sg11
Vtumor
p15968
sg13
I1
sa(dp15969
g7
I70
sg22
VC0029925
p15970
sg10
I17
sg11
Vovarian carcinoma
p15971
sg13
I2
sasa(dp15972
g2
S'In human ovarian carcinoma xenograft models, high levels of soluble VEGFC in ascites and serum were detected, in association with disease progression, tumor burden, and volume of ascites.\n'
p15973
sg4
(lp15974
(dp15975
g7
I68
sg8
VP49767
p15976
sg10
I5
sg11
VVEGFC
p15977
sg13
I1
sasg19
(lp15978
(dp15979
g7
I130
sg22
VC0242656
p15980
sg10
I19
sg11
Vdisease progression
p15981
sg13
I2
sa(dp15982
g7
I9
sg22
VC0029925
p15983
sg10
I17
sg11
Vovarian carcinoma
p15984
sg13
I2
sa(dp15985
g7
I151
sg22
VC0027651
p15986
sg10
I5
sg11
Vtumor
p15987
sg13
I1
sasa(dp15988
g2
S'VEGF-A, VEGF-C and PDGF-A may promote lymphatic metastasis in epithelial ovarian carcinoma through else mechanisms other than lymphangiogenesis.\n'
p15989
sg4
(lp15990
(dp15991
g7
I8
sg8
VP49767
p15992
sg10
I6
sg11
VVEGF-C
p15993
sg13
I1
sa(dp15994
g7
I19
sg8
VP04085
p15995
sg10
I6
sg11
VPDGF-A
p15996
sg13
I1
sasg19
(lp15997
(dp15998
g7
I38
sg22
VC0024232
p15999
sg10
I20
sg11
Vlymphatic metastasis
p16000
sg13
I2
sa(dp16001
g7
I73
sg22
VC0029925
p16002
sg10
I17
sg11
Vovarian carcinoma
p16003
sg13
I2
sasa(dp16004
g2
S'In vitro stimulation of ES2 ovarian carcinoma cells with LH and FSH induced expression of vascular endothelial growth factor (VEGF)-C. In vivo, ovariectomy of mice resulted in activation of the VEGF-C promoter in ovarian carcinoma xenografts, increased VEGF-C mRNA level, and enhanced tumor lymphangiogenesis and angiogenesis.\n'
p16005
sg4
(lp16006
(dp16007
g7
I64
sg8
VP01225
p16008
sg10
I3
sg11
VFSH
p16009
sg13
I1
sa(dp16010
g7
I90
sg8
g15
sg10
I34
sg11
Vvascular endothelial growth factor
p16011
sg13
I4
sa(dp16012
g7
I194
sg8
VP49767
p16013
sg10
I15
sg11
VVEGF-C promoter
p16014
sg13
I2
sa(dp16015
g7
I253
sg8
VP49767
p16016
sg10
I11
sg11
VVEGF-C mRNA
p16017
sg13
I2
sa(dp16018
g7
I126
sg8
g15
sg10
I4
sg11
VVEGF
p16019
sg13
I1
sasg19
(lp16020
(dp16021
g7
I28
sg22
VC0029925
p16022
sg10
I17
sg11
Vovarian carcinoma
p16023
sg13
I2
sa(dp16024
g7
I28
sg22
VC0029925
p16025
sg10
I17
sg11
Vovarian carcinoma
p16026
sg13
I2
sa(dp16027
g7
I285
sg22
VC0027651
p16028
sg10
I5
sg11
Vtumor
p16029
sg13
I1
sasa(dp16030
g2
S'Using immunohistochemistry, we examined maspin, VEGFA, VEGFC, and VEGFD expression in 60 ovarian carcinoma tissues (35 serous papillary carcinomas, 18 endometrioid carcinomas, and 7 primary ovarian mucinous carcinomas).\n'
p16031
sg4
(lp16032
(dp16033
g7
I55
sg8
VP49767
p16034
sg10
I5
sg11
VVEGFC
p16035
sg13
I1
sa(dp16036
g7
I40
sg8
VP36952
p16037
sg10
I6
sg11
Vmaspin
p16038
sg13
I1
sa(dp16039
g7
I66
sg8
g15
sg10
I5
sg11
VVEGFD
p16040
sg13
I1
sasg19
(lp16041
(dp16042
g7
I89
sg22
VC0029925
p16043
sg10
I17
sg11
Vovarian carcinoma
p16044
sg13
I2
sa(dp16045
g7
I126
sg22
VC0007133
p16046
sg10
I20
sg11
Vpapillary carcinomas
p16047
sg13
I2
sa(dp16048
g7
I198
sg22
VC0007130
p16049
sg10
I19
sg11
Vmucinous carcinomas
p16050
sg13
I2
sa(dp16051
g7
I151
sg22
VC0206687
p16052
sg10
I23
sg11
Vendometrioid carcinomas
p16053
sg13
I2
sasa(dp16054
g2
S'The aim of the work was to assess vascular endothelial growth factor VEGF-C and vascular endothelial growth factor VEGF-D expression in ovarian carcinomas.\n'
p16055
sg4
(lp16056
(dp16057
g7
I34
sg8
VP49767
p16058
sg10
I41
sg11
Vvascular endothelial growth factor VEGF-C
p16059
sg13
I5
sa(dp16060
g7
I80
sg8
g15
sg10
I41
sg11
Vvascular endothelial growth factor VEGF-D
p16061
sg13
I5
sasg19
(lp16062
(dp16063
g7
I136
sg22
VC0029925
p16064
sg10
I18
sg11
Vovarian carcinomas
p16065
sg13
I2
sasa(dp16066
g2
S'There was strong correlation between expression of VEGF-C and VEGF-D. Conversely, there was no significant correlation between VEGF-C and VEGF-D expression and clinicopathological features of ovarian carcinoma.\n'
p16067
sg4
(lp16068
(dp16069
g7
I62
sg8
g15
sg10
I6
sg11
VVEGF-D
p16070
sg13
I1
sa(dp16071
g7
I62
sg8
g15
sg10
I6
sg11
VVEGF-D
p16072
sg13
I1
sa(dp16073
g7
I51
sg8
VP49767
p16074
sg10
I6
sg11
VVEGF-C
p16075
sg13
I1
sa(dp16076
g7
I51
sg8
VP49767
p16077
sg10
I6
sg11
VVEGF-C
p16078
sg13
I1
sasg19
(lp16079
(dp16080
g7
I192
sg22
VC0029925
p16081
sg10
I17
sg11
Vovarian carcinoma
p16082
sg13
I2
sasa(dp16083
g2
S'The tissue expression levels of VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 in 80 specimens of ovarian carcinoma were examined immnohistochemically.\n'
p16084
sg4
(lp16085
(dp16086
g7
I61
sg8
VP35916
p16087
sg10
I7
sg11
VVEGFR-3
p16088
sg13
I1
sa(dp16089
g7
I48
sg8
VP35968
p16090
sg10
I7
sg11
VVEGFR-2
p16091
sg13
I1
sa(dp16092
g7
I40
sg8
VP49767
p16093
sg10
I6
sg11
VVEGF-C
p16094
sg13
I1
sasg19
(lp16095
(dp16096
g7
I88
sg22
VC0029925
p16097
sg10
I17
sg11
Vovarian carcinoma
p16098
sg13
I2
sasa(dp16099
g2
S'High tissue expression of VEGF-C and VEGFR-2 reflects the aggressiveness of the spread of tumor in ovarian carcinoma.\n'
p16100
sg4
(lp16101
(dp16102
g7
I26
sg8
VP49767
p16103
sg10
I6
sg11
VVEGF-C
p16104
sg13
I1
sa(dp16105
g7
I37
sg8
VP35968
p16106
sg10
I7
sg11
VVEGFR-2
p16107
sg13
I1
sasg19
(lp16108
(dp16109
g7
I90
sg22
VC0027651
p16110
sg10
I5
sg11
Vtumor
p16111
sg13
I1
sa(dp16112
g7
I58
sg22
VC0001807
p16113
sg10
I14
sg11
Vaggressiveness
p16114
sg13
I1
sa(dp16115
g7
I99
sg22
VC0029925
p16116
sg10
I17
sg11
Vovarian carcinoma
p16117
sg13
I2
sasa(dp16118
g2
S'Accordingly, this study attempted to analyze the association between the Her-2/NEU oncogene and VEGF-C in ovarian carcinoma and to elucidate the molecular mechanism of VEGF-C induction by Her-2/NEU.\n'
p16119
sg4
(lp16120
(dp16121
g7
I96
sg8
VP49767
p16122
sg10
I6
sg11
VVEGF-C
p16123
sg13
I1
sa(dp16124
g7
I79
sg8
VP04626
p16125
sg10
I3
sg11
VNEU
p16126
sg13
I1
sa(dp16127
g7
I73
sg8
VP04626
p16128
sg10
I5
sg11
VHer-2
p16129
sg13
I1
sa(dp16130
g7
I96
sg8
VP49767
p16131
sg10
I6
sg11
VVEGF-C
p16132
sg13
I1
sasg19
(lp16133
(dp16134
g7
I106
sg22
VC0029925
p16135
sg10
I17
sg11
Vovarian carcinoma
p16136
sg13
I2
sasa(dp16137
g2
S'Immunohistochemistry was used to determine the expression of Her-2/NEU and VEGF-C in tissues from 41 patients with epithelial ovarian carcinoma.\n'
p16138
sg4
(lp16139
(dp16140
g7
I75
sg8
VP49767
p16141
sg10
I6
sg11
VVEGF-C
p16142
sg13
I1
sa(dp16143
g7
I61
sg8
VP04626
p16144
sg10
I5
sg11
VHer-2
p16145
sg13
I1
sa(dp16146
g7
I67
sg8
VP04626
p16147
sg10
I3
sg11
VNEU
p16148
sg13
I1
sasg19
(lp16149
(dp16150
g7
I126
sg22
VC0029925
p16151
sg10
I17
sg11
Vovarian carcinoma
p16152
sg13
I2
sasa(dp16153
g2
S"Several Her-2/NEU-stably-transfected Caov-3 ovarian carcinoma cells were used to evaluate the effect of Her-2/NEU on VEGF-C, the possible regulation mechanism, and the biological function of VEGF-C. Our experimental results identified a significant association between the Her-2/NEU oncogene and VEGF-C expression in both epithelial ovarian cancer patients (p &lt; 0.05; Fisher's exact test) and in vitro cell lines.\n"
p16154
sg4
(lp16155
(dp16156
g7
I117
sg8
VP49767
p16157
sg10
I6
sg11
VVEGF-C
p16158
sg13
I1
sa(dp16159
g7
I14
sg8
VP04626
p16160
sg10
I3
sg11
VNEU
p16161
sg13
I1
sa(dp16162
g7
I117
sg8
VP49767
p16163
sg10
I6
sg11
VVEGF-C
p16164
sg13
I1
sa(dp16165
g7
I14
sg8
VP04626
p16166
sg10
I3
sg11
VNEU
p16167
sg13
I1
sa(dp16168
g7
I8
sg8
VP04626
p16169
sg10
I5
sg11
VHer-2
p16170
sg13
I1
sa(dp16171
g7
I117
sg8
VP49767
p16172
sg10
I6
sg11
VVEGF-C
p16173
sg13
I1
sasg19
(lp16174
(dp16175
g7
I44
sg22
VC0029925
p16176
sg10
I17
sg11
Vovarian carcinoma
p16177
sg13
I2
sa(dp16178
g7
I322
sg22
VC0677886
p16179
sg10
I25
sg11
Vepithelial ovarian cancer
p16180
sg13
I3
sasa(dp16181
g2
S'In conclusion, this work clearly establishes that the Her-2/NEU oncogene is essential for the regulation of VEGF-C in ovarian carcinoma.\n'
p16182
sg4
(lp16183
(dp16184
g7
I60
sg8
VP04626
p16185
sg10
I3
sg11
VNEU
p16186
sg13
I1
sa(dp16187
g7
I108
sg8
VP49767
p16188
sg10
I6
sg11
VVEGF-C
p16189
sg13
I1
sa(dp16190
g7
I54
sg8
VP04626
p16191
sg10
I5
sg11
VHer-2
p16192
sg13
I1
sasg19
(lp16193
(dp16194
g7
I118
sg22
VC0029925
p16195
sg10
I17
sg11
Vovarian carcinoma
p16196
sg13
I2
sasa(dp16197
g2
S'We conclude that VEGF-C, VEGF-D and VEGFR-3 play an important role in lymphatic spread and intraperitoneal tumour development in ovarian carcinoma.\n'
p16198
sg4
(lp16199
(dp16200
g7
I36
sg8
VP35916
p16201
sg10
I7
sg11
VVEGFR-3
p16202
sg13
I1
sa(dp16203
g7
I25
sg8
g15
sg10
I6
sg11
VVEGF-D
p16204
sg13
I1
sa(dp16205
g7
I17
sg8
VP49767
p16206
sg10
I6
sg11
VVEGF-C
p16207
sg13
I1
sasg19
(lp16208
(dp16209
g7
I129
sg22
VC0029925
p16210
sg10
I17
sg11
Vovarian carcinoma
p16211
sg13
I2
sa(dp16212
g7
I107
sg22
VC0027651
p16213
sg10
I6
sg11
Vtumour
p16214
sg13
I1
sasa(dp16215
g2
S'Grade 3/4 anorexia, diarrhea, nausea, vomiting, and febrile neutropenia occurred more frequently with CPT-P, whereas grade 3/4 leukopenia, neutropenia, thrombocytopenia, peripheral sensory neuropathy, and joint pain occurred more frequently with TC.\n'
p16216
sg4
(lp16217
(dp16218
g7
I102
sg8
VP23786
p16219
sg10
I5
sg11
VCPT-P
p16220
sg13
I1
sasg19
(lp16221
(dp16222
g7
I170
sg22
VC0151313
p16223
sg10
I29
sg11
Vperipheral sensory neuropathy
p16224
sg13
I3
sa(dp16225
g7
I38
sg22
VC0042963
p16226
sg10
I8
sg11
Vvomiting
p16227
sg13
I1
sa(dp16228
g7
I52
sg22
VC0746883
p16229
sg10
I19
sg11
Vfebrile neutropenia
p16230
sg13
I2
sa(dp16231
g7
I10
sg22
VC0003123
p16232
sg10
I8
sg11
Vanorexia
p16233
sg13
I1
sa(dp16234
g7
I205
sg22
VC0003862
p16235
sg10
I10
sg11
Vjoint pain
p16236
sg13
I2
sa(dp16237
g7
I127
sg22
VC0023530
p16238
sg10
I10
sg11
Vleukopenia
p16239
sg13
I1
sa(dp16240
g7
I30
sg22
VC0027497
p16241
sg10
I6
sg11
Vnausea
p16242
sg13
I1
sa(dp16243
g7
I20
sg22
VC0011991
p16244
sg10
I8
sg11
Vdiarrhea
p16245
sg13
I1
sasa(dp16246
g2
S'Major adverse reactions were grade 4 neutropenia observed in 37, 54 and 8% of the patients on CPT-P, VDS-P and CPT, respectively; and grades 3 and 4 diarrhoea observed in 12, 3 and 15% of the patients, respectively.\n'
p16247
sg4
(lp16248
sg19
(lp16249
(dp16250
g7
I101
sg22
VC0036916
p16251
sg10
I3
sg11
VVDS
p16252
sg13
I1
sa(dp16253
g7
I149
sg22
VC0011991
p16254
sg10
I9
sg11
Vdiarrhoea
p16255
sg13
I1
sasa(dp16256
g2
S'Most of these changes in transporter mRNA levels were also found in epinephrine-exposed human highly-differentiated hepatoma HepaRG cells, which additionally exhibited reduced protein expression of OATP2B1 and MRP3, increased expression of P-glycoprotein and decreased transport activity of NTCP, OATPs and OCT1.\n'
p16257
sg4
(lp16258
(dp16259
g7
I198
sg8
g15
sg10
I7
sg11
VOATP2B1
p16260
sg13
I1
sa(dp16261
g7
I291
sg8
g15
sg10
I4
sg11
VNTCP
p16262
sg13
I1
sa(dp16263
g7
I240
sg8
VP08183
p16264
sg10
I14
sg11
VP-glycoprotein
p16265
sg13
I1
sa(dp16266
g7
I307
sg8
VP14859
p16267
sg10
I4
sg11
VOCT1
p16268
sg13
I1
sasg19
(lp16269
(dp16270
g7
I116
sg22
VC0023903
p16271
sg10
I8
sg11
Vhepatoma
p16272
sg13
I1
sasa(dp16273
g2
S'Concomitantly, mRNA expressions of various sinusoidal and canalicular hepatic drug transporters were not detected (NTCP, OATP1B1, organic anion transporter 2 (OAT2), OCT1 and bile salt export pump) or were found to be lower (OATP1B3, OATP2B1, multidrug and toxin extrusion protein 1, BCRP and MRP3) in hepatoma HuH-7 cells than those found in human hepatocytes, whereas other transporters such as OAT7, MRP4 and MRP5 were up-regulated.\n'
p16274
sg4
(lp16275
(dp16276
g7
I412
sg8
g15
sg10
I4
sg11
VMRP5
p16277
sg13
I1
sa(dp16278
g7
I115
sg8
g15
sg10
I4
sg11
VNTCP
p16279
sg13
I1
sa(dp16280
g7
I159
sg8
g15
sg10
I4
sg11
VOAT2
p16281
sg13
I1
sa(dp16282
g7
I403
sg8
g15
sg10
I4
sg11
VMRP4
p16283
sg13
I1
sa(dp16284
g7
I234
sg8
g15
sg10
I7
sg11
VOATP2B1
p16285
sg13
I1
sa(dp16286
g7
I166
sg8
VP14859
p16287
sg10
I4
sg11
VOCT1
p16288
sg13
I1
sa(dp16289
g7
I243
sg8
VP14222
p16290
sg10
I39
sg11
Vmultidrug and toxin extrusion protein 1
p16291
sg13
I6
sa(dp16292
g7
I121
sg8
g15
sg10
I7
sg11
VOATP1B1
p16293
sg13
I1
sa(dp16294
g7
I130
sg8
g15
sg10
I27
sg11
Vorganic anion transporter 2
p16295
sg13
I4
sa(dp16296
g7
I397
sg8
g15
sg10
I4
sg11
VOAT7
p16297
sg13
I1
sa(dp16298
g7
I225
sg8
g15
sg10
I7
sg11
VOATP1B3
p16299
sg13
I1
sa(dp16300
g7
I284
sg8
g15
sg10
I4
sg11
VBCRP
p16301
sg13
I1
sasg19
(lp16302
(dp16303
g7
I302
sg22
VC0023903
p16304
sg10
I8
sg11
Vhepatoma
p16305
sg13
I1
sasa(dp16306
g2
S'Treatment by the reference PKC activator phorbol 12-myristate 13-acetate (PMA) for 48h was shown to decrease mRNA expression of various sinusoidal transporters, including OATP1B1, OATP2B1, NTCP, OCT1 and MRP3, but to increase that of OATP1B3, whereas mRNA expression of canalicular transporters was transiently enhanced (MDR1), decreased (BSEP and MRP2) or unchanged (BCRP) in human hepatoma HepaRG cells.\n'
p16307
sg4
(lp16308
(dp16309
g7
I339
sg8
g15
sg10
I4
sg11
VBSEP
p16310
sg13
I1
sa(dp16311
g7
I136
sg8
g15
sg10
I23
sg11
Vsinusoidal transporters
p16312
sg13
I2
sa(dp16313
g7
I171
sg8
g15
sg10
I7
sg11
VOATP1B1
p16314
sg13
I1
sa(dp16315
g7
I234
sg8
g15
sg10
I7
sg11
VOATP1B3
p16316
sg13
I1
sa(dp16317
g7
I321
sg8
VP08183
p16318
sg10
I4
sg11
VMDR1
p16319
sg13
I1
sa(dp16320
g7
I348
sg8
g15
sg10
I4
sg11
VMRP2
p16321
sg13
I1
sa(dp16322
g7
I180
sg8
g15
sg10
I7
sg11
VOATP2B1
p16323
sg13
I1
sa(dp16324
g7
I27
sg8
VP17252
p16325
sg10
I3
sg11
VPKC
p16326
sg13
I1
sa(dp16327
g7
I368
sg8
g15
sg10
I4
sg11
VBCRP
p16328
sg13
I1
sa(dp16329
g7
I195
sg8
VP14859
p16330
sg10
I4
sg11
VOCT1
p16331
sg13
I1
sa(dp16332
g7
I189
sg8
g15
sg10
I4
sg11
VNTCP
p16333
sg13
I1
sasg19
(lp16334
(dp16335
g7
I383
sg22
VC0023903
p16336
sg10
I8
sg11
Vhepatoma
p16337
sg13
I1
sa(dp16338
g7
I27
sg22
VC1868682
p16339
sg10
I3
sg11
VPKC
p16340
sg13
I1
sasa(dp16341
g2
S'We present evidence for the first time that ABCC3 is a potential sanguine biomarker and anticancer target in hepatocellular carcinoma.\n'
p16342
sg4
(lp16343
sg19
(lp16344
(dp16345
g7
I109
sg22
VC1512411
p16346
sg10
I24
sg11
Vhepatocellular carcinoma
p16347
sg13
I2
sasa(dp16348
g2
S'Accordingly, the ABCC3 protein was preferentially overexpressed within the nodules and tumors during hepatocellular carcinoma progression and was secreted into the bloodstream of rat hepatocarcinogenesis model.\n'
p16349
sg4
(lp16350
sg19
(lp16351
(dp16352
g7
I75
sg22
VC0028259
p16353
sg10
I7
sg11
Vnodules
p16354
sg13
I1
sa(dp16355
g7
I101
sg22
VC1512411
p16356
sg10
I24
sg11
Vhepatocellular carcinoma
p16357
sg13
I2
sa(dp16358
g7
I183
sg22
VC1512409
p16359
sg10
I20
sg11
Vhepatocarcinogenesis
p16360
sg13
I1
sa(dp16361
g7
I87
sg22
VC0027651
p16362
sg10
I6
sg11
Vtumors
p16363
sg13
I1
sasa(dp16364
g2
S'The ABCC3 protein was expressed in human hepatoma cells and, importantly, was also present in HepG2- and Huh7-conditioned media.\n'
p16365
sg4
(lp16366
sg19
(lp16367
(dp16368
g7
I41
sg22
VC0023903
p16369
sg10
I8
sg11
Vhepatoma
p16370
sg13
I1
sasa(dp16371
g2
S'Furthermore, ABCC3 was overexpressed in human hepatocellular carcinoma.\n'
p16372
sg4
(lp16373
sg19
(lp16374
(dp16375
g7
I46
sg22
VC1512411
p16376
sg10
I24
sg11
Vhepatocellular carcinoma
p16377
sg13
I2
sasa(dp16378
g2
S'This report is the first to describe liver overexpression of Abcc3 during the cancer initiation, promotion, and progression periods in rat hepatocarcinogenesis model and in human hepatocellular carcinoma.\n'
p16379
sg4
(lp16380
sg19
(lp16381
(dp16382
g7
I78
sg22
VC0006826
p16383
sg10
I6
sg11
Vcancer
p16384
sg13
I1
sa(dp16385
g7
I139
sg22
VC1512409
p16386
sg10
I20
sg11
Vhepatocarcinogenesis
p16387
sg13
I1
sa(dp16388
g7
I179
sg22
VC1512411
p16389
sg10
I24
sg11
Vhepatocellular carcinoma
p16390
sg13
I2
sasa(dp16391
g2
S'Our patient with HMC and PAP was diagnosed with MKS because she has two typical abnormality of MKS and she has no definite complications of retinal disease, learning disability, obesity and renal failure that develop in Bardet-Biedl syndrome, but not in MKS until 33 months of age.\n'
p16392
sg4
(lp16393
(dp16394
g7
I48
sg8
VP21741
p16395
sg10
I3
sg11
VMKS
p16396
sg13
I1
sa(dp16397
g7
I25
sg8
g15
sg10
I3
sg11
VPAP
p16398
sg13
I1
sa(dp16399
g7
I48
sg8
VP21741
p16400
sg10
I3
sg11
VMKS
p16401
sg13
I1
sasg19
(lp16402
(dp16403
g7
I48
sg22
VC0265215
p16404
sg10
I3
sg11
VMKS
p16405
sg13
I1
sa(dp16406
g7
I48
sg22
VC0265215
p16407
sg10
I3
sg11
VMKS
p16408
sg13
I1
sa(dp16409
g7
I178
sg22
VC0028754
p16410
sg10
I7
sg11
Vobesity
p16411
sg13
I1
sa(dp16412
g7
I140
sg22
VC0035309
p16413
sg10
I15
sg11
Vretinal disease
p16414
sg13
I2
sa(dp16415
g7
I190
sg22
VC0035078
p16416
sg10
I13
sg11
Vrenal failure
p16417
sg13
I2
sa(dp16418
g7
I220
sg22
VC0752166
p16419
sg10
I21
sg11
VBardet-Biedl syndrome
p16420
sg13
I2
sa(dp16421
g7
I25
sg22
VC1863340
p16422
sg10
I3
sg11
VPAP
p16423
sg13
I1
sa(dp16424
g7
I157
sg22
VC0751265
p16425
sg10
I19
sg11
Vlearning disability
p16426
sg13
I2
sa(dp16427
g7
I48
sg22
VC0265215
p16428
sg10
I3
sg11
VMKS
p16429
sg13
I1
sasa(dp16430
g2
S'A 11-year-old, 37 kg, female with Mckusick-Kaufman syndrome, chronic renal failure, hypertensive encephalopathy and severe asthma was scheduled for surgical arterial-venous fistula preparation and removal of infected peritoneal dialysis catheter.\n'
p16431
sg4
(lp16432
sg19
(lp16433
(dp16434
g7
I123
sg22
VC0004096
p16435
sg10
I6
sg11
Vasthma
p16436
sg13
I1
sa(dp16437
g7
I84
sg22
VC0151620
p16438
sg10
I27
sg11
Vhypertensive encephalopathy
p16439
sg13
I2
sa(dp16440
g7
I173
sg22
VC0016169
p16441
sg10
I7
sg11
Vfistula
p16442
sg13
I1
sa(dp16443
g7
I61
sg22
VC0022661
p16444
sg10
I21
sg11
Vchronic renal failure
p16445
sg13
I3
sa(dp16446
g7
I34
sg22
VC0948368
p16447
sg10
I25
sg11
VMckusick-Kaufman syndrome
p16448
sg13
I2
sasa(dp16449
g2
S'Pre-training, intra-CA1 injection of 5-HT3 receptor agonist Chlorophenylbiguanide (Mchl; 0.01 and 0.001 myg/rat; P &lt; 0.001) and antagonist Y-25130 (0.1 myg/rat; P &lt; 0.001) reduced memory acquisition and did not alter pain response, while higher dose of both drugs increased locomotor activity in normal rats.\n'
p16450
sg4
(lp16451
(dp16452
g7
I37
sg8
VP46098
p16453
sg10
I14
sg11
V5-HT3 receptor
p16454
sg13
I2
sasg19
(lp16455
sa(dp16456
g2
S'Chemo-naive patients with advanced non-small cell lung cancer (NSCLC) who received carboplatin-based chemotherapy were treated with doublet antiemetic therapy with dexamethasone and a 5-HT3 receptor antagonist during the first cycle of chemotherapy.\n'
p16457
sg4
(lp16458
(dp16459
g7
I184
sg8
VP46098
p16460
sg10
I14
sg11
V5-HT3 receptor
p16461
sg13
I2
sasg19
(lp16462
(dp16463
g7
I35
sg22
VC0007131
p16464
sg10
I26
sg11
Vnon-small cell lung cancer
p16465
sg13
I4
sa(dp16466
g7
I63
sg22
VC0007131
p16467
sg10
I5
sg11
VNSCLC
p16468
sg13
I1
sasa(dp16469
g2
S'Thirty patients with breast cancer, receiving 5HT3 receptor antagonists to prevent emesis during chemotherapy were randomly assigned to the intervention or control group.\n'
p16470
sg4
(lp16471
(dp16472
g7
I46
sg8
VP46098
p16473
sg10
I13
sg11
V5HT3 receptor
p16474
sg13
I2
sasg19
(lp16475
(dp16476
g7
I83
sg22
VC0042963
p16477
sg10
I6
sg11
Vemesis
p16478
sg13
I1
sa(dp16479
g7
I21
sg22
VC0678222
p16480
sg10
I13
sg11
Vbreast cancer
p16481
sg13
I2
sasa(dp16482
g2
S'Clonal analysis of primary tumor cell cultures of a human sarcomatoid cholangiocarcinoma identified different types of self-propagating sub-clones characterized by stable (keratin-7 positive or keratin-7 negative) phenotypes and an unstable phenotype consisting of mixtures of keratin-7 positive and negative cells, which lack stem cell features but may reversibly switch their phenotypes.\n'
p16483
sg4
(lp16484
(dp16485
g7
I172
sg8
VP08729
p16486
sg10
I9
sg11
Vkeratin-7
p16487
sg13
I1
sa(dp16488
g7
I172
sg8
VP08729
p16489
sg10
I9
sg11
Vkeratin-7
p16490
sg13
I1
sa(dp16491
g7
I172
sg8
VP08729
p16492
sg10
I9
sg11
Vkeratin-7
p16493
sg13
I1
sasg19
(lp16494
(dp16495
g7
I70
sg22
VC0206698
p16496
sg10
I18
sg11
Vcholangiocarcinoma
p16497
sg13
I1
sa(dp16498
g7
I19
sg22
VC0677930
p16499
sg10
I13
sg11
Vprimary tumor
p16500
sg13
I2
sasa(dp16501
g2
S'Autopsy revealed cholangiocarcinoma as the primary tumour confirmed by strong CK7 positivity and glypican-3 negativity.\n'
p16502
sg4
(lp16503
(dp16504
g7
I78
sg8
VP08729
p16505
sg10
I3
sg11
VCK7
p16506
sg13
I1
sa(dp16507
g7
I97
sg8
VP51654
p16508
sg10
I10
sg11
Vglypican-3
p16509
sg13
I1
sasg19
(lp16510
(dp16511
g7
I17
sg22
VC0206698
p16512
sg10
I18
sg11
Vcholangiocarcinoma
p16513
sg13
I1
sa(dp16514
g7
I51
sg22
VC0027651
p16515
sg10
I6
sg11
Vtumour
p16516
sg13
I1
sasa(dp16517
g2
S'A homozygous missense mutation in TRHR (c.392T &gt; C; p.I131T) was identified in an 8-year-old boy with moderate hypothyroidism (TSH: 2.61 mIU/L, Normal: 0.27 to 4.2; free thyroxine: 9.52 pmol/L, Normal: 10.9 to 25.7) who was overweight (body mass index: 20.4 kg/m2, p91) but had normal stature (122 cm; -0.58 standard deviation).\n'
p16518
sg4
(lp16519
(dp16520
g7
I34
sg8
VP34981
p16521
sg10
I4
sg11
VTRHR
p16522
sg13
I1
sasg19
(lp16523
(dp16524
g7
I227
sg22
VC0497406
p16525
sg10
I10
sg11
Voverweight
p16526
sg13
I1
sa(dp16527
g7
I114
sg22
VC0020676
p16528
sg10
I14
sg11
Vhypothyroidism
p16529
sg13
I1
sasa(dp16530
g2
S'A unique missense TRHR defect identified in a consanguineous family is associated with central hypothyroidism in homozygotes and hyperthyrotropinemia in heterozygotes, suggesting compensatory elevation of TSH with reduced biopotency.\n'
p16531
sg4
(lp16532
(dp16533
g7
I205
sg8
VP01222
p16534
sg10
I3
sg11
VTSH
p16535
sg13
I1
sasg19
(lp16536
(dp16537
g7
I87
sg22
VC0271801
p16538
sg10
I22
sg11
Vcentral hypothyroidism
p16539
sg13
I2
sasa(dp16540
g2
S'Isolated congenital central hypothyroidism (CeH) can result from mutations in TRHR, TSHB, and IGSF1, but its etiology often remains unexplained.\n'
p16541
sg4
(lp16542
(dp16543
g7
I84
sg8
VP01222
p16544
sg10
I4
sg11
VTSHB
p16545
sg13
I1
sa(dp16546
g7
I78
sg8
VP34981
p16547
sg10
I4
sg11
VTRHR
p16548
sg13
I1
sa(dp16549
g7
I94
sg8
g15
sg10
I5
sg11
VIGSF1
p16550
sg13
I1
sasg19
(lp16551
(dp16552
g7
I20
sg22
VC0271801
p16553
sg10
I22
sg11
Vcentral hypothyroidism
p16554
sg13
I2
sa(dp16555
g7
I44
sg22
VC0271801
p16556
sg10
I3
sg11
VCeH
p16557
sg13
I1
sasa(dp16558
g2
S'Plasma levels of C1q, mannose-binding lectin, C4d, Bb, C3, C3a, C5a and soluble C5b-9 were detected by enzyme-linked immunosorbent assay in 222 patients with active biopsy-proven lupus nephritis, 34 patients with lupus nephritis at remission, 82 patients with active systemic lupus erythematosus without renal involvement and 39 normal controls.\n'
p16559
sg4
(lp16560
(dp16561
g7
I22
sg8
VP11226
p16562
sg10
I22
sg11
Vmannose-binding lectin
p16563
sg13
I2
sa(dp16564
g7
I64
sg8
VP21730
p16565
sg10
I3
sg11
VC5a
p16566
sg13
I1
sasg19
(lp16567
(dp16568
g7
I179
sg22
VC0024143
p16569
sg10
I15
sg11
Vlupus nephritis
p16570
sg13
I2
sa(dp16571
g7
I267
sg22
VC0024141
p16572
sg10
I28
sg11
Vsystemic lupus erythematosus
p16573
sg13
I3
sa(dp16574
g7
I179
sg22
VC0024143
p16575
sg10
I15
sg11
Vlupus nephritis
p16576
sg13
I2
sa(dp16577
g7
I232
sg22
VC0687702
p16578
sg10
I9
sg11
Vremission
p16579
sg13
I1
sasa(dp16580
g2
S'The aim of this study was to investigate serum levels of mannose-binding lectin (MBL) in type 1 diabetes with diabetic nephropathy (DN) and persistent normoalbuminuria (PN).\n'
p16581
sg4
(lp16582
(dp16583
g7
I81
sg8
VP11226
p16584
sg10
I3
sg11
VMBL
p16585
sg13
I1
sa(dp16586
g7
I57
sg8
VP11226
p16587
sg10
I22
sg11
Vmannose-binding lectin
p16588
sg13
I2
sasg19
(lp16589
(dp16590
g7
I110
sg22
VC0011881
p16591
sg10
I20
sg11
Vdiabetic nephropathy
p16592
sg13
I2
sa(dp16593
g7
I89
sg22
VC0011854
p16594
sg10
I15
sg11
Vtype 1 diabetes
p16595
sg13
I3
sa(dp16596
g7
I132
sg22
VC0011881
p16597
sg10
I2
sg11
VDN
p16598
sg13
I1
sasa(dp16599
g2
S'A frameshift mutation on BBS7 gene was detected in No.2 pedigree, the patients of this pedigree combined with central obesity, polydactyly and mental handicap.\n'
p16600
sg4
(lp16601
(dp16602
g7
I25
sg8
g15
sg10
I9
sg11
VBBS7 gene
p16603
sg13
I2
sasg19
(lp16604
(dp16605
g7
I127
sg22
VC0152427
p16606
sg10
I11
sg11
Vpolydactyly
p16607
sg13
I1
sa(dp16608
g7
I110
sg22
VC0311277
p16609
sg10
I15
sg11
Vcentral obesity
p16610
sg13
I2
sa(dp16611
g7
I143
sg22
VC1306341
p16612
sg10
I15
sg11
Vmental handicap
p16613
sg13
I2
sa(dp16614
g7
I2
sg22
VC0079380
p16615
sg10
I19
sg11
Vframeshift mutation
p16616
sg13
I2
sa(dp16617
g7
I25
sg22
VC1859565
p16618
sg10
I4
sg11
VBBS7
p16619
sg13
I1
sasa(dp16620
g2
S'Nonsense YAP1 mutations have been shown to co-segregate with autosomal dominantly inherited coloboma.\n'
p16621
sg4
(lp16622
(dp16623
g7
I9
sg8
VP46937
p16624
sg10
I4
sg11
VYAP1
p16625
sg13
I1
sasg19
(lp16626
(dp16627
g7
I92
sg22
VC0009363
p16628
sg10
I8
sg11
Vcoloboma
p16629
sg13
I1
sasa(dp16630
g2
S'Therefore, we screened YAP1 for variants in a cohort of 258 undiagnosed UK patients with developmental eye disorders, including anophthalmia, microphthalmia and coloboma.\n'
p16631
sg4
(lp16632
(dp16633
g7
I23
sg8
VP46937
p16634
sg10
I4
sg11
VYAP1
p16635
sg13
I1
sasg19
(lp16636
(dp16637
g7
I161
sg22
VC0009363
p16638
sg10
I8
sg11
Vcoloboma
p16639
sg13
I1
sa(dp16640
g7
I128
sg22
VC0003119
p16641
sg10
I12
sg11
Vanophthalmia
p16642
sg13
I1
sa(dp16643
g7
I142
sg22
VC0026010
p16644
sg10
I14
sg11
Vmicrophthalmia
p16645
sg13
I1
sa(dp16646
g7
I103
sg22
VC0015397
p16647
sg10
I13
sg11
Veye disorders
p16648
sg13
I2
sasa(dp16649
g2
S'We identified a novel 1 bp deletion in YAP1 in a boy with bilateral microphthalmia and bilateral chorioretinal coloboma.\n'
p16650
sg4
(lp16651
(dp16652
g7
I39
sg8
VP46937
p16653
sg10
I4
sg11
VYAP1
p16654
sg13
I1
sasg19
(lp16655
(dp16656
g7
I68
sg22
VC0026010
p16657
sg10
I14
sg11
Vmicrophthalmia
p16658
sg13
I1
sa(dp16659
g7
I97
sg22
VC0240896
p16660
sg10
I22
sg11
Vchorioretinal coloboma
p16661
sg13
I2
sasa(dp16662
g2
S'Verteporfin, a drug that enhances phototherapy to treat neovascular macular degeneration, is an inhibitor of YAP1.\n'
p16663
sg4
(lp16664
(dp16665
g7
I109
sg8
VP46937
p16666
sg10
I4
sg11
VYAP1
p16667
sg13
I1
sasg19
(lp16668
(dp16669
g7
I68
sg22
VC0242383
p16670
sg10
I20
sg11
Vmacular degeneration
p16671
sg13
I2
sasa(dp16672
g2
S'yap (yap1) mutants lack a subset of RPE cells and/or exhibit coloboma.\n'
p16673
sg4
(lp16674
(dp16675
g7
I5
sg8
VP46937
p16676
sg10
I4
sg11
Vyap1
p16677
sg13
I1
sa(dp16678
g7
I0
sg8
VP46937
p16679
sg10
I3
sg11
Vyap
p16680
sg13
I1
sasg19
(lp16681
(dp16682
g7
I61
sg22
VC0009363
p16683
sg10
I8
sg11
Vcoloboma
p16684
sg13
I1
sasa(dp16685
g2
S'Exome sequence analysis of affected individuals from two families with autosomal-dominant inheritance of coloboma identified two different cosegregating heterozygous nonsense mutations (c.370C&gt;T [p.Arg124*] and c. 1066G&gt;T [p.Glu356*]) in YAP1.\n'
p16686
sg4
(lp16687
(dp16688
g7
I244
sg8
VP46937
p16689
sg10
I4
sg11
VYAP1
p16690
sg13
I1
sasg19
(lp16691
(dp16692
g7
I105
sg22
VC0009363
p16693
sg10
I8
sg11
Vcoloboma
p16694
sg13
I1
sa(dp16695
g7
I166
sg22
VC0544885
p16696
sg10
I18
sg11
Vnonsense mutations
p16697
sg13
I2
sasa(dp16698
g2
S'We investigated the allelic frequencies of TLR4 (D299G and T399I) and NOD2/CARD15 (R702W, G908R, and L1007finsC) SNPs in 87 asymptomatic serologically H. pylori-positive individuals (Group I), in 63 patients with antrum-predominant gastritis (Group II) and in 60 patients with corpus-predominant gastritis or pangastritis (Group III).\n'
p16699
sg4
(lp16700
(dp16701
g7
I75
sg8
g15
sg10
I6
sg11
VCARD15
p16702
sg13
I1
sa(dp16703
g7
I70
sg8
VP22301
p16704
sg10
I4
sg11
VNOD2
p16705
sg13
I1
sasg19
(lp16706
(dp16707
g7
I232
sg22
VC0017152
p16708
sg10
I9
sg11
Vgastritis
p16709
sg13
I1
sa(dp16710
g7
I232
sg22
VC0017152
p16711
sg10
I9
sg11
Vgastritis
p16712
sg13
I1
sa(dp16713
g7
I309
sg22
VC1277259
p16714
sg10
I12
sg11
Vpangastritis
p16715
sg13
I1
sasa(dp16716
g2
S'This activates TRPV1 on primary sensory nerves to induce acute pancreatitis.\n'
p16717
sg4
(lp16718
(dp16719
g7
I15
sg8
g15
sg10
I5
sg11
VTRPV1
p16720
sg13
I1
sasg19
(lp16721
(dp16722
g7
I57
sg22
VC0001339
p16723
sg10
I18
sg11
Vacute pancreatitis
p16724
sg13
I2
sasa(dp16725
g2
S'We found that constitutive genetic TRPV1 deletion or peripheral TRPV1 deletion reduced acetic acid-evoked abdominal constrictions, without affecting referred abdominal hyperalgesia or allodynia in an acute pancreatitis model of visceral pain.\n'
p16726
sg4
(lp16727
(dp16728
g7
I35
sg8
g15
sg10
I5
sg11
VTRPV1
p16729
sg13
I1
sasg19
(lp16730
(dp16731
g7
I228
sg22
VC0234245
p16732
sg10
I13
sg11
Vvisceral pain
p16733
sg13
I2
sa(dp16734
g7
I200
sg22
VC0001339
p16735
sg10
I18
sg11
Vacute pancreatitis
p16736
sg13
I2
sa(dp16737
g7
I168
sg22
VC0020429
p16738
sg10
I12
sg11
Vhyperalgesia
p16739
sg13
I1
sasa(dp16740
g2
S'It has been recently demonstrated that transient receptor potential vanilloid 1 (TRPV1) activation causes neurogenic inflammation and plays an important role in acute pancreatitis.\n'
p16741
sg4
(lp16742
(dp16743
g7
I39
sg8
g15
sg10
I40
sg11
Vtransient receptor potential vanilloid 1
p16744
sg13
I5
sa(dp16745
g7
I81
sg8
g15
sg10
I5
sg11
VTRPV1
p16746
sg13
I1
sasg19
(lp16747
(dp16748
g7
I117
sg22
VC0021368
p16749
sg10
I12
sg11
Vinflammation
p16750
sg13
I1
sa(dp16751
g7
I161
sg22
VC0001339
p16752
sg10
I18
sg11
Vacute pancreatitis
p16753
sg13
I2
sasa(dp16754
g2
S'Common pancreaticobiliary duct obstruction causes an increase in pancreatic LTB4 concentrations that in turn mediates activation of TRPV1 resulting in acute pancreatitis.\n'
p16755
sg4
(lp16756
(dp16757
g7
I132
sg8
g15
sg10
I5
sg11
VTRPV1
p16758
sg13
I1
sasg19
(lp16759
(dp16760
g7
I31
sg22
VC0028778
p16761
sg10
I11
sg11
Vobstruction
p16762
sg13
I1
sa(dp16763
g7
I151
sg22
VC0001339
p16764
sg10
I18
sg11
Vacute pancreatitis
p16765
sg13
I2
sasa(dp16766
g2
S'However, when primary sensory neurons were ablated by injection of the neurotoxin and TRPV1 agonist, resiniferatoxin, pancreatitis was ameliorated in wild-type mice but not in null mice, indicating that nerves bearing TRPV1 are part of the inflammatory pathway in acute pancreatitis because disappearance significantly reduced the inflammatory response.\n'
p16767
sg4
(lp16768
(dp16769
g7
I86
sg8
g15
sg10
I5
sg11
VTRPV1
p16770
sg13
I1
sa(dp16771
g7
I86
sg8
g15
sg10
I5
sg11
VTRPV1
p16772
sg13
I1
sasg19
(lp16773
(dp16774
g7
I264
sg22
VC0001339
p16775
sg10
I18
sg11
Vacute pancreatitis
p16776
sg13
I2
sa(dp16777
g7
I118
sg22
VC0030305
p16778
sg10
I12
sg11
Vpancreatitis
p16779
sg13
I1
sa(dp16780
g7
I331
sg22
VC1155266
p16781
sg10
I21
sg11
Vinflammatory response
p16782
sg13
I2
sasa(dp16783
g2
S'Nerves expressing TRPV1 participate in the neurogenic inflammation during acute pancreatitis.\n'
p16784
sg4
(lp16785
(dp16786
g7
I18
sg8
g15
sg10
I5
sg11
VTRPV1
p16787
sg13
I1
sasg19
(lp16788
(dp16789
g7
I74
sg22
VC0001339
p16790
sg10
I18
sg11
Vacute pancreatitis
p16791
sg13
I2
sa(dp16792
g7
I54
sg22
VC0021368
p16793
sg10
I12
sg11
Vinflammation
p16794
sg13
I1
sasa(dp16795
g2
S'Lim-domain only 4 (LMO4) plays a critical role in mediating the ototoxic side-effects of cisplatin, a highly effective anti-cancer drug.\n'
p16796
sg4
(lp16797
(dp16798
g7
I0
sg8
g15
sg10
I17
sg11
VLim-domain only 4
p16799
sg13
I3
sa(dp16800
g7
I19
sg8
VP61968
p16801
sg10
I4
sg11
VLMO4
p16802
sg13
I1
sasg19
(lp16803
(dp16804
g7
I124
sg22
VC0006826
p16805
sg10
I6
sg11
Vcancer
p16806
sg13
I1
sasa(dp16807
g2
S'The role of Lmo4 in lung tumorigenesis was measured using a mouse model of lung adenocarcinoma in which the oncogenic K-Ras protein has been knocked into the K-Ras locus.\n'
p16808
sg4
(lp16809
(dp16810
g7
I158
sg8
VP01116
p16811
sg10
I11
sg11
VK-Ras locus
p16812
sg13
I2
sa(dp16813
g7
I12
sg8
VP61968
p16814
sg10
I4
sg11
VLmo4
p16815
sg13
I1
sa(dp16816
g7
I108
sg8
VP01116
p16817
sg10
I23
sg11
Voncogenic K-Ras protein
p16818
sg13
I3
sasg19
(lp16819
(dp16820
g7
I75
sg22
VC0152013
p16821
sg10
I19
sg11
Vlung adenocarcinoma
p16822
sg13
I2
sa(dp16823
g7
I25
sg22
VC0007621
p16824
sg10
I13
sg11
Vtumorigenesis
p16825
sg13
I1
sasa(dp16826
g2
S'Finally, we evaluated the expression of LMO4 in tissue microarrays of early stage non-small cell lung cancer and observed that LMO4 is more highly expressed in lung squamous cell carcinoma compared to adenocarcinoma.\n'
p16827
sg4
(lp16828
(dp16829
g7
I40
sg8
VP61968
p16830
sg10
I4
sg11
VLMO4
p16831
sg13
I1
sa(dp16832
g7
I40
sg8
VP61968
p16833
sg10
I4
sg11
VLMO4
p16834
sg13
I1
sasg19
(lp16835
(dp16836
g7
I82
sg22
VC0007131
p16837
sg10
I26
sg11
Vnon-small cell lung cancer
p16838
sg13
I4
sa(dp16839
g7
I160
sg22
VC0149782
p16840
sg10
I28
sg11
Vlung squamous cell carcinoma
p16841
sg13
I4
sa(dp16842
g7
I201
sg22
VC0001418
p16843
sg10
I14
sg11
Vadenocarcinoma
p16844
sg13
I1
sasa(dp16845
g2
S'LIM-domain only protein 4 (LMO4) is a widely expressed protein with important roles in embryonic development and breast cancer.\n'
p16846
sg4
(lp16847
(dp16848
g7
I0
sg8
g15
sg10
I25
sg11
VLIM-domain only protein 4
p16849
sg13
I4
sa(dp16850
g7
I27
sg8
VP61968
p16851
sg10
I4
sg11
VLMO4
p16852
sg13
I1
sasg19
(lp16853
(dp16854
g7
I113
sg22
VC0678222
p16855
sg10
I13
sg11
Vbreast cancer
p16856
sg13
I2
sasa(dp16857
g2
S'A subsequent search of the neuroblastoma gene server for human orthologues of genes differentially expressed in the chick embryo neural crest screen retrieved the LIM domain only protein 4 (LMO4), which was expressed in both cell types analyzed.\n'
p16858
sg4
(lp16859
(dp16860
g7
I190
sg8
VP61968
p16861
sg10
I4
sg11
VLMO4
p16862
sg13
I1
sa(dp16863
g7
I163
sg8
VP61968
p16864
sg10
I25
sg11
VLIM domain only protein 4
p16865
sg13
I5
sasg19
(lp16866
(dp16867
g7
I136
sg22
VC0206138
p16868
sg10
I5
sg11
Vcrest
p16869
sg13
I1
sa(dp16870
g7
I27
sg22
VC0027819
p16871
sg10
I13
sg11
Vneuroblastoma
p16872
sg13
I1
sasa(dp16873
g2
S'Functional experiments in these two model systems revealed that LMO4 activity is required for neuroblastoma cell invasion and neural crest delamination.\n'
p16874
sg4
(lp16875
(dp16876
g7
I64
sg8
VP61968
p16877
sg10
I4
sg11
VLMO4
p16878
sg13
I1
sasg19
(lp16879
(dp16880
g7
I94
sg22
VC0027819
p16881
sg10
I13
sg11
Vneuroblastoma
p16882
sg13
I1
sa(dp16883
g7
I133
sg22
VC0206138
p16884
sg10
I5
sg11
Vcrest
p16885
sg13
I1
sa(dp16886
g7
I108
sg22
VC2699153
p16887
sg10
I13
sg11
Vcell invasion
p16888
sg13
I2
sasa(dp16889
g2
S'Moreover, we identified LMO4 as an essential cofactor in Snail2-mediated cadherin repression and in the epithelial-to-mesenchymal transition of both neural crest and neuroblastoma cells.\n'
p16890
sg4
(lp16891
(dp16892
g7
I57
sg8
g15
sg10
I24
sg11
VSnail2-mediated cadherin
p16893
sg13
I2
sa(dp16894
g7
I24
sg8
VP61968
p16895
sg10
I4
sg11
VLMO4
p16896
sg13
I1
sasg19
(lp16897
(dp16898
g7
I130
sg22
VC0599156
p16899
sg10
I10
sg11
Vtransition
p16900
sg13
I1
sa(dp16901
g7
I156
sg22
VC0206138
p16902
sg10
I5
sg11
Vcrest
p16903
sg13
I1
sa(dp16904
g7
I166
sg22
VC0027819
p16905
sg10
I13
sg11
Vneuroblastoma
p16906
sg13
I1
sasa(dp16907
g2
S'Together, our results suggest that the association of high levels of LMO4 with aggressive neuroblastomas is dependent on LMO4 regulation of cadherin expression and hence, tumor invasiveness.\n'
p16908
sg4
(lp16909
(dp16910
g7
I69
sg8
VP61968
p16911
sg10
I4
sg11
VLMO4
p16912
sg13
I1
sa(dp16913
g7
I140
sg8
g15
sg10
I8
sg11
Vcadherin
p16914
sg13
I1
sa(dp16915
g7
I69
sg8
VP61968
p16916
sg10
I4
sg11
VLMO4
p16917
sg13
I1
sasg19
(lp16918
(dp16919
g7
I90
sg22
VC0027819
p16920
sg10
I14
sg11
Vneuroblastomas
p16921
sg13
I1
sa(dp16922
g7
I79
sg22
VC0001807
p16923
sg10
I10
sg11
Vaggressive
p16924
sg13
I1
sa(dp16925
g7
I171
sg22
VC0027651
p16926
sg10
I5
sg11
Vtumor
p16927
sg13
I1
sasa(dp16928
g2
S'LMO4 participates in Stat3 signaling in hepatocytes and associates with histone deacetylase 2 (HDAC2) in cancer cells.\n'
p16929
sg4
(lp16930
(dp16931
g7
I95
sg8
g15
sg10
I5
sg11
VHDAC2
p16932
sg13
I1
sa(dp16933
g7
I0
sg8
VP61968
p16934
sg10
I4
sg11
VLMO4
p16935
sg13
I1
sa(dp16936
g7
I72
sg8
g15
sg10
I21
sg11
Vhistone deacetylase 2
p16937
sg13
I3
sa(dp16938
g7
I21
sg8
VP40763
p16939
sg10
I5
sg11
VStat3
p16940
sg13
I1
sasg19
(lp16941
(dp16942
g7
I105
sg22
VC0006826
p16943
sg10
I6
sg11
Vcancer
p16944
sg13
I1
sasa(dp16945
g2
S'Because LMO4 is up-regulated in human breast cancers, repression of ERalpha transactivation functions by LMO4 might contribute to the process of breast cancer progression by allowing the development of ERalpha-negative phenotypes, leading to increased aggressiveness of breast cancer cells.\n'
p16946
sg4
(lp16947
(dp16948
g7
I8
sg8
VP61968
p16949
sg10
I4
sg11
VLMO4
p16950
sg13
I1
sa(dp16951
g7
I68
sg8
VP03372
p16952
sg10
I7
sg11
VERalpha
p16953
sg13
I1
sa(dp16954
g7
I68
sg8
VP03372
p16955
sg10
I7
sg11
VERalpha
p16956
sg13
I1
sasg19
(lp16957
(dp16958
g7
I252
sg22
VC0001807
p16959
sg10
I14
sg11
Vaggressiveness
p16960
sg13
I1
sa(dp16961
g7
I152
sg22
VC0178874
p16962
sg10
I18
sg11
Vcancer progression
p16963
sg13
I2
sa(dp16964
g7
I38
sg22
VC0006142
p16965
sg10
I14
sg11
Vbreast cancers
p16966
sg13
I2
sa(dp16967
g7
I38
sg22
VC0006142
p16968
sg10
I13
sg11
Vbreast cancer
p16969
sg13
I2
sasa(dp16970
g2
S'LMO4 belongs to a family of LIM-only transcriptional regulators, the first two members of which are oncoproteins in acute T cell leukemia.\n'
p16971
sg4
(lp16972
(dp16973
g7
I0
sg8
VP61968
p16974
sg10
I4
sg11
VLMO4
p16975
sg13
I1
sa(dp16976
g7
I28
sg8
g15
sg10
I3
sg11
VLIM
p16977
sg13
I1
sasg19
(lp16978
(dp16979
g7
I116
sg22
VC1961099
p16980
sg10
I21
sg11
Vacute T cell leukemia
p16981
sg13
I4
sasa(dp16982
g2
S'Overexpression of LMO4 mRNA was observed in 5 of 10 human breast cancer cell lines.\n'
p16983
sg4
(lp16984
(dp16985
g7
I18
sg8
VP61968
p16986
sg10
I9
sg11
VLMO4 mRNA
p16987
sg13
I2
sasg19
(lp16988
(dp16989
g7
I58
sg22
VC0678222
p16990
sg10
I13
sg11
Vbreast cancer
p16991
sg13
I2
sasa(dp16992
g2
S'We used the 16-mer core sequences of the RRSs in the AAV ITRs and AAVS1 separately as query sequences and identified 18 new RRSs in or flanking the genes coding for the following: tyrosine kinase activator protein 1 (TKA-1); colony stimulating factor-1; insulin-like growth factor binding protein 2 (IGFBP-2); histone H2B.1; basement membrane heparan sulfate proteoglycan, also known as perlecan; the AF-9 gene product, which is involved in the chromosomal translocation t (9:11)(p22:q23); the betaB subunit of the hormone known as inhibin; interleukin-2 enhancer binding factor; an endoplasmic reticulum-Golgi intermediate compartment resident protein called p63; a global transcription activator (hSNF2L); the beta-actin repair domain; a retinoic acid-inducible factor, also known as midkine; a breast tumor autoantigen; a growth-arrest- and DNA-damage-inducible protein called gadd45; the cyclin-dependent kinase inhibitor called KIP2, which inhibits several G1 cyclin-cyclin-dependent kinase complexes; and the hereditary breast and ovarian cancer gene (BRCA1).\n'
p16993
sg4
(lp16994
(dp16995
g7
I225
sg8
VP04141
p16996
sg10
I27
sg11
Vcolony stimulating factor-1
p16997
sg13
I3
sa(dp16998
g7
I217
sg8
g15
sg10
I5
sg11
VTKA-1
p16999
sg13
I1
sa(dp17000
g7
I712
sg8
VP63261
p17001
sg10
I24
sg11
Vbeta-actin repair domain
p17002
sg13
I3
sa(dp17003
g7
I962
sg8
VP12004
p17004
sg10
I9
sg11
VG1 cyclin
p17005
sg13
I2
sa(dp17006
g7
I933
sg8
VP49918
p17007
sg10
I4
sg11
VKIP2
p17008
sg13
I1
sa(dp17009
g7
I541
sg8
VP60568
p17010
sg10
I37
sg11
Vinterleukin-2 enhancer binding factor
p17011
sg13
I4
sa(dp17012
g7
I880
sg8
VP24522
p17013
sg10
I6
sg11
Vgadd45
p17014
sg13
I1
sa(dp17015
g7
I445
sg8
g15
sg10
I27
sg11
Vchromosomal translocation t
p17016
sg13
I3
sa(dp17017
g7
I310
sg8
VP62807
p17018
sg10
I11
sg11
Vhistone H2B
p17019
sg13
I2
sa(dp17020
g7
I180
sg8
VP29401
p17021
sg10
I35
sg11
Vtyrosine kinase activator protein 1
p17022
sg13
I5
sa(dp17023
g7
I494
sg8
g15
sg10
I13
sg11
VbetaB subunit
p17024
sg13
I2
sa(dp17025
g7
I660
sg8
g15
sg10
I3
sg11
Vp63
p17026
sg13
I1
sa(dp17027
g7
I892
sg8
VP12004
p17028
sg10
I6
sg11
Vcyclin
p17029
sg13
I1
sa(dp17030
g7
I1058
sg8
VP38398
p17031
sg10
I5
sg11
VBRCA1
p17032
sg13
I1
sa(dp17033
g7
I254
sg8
VP01308
p17034
sg10
I44
sg11
Vinsulin-like growth factor binding protein 2
p17035
sg13
I6
sa(dp17036
g7
I480
sg8
g15
sg10
I3
sg11
Vp22
p17037
sg13
I1
sa(dp17038
g7
I300
sg8
VP18065
p17039
sg10
I7
sg11
VIGFBP-2
p17040
sg13
I1
sa(dp17041
g7
I892
sg8
VP38936
p17042
sg10
I33
sg11
Vcyclin-dependent kinase inhibitor
p17043
sg13
I3
sasg19
(lp17044
(dp17045
g7
I797
sg22
VC1458155
p17046
sg10
I12
sg11
Vbreast tumor
p17047
sg13
I2
sa(dp17048
g7
I445
sg22
VC0040715
p17049
sg10
I25
sg11
Vchromosomal translocation
p17050
sg13
I2
sa(dp17051
g7
I1015
sg22
VC0677776
p17052
sg10
I36
sg11
Vhereditary breast and ovarian cancer
p17053
sg13
I5
sasa(dp17054
g2
S'To investigate the role of pregnancy-associated plasma protein A (PAPP-A) in the outcome of ischemic cerebrovascular disease.\n'
p17055
sg4
(lp17056
(dp17057
g7
I66
sg8
g15
sg10
I6
sg11
VPAPP-A
p17058
sg13
I1
sa(dp17059
g7
I27
sg8
g15
sg10
I37
sg11
Vpregnancy-associated plasma protein A
p17060
sg13
I4
sasg19
(lp17061
(dp17062
g7
I101
sg22
VC0007820
p17063
sg10
I23
sg11
Vcerebrovascular disease
p17064
sg13
I2
sasa(dp17065
g2
S'We analyzed the levels of PAPP-A in the transient ischemic attack (TIA) patients, ischemic stroke (IS) patients and normal control, and followed up the outcome of the patients in the following 2 years.\n'
p17066
sg4
(lp17067
(dp17068
g7
I26
sg8
g15
sg10
I6
sg11
VPAPP-A
p17069
sg13
I1
sasg19
(lp17070
(dp17071
g7
I99
sg22
VC3272363
p17072
sg10
I2
sg11
VIS
p17073
sg13
I1
sa(dp17074
g7
I82
sg22
VC3272363
p17075
sg10
I15
sg11
Vischemic stroke
p17076
sg13
I2
sa(dp17077
g7
I40
sg22
VC0007787
p17078
sg10
I25
sg11
Vtransient ischemic attack
p17079
sg13
I3
sa(dp17080
g7
I67
sg22
VC0007787
p17081
sg10
I3
sg11
VTIA
p17082
sg13
I1
sasa(dp17083
g2
S'Higher PAPP-A concentration has a forecasting value on prognosis in ischemic cerebrovascular disease.\n'
p17084
sg4
(lp17085
(dp17086
g7
I7
sg8
g15
sg10
I6
sg11
VPAPP-A
p17087
sg13
I1
sasg19
(lp17088
(dp17089
g7
I77
sg22
VC0007820
p17090
sg10
I23
sg11
Vcerebrovascular disease
p17091
sg13
I2
sasa(dp17092
g2
S'Controlling for age, sex, and classical cardiovascular risk factors, N-terminal section brain natriuretic peptide and pregnancy-associated plasma protein-A were independent emerging cardiovascular risk factors for acute coronary syndrome, but pregnancy-associated plasma protein-A was not for stroke.\n'
p17093
sg4
(lp17094
sg19
(lp17095
(dp17096
g7
I293
sg22
VC0038454
p17097
sg10
I6
sg11
Vstroke
p17098
sg13
I1
sa(dp17099
g7
I214
sg22
VC0948089
p17100
sg10
I23
sg11
Vacute coronary syndrome
p17101
sg13
I3
sasa(dp17102
g2
S'The ADMA, hsCRP and PAPP-A can be recommended for including into clinical molecular panel for personalized diagnostic of causes of stroke along with clinical anamnestic data.\n'
p17103
sg4
(lp17104
(dp17105
g7
I20
sg8
g15
sg10
I6
sg11
VPAPP-A
p17106
sg13
I1
sasg19
(lp17107
(dp17108
g7
I131
sg22
VC0038454
p17109
sg10
I6
sg11
Vstroke
p17110
sg13
I1
sasa(dp17111
g2
S'The analysis of levels of ADMA, hsCR and PPAPP-A interpreted with regard to clinical anamnestic data can be proposed for enhancing quality of diagnostic of causes of stroke.\n'
p17112
sg4
(lp17113
(dp17114
g7
I32
sg8
VP14138
p17115
sg10
I4
sg11
VhsCR
p17116
sg13
I1
sasg19
(lp17117
(dp17118
g7
I166
sg22
VC0038454
p17119
sg10
I6
sg11
Vstroke
p17120
sg13
I1
sa(dp17121
g7
I32
sg22
VC2931876
p17122
sg10
I4
sg11
VhsCR
p17123
sg13
I1
sasa(dp17124
g2
S'This study investigated the correlation of plama levels of inflammatory biomarkers [soluble cluster of differentiation 40 ligand (sCD40L), alpha fetoprotein A (fetuin-A), and pregnancy-associated protein A (PAPP-A)] with carotid plaque in patients with acute ischemic stroke.\n'
p17125
sg4
(lp17126
(dp17127
g7
I207
sg8
g15
sg10
I6
sg11
VPAPP-A
p17128
sg13
I1
sa(dp17129
g7
I160
sg8
VP02765
p17130
sg10
I8
sg11
Vfetuin-A
p17131
sg13
I1
sa(dp17132
g7
I139
sg8
VP02771
p17133
sg10
I19
sg11
Valpha fetoprotein A
p17134
sg13
I3
sa(dp17135
g7
I175
sg8
VP02810
p17136
sg10
I30
sg11
Vpregnancy-associated protein A
p17137
sg13
I3
sasg19
(lp17138
(dp17139
g7
I229
sg22
VC0011389
p17140
sg10
I6
sg11
Vplaque
p17141
sg13
I1
sa(dp17142
g7
I259
sg22
VC3272363
p17143
sg10
I15
sg11
Vischemic stroke
p17144
sg13
I2
sasa(dp17145
g2
S'Enzyme- linked immunosorbent assay analysis revealed increased levels of serum pregnancy-associated plasma protein-A (PAPP-A) in ischemic cerebrovascular disease patients compared with healthy controls.\n'
p17146
sg4
(lp17147
(dp17148
g7
I118
sg8
g15
sg10
I6
sg11
VPAPP-A
p17149
sg13
I1
sa(dp17150
g7
I79
sg8
g15
sg10
I37
sg11
Vpregnancy-associated plasma protein-A
p17151
sg13
I3
sasg19
(lp17152
(dp17153
g7
I138
sg22
VC0007820
p17154
sg10
I23
sg11
Vcerebrovascular disease
p17155
sg13
I2
sasa(dp17156
g2
S'Multiple-factor logistic regression analysis on correction of age, gender, history of smoking, hypertension, diabetes mellitus, hypercholesteremia, and ischemic stroke family history showed that the risk for ischemic cerebrovascular disease in the population without the A allele at the A/C genetic locus in exon 14 of the PAPP-A was 2-folds greater than the population expressing the A allele.\n'
p17157
sg4
(lp17158
(dp17159
g7
I323
sg8
g15
sg10
I6
sg11
VPAPP-A
p17160
sg13
I1
sasg19
(lp17161
(dp17162
g7
I217
sg22
VC0007820
p17163
sg10
I23
sg11
Vcerebrovascular disease
p17164
sg13
I2
sa(dp17165
g7
I109
sg22
VC0011849
p17166
sg10
I17
sg11
Vdiabetes mellitus
p17167
sg13
I2
sa(dp17168
g7
I95
sg22
VC0020538
p17169
sg10
I12
sg11
Vhypertension
p17170
sg13
I1
sa(dp17171
g7
I128
sg22
VC0020443
p17172
sg10
I18
sg11
Vhypercholesteremia
p17173
sg13
I1
sa(dp17174
g7
I152
sg22
VC3272363
p17175
sg10
I15
sg11
Vischemic stroke
p17176
sg13
I2
sasa(dp17177
g2
S'These experimental findings suggested that ischemic cerebrovascular disease correlated with the C allele in exon 14 of PAPP-A.\n'
p17178
sg4
(lp17179
(dp17180
g7
I119
sg8
g15
sg10
I6
sg11
VPAPP-A
p17181
sg13
I1
sasg19
(lp17182
(dp17183
g7
I52
sg22
VC0007820
p17184
sg10
I23
sg11
Vcerebrovascular disease
p17185
sg13
I2
sasa(dp17186
g2
S'The aim of this study was to examine the prognostic value of serum pregnancy-associated plasma protein A (PAPP-A), S100 and high sensitivity C-reactive protein (hs-CRP) in heparin-naive patients of acute ischemic stroke.\n'
p17187
sg4
(lp17188
(dp17189
g7
I161
sg8
VP02741
p17190
sg10
I6
sg11
Vhs-CRP
p17191
sg13
I1
sa(dp17192
g7
I106
sg8
g15
sg10
I6
sg11
VPAPP-A
p17193
sg13
I1
sa(dp17194
g7
I67
sg8
g15
sg10
I37
sg11
Vpregnancy-associated plasma protein A
p17195
sg13
I4
sa(dp17196
g7
I124
sg8
VP02741
p17197
sg10
I35
sg11
Vhigh sensitivity C-reactive protein
p17198
sg13
I4
sa(dp17199
g7
I115
sg8
VP04271
p17200
sg10
I4
sg11
VS100
p17201
sg13
I1
sasg19
(lp17202
(dp17203
g7
I204
sg22
VC3272363
p17204
sg10
I15
sg11
Vischemic stroke
p17205
sg13
I2
sasa.